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General Introduction: 
 
Coronary artery disease (CAD) and relative morbidity are estimated as the primary cause 
of death in western countries.1 Percutaneous coronary intervention (PCI) assumed a 
dominant role in this field, and the number of procedures across Europe, both for stable 
and unstable CAD, continued to rise in the last decade.2 The implementation of refined 
treatment strategies, better devices and more efficacious pharmacological treatment to 
reduce the occurrence of ischemic complications early and late after PCI, reduced the 
burden of cardiovascular mortality. With this respect, dual antiplatelet therapy, constituted 
by the association of aspirin and an inhibitor of the platelet receptor P2Y12, become a 
pivotal pharmacological treatment after PCI, preventing both stent and non-stent related 
ischemic events.3-5 Evidence from multiple trials demonstrated that the beneficial anti-
ischemic effect of P2Y12-inhibitors implemented on top of aspirin is linearly related to the 
pharmacological potency and the overall duration of treatment.4-7 Nevertheless, the 
implementation of more potent or prolonged treatments raised the issue of a proportional 
increase of bleeding complications.6-8 Bleedings are far from being innocent bystanders, 
and such complications both during and after PCI have been shown to significantly impact 
mortality in a similar or even greater magnitude than coronary ischemic events.8, 9 Like 
Ulysses navigating between Scylla and Charibdis, two mythological monsters inhabiting 
the two coasts of the strait of Messina, menacing navigators passing too close to one side 
or the other, clinicians should be aware of the trade-off of both bleeding and ischemia and 
their impact on patients’ health.10  
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The use of the radial approach, as compared to the more traumatic femoral approach, has 
demonstrated a significant reduction of peri-procedural bleeding.11 This holds particularly 
true during the acute setting, when more potent antithrombotics are used, increasing 
bleeding liability.12, 13 In addition the use of radial artery might give additional benefits 
independently from bleeding prevention.14 As such international guidelines now advocate 
radial artery as the default access site for PCI.15, 16 On the other side, radial intervention 
might be complicated by radial artery occlusion, that despite not being associated with 
apparent clinical consequences, hamper future interventions from this route.17 Several 
predictors for radial occlusion have been described, yet a deeper understanding of their 
mechanisms is needed.17-19  
 
Stent type selection, and subsequent antiplatelet treatment, has also been considered an 
important factor for the ischemia/bleeding balance after PCI. Since the introduction of first-
generation drug-eluting stents (DES), which were developed to reduce in-stent restenosis, 
concern was raised about their higher thrombogenicity, especially for late or very late 
events (>12 months after intervention).20 As a reaction to this preliminary data, the 
community and international guidelines took position for prolonging DAPT in patients 
treated with DES to at least 12 months.21 This practice, initially advocated for first 
generation DES, has been automatically translated also to second-generation DES despite 
their technical improvements (i.e. reduced strut-thickness, more biocompatible or 
resorbable drug carriers). Hence, since longer DAPT was recommended after DES 
implantation, it was common practice to use bare-metal stents in patients deemed at high 
bleeding risk, despite no direct comparison between these two strategies was available. 
Multiple studies questioned this practice, especially in light of the promising results of new 
generation DES. The EXAMINATION trial randomly allocated patients with ST-segment 
elevated myocardial infarction to a treatment with BMS or DES. The results at 5-years 
follow-up suggested a significant reduction of the composite ischemic endpoint of all-cause 
death, recurrent myocardial infarction and any revascularization mostly driven by a 
significant 28% relative reduction of all cause mortality.22 On the same line, a meta-
analysis including randomized studies allocating patients to BMS vs. cobalt-chromium 
everolimus DES consistently demonstrated an improved safety and efficacy of 2nd 
generation DES, with a significant 33% reduction of cardiac death, 59% reduction of 
definite stent thrombosis and 71% reduction of target vessel revascularization.23 As such, 
if bleeding risk status should be considered a treatment modifier for stent selection 
deserves further clarification. 
 
With respect to the long-term prevention of ischemic recurrences, multiple trials questioned 
the recommended 12 months DAPT duration endorsed by international guidelines after 
stent implantation or ACS.2 Studies presented before 2014 tested both a prolonged or 
shortened DAPT duration in patients receiving coronary stents.24-27 The overall 
interpretation of the evidence available at that time did not suggest a significant benefit 
from a treatment prolongation beyond 12 months, whereas a consistent reduction of 
bleeding complication was observed with shorter treatment courses.28, 29 Still, due to their 
relatively small size, these trials were not powered to detect differences for rare events 
such as late stent thrombosis. Specifically designed to answer this question, the DAPT 
trial, a large randomized controlled trial sponsored by the Food and Drug Administration, 
randomly allocated 9961 patients previously treated with first and second generation DES, 
well tolerating and adhering to a first run-in phase of 12 months of dual antiplatelet 
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therapy, to a strategy of DAPT interruption or continuation up to 30 months.6 The DAPT 
trial demonstrated a significant 29% relative reduction of the composite ischemic endpoint 
and a 71% relative reduction of definite or probable stent thrombosis.6 Still, a prolonged 
treatment was associated with a roughly 60% increase of moderate or severe bleeding 
and with a significant increase of non-cardiac and all-cause mortality.6  
In light of the evidence produced by more than 10 randomized clinical trials, growing 
importance has been given to the selection of the right patient population for the decision 
of shortening or prolonging DAPT. As such, individualization of the treatment duration 
based on the single-patient risk profile appear a promising approach in order to deliver the 
proper treatment to the right recipient, in line with the principles of precision medicine. 
  
 
 
 
References: 
 
1. Mendis S PP, Norrving B. Global Atlas on Cardiovascular Disease Pre- vention and 
Control. Geneva: World Health Organization 2011. 
2. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, 
Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser 
U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart 
DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on 
myocardial revascularization: The Task Force on Myocardial Revascularization of the 
European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic 
INTRODUCTION
Surgery (EACTS)Developed with the special contribution of the European Association of 
Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541-619. 
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in 
Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to 
aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J 
Med 2001;345(7):494-502. 
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, 
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson 
CM, Antman EM, Investigators T-T. Prasugrel versus clopidogrel in patients with acute 
coronary syndromes. N Engl J Med 2007;357(20):2001-15. 
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, 
Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, 
Harrington RA, Investigators P, Freij A, Thorsen M. Ticagrelor versus clopidogrel in 
patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57. 
6. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand 
SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff MW, Hermiller J, 
Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi 
MJ, Massaro JM, Investigators DS. Twelve or 30 months of dual antiplatelet therapy after 
drug-eluting stents. N Engl J Med 2014;371(23):2155-66. 
7. Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients 
with Prior Myocardial Infarction. N Engl J Med 2015;373(13):1274-5. 
8. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa 
F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual 
INTRODUCTION
INTRODUCTION
1918
therapy, to a strategy of DAPT interruption or continuation up to 30 months.6 The DAPT 
trial demonstrated a significant 29% relative reduction of the composite ischemic endpoint 
and a 71% relative reduction of definite or probable stent thrombosis.6 Still, a prolonged 
treatment was associated with a roughly 60% increase of moderate or severe bleeding 
and with a significant increase of non-cardiac and all-cause mortality.6  
In light of the evidence produced by more than 10 randomized clinical trials, growing 
importance has been given to the selection of the right patient population for the decision 
of shortening or prolonging DAPT. As such, individualization of the treatment duration 
based on the single-patient risk profile appear a promising approach in order to deliver the 
proper treatment to the right recipient, in line with the principles of precision medicine. 
  
 
 
 
References: 
 
1. Mendis S PP, Norrving B. Global Atlas on Cardiovascular Disease Pre- vention and 
Control. Geneva: World Health Organization 2011. 
2. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, 
Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser 
U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart 
DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on 
myocardial revascularization: The Task Force on Myocardial Revascularization of the 
European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic 
INTRODUCTION
Surgery (EACTS)Developed with the special contribution of the European Association of 
Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541-619. 
3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in 
Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to 
aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J 
Med 2001;345(7):494-502. 
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, 
Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson 
CM, Antman EM, Investigators T-T. Prasugrel versus clopidogrel in patients with acute 
coronary syndromes. N Engl J Med 2007;357(20):2001-15. 
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, 
Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, 
Harrington RA, Investigators P, Freij A, Thorsen M. Ticagrelor versus clopidogrel in 
patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045-57. 
6. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand 
SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff MW, Hermiller J, 
Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi 
MJ, Massaro JM, Investigators DS. Twelve or 30 months of dual antiplatelet therapy after 
drug-eluting stents. N Engl J Med 2014;371(23):2155-66. 
7. Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients 
with Prior Myocardial Infarction. N Engl J Med 2015;373(13):1274-5. 
8. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa 
F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual 
INTRODUCTION
INTRODUCTION
2120
antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: 
meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. 
9. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, 
Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey 
KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute 
coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event 
Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 
2017;38(11):804-810. 
10. Bhatt DL. Intensifying platelet inhibition--navigating between Scylla and Charybdis. 
N Engl J Med 2007;357(20):2078-81. 
11. Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, 
Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, 
Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, 
Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, 
Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M, Vranckx P, Juni P, 
Investigators M. Radial versus femoral access in patients with acute coronary syndromes 
undergoing invasive management: a randomised multicentre trial. Lancet 
2015;385(9986):2465-76. 
12. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, 
Summaria F, Patrizi R, Borghi A, Di Russo C, Moretti C, Agostoni P, Loschiavo P, Lioy E, 
Sheiban I, Sangiorgi G. Radial versus femoral randomized investigation in ST-segment 
elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral 
Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll 
Cardiol 2012;60(24):2481-9. 
13. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela M, 
Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, 
Chrolavicius S, Mehta SR, group Rt. Radial versus femoral access for coronary 
angiography and intervention in patients with acute coronary syndromes (RIVAL): a 
randomised, parallel group, multicentre trial. Lancet 2011;377(9775):1409-20. 
14. Ando G, Cortese B, Russo F, Rothenbuhler M, Frigoli E, Gargiulo G, Briguori C, 
Vranckx P, Leonardi S, Guiducci V, Belloni F, Ferrari F, de la Torre Hernandez JM, Curello 
S, Liistro F, Perkan A, De Servi S, Casu G, Dellavalle A, Fischetti D, Micari A, Loi B, 
Mangiacapra F, Russo N, Tarantino F, Saia F, Heg D, Windecker S, Juni P, Valgimigli M, 
Investigators M. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute 
Coronary Syndrome Management: AKI-MATRIX. J Am Coll Cardiol 2017. 
15. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger 
MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser 
U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, 
Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, 
Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber 
K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, 
Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2015 ESC Guidelines for the 
management of acute coronary syndromes in patients presenting without persistent ST-
segment elevation: Task Force for the Management of Acute Coronary Syndromes in 
Patients Presenting without Persistent ST-Segment Elevation of the European Society of 
Cardiology (ESC). Eur Heart J 2016;37(3):267-315. 
16. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio 
ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott 
INTRODUCTION
INTRODUCTIONINTRODUCTIO
2120
antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: 
meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. 
9. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, 
Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey 
KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute 
coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event 
Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 
2017;38(11):804-810. 
10. Bhatt DL. Intensifying platelet inhibition--navigating between Scylla and Charybdis. 
N Engl J Med 2007;357(20):2078-81. 
11. Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, 
Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, 
Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, 
Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, 
Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M, Vranckx P, Juni P, 
Investigators M. Radial versus femoral access in patients with acute coronary syndromes 
undergoing invasive management: a randomised multicentre trial. Lancet 
2015;385(9986):2465-76. 
12. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, 
Summaria F, Patrizi R, Borghi A, Di Russo C, Moretti C, Agostoni P, Loschiavo P, Lioy E, 
Sheiban I, Sangiorgi G. Radial versus femoral randomized investigation in ST-segment 
elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral 
Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll 
Cardiol 2012;60(24):2481-9. 
13. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela M, 
Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, 
Chrolavicius S, Mehta SR, group Rt. Radial versus femoral access for coronary 
angiography and intervention in patients with acute coronary syndromes (RIVAL): a 
randomised, parallel group, multicentre trial. Lancet 2011;377(9775):1409-20. 
14. Ando G, Cortese B, Russo F, Rothenbuhler M, Frigoli E, Gargiulo G, Briguori C, 
Vranckx P, Leonardi S, Guiducci V, Belloni F, Ferrari F, de la Torre Hernandez JM, Curello 
S, Liistro F, Perkan A, De Servi S, Casu G, Dellavalle A, Fischetti D, Micari A, Loi B, 
Mangiacapra F, Russo N, Tarantino F, Saia F, Heg D, Windecker S, Juni P, Valgimigli M, 
Investigators M. Acute Kidney Injury After Radial or Femoral Access for Invasive Acute 
Coronary Syndrome Management: AKI-MATRIX. J Am Coll Cardiol 2017. 
15. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger 
MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser 
U, Mehilli J, Mukherjee D, Storey RF, Windecker S, Baumgartner H, Gaemperli O, 
Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H, Bugiardini R, Carerj S, 
Casselman F, Cuisset T, Erol C, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D, Huber 
K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, 
Sechtem U, Steg PG, Vrints C, Luis Zamorano J. 2015 ESC Guidelines for the 
management of acute coronary syndromes in patients presenting without persistent ST-
segment elevation: Task Force for the Management of Acute Coronary Syndromes in 
Patients Presenting without Persistent ST-Segment Elevation of the European Society of 
Cardiology (ESC). Eur Heart J 2016;37(3):267-315. 
16. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio 
ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott 
INTRODUCTION
INTRODUCTIONINTRODUCTIO
2322
E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P. 2017 ESC Guidelines for 
the management of acute myocardial infarction in patients presenting with ST-segment 
elevation: The Task Force for the management of acute myocardial infarction in patients 
presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur 
Heart J 2017. 
17. Uhlemann M, Mobius-Winkler S, Mende M, Eitel I, Fuernau G, Sandri M, Adams V, 
Thiele H, Linke A, Schuler G, Gielen S. The Leipzig prospective vascular ultrasound 
registry in radial artery catheterization: impact of sheath size on vascular complications. 
JACC Cardiovasc Interv 2012;5(1):36-43. 
18. Pancholy SB, Bertrand OF, Patel T. Comparison of a priori versus provisional 
heparin therapy on radial artery occlusion after transradial coronary angiography and 
patent hemostasis (from the PHARAOH Study). Am J Cardiol 2012;110(2):173-6. 
19. Pancholy SB, Patel TM. Effect of duration of hemostatic compression on radial 
artery occlusion after transradial access. Catheter Cardiovasc Interv 2012;79(1):78-81. 
20. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-
generation drug-eluting stents: a cause for concern. Circulation 2007;115(11):1440-55; 
discussion 1455. 
21. Task Force on Myocardial Revascularization of the European Society of C, the 
European Association for Cardio-Thoracic S, European Association for Percutaneous 
Cardiovascular I, Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, 
Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, 
Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, 
Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur J Cardiothorac 
Surg 2010;38 Suppl:S1-S52. 
22. Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Jimenez-Quevedo P, Mainar 
V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, 
Valgimigli M, Serruys PW. Clinical outcomes in patients with ST-segment elevation 
myocardial infarction treated with everolimus-eluting stents versus bare-metal stents 
(EXAMINATION): 5-year results of a randomised trial. Lancet 2016;387(10016):357-66. 
23. Valgimigli M, Sabate M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius 
S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G. Effects of cobalt-chromium 
everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: 
patient level meta-analysis. BMJ 2014;349:g6427. 
24. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi 
SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur 
SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-
month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: 
the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting 
(EXCELLENT) randomized, multicenter study. Circulation 2012;125(3):505-13. 
25. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, 
Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, Investigators R. A new strategy 
for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy 
of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent 
implantation). J Am Coll Cardiol 2012;60(15):1340-8. 
26. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, 3rd, 
Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Jr., Nicolela EL, 
Jr., Perin MA, Devito FS, Labrunie A, Salvadori D, Jr., Gusmao M, Staico R, Costa JR, Jr., 
de Castro JP, Abizaid AS, Bhatt DL, Investigators OT. Three vs twelve months of dual 
INTRODUCTION
INTRODUCTION
2322
E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P. 2017 ESC Guidelines for 
the management of acute myocardial infarction in patients presenting with ST-segment 
elevation: The Task Force for the management of acute myocardial infarction in patients 
presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur 
Heart J 2017. 
17. Uhlemann M, Mobius-Winkler S, Mende M, Eitel I, Fuernau G, Sandri M, Adams V, 
Thiele H, Linke A, Schuler G, Gielen S. The Leipzig prospective vascular ultrasound 
registry in radial artery catheterization: impact of sheath size on vascular complications. 
JACC Cardiovasc Interv 2012;5(1):36-43. 
18. Pancholy SB, Bertrand OF, Patel T. Comparison of a priori versus provisional 
heparin therapy on radial artery occlusion after transradial coronary angiography and 
patent hemostasis (from the PHARAOH Study). Am J Cardiol 2012;110(2):173-6. 
19. Pancholy SB, Patel TM. Effect of duration of hemostatic compression on radial 
artery occlusion after transradial access. Catheter Cardiovasc Interv 2012;79(1):78-81. 
20. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-
generation drug-eluting stents: a cause for concern. Circulation 2007;115(11):1440-55; 
discussion 1455. 
21. Task Force on Myocardial Revascularization of the European Society of C, the 
European Association for Cardio-Thoracic S, European Association for Percutaneous 
Cardiovascular I, Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, 
Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, 
Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, 
Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur J Cardiothorac 
Surg 2010;38 Suppl:S1-S52. 
22. Sabate M, Brugaletta S, Cequier A, Iniguez A, Serra A, Jimenez-Quevedo P, Mainar 
V, Campo G, Tespili M, den Heijer P, Bethencourt A, Vazquez N, van Es GA, Backx B, 
Valgimigli M, Serruys PW. Clinical outcomes in patients with ST-segment elevation 
myocardial infarction treated with everolimus-eluting stents versus bare-metal stents 
(EXAMINATION): 5-year results of a randomised trial. Lancet 2016;387(10016):357-66. 
23. Valgimigli M, Sabate M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius 
S, Cequier A, Eberli F, de Belder A, Serruys PW, Ferrante G. Effects of cobalt-chromium 
everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: 
patient level meta-analysis. BMJ 2014;349:g6427. 
24. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi 
SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur 
SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-
month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: 
the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting 
(EXCELLENT) randomized, multicenter study. Circulation 2012;125(3):505-13. 
25. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, 
Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, Investigators R. A new strategy 
for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy 
of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent 
implantation). J Am Coll Cardiol 2012;60(15):1340-8. 
26. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, 3rd, 
Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Jr., Nicolela EL, 
Jr., Perin MA, Devito FS, Labrunie A, Salvadori D, Jr., Gusmao M, Staico R, Costa JR, Jr., 
de Castro JP, Abizaid AS, Bhatt DL, Investigators OT. Three vs twelve months of dual 
INTRODUCTION
INTRODUCTION
2524
antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 
2013;310(23):2510-22. 
27. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, 
Colombo F, Tebaldi M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, 
Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R, Prolonging 
Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study I. 
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a 
randomized multicenter trial. Circulation 2012;125(16):2015-26. 
28. Collet JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, Cuisset T, 
Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P, Monsegu J, 
Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, 
Montalescot G, investigators A. Dual-antiplatelet treatment beyond 1 year after drug-
eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 
2014;384(9954):1577-85. 
29. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, 
Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, 
Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon 
DS, Seung KB, Lee K, Jang JS, Park SJ. Optimal duration of dual antiplatelet therapy after 
drug-eluting stent implantation: a randomized, controlled trial. Circulation 2014;129(3):304-
12. 
 
Part 1
Trade-off for ischemia and 
bleeding after percutaneous 
coronary intervention: 
international guidelines position 
and status of the community 
2524
antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 
2013;310(23):2510-22. 
27. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, 
Colombo F, Tebaldi M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, 
Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R, Prolonging 
Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study I. 
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a 
randomized multicenter trial. Circulation 2012;125(16):2015-26. 
28. Collet JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, Cuisset T, 
Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P, Monsegu J, 
Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, 
Montalescot G, investigators A. Dual-antiplatelet treatment beyond 1 year after drug-
eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 
2014;384(9954):1577-85. 
29. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, 
Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, 
Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon 
DS, Seung KB, Lee K, Jang JS, Park SJ. Optimal duration of dual antiplatelet therapy after 
drug-eluting stent implantation: a randomized, controlled trial. Circulation 2014;129(3):304-
12. 
 
Part 1
Trade-off for ischemia and 
bleeding after percutaneous 
coronary intervention: 
international guidelines position 
and status of the community 
Chapter 1.1
Dual Antiplatelet Therapy Duration: Reconciling the 
Inconsistencies
Francesco Costa, Stephan Windecker, Marco Valgimigli
Drugs 2017 2017 Oct;77(16):1733-1754  (Impact Factor: 5.000)
 
Chapter 1.1
Dual Antiplatelet Therapy Duration: Reconciling the 
Inconsistencies
Francesco Costa, Stephan Windecker, Marco Valgimigli
Drugs 2017 2017 Oct;77(16):1733-1754  (Impact Factor: 5.000)
 
2928
REVIEW ARTICLE
Dual Antiplatelet Therapy Duration: Reconciling
the Inconsistencies
Francesco Costa1,2 • Stephan Windecker3 • Marco Valgimigli2,3
 Springer International Publishing AG 2017
Abstract Dual antiplatelet therapy (DAPT) prevents
recurrent ischemic events after an acute coronary syndrome
(ACS) as well as stent thrombosis (ST) in patients with
prior stent implantation. Nevertheless, these beneﬁts are
counterbalanced by a signiﬁcant bleeding hazard, which is
directly related to the treatment duration. Although DAPT
has been extensively studied in numerous clinical trials,
optimal treatment duration is still debated, mostly because
of apparent inconsistencies among studies. Shortened
treatment duration of 6 or 3 months was shown to mitigate
bleeding risk compared with consensus-grounded
12-month standard duration, without any apparent excess
of ischemic events. However, recent trials showed that a
[12-month course of treatment reduces ischemic events
but increases bleeding compared with 12 months. The
inconsistent beneﬁt of a longer DAPT course compared
with shorter treatment durations is puzzling, and requires a
careful appraisal of between-studies differences. We
sought to summarize the existing evidence aiming at rec-
onciling apparent inconsistencies among these studies, as
well as thoroughly discuss the possible increased risk of
fatal events associated with long-term DAPT. Beneﬁts and
risks of prolonging or shortening DAPT duration will be
discussed, with a focus on treatment individualization.
Finally, we will provide an outlook for possible future
directions in the ﬁeld.
Key Points
Dual antiplatelet therapy is the cornerstone treatment
for secondary prevention of ischemic events after
acute coronary syndrome and stent implantation.
Despite apparent inconsistencies among major
clinical trials, a prolonged course with dual
antiplatelet therapy reduces ischemia but increase
bleeding to a similar extent.
In order to maximize treatment beneﬁts over risks,
dual antiplatelet therapy duration should be
individualized on a patient-by-patient basis.
1 Introduction
Dual antiplatelet therapy (DAPT) in the form of aspirin
plus a P2Y12 inhibitor is one of the most commonly pre-
scribed treatments in cardiovascular medicine. For patients
with coronary artery disease (CAD), DAPT is of para-
mount importance for secondary prevention after an acute
coronary syndrome (ACS) and for preventing stent
thrombosis in patients with previous stent implantation.
Twenty years have passed since the ﬁrst clinical trial
testing a DAPT strategy after percutaneous coronary
intervention (PCI) [1]. Thereafter, DAPT has been inten-
sively investigated in more than 35 randomized clinical
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trials, which lead to a continuous reﬁnement of treatment
strategies and clinical guidelines [2–10]. The optimal
duration of DAPT after coronary stent implantation has
also varied during the past two decades [1, 11–15]. After an
initial phase in which 1–6 months’ DAPT was recom-
mended after stent implantation [1, 11, 13, 15], the evi-
dence of a higher thrombotic milieu with ﬁrst-generation
drug-eluting stents (DES) in 2006 abruptly shifted towards
a more conservative position [16–18], with guidelines
recommending, based on consensus, at least 12 months of
DAPT [19]. In the following 8 years, the introduction of
safer stent platforms [20–23], and further evidence from six
randomized clinical trials supporting shorter DAPT courses
with second-generation DES, moved the recommended
therapy duration back to 6–12 months [6, 24]. However, in
2014 and 2015, two large clinical trials again challenged
this position by showing a signiﬁcant reduction of non-fatal
ischemic events when prolonging treatment beyond 1 year
[5, 25]. This beneﬁt came at the cost of a signiﬁcant
increase in severe bleeding [5, 25]. Whether this novel
evidence represents a new paradigm shift is debated. The
clinical community expressed concerns over the repro-
ducibility of such beneﬁts in clinical practice and voiced a
stance from guidelines [26]. The main challenge in inter-
preting current evidence arises from the difﬁculties in
understanding the reason for the inconsistent results across
studies, in terms of beneﬁt of prolonged DAPT in some
studies but lack thereof in others. In fact, clinical trials
testing 3 or 6 months versus 12 months’ DAPT showed no
difference in ischemic events [3, 27–33], with improved
safety after short-term DAPT, whereas 30 months or
longer DAPT duration signiﬁcantly reduced ischemic
events as compared with 12 months [3, 5]. The interpre-
tation of these results might appear puzzling, and one
burning clinical question remains open: what is the ‘sweet
spot’ of DAPT duration that maximizes the beneﬁts and the
risks of the treatment? Should DAPT duration be adapted
on a patient-by-patient basis? And if so, which patient
subgroup would beneﬁt more from a longer treatment
course?
In this review we will try to reconcile 20 years of
apparently contrasting evidence regarding DAPT duration
and to provide an outlook for future directions in the ﬁeld.
2 Optimal Duration of Dual Antiplatelet Therapy
(DAPT)—State of the Art
In total, 14 randomized controlled trials (RCTs) have tested
different DAPT duration strategies in patients receiving
coronary stent implantation (Table 1). These trials can be
grouped based on three research questions:
Q1: Is a \12-month DAPT similarly effective as a
12-month DAPT regimen?
Q2: Is a[12-month DAPT similarly or more effective
than 6-month DAPT regimen?
Q3: Is a [12-month DAPT more effective than a
12-month DAPT regimen?
2.1 Studies of <12 Months’ DAPT Versus
12 Months’ DAPT
A shorter (i.e., 3–6 months) DAPT course after coronary
stent implantation has been compared with the standard of
care (i.e., 12 months) in seven RCTs (Table 1) [27–33].
These studies tested the hypothesis that a shorter DAPT
regimen was non-inferior to the standard of care. Patients
were randomly allocated to DAPT duration at the time of
stent implantation in all but one trial [29].
The EXCELLENT (Efﬁcacy of Xience/Promus Versus
Cypher to Reduce Late Loss After Stenting) trial included
1443 patients treated with DES implantation and random-
ized to 6 versus 12 months’ DAPT thereafter [30]. Most
patients were treated with everolimus-eluting stents and
roughly half presented with ACS, but only a minority
(&3%) with ST-segment elevated myocardial infarction
(STEMI). Three-vessel disease was present in 20%, long
lesion (i.e., [20 mm) in 40% and the vast majority of
patients included were treated for a single lesion, overall
determining a low-to-moderate PCI complexity. The rate of
the primary endpoint, a composite of cardiac death,
myocardial infarction (MI), or ischemia-driven target ves-
sel revascularization at 12 months, was 4.8% in the
6-month DAPT group and 4.3% in the 12-month DAPT
group (p\ 0.001 for non-inferiority with a predeﬁned non-
inferiority margin of 4.0%). The rate of the safety endpoint,
a composite of thrombosis in myocardial infarction (TIMI)
major and minor bleeding, trended higher in the 12-month
DAPT group but the difference was not statistically sig-
niﬁcant (0.6 vs 1.4%; hazard ratio [HR] 0.40; 95% CI
0.13–1.27; p = 0.12) [30].
The SECURITY (Second-Generation Drug-Eluting
Stent Implantation Followed by Six- Versus Twelve-Month
Dual Antiplatelet Therapy) trial randomized 1399 patients
at the time of PCI to 6 or 12 months’ DAPT after DES
implantation [31]. All patients were treated with second-
generation DES. Only 38% of patients presented with ACS,
patients with STEMI were not included, and overall PCI
complexity was low. The net clinical beneﬁt endpoint, a
composite of cardiac death, MI, stroke, deﬁnite or probable
stent thrombosis, or BARC (Bleeding Academic Research
Consortium) type 3 or 5 bleeding at 12 months, was 4.5%
in the 6-month DAPT group and 3.7% in the 12-month
DAPT group (p\ 0.05 for noninferiority with a predeﬁned
F. Costa et al.
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1
trials, which lead to a continuous reﬁnement of treatment
strategies and clinical guidelines [2–10]. The optimal
duration of DAPT after coronary stent implantation has
also varied during the past two decades [1, 11–15]. After an
initial phase in which 1–6 months’ DAPT was recom-
mended after stent implantation [1, 11, 13, 15], the evi-
dence of a higher thrombotic milieu with ﬁrst-generation
drug-eluting stents (DES) in 2006 abruptly shifted towards
a more conservative position [16–18], with guidelines
recommending, based on consensus, at least 12 months of
DAPT [19]. In the following 8 years, the introduction of
safer stent platforms [20–23], and further evidence from six
randomized clinical trials supporting shorter DAPT courses
with second-generation DES, moved the recommended
therapy duration back to 6–12 months [6, 24]. However, in
2014 and 2015, two large clinical trials again challenged
this position by showing a signiﬁcant reduction of non-fatal
ischemic events when prolonging treatment beyond 1 year
[5, 25]. This beneﬁt came at the cost of a signiﬁcant
increase in severe bleeding [5, 25]. Whether this novel
evidence represents a new paradigm shift is debated. The
clinical community expressed concerns over the repro-
ducibility of such beneﬁts in clinical practice and voiced a
stance from guidelines [26]. The main challenge in inter-
preting current evidence arises from the difﬁculties in
understanding the reason for the inconsistent results across
studies, in terms of beneﬁt of prolonged DAPT in some
studies but lack thereof in others. In fact, clinical trials
testing 3 or 6 months versus 12 months’ DAPT showed no
difference in ischemic events [3, 27–33], with improved
safety after short-term DAPT, whereas 30 months or
longer DAPT duration signiﬁcantly reduced ischemic
events as compared with 12 months [3, 5]. The interpre-
tation of these results might appear puzzling, and one
burning clinical question remains open: what is the ‘sweet
spot’ of DAPT duration that maximizes the beneﬁts and the
risks of the treatment? Should DAPT duration be adapted
on a patient-by-patient basis? And if so, which patient
subgroup would beneﬁt more from a longer treatment
course?
In this review we will try to reconcile 20 years of
apparently contrasting evidence regarding DAPT duration
and to provide an outlook for future directions in the ﬁeld.
2 Optimal Duration of Dual Antiplatelet Therapy
(DAPT)—State of the Art
In total, 14 randomized controlled trials (RCTs) have tested
different DAPT duration strategies in patients receiving
coronary stent implantation (Table 1). These trials can be
grouped based on three research questions:
Q1: Is a \12-month DAPT similarly effective as a
12-month DAPT regimen?
Q2: Is a[12-month DAPT similarly or more effective
than 6-month DAPT regimen?
Q3: Is a [12-month DAPT more effective than a
12-month DAPT regimen?
2.1 Studies of <12 Months’ DAPT Versus
12 Months’ DAPT
A shorter (i.e., 3–6 months) DAPT course after coronary
stent implantation has been compared with the standard of
care (i.e., 12 months) in seven RCTs (Table 1) [27–33].
These studies tested the hypothesis that a shorter DAPT
regimen was non-inferior to the standard of care. Patients
were randomly allocated to DAPT duration at the time of
stent implantation in all but one trial [29].
The EXCELLENT (Efﬁcacy of Xience/Promus Versus
Cypher to Reduce Late Loss After Stenting) trial included
1443 patients treated with DES implantation and random-
ized to 6 versus 12 months’ DAPT thereafter [30]. Most
patients were treated with everolimus-eluting stents and
roughly half presented with ACS, but only a minority
(&3%) with ST-segment elevated myocardial infarction
(STEMI). Three-vessel disease was present in 20%, long
lesion (i.e., [20 mm) in 40% and the vast majority of
patients included were treated for a single lesion, overall
determining a low-to-moderate PCI complexity. The rate of
the primary endpoint, a composite of cardiac death,
myocardial infarction (MI), or ischemia-driven target ves-
sel revascularization at 12 months, was 4.8% in the
6-month DAPT group and 4.3% in the 12-month DAPT
group (p\ 0.001 for non-inferiority with a predeﬁned non-
inferiority margin of 4.0%). The rate of the safety endpoint,
a composite of thrombosis in myocardial infarction (TIMI)
major and minor bleeding, trended higher in the 12-month
DAPT group but the difference was not statistically sig-
niﬁcant (0.6 vs 1.4%; hazard ratio [HR] 0.40; 95% CI
0.13–1.27; p = 0.12) [30].
The SECURITY (Second-Generation Drug-Eluting
Stent Implantation Followed by Six- Versus Twelve-Month
Dual Antiplatelet Therapy) trial randomized 1399 patients
at the time of PCI to 6 or 12 months’ DAPT after DES
implantation [31]. All patients were treated with second-
generation DES. Only 38% of patients presented with ACS,
patients with STEMI were not included, and overall PCI
complexity was low. The net clinical beneﬁt endpoint, a
composite of cardiac death, MI, stroke, deﬁnite or probable
stent thrombosis, or BARC (Bleeding Academic Research
Consortium) type 3 or 5 bleeding at 12 months, was 4.5%
in the 6-month DAPT group and 3.7% in the 12-month
DAPT group (p\ 0.05 for noninferiority with a predeﬁned
F. Costa et al.
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noninferiority margin of 2.0%). Only 12 cases of major
bleeding were observed, with no statistically signiﬁcant
difference in the two arms [31].
The ISAR-SAFE (Intracoronary Stenting and
Antithrombotic Regimen: Safety and Efﬁcacy of 6 Months’
Dual Antiplatelet Therapy After Drug-Eluting Stenting)
trial randomized 4000 patients 6 months after PCI with
DES implantation to DAPT interruption or continuation up
to 12 months [29]. The study was terminated earlier due to
slow enrollment before reaching the planned level of 6000
patients, but still appeared to reach the non-inferiority
hypothesis. Almost half of enrolled patients presented with
ACS, and 10% with STEMI. Three-vessel disease was
present in 30%, 63% of patients were treated for a single
lesion, and median overall stent length was 28 mm. The
primary endpoint, a composite of death, MI, stent throm-
bosis, stroke, or TIMI major bleeding occurred in 1.5% of
patients treated with DAPT for 6 months and in 1.6% of
those treated for 12 months (p\ 0.001 for noninferiority
with a predeﬁned noninferiority margin of 2.0%). TIMI
major bleeding was rare, and similar in the two study arms
[29].
More recently, the I-LOVE-IT 2 (Evaluate Safety and
Effectiveness of the Tivoli DES and the Firebird DES for
Treatment of Coronary Revascularization) trial randomized
1829 patients across 32 centers in China to 6 or 12 months’
DAPT [32]. According to the factorial 2:2 design of the
study, patients were also randomized to stent type,
receiving a balanced mixture of durable-polymer or
bioresorabable-polymer cobalt-chromium sirolimus-eluting
stents. The majority of enrolled patients presented with
ACS (82%), 58% with unstable angina and 13% with
STEMI. Three-vessel disease was rare (\2%), and median
SYNTAX score at baseline was 11–12. However, the
median stent length per patient was 40 mm, with more than
25% of patients receiving a stent length[60 mm. The rate
of the primary endpoint, a composite of cardiac death, MI
and target lesion revascularization, was 6.8% in the
6-month DAPT group and 5.9% in the 12-month DAPT
group (p\ 0.05 for non-inferiority with a predeﬁned non-
inferiority margin of 3.7%). The rate of major bleeding was
similar in the two groups (1.2 vs 0.7%; p = 0.21) [32].
Similarly, the IVUS-XPL (Impact of Intravascular
Ultrasound Guidance on Outcomes of XIENCE PRIME
Stents in Long Lesions) study, used a factorial 2:2 design
randomizing 1400 patients to an intravascular ultrasound
guided procedure or standard of care and to 6 or
12 months’ DAPT [33]. The study sample size was cal-
culated primarily to test the superiority of intravascular
ultrasound guidance versus angiographic guidance and not
DAPT duration. Almost all patients included in the study
presented either with stable coronary artery disease
(SCAD) or with unstable angina. A second-generationT
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Chapter 1.1
everolimus-eluting stent was used in all patients. Three-
vessel disease was present in 31%, and median overall stent
length was 47 mm. Due to the design of the study, which
speciﬁcally included patients with long coronary lesions,
the overall PCI complexity in the study was at least mod-
erate. At 12-months’ follow-up, the composite of cardiac
death, MI, stroke, and TIMI major bleeding was similar
between patients treated for 6 months or 12 months (2.2 vs
2.1%; p = 0.85). Interestingly, at the subgroup analysis for
the primary endpoint, patients randomly allocated to the
intravascular ultrasound (IVUS) guided stent implantation
beneﬁted signiﬁcantly more from a shorter DAPT treat-
ment compared with those treated with angiographic
guidance alone (Pint = 0.018), in line with the hypothesis
that an optimized stent implantation with IVUS guidance in
patients with long lesions might reduce the burden of
device-related complications and the need for a longer
DAPT treatment [33].
Two additional studies tested an even shorter DAPT
duration, as short as 3 months after endeavor zotarolimus-
eluting stent (E-ZES) implantation [27, 28]. The RESET
(Real Safety and Efﬁcacy of 3-Month Dual Antiplatelet
Therapy Following Endeavor ZES Implantation) trial ran-
domized 2117 patients to standard-of-care treatment with
DES plus 12 months’ DAPT or to a strategy including
E-ZES implantation plus 3 months’ DAPT [28]. Overall
the study population was at low risk, with patients almost
exclusively with either SCAD or unstable angina.
Three-vessel disease was present in 15%, the median
stent length was 24 mm and the vast majority of patients
included were treated for a single lesion. This determined
an overall low PCI complexity. A strategy of E-ZES plus
3 months’ DAPT was non-inferior to the standard of care
of DES plus 12 months’ DAPT (4.7 vs 4.7%; p\ 0.001 for
non-inferiority) for the net clinical beneﬁt primary end-
point [28]. Similarly, the OPTIMIZE (Optimized Duration
of Clopidogrel Therapy Following Treatment with the
Zotarolimus-Eluting Stent in Real-World Clinical Practice)
trial tested the non-inferiority of 3 months compared with
12 months’ DAPT in 3119 patients systematically treated
with E-ZES [27]. The population included in the OPTI-
MIZE study was largely stable, with only 5% of patients
enrolled with non-ST segment elevated MI, whereas
patients with STEMI were not included. More than 80% of
patients had a single lesion, with a median lesion length of
18 mm. Again, in this speciﬁc patient population, a strat-
egy of 3-month DAPT was non-inferior to 12 months’
treatment (6.0 vs 5.8%; p = 0.002 for non-inferiority) with
respect to the net clinical beneﬁt primary endpoint (i.e.,
death, MI, stroke and major bleeding) [27].
While it was claimed that a very short DAPT regimen
consisting of 1-month DAPT sufﬁces after DES based on
two RCTs testing 1-month DAPT after bare-metal stent
(BMS) or second-generation DES [34–36], it should be
emphasized that no single DAPT study has so far tested
1-month DAPT versus a longer DAPT regimen. This study
is ongoing (ClinicalTrials.gov: NCT03023020) and will
inform the community on the beneﬁts and risks of such a
short-term DAPT regimen after contemporary DES
implantation in high bleeding risk patients.
2.2 Studies of 6-Month Versus >12-Month DAPT
Three RCTs compared 6 months’ treatment with
[12 months’ treatment (Table 1) [4, 37, 38].
The PRODIGY (PROlonging Dual antIplatelet treat-
ment after Grading stent-induced intimal hYperplasia
study) trial used a 4:2 factorial design to randomly allocate
2013 all-comer PCI patients to treatment with four coro-
nary stents (i.e., BMS, paclitaxel-eluting stent, E-ZES,
everolimus-eluting stent) and two DAPT duration strate-
gies (6 vs 24 months’ DAPT) [4]. The overall complexity
of the PRODIGY population was high, with three-quarters
of patients presenting with ACS, a mean age of&68 years,
&66% with multivessel disease, and &40 mm of overall
implanted stent length. At 24 months’ follow-up, there was
no difference in the primary efﬁcacy endpoint of death, MI,
and stroke between 6 and 24 months’ DAPT, while there
was an excess of bleeding in patients in the longer DAPT
duration arm [4].
Similarly, the ITALIC (6- Versus 24-Month Dual
Antiplatelet Therapy After Implantation of Drug-Eluting
Stent in Patients Nonresistant to Aspirin) study was
designed to test the non-inferiority of 6 versus 24 months’
DAPT [37]. The trial was stopped early after 80% of the
initially planned sample size. All patients were treated with
second-generation everolimus-eluting stents. Only a quar-
ter presented with ACS at the time of stent implantation. At
the end of follow-up the event rate for the primary endpoint
was low, with little differences between the two study
arms, and the trial appeared to meet its non-inferiority
hypothesis [37].
Recently, the NIPPON (NoborI dual antiplatelet therapy
as aPPrOpriate DuratioN) trial tested the non-inferiority of
a 6- versus 18-month randomized DAPT duration among
3775 patients treated with bioabsorbable polymer DES in
Japan [38, 39]. At 18 months’ follow-up, the rate of the
primary endpoint of all-cause death, MI, cerebrovascular
accident (CVA), and major bleeding was similar between
the two study arms (1.45% for 18 months’ DAPT vs 1.92%
for 6 months’ DAPT), meeting the prespeciﬁed non-infe-
riority margin. However, the results from this study should
be interpreted with caution due to the early study termi-
nation and the wide non-inferiority margin selected (i.e.,
2%), which exceeded the event rate of the experimental
arm [38, 39].
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noninferiority margin of 2.0%). Only 12 cases of major
bleeding were observed, with no statistically signiﬁcant
difference in the two arms [31].
The ISAR-SAFE (Intracoronary Stenting and
Antithrombotic Regimen: Safety and Efﬁcacy of 6 Months’
Dual Antiplatelet Therapy After Drug-Eluting Stenting)
trial randomized 4000 patients 6 months after PCI with
DES implantation to DAPT interruption or continuation up
to 12 months [29]. The study was terminated earlier due to
slow enrollment before reaching the planned level of 6000
patients, but still appeared to reach the non-inferiority
hypothesis. Almost half of enrolled patients presented with
ACS, and 10% with STEMI. Three-vessel disease was
present in 30%, 63% of patients were treated for a single
lesion, and median overall stent length was 28 mm. The
primary endpoint, a composite of death, MI, stent throm-
bosis, stroke, or TIMI major bleeding occurred in 1.5% of
patients treated with DAPT for 6 months and in 1.6% of
those treated for 12 months (p\ 0.001 for noninferiority
with a predeﬁned noninferiority margin of 2.0%). TIMI
major bleeding was rare, and similar in the two study arms
[29].
More recently, the I-LOVE-IT 2 (Evaluate Safety and
Effectiveness of the Tivoli DES and the Firebird DES for
Treatment of Coronary Revascularization) trial randomized
1829 patients across 32 centers in China to 6 or 12 months’
DAPT [32]. According to the factorial 2:2 design of the
study, patients were also randomized to stent type,
receiving a balanced mixture of durable-polymer or
bioresorabable-polymer cobalt-chromium sirolimus-eluting
stents. The majority of enrolled patients presented with
ACS (82%), 58% with unstable angina and 13% with
STEMI. Three-vessel disease was rare (\2%), and median
SYNTAX score at baseline was 11–12. However, the
median stent length per patient was 40 mm, with more than
25% of patients receiving a stent length[60 mm. The rate
of the primary endpoint, a composite of cardiac death, MI
and target lesion revascularization, was 6.8% in the
6-month DAPT group and 5.9% in the 12-month DAPT
group (p\ 0.05 for non-inferiority with a predeﬁned non-
inferiority margin of 3.7%). The rate of major bleeding was
similar in the two groups (1.2 vs 0.7%; p = 0.21) [32].
Similarly, the IVUS-XPL (Impact of Intravascular
Ultrasound Guidance on Outcomes of XIENCE PRIME
Stents in Long Lesions) study, used a factorial 2:2 design
randomizing 1400 patients to an intravascular ultrasound
guided procedure or standard of care and to 6 or
12 months’ DAPT [33]. The study sample size was cal-
culated primarily to test the superiority of intravascular
ultrasound guidance versus angiographic guidance and not
DAPT duration. Almost all patients included in the study
presented either with stable coronary artery disease
(SCAD) or with unstable angina. A second-generationT
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everolimus-eluting stent was used in all patients. Three-
vessel disease was present in 31%, and median overall stent
length was 47 mm. Due to the design of the study, which
speciﬁcally included patients with long coronary lesions,
the overall PCI complexity in the study was at least mod-
erate. At 12-months’ follow-up, the composite of cardiac
death, MI, stroke, and TIMI major bleeding was similar
between patients treated for 6 months or 12 months (2.2 vs
2.1%; p = 0.85). Interestingly, at the subgroup analysis for
the primary endpoint, patients randomly allocated to the
intravascular ultrasound (IVUS) guided stent implantation
beneﬁted signiﬁcantly more from a shorter DAPT treat-
ment compared with those treated with angiographic
guidance alone (Pint = 0.018), in line with the hypothesis
that an optimized stent implantation with IVUS guidance in
patients with long lesions might reduce the burden of
device-related complications and the need for a longer
DAPT treatment [33].
Two additional studies tested an even shorter DAPT
duration, as short as 3 months after endeavor zotarolimus-
eluting stent (E-ZES) implantation [27, 28]. The RESET
(Real Safety and Efﬁcacy of 3-Month Dual Antiplatelet
Therapy Following Endeavor ZES Implantation) trial ran-
domized 2117 patients to standard-of-care treatment with
DES plus 12 months’ DAPT or to a strategy including
E-ZES implantation plus 3 months’ DAPT [28]. Overall
the study population was at low risk, with patients almost
exclusively with either SCAD or unstable angina.
Three-vessel disease was present in 15%, the median
stent length was 24 mm and the vast majority of patients
included were treated for a single lesion. This determined
an overall low PCI complexity. A strategy of E-ZES plus
3 months’ DAPT was non-inferior to the standard of care
of DES plus 12 months’ DAPT (4.7 vs 4.7%; p\ 0.001 for
non-inferiority) for the net clinical beneﬁt primary end-
point [28]. Similarly, the OPTIMIZE (Optimized Duration
of Clopidogrel Therapy Following Treatment with the
Zotarolimus-Eluting Stent in Real-World Clinical Practice)
trial tested the non-inferiority of 3 months compared with
12 months’ DAPT in 3119 patients systematically treated
with E-ZES [27]. The population included in the OPTI-
MIZE study was largely stable, with only 5% of patients
enrolled with non-ST segment elevated MI, whereas
patients with STEMI were not included. More than 80% of
patients had a single lesion, with a median lesion length of
18 mm. Again, in this speciﬁc patient population, a strat-
egy of 3-month DAPT was non-inferior to 12 months’
treatment (6.0 vs 5.8%; p = 0.002 for non-inferiority) with
respect to the net clinical beneﬁt primary endpoint (i.e.,
death, MI, stroke and major bleeding) [27].
While it was claimed that a very short DAPT regimen
consisting of 1-month DAPT sufﬁces after DES based on
two RCTs testing 1-month DAPT after bare-metal stent
(BMS) or second-generation DES [34–36], it should be
emphasized that no single DAPT study has so far tested
1-month DAPT versus a longer DAPT regimen. This study
is ongoing (ClinicalTrials.gov: NCT03023020) and will
inform the community on the beneﬁts and risks of such a
short-term DAPT regimen after contemporary DES
implantation in high bleeding risk patients.
2.2 Studies of 6-Month Versus >12-Month DAPT
Three RCTs compared 6 months’ treatment with
[12 months’ treatment (Table 1) [4, 37, 38].
The PRODIGY (PROlonging Dual antIplatelet treat-
ment after Grading stent-induced intimal hYperplasia
study) trial used a 4:2 factorial design to randomly allocate
2013 all-comer PCI patients to treatment with four coro-
nary stents (i.e., BMS, paclitaxel-eluting stent, E-ZES,
everolimus-eluting stent) and two DAPT duration strate-
gies (6 vs 24 months’ DAPT) [4]. The overall complexity
of the PRODIGY population was high, with three-quarters
of patients presenting with ACS, a mean age of&68 years,
&66% with multivessel disease, and &40 mm of overall
implanted stent length. At 24 months’ follow-up, there was
no difference in the primary efﬁcacy endpoint of death, MI,
and stroke between 6 and 24 months’ DAPT, while there
was an excess of bleeding in patients in the longer DAPT
duration arm [4].
Similarly, the ITALIC (6- Versus 24-Month Dual
Antiplatelet Therapy After Implantation of Drug-Eluting
Stent in Patients Nonresistant to Aspirin) study was
designed to test the non-inferiority of 6 versus 24 months’
DAPT [37]. The trial was stopped early after 80% of the
initially planned sample size. All patients were treated with
second-generation everolimus-eluting stents. Only a quar-
ter presented with ACS at the time of stent implantation. At
the end of follow-up the event rate for the primary endpoint
was low, with little differences between the two study
arms, and the trial appeared to meet its non-inferiority
hypothesis [37].
Recently, the NIPPON (NoborI dual antiplatelet therapy
as aPPrOpriate DuratioN) trial tested the non-inferiority of
a 6- versus 18-month randomized DAPT duration among
3775 patients treated with bioabsorbable polymer DES in
Japan [38, 39]. At 18 months’ follow-up, the rate of the
primary endpoint of all-cause death, MI, cerebrovascular
accident (CVA), and major bleeding was similar between
the two study arms (1.45% for 18 months’ DAPT vs 1.92%
for 6 months’ DAPT), meeting the prespeciﬁed non-infe-
riority margin. However, the results from this study should
be interpreted with caution due to the early study termi-
nation and the wide non-inferiority margin selected (i.e.,
2%), which exceeded the event rate of the experimental
arm [38, 39].
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2.3 Studies of 12-Month Versus >12-Month DAPT
Four RCTs compared the standard 12 months’ DAPT with
a prolonged treatment beyond 12 months, and ranging
from 18 to 48 months (Table 1) [5, 40–42]. In general, this
group of studies tested the hypothesis that a prolonged
DAPT duration was superior to the standard treatment with
respect to very late stent thrombosis and other ischemic
events.
In the ARCTIC INTERRUPTION (Dual-Antiplatelet
Treatment Beyond 1 Year After Drug-Eluting Stent
Implantation) trial [40], which was an extension of the
ARCTIC study of bedside platelet function monitoring to
adjust antiplatelet therapy [43], the primary study hypoth-
esis was the superiority of C18-month DAPT duration
compared with the standard 12-month period after stent
implantation [40]. The study included a highly selected
patient population, comprising only patients undergoing
elective stenting. Ultimately, the primary efﬁcacy endpoint
was identical between the two study arms (4% for both
treatments), with a signiﬁcant excess of major or minor
bleeding in the prolonged DAPT arm [40].
The DES LATE (Optimal Duration of Clopidogrel
Therapy With DES to Reduce Late Coronary Arterial
Thrombotic Events) trial conglobated the extended follow-
up of 2701 patients from the REAL-LATE and ZEST-
LATE trials, with an additional cohort of 2344 patients
[42]. All patients free from adverse events after DES
implantation and an initial phase of 12 months’ DAPT
were included. In DES LATE, 80% of patients received
ﬁrst-generation DES. The primary endpoint of cardiac
death, MI, or stroke was similar in the two study arms,
occurring in 2.6% of patients in the prolonged DAPT and
2.4% in the standard DAPT group [42].
In the DAPT (Dual Antiplatelet Therapy) study, 22,866
patients treated with DES implantation were screened for
inclusion and received an initial 12 months’ DAPT with
aspirin and thienopyridines (i.e., clopidogrel or prasugrel)
during the study run-in phase [5]. At 12 months, 9961
patients had no further ischemic and bleeding events, were
compliant to the prescribed treatment, and were random-
ized to continue DAPT for up to 30 months or discontinue
the treatment while continuing aspirin monotherapy.
Roughly 50% of patients included were initially treated for
an ACS, and importantly, &38% received a ﬁrst-genera-
tion DES. In the DAPT study population, extended DAPT
resulted in a 1% absolute reduction in very late stent
thrombosis, a 1.6% absolute reduction of major adverse
cardiovascular and cerebrovascular events (MACCE), dri-
ven by a 2% reduction of MI. However, bleeding was
increased to a similar extent, with a 0.9% absolute increase
in moderate or severe GUSTO (Global Utilization of
Streptokinase and t-PA for Occluded Coronary Arteries)
bleeding and 2.6% increase in BARC 2, 3, or 5 bleeding.
All-cause mortality at 33 months’ follow-up was higher
among patients randomized to an extended DAPT treat-
ment [5]. A signal towards an increase in all-cause death
after DAPT prolongation beyond 1 year was inconsistent in
several meta-analyses [3, 44, 45]. In a separate analysis of
the DAPT trial restricted to the subgroup of patients treated
with contemporary everolimus-eluting stents, extended
DAPT resulted in a 0.4% absolute reduction in stent
thrombosis, a 1.1% absolute reduction in MI, and a 1.2%
absolute increase in moderate/severe bleeding, with an
overall 1.1% absolute risk increase of all-cause death after
extended DAPT treatment [46]. The increased risk of death
appeared to some extent to be associated with cancer
fatalities [47], and although this signal was also observed in
other studies [48], the authors interpreted this ﬁnding as
due to chance in line with an internal revision from the
American Food and Drug Administration (FDA) [49].
More recently, the OPTIDUAL (Optimal Dual Anti-
platelet Therapy) trial tested the hypothesis that 48 months
of DAPT with clopidogrel was superior to 12 months of
DAPT after DES implantation [41]. The trial was stopped
prematurely after enrolling 1385 of 1966 planned patients.
Overall, a third of included patients received a DES during
an ACS, and a third received a ﬁrst-generation DES. The
study ultimately failed to show superiority of an extended
DAPT treatment, with a similar rate of the primary end-
point of death, MI, stroke, or major hemorrhage between
the two study arms (5.8 vs 7.5%; HR 0.75; 95% CI
0.50–1.28). A substantial equipoise for the safety endpoint
of moderate and severe GUSTO bleeding (1.9 vs 1.7%) and
BARC 2, 3, or 5 bleeding (2.6 vs 2.9%) was also shown
between the extended and the standard DAPT duration
arms [41].
2.4 Other Studies of DAPT Duration in Patients
with Prior Myocardial Infarction
Two RCTs included patients with high-risk or established
cardiovascular disease, randomized to DAPT or aspirin
monotherapy [25, 50].
The CHARISMA (Clopidogrel for High Atherothrom-
botic Risk and Ischemic Stabilization, Management, and
Avoidance) trial randomized 15,603 patients with multiple
atherothrombotic risk factors or a history of vascular dis-
ease to clopidogrel on top of aspirin, or aspirin
monotherapy [50]. The composite primary endpoint of
death, MI, or stroke at 28 months was similar in the two
study groups (6.8% in the DAPT group and 7.3% in the
aspirin monotherapy group; p = 0.22). In addition, no
signiﬁcant difference for major bleeding was noted in the
two study arms [50]. However, in a prespeciﬁed analysis of
the CHARISMA trial where only 12,153 patients with
F. Costa et al.
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established cardiovascular disease were considered, DAPT
was associated with a 1% absolute reduction of the primary
endpoint (6.9 vs 7.9%; RR 0.88; 95% CI 0.77–0.99;
p = 0.046) [51].
Similarly, the PEGASUS-TIMI 54 (Prevention of Car-
diovascular Events in Patients with Prior Heart Attack
Using Ticagrelor Compared to Placebo on a Background of
Aspirin—Thrombolysis in Myocardial Infarction 54) trial
was designed to test the effect of a dual antiplatelet treat-
ment with ticagrelor (90 mg twice daily [BID] or 60 mg
BID) on top of aspirin compared with aspirin monotherapy
in patients with high-risk features who previously had an
MI 1–3 years earlier [25]. After a mean of 33 months of
therapy, DAPT with aspirin and ticagrelor versus aspirin
monotherapy resulted in a 1.2–1.3% absolute reduction in
the primary composite endpoint of cardiovascular death,
MI, or stroke and a 1.2–1.5% absolute increase in major
bleeding, with no excess in fatal bleeding or intracranial
hemorrhage [25].
Results from these two trials suggest that DAPT extension
in patients with prior MI could be beneﬁcial, but patients’
selection is key in order to disentangle the ischemic beneﬁt
and the bleeding risk, which was indeed similar after longer
treatment. However, given the speciﬁc design of these two
studies, direct comparisonswith all the other aforementioned
DAPT duration trials are challenging. A signiﬁcant propor-
tion of patients included in these trials discontinued DAPT
for several months or years after the initial qualifying
ischemic event [52]. Hence, most patients restarted DAPT at
the time of study inclusion after being off-treatment with
DAPT. The presence of this time-gap between the initial
DAPT period mandated by the index ischemic event and the
reinitiation of therapy could be an important confounder,
mining the comparability with the other 14 DAPT duration
RCTs. Indeed, data suggest that the biggest beneﬁt from
extended DAPT duration derives from patients that do not
discontinue DAPT treatment [52]. In fact, in a pre-speciﬁed
subgroup analysis from the PEGASUS trial, patients who
discontinued DAPT for 1 year or longer and then reinitiated
DAPT did not derive any beneﬁt from the addition of tica-
grelor on top of aspirin [52].
2.5 Summary of the Available Evidence
Taken together, results from these diverse trials showed
• a reduction of major bleeding associated with shortened
(3–6 months) compared with 12-month DAPT dura-
tion, with no difference in ischemic events;
• reduction of ischemic events in study arms where
DAPT was prolonged to 30 months or more compared
with 1-year therapy, with an associated increase of
major bleeding.
Hence, while a direct correlation between DAPT dura-
tion (longer) and bleeding risk (increased) was observed
across studies, a similar clear relationship was not found
for ischemic events. The beneﬁt of extending DAPT was
observed only in studies where [12-month DAPT was
compared with a shorter regimen, but not in those where
3–6 months’ therapy was contrasted with C1-year treat-
ment duration.
These apparently inconsistent results deserve a deeper
reading of between-trial differences. In addition, the
uncertainty regarding the net clinical beneﬁt of longer
DAPT treatment, which is based on the similar ﬁgures for
ischemic risk reduction and bleeding risk increase, con-
ﬁrms that the ‘one size ﬁts all’ theory should no longer be
pursued when selecting DAPT duration. Multiple subgroup
analyses from clinical trials have been proposed to inform
DAPT decision making, and to ﬁnd speciﬁc patient subsets
in which the beneﬁts of prolonged/shortened DAPT dura-
tion were maximized over risks.
3 DAPT Duration in 2017—Outstanding
Questions, Apparent Inconsistencies and Future
Directions
3.1 Why are Study Results Not Consistent
with Respect to the Beneﬁt of Prolonged DAPT
for Non-Fatal Ischemic Endpoints?
It remains to be explained why the ischemic beneﬁt of
long-term DAPT is inconsistently observed across studies
and only in those where a[12-month DAPT is compared
with 1 year of treatment. These apparent inconsistencies
might be explained by taking into account several factors.
3.1.1 Study Power
The DAPT study was the ﬁrst study powered to detect a
difference in hard clinical endpoints between standard
12-month DAPT and longer treatment duration up to
30 months, assuming an annual event rate in the short
DAPT group of 0.5% for stent thrombosis and 2.9% for
MACCE [5]. This study ultimately included 9961 patients,
with an event rate of 1.4% for deﬁnite or probable stent
thrombosis and 5.9% for MACCE in the short DAPT
group. The contrast between study arms in terms of dif-
ference in treatment duration between the two strategies
was 18 months, and 9499 patients reached the follow-up
time of 30 months. Hence, the standardized sample size
(i.e., number of patients included corrected by the actual
treatment difference between study arms) was 14,248
patient-years in the DAPT trial, which ultimately found a
statistically signiﬁcant beneﬁt from longer DAPT treatment
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2.3 Studies of 12-Month Versus >12-Month DAPT
Four RCTs compared the standard 12 months’ DAPT with
a prolonged treatment beyond 12 months, and ranging
from 18 to 48 months (Table 1) [5, 40–42]. In general, this
group of studies tested the hypothesis that a prolonged
DAPT duration was superior to the standard treatment with
respect to very late stent thrombosis and other ischemic
events.
In the ARCTIC INTERRUPTION (Dual-Antiplatelet
Treatment Beyond 1 Year After Drug-Eluting Stent
Implantation) trial [40], which was an extension of the
ARCTIC study of bedside platelet function monitoring to
adjust antiplatelet therapy [43], the primary study hypoth-
esis was the superiority of C18-month DAPT duration
compared with the standard 12-month period after stent
implantation [40]. The study included a highly selected
patient population, comprising only patients undergoing
elective stenting. Ultimately, the primary efﬁcacy endpoint
was identical between the two study arms (4% for both
treatments), with a signiﬁcant excess of major or minor
bleeding in the prolonged DAPT arm [40].
The DES LATE (Optimal Duration of Clopidogrel
Therapy With DES to Reduce Late Coronary Arterial
Thrombotic Events) trial conglobated the extended follow-
up of 2701 patients from the REAL-LATE and ZEST-
LATE trials, with an additional cohort of 2344 patients
[42]. All patients free from adverse events after DES
implantation and an initial phase of 12 months’ DAPT
were included. In DES LATE, 80% of patients received
ﬁrst-generation DES. The primary endpoint of cardiac
death, MI, or stroke was similar in the two study arms,
occurring in 2.6% of patients in the prolonged DAPT and
2.4% in the standard DAPT group [42].
In the DAPT (Dual Antiplatelet Therapy) study, 22,866
patients treated with DES implantation were screened for
inclusion and received an initial 12 months’ DAPT with
aspirin and thienopyridines (i.e., clopidogrel or prasugrel)
during the study run-in phase [5]. At 12 months, 9961
patients had no further ischemic and bleeding events, were
compliant to the prescribed treatment, and were random-
ized to continue DAPT for up to 30 months or discontinue
the treatment while continuing aspirin monotherapy.
Roughly 50% of patients included were initially treated for
an ACS, and importantly, &38% received a ﬁrst-genera-
tion DES. In the DAPT study population, extended DAPT
resulted in a 1% absolute reduction in very late stent
thrombosis, a 1.6% absolute reduction of major adverse
cardiovascular and cerebrovascular events (MACCE), dri-
ven by a 2% reduction of MI. However, bleeding was
increased to a similar extent, with a 0.9% absolute increase
in moderate or severe GUSTO (Global Utilization of
Streptokinase and t-PA for Occluded Coronary Arteries)
bleeding and 2.6% increase in BARC 2, 3, or 5 bleeding.
All-cause mortality at 33 months’ follow-up was higher
among patients randomized to an extended DAPT treat-
ment [5]. A signal towards an increase in all-cause death
after DAPT prolongation beyond 1 year was inconsistent in
several meta-analyses [3, 44, 45]. In a separate analysis of
the DAPT trial restricted to the subgroup of patients treated
with contemporary everolimus-eluting stents, extended
DAPT resulted in a 0.4% absolute reduction in stent
thrombosis, a 1.1% absolute reduction in MI, and a 1.2%
absolute increase in moderate/severe bleeding, with an
overall 1.1% absolute risk increase of all-cause death after
extended DAPT treatment [46]. The increased risk of death
appeared to some extent to be associated with cancer
fatalities [47], and although this signal was also observed in
other studies [48], the authors interpreted this ﬁnding as
due to chance in line with an internal revision from the
American Food and Drug Administration (FDA) [49].
More recently, the OPTIDUAL (Optimal Dual Anti-
platelet Therapy) trial tested the hypothesis that 48 months
of DAPT with clopidogrel was superior to 12 months of
DAPT after DES implantation [41]. The trial was stopped
prematurely after enrolling 1385 of 1966 planned patients.
Overall, a third of included patients received a DES during
an ACS, and a third received a ﬁrst-generation DES. The
study ultimately failed to show superiority of an extended
DAPT treatment, with a similar rate of the primary end-
point of death, MI, stroke, or major hemorrhage between
the two study arms (5.8 vs 7.5%; HR 0.75; 95% CI
0.50–1.28). A substantial equipoise for the safety endpoint
of moderate and severe GUSTO bleeding (1.9 vs 1.7%) and
BARC 2, 3, or 5 bleeding (2.6 vs 2.9%) was also shown
between the extended and the standard DAPT duration
arms [41].
2.4 Other Studies of DAPT Duration in Patients
with Prior Myocardial Infarction
Two RCTs included patients with high-risk or established
cardiovascular disease, randomized to DAPT or aspirin
monotherapy [25, 50].
The CHARISMA (Clopidogrel for High Atherothrom-
botic Risk and Ischemic Stabilization, Management, and
Avoidance) trial randomized 15,603 patients with multiple
atherothrombotic risk factors or a history of vascular dis-
ease to clopidogrel on top of aspirin, or aspirin
monotherapy [50]. The composite primary endpoint of
death, MI, or stroke at 28 months was similar in the two
study groups (6.8% in the DAPT group and 7.3% in the
aspirin monotherapy group; p = 0.22). In addition, no
signiﬁcant difference for major bleeding was noted in the
two study arms [50]. However, in a prespeciﬁed analysis of
the CHARISMA trial where only 12,153 patients with
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established cardiovascular disease were considered, DAPT
was associated with a 1% absolute reduction of the primary
endpoint (6.9 vs 7.9%; RR 0.88; 95% CI 0.77–0.99;
p = 0.046) [51].
Similarly, the PEGASUS-TIMI 54 (Prevention of Car-
diovascular Events in Patients with Prior Heart Attack
Using Ticagrelor Compared to Placebo on a Background of
Aspirin—Thrombolysis in Myocardial Infarction 54) trial
was designed to test the effect of a dual antiplatelet treat-
ment with ticagrelor (90 mg twice daily [BID] or 60 mg
BID) on top of aspirin compared with aspirin monotherapy
in patients with high-risk features who previously had an
MI 1–3 years earlier [25]. After a mean of 33 months of
therapy, DAPT with aspirin and ticagrelor versus aspirin
monotherapy resulted in a 1.2–1.3% absolute reduction in
the primary composite endpoint of cardiovascular death,
MI, or stroke and a 1.2–1.5% absolute increase in major
bleeding, with no excess in fatal bleeding or intracranial
hemorrhage [25].
Results from these two trials suggest that DAPT extension
in patients with prior MI could be beneﬁcial, but patients’
selection is key in order to disentangle the ischemic beneﬁt
and the bleeding risk, which was indeed similar after longer
treatment. However, given the speciﬁc design of these two
studies, direct comparisonswith all the other aforementioned
DAPT duration trials are challenging. A signiﬁcant propor-
tion of patients included in these trials discontinued DAPT
for several months or years after the initial qualifying
ischemic event [52]. Hence, most patients restarted DAPT at
the time of study inclusion after being off-treatment with
DAPT. The presence of this time-gap between the initial
DAPT period mandated by the index ischemic event and the
reinitiation of therapy could be an important confounder,
mining the comparability with the other 14 DAPT duration
RCTs. Indeed, data suggest that the biggest beneﬁt from
extended DAPT duration derives from patients that do not
discontinue DAPT treatment [52]. In fact, in a pre-speciﬁed
subgroup analysis from the PEGASUS trial, patients who
discontinued DAPT for 1 year or longer and then reinitiated
DAPT did not derive any beneﬁt from the addition of tica-
grelor on top of aspirin [52].
2.5 Summary of the Available Evidence
Taken together, results from these diverse trials showed
• a reduction of major bleeding associated with shortened
(3–6 months) compared with 12-month DAPT dura-
tion, with no difference in ischemic events;
• reduction of ischemic events in study arms where
DAPT was prolonged to 30 months or more compared
with 1-year therapy, with an associated increase of
major bleeding.
Hence, while a direct correlation between DAPT dura-
tion (longer) and bleeding risk (increased) was observed
across studies, a similar clear relationship was not found
for ischemic events. The beneﬁt of extending DAPT was
observed only in studies where [12-month DAPT was
compared with a shorter regimen, but not in those where
3–6 months’ therapy was contrasted with C1-year treat-
ment duration.
These apparently inconsistent results deserve a deeper
reading of between-trial differences. In addition, the
uncertainty regarding the net clinical beneﬁt of longer
DAPT treatment, which is based on the similar ﬁgures for
ischemic risk reduction and bleeding risk increase, con-
ﬁrms that the ‘one size ﬁts all’ theory should no longer be
pursued when selecting DAPT duration. Multiple subgroup
analyses from clinical trials have been proposed to inform
DAPT decision making, and to ﬁnd speciﬁc patient subsets
in which the beneﬁts of prolonged/shortened DAPT dura-
tion were maximized over risks.
3 DAPT Duration in 2017—Outstanding
Questions, Apparent Inconsistencies and Future
Directions
3.1 Why are Study Results Not Consistent
with Respect to the Beneﬁt of Prolonged DAPT
for Non-Fatal Ischemic Endpoints?
It remains to be explained why the ischemic beneﬁt of
long-term DAPT is inconsistently observed across studies
and only in those where a[12-month DAPT is compared
with 1 year of treatment. These apparent inconsistencies
might be explained by taking into account several factors.
3.1.1 Study Power
The DAPT study was the ﬁrst study powered to detect a
difference in hard clinical endpoints between standard
12-month DAPT and longer treatment duration up to
30 months, assuming an annual event rate in the short
DAPT group of 0.5% for stent thrombosis and 2.9% for
MACCE [5]. This study ultimately included 9961 patients,
with an event rate of 1.4% for deﬁnite or probable stent
thrombosis and 5.9% for MACCE in the short DAPT
group. The contrast between study arms in terms of dif-
ference in treatment duration between the two strategies
was 18 months, and 9499 patients reached the follow-up
time of 30 months. Hence, the standardized sample size
(i.e., number of patients included corrected by the actual
treatment difference between study arms) was 14,248
patient-years in the DAPT trial, which ultimately found a
statistically signiﬁcant beneﬁt from longer DAPT treatment
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[5]. Seven RCTs randomized patients to 6 versus
12 months’ DAPT. Taken together, these studies included
a total of 15,404 patients, with an event rate of 0.55% for
deﬁnite or probable stent thrombosis and 1.82% for MI in
the short treatment arm [45]. In fact, in this group of studies
the difference in treatment duration between the two tested
pharmacological strategies was only 6 months, accounting
for a total of 7702 patient-years of treatment. Moreover, the
observed risk of spontaneous MI or stent thrombosis (ST)
observed cumulatively in studies assessing DAPT duration
of\12 months was lower than that observed in the DAPT
study. As such, the apparent inconsistency of treatment
beneﬁt within the ﬁrst year might be related to a lack of
study power within trials testing DAPT treatment of
\12 months to detect a treatment effect, which is deﬁni-
tively smaller than what many had anticipated.
3.1.2 Stent Type
The type of implanted stent across DAPT studies is of
paramount importance to understand between-study dif-
ferences (Table 1). First-generation DES, as well as BMS,
are associated with a higher rate of device-related ischemic
complications compared with newer-generation DES
[23, 34, 53–57]. RCTs testing 12-month versus\12-month
DAPT duration implemented second-generation DES
exclusively, or in a vast majority of cases [27, 28, 31–33].
Contrariwise, studies testing 12-month versus[12-month
DAPT duration included a signiﬁcant proportion of patients
treated with ﬁrst-generation DES (raging from 34 to 64%
of included patients) (Table 1) [5, 42]. Interestingly, this
information is not available for the PEGASUS study [58].
In the PRODIGY trial, the type of stent implanted, which
was randomly allocated according to the 4:2 factorial study
design, was a treatment modiﬁer for DAPT duration with
respect to the primary endpoint (Pint = 0.004), and an
excess of deﬁnite or probable stent thrombosis was
observed among patients treated with ﬁrst-generation DES
allocated to a shorter DAPT treatment (HR 0.12; 95% CI
0.02–1.00; p = 0.049) [53]. Similarly, in the DAPT trial
the beneﬁt of longer DAPT (30 versus 12 months) was
inconsistent between implanted stent types (Pint = 0.048),
with a signiﬁcant reduction of MACCE from longer DAPT
only among patients treated with ﬁrst-generation DES
(absolute risk difference [ARD] for MACCE: sirolimus-
eluting stents ARD = –2.6%; paclitaxel-eluting stents
ARD = –3.9%) but not in those treated with second-gen-
eration DES [5].
Therefore, the trade-off between beneﬁts and risks of a
prolonged DAPT regimen may dramatically change based
on type of stent implanted at the time of intervention.
In the whole DAPT study, the number needed to treat
for beneﬁt (NNTB) in terms of ischemic events (deﬁnite or
probable stent thrombosis: ARD = 1%, NNTB = 100;
MI: ARD = 2%, NNTB = 50) and the number needed to
treat for harm (NNTH) to provoke a bleeding
(ARD = 0.9%, NNTH = 111) slightly favored a longer
DAPT strategy [5]. However, when the analysis is
restricted to the group of patients treated with contempo-
rary everolimus-eluting stents, the balance between ische-
mia and bleeding appears upturned, disfavoring longer
DAPT treatment in terms of NNTB in terms of ischemic
events (deﬁnite or probable stent thrombosis:
ARD = 0.5%, NNTB = 200; MI: ARD = 1.1%,
NNTB = 91) versus NNTH from bleeding (ARD = 1.2%,
NNTH = 83), with no beneﬁt from longer DAPT in terms
of the overall MACCE rate, and an excess of non-cardio-
vascular death [46].
Since ﬁrst-generation DES are no longer used in clinical
practice, interpretation of trials largely based on the use of
second-generation DES is critical in order to have a clearer
understanding of the trade-off between ischemia and
bleeding in contemporary practice [59].
In summary, current data suggests that the ischemic
beneﬁt of longer DAPT appears more evident among
patients treated with ﬁrst-generation DES, which are no
longer used in clinical practice. The ischemic beneﬁt
observed among patients treated with contemporary DES is
smaller, and might be outweighed by the bleeding hazard
of longer treatment duration if patients are not selected to
be at relatively higher ischemic but lower bleeding risk.
3.1.3 Patient Selection
Baseline and procedural characteristics might have an
important inﬂuence on the impact of DAPT duration
(Table 1). Intuitively, patients with a perceived higher
ischemic risk at baseline or undergoing more complex
procedures might derive a larger beneﬁt from longer or
more potent platelet inhibition [51, 60, 61]. Within DAPT
duration trials, the type of population included was
heterogeneous. The overall different risk proﬁle among
trials might be evaluated through three markers of risk:
age, type of clinical presentation, and PCI complexity. The
average age of patients enrolled in clinical trials for DAPT
duration was highly variable, and spanned from 60.2 years
in the I-LOVE-IT 2 trial to 67.9 years in the PRODIGY
trial (Fig. 1). Elderly patients are often underrepresented in
clinical trials, and a higher age denotes higher risk of
events [62]. A treatment-by-age heterogeneity was
observed for the primary endpoint in the ISAR-SAFE
(Pint = 0.03) and IVUS-XPL trial (Pint = 0.05), indicating
a signiﬁcant interaction between age and treatment dura-
tion (i.e., 6 vs 12 months’ DAPT) disfavoring longer
treatment duration in elderly patients (i.e., [65 years)
[29, 33]. In addition, a similar trend was shown in the
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PRODIGY trial, with longer treatment showing a less
favorable safety proﬁle for older than younger patients
[63].
The type of clinical presentation was also at variance
across DAPT duration trials (Table 1). ACS patients were
excluded from the ARCTIC interruption study, and only
few ACS patients were actually included in the ITALIC,
OPTIMIZE, SECURITY, and OPTIDUAL studies. STEMI
patients were enrolled in half of DAPT duration trials
(Table 1). Clinical presentation appeared as an important
treatment modiﬁer for DAPT duration in the DAPT trial,
with a higher beneﬁt for longer DAPT among patients
presenting with MI at the time of index PCI [64]. Patients
with prior MI were also associated with a signiﬁcant
reduction in cardiovascular mortality after longer DAPT in
a subsequent meta-analysis [65]. Contrariwise, stable pa-
tients appeared to derive a smaller beneﬁt from longer
DAPT, which is largely outweighed by the increase in
bleeding [66]. In the PRODIGY trial, bleeding events
occurred relatively more often after longer DAPT among
stable versus unstable patients at the time of presentation
[67]. This was associated with a better net clinical beneﬁt
proﬁle using shorter rather than long DAPT among
stable patients [67].
PCI complexity, although difﬁcult to categorize and
compare across trials, was also heterogeneous (Fig. 2). The
proportion of patients included with multivessel disease
ranged from 68.5% in the IVUS-XPL study to 25% in the
I-LOVE-IT 2 study [32, 33]. The mean number of lesions
treated per patient at the time of index PCI ranged from
1.27 to 1.55 (Fig. 2). The number of stents implanted
during the index procedure varied from 1.86 in the
PRODIGY trial to 1.27 in RESET [4, 28]. Also, the mean
overall stent length was variable, ranging from 47 mm in
the IVUS-XPL trial to 18 mm in the OPTIDUAL trial
(Fig. 2). A pooled data analysis from six RCTs demon-
strated a signiﬁcant beneﬁt from a standard 12-month
DAPT, compared with shorter treatment among patients
with complex PCI, deﬁned using six markers of risk (i.e.,
three coronary vessels treated, three or more stents
implanted, three or more lesions treated, bifurcation
stenting, overall stent length of[60 mm, revascularization
of a chronic total occlusion) [68]. Importantly, the mag-
nitude of the beneﬁt from longer DAPT was directly
related to the number of markers of complexity present, in
line with the hypothesis that the higher the complexity of
PCI, the higher the beneﬁt from longer DAPT [68].
3.1.4 Timing of Randomization
Study design and timing of randomization varied among
trials. Six trials included a run-in phase between stent
implantation and randomization to DAPT duration (Fig. 3).
During this initial period, patients experiencing a novel
ischemic or bleeding event were excluded from random-
ization in the study. Hence, the type of population ﬁnally
randomized in the study was at a relatively lower risk due
to the exclusion of those patients having suffered events
during the run-in phase. In this respect, it may be assumed
that the longer the observational/run-in phase, the greater
the degree of patient selection before entering the study. In
the DAPT trial, among 22,866 patients receiving a DES
and treated with DAPT during the run-in phase of the
study, less than half were ultimately randomized in the
study [5]. Similarly, in the ARCTIC interruption trial [40],
only half of the initial 2440 patients included in the bedside
platelet function testing phase of the trial [43] were without
contraindication to prolong DAPT and were ﬁnally enrol-
led in the DAPT duration study. Hence, clinicians should
be careful before drawing conclusions from these studies
and generalizing them to an all-comer, real-world
population.
3.2 In Which Patients Should We Prolong
and in Which Patients Should We Shorten
DAPT?
Multiple patient or procedural characteristics may be fac-
tored in when deciding upon DAPT duration (Fig. 4).
Important information has been provided by subgroup
analyses of DAPT duration trials [64, 66, 69, 70]. How-
ever, subgroup analysis from RCTs has to be considered
hypothesis generating, and should be interpreted with
caution, as it might be confounded by type I and/or II
errors. In addition, the interrelations between multiple
coexisting factors (e.g., clinical presentation and peripheral
artery disease) are complex and have never been studied.
3.2.1 Clinical Presentation
The type of clinical presentation (i.e., SCAD, unsta-
ble angina, non-STEMI, or STEMI) at the time of PCI is a
major determinant of a patient’s mortality risk, which
ranges between 0.36% in SCAD and 4.78% in high-risk
STEMI patients, or the risk for ischemic recurrences [71].
For this reason, a more potent (i.e., use of ticagrelor or
prasugrel vs clopidogrel) or prolonged regimen (i.e., 12 vs
6 months’ treatment) is advocated by international guide-
lines among patients presenting with ACS, but not those
with SCAD [6, 7]. In the PRODIGY trial, 1465 (74.3%)
patients presented with ACS and 505 (25.7%) with SCAD
[4]. No heterogeneity was noted with respect to the ran-
domized DAPT duration for the primary efﬁcacy endpoint
among patients presenting with ACS or SCAD. However,
there was a borderline quantitative interaction between
clinical presentations and bleeding outcomes (Pint = 0.056
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[5]. Seven RCTs randomized patients to 6 versus
12 months’ DAPT. Taken together, these studies included
a total of 15,404 patients, with an event rate of 0.55% for
deﬁnite or probable stent thrombosis and 1.82% for MI in
the short treatment arm [45]. In fact, in this group of studies
the difference in treatment duration between the two tested
pharmacological strategies was only 6 months, accounting
for a total of 7702 patient-years of treatment. Moreover, the
observed risk of spontaneous MI or stent thrombosis (ST)
observed cumulatively in studies assessing DAPT duration
of\12 months was lower than that observed in the DAPT
study. As such, the apparent inconsistency of treatment
beneﬁt within the ﬁrst year might be related to a lack of
study power within trials testing DAPT treatment of
\12 months to detect a treatment effect, which is deﬁni-
tively smaller than what many had anticipated.
3.1.2 Stent Type
The type of implanted stent across DAPT studies is of
paramount importance to understand between-study dif-
ferences (Table 1). First-generation DES, as well as BMS,
are associated with a higher rate of device-related ischemic
complications compared with newer-generation DES
[23, 34, 53–57]. RCTs testing 12-month versus\12-month
DAPT duration implemented second-generation DES
exclusively, or in a vast majority of cases [27, 28, 31–33].
Contrariwise, studies testing 12-month versus[12-month
DAPT duration included a signiﬁcant proportion of patients
treated with ﬁrst-generation DES (raging from 34 to 64%
of included patients) (Table 1) [5, 42]. Interestingly, this
information is not available for the PEGASUS study [58].
In the PRODIGY trial, the type of stent implanted, which
was randomly allocated according to the 4:2 factorial study
design, was a treatment modiﬁer for DAPT duration with
respect to the primary endpoint (Pint = 0.004), and an
excess of deﬁnite or probable stent thrombosis was
observed among patients treated with ﬁrst-generation DES
allocated to a shorter DAPT treatment (HR 0.12; 95% CI
0.02–1.00; p = 0.049) [53]. Similarly, in the DAPT trial
the beneﬁt of longer DAPT (30 versus 12 months) was
inconsistent between implanted stent types (Pint = 0.048),
with a signiﬁcant reduction of MACCE from longer DAPT
only among patients treated with ﬁrst-generation DES
(absolute risk difference [ARD] for MACCE: sirolimus-
eluting stents ARD = –2.6%; paclitaxel-eluting stents
ARD = –3.9%) but not in those treated with second-gen-
eration DES [5].
Therefore, the trade-off between beneﬁts and risks of a
prolonged DAPT regimen may dramatically change based
on type of stent implanted at the time of intervention.
In the whole DAPT study, the number needed to treat
for beneﬁt (NNTB) in terms of ischemic events (deﬁnite or
probable stent thrombosis: ARD = 1%, NNTB = 100;
MI: ARD = 2%, NNTB = 50) and the number needed to
treat for harm (NNTH) to provoke a bleeding
(ARD = 0.9%, NNTH = 111) slightly favored a longer
DAPT strategy [5]. However, when the analysis is
restricted to the group of patients treated with contempo-
rary everolimus-eluting stents, the balance between ische-
mia and bleeding appears upturned, disfavoring longer
DAPT treatment in terms of NNTB in terms of ischemic
events (deﬁnite or probable stent thrombosis:
ARD = 0.5%, NNTB = 200; MI: ARD = 1.1%,
NNTB = 91) versus NNTH from bleeding (ARD = 1.2%,
NNTH = 83), with no beneﬁt from longer DAPT in terms
of the overall MACCE rate, and an excess of non-cardio-
vascular death [46].
Since ﬁrst-generation DES are no longer used in clinical
practice, interpretation of trials largely based on the use of
second-generation DES is critical in order to have a clearer
understanding of the trade-off between ischemia and
bleeding in contemporary practice [59].
In summary, current data suggests that the ischemic
beneﬁt of longer DAPT appears more evident among
patients treated with ﬁrst-generation DES, which are no
longer used in clinical practice. The ischemic beneﬁt
observed among patients treated with contemporary DES is
smaller, and might be outweighed by the bleeding hazard
of longer treatment duration if patients are not selected to
be at relatively higher ischemic but lower bleeding risk.
3.1.3 Patient Selection
Baseline and procedural characteristics might have an
important inﬂuence on the impact of DAPT duration
(Table 1). Intuitively, patients with a perceived higher
ischemic risk at baseline or undergoing more complex
procedures might derive a larger beneﬁt from longer or
more potent platelet inhibition [51, 60, 61]. Within DAPT
duration trials, the type of population included was
heterogeneous. The overall different risk proﬁle among
trials might be evaluated through three markers of risk:
age, type of clinical presentation, and PCI complexity. The
average age of patients enrolled in clinical trials for DAPT
duration was highly variable, and spanned from 60.2 years
in the I-LOVE-IT 2 trial to 67.9 years in the PRODIGY
trial (Fig. 1). Elderly patients are often underrepresented in
clinical trials, and a higher age denotes higher risk of
events [62]. A treatment-by-age heterogeneity was
observed for the primary endpoint in the ISAR-SAFE
(Pint = 0.03) and IVUS-XPL trial (Pint = 0.05), indicating
a signiﬁcant interaction between age and treatment dura-
tion (i.e., 6 vs 12 months’ DAPT) disfavoring longer
treatment duration in elderly patients (i.e., [65 years)
[29, 33]. In addition, a similar trend was shown in the
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PRODIGY trial, with longer treatment showing a less
favorable safety proﬁle for older than younger patients
[63].
The type of clinical presentation was also at variance
across DAPT duration trials (Table 1). ACS patients were
excluded from the ARCTIC interruption study, and only
few ACS patients were actually included in the ITALIC,
OPTIMIZE, SECURITY, and OPTIDUAL studies. STEMI
patients were enrolled in half of DAPT duration trials
(Table 1). Clinical presentation appeared as an important
treatment modiﬁer for DAPT duration in the DAPT trial,
with a higher beneﬁt for longer DAPT among patients
presenting with MI at the time of index PCI [64]. Patients
with prior MI were also associated with a signiﬁcant
reduction in cardiovascular mortality after longer DAPT in
a subsequent meta-analysis [65]. Contrariwise, stable pa-
tients appeared to derive a smaller beneﬁt from longer
DAPT, which is largely outweighed by the increase in
bleeding [66]. In the PRODIGY trial, bleeding events
occurred relatively more often after longer DAPT among
stable versus unstable patients at the time of presentation
[67]. This was associated with a better net clinical beneﬁt
proﬁle using shorter rather than long DAPT among
stable patients [67].
PCI complexity, although difﬁcult to categorize and
compare across trials, was also heterogeneous (Fig. 2). The
proportion of patients included with multivessel disease
ranged from 68.5% in the IVUS-XPL study to 25% in the
I-LOVE-IT 2 study [32, 33]. The mean number of lesions
treated per patient at the time of index PCI ranged from
1.27 to 1.55 (Fig. 2). The number of stents implanted
during the index procedure varied from 1.86 in the
PRODIGY trial to 1.27 in RESET [4, 28]. Also, the mean
overall stent length was variable, ranging from 47 mm in
the IVUS-XPL trial to 18 mm in the OPTIDUAL trial
(Fig. 2). A pooled data analysis from six RCTs demon-
strated a signiﬁcant beneﬁt from a standard 12-month
DAPT, compared with shorter treatment among patients
with complex PCI, deﬁned using six markers of risk (i.e.,
three coronary vessels treated, three or more stents
implanted, three or more lesions treated, bifurcation
stenting, overall stent length of[60 mm, revascularization
of a chronic total occlusion) [68]. Importantly, the mag-
nitude of the beneﬁt from longer DAPT was directly
related to the number of markers of complexity present, in
line with the hypothesis that the higher the complexity of
PCI, the higher the beneﬁt from longer DAPT [68].
3.1.4 Timing of Randomization
Study design and timing of randomization varied among
trials. Six trials included a run-in phase between stent
implantation and randomization to DAPT duration (Fig. 3).
During this initial period, patients experiencing a novel
ischemic or bleeding event were excluded from random-
ization in the study. Hence, the type of population ﬁnally
randomized in the study was at a relatively lower risk due
to the exclusion of those patients having suffered events
during the run-in phase. In this respect, it may be assumed
that the longer the observational/run-in phase, the greater
the degree of patient selection before entering the study. In
the DAPT trial, among 22,866 patients receiving a DES
and treated with DAPT during the run-in phase of the
study, less than half were ultimately randomized in the
study [5]. Similarly, in the ARCTIC interruption trial [40],
only half of the initial 2440 patients included in the bedside
platelet function testing phase of the trial [43] were without
contraindication to prolong DAPT and were ﬁnally enrol-
led in the DAPT duration study. Hence, clinicians should
be careful before drawing conclusions from these studies
and generalizing them to an all-comer, real-world
population.
3.2 In Which Patients Should We Prolong
and in Which Patients Should We Shorten
DAPT?
Multiple patient or procedural characteristics may be fac-
tored in when deciding upon DAPT duration (Fig. 4).
Important information has been provided by subgroup
analyses of DAPT duration trials [64, 66, 69, 70]. How-
ever, subgroup analysis from RCTs has to be considered
hypothesis generating, and should be interpreted with
caution, as it might be confounded by type I and/or II
errors. In addition, the interrelations between multiple
coexisting factors (e.g., clinical presentation and peripheral
artery disease) are complex and have never been studied.
3.2.1 Clinical Presentation
The type of clinical presentation (i.e., SCAD, unsta-
ble angina, non-STEMI, or STEMI) at the time of PCI is a
major determinant of a patient’s mortality risk, which
ranges between 0.36% in SCAD and 4.78% in high-risk
STEMI patients, or the risk for ischemic recurrences [71].
For this reason, a more potent (i.e., use of ticagrelor or
prasugrel vs clopidogrel) or prolonged regimen (i.e., 12 vs
6 months’ treatment) is advocated by international guide-
lines among patients presenting with ACS, but not those
with SCAD [6, 7]. In the PRODIGY trial, 1465 (74.3%)
patients presented with ACS and 505 (25.7%) with SCAD
[4]. No heterogeneity was noted with respect to the ran-
domized DAPT duration for the primary efﬁcacy endpoint
among patients presenting with ACS or SCAD. However,
there was a borderline quantitative interaction between
clinical presentations and bleeding outcomes (Pint = 0.056
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for BARC 2, 3, or 5; Pint = 0.091 for BARC 3 or 5),
suggesting a higher risk of bleeding after a longer DAPT in
the SCAD patients, but not in ACS patients [67]. The
analysis of net adverse clinical events (NACE) consisting
of death, MI, cerebrovascular accident, or BARC 2, 3, or 5
bleeding showed signiﬁcant harm from longer DAPT in
SCAD patients (NACE in the 24-month vs 6-month DAPT
arm: 13.3 vs 5.6%; HR 2.5; 95% CI 1.35–4.69; p = 0.004;
NNTH = 13), and no beneﬁt in the ACS population (16.1
vs 14.1%; HR 1.15; 95% CI 0.88–1.50; p = 0.29), with
positive quantitative interaction testing (Pint = 0.024) [67].
In the DAPT trial, 30.7% presented with MI at the time
of stent implantation [64]. Thirty-month DAPT compared
with 12-month treatment signiﬁcantly reduced deﬁnite or
probable stent thrombosis both in patients with MI (0.5 vs
1.9%; p\ 0.001) and without MI (0.4 vs 1.1%; p\ 0.001)
(Pint = 0.69). Yet, the reduction of MACCE from longer
DAPT was bigger for patients with MI (3.9 vs 6.8%;
p\ 0.001) than patients without MI (4.4 vs 5.3%;
p = 0.08) at the time of presentation, with a positive
interaction testing (Pint = 0.03) [64]. Importantly, longer
DAPT was associated with a signiﬁcant increase in all-
cause death among patients presenting without MI (2.1 vs
1.5%; p = 0.04) [64, 66], whereas no such detrimental
effect was observed in patients with prior MI.
A recent individual patient data meta-analysis from six
trials and 11,473 patients compared the effect of
3–6 months’ DAPT with 12 months’ DAPT among
patients presenting with ACS or SCAD [9]. In patients with
ACS (n = 4758), shortening DAPT to 6 months was not
associated with a signiﬁcant increase of MI or deﬁnite/
probable stent thrombosis compared with 12 months’
DAPT (HR 1.28; 95% CI 0.73–2.27). However, in the
same population, shortening DAPT to 3 months was
associated with a two-fold increase in the risk of MI or
deﬁnite/probable stent thrombosis compared with
12 months’ DAPT (HR 2.08; 95% CI 0.73–2.27). In
patients with SCAD at presentation (n = 6715), there was
no difference in the risk of MI or deﬁnite/probable stent
thrombosis when shortening DAPT to 3 or 6 months
compared with 12 months [9].
A second meta-analysis from six RCTs included a total
of 33,435 patients with prior MI, and compared the effect
of standard (12 months) versus extended ([12 months)
DAPT [65]. In this high-risk patient category, extended
DAPT signiﬁcantly decreased the risk of the primary
ischemic endpoint of cardiovascular death, MI, or stroke
(6.4 vs 7.5%; ARD = 1.1%; p = 0.001). This beneﬁt was
consistent within each component of the primary endpoint,
including a signiﬁcant 15% relative reduction of cardio-
vascular death (RR 0.85; 95% CI 0.74–0.98). Concurrently,
extended DAPT signiﬁcantly increased risk of major
bleeding (1.85 vs 1.09%; ARD = 0.76%; p = 0.004), with
no excess in fatal bleeding [65]. Yet, despite in this pooled
analysis no between-study heterogeneity was noted, sup-
porting a possible class-effect beneﬁt for different P2Y12
Fig. 1 Patients’ age in dual antiplatelet therapy duration trials
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Fig. 2 Percutaneous intervention complexity in dual antiplatelet
therapy duration trials taking into account overall stent length (blue
bars), mean number of implanted stents per patient (red bars),
proportion of patients with multivessel disease (green bars) and mean
number of treated lesions per patient (orange bars)
Reconciling the Inconsistencies for Dual Antiplatelet Therapy Duration
DAPT DURATION
3938
1
for BARC 2, 3, or 5; Pint = 0.091 for BARC 3 or 5),
suggesting a higher risk of bleeding after a longer DAPT in
the SCAD patients, but not in ACS patients [67]. The
analysis of net adverse clinical events (NACE) consisting
of death, MI, cerebrovascular accident, or BARC 2, 3, or 5
bleeding showed signiﬁcant harm from longer DAPT in
SCAD patients (NACE in the 24-month vs 6-month DAPT
arm: 13.3 vs 5.6%; HR 2.5; 95% CI 1.35–4.69; p = 0.004;
NNTH = 13), and no beneﬁt in the ACS population (16.1
vs 14.1%; HR 1.15; 95% CI 0.88–1.50; p = 0.29), with
positive quantitative interaction testing (Pint = 0.024) [67].
In the DAPT trial, 30.7% presented with MI at the time
of stent implantation [64]. Thirty-month DAPT compared
with 12-month treatment signiﬁcantly reduced deﬁnite or
probable stent thrombosis both in patients with MI (0.5 vs
1.9%; p\ 0.001) and without MI (0.4 vs 1.1%; p\ 0.001)
(Pint = 0.69). Yet, the reduction of MACCE from longer
DAPT was bigger for patients with MI (3.9 vs 6.8%;
p\ 0.001) than patients without MI (4.4 vs 5.3%;
p = 0.08) at the time of presentation, with a positive
interaction testing (Pint = 0.03) [64]. Importantly, longer
DAPT was associated with a signiﬁcant increase in all-
cause death among patients presenting without MI (2.1 vs
1.5%; p = 0.04) [64, 66], whereas no such detrimental
effect was observed in patients with prior MI.
A recent individual patient data meta-analysis from six
trials and 11,473 patients compared the effect of
3–6 months’ DAPT with 12 months’ DAPT among
patients presenting with ACS or SCAD [9]. In patients with
ACS (n = 4758), shortening DAPT to 6 months was not
associated with a signiﬁcant increase of MI or deﬁnite/
probable stent thrombosis compared with 12 months’
DAPT (HR 1.28; 95% CI 0.73–2.27). However, in the
same population, shortening DAPT to 3 months was
associated with a two-fold increase in the risk of MI or
deﬁnite/probable stent thrombosis compared with
12 months’ DAPT (HR 2.08; 95% CI 0.73–2.27). In
patients with SCAD at presentation (n = 6715), there was
no difference in the risk of MI or deﬁnite/probable stent
thrombosis when shortening DAPT to 3 or 6 months
compared with 12 months [9].
A second meta-analysis from six RCTs included a total
of 33,435 patients with prior MI, and compared the effect
of standard (12 months) versus extended ([12 months)
DAPT [65]. In this high-risk patient category, extended
DAPT signiﬁcantly decreased the risk of the primary
ischemic endpoint of cardiovascular death, MI, or stroke
(6.4 vs 7.5%; ARD = 1.1%; p = 0.001). This beneﬁt was
consistent within each component of the primary endpoint,
including a signiﬁcant 15% relative reduction of cardio-
vascular death (RR 0.85; 95% CI 0.74–0.98). Concurrently,
extended DAPT signiﬁcantly increased risk of major
bleeding (1.85 vs 1.09%; ARD = 0.76%; p = 0.004), with
no excess in fatal bleeding [65]. Yet, despite in this pooled
analysis no between-study heterogeneity was noted, sup-
porting a possible class-effect beneﬁt for different P2Y12
Fig. 1 Patients’ age in dual antiplatelet therapy duration trials
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Fig. 2 Percutaneous intervention complexity in dual antiplatelet
therapy duration trials taking into account overall stent length (blue
bars), mean number of implanted stents per patient (red bars),
proportion of patients with multivessel disease (green bars) and mean
number of treated lesions per patient (orange bars)
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inhibitors used, a separate study suggested an advantage of
extended treatment with ticagrelor versus a similar strategy
with thienopyridines, since the former appeared to exert a
relatively more favorable effect on all-cause mortality [72].
In summary, current evidence provides support to the
concept that DAPT duration should be based on patients’
clinical presentation. The trade-off between efﬁcacy and
safety of extended DAPT beyond 1 year appeared partic-
ularly beneﬁcial in higher risk patients with prior MI.
Concurrently, patients at lower risk, such as those pre-
senting with stable angina at time of PCI, appear to be
better suited to a shorter course of treatment for 3 or
6 months.
3.2.2 Complex PCI
The complexity of coronary intervention has been consis-
tently considered an important element to be taken into
account for decisions around DAPT duration [26]. A recent
patient-level meta-analysis from six RCTs (N = 9577)
investigating DAPT durations (C12 vs B6 months) after
coronary stenting deﬁned complex PCI based on six
covariates, including three-vessel PCI, and/or an implanta-
tion of three or more coronary stents, and/or three or more
coronary lesions, and/or bifurcation stenting (i.e., bifurca-
tion technique using stents in both the main and the side
branch), and/or a ﬁnal total stent length[60 mm, and/or
treatment of a chronic total occlusion [68]. Ultimately,
17.5% of patients had at least one of these characteristics and
were considered to be in the complex PCI group [68].
Patients undergoing complex PCI had a higher MACCE rate
(5.0 vs 2.5%; p = 0.001). In this group, long DAPT
(C12 months) compared with short DAPT (B6 months)
almost halved the adjusted MACCE rate (unadjusted event
rates: 4.0 vs 6.0%; adjusted HR 0.56, 95% CI 0.35–0.89),
whereas no beneﬁt for a longer treatment was observed in the
non-complex PCI group (2.5 vs 2.6%; adjusted HR 1.01;
95% CI 0.75–1.35) (Pint = 0.01). Interestingly, the magni-
tude of beneﬁt in favor of long DAPT was directly and
positively related to the number of complex PCI factors.
Longer DAPTwas associatedwith an increased risk ofmajor
bleeding irrespective of PCI complexity (Pint = 0.15) [68].
In summary, patients undergoing complex PCI represent
a higher-risk population, which appeared to be better suited
to 12 months or more of DAPT because of a signiﬁcant
reduction of ischemic adverse events, even if this beneﬁt
came at a consistently higher price to pay in term of
bleeding.
Fig. 3 Main features of trial designs in dual antiplatelet therapy
duration trials. In the ITALIC trial, although patients were random-
ized at the time of PCI, study protocol was pre-speciﬁed to include
events from the moment in which DAPT therapy started to differ
between groups (i.e., at 6 months). DAPT dual antiplatelet therapy,
PCI percutaneous coronary intervention
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3.2.3 Peripheral Artery Disease
The presence of concomitant peripheral artery disease
(PAD) among patients with CAD has been invariably
shown as an important marker of ischemic events and
mortality [73, 74]. Among 3096 patients with PAD in the
CHARISMA trial, DAPT compared with aspirin alone was
associated with a lower rate of MI and hospitalization for
ischemic events, but a higher rate of minor bleeding [75].
In the PEGASUS trial, patients with a history of PAD
carried a 60% higher risk of MACCE [76]. In this higher-
risk subgroup, treatment with ticagrelor 60 mg BID com-
pared with placebo provided a robust absolute risk reduc-
tion of 5.2% at 3 years for the primary ischemic endpoint,
with a signiﬁcant reduction of acute limb ischemic events
and a reduction of both cardiovascular and all-cause mor-
tality [76]. In the all-comer PRODIGY trial, 12.5% of
patients included had a history of symptomatic PAD [77].
Again, a history of PAD was associated with a higher risk
of death and ischemic events (HR 2.80; 95% CI 2.05–3.83;
Fig. 4 The ‘moving target’ of dual antiplatelet therapy duration. An
algorithm for the selection of dual antiplatelet therapy duration based
on four interrelating factors (bleeding risk, clinical presentation,
complex PCI, and peripheral artery disease) is presented in the ﬁgure.
The presence or the absence of each factor, and its relation with the
others, drives the suggested DAPT duration. The concentric circles
represent DAPT duration from its inception (i.e., 1, 3, 6, 12, or
[12 months from inner to the outer circle). DAPT duration is
obtained from the intercept of the lines originating from each relevant
factor (e.g., high bleeding risk ‘yes’ and complex PCI ‘no’). The
interrelationships between factors and the suggested DAPT duration
presented in this ﬁgure should be considered as the authors’ personal
opinion, as no studies evaluated the interrelation between multiple
subgroups. These represent an attempt to summarize the evidence and
give a practical outlook for clinicians. ACS acute coronary syndrome,
PAD peripheral artery disease, PCI percutaneous coronary interven-
tion, SCAD stable coronary artery disease
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inhibitors used, a separate study suggested an advantage of
extended treatment with ticagrelor versus a similar strategy
with thienopyridines, since the former appeared to exert a
relatively more favorable effect on all-cause mortality [72].
In summary, current evidence provides support to the
concept that DAPT duration should be based on patients’
clinical presentation. The trade-off between efﬁcacy and
safety of extended DAPT beyond 1 year appeared partic-
ularly beneﬁcial in higher risk patients with prior MI.
Concurrently, patients at lower risk, such as those pre-
senting with stable angina at time of PCI, appear to be
better suited to a shorter course of treatment for 3 or
6 months.
3.2.2 Complex PCI
The complexity of coronary intervention has been consis-
tently considered an important element to be taken into
account for decisions around DAPT duration [26]. A recent
patient-level meta-analysis from six RCTs (N = 9577)
investigating DAPT durations (C12 vs B6 months) after
coronary stenting deﬁned complex PCI based on six
covariates, including three-vessel PCI, and/or an implanta-
tion of three or more coronary stents, and/or three or more
coronary lesions, and/or bifurcation stenting (i.e., bifurca-
tion technique using stents in both the main and the side
branch), and/or a ﬁnal total stent length[60 mm, and/or
treatment of a chronic total occlusion [68]. Ultimately,
17.5% of patients had at least one of these characteristics and
were considered to be in the complex PCI group [68].
Patients undergoing complex PCI had a higher MACCE rate
(5.0 vs 2.5%; p = 0.001). In this group, long DAPT
(C12 months) compared with short DAPT (B6 months)
almost halved the adjusted MACCE rate (unadjusted event
rates: 4.0 vs 6.0%; adjusted HR 0.56, 95% CI 0.35–0.89),
whereas no beneﬁt for a longer treatment was observed in the
non-complex PCI group (2.5 vs 2.6%; adjusted HR 1.01;
95% CI 0.75–1.35) (Pint = 0.01). Interestingly, the magni-
tude of beneﬁt in favor of long DAPT was directly and
positively related to the number of complex PCI factors.
Longer DAPTwas associatedwith an increased risk ofmajor
bleeding irrespective of PCI complexity (Pint = 0.15) [68].
In summary, patients undergoing complex PCI represent
a higher-risk population, which appeared to be better suited
to 12 months or more of DAPT because of a signiﬁcant
reduction of ischemic adverse events, even if this beneﬁt
came at a consistently higher price to pay in term of
bleeding.
Fig. 3 Main features of trial designs in dual antiplatelet therapy
duration trials. In the ITALIC trial, although patients were random-
ized at the time of PCI, study protocol was pre-speciﬁed to include
events from the moment in which DAPT therapy started to differ
between groups (i.e., at 6 months). DAPT dual antiplatelet therapy,
PCI percutaneous coronary intervention
F. Costa et al.
Chapter 1.1
3.2.3 Peripheral Artery Disease
The presence of concomitant peripheral artery disease
(PAD) among patients with CAD has been invariably
shown as an important marker of ischemic events and
mortality [73, 74]. Among 3096 patients with PAD in the
CHARISMA trial, DAPT compared with aspirin alone was
associated with a lower rate of MI and hospitalization for
ischemic events, but a higher rate of minor bleeding [75].
In the PEGASUS trial, patients with a history of PAD
carried a 60% higher risk of MACCE [76]. In this higher-
risk subgroup, treatment with ticagrelor 60 mg BID com-
pared with placebo provided a robust absolute risk reduc-
tion of 5.2% at 3 years for the primary ischemic endpoint,
with a signiﬁcant reduction of acute limb ischemic events
and a reduction of both cardiovascular and all-cause mor-
tality [76]. In the all-comer PRODIGY trial, 12.5% of
patients included had a history of symptomatic PAD [77].
Again, a history of PAD was associated with a higher risk
of death and ischemic events (HR 2.80; 95% CI 2.05–3.83;
Fig. 4 The ‘moving target’ of dual antiplatelet therapy duration. An
algorithm for the selection of dual antiplatelet therapy duration based
on four interrelating factors (bleeding risk, clinical presentation,
complex PCI, and peripheral artery disease) is presented in the ﬁgure.
The presence or the absence of each factor, and its relation with the
others, drives the suggested DAPT duration. The concentric circles
represent DAPT duration from its inception (i.e., 1, 3, 6, 12, or
[12 months from inner to the outer circle). DAPT duration is
obtained from the intercept of the lines originating from each relevant
factor (e.g., high bleeding risk ‘yes’ and complex PCI ‘no’). The
interrelationships between factors and the suggested DAPT duration
presented in this ﬁgure should be considered as the authors’ personal
opinion, as no studies evaluated the interrelation between multiple
subgroups. These represent an attempt to summarize the evidence and
give a practical outlook for clinicians. ACS acute coronary syndrome,
PAD peripheral artery disease, PCI percutaneous coronary interven-
tion, SCAD stable coronary artery disease
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p\ 0.001), and prolonged versus short DAPT signiﬁcantly
reduced the incidence of the primary efﬁcacy endpoint in
PAD patients (16.1 vs 27.3%; HR 0.54; 95% CI 0.31–0.95;
p = 0.03) but not in patients without PAD (9.3 vs 7.4%;
HR 1.28; 95% CI 0.92–1.77; p = 0.14), with a positive
interaction testing (p = 0.01) [77]. Longer DAPT provided
a consistent beneﬁt in patients with PAD, also reducing
deﬁnite or probable stent thrombosis and all-cause mor-
tality [77].
In summary, there is compelling evidence that patients
with a history of PAD are at higher ischemic risk,
encouraging a prolonged antiplatelet therapy regimen in
this subgroup.
3.2.4 Risk Scores
Clinical risk scores, which integrate risk factors to establish
an individual’s absolute risk of a given condition, are often
used in clinical practice to estimate bleeding risks in
patients with atrial ﬁbrillation and treated with oral anti-
coagulants [78]. The concept of using a risk score to guide
DAPT decision making for treatment duration was tested
for the ﬁrst time in the PRODIGY trial [79]. In this ret-
rospective analysis, the authors used the PRODIGY dataset
to bench-test three validated bleeding risk scores in patients
with ACS (i.e., CRUSADE and ACUITY) [80, 81] and
atrial ﬁbrillation (i.e., HAS-BLED) [82]. The CRUSADE
score showed a higher discrimination [79]. Most impor-
tantly, when patients from the PRODIGY trial were strat-
iﬁed according to the CRUSADE score in high (CRUSADE
[40) versus non-high (CRUSADE B40) bleeding risk,
patients at higher bleeding risk had an almost 3-fold greater
rate of major bleeding when treated with 24- versus
6-month DAPT (9.7 vs 3.7%; ARD 6%; 95% CI 0.4–12.3;
p = 0.04; NNTH = 17), whereas patients with non-high
risk did not experience a signiﬁcant increase in major
bleeding when treated with long versus short DAPT
duration (2.4 vs 1.6%; ARD 0.8%; 95% CI –0.6 to 2.2;
p = 0.25) (Pint = 0.05) [79]. Consistently, the risk for red
blood cell transfusion in the 24- versus 6-month DAPT
duration arms was ﬁve times higher among patients at
higher bleeding risk according to CRUSADE (8.3 vs 1.8%;
ARD 6.5%; 95% CI 1.6–12.3; p = 0.02; NNTH = 15), but
not in those without high CRUSADE score (1.7 vs 1.2%;
ARD 0.5%; 95% CI –0.6 to 1.7; p = 0.45) (Pint = 0.01).
However, no interaction between the bleeding risk status
deﬁned according to the CRUSADE score and DAPT
duration was observed for the primary ischemic endpoint in
the PRODIGY study (Pint = 0.58) [79]. These bleeding
risk scores were not initially designed for long-term event
prediction in a CAD population; in fact, CRUSADE and
ACUITY were created to predict in-hospital, mostly
access-site-related bleeding, whereas HAS-BLED was
designed to predict long-term bleeding in patients with
atrial ﬁbrillation with an indication to oral anticoagulation
[80–82].
Within the DAPT trial, the authors developed a speciﬁc
tool for decision making on treatment duration so as to
possibly identify patients in the DAPT trial (N = 11,648)
with a net beneﬁt for ischemia and bleeding from a treat-
ment extension of up to 30 months compared with standard
treatment of 12 months [83]. Eight factors were identiﬁed
(i.e., congestive heart failure/low left ventricular ejection
fraction, vein graft stenting, MI at presentation, prior MI or
PCI, diabetes mellitus, stent diameter \3 mm, smoking,
and paclitaxel-eluting stent) that were independently
associated with ischemia but not with bleeding, and one
factor (i.e., age) was identiﬁed that was independently
associated with bleeding, but not with ischemia. From this
model, they developed a risk score (DAPT score) ranging
from -2 to ?10, to predict the difference between the
anticipated reduction in ischemic events and the anticipated
increase in bleeding events with extended DAPT, with
lower scores identifying patients at higher bleeding versus
ischemic risk, and higher scores identifying patients at
higher ischemic versus bleeding risk.
The DAPT score showed modest discrimination during
internal validation and external validation in 8136 patients
enrolled in the PROTECT (Patient-Related Outcomes with
Endeavor vs Cypher Stenting) trial [83]. Importantly,
patients with a high DAPT score (i.e., score C2) derived a
larger reduction in MI and stent thrombosis after a pro-
longed 30-month DAPT (risk difference -3.0%; 95% CI -
4.1 to -2.0; p\ 0.001), with only a modest increase in
major bleeding (risk difference 0.4%; 95% CI -0.3 to 1.0;
p = 0.26). In turn, patients with a low DAPT score (i.e.,
score\2) did not derive any reduction of ischemic events
from prolonging DAPT (risk difference -0.7%; 95% CI -
1.4 to 0.09; p = 0.07), but suffered a signiﬁcant increase in
major bleeding (risk difference 1.5%, 95% CI 0.8–2.3,
p\ 0.001). The DAPT score appeared to signiﬁcantly
modulate the outcomes for DAPT duration both for
ischemic (Pint\ 0.001) and bleeding events (Pint = 0.02).
Still, these ﬁgures were not conﬁrmed in the everolimus-
eluting stent subgroup (ischemia Pint = 0.18; bleeding
Pint = 0.15) [83].
Although the DAPT score represented the ﬁrst attempt
to develop a speciﬁc tool to guide DAPT decision making,
it suffers from several limitations due to the original trial
design and population. The population of the DAPT trial
was highly selected due to the initial run-in phase of the
study, which excluded almost 50% of the initially screened
population [5]. As per the DAPT trial design, the DAPT
score is only able to inform the decision to continue or not
continue DAPT beyond 12 months, whereas it cannot
inform earlier DAPT suspension within the ﬁrst year of
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treatment. Since current guidelines recommend at least
6 months of DAPT in stable patients, and most bleeding
events occur early after treatment initiation, earlier treat-
ment decision making at the time of PCI or in the ﬁrst
3–6 months of treatment is advisable [6]. Hence, whether
the DAPT score performance might be replicated in an
external population to provide earlier decision making for
DAPT duration remains to be ascertained. In a recent
analysis, the DAPT score failed to demonstrate a differ-
ential treatment effect within the ﬁrst year of treatment, and
inform decision making for 6 versus 12 months’ DAPT
after implantation of predominantly second-generation
DES in the ISAR-SAFE trial [84].
More recently, the PRECISE-DAPT (PREdicting
bleeding Complications In patients undergoing Stent
implantation and subsEquent Dual Anti Platelet Therapy)
study group pooled data from eight RCTs and 14,963
patients with indication for DAPT who underwent elective,
urgent, or emergent PCI [85]. The aim of the study was to
ﬁnd independent predictors at the time of PCI of long-term
bleeding while on DAPT and develop a predicting tool to
inform DAPT duration earlier at the time of stent implan-
tation. In fact, the median time to a ﬁrst major bleeding
after DAPT initiation was %5 months in the PRECISE-
DAPT study. Ultimately, a simple ﬁve-item (age, crea-
tinine clearance, hemoglobin, white blood cell count, prior
spontaneous bleeding) prediction algorithm for the pre-
diction of out-of-hospital bleeding in patients treated with
DAPT was proposed.
The predictive performance of this novel score was
assessed in the derivation cohort and validated in 8595 and
6172 patients treated with PCI from the PLATO trial and
BernPCI registry, respectively [86]. The PRECISE-DAPT
score showed good discrimination in both validation
cohorts and appeared superior to its comparator (i.e.,
PARIS bleeding score [87]) in terms of integrated dis-
crimination and net reclassiﬁcation [85].
The PRECISE-DAPT score was tested in patients ran-
domized to different DAPT durations (N = 10,081) to
evaluate bleeding and ischemic events resulting from a
long (12–24 months) or short (3–6 months) treatment
duration in relation to the score-predicted bleeding risk
[85].
It was observed that among patients deemed at high
bleeding risk based on PRECISE DAPT (score C25),
prolonged DAPT compared with short DAPT was associ-
ated with no ischemic beneﬁt and a signiﬁcant bleeding
increase, resulting in one major bleeding incident for every
38 patients treated. On the other hand, a prolonged DAPT
in patients without high bleeding risk at baseline (score
\25) was not associated with a signiﬁcant excess of
bleeding compared with short DAPT, but provided a sig-
niﬁcant reduction of the composite ischemic endpoint of
MI, deﬁnite stent thrombosis, stroke, and target vessel
revascularization, preventing one ischemic event for every
65 patients treated. The favorable proﬁle of this decision-
making algorithm remained consistent when the analysis
was conﬁned to patients presenting with ACS at the time of
stent implantation. Hence, addressing upfront at the time of
PCI a\12-month treatment duration in patients deemed at
high bleeding risk (PRECISE-DAPT score C25) may
prevent exposing them to an excessive bleeding hazard. In
turn, patients at non-high bleeding risk (PRECISE-DAPT
score\25) might receive a standard (i.e., 12 months) or a
prolonged (i.e.[12 months) course of treatment if toler-
ated [85].
It should be emphasized that the accuracy of these
prediction tools ranged from low/moderate to good, and
clinicians must remain aware that these tools cannot be a
substitute for a case-by-case clinical evaluation [88]. In
addition, none of these risk prediction models has been
prospectively tested in the setting of prospective RCTs;
hence, their value in improving patient outcomes requires
further investigation.
4 Future Studies
Optimization of DAPT duration remains the subject of
intense investigation. Since international guidelines
entailed the possibility of a very short (i.e., 1 month)
DAPT course after BMS in patients at high risk for
bleeding, and several studies showed that novel DES are
safer than BMS in terms of device-related adverse events
during a standard [56] or abbreviated DAPT course [36],
the optimal duration of DAPT in patients at high bleeding
risk and treated with contemporary DES is under
investigation.
The MASTER-DAPT (Management of High Bleeding
Risk Patients Post-Bioresorbable Polymer Coated Stent
Implantation with an Abbreviated Versus Prolonged DAPT
Regimen) study (NCT03023020) will enroll patients
deemed at high bleeding risk undergoing PCI with biore-
sorbable polymer-coated stent implantation, and will
evaluate the safety of an abbreviated treatment with DAPT
(i.e., 1 month) compared with the guideline-recommended
standard of care (i.e., at least 3 or 6 months of DAPT in
patients with or without concomitant need for oral antico-
agulation). High bleeding risk inclusion criteria in the
MASTER-DAPT study will include an indication for oral
anticoagulants, PRECISE-DAPT score C25, the occur-
rence of a recent or previous bleeding event for which the
underlying cause has not been deﬁnitively treated, older
age, diagnosed malignancy at high bleeding risk, and other
clinical factors. The study will be powered to test the non-
inferiority in terms of NACE and MACCE of the
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1
p\ 0.001), and prolonged versus short DAPT signiﬁcantly
reduced the incidence of the primary efﬁcacy endpoint in
PAD patients (16.1 vs 27.3%; HR 0.54; 95% CI 0.31–0.95;
p = 0.03) but not in patients without PAD (9.3 vs 7.4%;
HR 1.28; 95% CI 0.92–1.77; p = 0.14), with a positive
interaction testing (p = 0.01) [77]. Longer DAPT provided
a consistent beneﬁt in patients with PAD, also reducing
deﬁnite or probable stent thrombosis and all-cause mor-
tality [77].
In summary, there is compelling evidence that patients
with a history of PAD are at higher ischemic risk,
encouraging a prolonged antiplatelet therapy regimen in
this subgroup.
3.2.4 Risk Scores
Clinical risk scores, which integrate risk factors to establish
an individual’s absolute risk of a given condition, are often
used in clinical practice to estimate bleeding risks in
patients with atrial ﬁbrillation and treated with oral anti-
coagulants [78]. The concept of using a risk score to guide
DAPT decision making for treatment duration was tested
for the ﬁrst time in the PRODIGY trial [79]. In this ret-
rospective analysis, the authors used the PRODIGY dataset
to bench-test three validated bleeding risk scores in patients
with ACS (i.e., CRUSADE and ACUITY) [80, 81] and
atrial ﬁbrillation (i.e., HAS-BLED) [82]. The CRUSADE
score showed a higher discrimination [79]. Most impor-
tantly, when patients from the PRODIGY trial were strat-
iﬁed according to the CRUSADE score in high (CRUSADE
[40) versus non-high (CRUSADE B40) bleeding risk,
patients at higher bleeding risk had an almost 3-fold greater
rate of major bleeding when treated with 24- versus
6-month DAPT (9.7 vs 3.7%; ARD 6%; 95% CI 0.4–12.3;
p = 0.04; NNTH = 17), whereas patients with non-high
risk did not experience a signiﬁcant increase in major
bleeding when treated with long versus short DAPT
duration (2.4 vs 1.6%; ARD 0.8%; 95% CI –0.6 to 2.2;
p = 0.25) (Pint = 0.05) [79]. Consistently, the risk for red
blood cell transfusion in the 24- versus 6-month DAPT
duration arms was ﬁve times higher among patients at
higher bleeding risk according to CRUSADE (8.3 vs 1.8%;
ARD 6.5%; 95% CI 1.6–12.3; p = 0.02; NNTH = 15), but
not in those without high CRUSADE score (1.7 vs 1.2%;
ARD 0.5%; 95% CI –0.6 to 1.7; p = 0.45) (Pint = 0.01).
However, no interaction between the bleeding risk status
deﬁned according to the CRUSADE score and DAPT
duration was observed for the primary ischemic endpoint in
the PRODIGY study (Pint = 0.58) [79]. These bleeding
risk scores were not initially designed for long-term event
prediction in a CAD population; in fact, CRUSADE and
ACUITY were created to predict in-hospital, mostly
access-site-related bleeding, whereas HAS-BLED was
designed to predict long-term bleeding in patients with
atrial ﬁbrillation with an indication to oral anticoagulation
[80–82].
Within the DAPT trial, the authors developed a speciﬁc
tool for decision making on treatment duration so as to
possibly identify patients in the DAPT trial (N = 11,648)
with a net beneﬁt for ischemia and bleeding from a treat-
ment extension of up to 30 months compared with standard
treatment of 12 months [83]. Eight factors were identiﬁed
(i.e., congestive heart failure/low left ventricular ejection
fraction, vein graft stenting, MI at presentation, prior MI or
PCI, diabetes mellitus, stent diameter \3 mm, smoking,
and paclitaxel-eluting stent) that were independently
associated with ischemia but not with bleeding, and one
factor (i.e., age) was identiﬁed that was independently
associated with bleeding, but not with ischemia. From this
model, they developed a risk score (DAPT score) ranging
from -2 to ?10, to predict the difference between the
anticipated reduction in ischemic events and the anticipated
increase in bleeding events with extended DAPT, with
lower scores identifying patients at higher bleeding versus
ischemic risk, and higher scores identifying patients at
higher ischemic versus bleeding risk.
The DAPT score showed modest discrimination during
internal validation and external validation in 8136 patients
enrolled in the PROTECT (Patient-Related Outcomes with
Endeavor vs Cypher Stenting) trial [83]. Importantly,
patients with a high DAPT score (i.e., score C2) derived a
larger reduction in MI and stent thrombosis after a pro-
longed 30-month DAPT (risk difference -3.0%; 95% CI -
4.1 to -2.0; p\ 0.001), with only a modest increase in
major bleeding (risk difference 0.4%; 95% CI -0.3 to 1.0;
p = 0.26). In turn, patients with a low DAPT score (i.e.,
score\2) did not derive any reduction of ischemic events
from prolonging DAPT (risk difference -0.7%; 95% CI -
1.4 to 0.09; p = 0.07), but suffered a signiﬁcant increase in
major bleeding (risk difference 1.5%, 95% CI 0.8–2.3,
p\ 0.001). The DAPT score appeared to signiﬁcantly
modulate the outcomes for DAPT duration both for
ischemic (Pint\ 0.001) and bleeding events (Pint = 0.02).
Still, these ﬁgures were not conﬁrmed in the everolimus-
eluting stent subgroup (ischemia Pint = 0.18; bleeding
Pint = 0.15) [83].
Although the DAPT score represented the ﬁrst attempt
to develop a speciﬁc tool to guide DAPT decision making,
it suffers from several limitations due to the original trial
design and population. The population of the DAPT trial
was highly selected due to the initial run-in phase of the
study, which excluded almost 50% of the initially screened
population [5]. As per the DAPT trial design, the DAPT
score is only able to inform the decision to continue or not
continue DAPT beyond 12 months, whereas it cannot
inform earlier DAPT suspension within the ﬁrst year of
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treatment. Since current guidelines recommend at least
6 months of DAPT in stable patients, and most bleeding
events occur early after treatment initiation, earlier treat-
ment decision making at the time of PCI or in the ﬁrst
3–6 months of treatment is advisable [6]. Hence, whether
the DAPT score performance might be replicated in an
external population to provide earlier decision making for
DAPT duration remains to be ascertained. In a recent
analysis, the DAPT score failed to demonstrate a differ-
ential treatment effect within the ﬁrst year of treatment, and
inform decision making for 6 versus 12 months’ DAPT
after implantation of predominantly second-generation
DES in the ISAR-SAFE trial [84].
More recently, the PRECISE-DAPT (PREdicting
bleeding Complications In patients undergoing Stent
implantation and subsEquent Dual Anti Platelet Therapy)
study group pooled data from eight RCTs and 14,963
patients with indication for DAPT who underwent elective,
urgent, or emergent PCI [85]. The aim of the study was to
ﬁnd independent predictors at the time of PCI of long-term
bleeding while on DAPT and develop a predicting tool to
inform DAPT duration earlier at the time of stent implan-
tation. In fact, the median time to a ﬁrst major bleeding
after DAPT initiation was %5 months in the PRECISE-
DAPT study. Ultimately, a simple ﬁve-item (age, crea-
tinine clearance, hemoglobin, white blood cell count, prior
spontaneous bleeding) prediction algorithm for the pre-
diction of out-of-hospital bleeding in patients treated with
DAPT was proposed.
The predictive performance of this novel score was
assessed in the derivation cohort and validated in 8595 and
6172 patients treated with PCI from the PLATO trial and
BernPCI registry, respectively [86]. The PRECISE-DAPT
score showed good discrimination in both validation
cohorts and appeared superior to its comparator (i.e.,
PARIS bleeding score [87]) in terms of integrated dis-
crimination and net reclassiﬁcation [85].
The PRECISE-DAPT score was tested in patients ran-
domized to different DAPT durations (N = 10,081) to
evaluate bleeding and ischemic events resulting from a
long (12–24 months) or short (3–6 months) treatment
duration in relation to the score-predicted bleeding risk
[85].
It was observed that among patients deemed at high
bleeding risk based on PRECISE DAPT (score C25),
prolonged DAPT compared with short DAPT was associ-
ated with no ischemic beneﬁt and a signiﬁcant bleeding
increase, resulting in one major bleeding incident for every
38 patients treated. On the other hand, a prolonged DAPT
in patients without high bleeding risk at baseline (score
\25) was not associated with a signiﬁcant excess of
bleeding compared with short DAPT, but provided a sig-
niﬁcant reduction of the composite ischemic endpoint of
MI, deﬁnite stent thrombosis, stroke, and target vessel
revascularization, preventing one ischemic event for every
65 patients treated. The favorable proﬁle of this decision-
making algorithm remained consistent when the analysis
was conﬁned to patients presenting with ACS at the time of
stent implantation. Hence, addressing upfront at the time of
PCI a\12-month treatment duration in patients deemed at
high bleeding risk (PRECISE-DAPT score C25) may
prevent exposing them to an excessive bleeding hazard. In
turn, patients at non-high bleeding risk (PRECISE-DAPT
score\25) might receive a standard (i.e., 12 months) or a
prolonged (i.e.[12 months) course of treatment if toler-
ated [85].
It should be emphasized that the accuracy of these
prediction tools ranged from low/moderate to good, and
clinicians must remain aware that these tools cannot be a
substitute for a case-by-case clinical evaluation [88]. In
addition, none of these risk prediction models has been
prospectively tested in the setting of prospective RCTs;
hence, their value in improving patient outcomes requires
further investigation.
4 Future Studies
Optimization of DAPT duration remains the subject of
intense investigation. Since international guidelines
entailed the possibility of a very short (i.e., 1 month)
DAPT course after BMS in patients at high risk for
bleeding, and several studies showed that novel DES are
safer than BMS in terms of device-related adverse events
during a standard [56] or abbreviated DAPT course [36],
the optimal duration of DAPT in patients at high bleeding
risk and treated with contemporary DES is under
investigation.
The MASTER-DAPT (Management of High Bleeding
Risk Patients Post-Bioresorbable Polymer Coated Stent
Implantation with an Abbreviated Versus Prolonged DAPT
Regimen) study (NCT03023020) will enroll patients
deemed at high bleeding risk undergoing PCI with biore-
sorbable polymer-coated stent implantation, and will
evaluate the safety of an abbreviated treatment with DAPT
(i.e., 1 month) compared with the guideline-recommended
standard of care (i.e., at least 3 or 6 months of DAPT in
patients with or without concomitant need for oral antico-
agulation). High bleeding risk inclusion criteria in the
MASTER-DAPT study will include an indication for oral
anticoagulants, PRECISE-DAPT score C25, the occur-
rence of a recent or previous bleeding event for which the
underlying cause has not been deﬁnitively treated, older
age, diagnosed malignancy at high bleeding risk, and other
clinical factors. The study will be powered to test the non-
inferiority in terms of NACE and MACCE of the
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abbreviated DAPT regimen compared with the standard of
care, and its superiority with respect to the occurrence of
major bleeding within 12 months (Table 2).
European guidelines also entail the possibility of
shortening DAPT duration from 12 months down to
6 months in patients presenting with ACS and deemed at
high bleeding risk [6, 7]. This treatment opportunity has
been explored in sub-group analyses [64, 67, 85] and meta-
analyses [9, 65], yet prospective data are lacking. The
SMART-DATE (Safety of 6-Month Duration of Dual
Antiplatelet Therapy After Acute Coronary Syndromes)
study will enroll 2700 patients treated with PCI after an
ACS and evaluate whether 6 months of DAPT is non-in-
ferior to 12 months in terms of MACCE at 18 months
(NCT01701453). Similarly, the REDUCE study will
evaluate the feasibility of 3 months DAPT after ACS and
implantation of a novel biodegradable polymer sirolimus-
eluting stent with a progenitor cell-capturing technology,
which should favor early stent endothelization
(NCT02118870) (Table 2). However, these trials when
available have to be interpreted with caution given the non-
inferiority design and the low number of patients included.
The GLOBAL LEADERS (NCT01813435), TWI-
LIGHT (NCT02270242) and STOPDAPT-2
(NCT02619760) studies will investigate whether, at the
time DAPT is stopped, continuation of treatment with a
P2Y12 inhibitor monotherapy leads to more favorable
outcomes compared with aspirin monotherapy (Table 2)
[89, 90].
Finally, treatment duration in patients that received a
bioresorbable vascular scaffold (BVS) remains an impor-
tant matter of debate [91]. Current BVS technology showed
a higher risk of device thrombosis, especially late after
implantation, which might be related to the slow resorption
process of the scaffold [92, 93]. Thus, a general recom-
mendation regarding DAPT duration cannot be extrapo-
lated to patients treated with the current generation of BVS,
and whether these patients might beneﬁt from longer
DAPT treatment due to their higher thrombotic milieu is
suggestive, but still not supported by prospective data.
With this purpose in mind, the BVS LATE study will
evaluate optimal DAPT duration in 2000 patients who
received BVS and underwent an initial uneventful treat-
ment with DAPT for 12–14 months (NCT02939872)
(Table 2).
5 Conclusions
In August 2017, the European Society of Cardiology will
publish the Focused Update on Dual Antiplatelet Therapy
in Coronary Artery Disease, which is the ﬁrst document of
its kind that will maintain a speciﬁc focus on DAPTT
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abbreviated DAPT regimen compared with the standard of
care, and its superiority with respect to the occurrence of
major bleeding within 12 months (Table 2).
European guidelines also entail the possibility of
shortening DAPT duration from 12 months down to
6 months in patients presenting with ACS and deemed at
high bleeding risk [6, 7]. This treatment opportunity has
been explored in sub-group analyses [64, 67, 85] and meta-
analyses [9, 65], yet prospective data are lacking. The
SMART-DATE (Safety of 6-Month Duration of Dual
Antiplatelet Therapy After Acute Coronary Syndromes)
study will enroll 2700 patients treated with PCI after an
ACS and evaluate whether 6 months of DAPT is non-in-
ferior to 12 months in terms of MACCE at 18 months
(NCT01701453). Similarly, the REDUCE study will
evaluate the feasibility of 3 months DAPT after ACS and
implantation of a novel biodegradable polymer sirolimus-
eluting stent with a progenitor cell-capturing technology,
which should favor early stent endothelization
(NCT02118870) (Table 2). However, these trials when
available have to be interpreted with caution given the non-
inferiority design and the low number of patients included.
The GLOBAL LEADERS (NCT01813435), TWI-
LIGHT (NCT02270242) and STOPDAPT-2
(NCT02619760) studies will investigate whether, at the
time DAPT is stopped, continuation of treatment with a
P2Y12 inhibitor monotherapy leads to more favorable
outcomes compared with aspirin monotherapy (Table 2)
[89, 90].
Finally, treatment duration in patients that received a
bioresorbable vascular scaffold (BVS) remains an impor-
tant matter of debate [91]. Current BVS technology showed
a higher risk of device thrombosis, especially late after
implantation, which might be related to the slow resorption
process of the scaffold [92, 93]. Thus, a general recom-
mendation regarding DAPT duration cannot be extrapo-
lated to patients treated with the current generation of BVS,
and whether these patients might beneﬁt from longer
DAPT treatment due to their higher thrombotic milieu is
suggestive, but still not supported by prospective data.
With this purpose in mind, the BVS LATE study will
evaluate optimal DAPT duration in 2000 patients who
received BVS and underwent an initial uneventful treat-
ment with DAPT for 12–14 months (NCT02939872)
(Table 2).
5 Conclusions
In August 2017, the European Society of Cardiology will
publish the Focused Update on Dual Antiplatelet Therapy
in Coronary Artery Disease, which is the ﬁrst document of
its kind that will maintain a speciﬁc focus on DAPTT
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throughout the spectrum of CAD. After more than 20 years
from the ﬁrst appraisal of its value in preventing stent
thrombosis, DAPT has been one of the most extensively
investigated treatments in cardiology. This effort resulted
in a signiﬁcant amount of data, which have provided a solid
basis for guidelines recommendations. While results of the
main studies are apparently inconsistent throughout, dif-
ferences in study designs, type of coronary devices, and
targeted populations should be taken into account to rec-
oncile these differences. Ultimately, current evidence is
consistent with the notion that longer DAPT duration is
associated with a reduction of non-fatal ischemic events,
but also with an increase in major bleeding of the same/
similar order of magnitude. In order to disentangle these
risks and maximize treatment beneﬁts, DAPT duration
should be individualized on a single-patient basis, taking
into account the baseline ischemic versus bleeding risk
status.
The individualization of DAPT duration should be based
on several clinical and procedural considerations, as well as
dedicated, clinical risk scores that might better inform the
decision making in the context of a comprehensive clinical
evaluation. This should be equally based on the evaluation
of patients’ risks and their needs and preferences, in order
to also improve quality of life and adherence. The concept
of treatment individualization was beautifully described
more than 2400 years ago by the father of western medi-
cine, Hippocrates, who stated ‘‘It’s more important to know
what sort of person has a disease than to know what sort of
disease a person has’’. In the time of ‘precision’ cardio-
vascular medicine, this ancient adage appears indeed
extremely modern.
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throughout the spectrum of CAD. After more than 20 years
from the ﬁrst appraisal of its value in preventing stent
thrombosis, DAPT has been one of the most extensively
investigated treatments in cardiology. This effort resulted
in a signiﬁcant amount of data, which have provided a solid
basis for guidelines recommendations. While results of the
main studies are apparently inconsistent throughout, dif-
ferences in study designs, type of coronary devices, and
targeted populations should be taken into account to rec-
oncile these differences. Ultimately, current evidence is
consistent with the notion that longer DAPT duration is
associated with a reduction of non-fatal ischemic events,
but also with an increase in major bleeding of the same/
similar order of magnitude. In order to disentangle these
risks and maximize treatment beneﬁts, DAPT duration
should be individualized on a single-patient basis, taking
into account the baseline ischemic versus bleeding risk
status.
The individualization of DAPT duration should be based
on several clinical and procedural considerations, as well as
dedicated, clinical risk scores that might better inform the
decision making in the context of a comprehensive clinical
evaluation. This should be equally based on the evaluation
of patients’ risks and their needs and preferences, in order
to also improve quality of life and adherence. The concept
of treatment individualization was beautifully described
more than 2400 years ago by the father of western medi-
cine, Hippocrates, who stated ‘‘It’s more important to know
what sort of person has a disease than to know what sort of
disease a person has’’. In the time of ‘precision’ cardio-
vascular medicine, this ancient adage appears indeed
extremely modern.
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Abstract The joint European Society of Cardiology and Eu-
ropean Association of Cardio-Thoracic Surgery (ESC/
EACTS) guidelines on myocardial revascularization collect
and summarize the evidence regarding decision-making, di-
agnostics, and therapeutics in various clinical scenarios of
coronary artery disease, including elective, urgent, and emer-
gency settings. The 2014 document updates and extends the
effort started in 2010, year of the first edition of these guide-
lines. Importantly, this latest edition provides a systematic
review of all randomized clinical trials performed since
1980, comparing different strategies of myocardial revascular-
ization, including coronary artery bypass graft (CABG), bal-
loon angioplasty, percutaneous coronary intervention (PCI)
with bare-metal stents (BMS) and first- and second-
generation drug-eluting stents (DES). This review aims to
highlight the most relevant novelties introduced by the 2014
edition of the ESC/EACTS myocardial revascularization
guidelines as compared with the previous edition and to de-
scribe similarities and differences with the American socie-
ties’ guidelines.
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Introduction
The most recent edition of the European Society of Cardiology
(ESC) and the European Association for Cardio-Thoracic Sur-
gery (EACTS) joint guidelines on myocardial revasculariza-
tion celebrates the 50th anniversary of the first coronary artery
bypass graft (CABG) procedure [1, 2]. The first percutaneous
coronary revascularization procedure was performed only
13 years thereafter, in 1977. Since their first introduction, re-
vascularization techniques gained expertise and clinical rele-
vance worldwide, becoming one of the most commonly per-
formed interventions in modern medicine. The ESC joint
guidelines inform European and non-European practitioners
since the early 2000s and represent the endeavor of dozens of
clinical and research professionals in the field of cardiovascular
medicine. The 2014 edition of the ESC/EACTS revasculariza-
tion guidelines provides a concise and updated summary of the
evidence surrounding the value of revascularization in various
clinical scenarios, including elective, urgent, and emergency
settings. Unique to this edition, they provide a systematic re-
view of all randomized clinical trials performed since 1980,
comparing different strategies of myocardial revascularization,
including CABG, balloon angioplasty, percutaneous coronary
intervention (PCI) with bare-metal stents (BMS) and first- and
second-generation drug-eluting stents (DES).
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The following perspective paper is intended to highlight
the most relevant novelties in the field of revascularization
introduced in these guidelines, as compared with the previous
2010 edition [3]. In addition, similarities and differences with
respect to the American societies’ guidelines on myocardial
revascularization are discussed whenever proper [4–9].
The Heart Team: from Inception to Mainstream
The 2010 edition of the ESC guidelines introduced and
strongly empowered the concept of the Heart Team. This has
been a great achievement whereby all relevant cardiac special-
ties and heart care providers are brought together to choose the
best revascularization modality for each single patient. Cur-
rent guidelines further extend the importance of the Heart
Team discussion, by inciting the development of shared insti-
tutional protocols, in order to better select the patients that
deserve a multidisciplinary evaluation, saving time, resources,
and delays of urgent procedures, especially in centers without
on-site surgery. American guidelines also advocate the insti-
tution of the Heart Team, indicating the need for multidisci-
plinary discussion in patients with left main coronary artery
disease (CAD) or complex multivessel CAD.
Applying Risk Scores in Practice
Aiming at achieving the best revascularization modality for
each individual patient, the 2014 ESC/EACTS revasculariza-
tion guidelines have updated and expanded the risk score sec-
tion. The Society of Thoracic Surgeons (STS) score is recog-
nized as the appropriate, recommended tool to stratify surgical
risk during CABG, whereas the role of the EuroScore has
been reconsidered and its use is no longer indicated, based
on the concern that it overestimates the surgical risk
(Table 1). However, the newly introduced EuroScore II
overcomes this limitation, and its use should be preferred over
the first iteration of this surgical risk score.
The Synergy Between Percutaneous Coronary Intervention
with TAXUS and Cardiac Surgery (SYNTAX) score, introduced
in the previous edition, is now recommended for the risk strati-
fication of patients who undergo revascularization (CABG vs.
PCI). The more recent SYNTAX II score has been introduced in
this guidelines edition for the very first time (Table 1). The latter
is a combination of anatomical and clinical factors that were
found to be superior to the conventional SYNTAX score in guid-
ing decision-making between CABG and PCI [10].
Among the aforementioned scores, STS and SYNTAX are
also mentioned in the American guidelines as reasonable tools
to guide the decision-making of the revascularization modality.
Revascularization of the Left Main Coronary Artery
There is increasing evidence that both CABG and PCI may
provide effective treatment for selected patients with left main
CAD, especially those with an overall low to intermediate an-
atomical complexity. A prespecified analysis of the SYNTAX
trial evaluated a subgroup of patients with predominant distal
left main disease [11]. Despite its limited statistical power, this
study showed that CABG and PCI had a comparable rate of the
primary endpoint—a composite of death, myocardial infarc-
tion, stroke, and repeat revascularization—in the low and inter-
mediate SYNTAX tertile (SYNTAX score ≤22 and SYNTAX
score 23–32). In contrast, it observed a numerical increase of
deaths and a significant increase of repeat revascularizations in
the PCI group with the highest SYNTAX tertile (SYNTAX
>32). In keeping with this, the PRECOMBAT trial showed
comparable outcomes at 1 and 2 years in patients with LM
disease treated with CABG or PCI [12].
Based on these data, the indication for PCI of left main
CAD with low anatomical complexity (SYNTAX score ≤22)
has been upgraded and now equated to CABG, whereas in
anatomies with intermediate (SYNTAX score 23–32) com-
plexity, PCI should be considered, but CABG remains the
preferred revascularization modality (Table 2).
Similar to the 2010 edition, the most recent revasculariza-
tion guidelines reiterate the contraindication to the elective
treatment of left main CAD with PCI, in case of high anatom-
ical complexity (SYNTAX >32) in patients who have an ac-
ceptable surgical risk (Table 2). Properly powered trials eval-
uating the outcomes of the new-generation DES vs. CABG
are still lacking. The EXCEL trial is expected to provide im-
portant insights on this matter.
At variance from the European document, the American
societies’ guidelines recommend CABG for the treatment of
left main CAD and suggest PCI as an alternative in patients
with an increased surgical risk and an amenable anatomy [4, 6,
9] (Table 2).
Table 1 Comparison among guidelines indications for risk scoring
ESC GL 2014 ESC GL 2010 American societies’ GL
CABG PCI CABG PCI CABG and PCI
STS score I B – I B – • IIa Ba
EuroScore III B III C I B IIb B –
EuroScore II IIa B IIb C – – –
SYNTAX I B I B III B IIa B • IIa Ba
SYNTAX II IIa B IIa B – – –
ESC European Society of Cardiology, GL guidelines
a From the 2011 ACCF/AHA/SCAI PCI Guideline [4]: this document
specifies that calculation of STS and SYNTAX is reasonable in patients
with unprotected left main and complex CAD
J. of Cardiovasc. Trans. Res.
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Revascularization of the Proximal Left Anterior
Descending Artery
PCI indication was upgraded for the treatment of the proximal
left anterior descending artery (LAD) disease (Table 3). In this
regard, one study comparing PCI with DES and CABG in
patients with isolated proximal LAD disease demonstrated
similar outcomes over a 10-year follow-up [13]. Similarly,
no survival benefit with CABG vs. PCI was observed for the
treatment of two-vessel disease including proximal LAD. Ac-
cordingly, PCI is now equally recommended as CABG for the
treatment of proximal LAD alone as well as in the context of a
two-vessel disease. This recommendation slightly diverges
from the American document, which considers CABG supe-
rior for the treatment of two-vessel disease including the prox-
imal LAD [6, 9].
Revascularization for Three-Vessel Coronary Artery
Disease
At variance with previous guidelines, PCI is now equally rec-
ommended as CABG for the treatment of three-vessel disease
with a low anatomical complexity (SYNTAX score≤22)
[14–16], whereas in more complex anatomies (SYNTAX
score >22), PCI is still contraindicated (Table 4).
These recommendations are largely based on the results of
the 5-year follow-up of the SYNTAX trial. CABG showed
better outcomes in the overall three-vessel disease population,
whereas PCI demonstrated to be a reasonable alternative in
those with a low SYNTAX score ≤22, although at the price of
an increased risk of repeat revascularization [16]. The risk of
stroke in this population has been shown to be lower after PCI
as compared to CABG. The SYNTAX trial tested the effect of
TAXUS stent implantation, a first-generation DES. Given the
overwhelming evidence showing superior outcomes when
newer generation DES are compared to paclitaxel-eluting
stent in patients undergoing coronary stent implantation, it
remains likely that the use of newer generation DES may
further improve the efficacy and safety of PCI when compared
to CABG in this high-risk population. This hypothesis re-
quires validation in prospective clinical trials.
Revascularization in Patients with Comorbidities
The 2014 edition largely focuses on revascularization modal-
ities in patients with various comorbidities, especially diabetes
mellitus and chronic kidney disease.
Table 2 Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD and left main coronary artery disease with suitable
anatomy and low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GLc
CABG PCI CABG PCI PCI
SYNTAX score ≤22 I B I B I A IIa/b Ba • IIa B—if low risk of PCI complications and significantly increased
surgical risk (e.g., STS ≥5 %)
SYNTAX score 23–32 I B IIa B I A IIb Bb • IIb B—if low to intermediate risk of PCI complications and increased
surgical risk (e.g., STS >2 %)
SYNTAX score >32 I B III B I A III B • III B—if unfavorable anatomy for PCI and good candidates for CABG
GL guidelines
a Indication IIa B for left main lesion at ostium/shaft. Indication IIb B for left main lesion at distal bifurcation
b Indication for left main disease associated to two- or three-vessel disease and a SYNTAX score ≤32
c Indication to improve survival with revascularization as compared to medical therapy
Table 3 Recommendation for
the type of revascularization
(CABG or PCI) in patients with
SCAD and proximal left anterior
descending coronary artery
disease with suitable anatomy and
low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GLa
CABG PCI CABG PCI
One-vessel disease I A I A I A IIa B • IIa B for CABG with LIMA
• IIb B for PCI
Two-vessel disease I B I C I A IIa B • I B for CABG
• IIb B for PCI
GL guidelines
a Indication to improve survival with revascularization as compared to medical therapy
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CABG is strongly recommended over PCI for patients with
diabetes and multivessel disease, provided surgical risk is ac-
ceptable. In cases where a percutaneous treatment is indicated,
new-generation DES should be preferred over bare-metal
stents [15, 17]. In keeping with this, American guidelines also
indicate CABG as the treatment of choice in patients with
diabetes and multivessel disease [9].
These recommendations are mainly based on the results of
the FREEDOM trial [15]; this study randomized diabetic pa-
tients with multivessel disease to CABG or PCI+DES and
found a significantly higher rate of the primary endpoint—a
composite of death, myocardial infarction, and stroke—in the
PCI group. Moreover, death and myocardial infarction oc-
curred more frequently in the PCI group, whereas stroke rate
was higher after CABG. Similar results are provided by a
recent meta-analysis that confirmed a survival benefit of
CABG over PCI in diabetic patients with multivessel disease,
irrespectively the use of DES or BMS [17].
As in diabetic patients, new guidelines recommend
new-generation DES over BMS in patients with chronic
kidney disease (CKD). In patients with CKD and
multivessel disease, CABG is still the treatment of choice,
with off-pump CABG that may be preferred over the on-
pump approach [18].
The lack of properly powered randomized trials comparing
different revascularization modalities is notable in this setting.
In patients at risk of contrast-induced acute kidney injury, the
use of short-term, high-dose statin therapy should be consid-
ered [19].
Antiplatelet Therapy and Revascularization
New guidelines no longer indicate to pretreat with clopidogrel
all patients scheduled for a diagnostic coronary angiogram
(Supplementary Table 1); indeed, pretreatment did not outper-
form no-pretreatment option in a meta-analysis of 37,814 pa-
tients, which included both prospective controlled studies and
retrospective registry data [20]. Differently, it remains reason-
able to pretreat patients with known coronary anatomy sched-
uled for PCI. Pretreatment may still be considered in cases
where the probability of CAD is high and the anticipated need
for urgent CABG unlikely.
The indications for dual antiplatelet therapy (DAPT) dura-
tion have been updated (Table 5). In patients with spontaneous
coronary artery dissection (SCAD) receiving a DES, 6-month
DAPT is now recommended. A shortened DAPT duration
may be considered in case of high bleeding risk. This indica-
tion was extrapolated from several trials comparing standard
or prolonged DAPT regimens with shorter courses, which
eventually failed to demonstrate a benefit from a prolonged
DAPT, but rather observed an increased risk of bleeding after
a longer therapy [21, 22].
If the individual ischemic risk is high and bleeding risk is
low, DAPT may be prolonged beyond 6 months. American
guidelines (GL) recommend at least 12 months of therapy in
patients with SCAD treated with DES, unless at high bleeding
risk (Supplementary Table 1).
The novel P2Y12 inhibitors, prasugrel or ticagrelor, are rec-
ommended as first-line treatment during acute coronary syn-
drome (ACS), whereas clopidogrel should be used only when
prasugrel and ticagrelor are not available (Supplementary
Table 2 and 3). American guidelines are less prescriptive
and state that it is reasonable to prefer ticagrelor over
clopidogrel, provided ischemic risk is high and an early inva-
sive strategy is planned, whereas they state that prasugrel
should be preferred over clopidogrel if the bleeding risk is
low [8].
Importantly, after the presentation of the ACCOAST
trial, the European GL now contraindicate the pretreatment
with prasugrel in patients with non-ST-segment elevation-
ACS (NSTE-ACS) and unknown coronary anatomy, given
the increased risk of major bleeding and the lack of is-
chemic benefit [23]. Notably, the administration of P2Y12
inhibitors before catheterization in ST segment elevation
myocardial infarction (STEMI) is recommended, and ide-
ally, they should be administered at the time of the first
medical contact. This recommendation is in keeping with
American guidelines and is supported by a small random-
ized study [24], two observational studies [25, 26], and
one meta-analysis [20] showing a reduction of death and
MACE without increase of bleeding, in STEMI patients
pretreated with clopidogrel.
Table 4 Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD and three-vessel coronary artery disease with
suitable anatomy and low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GL
CABG PCI CABG PCI
SYNTAX score ≤22 I A I B I A IIa B • IIa B—it is reasonable to choose CABG over PCI in patients with complex
three-vessel disease (e.g., SYNTAX >22) who are good candidates for CABGSYNTAX score 23–32 I A III B I A III A
SYNTAX score >32 I A III B I A III A
J. of Cardiovasc. Trans. Res.
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CABG is strongly recommended over PCI for patients with
diabetes and multivessel disease, provided surgical risk is ac-
ceptable. In cases where a percutaneous treatment is indicated,
new-generation DES should be preferred over bare-metal
stents [15, 17]. In keeping with this, American guidelines also
indicate CABG as the treatment of choice in patients with
diabetes and multivessel disease [9].
These recommendations are mainly based on the results of
the FREEDOM trial [15]; this study randomized diabetic pa-
tients with multivessel disease to CABG or PCI+DES and
found a significantly higher rate of the primary endpoint—a
composite of death, myocardial infarction, and stroke—in the
PCI group. Moreover, death and myocardial infarction oc-
curred more frequently in the PCI group, whereas stroke rate
was higher after CABG. Similar results are provided by a
recent meta-analysis that confirmed a survival benefit of
CABG over PCI in diabetic patients with multivessel disease,
irrespectively the use of DES or BMS [17].
As in diabetic patients, new guidelines recommend
new-generation DES over BMS in patients with chronic
kidney disease (CKD). In patients with CKD and
multivessel disease, CABG is still the treatment of choice,
with off-pump CABG that may be preferred over the on-
pump approach [18].
The lack of properly powered randomized trials comparing
different revascularization modalities is notable in this setting.
In patients at risk of contrast-induced acute kidney injury, the
use of short-term, high-dose statin therapy should be consid-
ered [19].
Antiplatelet Therapy and Revascularization
New guidelines no longer indicate to pretreat with clopidogrel
all patients scheduled for a diagnostic coronary angiogram
(Supplementary Table 1); indeed, pretreatment did not outper-
form no-pretreatment option in a meta-analysis of 37,814 pa-
tients, which included both prospective controlled studies and
retrospective registry data [20]. Differently, it remains reason-
able to pretreat patients with known coronary anatomy sched-
uled for PCI. Pretreatment may still be considered in cases
where the probability of CAD is high and the anticipated need
for urgent CABG unlikely.
The indications for dual antiplatelet therapy (DAPT) dura-
tion have been updated (Table 5). In patients with spontaneous
coronary artery dissection (SCAD) receiving a DES, 6-month
DAPT is now recommended. A shortened DAPT duration
may be considered in case of high bleeding risk. This indica-
tion was extrapolated from several trials comparing standard
or prolonged DAPT regimens with shorter courses, which
eventually failed to demonstrate a benefit from a prolonged
DAPT, but rather observed an increased risk of bleeding after
a longer therapy [21, 22].
If the individual ischemic risk is high and bleeding risk is
low, DAPT may be prolonged beyond 6 months. American
guidelines (GL) recommend at least 12 months of therapy in
patients with SCAD treated with DES, unless at high bleeding
risk (Supplementary Table 1).
The novel P2Y12 inhibitors, prasugrel or ticagrelor, are rec-
ommended as first-line treatment during acute coronary syn-
drome (ACS), whereas clopidogrel should be used only when
prasugrel and ticagrelor are not available (Supplementary
Table 2 and 3). American guidelines are less prescriptive
and state that it is reasonable to prefer ticagrelor over
clopidogrel, provided ischemic risk is high and an early inva-
sive strategy is planned, whereas they state that prasugrel
should be preferred over clopidogrel if the bleeding risk is
low [8].
Importantly, after the presentation of the ACCOAST
trial, the European GL now contraindicate the pretreatment
with prasugrel in patients with non-ST-segment elevation-
ACS (NSTE-ACS) and unknown coronary anatomy, given
the increased risk of major bleeding and the lack of is-
chemic benefit [23]. Notably, the administration of P2Y12
inhibitors before catheterization in ST segment elevation
myocardial infarction (STEMI) is recommended, and ide-
ally, they should be administered at the time of the first
medical contact. This recommendation is in keeping with
American guidelines and is supported by a small random-
ized study [24], two observational studies [25, 26], and
one meta-analysis [20] showing a reduction of death and
MACE without increase of bleeding, in STEMI patients
pretreated with clopidogrel.
Table 4 Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD and three-vessel coronary artery disease with
suitable anatomy and low predicted surgical mortality
ESC GL 2014 ESC GL 2010 American societies’ GL
CABG PCI CABG PCI
SYNTAX score ≤22 I A I B I A IIa B • IIa B—it is reasonable to choose CABG over PCI in patients with complex
three-vessel disease (e.g., SYNTAX >22) who are good candidates for CABGSYNTAX score 23–32 I A III B I A III A
SYNTAX score >32 I A III B I A III A
J. of Cardiovasc. Trans. Res.
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Anticoagulant Therapy and Revascularization
The anticoagulation section has also been revised with some
novelties regarding the management of bivalirudin and use of
novel oral anticoagulants (NOAC).
In the previous edition of the European guidelines as well
as in Americans’ [7], bivalirudin had a first-class indication as
recommended anticoagulant during PCI in STEMI compared
to heparin plus glycoprotein IIb/IIIa inhibitors (GPI) (Supple-
mentary Table 3). However, the recently published HEAT
PPCI trial [27] did not show a reduction of bleeding in patients
treated with bivalirudin as compared to heparin alone. Ac-
cordingly, the current document gives bivalirudin a second-
class indication as anticoagulant in the setting of STEMI as
compared to heparin without GPI. While this new indication
has been largely interpreted as downgrading, it should be em-
phasized that previous guidelines set a recommendation of
bivalirudin instead of unfractionated heparin (UFH) plus rou-
tine use of glycoprotein IIb/IIIa inhibitors, whereas the more
recent availability of comparative effectiveness data of
bivalirudin versus UFH alone has made possible to provide
new recommendations of bivalirudin as contrasted to UFH
without routine use of glycoprotein IIb/IIIa inhibitors.
In the NSTE-ACS setting, bivalirudin administered during
the PCI and prolonged for up to 4 h thereafter has a class IA
indication as an alternative to UFH+GPI and is recommended
whenever available (Supplementary Table 2). This indication is
mainly driven by the results of the ACUITYand ISAR-REACT
4 trials where bivalirudin compared to UFH+GPI showed a
similar efficacy and a better bleeding profile [28, 29]. It has to
be highlighted that most of the evidence in this setting comes
from trials testing bivalirudin versus UFH+GPI, a combination
that is no longer routinely applied; thus, confirmation of
bivalirudin benefit in properly powered trials is still needed [30].
In elective patients instead, bivalirudin is recommended in
case of heparin-induced thrombocytopenia (Supplementary
Table 1).
In addition, a prolonged infusion of bivalirudin should now
be considered for up to 4 h after PCI, based on the concern of
an increased risk of acute stent thrombosis.
With respect to NOACS, these guidelines also mention the
possibility of adding a third agent, namely, rivaroxaban, on
top of the standard DAPT with aspirin and clopidogrel for
ACS patients treated with PCI in patients at low bleeding risk.
This is based on the recent ATLAS-ACS2 trial that observed a
mortality benefit from a triple therapy consisting of ASA,
clopidogrel, and low-dose rivaroxaban (i.e., 2.5 twice daily)
in patients recently treated for ACS [31]. However, this was at
an expense of an increase of severe bleeding, and no data
currently exists on the value of rivaroxaban when tested in
patients taking the new P2Y12 inhibitors.
The lack of formal guidance with respect to DAPT duration
in patients requiring long-term oral anticoagulation has now
been overcome with this edition of the guidelines. Also in this
setting, new-generation DES should be preferred over BMS,
provided that the bleeding risk is low (HAS BLED ≤2).
In patients with SCAD with absolute indication to
anticoagulation and low bleeding risk (HAS BLED ≤2), the
duration of the triple therapy—consisting of aspirin,
clopidogrel, and a (N)OAC—should be of at least 1 month
and ideally continued up to 12 months, whereas in patients
presenting ACS, triple therapy should be considered for 6 to
12 months, irrespective of the stent used. Importantly, for pa-
tients at high bleeding risk (HAS BLED>2), the duration of
triple therapy should be of 1 month irrespective the presenta-
tion (i.e., SCAD or ACS) and the type of stent used.
Recommendations on New-Generation Drug-Eluting
Stents
At variance with the previous document, which listed several
relative limitations to the use of DES, in the current edition,
second-generation drug-eluting stents receive an unrestricted
indication of use (Table 6). To support this, a network meta-
analysis recently published byWindecker et al. included more
than 100 studies comparing revascularization and medical
therapy in patients with stable coronary artery disease [32].
This meta-analysis showed a survival benefit for CABG as
compared to medical treatment, in keeping with previous data.
In addition, new-generation DES, but not balloon angioplasty,
BMS, or first-generation DES, showed a survival improve-
ment compared to medical therapy. This is the first report that
demonstrates a reduction of mortality in SCAD with percuta-
neous revascularization. A possible biological explanation for
the survival benefit of these new stents could be related to the
lower risk of myocardial infarction and stent thrombosis. This
is consistent with other recent studies that showed a dramatic
improvement in cardiac outcomes, including cardiac survival,
myocardial infarction, and stent thrombosis with cobalt-
chromium everolimus-eluting stents (new-generation de-
vices), compared with both first-generation DES and bare-
metal stents [33, 32, 34].
According to this evidence, new guidelines recommend
new-generation DES as default in all clinical conditions and
lesion subsets. In addition, the previous concerns associated
with early DAPT cessation are not confirmed by recent data,
and new-generation DES are recommended over BMS also in
patients who may require earlier discontinuation of antiplate-
let therapy. American guidelines profoundly diverge from the
current ESC position and list several, strong contraindication
to DES use as the inability, or the unproven ability, to comply
or tolerate a prolonged DAPT (Table 6). It is worth mention-
ing that American guidelines on percutaneous coronary inter-
vention date back to 2011, so it is possible that these differ-
ences will be in part leveled with updated editions.
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The 2014 edition of the ESC/EACTS guidelines implements
important novelties including the unrestricted indication to
new-generation DES, the modulation of DAPT duration ac-
cording to clinical presentation, and the new indications for
the treatment of left main and three-vessel CAD. The value of
bioresorbable polymer or no-polymer DES overmore conven-
tional durable polymer DES remains under evaluation, and
whether this more sophisticated technology will translate into
improved patient outcomes remains unsettled. The use of bio-
resorbable vascular scaffolds, instead of permanent metallic
DES, while highly promising for restoring physiological ves-
sel motion long-term after intervention remains also a matter
for ongoing research. The recent DAPT and PEGASUS trials
explored the effectiveness of a long-term treatment with a
P2Y12 inhibitor, clopidogrel/prasugrel for the first, ticagrelor
for the latter, showing ischemic benefit for reductions of pa-
t i en t and dev ice -o r i en t ed non- fa t a l endpo in t s ,
counterbalanced by higher bleeding rates [35, 36]. The opti-
mal DAPT type and duration, which maximize the benefits in
terms of ischemic protection and minimize the risks in terms
of bleeding, will be most likely based on the individual pa-
tient’s risk profile. It is probable that in the near future, strat-
egies based on weighting patients risk by the use of clinical
(i.e., risk scores), biochemical (i.e., circulating biomarkers), or
genetic-based tools (i.e., gene polymorphisms) will help phy-
sicians to better individualize this treatment.
The MATRIX program is the first large multicenter study
showing the superiority of the radial as compared to femoral
access, for the reduction of a net clinical benefit endpoint, driv-
en by lower major bleeding and mortality rates [30, 37–41].
Future recommendations will most likely further upgrade the
use of radial over femoral route for ACS patients undergoing
invasive management, which will have implications in terms of
training programs as well as health care quality assessment.
The decision to revascularize a given lesion or vessel in the
near future will likely depend even more on functional param-
eters. Some techniques have already demonstrated solid re-
sults (i.e., fractional flow reserve—FFR) whereas some more
recent potentially simplified iterations look promising (i.e.,
instantaneous wave-free ratio—IFR). The results of future
studies evaluating the incremental value of a routine function-
al evaluation and imaging-based stent optimization algorithm
may further optimize outcomes and patient selection in revas-
cularization procedures. The recent COSIRA study reported
the efficacy of a coronary sinus reducer to relieve symptoms in
patients with refractory angina not amenable for revasculari-
zation. This device may serve the growing proportion of pa-
tients that remains symptomatic despite maximal antianginal
therapy [42]. However, even if the concept of a mechanical
treatment of refractory angina is intriguing, more informative
clinical studies are needed to confirm the role of such device in
clinical practice.
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Table 6 Position of European and American guidelines with respect to the use of drug-eluting stents
ESC GL 2014 ESC GL 2010 American societies’ GL
• Unrestricted use
of new-generation DES
The use of DES is relatively contraindicated if
• Clinical history difficult to obtain, especially in the
setting of acute severe clinical conditions (STEMI
or cardiogenic shock).
• Expected poor compliance with DAPT, including
patients with multiple comorbidities and
polypharmacy.
• Non-elective surgery required in the short-term
that would require interruption of DAPT.
• Increased risk of bleeding.
• Known allergy to ASA or clopidogrel/prasugrel/
ticagrelor.
• Absolute indication for long-term anticoagulation.
• Before implantation of DES, the interventional cardiologist
should discuss with the patient the need for and duration
of DAPT and the ability of the patient to comply with
and tolerate DAPT.
• Balloon angioplasty or BMS should be used in patients
with high bleeding risk, inability to comply with 12 months
of DAPT, or anticipated invasive or surgical procedures
within the next 12 months, during which time DAPT
may be interrupted.
• DES should not be implanted if the patient is not likely to
be able to tolerate and comply with prolonged DAPT
or this cannot be determined before stent implantation.
• DES should not be implanted if the patient is not likely
to be able to tolerate and comply with prolonged DAPT
or this cannot be determined before stent implantation.
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Anticoagulant Therapy and Revascularization
The anticoagulation section has also been revised with some
novelties regarding the management of bivalirudin and use of
novel oral anticoagulants (NOAC).
In the previous edition of the European guidelines as well
as in Americans’ [7], bivalirudin had a first-class indication as
recommended anticoagulant during PCI in STEMI compared
to heparin plus glycoprotein IIb/IIIa inhibitors (GPI) (Supple-
mentary Table 3). However, the recently published HEAT
PPCI trial [27] did not show a reduction of bleeding in patients
treated with bivalirudin as compared to heparin alone. Ac-
cordingly, the current document gives bivalirudin a second-
class indication as anticoagulant in the setting of STEMI as
compared to heparin without GPI. While this new indication
has been largely interpreted as downgrading, it should be em-
phasized that previous guidelines set a recommendation of
bivalirudin instead of unfractionated heparin (UFH) plus rou-
tine use of glycoprotein IIb/IIIa inhibitors, whereas the more
recent availability of comparative effectiveness data of
bivalirudin versus UFH alone has made possible to provide
new recommendations of bivalirudin as contrasted to UFH
without routine use of glycoprotein IIb/IIIa inhibitors.
In the NSTE-ACS setting, bivalirudin administered during
the PCI and prolonged for up to 4 h thereafter has a class IA
indication as an alternative to UFH+GPI and is recommended
whenever available (Supplementary Table 2). This indication is
mainly driven by the results of the ACUITYand ISAR-REACT
4 trials where bivalirudin compared to UFH+GPI showed a
similar efficacy and a better bleeding profile [28, 29]. It has to
be highlighted that most of the evidence in this setting comes
from trials testing bivalirudin versus UFH+GPI, a combination
that is no longer routinely applied; thus, confirmation of
bivalirudin benefit in properly powered trials is still needed [30].
In elective patients instead, bivalirudin is recommended in
case of heparin-induced thrombocytopenia (Supplementary
Table 1).
In addition, a prolonged infusion of bivalirudin should now
be considered for up to 4 h after PCI, based on the concern of
an increased risk of acute stent thrombosis.
With respect to NOACS, these guidelines also mention the
possibility of adding a third agent, namely, rivaroxaban, on
top of the standard DAPT with aspirin and clopidogrel for
ACS patients treated with PCI in patients at low bleeding risk.
This is based on the recent ATLAS-ACS2 trial that observed a
mortality benefit from a triple therapy consisting of ASA,
clopidogrel, and low-dose rivaroxaban (i.e., 2.5 twice daily)
in patients recently treated for ACS [31]. However, this was at
an expense of an increase of severe bleeding, and no data
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The lack of formal guidance with respect to DAPT duration
in patients requiring long-term oral anticoagulation has now
been overcome with this edition of the guidelines. Also in this
setting, new-generation DES should be preferred over BMS,
provided that the bleeding risk is low (HAS BLED ≤2).
In patients with SCAD with absolute indication to
anticoagulation and low bleeding risk (HAS BLED ≤2), the
duration of the triple therapy—consisting of aspirin,
clopidogrel, and a (N)OAC—should be of at least 1 month
and ideally continued up to 12 months, whereas in patients
presenting ACS, triple therapy should be considered for 6 to
12 months, irrespective of the stent used. Importantly, for pa-
tients at high bleeding risk (HAS BLED>2), the duration of
triple therapy should be of 1 month irrespective the presenta-
tion (i.e., SCAD or ACS) and the type of stent used.
Recommendations on New-Generation Drug-Eluting
Stents
At variance with the previous document, which listed several
relative limitations to the use of DES, in the current edition,
second-generation drug-eluting stents receive an unrestricted
indication of use (Table 6). To support this, a network meta-
analysis recently published byWindecker et al. included more
than 100 studies comparing revascularization and medical
therapy in patients with stable coronary artery disease [32].
This meta-analysis showed a survival benefit for CABG as
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BMS, or first-generation DES, showed a survival improve-
ment compared to medical therapy. This is the first report that
demonstrates a reduction of mortality in SCAD with percuta-
neous revascularization. A possible biological explanation for
the survival benefit of these new stents could be related to the
lower risk of myocardial infarction and stent thrombosis. This
is consistent with other recent studies that showed a dramatic
improvement in cardiac outcomes, including cardiac survival,
myocardial infarction, and stent thrombosis with cobalt-
chromium everolimus-eluting stents (new-generation de-
vices), compared with both first-generation DES and bare-
metal stents [33, 32, 34].
According to this evidence, new guidelines recommend
new-generation DES as default in all clinical conditions and
lesion subsets. In addition, the previous concerns associated
with early DAPT cessation are not confirmed by recent data,
and new-generation DES are recommended over BMS also in
patients who may require earlier discontinuation of antiplate-
let therapy. American guidelines profoundly diverge from the
current ESC position and list several, strong contraindication
to DES use as the inability, or the unproven ability, to comply
or tolerate a prolonged DAPT (Table 6). It is worth mention-
ing that American guidelines on percutaneous coronary inter-
vention date back to 2011, so it is possible that these differ-
ences will be in part leveled with updated editions.
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tional durable polymer DES remains under evaluation, and
whether this more sophisticated technology will translate into
improved patient outcomes remains unsettled. The use of bio-
resorbable vascular scaffolds, instead of permanent metallic
DES, while highly promising for restoring physiological ves-
sel motion long-term after intervention remains also a matter
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explored the effectiveness of a long-term treatment with a
P2Y12 inhibitor, clopidogrel/prasugrel for the first, ticagrelor
for the latter, showing ischemic benefit for reductions of pa-
t i en t and dev ice -o r i en t ed non- fa t a l endpo in t s ,
counterbalanced by higher bleeding rates [35, 36]. The opti-
mal DAPT type and duration, which maximize the benefits in
terms of ischemic protection and minimize the risks in terms
of bleeding, will be most likely based on the individual pa-
tient’s risk profile. It is probable that in the near future, strat-
egies based on weighting patients risk by the use of clinical
(i.e., risk scores), biochemical (i.e., circulating biomarkers), or
genetic-based tools (i.e., gene polymorphisms) will help phy-
sicians to better individualize this treatment.
The MATRIX program is the first large multicenter study
showing the superiority of the radial as compared to femoral
access, for the reduction of a net clinical benefit endpoint, driv-
en by lower major bleeding and mortality rates [30, 37–41].
Future recommendations will most likely further upgrade the
use of radial over femoral route for ACS patients undergoing
invasive management, which will have implications in terms of
training programs as well as health care quality assessment.
The decision to revascularize a given lesion or vessel in the
near future will likely depend even more on functional param-
eters. Some techniques have already demonstrated solid re-
sults (i.e., fractional flow reserve—FFR) whereas some more
recent potentially simplified iterations look promising (i.e.,
instantaneous wave-free ratio—IFR). The results of future
studies evaluating the incremental value of a routine function-
al evaluation and imaging-based stent optimization algorithm
may further optimize outcomes and patient selection in revas-
cularization procedures. The recent COSIRA study reported
the efficacy of a coronary sinus reducer to relieve symptoms in
patients with refractory angina not amenable for revasculari-
zation. This device may serve the growing proportion of pa-
tients that remains symptomatic despite maximal antianginal
therapy [42]. However, even if the concept of a mechanical
treatment of refractory angina is intriguing, more informative
clinical studies are needed to confirm the role of such device in
clinical practice.
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Table 1. Respondent characteristics.
Survey before 
AHA (n= 884)
Survey after 
AHA (n=415)
Age 45.0 46.2
Country of work
Europe 65.1% 71.5%
North America 8.0% 9.1%
South America 8.4% 8.4%
Asia 13.9% 4.9%
Africa 3.9% 4.2%
Australia 0.7% 1.9%
Professional figure
Interventional cardiologist (>10 years of experience) 49.8% 56.6%
Interventional cardiologist (>5 years of experience) 20.7% 17.3%
Interventional cardiologist (<5 years of experience) 16.9% 16.4%
Cardiologist in training 5.8% 4.6%
Non-interventional cardiologist 5.7% 4.1%
Other 1.2% 1.0%
Type of practice
University hospital 49.3% 53.7%
Non-academic public hospital 31.5% 29.6%
Private institution 19.3% 21.2%
Chapter 1.3
70
EuroIntervention 2
0
1
5
;11
:68-74
2D:I>@?E9C68:>6?:?A2E:6?EDAC6D6?E:?8H:E9DE23=65:D62D62?5
2>@?E9C68:>6?7@C)A2E:6?ED
C@FE:?6=JAC@=@?865
'*36J@?5@?6J62C*9C66BF2CE6CD@7C6DA@?56?ED564=2C65E92E
E96JE2<63@E9:D4926>:42?53=665:?8C:D<:?E@4@?D:56C2E:@?H96?
AC6D4C:3:?8'*:DE@CJ@7DE6?EE9C@>3@D:DDE6?E:?8@7
E96=67E>2:?@CAC@I:>2==67E2?E6C:@C56D46?5:?84@C@?2CJ2CE6CJ
2?5DE23=6G6CDFDF?DE23=6AC6D6?E2E:@?H6C6E96
4@G2C:2E6D>@DE7C6BF6?E=JFD65:?AC24E:46E@H6:89E96:D4926>:4
C:D<(Figure 1)&?E96@E96C92?5AC6G:@FD3=665:?8286
 2?5 C6?2= 7F?4E:@?  92G6 >@C6 7C6BF6?E=J 366?
:56?E:7:652D:>A@CE2?EE@7@C642DE3=665:?8(Figure 2)*9:D4=:?:42=
2?5	@C 2?8:@8C2A9:4 D6E @7<6J 4@G2C:2E6DFD65 E@AC65:4E :D4926
>:4@C3=665:?8C:D<H2D4@?D:DE6?E24C@DD:?DE:EFE:@?492C24E6C:DE:4D
:624256>:4@C?@E24256>:42?5>65:42=BF2=:7:42E:@?	6IA6C:
6?46 :6 :?E6CG6?E:@?2= 42C5:@=@8:DEH:E9>@C6 E92?
J62CD @7
6IA6C:6?46GD@E96CD@C42C5:@=@8:DE:?EC2:?:?8GD@E96CD
-:E9C6DA64EE@492?86DE@E96:?:E:2==JAC6D4C:365EC62E>6?E
@7A2CE:4:A2?EDC6A@CE65H6:89:?8E96@44FCC6?46@7>:?@C@C?F:
D2?463=665:?8H9:=6@?'*:?E96564:D:@?>2<:?8@?'*
5FC2E:@?27E6C:EDAC6D4C:AE:@?H96C62DE96>2;@C:EJ564=2C652596C
:?8E@E96@C:8:?2==JAC6D4C:365'*5FC2E:@?
*9636=:67E92E7:CDE86?6C2E:@?)2C6>@C6E9C@>3@86?:4E92?
?6H6C86?6C2E:@? 56G:46D 2?5 2D DF49 C6BF:C6 =@?8E6C> '*
H2DH:56=J96=5@H6G6C@7A2CE:4:A2?EDE9@F89E
E92EE96C62C6DE:==:?DF77:4:6?E52E2E@4@?4=F56E92EGF=?6C23:=:EJE@
D9@CE'*:DDE6?EDA64:7:4H:E9:?E964=2DD@7?6H6C86?6C2E:@?
)*96>2;@C:EJ28C665E92ED:I>@?E9'*:D2D276A92C>2
4@=@8:42=DEC2E68J27E6C:>A=2?E2E:@?@7?6H6C86?6C2E:@?)3FE
6IAC6DD652?6657@C>@C64=:?:42=52E2A2CE:4F=2C=J:725FC2E:@?
D9@CE6C E92?D:I>@?E9D :D E@36C64@>>6?5657@C6I2>A=627E6C
:>A=2?E2E:@?@7?6H86?6C2E:@??@?A@=J>6C:4)*96>2;@C:EJ
2=D@DE2E65E92E E96C62C6 :?DF77:4:6?E52E2 E@5C2H4@?4=FD:@?D@?
E96@AE:>2='*5FC2E:@?C68:>6?27E6C3:@C6D@C323=66G6C@=:>FD
G2D4F=2CD4277@=5:>A=2?E2E:@?
(6DA@?56?ED86?6C2==J28C665E92E=@?8E6C>'*6I6CEDAC@
E64E:G667764EDH6==36J@?5E96AC6G6?E:@?@7DE6?EC6=2E65:D4926
>:4C64FCC6?46D
Figure 1.$6/+=/=/6/->A23-290>2/09669A381@+<3+,6/=9<=-9</=
C9?1/8/<+66C?=/>9A/312>2/3=-2+/73-<3=5+0>/<&37:6+8>+>398
7?6>3:6/+8=A/<=+669A/.
Figure 2.$6/+=/=/6/->A23-290>2/09669A381@+<3+,6/=9<=-9</=
C9?1/8/<+66C?=/>9A/312>2/,6//.381<3=5+0>/<&37:6+8>+>398
7?6>3:6/+8=A/<=+669A/.
 ?A2E:6?ED566>652E9:89C:D<@73=665:?8D:IC6DA@?56CD@FE
@7 E6? H:E9 2 8C25:6?E ?@E65 24C@DD AC@76DD:@?2= 24E:G:EJ 
?@?:?E6CG6?E:@?2= 42C5:@=@8:DED 2?5  42C5:@=@8:DED :? EC2:?
:?8H@F=5AC676CE@:>A=2?E32C6>6E2=DE6?ED7@==@H653J
52J
'*
ANTICIPATION AND INTERPRETATION OF TRIAL RESULTS 
PRESENTED AT AHA 2014
67@C6
@7C6DA@?56?ED36=:6G65E92EE966G:56?46
8F:5:?8 '* 5FC2E:@? :? A2E:6?ED C646:G:?8 ) H2D 2G6C286
2?52DD6CE65E92E:EH2D4@?7FD:?8*966IA64E2E:@?D7@CE96
FA4@>:?8EC:2=DH6C62=:8?65E@E96C6DF=ED@7AC6G:@FDC2?5@>:D65
DEF5:6D2G2:=23=62E E92E E:>6  ?56656IA64E65 E96'*
EC:2=?@EE@D9@HE96DFA6C:@C:EJ@7
>@?E9GD>@?E9'*
2?56IA64E65  )() E@ D9@H?@?:?76C:@C:EJ@7 2 D:I
>@?E9'*DEC2E68J2D4@>A2C65E@2>@?E9DEC2E68J(Online 
Table 1)
 ? C6=2E:@? E@ E96'* EC:2= 7@==@H:?8
 @7
C6DA@?56?ED:?E6CAC6E65E96C6DF=ED@7E96EC:2=2DD9@H:?8DF3DE2?
E:2=C6>2:?:?86BF:A@:D636EH66?E96EH@EC62E>6?EDEC2E68:6D:6
6IE6?5655FC2E:@?0
>@?E9D1GDDE2?52C55FC2E:@?0>@?E9D1
:?E6C>D@7677:424J2?5D276EJ82:?DEE9:DC6DA@?565E92E
2DE2?52C5>@?E9'*5FC2E:@?C6>2:?65E96AC676CC654=:?:42=
DEC2E68J(Figure 3)C6A@CE65E92EE92EE96JH6C64@?G:?465
@7E96DFA6C:@C:EJ@7
>@?E9'*5FC2E:@?2?536=:6G65
E92E:ED9@F=5364@>6E96?6HDE2?52C5@742C6*96D6C6DF=EDH6C6
4@?D:DE6?E24C@DD86@8C2A9:4C68:@?D*96C62D@?DC6A@CE657@C?@E
25@AE:?8 E96 6IE6?5655FC2E:@?FD65 :? E96'* EC:2= 2D 2 ?6H
DE2?52C5@742C6H6C64@?46C?C682C5:?83=665:?8C:D<7@C@7
C6DA@?56?EDE96FD6@729:89AC@A@CE:@?@762C=J86?6C2E:@?)
:?E96EC:2=7@C@7C6DA@?56?ED4@?46C?23@FEE969:896C>@C
E2=:EJ@3D6CG65 :? E96
>@?E98C@FA 7@C@7 C6DA@?56?ED
=:>:E65FD6@7?6H'.:?9:3:E@CD7@C@7C6DA@?56?ED2?5
EAPCI SURVEY ON DAPT
6766
1
69
EuroIntervention 2
0
1
5
;11
:68-74
EAPCI dual antiplatelet therapy survey
Introduction
*96 :>A@CE2?46 @7 5F2= 2?E:A=2E6=6E E96C2AJ '* :? A2E:6?ED
H:E924FE64@C@?2CJDJ?5C@>6D2?527E6C4@C@?2CJDE6?E:>A=2?E2
E:@?92D366?DF3DE2?E:2E65:??F>6C@FDEC:2=D2?592D2=D@366?
6?5@CD653J:?E6C?2E:@?2=8F:56=:?6D@H6G6CE96@AE:>2=5FC2
E:@?@7'*27E6C4@C@?2CJDE6?E:?8H9:49>2I:>:D6DE9636?67:ED
:?E6C>D@7:D4926>:4AC@E64E:@?2?5>:?:>:D6DE96C:D<D:?E6C>D@7
3=665:?8C6>2:?DF?4=62C
Editorial, see page 15
6EH66?

2?5
C6DF=ED92G6366?C6A@CE657C@>2?F>
36C@7C2?5@>:D654=:?:42=EC:2=D4@>A2C:?85:776C6?E'*5FC2
E:@?C68:>6?D27E6C4@C@?2CJDE6?E :>A=2?E2E:@?2E27C@>E96D6
DEF5:6D72:=65E@D9@H4=62C6G:56?46@736?67:E:?E6C>D@7:D4926
>:4 6G6?ED :? AC@=@?8:?8 '* 36J@?5 @?6 J62C $@C6@G6C
2'*C68:>6?D9@CE6CE92?>@?E9DH2DD9@H?E@36D276CE92?
E964FCC6?E=JC64@>>6?565>@?E9'*5FC2E:@?FC:?8E96
>6C:42?62CEDD@4:2E:@?)4:6?E:7:4)6DD:@?D


C6DF=ED 7C@> E9C66 255:E:@?2= 4=:?:42= EC:2=D :?G6DE:82E:?8 E96@AE:
>2='*5FC2E:@?27E6CDE6?E:?8:?2?288C682E6@72AAC@I:>2E6=J




C2?5@>:D65A2E:6?EDO'* )()2?5 *# O
H6C6C6A@CE657@CE967:CDEE:>6
 ?E96=:89E@7E962?E:4:A2E65:>A24E@7E9652E27C@>E96D6E9C66
EC:2=D@?4=:?:42=AC24E:46E96FC@A62?DD@4:2E:@?@7'6C4FE2?6@FD
@C@?2CJ ?E6CG6?E:@?D' D@F89E E@2DD6DD E96@A:?:@?D@7
E96 D4:6?E:7:4 4@>>F?:EJ 4@?46C?:?8'*5FC2E:@?3@E9367@C6
2?527E6C
*@5@E9:D E962DD@4:2E:@?F?56CE@@<2G@=
F?E2CJH6332D65DFCG6J@7E964@>>F?:EJC682C5:?8@A:?:@?D@?
'*5FC2E:@?27E6C4@C@?2CJDE6?E:?8*964FCC6?E>2?FD4C:AE:D
2DF>>2CJ@7E96C6DF=ED
Methods
*9:DDFCG6J:?:E:2E:G6H2D56D:8?65E@255C6DDE9C66>2;@C5@>2:?D
4@?46C?:?8 '* 5FC2E:@? : 4=:?:42= AC24E:46 C682C5:?8 '*
5FC2E:@?32D65@?E966G:56?462G2:=23=6367@C6
::E96
6IA64E2E:@?D@7 2?5 E96 C624E:@?D E@ E96 C6DF=ED @7'*  )(
)2?5 *# H9@D6AC:>2CJ7:?5:?8DH6C6AC6D6?E657@CE96
7:CDEE:>65FC:?8
2?5:::E962?E:4:A2E65:>A24E@7E9:D
?6H6G:56?46@?4=:?:42=AC24E:46244@C5:?8E@E96@A:?:@?@7AC24
E:D:?8A9JD:4:2?D44@C5:?8=J E9:DDFCG6JH2D3F:=E :?E@ EH@D6ED
@7BF6DE:@?D5:DEC:3FE65367@C62?527E6C E96
4@?8C6DD
*96 BF6DE:@?D :?4=F565H6C6 5C27E65 3J E96 '  )4:6?E:7:4
@4F>6?E@>>:EE66 2?5 DF3D6BF6?E=J 2AAC@G65 3J E96' 
3@2C5 *96 DFCG6J H2D F?56CE2<6? FD:?8 2 7C66 H6332D65 DFC
G6J E@@= )FCG6J$@?<6J '2=@ =E@  +) 2?5 4@>AC:D65
>F=E:A=649@:46BF6DE:@?D:?4=F5:?8E96A@DD:3:=:EJ@7255:?87FC
E96C 4@>>6?ED :7 C6BF:C65  EH2D ?@E>2?52E@CJ E@ C6A=J E@ E96
6?E:C6 DFCG6J *96 D2>A=6 A@AF=2E:@? 4@>AC:D65 E96>2:=:?8 =:DE
@7FC@ ?E6CG6?E:@?O E96@77:4:2= ;@FC?2=@7 E96' &G6C2==
2E@E2=@7

:?5:G:5F2=DH6C6:?G:E65E@A2CE:4:A2E6*96:?G:E2
E:@?E@E967:CDEA2CE@7E96DFCG6JH2DD6?E@?E96
E9&4E@36C

2?52C6>:?56CH2DD6?E@?E96E9%@G6>36C
@CE96D64@?5
A2CE@7E96DFCG6JE96:?G:E2E:@?H2DD6?E@?E96?563CF2CJ

2?52C6>:?56C@?E96E963CF2CJ

Results
RESPONDENT CHARACTERISTICS
&7 E96 

 :?G:E2E:@?D D6?E 2 E@E2= @7   2?5 
A9JD:4:2?DC6DA@?565E@E967:CDE2?5E96D64@?5A2CE@7E96
DFCG6JC6DA64E:G6=J>@?8E9@D67@CE967:CDE2?5
 7@C E96 D64@?5A2CE @7 E96 DFCG6JAC@G:565A6CD@?2= 2?5
AC@76DD:@?2= :?7@C>2E:@? H:E9 C6DA64E E@ 286 >65:42= 2?5 :?DE:
EFE:@?2= BF2=:7:42E:@? 2?5 86@8C2A9:4 C68:@? @7 AC24E:46 (Online 
appendix) *96 492C24E6C:DE:4D @7 E96 C6DA@?56?ED 2C6 56E2:=65 :?
Table 1 '2CE:4:A2E:@? :? E96 DFCG6JH2D 8=@32=H:E9 E96>2;@C
:EJ@7C6DA@?56?ED36:?8FC@A62?7@CE967:CDE2?5
7@CE96D64@?5A2CE@7E96DFCG6J(Table 1, Online Figure 1)*96
>2;@C:EJ@7A2CE:4:A2?EDH6C6:?E6CG6?E:@?2=42C5:@=@8:DED2EG2C:@FD
42C66CDE286D2?5
C6DA64E:G6=J7@==@H653J42C5:
@=@8:DED :? EC2:?:?8 2?5 C6DA64E:G6=J 2?5?@?:?E6C
G6?E:@?2=42C5:@=@8:DED2?5C6DA64E:G6=J>:?@C:EJ
@7C6DA@?56CD564=2C65AC@76DD:@?2=BF2=:7:42E:@?D@E96CE92?42C5:
@=@8:42=@?6D2?5C6DA64E:G6=J(Table 1)3@FE92=7@7
A2CE:4:A2?EDH@C<65:?2?24256>:46?G:C@?>6?EH9:=6E96C6>2:?
:?8
H6C6277:=:2E65E@?@?F?:G6CD:EJ32D6546?EC6D@CAC:G2E6
:?DE:EFE:@?D(Table 1)*96>62?286@7C6DA@?56?EDH2DJ62CD
DECLARED CLINICAL PRACTICE OF RESPONDENTS 
CONCERNING DAPT DURATION BEFORE AHA 2014
*96>2:?7:?5:?8D@7 E9:DA2CE@7 E96DFCG6J2C6D9@H?:?Online 
Table 1*96>2;@C:EJ@7C6DA@?56?ED:?5:42E652C64@>
>6?52E:@? 7@C 2 >@?E9'* 5FC2E:@? :? 2== A2E:6?ED EC62E65
H:E9 5CF86=FE:?8 DE6?ED ) @?6 BF2CE6C  D6=64E65
Table 1. Respondent characteristics.
Survey before 
AHA (n= 884)
Survey after 
AHA (n=415)
Age 45.0 46.2
Country of work
Europe 65.1% 71.5%
North America 8.0% 9.1%
South America 8.4% 8.4%
Asia 13.9% 4.9%
Africa 3.9% 4.2%
Australia 0.7% 1.9%
Professional figure
Interventional cardiologist (>10 years of experience) 49.8% 56.6%
Interventional cardiologist (>5 years of experience) 20.7% 17.3%
Interventional cardiologist (<5 years of experience) 16.9% 16.4%
Cardiologist in training 5.8% 4.6%
Non-interventional cardiologist 5.7% 4.1%
Other 1.2% 1.0%
Type of practice
University hospital 49.3% 53.7%
Non-academic public hospital 31.5% 29.6%
Private institution 19.3% 21.2%
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PRACTICE AFTER THE DAPT, ISAR-SAFE AND ITALIC TRIALS
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EAPCI dual antiplatelet therapy survey
INTERPRETATION OF THE SURVEY RESULTS
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INTERPRETATION OF THE SURVEY RESULTS
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Aims Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases
bleeding to a similar extent. We sought to determine the prognostic impact of myocardial infarction (MI) vs. bleed-
ing during an extended follow-up period to gain insight into the trade-off between efﬁcacy and safety among
patients after ACS.
...................................................................................................................................................................................................
Methods
and results
In 12 944 patients with non-ST-segment elevation ACS from the Thrombin Receptor Antagonist for Clinical Event
Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated the relative impact of MI and bleeding
occurring>30 days post-ACS and subsequent all-cause mortality. Bleeding was graded according to Bleeding
Academic Research Consortium (BARC) criteria. MI was associated with a ﬁve-fold increase in mortality. BARC
type 2 and 3, but not type 1, bleeding had a signiﬁcant impact on mortality. MI was associated with a greater risk of
mortality compared with BARC 2 [relative risk (RR) 3.5; 95% conﬁdence interval (CI) 2.08–4.77; P< 0.001] and
BARC 3a bleeding (RR 2.23; 95% CI 1.36–3.64; P ¼ 0.001), and a risk similar to BARC 3b bleeding (RR 1.37; 95%
CI 0.81–2.30; P¼ 0.242). Risk of death after MI was signiﬁcantly lower than after BARC 3c bleeding (RR 0.22; 95%
CI 0.13–0.36; P< 0.001). MI and bleeding had similar time-associations with mortality, which remained signiﬁcant
for several months, still being higher early after the event.
...................................................................................................................................................................................................
Conclusion In patients treated with antiplatelet therapy after ACS, both MI and bleeding signiﬁcantly impacted mortality with
similar time-dependency. Although BARC 2 and 3a bleeding were less prognostic for death than MI, the risk of
mortality was equivalent between BARC 3b bleeding and MI, and was higher following BARC 3c bleeding.
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Aims Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases
bleeding to a similar extent. We sought to determine the prognostic impact of myocardial infarction (MI) vs. bleed-
ing during an extended follow-up period to gain insight into the trade-off between efﬁcacy and safety among
patients after ACS.
...................................................................................................................................................................................................
Methods
and results
In 12 944 patients with non-ST-segment elevation ACS from the Thrombin Receptor Antagonist for Clinical Event
Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated the relative impact of MI and bleeding
occurring>30 days post-ACS and subsequent all-cause mortality. Bleeding was graded according to Bleeding
Academic Research Consortium (BARC) criteria. MI was associated with a ﬁve-fold increase in mortality. BARC
type 2 and 3, but not type 1, bleeding had a signiﬁcant impact on mortality. MI was associated with a greater risk of
mortality compared with BARC 2 [relative risk (RR) 3.5; 95% conﬁdence interval (CI) 2.08–4.77; P< 0.001] and
BARC 3a bleeding (RR 2.23; 95% CI 1.36–3.64; P ¼ 0.001), and a risk similar to BARC 3b bleeding (RR 1.37; 95%
CI 0.81–2.30; P¼ 0.242). Risk of death after MI was signiﬁcantly lower than after BARC 3c bleeding (RR 0.22; 95%
CI 0.13–0.36; P< 0.001). MI and bleeding had similar time-associations with mortality, which remained signiﬁcant
for several months, still being higher early after the event.
...................................................................................................................................................................................................
Conclusion In patients treated with antiplatelet therapy after ACS, both MI and bleeding signiﬁcantly impacted mortality with
similar time-dependency. Although BARC 2 and 3a bleeding were less prognostic for death than MI, the risk of
mortality was equivalent between BARC 3b bleeding and MI, and was higher following BARC 3c bleeding.
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Introduction
Dual antiplatelet therapy (DAPT) reduces the occurrence of both
stent-related and spontaneous myocardial infarction (MI) after acute
coronary syndrome (ACS).1–3 However, this benefit is counterbal-
anced by an increase in bleeding.2–4 Bleeding, which was historically
considered an acceptable price to pay for antithrombotic therapy,
has been recently shown to independently impact mortality, and a
causal relationship is generally accepted, although mechanisms are
not fully understood.5–8 International guidelines not only recommend
at least 12 months of DAPT after ACS or coronary stent implanta-
tion, but they also encourage considering bleeding risk when selecting
treatment duration.9–12Adequately accounting for the efficacy on
coronary thrombotic events and safety in medical decision-making
on type and duration of antiplatelet therapy is challenging.13
In light of recent clinical trial data with DAPT regimens beyond 1
year showing further reduction of ischaemic events at the price of a
similar increase in bleeding, the number of patients who may qualify for
longer-term DAPT is going to increase.14,15 Therefore, it is critical to
understand the prognostic implications of MI, especially spontaneous
MI, relative to bleeding in order to assist clinicians in selecting patients
for more potent or prolonged antiplatelet treatment. Previous studies
reported on the prognostic implications of in-hospital—largely
procedural—bleeding vs. ischaemic events.16,17 However, the impact
of spontaneous (i.e. non-procedural) bleeding occurring later during
treatment has been less extensively investigated,18,19 and its effect on
mortality, depending on the severity and how it compares with the
mortality risks following anMI, remains unclear.
In this analysis, using a large randomized clinical trial of patients
with non-ST-segment elevation (NSTE) ACS with long-term follow-
up, we aimed to assess the relative impact on all-cause mortality of
MI and bleeding occurring late after the initial ACS presentation on
all-cause mortality.
Methods
Patient population
The Thrombin Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome (TRACER) trial design and inclusion and
exclusion criteria have been described previously.20 In brief, TRACER
was an international, prospective, randomized, double-blind trial of vora-
paxar vs. placebo in patients hospitalized for NSTE ACSmanaged accord-
ing to contemporary practice. A total of 12 944 patients from 37
countries and 818 sites were enrolled, and 12 702 who were alive and
free from recurrent MI at 30 days after randomization were considered
in the current analysis.
All enrolled patients had acute symptoms of coronary ischaemia within
24 h before hospital presentation and at least one of the following find-
ings: a cardiac troponin (I or T) or creatine kinase-MB level that was
higher than the upper limit of the normal range or a new ST-segment
depression of >0.1 mV or transient ST-segment elevation (<30min)
of >0.1 mV in at least two contiguous leads. Also, at least two of the fol-
lowing criteria were required: age 55 years; previous MI, percutaneous
coronary intervention (PCI), or coronary artery bypass grafting (CABG);
or presence of diabetes mellitus or peripheral arterial disease.
Study procedures
Patients were randomly assigned in a 1:1 ratio to receive vorapaxar (a
loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter),
which is an oral protease-activated receptor 1 antagonist, or matching
placebo. Type and timing of revascularization were at the discretion of
the operating physician. Concomitant antiplatelet treatments were also
decided by the treating physician and according to international guide-
lines;>90% of patients were treated with clopidogrel during the index
ACS hospitalization.
Endpoints
The endpoint of interest for this analysis was all-cause death. We aimed
to assess the association of mortality with (i) any MI and (ii) bleeding that
was not related to CABG. We only included MI and bleeding events that
occurred at least 30 days after randomization. This time window was jus-
tified by the need to focus only on late events occurring in patients
already stabilized post-ACS, excluding early events that are largely influ-
enced by in-hospital interventional or surgical procedures. Bleeding
events were graded according to the Bleeding Academic Research
Consortium (BARC) criteria.21 In brief, BARC bleeding was defined as fol-
lows: BARC type 1, any bleeding that is not actionable; type 2, any overt,
actionable sign of bleeding; type 3a, overt bleeding with a haemoglobin
drop of 3–5 g/dL or any transfusion; type 3b, overt bleeding with a
haemoglobin drop>5 g/dL, requiring vasopressors, surgical intervention,
or due to cardiac tamponade; type 3c, any intracranial or intraocular
bleeding; type 4, any bleeding that was CABG-related; and finally type 5,
any bleeding resulting in death. MI was classified according to the Third
Universal Definition of Myocardial Infarction.22
An independent clinical events committee (CEC) adjudicated all
events. Definitions were previously described.20 Bleeding events were
classified by the CEC according to the TIMI (Thrombolysis In Myocardial
Infarction) and GUSTO (Global Use of Strategies to Open Occluded
Coronary Arteries) definitions. The BARC classification was derived with
an algorithm on data points adjudicated by the CEC. The ethics commit-
tee or institutional review board of each participating institution
approved the study protocol, and written informed consent was required
prior to study inclusion. The study was conducted in accordance with the
principles of the Declaration of Helsinki. The Duke University
Institutional Review Board approved the use of the TRACER database
for secondary analyses.
Statistical analysis
Demographic and baseline variables were summarized by the worst
BARC bleeding event experienced from 30 days postrandomization (see
Supplementary material online, Table S1) and by whether an MI occurred
during this period (see Supplementary material online, Table S2).
Continuous variables were presented as medians (inter-quartile ranges),
and categorical variables were presented as counts (proportions).
All-cause mortality risk was investigated using Cox proportional haz-
ards models. All models described below included covariates for MI and
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..BARC bleeding during the first 30 days postrandomization, as well as age,
body mass index, female sex, Killip class2 at enrolment, history of periph-
eral arterial disease, prior stroke, prior MI, hypertension, hyperlipidaemia,
diabetes mellitus, smoker at enrolment, and systolic blood pressure at enrol-
ment. Randomized treatment was not included as a covariate in the models
because of the lack of association with all-cause mortality.20 MI and BARC
bleeding events after 30 days were included as time-dependent binary indi-
cators. Risk of recurrent events has been modelled taking into account the
first occurrence of such an event, whereas in case of events of different
severity (i.e. BARC 2 followed by BARC 3 bleeding), these have been con-
sidered as separate covariates. Hazard ratios (HRs) and P-values for the risk
of all-cause death associated with post-30-day bleeding and post-30-day MI
events were obtained from Model 1—BARC 3a, 3b, and 3c bleeding events
were treated the same as BARC 3 bleeding events (Table 1)—and from
Model 2, where they were evaluated separately (Table 2). The relative
hazard of MI vs. bleeding events was estimated from the same models.
Additional analyses investigated the time-dependent nature of the risk of
death associated with post-30-day bleeding and MI events as a function of
the time elapsed since the event. In these analyses, the natural log of the haz-
ard of death was modelled as a function of (i) natural log, (ii) square root, (iii)
quadratic, and (iv) piecewise linear function (with separate slopes for 0–30
days and after 30 days) of time elapsed since the bleeding or MI event. The
best-fitting model was selected using the Akaike Information Criterion. For
patients who experienced both a bleeding event and an MI, both events
were counted and each was considered individually as predictors of death
(i.e. the models included covariates for MI and bleeding events).
All statistical tests were performed at a significance level of 0.05. All
analyses were performed at the Duke Clinical Research Institute
(Durham, NC, USA) using SAS software, version 9.4 (SAS Institute Inc.,
Cary, NC, USA).
....................................................................................................................................................................................................................
Table 1 Model 1: Association between risk of mortality and BARC 1, 2, and 3 (any 3a, 3b, 3c pooled) bleeding events
occurring>30 days after randomization (adjusted for known mortality risk factors)
Covariate Definition Death for
no event
Death for
event
Adjusteda
HR (95% CI)
P-value for
covariate risk (HR)
MI — 3.19% 16.43% 5.36 <0.001
(382/11 984) (118/718) (4.26–6.74)
Any BARC bleeding <0.001
Nuisance (BARC 1) Non-actionable bleeding 3.95% 3.76% 0.89 0.551
(467/11 824) (33/878) (0.61–1.31)
Minor (BARC 2) Any overt, actionable sign of bleeding 3.79% 6.32% 1.70 0.001
(455/11 990) (45/712) (1.23–2.36)
Major (BARC 3a–c) Any overt, actionable bleeding
associated with 3 g/dL hgb drop,
transfusion, or more severe bleeding
3.41% 22.83% 5.73 <0.001
(421/12 356) (79/346) (4.32–7.59)
CI, conﬁdence interval; hgb, haemoglobin; HR, hazard ratio; MI, myocardial infarction; BARC, Bleeding Academic Research Consortium.
aAdjustment covariates include: MI and BARC bleeding through Day 30 post-randomization, age, body mass index, female sex, Killip class2 at enrolment, history of peripheral
arterial disease, prior stroke, prior MI, hypertension, hyperlipidaemia, diabetes mellitus, smoker at enrolment, and systolic blood pressure at enrolment.
....................................................................................................................................................................................................................
Table 2 Model 2: Association between risk of mortality and BARC 1, 2, 3a, 3b, and 3c bleeding events occurring more
than 30 days after randomization (adjusted for known mortality risk factors)
Covariate Definition Death for
no event
Death
for event
Adjusteda
HR (95% CI)
P-value for
covariate risk (HR)
MI — 3.19% 16.43% 6.15 <0.001
(382/11 984) (118/718) (4.90–7.74)
Major bleeding
BARC 3a Overt bleeding with hgb drop 3–5 g/dL
or any transfusion
3.75% 18.29% 2.77 <0.001
(470/12 538) (30/164) (1.86–4.12)
BARC 3b Overt bleeding with hgb drop > 5 g/dL,
requiring vasopressors, surgical intervention,
or due to cardiac tamponade
3.78% 20.00% 4.51 <0.001
(475/12 577) (25/125) (2.86–7.10)
BARC 3c Intracranial or intraocular bleeding 3.76% 42.11% 28.2 <0.001
(476/12 645) (24/57) (17.5–45.7)
CI, conﬁdence interval; hgb, haemoglobin; HR, hazard ratio; MI, myocardial infarction; BARC, Bleeding Academic Research Consortium.
aAdjustment covariates include: MI and BARC bleeding through Day 30 post-randomization, age, body mass index, female sex, Killip class2 at enrolment, history of peripheral
arterial disease, prior stroke, prior MI, hypertension, hyperlipidaemia, diabetes mellitus, smoker at enrolment, and systolic blood pressure at enrolment.
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Introduction
Dual antiplatelet therapy (DAPT) reduces the occurrence of both
stent-related and spontaneous myocardial infarction (MI) after acute
coronary syndrome (ACS).1–3 However, this benefit is counterbal-
anced by an increase in bleeding.2–4 Bleeding, which was historically
considered an acceptable price to pay for antithrombotic therapy,
has been recently shown to independently impact mortality, and a
causal relationship is generally accepted, although mechanisms are
not fully understood.5–8 International guidelines not only recommend
at least 12 months of DAPT after ACS or coronary stent implanta-
tion, but they also encourage considering bleeding risk when selecting
treatment duration.9–12Adequately accounting for the efficacy on
coronary thrombotic events and safety in medical decision-making
on type and duration of antiplatelet therapy is challenging.13
In light of recent clinical trial data with DAPT regimens beyond 1
year showing further reduction of ischaemic events at the price of a
similar increase in bleeding, the number of patients who may qualify for
longer-term DAPT is going to increase.14,15 Therefore, it is critical to
understand the prognostic implications of MI, especially spontaneous
MI, relative to bleeding in order to assist clinicians in selecting patients
for more potent or prolonged antiplatelet treatment. Previous studies
reported on the prognostic implications of in-hospital—largely
procedural—bleeding vs. ischaemic events.16,17 However, the impact
of spontaneous (i.e. non-procedural) bleeding occurring later during
treatment has been less extensively investigated,18,19 and its effect on
mortality, depending on the severity and how it compares with the
mortality risks following anMI, remains unclear.
In this analysis, using a large randomized clinical trial of patients
with non-ST-segment elevation (NSTE) ACS with long-term follow-
up, we aimed to assess the relative impact on all-cause mortality of
MI and bleeding occurring late after the initial ACS presentation on
all-cause mortality.
Methods
Patient population
The Thrombin Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome (TRACER) trial design and inclusion and
exclusion criteria have been described previously.20 In brief, TRACER
was an international, prospective, randomized, double-blind trial of vora-
paxar vs. placebo in patients hospitalized for NSTE ACSmanaged accord-
ing to contemporary practice. A total of 12 944 patients from 37
countries and 818 sites were enrolled, and 12 702 who were alive and
free from recurrent MI at 30 days after randomization were considered
in the current analysis.
All enrolled patients had acute symptoms of coronary ischaemia within
24 h before hospital presentation and at least one of the following find-
ings: a cardiac troponin (I or T) or creatine kinase-MB level that was
higher than the upper limit of the normal range or a new ST-segment
depression of >0.1 mV or transient ST-segment elevation (<30min)
of >0.1 mV in at least two contiguous leads. Also, at least two of the fol-
lowing criteria were required: age 55 years; previous MI, percutaneous
coronary intervention (PCI), or coronary artery bypass grafting (CABG);
or presence of diabetes mellitus or peripheral arterial disease.
Study procedures
Patients were randomly assigned in a 1:1 ratio to receive vorapaxar (a
loading dose of 40 mg and a daily maintenance dose of 2.5 mg thereafter),
which is an oral protease-activated receptor 1 antagonist, or matching
placebo. Type and timing of revascularization were at the discretion of
the operating physician. Concomitant antiplatelet treatments were also
decided by the treating physician and according to international guide-
lines;>90% of patients were treated with clopidogrel during the index
ACS hospitalization.
Endpoints
The endpoint of interest for this analysis was all-cause death. We aimed
to assess the association of mortality with (i) any MI and (ii) bleeding that
was not related to CABG. We only included MI and bleeding events that
occurred at least 30 days after randomization. This time window was jus-
tified by the need to focus only on late events occurring in patients
already stabilized post-ACS, excluding early events that are largely influ-
enced by in-hospital interventional or surgical procedures. Bleeding
events were graded according to the Bleeding Academic Research
Consortium (BARC) criteria.21 In brief, BARC bleeding was defined as fol-
lows: BARC type 1, any bleeding that is not actionable; type 2, any overt,
actionable sign of bleeding; type 3a, overt bleeding with a haemoglobin
drop of 3–5 g/dL or any transfusion; type 3b, overt bleeding with a
haemoglobin drop>5 g/dL, requiring vasopressors, surgical intervention,
or due to cardiac tamponade; type 3c, any intracranial or intraocular
bleeding; type 4, any bleeding that was CABG-related; and finally type 5,
any bleeding resulting in death. MI was classified according to the Third
Universal Definition of Myocardial Infarction.22
An independent clinical events committee (CEC) adjudicated all
events. Definitions were previously described.20 Bleeding events were
classified by the CEC according to the TIMI (Thrombolysis In Myocardial
Infarction) and GUSTO (Global Use of Strategies to Open Occluded
Coronary Arteries) definitions. The BARC classification was derived with
an algorithm on data points adjudicated by the CEC. The ethics commit-
tee or institutional review board of each participating institution
approved the study protocol, and written informed consent was required
prior to study inclusion. The study was conducted in accordance with the
principles of the Declaration of Helsinki. The Duke University
Institutional Review Board approved the use of the TRACER database
for secondary analyses.
Statistical analysis
Demographic and baseline variables were summarized by the worst
BARC bleeding event experienced from 30 days postrandomization (see
Supplementary material online, Table S1) and by whether an MI occurred
during this period (see Supplementary material online, Table S2).
Continuous variables were presented as medians (inter-quartile ranges),
and categorical variables were presented as counts (proportions).
All-cause mortality risk was investigated using Cox proportional haz-
ards models. All models described below included covariates for MI and
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..BARC bleeding during the first 30 days postrandomization, as well as age,
body mass index, female sex, Killip class2 at enrolment, history of periph-
eral arterial disease, prior stroke, prior MI, hypertension, hyperlipidaemia,
diabetes mellitus, smoker at enrolment, and systolic blood pressure at enrol-
ment. Randomized treatment was not included as a covariate in the models
because of the lack of association with all-cause mortality.20 MI and BARC
bleeding events after 30 days were included as time-dependent binary indi-
cators. Risk of recurrent events has been modelled taking into account the
first occurrence of such an event, whereas in case of events of different
severity (i.e. BARC 2 followed by BARC 3 bleeding), these have been con-
sidered as separate covariates. Hazard ratios (HRs) and P-values for the risk
of all-cause death associated with post-30-day bleeding and post-30-day MI
events were obtained from Model 1—BARC 3a, 3b, and 3c bleeding events
were treated the same as BARC 3 bleeding events (Table 1)—and from
Model 2, where they were evaluated separately (Table 2). The relative
hazard of MI vs. bleeding events was estimated from the same models.
Additional analyses investigated the time-dependent nature of the risk of
death associated with post-30-day bleeding and MI events as a function of
the time elapsed since the event. In these analyses, the natural log of the haz-
ard of death was modelled as a function of (i) natural log, (ii) square root, (iii)
quadratic, and (iv) piecewise linear function (with separate slopes for 0–30
days and after 30 days) of time elapsed since the bleeding or MI event. The
best-fitting model was selected using the Akaike Information Criterion. For
patients who experienced both a bleeding event and an MI, both events
were counted and each was considered individually as predictors of death
(i.e. the models included covariates for MI and bleeding events).
All statistical tests were performed at a significance level of 0.05. All
analyses were performed at the Duke Clinical Research Institute
(Durham, NC, USA) using SAS software, version 9.4 (SAS Institute Inc.,
Cary, NC, USA).
....................................................................................................................................................................................................................
Table 1 Model 1: Association between risk of mortality and BARC 1, 2, and 3 (any 3a, 3b, 3c pooled) bleeding events
occurring>30 days after randomization (adjusted for known mortality risk factors)
Covariate Definition Death for
no event
Death for
event
Adjusteda
HR (95% CI)
P-value for
covariate risk (HR)
MI — 3.19% 16.43% 5.36 <0.001
(382/11 984) (118/718) (4.26–6.74)
Any BARC bleeding <0.001
Nuisance (BARC 1) Non-actionable bleeding 3.95% 3.76% 0.89 0.551
(467/11 824) (33/878) (0.61–1.31)
Minor (BARC 2) Any overt, actionable sign of bleeding 3.79% 6.32% 1.70 0.001
(455/11 990) (45/712) (1.23–2.36)
Major (BARC 3a–c) Any overt, actionable bleeding
associated with 3 g/dL hgb drop,
transfusion, or more severe bleeding
3.41% 22.83% 5.73 <0.001
(421/12 356) (79/346) (4.32–7.59)
CI, conﬁdence interval; hgb, haemoglobin; HR, hazard ratio; MI, myocardial infarction; BARC, Bleeding Academic Research Consortium.
aAdjustment covariates include: MI and BARC bleeding through Day 30 post-randomization, age, body mass index, female sex, Killip class2 at enrolment, history of peripheral
arterial disease, prior stroke, prior MI, hypertension, hyperlipidaemia, diabetes mellitus, smoker at enrolment, and systolic blood pressure at enrolment.
....................................................................................................................................................................................................................
Table 2 Model 2: Association between risk of mortality and BARC 1, 2, 3a, 3b, and 3c bleeding events occurring more
than 30 days after randomization (adjusted for known mortality risk factors)
Covariate Definition Death for
no event
Death
for event
Adjusteda
HR (95% CI)
P-value for
covariate risk (HR)
MI — 3.19% 16.43% 6.15 <0.001
(382/11 984) (118/718) (4.90–7.74)
Major bleeding
BARC 3a Overt bleeding with hgb drop 3–5 g/dL
or any transfusion
3.75% 18.29% 2.77 <0.001
(470/12 538) (30/164) (1.86–4.12)
BARC 3b Overt bleeding with hgb drop > 5 g/dL,
requiring vasopressors, surgical intervention,
or due to cardiac tamponade
3.78% 20.00% 4.51 <0.001
(475/12 577) (25/125) (2.86–7.10)
BARC 3c Intracranial or intraocular bleeding 3.76% 42.11% 28.2 <0.001
(476/12 645) (24/57) (17.5–45.7)
CI, conﬁdence interval; hgb, haemoglobin; HR, hazard ratio; MI, myocardial infarction; BARC, Bleeding Academic Research Consortium.
aAdjustment covariates include: MI and BARC bleeding through Day 30 post-randomization, age, body mass index, female sex, Killip class2 at enrolment, history of peripheral
arterial disease, prior stroke, prior MI, hypertension, hyperlipidaemia, diabetes mellitus, smoker at enrolment, and systolic blood pressure at enrolment.
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Results
In the TRACER trial, a total of 12 702 patients were alive and free
from any recurrent MI at 30 days. A total of 718 patients (5.6%) suf-
fered a recurrent MI 30 days after the index event, most of which
were spontaneous (Table 3). Bleeding events occurring during study
follow-up were distributed as follows: BARC 1 occurred in 878
patients (6.9%); BARC 2 occurred in 712 patients (5.6%); BARC 3
occurred in 346 patients (2.7%) (Table 1). More than one post-30-
day MI occurred in 0.98% of patients during follow-up, whereas mul-
tiple BARC 2 or 3 bleeding events occurred in 1.39%. The proportion
of patients experiencing both bleeding and MI during follow-up was
1.46%, with similar rates of patients experiencing an MI first (0.72%)
or bleeding first (0.75%) (Figure 1). Demographic and clinical charac-
teristics of patients experiencing bleeding and MI events are pre-
sented in the Supplementary materia online, Tables S1 and S2,
respectively. Patients with vs. without bleeding were older; more
often affected by dyslipidaemia or diabetes; and more often had a his-
tory of stroke, peripheral vascular disease, and atrial fibrillation.
Patients with vs. without MI were older and more often affected by
hypertension, dyslipidaemia, diabetes, and other comorbidities.
Mortality following bleeding or
myocardial infarction
Death occurred in 500 patients (3.9%) at the end of follow-up.
Table 1 reports the number of patients who died following MI or
bleeding events. When considered as time-dependent covariates in
the multivariable-adjusted model, both post-30-day bleeding and MI
were associated with mortality (Table 1). Patients with an MI�30
days after randomization had a five-fold increase in the hazard of
death [adjusted HR 5.36; 95% confidence interval (CI) 4.26–6.74;
P< 0.001]. BARC 1 bleeding did not affect survival (adjusted HR
0.89; 95% CI 0.61–1.31; P¼ 0.551), whereas BARC 2 and 3 bleeding
types were associated with a significant increase in the risk of mortal-
ity, with a progressive increase in risk with more severe categories of
bleeding (Table 1). When BARC 3 major bleeding subcategories
(BARC 3a, 3b, and 3c) were separately included in a secondmultivari-
ate-adjustedmodel for mortality, a consistent risk progression among
more severe bleeding events was also noted (Table 2). The
prognostic impact was independent from the randomized treatment
with vorapaxar for both MI (Pint¼0.19) and different bleeding types
(BARC 1: Pint¼0.61; BARC 2: Pint¼0.20; BARC 3: Pint¼0.17).
Relative impact of bleeding vs.
myocardial infarction on mortality
The relative impact on mortality of an MI vs. a bleeding event is dis-
played graphically in Figure 2. The relative hazard of death was three-
fold higher in patients experiencing anMI vs. a BARC 2 bleeding event
[5.36 vs. 1.70; relative risk (RR) 3.15; 95% CI 2.08–4.77; P< 0.001],
whereas no significant difference was noted for BARC 3 bleeding
(5.36 vs. 5.73; RR 0.94; 95% CI 0.63–1.40; P¼ 0.747). In a second
adjusted model for mortality that accounted for the BARC 3 subcate-
gories (BARC 3a, 3b, and 3c) separately, the risk of mortality associ-
ated with MI was significantly higher than for BARC 3a bleeding (6.15
vs. 2.77; RR 2.23; 95% CI 1.36–3.64; P¼ 0.001). MI was associated
Figure 1 Distribution of minor and major bleeding and myocar-
dial infarction in the TRACER trial. The Venn diagram shows
patients experiencing minor or major bleeding (in red) and myocar-
dial infarction (in blue). Smaller circles represent patients experienc-
ing more than one event during follow-up. The intersection
represents patients experiencing both myocardial infarction and
bleeding during follow-up. MI, myocardial infarction.
....................................................................................................................................................................................................................
Table 3 Myocardial infarction occurring>30 days after randomization in the TRACER trial, stratiﬁed according to the
Third Universal Deﬁnition of Myocardial Infarction
Event Definition Frequency Valid per cent (%)
Myocardial infarction 718 —
Type 1 Spontaneous 594 82.7
Type 2 Secondary to ischaemic imbalance 46 6.41
Type 3 Resulting in SCD 0 0.0
Type 4a Related to PCI 34 6.69
Type 4b Related to stent thrombosis 35 4.87
Type 5 Related to CABG 7 5.07
STEMI 77 10.75
New Q-wave 31 5.18
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; SCD, sudden cardiac death; STEMI, ST-segment elevation myocardial infarction.
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..with a non-significant increase in the risk of death compared with
BARC 3b bleeding (6.15 vs. 4.51; RR 1.37; 95% CI 0.81–2.30;
P¼ 0.242). Mortality following MI was significantly lower than follow-
ing a BARC 3c bleeding event (6.15 vs. 28.2; RR 0.22; 95% CI 0.13–
0.36; P< 0.001) (Figure 2).
Time relation of bleeding and myocardial
infarction with hazard of mortality
The time-pattern of the associated hazard of mortality was similar
between MI and bleeding events. For both MI and bleeding, the risk
of death was higher early after the event; it rapidly dissipated in the
subsequent days, but it still kept a significant prognostic impact for
several months thereafter. The mortality risk was no longer signifi-
cantly different from that in patients without an MI or bleeding event
215 days after an MI; 183 days after a BARC 2 minor bleeding event;
and 538, 239, and 113 days for BARC 3a, 3b, and 3c bleeding, respec-
tively (Figure 3).
Discussion
We have confirmed the prognostic significance of MI and bleeding
occurring late after hospitalization, and found that the relative prog-
nostic impact of MI compared with bleeding markedly varied based
on the severity of bleeding. The risk of mortality following an MI was
three-fold higher compared with that of BARC 2 bleeding, whereas it
was similar to that of BARC 3 bleeding. When BARC 3 subcategories
were separately appraised, MI had a higher mortality risk than BARC
3a bleeding, and was substantially equivalent to the risk of mortality
following BARC 3b bleeding. Importantly, the risk of death was high-
est after intracranial or intraocular haemorrhages (captured in the
BARC 3c category), and it was �4.5-fold higher than the risk of
bleeding following MI.
Our analysis was based on centrally adjudicated events and ana-
lysed bleeding according to a standardized, widely accepted and
reproducible bleeding definition. Prior analyses have observed a simi-
larly increased risk of mortality between spontaneous MI and bleed-
ing during a 4 year follow-up.23 However, this consideration might
largely depend on bleeding definition and the type of bleeding
Figure 2 Differential impact of myocardial infarction vs. bleeding on mortality. Blue rhombuses represent the magnitude (adjusted hazard ratio) of
the impact on mortality of late myocardial infarction, whereas red rhombuses represent that of bleeding of different severity. On the right part of the
figure, the estimate of the relative risk (ratio of the hazard ratios) for each category is presented. *The estimates of the impact of events on mortality
is derived fromModel 1, including BARC 3 bleeding as a single category. †The estimates of the impact of events on mortality is derived fromModel 2,
including BARC 3 bleeding subcategories separately. MI, myocardial infarction.
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Results
In the TRACER trial, a total of 12 702 patients were alive and free
from any recurrent MI at 30 days. A total of 718 patients (5.6%) suf-
fered a recurrent MI 30 days after the index event, most of which
were spontaneous (Table 3). Bleeding events occurring during study
follow-up were distributed as follows: BARC 1 occurred in 878
patients (6.9%); BARC 2 occurred in 712 patients (5.6%); BARC 3
occurred in 346 patients (2.7%) (Table 1). More than one post-30-
day MI occurred in 0.98% of patients during follow-up, whereas mul-
tiple BARC 2 or 3 bleeding events occurred in 1.39%. The proportion
of patients experiencing both bleeding and MI during follow-up was
1.46%, with similar rates of patients experiencing an MI first (0.72%)
or bleeding first (0.75%) (Figure 1). Demographic and clinical charac-
teristics of patients experiencing bleeding and MI events are pre-
sented in the Supplementary materia online, Tables S1 and S2,
respectively. Patients with vs. without bleeding were older; more
often affected by dyslipidaemia or diabetes; and more often had a his-
tory of stroke, peripheral vascular disease, and atrial fibrillation.
Patients with vs. without MI were older and more often affected by
hypertension, dyslipidaemia, diabetes, and other comorbidities.
Mortality following bleeding or
myocardial infarction
Death occurred in 500 patients (3.9%) at the end of follow-up.
Table 1 reports the number of patients who died following MI or
bleeding events. When considered as time-dependent covariates in
the multivariable-adjusted model, both post-30-day bleeding and MI
were associated with mortality (Table 1). Patients with an MI�30
days after randomization had a five-fold increase in the hazard of
death [adjusted HR 5.36; 95% confidence interval (CI) 4.26–6.74;
P< 0.001]. BARC 1 bleeding did not affect survival (adjusted HR
0.89; 95% CI 0.61–1.31; P¼ 0.551), whereas BARC 2 and 3 bleeding
types were associated with a significant increase in the risk of mortal-
ity, with a progressive increase in risk with more severe categories of
bleeding (Table 1). When BARC 3 major bleeding subcategories
(BARC 3a, 3b, and 3c) were separately included in a secondmultivari-
ate-adjustedmodel for mortality, a consistent risk progression among
more severe bleeding events was also noted (Table 2). The
prognostic impact was independent from the randomized treatment
with vorapaxar for both MI (Pint¼0.19) and different bleeding types
(BARC 1: Pint¼0.61; BARC 2: Pint¼0.20; BARC 3: Pint¼0.17).
Relative impact of bleeding vs.
myocardial infarction on mortality
The relative impact on mortality of an MI vs. a bleeding event is dis-
played graphically in Figure 2. The relative hazard of death was three-
fold higher in patients experiencing anMI vs. a BARC 2 bleeding event
[5.36 vs. 1.70; relative risk (RR) 3.15; 95% CI 2.08–4.77; P< 0.001],
whereas no significant difference was noted for BARC 3 bleeding
(5.36 vs. 5.73; RR 0.94; 95% CI 0.63–1.40; P¼ 0.747). In a second
adjusted model for mortality that accounted for the BARC 3 subcate-
gories (BARC 3a, 3b, and 3c) separately, the risk of mortality associ-
ated with MI was significantly higher than for BARC 3a bleeding (6.15
vs. 2.77; RR 2.23; 95% CI 1.36–3.64; P¼ 0.001). MI was associated
Figure 1 Distribution of minor and major bleeding and myocar-
dial infarction in the TRACER trial. The Venn diagram shows
patients experiencing minor or major bleeding (in red) and myocar-
dial infarction (in blue). Smaller circles represent patients experienc-
ing more than one event during follow-up. The intersection
represents patients experiencing both myocardial infarction and
bleeding during follow-up. MI, myocardial infarction.
....................................................................................................................................................................................................................
Table 3 Myocardial infarction occurring>30 days after randomization in the TRACER trial, stratiﬁed according to the
Third Universal Deﬁnition of Myocardial Infarction
Event Definition Frequency Valid per cent (%)
Myocardial infarction 718 —
Type 1 Spontaneous 594 82.7
Type 2 Secondary to ischaemic imbalance 46 6.41
Type 3 Resulting in SCD 0 0.0
Type 4a Related to PCI 34 6.69
Type 4b Related to stent thrombosis 35 4.87
Type 5 Related to CABG 7 5.07
STEMI 77 10.75
New Q-wave 31 5.18
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; SCD, sudden cardiac death; STEMI, ST-segment elevation myocardial infarction.
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..with a non-significant increase in the risk of death compared with
BARC 3b bleeding (6.15 vs. 4.51; RR 1.37; 95% CI 0.81–2.30;
P¼ 0.242). Mortality following MI was significantly lower than follow-
ing a BARC 3c bleeding event (6.15 vs. 28.2; RR 0.22; 95% CI 0.13–
0.36; P< 0.001) (Figure 2).
Time relation of bleeding and myocardial
infarction with hazard of mortality
The time-pattern of the associated hazard of mortality was similar
between MI and bleeding events. For both MI and bleeding, the risk
of death was higher early after the event; it rapidly dissipated in the
subsequent days, but it still kept a significant prognostic impact for
several months thereafter. The mortality risk was no longer signifi-
cantly different from that in patients without an MI or bleeding event
215 days after an MI; 183 days after a BARC 2 minor bleeding event;
and 538, 239, and 113 days for BARC 3a, 3b, and 3c bleeding, respec-
tively (Figure 3).
Discussion
We have confirmed the prognostic significance of MI and bleeding
occurring late after hospitalization, and found that the relative prog-
nostic impact of MI compared with bleeding markedly varied based
on the severity of bleeding. The risk of mortality following an MI was
three-fold higher compared with that of BARC 2 bleeding, whereas it
was similar to that of BARC 3 bleeding. When BARC 3 subcategories
were separately appraised, MI had a higher mortality risk than BARC
3a bleeding, and was substantially equivalent to the risk of mortality
following BARC 3b bleeding. Importantly, the risk of death was high-
est after intracranial or intraocular haemorrhages (captured in the
BARC 3c category), and it was �4.5-fold higher than the risk of
bleeding following MI.
Our analysis was based on centrally adjudicated events and ana-
lysed bleeding according to a standardized, widely accepted and
reproducible bleeding definition. Prior analyses have observed a simi-
larly increased risk of mortality between spontaneous MI and bleed-
ing during a 4 year follow-up.23 However, this consideration might
largely depend on bleeding definition and the type of bleeding
Figure 2 Differential impact of myocardial infarction vs. bleeding on mortality. Blue rhombuses represent the magnitude (adjusted hazard ratio) of
the impact on mortality of late myocardial infarction, whereas red rhombuses represent that of bleeding of different severity. On the right part of the
figure, the estimate of the relative risk (ratio of the hazard ratios) for each category is presented. *The estimates of the impact of events on mortality
is derived fromModel 1, including BARC 3 bleeding as a single category. †The estimates of the impact of events on mortality is derived fromModel 2,
including BARC 3 bleeding subcategories separately. MI, myocardial infarction.
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..explored.24 In fact, accounting for bleeding severity, we found that
recurrent MI had higher prognostic impact on mortality than bleed-
ing, except for BARC 3c categories. This information is of major
importance, as it indicates that it might be fair to pursue a more
potent antiplatelet regimen to avoid an MI even at the expense of
mild-to-moderate bleeding in patients with high ischaemic risk. In
addition, our data suggest that combining all bleeding, including minor
bleeds that are more frequent but less prognostically significant, into
a safety endpoint or net clinical outcome including MI may pose signif-
icant challenges in interpreting the clinical benefit of drugs.
The temporal association with mortality was similar between MI
and minor or major bleeding. Although the highest risk of mortality
was present in the first week after the event, its magnitude rapidly
decreased thereafter, despite remaining elevated for several months.
Prior studies assessing the temporal association of ischaemia and
bleeding with mortality have had contrasting results.16,18 In one
report based on an NSTE MI population, the impact of bleeding was
sustained over time up to 1 year after the event, whereas the impact
of MI rapidly dissipated and was no longer significant after 30 days.16
In a second report focusing on ST-segment elevation MI patients,
recurrent MI had a more long-lasting effect on mortality (>1 year),
whereas severe bleeding did not have a significant impact on mortal-
ity as early as 30 days after the event.18 A similar result in an all-ACS
population was observed by Hochholzer et al.,19 who found the risk
of bleeding being no more significantly elevated 40 days after the
event. Reconciling these inconsistent results is challenging as they
concern different populations, different types and definitions of
events, and different statistical methods. Accordingly, further studies
are needed to confirm the time-association pattern between MI and
bleeding with mortality.
The findings of our analysis might also help explain the efficacy/
safety balance of recent clinical trials exploring newer strategies of
prolonged DAPT, which have demonstrated an ischaemic benefit
obtained at the expense of increased bleeding complications.14,15,25,26
The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin–Thrombolysis in Myocardial
Infarction 54) trial tested the effect of a long course of treatment
with two different doses of ticagrelor (90 and 60 mg) vs. placebo in
patients with an MI that occurred 1–3 years earlier.15 Ticagrelor
Figure 3 Evolution of the prognostic impact of minor andmajor bleeding vs. myocardial infarction over time. This figure shows the adjusted hazard
ratio for mortality of myocardial infarction vs. minor (BARC 2) and major (BARC 3a–c) bleeding as a function of time elapsed after the event. Inside
graph: The decline in hazard ratio as an exponential function of time in the first 30 days. Outside graph: The decline in hazard ratio for the first year
after the event. Solid lines represent point estimates; dashed lines represent 95% confidence intervals. MI, myocardial infarction; BARC, Bleeding
Academic Research Consortium.
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reduced the primary efficacy endpoint by an absolute 1.2%, mainly by
reducing MIs and stroke, but with no significant impact on mortality.
Interestingly, the treatment with ticagrelor also increased major
bleeding to a similar extent. The DAPT trial included patients treated
with drug-eluting stents, who after a 12 month run-in phase of stand-
ard DAPT with thienopyridines were randomized to stop or con-
tinue the P2Y12 inhibitor.
14 After 30 months, patients randomized to
an extended DAPT course showed a reduction of ischaemic events
at the expense of a similar increase. Taken together, these trials and
our current findings strongly suggest that DAPT duration should be
weighed considering the ischaemic vs. bleeding risk profile of the
patient, as both complications may concur to significantly increase
mortality, with comparative effects that largely depend on the bleed-
ing severity.14,15,27–29
Net clinical benefit outcomes have become a popular endpoint to
account for both efficacy and bleeding effect. However, there is an
intrinsic risk of misinterpretation when heterogeneity among compo-
nents exists with respect to either importance, number of events, or
magnitude of treatment effect.30 In this scenario, one can imagine
that if the directions of minor bleeding and MI are different, but minor
bleeding occurs more frequently, the net clinical benefit will be
pushed towards the treatment with fewer events, irrespective of
their clinical significance. To overcome this limitation of the classic
time-to-event analysis, alternative statistical approaches have been
proposed.31–33 These methods rank or weigh events according to
their clinical significance, minimizing imbalances from differences in
direction and magnitude of single components of the endpoint.
However, the evidence regarding how various bleeding types should
be weighed in combined endpoints against MI is so far limited. Hence,
our study could be useful, informing a more objective way to rank/
weigh ischaemic and bleeding events.
The limitations of our study must be acknowledged. This is a post
hoc analysis, and the interplay between MI, bleeding, and mortality is
very complex; we could not account for all possible factors impli-
cated in their causal relationship. Second, we did not evaluate the
prognostic impact of MI subcategories; however, because we
excluded events occurring during the first 30 days, PCI- and CABG-
related MI were observed rarely. Finally, although bleeding events
were stratified by severity, we did not have a systematic measure of
infarct severity or size. For example, imaging assessing infarct size or
changes in ejection fraction are typically not systematically performed
in large phase 3 randomized clinical trials and were not available in
TRACER. It is likely to expect a different impact on mortality of
events related with larger areas of myocardium at risk and/or with
proximal segments of the coronary arteries.34,35
Conclusions
Recurrent MI occurring 30 days after hospitalization for NSTE ACS
appeared to be associated with a higher risk of mortality compared
with mild-to-moderate bleeding, and had a similar prognostic implica-
tion compared with severe, non-intracranial bleeding. Intracranial
and intraocular bleeding were associated with a mortality risk that
was higher than for MI. These findings may help interpret the risk-
and-benefit profile of antithrombotic medications.
Supplementary material
Supplementary material is available at European Heart Journal online.
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..explored.24 In fact, accounting for bleeding severity, we found that
recurrent MI had higher prognostic impact on mortality than bleed-
ing, except for BARC 3c categories. This information is of major
importance, as it indicates that it might be fair to pursue a more
potent antiplatelet regimen to avoid an MI even at the expense of
mild-to-moderate bleeding in patients with high ischaemic risk. In
addition, our data suggest that combining all bleeding, including minor
bleeds that are more frequent but less prognostically significant, into
a safety endpoint or net clinical outcome including MI may pose signif-
icant challenges in interpreting the clinical benefit of drugs.
The temporal association with mortality was similar between MI
and minor or major bleeding. Although the highest risk of mortality
was present in the first week after the event, its magnitude rapidly
decreased thereafter, despite remaining elevated for several months.
Prior studies assessing the temporal association of ischaemia and
bleeding with mortality have had contrasting results.16,18 In one
report based on an NSTE MI population, the impact of bleeding was
sustained over time up to 1 year after the event, whereas the impact
of MI rapidly dissipated and was no longer significant after 30 days.16
In a second report focusing on ST-segment elevation MI patients,
recurrent MI had a more long-lasting effect on mortality (>1 year),
whereas severe bleeding did not have a significant impact on mortal-
ity as early as 30 days after the event.18 A similar result in an all-ACS
population was observed by Hochholzer et al.,19 who found the risk
of bleeding being no more significantly elevated 40 days after the
event. Reconciling these inconsistent results is challenging as they
concern different populations, different types and definitions of
events, and different statistical methods. Accordingly, further studies
are needed to confirm the time-association pattern between MI and
bleeding with mortality.
The findings of our analysis might also help explain the efficacy/
safety balance of recent clinical trials exploring newer strategies of
prolonged DAPT, which have demonstrated an ischaemic benefit
obtained at the expense of increased bleeding complications.14,15,25,26
The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin–Thrombolysis in Myocardial
Infarction 54) trial tested the effect of a long course of treatment
with two different doses of ticagrelor (90 and 60 mg) vs. placebo in
patients with an MI that occurred 1–3 years earlier.15 Ticagrelor
Figure 3 Evolution of the prognostic impact of minor andmajor bleeding vs. myocardial infarction over time. This figure shows the adjusted hazard
ratio for mortality of myocardial infarction vs. minor (BARC 2) and major (BARC 3a–c) bleeding as a function of time elapsed after the event. Inside
graph: The decline in hazard ratio as an exponential function of time in the first 30 days. Outside graph: The decline in hazard ratio for the first year
after the event. Solid lines represent point estimates; dashed lines represent 95% confidence intervals. MI, myocardial infarction; BARC, Bleeding
Academic Research Consortium.
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reduced the primary efficacy endpoint by an absolute 1.2%, mainly by
reducing MIs and stroke, but with no significant impact on mortality.
Interestingly, the treatment with ticagrelor also increased major
bleeding to a similar extent. The DAPT trial included patients treated
with drug-eluting stents, who after a 12 month run-in phase of stand-
ard DAPT with thienopyridines were randomized to stop or con-
tinue the P2Y12 inhibitor.
14 After 30 months, patients randomized to
an extended DAPT course showed a reduction of ischaemic events
at the expense of a similar increase. Taken together, these trials and
our current findings strongly suggest that DAPT duration should be
weighed considering the ischaemic vs. bleeding risk profile of the
patient, as both complications may concur to significantly increase
mortality, with comparative effects that largely depend on the bleed-
ing severity.14,15,27–29
Net clinical benefit outcomes have become a popular endpoint to
account for both efficacy and bleeding effect. However, there is an
intrinsic risk of misinterpretation when heterogeneity among compo-
nents exists with respect to either importance, number of events, or
magnitude of treatment effect.30 In this scenario, one can imagine
that if the directions of minor bleeding and MI are different, but minor
bleeding occurs more frequently, the net clinical benefit will be
pushed towards the treatment with fewer events, irrespective of
their clinical significance. To overcome this limitation of the classic
time-to-event analysis, alternative statistical approaches have been
proposed.31–33 These methods rank or weigh events according to
their clinical significance, minimizing imbalances from differences in
direction and magnitude of single components of the endpoint.
However, the evidence regarding how various bleeding types should
be weighed in combined endpoints against MI is so far limited. Hence,
our study could be useful, informing a more objective way to rank/
weigh ischaemic and bleeding events.
The limitations of our study must be acknowledged. This is a post
hoc analysis, and the interplay between MI, bleeding, and mortality is
very complex; we could not account for all possible factors impli-
cated in their causal relationship. Second, we did not evaluate the
prognostic impact of MI subcategories; however, because we
excluded events occurring during the first 30 days, PCI- and CABG-
related MI were observed rarely. Finally, although bleeding events
were stratified by severity, we did not have a systematic measure of
infarct severity or size. For example, imaging assessing infarct size or
changes in ejection fraction are typically not systematically performed
in large phase 3 randomized clinical trials and were not available in
TRACER. It is likely to expect a different impact on mortality of
events related with larger areas of myocardium at risk and/or with
proximal segments of the coronary arteries.34,35
Conclusions
Recurrent MI occurring 30 days after hospitalization for NSTE ACS
appeared to be associated with a higher risk of mortality compared
with mild-to-moderate bleeding, and had a similar prognostic implica-
tion compared with severe, non-intracranial bleeding. Intracranial
and intraocular bleeding were associated with a mortality risk that
was higher than for MI. These findings may help interpret the risk-
and-benefit profile of antithrombotic medications.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Coronary thrombus has been associated with acute coro-nary syndromes and disease progression. The rupture 
of thin cap ﬁbro-atheromas allows the blood to come in con-
tact with the highly thrombogenic contents of the plaque (eg, 
necrotic core/collagen) favoring the occurrence of most of 
acute coronary syndromes.1,2 In addition, invasive imaging 
studies have shown that coronary thrombosis can also be pres-
ent in stable coronary artery disease (CAD) and has been asso-
ciated with plaque progression.3,4
Thrombus-containing lesions (TCLs) seems to be associ-
ated with an increased risk of distal embolization and no or 
poor distal ﬂow and low myocardial blush grades after per-
cutaneous coronary intervention.5,6 However, the prognostic 
relevance of coronary thrombus as assessed by angiography 
is still unclear, and the results presented in the literature are 
disputed.7–9
The aim of the present study is to examine the angiographic 
anatomic characteristics of TCL and their correlations with 
clinical events (all-cause death, myocardial infarction [MI], 
and all revascularizations) in the largest-ever pooled all-comer 
population enrolled in contemporary percutaneous coronary 
intervention trials.
Background—The distribution of thrombus-containing lesions (TCLs) in an all-comer population admitted with a 
heterogeneous clinical presentation (stable, ustable angina, or an acute coronary syndrome) and treated with percutaneous 
coronary intervention is yet unclear, and the long-term prognostic implications are still disputed. This study sought 
to assess the distribution and prognostic implications of coronary thrombus, detected by coronary angiography, in a 
population recruited in all-comer percutaneous coronary intervention trials.
Methods and Results—Patient-level data from 3 contemporary coronary stent trials were pooled by an independent academic 
research organization (Cardialysis, Rotterdam, the Netherlands). Clinical outcomes in terms of major adverse cardiac 
events (major adverse cardiac events, a composite of death, myocardial infarction, and repeat revascularization), death, 
myocardial infarction, and repeated revascularization were compared between patients with and without angiographic 
TCL. Preprocedural TCL was present in 257 patients (5.8%) and absent in 4193 (94.2%) patients. At 3-year follow-up, 
there was no difference for major adverse cardiac events (25.3 versus 25.4%; P=0.683); all-cause death (7.4 versus 6.8%; 
P=0.683); myocardial infarction (5.8 versus 6.0%; P=0.962), and any revascularizations (17.5 versus 17.7%; P=0.822) 
between patients with and without TCL. The comparison of outcomes in groups weighing the jeopardized myocardial by 
TCL also did not show a signiﬁcant difference. TCL were seen more often in the ﬁrst 2 segments of the right (43.6%) and 
left anterior descending (36.8%) coronary arteries. The association of TCL and bifurcation lesions was present in 40.1% 
of the prespeciﬁed segments.
Conclusions—TCL involved mainly the proximal coronary segments and did not have any effect on clinical outcomes. 
A more detailed thrombus burden quantiﬁcation is required to investigate its prognostic implications.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identiﬁers: NCT00114972, NCT01443104, 
NCT00617084.  (Circ Cardiovasc Interv. 2015;8:e002279. DOI: 10.1161/CIRCINTERVENTIONS.114.002279.)
Key Words: drug-eluting stent ◼ outcome ◼ percutaneous coronary intervention ◼ thrombus
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Methods
Patient Population
We analyzed patient-level data from 3 all-comer coronary drug-
eluting stent trials: LEADERS (Limus Eluted From a Durable Versus 
Erodable Stent Coating) trial, RESOLUTE (Resolute All Comers) 
trial, and SYNTAX (Synergy Between Percutaneous Coronary 
Intervention With Taxus and Cardiac Surgery). Detailed individual 
study design and trial results are available elsewhere.10–12 In brief, 
all studies included patients with obstructive CAD that was amend-
able to coronary stent implantation (Table I in the Data Supplement). 
These trials had an all-comers design, but in the SYNTAX trial, the 
enrolled patients must had complex (3-vessel or left main) CAD to be 
enrolled. All studies complied with the Declaration of Helsinki and 
were approved by the ethical review board in each institution. All pa-
tients provided written, informed consent for participation in the indi-
vidual study. The angiographic images were reviwed by independent 
core laboratory analysts (Cardialysis, Rotterdam, The Netherlands) 
who identify the presence or absence of thrombus. Aiming to evaluate 
the clinical characteristics and prognosis, the patients were divided 
into 2 groups according to the presence or absence of at least one TCL 
as assessed by coronary angiography.
Clinical Outcomes
Major adverse cardiac events (MACE) were deﬁned as a composite 
of all-cause death, MI, and any repeat revascularization. There was a 
wide variation in the deﬁnition of MI among studies. This is because 
of each study inclusion criteria, variations in study design, and the 
different periods during which studies were performed. Because all 
clinical events from each individual trial were adjudicated by inde-
pendent clinical event committees, no attempt was made to readjudi-
cate MI events in the different trials to compensate for the differences 
in individual deﬁnition of MI. Therefore, all MIs reported in the cur-
rent study are as per individual study protocol deﬁnitions.
WHAT IS KNOWN
s The effect of coronary thrombus on prognosis is dis-
puted, particularly in the era of sophisticated coro-
nary intervention.
WHAT THE STUDY ADDS
s  In a population with a broad spectrum of coronary 
disease, the presence of intracoronary thrombus was 
not associated with an increased incidence of ad-
verse outcomes.
s Thombi were most commonly located in proxi-
mal coronary locations and at the site of coronary 
bifurcations.
Table 1. Segment Weighing Factor
Segment No. Right Dominance Left Dominance
1 1 0
2 1 0
3 1 0
4 1 na
16 0.5 na
16a 0.5 na
16b 0.5 na
16c 0.5 na
5 5 6
6 3.5 3.5
7 2.5 2.5
8 1 1
9 1 1
9a 1 1
10 0.5 0.5
10a 0.5 0.5
11 1.5 2.5
12 1 1
12a 1 1
12b 1 1
13 0.5 1.5
14 0.5 1
14a 0.5 1
14b 0.5 1
15 na 1
Table 2. Baseline Clinical Characteristics
Pts Without 
Thrombus 
Containing  
Lesions 
N=4193
Pts With  
Thrombus 
Containing 
Lesions 
N=257 P Values
Age 64.6±107 62.7±10.7 0.006
Male, % 3127 (74.6) 208 (80.9) 0.022
Diabetes mellitus, % 1032 (24.6) 50 (19.5) 0.061
Body mass index, kg/m2 27.7±4.5 27.8±4.5 0.831
Hypertension, % 3061 (73.0) 150 (58.4) <0.001
Hyperlipidemia, % 2842 (67.8) 136 (52.9) <0.001
Current smoker, % 1279 (30.5) 132 (51.4) <0.001
Peripheral vascular 
disease, %
317 (7.6) 16 (6.2) 0.446
Family history of 
premature CAD, %
1443 (27.3) 87 (33.9) 0.518
History of stroke/ 
TIA, %
222 (5.3) 13 (5.1) 0.849
Creatinine >200 
μmol/L
1.3 0.4 0.530
Creatinine 
clearance, mL/min
90.6±37.4 98.7±33.9 0.001
Previous 
myocardial 
infarction, %
1225 (29.2) 55 (21.4) 0.006
Previous PCI, % 1027 (24.5) 32 (12.5) <0.001
Presentation <0.001
  NSTEMI, % 558 (13.3) 62 (24.1)
  Stable CAD, % 2131 (50.8) 50 (14.0)
  STEMI, % 539 (12.9) 112 (43.6)
  Unstable angina, % 965 (23.0) 33 (12.8)
LVEF, % 56.8±11.9 54.7±11.9 0.052
CAD indicates coronary artery disease; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation 
myocardial infarction; PCI, percutaneous coronary intervention; Pts, 
patients; STEMI,  ST-segment–elevation myocardial infarction; and TIA, 
transient ischemic attack.
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Angiographic Assessment
The angiographic assessment was performed by an independent 
corelab (Cardialysis, Rotterdam, The Netherlands) based on the 
SYNTAX score concept. The SYNTAX score for each patient was 
calculated by scoring all coronary lesions with a diameter stenosis 
≥50%, in vessels ≥1.5 mm, using the SYNTAX score algorithm, 
which is described in full elsewhere.13 All angiographic variables 
were recorded prospectively by a team of 2 core laboratory analysts.
A bifurcation was classiﬁed by a division of a main, parent, branch 
into 2 daughter branches of at least 1.5 mm diameter according to 
the Medina classiﬁcation.14 The smaller of the 2 daughter branches 
was designated as the side branch. After the SYNTAX score recom-
mendations, bifurcations were only scored for the following seg-
ment junctions: 5/6/11, 6/7/9, 7/8/10, 11/13/12a, 13/14/14a, 3/4/16, 
and 13/14/15. Coronary thrombus was deﬁned according to the 
Academic Research Consortium deﬁnition as spheric, ovoid, or ir-
regular intraluminal ﬁlling defect or lucency surrounded on 3 sides 
by contrast medium seen just distal or within the coronary stenosis in 
multiple projections or a visible embolization of intraluminal mate-
rial downstream.15 To further evaluate the prognostic effect of throm-
bus, the summation of segment weighing factors (Table 1) used in the 
SYNTAX score was used if TCLs were present.
Data Analysis
All patients with a calculated SYNTAX score were included in the 
analysis. Discrete data were summarized as percent (frequencies) 
and were compared using the chi-squared test. Continuous data were 
expressed as mean±SD and were compared using Student’s t test or 
Wilcoxon rank-sum test based on their distributions. Survival curves 
were constructed for time-to-event variables using Kaplan–Meier 
estimates and compared by the log-rank test. Comparison of events 
rates between groups were adjusted for confounding factors in a Cox-
regression model. All variables were stratiﬁed according to presence 
of at least one TCL using a Cox-regression model. The differences 
were regarded signiﬁcant when P<0.05 (2-tailed). The Breslow-
Day chi-squared test was calculated to test the statistical evidence 
of heterogeneity across the studies (P<0.1). The chi-squared test and 
I2 statistic were calculated to test the statistical evidence of hetero-
geneity across the studies16 (Table II and Figures I–V in the Data 
Supplement). SPSS version 21.0 (SPSS Inc, Chicago, IL) was used 
for all other statistical analyses.
Results
Baseline Characteristics
Table 2 depicts patients’ baseline demographics. Prepro-
cedural thrombus was present in 257 patients (5.8%) and 
absent in 4193 (94.2%). Patients with at least one TCL were 
younger (62.7±10.7 versus 64.6±10.7; P=0.006), more fre-
quently male (80.9% versus 74.6%; P=0.022) and current 
smokers (51.4% versus 30.5%; P<0.001), less likely to have 
Table 3. Baseline Angiographic Characteristics
Pts Without Thrombus 
Containing Lesions, N=4193
Pts With Thrombus 
Containing Lesions, N=257 P Values
Baseline SYNTAX score±SD 17.7±11.6 18.6±10.7 0.239
Number of total occlusions/patient±SD 0.27±0.49 0.37±0.56 0.010
Number of aorto-ostial lesions/patient±SD 0.06±0.25 0.07±0.27 0.714
Number of lesions with severe tortuosity/ 
patient±SD
0.81±1.09 0.73±1.07 0.265
Number of lesions with length >20 mm/ 
patient±SD
0.51±0.76 0.51±0.65 0.884
Number of lesions with heavy calciﬁcation/ 
patient±SD
0.40±0.87 0.35±0.82 0.367
Number segments with diffuse disease/ 
patient±SD
0.04±0.19 0.04±0.18 0.877
Lesions in left main/patient 0.10±0.31 0.07±0.26 0.086
Lesions in LAD proximal/patient 0.33±0.50 0.34±0.50 0.820
Lesions in LAD mid/patient 0.58±0.58 0.54±0.58 0.243
Lesions in LAD apical/patient 0.15±0.38 0.13±0.36 0.275
Lesions in ﬁrst diagonal/patient 0.25±0.45 0.28±0.48 0.247
Lesions in second diagonal/patient 0.01±0.11 0.02±0.12 0.722
Lesions in proximal circumﬂex/patient 0.19±0.40 0.17±0.37 0.481
Lesions in distal circumﬂex/patient 0.35±0.52 0.30±0.49 0.116
Lesions in intermediate/patient 0.08±0.27 0.09±0.31 0.416
Lesions in ﬁrst obtuse marginal/patient 0.13±0.34 0.13±0.34 0.686
Lesions in second obtuse marginal/patient 0.12±0.34 0.09±0.29 0.107
Lesions in RCA proximal/patient 0.27±0.45 0.33±0.47 0.045
Lesions in RCA mid/patient 0.34±0.49 0.34±0.48 0.983
Lesions in RCA distal/patient 0.25±0.46 0.27±0.48 0.447
Lesions in posterolateral/patient 0.07±0.25 0.05±0.23 0.21
Lesions in posterior descending /patient 0.01±0.09 0.00±0.00 0.17
LAD indicates left anterior descending coronary artery; Pts, patients; RCA, right coronary artery; and SYNTAX, Synergy Between 
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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Methods
Patient Population
We analyzed patient-level data from 3 all-comer coronary drug-
eluting stent trials: LEADERS (Limus Eluted From a Durable Versus 
Erodable Stent Coating) trial, RESOLUTE (Resolute All Comers) 
trial, and SYNTAX (Synergy Between Percutaneous Coronary 
Intervention With Taxus and Cardiac Surgery). Detailed individual 
study design and trial results are available elsewhere.10–12 In brief, 
all studies included patients with obstructive CAD that was amend-
able to coronary stent implantation (Table I in the Data Supplement). 
These trials had an all-comers design, but in the SYNTAX trial, the 
enrolled patients must had complex (3-vessel or left main) CAD to be 
enrolled. All studies complied with the Declaration of Helsinki and 
were approved by the ethical review board in each institution. All pa-
tients provided written, informed consent for participation in the indi-
vidual study. The angiographic images were reviwed by independent 
core laboratory analysts (Cardialysis, Rotterdam, The Netherlands) 
who identify the presence or absence of thrombus. Aiming to evaluate 
the clinical characteristics and prognosis, the patients were divided 
into 2 groups according to the presence or absence of at least one TCL 
as assessed by coronary angiography.
Clinical Outcomes
Major adverse cardiac events (MACE) were deﬁned as a composite 
of all-cause death, MI, and any repeat revascularization. There was a 
wide variation in the deﬁnition of MI among studies. This is because 
of each study inclusion criteria, variations in study design, and the 
different periods during which studies were performed. Because all 
clinical events from each individual trial were adjudicated by inde-
pendent clinical event committees, no attempt was made to readjudi-
cate MI events in the different trials to compensate for the differences 
in individual deﬁnition of MI. Therefore, all MIs reported in the cur-
rent study are as per individual study protocol deﬁnitions.
WHAT IS KNOWN
s The effect of coronary thrombus on prognosis is dis-
puted, particularly in the era of sophisticated coro-
nary intervention.
WHAT THE STUDY ADDS
s  In a population with a broad spectrum of coronary 
disease, the presence of intracoronary thrombus was 
not associated with an increased incidence of ad-
verse outcomes.
s Thombi were most commonly located in proxi-
mal coronary locations and at the site of coronary 
bifurcations.
Table 1. Segment Weighing Factor
Segment No. Right Dominance Left Dominance
1 1 0
2 1 0
3 1 0
4 1 na
16 0.5 na
16a 0.5 na
16b 0.5 na
16c 0.5 na
5 5 6
6 3.5 3.5
7 2.5 2.5
8 1 1
9 1 1
9a 1 1
10 0.5 0.5
10a 0.5 0.5
11 1.5 2.5
12 1 1
12a 1 1
12b 1 1
13 0.5 1.5
14 0.5 1
14a 0.5 1
14b 0.5 1
15 na 1
Table 2. Baseline Clinical Characteristics
Pts Without 
Thrombus 
Containing  
Lesions 
N=4193
Pts With  
Thrombus 
Containing 
Lesions 
N=257 P Values
Age 64.6±107 62.7±10.7 0.006
Male, % 3127 (74.6) 208 (80.9) 0.022
Diabetes mellitus, % 1032 (24.6) 50 (19.5) 0.061
Body mass index, kg/m2 27.7±4.5 27.8±4.5 0.831
Hypertension, % 3061 (73.0) 150 (58.4) <0.001
Hyperlipidemia, % 2842 (67.8) 136 (52.9) <0.001
Current smoker, % 1279 (30.5) 132 (51.4) <0.001
Peripheral vascular 
disease, %
317 (7.6) 16 (6.2) 0.446
Family history of 
premature CAD, %
1443 (27.3) 87 (33.9) 0.518
History of stroke/ 
TIA, %
222 (5.3) 13 (5.1) 0.849
Creatinine >200 
μmol/L
1.3 0.4 0.530
Creatinine 
clearance, mL/min
90.6±37.4 98.7±33.9 0.001
Previous 
myocardial 
infarction, %
1225 (29.2) 55 (21.4) 0.006
Previous PCI, % 1027 (24.5) 32 (12.5) <0.001
Presentation <0.001
  NSTEMI, % 558 (13.3) 62 (24.1)
  Stable CAD, % 2131 (50.8) 50 (14.0)
  STEMI, % 539 (12.9) 112 (43.6)
  Unstable angina, % 965 (23.0) 33 (12.8)
LVEF, % 56.8±11.9 54.7±11.9 0.052
CAD indicates coronary artery disease; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; NSTEMI, non–ST-segment–elevation 
myocardial infarction; PCI, percutaneous coronary intervention; Pts, 
patients; STEMI,  ST-segment–elevation myocardial infarction; and TIA, 
transient ischemic attack.
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Angiographic Assessment
The angiographic assessment was performed by an independent 
corelab (Cardialysis, Rotterdam, The Netherlands) based on the 
SYNTAX score concept. The SYNTAX score for each patient was 
calculated by scoring all coronary lesions with a diameter stenosis 
≥50%, in vessels ≥1.5 mm, using the SYNTAX score algorithm, 
which is described in full elsewhere.13 All angiographic variables 
were recorded prospectively by a team of 2 core laboratory analysts.
A bifurcation was classiﬁed by a division of a main, parent, branch 
into 2 daughter branches of at least 1.5 mm diameter according to 
the Medina classiﬁcation.14 The smaller of the 2 daughter branches 
was designated as the side branch. After the SYNTAX score recom-
mendations, bifurcations were only scored for the following seg-
ment junctions: 5/6/11, 6/7/9, 7/8/10, 11/13/12a, 13/14/14a, 3/4/16, 
and 13/14/15. Coronary thrombus was deﬁned according to the 
Academic Research Consortium deﬁnition as spheric, ovoid, or ir-
regular intraluminal ﬁlling defect or lucency surrounded on 3 sides 
by contrast medium seen just distal or within the coronary stenosis in 
multiple projections or a visible embolization of intraluminal mate-
rial downstream.15 To further evaluate the prognostic effect of throm-
bus, the summation of segment weighing factors (Table 1) used in the 
SYNTAX score was used if TCLs were present.
Data Analysis
All patients with a calculated SYNTAX score were included in the 
analysis. Discrete data were summarized as percent (frequencies) 
and were compared using the chi-squared test. Continuous data were 
expressed as mean±SD and were compared using Student’s t test or 
Wilcoxon rank-sum test based on their distributions. Survival curves 
were constructed for time-to-event variables using Kaplan–Meier 
estimates and compared by the log-rank test. Comparison of events 
rates between groups were adjusted for confounding factors in a Cox-
regression model. All variables were stratiﬁed according to presence 
of at least one TCL using a Cox-regression model. The differences 
were regarded signiﬁcant when P<0.05 (2-tailed). The Breslow-
Day chi-squared test was calculated to test the statistical evidence 
of heterogeneity across the studies (P<0.1). The chi-squared test and 
I2 statistic were calculated to test the statistical evidence of hetero-
geneity across the studies16 (Table II and Figures I–V in the Data 
Supplement). SPSS version 21.0 (SPSS Inc, Chicago, IL) was used 
for all other statistical analyses.
Results
Baseline Characteristics
Table 2 depicts patients’ baseline demographics. Prepro-
cedural thrombus was present in 257 patients (5.8%) and 
absent in 4193 (94.2%). Patients with at least one TCL were 
younger (62.7±10.7 versus 64.6±10.7; P=0.006), more fre-
quently male (80.9% versus 74.6%; P=0.022) and current 
smokers (51.4% versus 30.5%; P<0.001), less likely to have 
Table 3. Baseline Angiographic Characteristics
Pts Without Thrombus 
Containing Lesions, N=4193
Pts With Thrombus 
Containing Lesions, N=257 P Values
Baseline SYNTAX score±SD 17.7±11.6 18.6±10.7 0.239
Number of total occlusions/patient±SD 0.27±0.49 0.37±0.56 0.010
Number of aorto-ostial lesions/patient±SD 0.06±0.25 0.07±0.27 0.714
Number of lesions with severe tortuosity/ 
patient±SD
0.81±1.09 0.73±1.07 0.265
Number of lesions with length >20 mm/ 
patient±SD
0.51±0.76 0.51±0.65 0.884
Number of lesions with heavy calciﬁcation/ 
patient±SD
0.40±0.87 0.35±0.82 0.367
Number segments with diffuse disease/ 
patient±SD
0.04±0.19 0.04±0.18 0.877
Lesions in left main/patient 0.10±0.31 0.07±0.26 0.086
Lesions in LAD proximal/patient 0.33±0.50 0.34±0.50 0.820
Lesions in LAD mid/patient 0.58±0.58 0.54±0.58 0.243
Lesions in LAD apical/patient 0.15±0.38 0.13±0.36 0.275
Lesions in ﬁrst diagonal/patient 0.25±0.45 0.28±0.48 0.247
Lesions in second diagonal/patient 0.01±0.11 0.02±0.12 0.722
Lesions in proximal circumﬂex/patient 0.19±0.40 0.17±0.37 0.481
Lesions in distal circumﬂex/patient 0.35±0.52 0.30±0.49 0.116
Lesions in intermediate/patient 0.08±0.27 0.09±0.31 0.416
Lesions in ﬁrst obtuse marginal/patient 0.13±0.34 0.13±0.34 0.686
Lesions in second obtuse marginal/patient 0.12±0.34 0.09±0.29 0.107
Lesions in RCA proximal/patient 0.27±0.45 0.33±0.47 0.045
Lesions in RCA mid/patient 0.34±0.49 0.34±0.48 0.983
Lesions in RCA distal/patient 0.25±0.46 0.27±0.48 0.447
Lesions in posterolateral/patient 0.07±0.25 0.05±0.23 0.21
Lesions in posterior descending /patient 0.01±0.09 0.00±0.00 0.17
LAD indicates left anterior descending coronary artery; Pts, patients; RCA, right coronary artery; and SYNTAX, Synergy Between 
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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hypertension (58.4% versus 73.0%; P<0.001), and hyperlip-
idemia (52.9 versus 67.8%; P<0.001). The left ventricular 
ejection fraction tended to be higher in patients without TCL 
(56.8±11.9 versus 54.7±11.9; P=0.052). Presence of throm-
bus at baseline was more frequently related with an acute pre-
sentation (P<0.001).
Angiographic Characteristics
Patients with and without TCL had similar angiographic 
characteristics (Table 3). There were differences for higher 
prevalence of total occlusions (0.37±0.56 versus 0.27±0.49 
total oclusions/patient; P=0.010) and more frequent involve-
ment of the proximal right coronary artery (0.33±0.47 versus 
0.27±0.45 lesions/patient; P=0.045) in the thrombus group.
Clinical Outcomes
There was no difference between the groups (Table 4 and 
Figure 1) for any of the studied outcomes ≤3-year follow-up. 
MACE occurred in 1067 patients (25.4%) in the group with-
out thrombus at baseline and 65 (25.3%) in the group with 
thrombus (P=0.874). Consistently, all-cause death (P=0.683), 
MI (P=0.962), and any revascularization (P=0.822) was not 
signiﬁcantly different in the 2 groups.
Subgroup Analysis
In the stratiﬁed analysis, the occurrence of MACE was 
homogenously distributed across the clinical and angio-
graphic covariates, with the only exception of clinical presen-
tation (Figure 2). There was a signiﬁcant interaction between 
the patients presenting with acute coronary syndrome (hazard 
ratio 0.881, conﬁdence interval 0.65–1.19) and stable CAD 
(hazard ratio 1.637, 95% conﬁdence interval 1.04–2.59) with 
respect to the presence of thrombus at baseline (P=0.028).
A more detailed analysis of the subgroup with stable 
CAD can be found in Table III in the Data Supplement. The 
thrombus at baseline was related to a higher rate of MACE 
(38% versus 26%, P=0.03) mainly because of an increased 
rate of repeated revascularization (30% versus 18%, P=0.01). 
However, after adjustment for confounders (ie, age, creatinine 
Table 4. Kaplan–Meier Events Rate Comparison Between 
Groups
Pts Without 
Thrombus 
Containing Lesions, 
N=4193
Pts With  
Thrombus 
Containing 
Lesions, N=257 P Values
30 days, n (%)
  MACE 254 (6.1) 17 (6.6) 0.714
  All-cause death 47 (1.1) 3 (1.2) 0.937
  All MI 163 (3.9) 9 (3.5) 0.754
  All revascularization 114 (2.7) 11 (4.3) 0.131
1-year
  MACE 669 (16.0) 48 (18.7) 0.229
  All-cause death 127 (3.0) 10 (3.9) 0.423
  All MI 196 (4.7) 11 (4.3) 0.778
  All revascularization 480 (11.5) 35 (13.7) 0.217
3-year
  MACE 1067 (25.4) 65 (25.3) 0.874
  All-cause death 287 (6.8) 19 (7.4) 0.683
  All MI 250 (6.0) 15 (5.8) 0.962
  All revascularization 742 (17.7) 45 (17.5) 0.822
MACE indicates major adverse cardiac events (composite of all-cause death, 
myocardial infarction, and all revascularization); and MI, myocardial infarction.
Figure 1. Kaplan–Meier cumulative curves for MACE (A; composite of all-cause death, myocardial infarction, and all revascularizations), all-cause 
death (B), myocardial infarction (MI; C), and all revascularizations (D). MACE indicates major adverse cardiac events; and MI, myocardial infarction.
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clearance, previous MI, LVEF, and number of total occlusions/
patient), this effect was no longer present (Figures VIA–VID 
and VIIA–VIID in the Data Supplement).
Anatomic Characteristics of Thrombus Containing 
Lesions
In the subgroup of patients with TCL (n=257), 261 lesions had 
angiographic thrombus. As shown in Figure 3, the presence 
of TCL occurred preferentially in proximal segments. More 
speciﬁcally, 43.6% of these complex lesions were seen in the 
ﬁrst 2 segments of the right coronary artery and 36.8% in the 
ﬁrst 2 segments of the left anterior descending coronary artery.
As demonstrated in Figure 4, TCLs were seen often in cor-
onary bifurcations. The association of thrombus-containing 
and bifurcation lesions was present in 40.1% of the aforemen-
tioned prespeciﬁed segments. In the left anterior descending 
coronary artery, there was appreciable coexistence of throm-
bus and bifurcation lesions (45.9% of the lesions). On the other 
hand, the combination thrombus–bifurcation was not frequent 
in the distal right coronary artery (8.6% of the lesions).
Figure 3. Distribution of angiographic thrombus containing lesions.
Figure 2. Stratiﬁed analysis for MACE (composite of all-cause death, all myocardial infarction, and all revascularizations according to the pres-
ence or absence of thrombus containing lesions. ACS indicates acute coronary syndromes; CAD, coronary artery disease; CI, conﬁdence 
interval; CrCl, creatinine clearance; DM, diabetes mellitus; HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac 
events; SS, anatomic SYNTAX score; and SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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hypertension (58.4% versus 73.0%; P<0.001), and hyperlip-
idemia (52.9 versus 67.8%; P<0.001). The left ventricular 
ejection fraction tended to be higher in patients without TCL 
(56.8±11.9 versus 54.7±11.9; P=0.052). Presence of throm-
bus at baseline was more frequently related with an acute pre-
sentation (P<0.001).
Angiographic Characteristics
Patients with and without TCL had similar angiographic 
characteristics (Table 3). There were differences for higher 
prevalence of total occlusions (0.37±0.56 versus 0.27±0.49 
total oclusions/patient; P=0.010) and more frequent involve-
ment of the proximal right coronary artery (0.33±0.47 versus 
0.27±0.45 lesions/patient; P=0.045) in the thrombus group.
Clinical Outcomes
There was no difference between the groups (Table 4 and 
Figure 1) for any of the studied outcomes ≤3-year follow-up. 
MACE occurred in 1067 patients (25.4%) in the group with-
out thrombus at baseline and 65 (25.3%) in the group with 
thrombus (P=0.874). Consistently, all-cause death (P=0.683), 
MI (P=0.962), and any revascularization (P=0.822) was not 
signiﬁcantly different in the 2 groups.
Subgroup Analysis
In the stratiﬁed analysis, the occurrence of MACE was 
homogenously distributed across the clinical and angio-
graphic covariates, with the only exception of clinical presen-
tation (Figure 2). There was a signiﬁcant interaction between 
the patients presenting with acute coronary syndrome (hazard 
ratio 0.881, conﬁdence interval 0.65–1.19) and stable CAD 
(hazard ratio 1.637, 95% conﬁdence interval 1.04–2.59) with 
respect to the presence of thrombus at baseline (P=0.028).
A more detailed analysis of the subgroup with stable 
CAD can be found in Table III in the Data Supplement. The 
thrombus at baseline was related to a higher rate of MACE 
(38% versus 26%, P=0.03) mainly because of an increased 
rate of repeated revascularization (30% versus 18%, P=0.01). 
However, after adjustment for confounders (ie, age, creatinine 
Table 4. Kaplan–Meier Events Rate Comparison Between 
Groups
Pts Without 
Thrombus 
Containing Lesions, 
N=4193
Pts With  
Thrombus 
Containing 
Lesions, N=257 P Values
30 days, n (%)
  MACE 254 (6.1) 17 (6.6) 0.714
  All-cause death 47 (1.1) 3 (1.2) 0.937
  All MI 163 (3.9) 9 (3.5) 0.754
  All revascularization 114 (2.7) 11 (4.3) 0.131
1-year
  MACE 669 (16.0) 48 (18.7) 0.229
  All-cause death 127 (3.0) 10 (3.9) 0.423
  All MI 196 (4.7) 11 (4.3) 0.778
  All revascularization 480 (11.5) 35 (13.7) 0.217
3-year
  MACE 1067 (25.4) 65 (25.3) 0.874
  All-cause death 287 (6.8) 19 (7.4) 0.683
  All MI 250 (6.0) 15 (5.8) 0.962
  All revascularization 742 (17.7) 45 (17.5) 0.822
MACE indicates major adverse cardiac events (composite of all-cause death, 
myocardial infarction, and all revascularization); and MI, myocardial infarction.
Figure 1. Kaplan–Meier cumulative curves for MACE (A; composite of all-cause death, myocardial infarction, and all revascularizations), all-cause 
death (B), myocardial infarction (MI; C), and all revascularizations (D). MACE indicates major adverse cardiac events; and MI, myocardial infarction.
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clearance, previous MI, LVEF, and number of total occlusions/
patient), this effect was no longer present (Figures VIA–VID 
and VIIA–VIID in the Data Supplement).
Anatomic Characteristics of Thrombus Containing 
Lesions
In the subgroup of patients with TCL (n=257), 261 lesions had 
angiographic thrombus. As shown in Figure 3, the presence 
of TCL occurred preferentially in proximal segments. More 
speciﬁcally, 43.6% of these complex lesions were seen in the 
ﬁrst 2 segments of the right coronary artery and 36.8% in the 
ﬁrst 2 segments of the left anterior descending coronary artery.
As demonstrated in Figure 4, TCLs were seen often in cor-
onary bifurcations. The association of thrombus-containing 
and bifurcation lesions was present in 40.1% of the aforemen-
tioned prespeciﬁed segments. In the left anterior descending 
coronary artery, there was appreciable coexistence of throm-
bus and bifurcation lesions (45.9% of the lesions). On the other 
hand, the combination thrombus–bifurcation was not frequent 
in the distal right coronary artery (8.6% of the lesions).
Figure 3. Distribution of angiographic thrombus containing lesions.
Figure 2. Stratiﬁed analysis for MACE (composite of all-cause death, all myocardial infarction, and all revascularizations according to the pres-
ence or absence of thrombus containing lesions. ACS indicates acute coronary syndromes; CAD, coronary artery disease; CI, conﬁdence 
interval; CrCl, creatinine clearance; DM, diabetes mellitus; HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac 
events; SS, anatomic SYNTAX score; and SYNTAX, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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Clinical Outcomes According to Myocardium at Risk
We divided the subgroup of patients with TCL into tertiles of 
the sum of segment weighing factors (Table 1). As shown in 
Figure 5, the weighting for myocardium at risk did not pro-
duce signiﬁcant difference in outcomes (MACE, all-cause 
death, MI or all revascularizations) for patients with TCL.
Figure 5. Kaplan–Meier cumulative curves for MACE (A; composite of all-cause death, myocardial infarction and all revascularizations), 
all-cause death (B), myocardial infarction (MI; C), and all revascularizations (D) according to tertiles of the sum of segment weighing fac-
tors in patients with thrombus-containing lesions.
Figure 4. Per-segment association of thrombus and bifurcation lesions according to Medina14 classiﬁcation. Dg indicates diagonal 
branch; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; LM, left main coronary artery; Mg, marginal; 
PD, Posterior descending branch; Pl, posterolateral branch; and RCA, right coronary artery.
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Discussion
The ﬁndings of our study can be summarized as follows: (1) TCL 
were seen more often in the proximal segments; (2) there was a 
considerable coexistence of bifurcation and TCLs; (3) the pres-
ence of thrombus at baseline was not related to any additional risk 
of MACE, even after weighing for myocardium at risk.
Anatomy of Angiographic Coronary Thrombus
Coronary thrombus is mostly formed after rupture of athero-
sclerotic lesions containing a large necrotic core and a thin 
ﬁbrous cap.1,2 In the present study, we found that thrombus 
was angiographically detected in the proximal coronary seg-
ments and mainly in the right and left anterior descending 
coronary arteries. Our results are similar to those reported by 
Wang et al who analyzed coronary angiograms from 208 con-
secutive patients presented with ST-elevation MI.17 However, 
in their methodology, they were evaluating the site of coronary 
occlusion. Although they used a slightly different coronary 
segmentation (BARI classiﬁcation), they also have found that 
the 2 most proximal segments of right coronary artery and 
left anterior descending coronary artery were also responsible 
for the absolute majority (65.4%) of acute coronary occlu-
sion.17 In the present analysis, a 25-fold larger population was 
studied and included a population with a broader spectrum of 
the disease (also stable CAD and NSTEMI) in which the ves-
sel occlusion was not mandatory for diagnosis of thrombus. 
Importantly, all angiographic assessments were performed by 
an experienced independent core laboratory, which has proven 
to have a higher consistency and better prognostic discrimina-
tion than investigator-reported angiographic ﬁndings.18
Interestingly, distribution of thin cap ﬁbroatheroma, 
as assessed by virtual histology intravascular ultrasound 
(VH-IVUS) and optical coherence tomography, resembles the 
distribution of thrombus found in the present study; this may 
indicate that thin cap ﬁbroatheromas are the underlying sub-
strate of coronary thrombus found in this study19,20 (Table 5). 
These invasive imaging ﬁndings are also in line with previous 
anatomopathological studies.2,4,21
It has to be highlighted, however, that angiography, because 
of its limited resolution, is far from being the gold stan-
dard tool for coronary thrombus diagnosis. For instance, in 
the present analysis, there was a low percentage (9.2%) of 
patients with acute coronary syndromes that were classiﬁed 
as having TCL. Similarly, Goto et al detected angiographic 
thrombus in only 14.6% of patients in a population of exclu-
sively acute coronary syndromes.7 Importantly, although Goto 
et al deﬁned thrombus as “an intraluminal ﬁlling defect or an 
area of contrast staining noted within the target stenosis,”7 we 
used the deﬁnition recommended by the Academic Research 
Consortium.15
Another interesting aspect of our ﬁndings is the relatively 
frequent association between thrombus and bifurcation. In 
the LAD, a bifurcation lesion was present in almost half of 
the TCL. The most plausible explanations for this associa-
tion are the following: (1) the most frequent location of thin 
cap ﬁbroatheromas is in bifurcation22 and (2) the endothelial 
shear stress in coronary bifurcations has a particular distri-
bution. In relatively straight segments, the endothelial shear 
stress is pulsatile and unidirectional.23 Conversely, in coronary 
bifurcations, disturbed laminar ﬂow occurs, and pulsatile ﬂow 
generates low or oscillatory endothelial shear stress.23 The role 
of endothelial shear stress in more advanced atherosclerosis 
was demonstrated 45 years ago24 and have been reproduced 
in autopsy-based coronary models, human in vivo studies in 
arterial models derived from intravascular ultrasound or mag-
netic resonance, and in vivo animal experiments.23,25
Thrombus and Clinical Events
In the present study, the presence of thrombus did not have 
any effect on clinical events, even when it was adjusted for 
the amount of myocardial at risk. Corroborating our ﬁndings, 
Singh et al have shown that the introduction of the coronary 
stents and the use of more contemporary antiplatelet therapy 
made the presence of thrombus irrelevant for long-term death 
and MI.8 On the other hand, Sianos et al have demonstrated 
that large thrombus burden is an independent predictor of 
Table 5. Distribution of Complex Coronary Lesions
% in Proximal 
Segment
% in Mid 
Segment % Total
Wang et al17
  Observation: Site of coronary 
occlusion distribution, %
   RCA 12.5 14.4 26.9
   LAD 14.5 24.0 38.5
   LCX 8.6 4.3 13.0
   LM ... ... 0.5
Present study
  Observation: Thrombus 
containing lesions 
distribution, %
   RCA 21.8 21.8 43.7
   LAD 18.0 18.8 36.8
   LCX 7.7 5.0 12.6
   LM ... ... 2.7
PROSPECT substudy19
  Observation: VH-TCFA– 
containing lesion distribution, %
   RCA 17.1 15.1 32.2
   LAD 24.2 10.8 35
   LCX 15.2 11.8 27
   LM ... ... n.a.
Tian et al20
  Observation: OCT- 
TCFA–containing lesion 
distribution, %
   RCA n.a. n.a. 45.0
   LAD n.a. n.a. 35.9
   LCX n.a. n.a. 19.1
   LM ... ... n.a.
LAD indicates left anterior descending coronary artery; LCX, left circumﬂex 
coronary artery; LM, left main coronary artery; OCT, optical coherence 
tomography; RCA, right coronary artery; TCFA, thin cap ﬁbroatheroma; and VH, 
virtual histology intravascular ultrasound.
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Clinical Outcomes According to Myocardium at Risk
We divided the subgroup of patients with TCL into tertiles of 
the sum of segment weighing factors (Table 1). As shown in 
Figure 5, the weighting for myocardium at risk did not pro-
duce signiﬁcant difference in outcomes (MACE, all-cause 
death, MI or all revascularizations) for patients with TCL.
Figure 5. Kaplan–Meier cumulative curves for MACE (A; composite of all-cause death, myocardial infarction and all revascularizations), 
all-cause death (B), myocardial infarction (MI; C), and all revascularizations (D) according to tertiles of the sum of segment weighing fac-
tors in patients with thrombus-containing lesions.
Figure 4. Per-segment association of thrombus and bifurcation lesions according to Medina14 classiﬁcation. Dg indicates diagonal 
branch; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; LM, left main coronary artery; Mg, marginal; 
PD, Posterior descending branch; Pl, posterolateral branch; and RCA, right coronary artery.
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Discussion
The ﬁndings of our study can be summarized as follows: (1) TCL 
were seen more often in the proximal segments; (2) there was a 
considerable coexistence of bifurcation and TCLs; (3) the pres-
ence of thrombus at baseline was not related to any additional risk 
of MACE, even after weighing for myocardium at risk.
Anatomy of Angiographic Coronary Thrombus
Coronary thrombus is mostly formed after rupture of athero-
sclerotic lesions containing a large necrotic core and a thin 
ﬁbrous cap.1,2 In the present study, we found that thrombus 
was angiographically detected in the proximal coronary seg-
ments and mainly in the right and left anterior descending 
coronary arteries. Our results are similar to those reported by 
Wang et al who analyzed coronary angiograms from 208 con-
secutive patients presented with ST-elevation MI.17 However, 
in their methodology, they were evaluating the site of coronary 
occlusion. Although they used a slightly different coronary 
segmentation (BARI classiﬁcation), they also have found that 
the 2 most proximal segments of right coronary artery and 
left anterior descending coronary artery were also responsible 
for the absolute majority (65.4%) of acute coronary occlu-
sion.17 In the present analysis, a 25-fold larger population was 
studied and included a population with a broader spectrum of 
the disease (also stable CAD and NSTEMI) in which the ves-
sel occlusion was not mandatory for diagnosis of thrombus. 
Importantly, all angiographic assessments were performed by 
an experienced independent core laboratory, which has proven 
to have a higher consistency and better prognostic discrimina-
tion than investigator-reported angiographic ﬁndings.18
Interestingly, distribution of thin cap ﬁbroatheroma, 
as assessed by virtual histology intravascular ultrasound 
(VH-IVUS) and optical coherence tomography, resembles the 
distribution of thrombus found in the present study; this may 
indicate that thin cap ﬁbroatheromas are the underlying sub-
strate of coronary thrombus found in this study19,20 (Table 5). 
These invasive imaging ﬁndings are also in line with previous 
anatomopathological studies.2,4,21
It has to be highlighted, however, that angiography, because 
of its limited resolution, is far from being the gold stan-
dard tool for coronary thrombus diagnosis. For instance, in 
the present analysis, there was a low percentage (9.2%) of 
patients with acute coronary syndromes that were classiﬁed 
as having TCL. Similarly, Goto et al detected angiographic 
thrombus in only 14.6% of patients in a population of exclu-
sively acute coronary syndromes.7 Importantly, although Goto 
et al deﬁned thrombus as “an intraluminal ﬁlling defect or an 
area of contrast staining noted within the target stenosis,”7 we 
used the deﬁnition recommended by the Academic Research 
Consortium.15
Another interesting aspect of our ﬁndings is the relatively 
frequent association between thrombus and bifurcation. In 
the LAD, a bifurcation lesion was present in almost half of 
the TCL. The most plausible explanations for this associa-
tion are the following: (1) the most frequent location of thin 
cap ﬁbroatheromas is in bifurcation22 and (2) the endothelial 
shear stress in coronary bifurcations has a particular distri-
bution. In relatively straight segments, the endothelial shear 
stress is pulsatile and unidirectional.23 Conversely, in coronary 
bifurcations, disturbed laminar ﬂow occurs, and pulsatile ﬂow 
generates low or oscillatory endothelial shear stress.23 The role 
of endothelial shear stress in more advanced atherosclerosis 
was demonstrated 45 years ago24 and have been reproduced 
in autopsy-based coronary models, human in vivo studies in 
arterial models derived from intravascular ultrasound or mag-
netic resonance, and in vivo animal experiments.23,25
Thrombus and Clinical Events
In the present study, the presence of thrombus did not have 
any effect on clinical events, even when it was adjusted for 
the amount of myocardial at risk. Corroborating our ﬁndings, 
Singh et al have shown that the introduction of the coronary 
stents and the use of more contemporary antiplatelet therapy 
made the presence of thrombus irrelevant for long-term death 
and MI.8 On the other hand, Sianos et al have demonstrated 
that large thrombus burden is an independent predictor of 
Table 5. Distribution of Complex Coronary Lesions
% in Proximal 
Segment
% in Mid 
Segment % Total
Wang et al17
  Observation: Site of coronary 
occlusion distribution, %
   RCA 12.5 14.4 26.9
   LAD 14.5 24.0 38.5
   LCX 8.6 4.3 13.0
   LM ... ... 0.5
Present study
  Observation: Thrombus 
containing lesions 
distribution, %
   RCA 21.8 21.8 43.7
   LAD 18.0 18.8 36.8
   LCX 7.7 5.0 12.6
   LM ... ... 2.7
PROSPECT substudy19
  Observation: VH-TCFA– 
containing lesion distribution, %
   RCA 17.1 15.1 32.2
   LAD 24.2 10.8 35
   LCX 15.2 11.8 27
   LM ... ... n.a.
Tian et al20
  Observation: OCT- 
TCFA–containing lesion 
distribution, %
   RCA n.a. n.a. 45.0
   LAD n.a. n.a. 35.9
   LCX n.a. n.a. 19.1
   LM ... ... n.a.
LAD indicates left anterior descending coronary artery; LCX, left circumﬂex 
coronary artery; LM, left main coronary artery; OCT, optical coherence 
tomography; RCA, right coronary artery; TCFA, thin cap ﬁbroatheroma; and VH, 
virtual histology intravascular ultrasound.
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major adverse events (deﬁned as death, repeat MI infarct-
related artery infarct-related artery) in patients treated with 
drug-eluting stents for STEMI.9 Additionally, large throm-
bus burden has been related to larger myocardial damage as 
detected by contrast-enhanced cardiac magnetic resonance.26 
The aforementioned ﬁndings suggest that, for clinical prog-
nostic discrimination, the angiographic thrombus assessment 
should be no longer classiﬁed as a binary variable but as a 
more detailed thrombotic burden quantiﬁcation.
Limitations
The present study has all inherent limitations of a post hoc 
analysis. In addition, the number of stable patients with TCL 
was limited and may have hindered an accurate risk estima-
tion in this subset. The classiﬁcation of bifurcation lesions 
was restricted to those deﬁned by the SYNTAX score, and 
we could not stablish whether TCL could be associated with 
smaller side branches. However, the use of the SYNTAX 
score concepts have demonstrated consistent prognostic effect 
for percutaneous coronary intervention–treated patients.12,27–29 
Information on thrombus aspiration was not available in this 
study. Nevertheless, the recent Thrombus Aspiration in ST-
Elevation MI in Scandinavia (TASTE) trial showed that rou-
tine thrombus aspiration exclusively in a context of primary 
percutaneous coronary intervention did not reduce the rate 
of death from any cause or the composite of death from any 
cause, rehospitalization for MI, or stent thrombosis at 1 year.30 
Also, the Trial of Routine Aspiration Thrombectomy With 
Percutaneous Coronary Intervention (PCI) Versus PCI Alone 
in Patients With ST-Segment–Elevation Myocardial Infarc-
tion (STEMI) Undergoing Primary PCI (TOTAL) randomly 
assigned 10 732 patients with STEMI undergoing primary PCI 
to routine manual thrombectomy versus PCI alone. Manual 
thrombectomy did not reduce the risk of cardiovascular death, 
recurrent myocardial infarction, cardiogenic shock, or New 
York Heart Association (NYHA) class IV heart failure within 
180 days but was associated with an increased rate of stroke 
within 30 days.31
Conclusions
In this patient-level pooled analysis of 3 contemporary, all-
comers stent trials, coronary TCL involved mainly the proximal 
coronary segments and frequently bifurcations. Angiographic 
thrombus did not have any effect on 3-year MACE, demon-
strating that a more detailed thrombus burden quantiﬁcation is 
required to investigate its prognostic implications.
Disclosures
None.
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major adverse events (deﬁned as death, repeat MI infarct-
related artery infarct-related artery) in patients treated with 
drug-eluting stents for STEMI.9 Additionally, large throm-
bus burden has been related to larger myocardial damage as 
detected by contrast-enhanced cardiac magnetic resonance.26 
The aforementioned ﬁndings suggest that, for clinical prog-
nostic discrimination, the angiographic thrombus assessment 
should be no longer classiﬁed as a binary variable but as a 
more detailed thrombotic burden quantiﬁcation.
Limitations
The present study has all inherent limitations of a post hoc 
analysis. In addition, the number of stable patients with TCL 
was limited and may have hindered an accurate risk estima-
tion in this subset. The classiﬁcation of bifurcation lesions 
was restricted to those deﬁned by the SYNTAX score, and 
we could not stablish whether TCL could be associated with 
smaller side branches. However, the use of the SYNTAX 
score concepts have demonstrated consistent prognostic effect 
for percutaneous coronary intervention–treated patients.12,27–29 
Information on thrombus aspiration was not available in this 
study. Nevertheless, the recent Thrombus Aspiration in ST-
Elevation MI in Scandinavia (TASTE) trial showed that rou-
tine thrombus aspiration exclusively in a context of primary 
percutaneous coronary intervention did not reduce the rate 
of death from any cause or the composite of death from any 
cause, rehospitalization for MI, or stent thrombosis at 1 year.30 
Also, the Trial of Routine Aspiration Thrombectomy With 
Percutaneous Coronary Intervention (PCI) Versus PCI Alone 
in Patients With ST-Segment–Elevation Myocardial Infarc-
tion (STEMI) Undergoing Primary PCI (TOTAL) randomly 
assigned 10 732 patients with STEMI undergoing primary PCI 
to routine manual thrombectomy versus PCI alone. Manual 
thrombectomy did not reduce the risk of cardiovascular death, 
recurrent myocardial infarction, cardiogenic shock, or New 
York Heart Association (NYHA) class IV heart failure within 
180 days but was associated with an increased rate of stroke 
within 30 days.31
Conclusions
In this patient-level pooled analysis of 3 contemporary, all-
comers stent trials, coronary TCL involved mainly the proximal 
coronary segments and frequently bifurcations. Angiographic 
thrombus did not have any effect on 3-year MACE, demon-
strating that a more detailed thrombus burden quantiﬁcation is 
required to investigate its prognostic implications.
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 Radial and Femoral Access in Percutaneous 
Intervention 
 Francesco  Costa and  Marco  Valgimigli 
 Abstract  Femoral and radial accesses are the most commonly used approaches in 
interventional cardiology. Femoral access-site has been implemented for many 
years in percutaneous coronary intervention and still today is the most used approach 
in several countries. Radial access, more recently introduced, guarantees a less inva-
sive procedure and a reduced incidence of vascular access site complications. 
 The purpose of this chapter is to review critically the most recent evidence com-
paring radial and femoral approaches for percutaneous coronary intervention. 
Advantages and limitations of each technique will be evaluated with respect to the 
most recent interventional procedures. 
 Keywords  Percutaneous coronary intervention •  PCI •  Radial access •  Femoral 
access •  Bleeding •  Vascular access site complications •  STEMI •  Non-ST elevated 
myocardial infarction •  Myocardial infarction •  Coronary artery disease 
 Introduction 
 Femoral and radial access sites are the most commonly used approaches in current 
interventional cardiology. However, it is interesting to mention that at the inception 
of invasive cardiology, the brachial access, introduced by Sones in the early 50’s, [ 1 ] 
was the default access for left cardiac catheterization. The brachial artery, ﬁ rst 
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approached with a surgical cutdown and later percutaneously with the Seldinger’s 
technique [ 2 ], was extensively used until the late 60’s when Amplatz and Judkins 
demonstrated the feasibility of the percutaneous femoral access in a large case 
series [ 3 ]. Afterwards, interventional cardiology made huge progress in the tech-
niques and devices used and femoral access became the default approach for almost 
all of them. 
 In the last 20 years, after Campeau’s report of a transradial approach (TRA) for 
coronary angiography, the radial artery has been increasingly employed as an alter-
native access site for both diagnostic and therapeutic procedures [ 4 ]. 
 The main advantage of the radial artery use is a reduced invasiveness, given by 
its superﬁ cial position, the smaller caliber and the high predictability of its compres-
sion. The lack of important adjacent structures decreases the hazard during the 
puncture. However, these beneﬁ ts come at the cost of an increased complexity in the 
maneuverability of the catheters, with an increased procedure time and radiation 
exposure, especially in non-experienced operators [ 5 ]. Moreover, its anatomical 
limitations do not permit the use of bulky devices or bigger catheters, occasionally 
needed for more complex procedures. 
 Discussion 
 The Bleeding Issue: Access Site and Non-access Site Bleeding 
During Percutaneous Coronary Intervention (PCI) and Their 
Impact on Patients’ Outcome 
 Bleeding is a frequent complication during PCI and 30–70 % of these events are 
related to the access site. This broad variability depends mostly on the patient’s 
clinical presentation. In fact, acute patients are more prone to access site bleeding, 
whereas in stable patients two-thirds are not access site related [ 6 ]. 
 The radial approach brings a 65 % reduction of major vascular access site com-
plications, 49 % of non–CABG-related major bleeding, and 35 % reduction of the 
transfusion rate compared with the femoral approach [ 7 ]. Interestingly, radial access 
beneﬁ t persisted when vascular closure devices were used in the femoral cohort [ 8 ]. 
 The reduction of bleeding events is of paramount importance considering the 
strong correlation between major bleeding and mortality [ 9 ,  10 ]. In a study of over 
26,000 patients with non–ST-segment elevation ACS, there was a signiﬁ cant 
 interaction between bleeding severity and the rate of death at 30-days, death at 6 
months or the composite of death and MI [ 11 ]. 
 A sub-analysis of the TRITON-TIMI 38 trial [ 12 ] showed that serious spontane-
ous bleeding tended to have a sustained impact on mortality for approximately 1 
month, as it was shown by an elevated hazard ratio within the ﬁ rst 30 days after PCI 
followed by a non-signiﬁ cant trend thereafter. Similarly, a recent analysis from the 
PLATO trial also demonstrated that procedure-related bleeding is strongly associ-
ated with short-term mortality [ 13 ]. 
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 To further corroborate these ﬁ ndings, the application of bleeding prevention 
strategies demonstrated a better survival during an acute coronary syndrome. The 
OASIS-5 trial compared fondaparinux with enoxaparin in a court of 20,078 patients 
with non-ST-segment elevation ACS. This study showed that fondaparinux was not 
inferior to enoxaparin with respect to 9 day composite ischemic endpoints, and 
superior with respect to major bleeding at 9 days (fondaparinux 2.2 % vs. enoxapa-
rin 4.1 %, p < 0.001) [ 14 ] eventually resulting in a signiﬁ cant reduction of death 
from all causes at 1 month (deaths in fondaparinux arm 574 vs. deaths in enoxaparin 
arm 638, p = 0.05). 
 Similarly, in HORIZONS AMI, the implementation of the direct thrombin inhib-
itor bivalirudin, compared with unfractionated heparin plus glycoprotein IIb/IIIa 
inhibitors in patients undergoing primary PCI, resulted in both a reduction of major 
bleeding (4.9 % vs. 8.3 %, p < 0.001) and mortality at 30 days (2.1 % vs. 3.1 %, 
p = 0.047) [ 15 ]. 
 However, it is worth mentioning that patients with a higher bleeding risk usually 
carry also a higher ischemic risk. In fact, bleeding more frequently occurs in sicker 
patients, and a possible lack of cause-effect between the two events could be argued, 
being this correlation driven by host or putative mechanisms [ 16 ]. On the other hand, 
discontinuation of antithrombotic therapy, transfusions and severe anemia after bleed-
ing are likely to be important prognostic modiﬁ ers and all need to be prevented [ 17 ]. 
 Finally, it has been demonstrated that non-access site related bleeding carries a 
relatively higher risk of death compared with access site bleeding (HR 2.2) [ 18 ,  19 ]. 
Access site selection hardly affects non-access-site bleeding, on the other hand, the 
application of a modern antithrombotic regimen and optimal anti platelet therapy 
could mitigate the excess bleeding risk and improve the outcome [ 15 ,  20 ]. 
 Is Radial Access Effective as Femoral? 
 The limits of the radial technique have been pushed far forward since its ﬁ rst intro-
duction. The advances in experience and technology allow today the treatment of 
complex PCI cases like bifurcations, unprotected left main coronary artery [ 21 ] and 
chronic total occlusions [ 22 ] from the radial access. Importantly, the rates of proce-
dural success are similar to the femoral approach [ 23 ] but only for experienced 
radial operators. 
 Many studies tried to delineate the learning curve of the radial technique. Ball 
et al. prospectively collected from 1999 to 2008 a total of 1672 patients with non- 
urgent, single vessel disease, underwent TR-PCI by 28 operators. The outcomes 
were stratiﬁ ed into chronological groups of cases for operators starting transracial 
technique in their institution: the ﬁ rst group from case 1 to case 50 and so on 51–100, 
101–150, 151–300. The control group consisted of experienced radial operators 
with more than 300 TR-PCI. The study found that the PCI failure rate was inversely 
related with the case volume, with a 32 % decrease in PCI failure every additional 
50 PCIs performed. The author’s eventually concluded that a case volume of at least 
50 PCI is needed to achieve an outcome comparable with an expert radial operator. 
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However, considering that this study included non-urgent, single vessel disease, the 
learning curve for more complex PCI is likely to be steeper [ 24 ]. Similarly, Looi 
et al. showed how after 6 months of practice in diagnostic radial angiography, fel-
lows reached results comparable with senior operators [ 25 ]. 
 Interestingly, another single study about the radial approach learning curve 
showed that the left radial approach had a shorter learning curve compared to right 
radial access [ 26 ]. These results could be explained by a lower impact of subclavian 
tortuosity in the left radial artery (OR 2,7) and by an easier maneuverability of the 
catheters that, originally designed for the femoral route, adapt better to the left 
radial anatomy [ 26 ]. 
 Certainly, the more complex is the radial anatomy, the more difﬁ cult and longer 
is the procedure with consequences on procedural times and radiation exposure. 
This is particularly true for the diagnostic angiograms whereas the impact on PCI is 
milder. As could be expected, procedural times and radiation dose decrease with 
operator’s expertise [ 5 ]. 
 Radial vs. Femoral: The Evidence 
 In the past few years an important burden of evidence has been collected for the 
comparison of femoral and radial access approaches. 
 The MORTAL registry, published in 2008 by Chase et al. retrospectively ana-
lyzed 38,872 patients treated with PCI either via TRA (7,972 patients) or TFA 
(30,900 patients). The results showed that TRA reduced the need for blood transfu-
sion (1.4 % vs. 2.8 %) and 1-year mortality (3.9 % vs. 2.8 %). Importantly, the 
patient population mainly consisted of ACS treated on an urgent basis [ 27 ]. Other 
observational studies demonstrated afterwards the same conclusions. 
 The lack of a randomized trial comparing the two strategies was ﬁ nally over-
come with the presentation of the pivotal radial versus femoral access for coronary 
angiography and intervention in patients with acute coronary syndromes (RIVAL) 
trial. RIVAL recruited 7,021 patients in 32 countries, of which 3,507 patients were 
randomly assigned to radial access and 3,514 to femoral access. The primary out-
come was the composite of death, myocardial infarction, stroke, or non- coronary 
artery bypass graft (non-CABG)-related major bleeding at 30 days. The trial 
 ultimately failed to demonstrate a signiﬁ cant superiority of the radial access with 
respect to the primary endpoint (3.7 % vs. 4.0 %, [HR] 0.92, 95 %CI 0.72–1.17; 
p = 0.50). Major vascular access site complications were signiﬁ cantly reduced in the 
radial arm (1.4 % vs. 3.7 % P < 0.0001), whereas non-CABG-related TIMI major 
bleeding (0.5 % vs. 0.5 % P = 1.00) and access site major bleeding (0.2 % vs. 0.3 % 
P = NS) were similar in the two groups [ 7 ]. 
 Importantly, it has been shown that, in patients with STEMI, there was a beneﬁ t 
with radial access for the composite of death, MI and stroke (P int = 0.011), and death 
for all causes (interaction P int = 0.001). A signiﬁ cant interaction for the primary out-
come was ﬁ nally noted in the highest tertile volume radial centers (HR 0.49, 95 %CI 
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0.28–0.87; p = 0.015). These ﬁ ndings strongly questioned the previous results sug-
gested by the observational studies. However, at a deeper analysis some of the rea-
sons of such a divergence could be identiﬁ ed. 
 First, a post-hoc analysis that evaluated the actual location of the access-site 
major bleeding showed that all the six reported events found in the radial group did 
not consist of real radial-related complications but of consequences of IABP or 
radial-to-femoral cross-over confounded by the intention-to-treat design of the 
study. Thus, after reallocating the bleeding events in the pertinent group, a signiﬁ -
cant relation between access-site major bleeding and femoral access (0 vs. 18 
events) was present also in RIVAL [ 7 ]. 
 Second, the bleeding deﬁ nition used to adjudicate the events is of paramount 
importance. In fact, the use Acute Catheterization and Urgent Intervention strategy 
(ACUITY) trial bleeding criteria showed a signiﬁ cant reduction of major bleeding 
in the radial cohort (p < 0.0001). 
 Third, the number of bleeding events was unusually low in the RIVAL popula-
tion compared with previous ACS trials and only 32 % were access site related. 
Therefore, the trial may have been underpowered to detect a difference in non–
CABG-related major bleeding and consequently to demonstrate a superiority of 
radial access on the primary endpoint [ 7 ]. 
 The RIVAL result left many perplexities, and further evidence was needed. The 
Radial versus Femoral Randomized Investigation in ST- Elevation Acute Coronary 
Syndrome (RIFLE-STEACS) trial, presented in 2011, randomized 1,001 patients 
undergoing primary PCI to radial or femoral access. The aim of the study was to 
demonstrate a beneﬁ t on hard endpoints of the radial access in the STEMI popula-
tion [ 28 ]. The trial used the new Bleeding Academic Research Consortium (BARC) 
deﬁ nition and was powered to assess the superiority over the primary endpoint of 
death, MI, TLR, stroke or non–CABG-related major bleeding at 30 days. RIFLE- 
STEACS demonstrated a net reduction of the primary endpoint (13.6 % vs. 21 %; 
P = 0.003), of the non–CABG-related major bleeding (7.8 % vs. 12.2 %; P = 0.026) 
and of mortality (5.2 % vs. 9.2 % P = 0.02) in the radial arm at 30 days. 
 This apparently striking results need to be critically analyzed. 
 Firstly, the operators in the RIFLE-STEACS were all expert radialists perform-
ing more than 300 PCI/year. Notwithstanding, the crossover rate from radial to 
femoral was 9.6 %, mainly due to shock, peripheral vascular disease and previous 
thrombolysis. 
 Secondly, the total mortality and the bleeding rates of the RIFLE-STEACS popu-
lation were particularly high compared to previous STEMI trials, probably because 
the population included higher risk patients with cardiogenic shock and rescue 
PCIs, and the treatment frequently included GP inhibitors (70 %). 
 Finally, even if the access-site bleeding was reduced by the radial access in the 
main study, at a post-hoc analysis this beneﬁ t was no longer present when the TIMI 
bleeding deﬁ nition was used [ 28 ]. 
 Another recent randomized trial evaluated the effect of the access-site in patients 
undergoing PCI. The STEMI-RADIAL randomized 707 patients with STEMI to 
radial and femoral approach before the primary PCI [ 29 ]. The primary endpoint, 
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consisting of a composite of major bleeding and vascular access site complications 
at 30 days, occurred signiﬁ cantly more in the femoral access group (1.4 % vs. 
7.2 %; P < 0.0001). The rate of net adverse clinical events (NACE) deﬁ ned as a 
composite of death, MI, stroke, and major bleeding/vascular complications was also 
reduced by the radial access strategy (4.6 % vs. 11 %; P = 0.0028). In contrast with 
the RIFLE-STEACS, mortality at 30 days in the STEMI-RADIAL was similar in 
the two groups (2.3 % vs. 3.1 %; P = 0.64), result probably driven by the exclusion 
of very high-risk patients. 
 Mortality: Does the Access Site Matter? 
 The impact of access-site on mortality has been tested by numerous randomized 
trials, observational studies and metanalysis. 
 Before the RIVAL publication many observational studies including the already 
mentioned MORTAL registry showed a mortality reduction with the radial approach. 
The PREVAIL, a non randomized prospective study, also showed a beneﬁ t of radial 
on hard endpoints including death (1.1 % vs. 4.9 %) [ 30 ]. Similarly, a systematic 
review of the literature involving 2,808 STEMI patients, who were largely recruited 
in a non-randomized fashion, showed that trans-radial intervention was associated 
with almost 50 % decrease of overall mortality [ 31 ]. 
 The RIVAL overturned these data, not showing a signiﬁ cant mortality difference 
between the two groups. However, the subgroup analysis of patients with STEMI 
showed an impressive 54 % mortality reduction after the trans-radial treatment. 
Conversely, patients with NSTEACS showed a worrisome trend towards a 66 % 
increase in mortality (P = 0.082) [ 7 ]. 
 Finally in the RIFLE-STEACS trial a 50 % mortality reduction was found in the 
radial group [ 28 ]. Consistent with these ﬁ ndings, an observational region-wide 
study compared the medium-term outcomes of trans-radial versus trans-femoral 
intervention in 12,407 patients who underwent PCI for STEMI. This study showed 
a 30 % mortality reduction at 2 years in favor of the trans-radial intervention reﬂ ect-
ing an early signiﬁ cant mortality beneﬁ t within 30 days after treatment [ 32 ]. 
 From all the data collected so far, radial access emerged as the most important 
single mortality reducer during primary PCI. However, the reason of such an 
impressive impact on survival is not completely clear. The reduction in access site 
major bleeding is a clear beneﬁ t of the radial access but can hardly explain these 
massive differences. Furthermore, non-access site bleeding affects mortality two 
times more than access site bleeding and reasonably cannot be inﬂ uenced by the 
access selection [ 6 ]. 
 Analyzing the detailed cause of death in the RIFLE-STEACS trial, most of the 
patients died early after PCI and frequently from acute heart failure. Accordingly, it 
is difﬁ cult to speculate why the radial approach provides such a signiﬁ cant beneﬁ t. 
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Potential beneﬁ cial mechanisms of the radial approach could be related to the earlier 
ambulation (lower risk of venous thromboembolism) and earlier hospital discharge 
(lower risk of nosocomial infection) but these hypotheses have yet to be tested [ 33 ]. 
 Although the impact of the radial approach on mortality remains elusive, this 
should not underestimate the growing evidence showing a sensible beneﬁ t from the 
radial approach. 
 Cost and Hospitality stay: 
 Radial access sensibly reduces the hospital costs. Saﬂ ey et al. examined costs 
among 61,509 procedures and observed a reduction of expenses in radial proce-
dures, mostly driven by a reduced in hospital length of stay [ 34 ]. This beneﬁ t was 
consistent in the RIFLE-STEACS and in the STEMI-RADIAL trials. 
 Limitations of the Radial Artery 
 Trans-radial approach carries several limitations. 
 First of all radial artery anatomy is still a technical limitation, being 50–70 % 
smaller than the femoral artery, it does not allow the same ﬂ exibility in the device 
and procedure strategy selection as compared to the femoral approach. In fact, 
the rate of vascular access site failure in the RIVAL study was higher in the 
radial group (7 % vs. 0.9 %). Access site failure was mostly related to radial 
spasm (5 %) and vessel tortuosity in the radial (1.3 %) and in the subclavian seg-
ment (1.9 %). 
 Part of the technical complexity of the radial approach is obtaining an optimal 
support of the guiding catheter, especially during left coronary artery intervention 
[ 35 ]. This could be challenging for the imperfect compatibility of the standard cath-
eters, designed for the femoral route, with the radial anatomy [ 36 ]. Even if some of 
these technical difﬁ culties could be overcome with left radial access, [ 37 ] more than 
90 % of operators use the right approach [ 36 ] and dedicated radial catheter are not 
commonly utilized. 
 Noteworthy, the radial approach reduces dramatically access-site complication 
but it cannot be considered a complication-free procedure. Compartmental syn-
drome or catheter entrapment with radial avulsion are rare, but must be carefully 
prevented. More frequent is the radial artery patency loss that occurs in up to 12 % 
of patients at 24 h after radial catheterization [ 38 ]. This should not be considered a 
minor complication because it might hinder the potential future use of the radial 
artery (arterial ﬁ stula for dialysis, arterial harvesting for CABG, further catheteriza-
tions), and could eventually be prevented with the systematic use of the patent 
hemostasis technique [ 38 ]. 
 Lastly, the radiation dose appears to be higher with the radial approach [ 5 ]. This 
is true especially during the ﬁ rst part of the learning curve, and it is reduced with 
operator experience. 
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 When Femoral Artery Is Necessary 
 Given the strong relationship between radial access and reduced vascular complica-
tions, the American College of Cardiology Foundation, American Heart Association, 
Society for Cardiovascular Angiography and Interventions PCI practice guidelines 
now give a strong recommendation to the radial approach [ 39 ], and the European 
Association of Percutaneous Cardiovascular Interventions group has recently stated 
in a position paper that it should be the default access site for PCI [ 40 ]. 
 Nevertheless, in many situations the femoral approach is still essential. Not men-
tioning the imperative necessity of the femoral access for all structural heart disease 
procedures, the use of bulky devices such as intra-aortic balloon pump, Impella device 
or ECMO require a large diameter arterial access. Moreover, femoral access is still 
the ﬁ rst choice during complex PCI’s when better control and ﬂ exibility are needed. 
 Conclusion 
 The beneﬁ t of the radial use in clinical practice has been shown in many different 
randomized trials. Although the mechanism of beneﬁ t for some end points remains 
unclear, a continuous effort should be made to improve proﬁ ciency in the radial 
approach without loosing expertise in the femoral technique. 
 Furthermore, the implementation of strategies to prevent non-access site related 
bleeding, such as the use of bivalirudin and the optimal adjustment of anti-platelet 
therapy, are likely to be important steps to improve the prognosis of ACS patients. 
 In the near future ongoing trials such as SAFARI-STEMI (NCT01398254) and 
MATRIX (NCT01433627) will give useful information about the role of vascular 
access in the context of a modern anticoagulant therapy. 
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The use of the radial artery as preferred access site for coronary diagnostics and interventions is rapidly increas-
ing worldwide given the extensive evidence demonstrating its 
beneﬁt on vascular complications and mortality,1–3 its cost-
effectiveness,4 and the increased patient satisfaction in com-
parison with the femoral approach.2 However, this approach 
could be complicated by radial artery occlusion (RAO), which 
only rarely causes hand ischemia but more commonly impede 
future utilization of the radial artery as an access site for cathe-
terization or as a conduit for hemodialysis and coronary artery 
bypass graft. The occurrence of RAO after catheterization has 
been reported in ≤30% of patients,5 and thrombosis or inti-
mal hyperplasia caused by the vascular damage are suggested 
pathophysiological mechanisms. In addition, radial artery 
cannulation has also been related with several nonocclusive 
modiﬁcations as acute wall injuries, endothelial dysfunction, 
and impaired vasomotion.
The aim of the Rotterdam Radial Access Research 
(R-RADAR) study was to describe with high-resolution 
ultrasound structural changes in the radial artery wall at its 
puncture site after transradial catheterization and investigate 
whether these changes might predict RAO or loss of pulsation, 
local pain, or functional impairment of the upper extremity.
Methods
Study Population
A total of 100 consecutive patients undergoing transradial catheteriza-
tion for diagnostic coronary angiography with or without intervention 
Background—Radial artery wall might be damaged after cannulation for cardiac catheterization. We investigated structural 
changes of the radial artery wall after catheterization to understand whether these might predict radial pulsation loss or 
occlusion and local pain or functional impairment of the upper extremity.
Methods and Results—Ninety patients underwent transradial coronary angiography or intervention and were scanned with 
a high-resolution 40-MHz ultrasound before cannulation and at 3 hours and 30 days after procedure. Acute injuries of 
the radial artery occurred in all patients: dissection and intramural hematoma were the most common. However, these 
phenomena did not predict loss of radial pulsation or occlusion, local pain, or functional impairment at 30 days. Overall, 
the radial artery lumen was signiﬁcantly reduced distal to the puncture site. Radial artery intima and total wall thickness 
increased 3 hours after puncture and persisted at 30 days. Radial occlusion and pulsation loss were observed in 3.9% and 
9.2% of patients, respectively, at 30 days. Smaller radial artery lumen at baseline increased the risk of radial pulsation 
loss at 30 days (odds ratio, 1.23; P=0.049). The number of radial puncture attempts predicted pulsation loss (odds ratio, 
2.64; P=0.027), occlusion (odds ratio, 3.49; P=0.022), and symptoms (odds ratio, 2.24; P=0.05) at 30-day follow-up.
Conclusions—After catheterization, radial artery puncture site is associated with increased intima and total wall thickness 
and with modest decrease of inner lumen diameter. Acute injuries of the vessel wall were ubiquitous, but contrary to 
repeated puncture attempts, did not seem to affect postprocedural radial occlusion or loss of pulsation.  
(Circ Cardiovasc Interv. 2016;9:e003129. DOI: 10.1161/CIRCINTERVENTIONS.115.003129.)
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◼ punctures ◼ radial artery
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2  Costa et al  Radial Artery Ultrasound Within Catheterization 
were enrolled in this prospective single-center registry. Radial artery 
catheterization within 2 months or clinical instability (including pre-
sentation with ST-segment–elevation myocardial infarction) were the 
main exclusion criteria. The Erasmus Medical Center Review Board 
approved the trial, and all patients gave written informed consent to 
participate. Eventually, 90 patients were treated through the prese-
lected radial artery and constitute the ﬁnal population.
Ultrasound Evaluation
Ultrasound studies were performed by 2 experienced sonographers 
(K.W. and J.L.) with a Visualsonics MS550D and a 22 to 55-MHz 
probe (VisualSonics Inc., Toronto, Canada), a high-resolution ultra-
sound system with a spatial resolution of 30 to 50 μm.6–8 At baseline, 
an estimated puncture site with adequate radial pulsation was marked. 
The area was photographed and digitally stored as a reference for the 
evaluation at follow-up (Figure I in the Data Supplement). Ultrasound 
evaluation was then performed before radial cannulation, 3 hours af-
ter the procedure when the compressive device was removed, and 
again after 4 to 6 weeks. Longitudinal and cross-sectional views 
were acquired (Figure II in the Data Supplement). Interpretable ultra-
sound studies could be obtained in all patients. However, 10 patients 
were excluded from the analysis because the studied right radial ar-
tery was eventually not used for catheterization (Table I in the Data 
Supplement).
Transradial Coronary Catheterization
After local anesthesia of the puncture site with xylocaine 2%, a 6F 
sheath (Radifocus, Terumo, Japan; outer diameter, 2.45 mm) was in-
serted at or close to the previously marked site. The anterior wall 
technique was used to achieve artery cannulation in all patients of 
the study. Sheath insertion was followed by an intra-arterial bolus of 
2500 IU of unfractionated heparin in diagnostic procedures, whereas 
for percutaneous coronary intervention, 100 IU/kg body weight of 
unfractionated heparin or bivalirudin at the product-labeling dose was 
used. A mixture of 0.2-mg nitroglycerin and 2.5-mg verapamil for 
prevention of radial artery spasm was injected in all patients. At the 
end of the procedure, the radial sheath was removed and a dedicated 
compression device (TR BAND, Terumo, Japan) was applied. It was 
recommended to achieve nonocclusive compression by performing 
the reverse Barbeau test.9 In 30-minute intervals, air was released 
from the compression device until removal after 3 hours. All patients 
underwent physical and ultrasound examination of the radial artery at 
baseline before the catheterization, 3 hours after sheath removal, and 
4 to 6 weeks after the procedure.
Echographic End Points
The echographic measurements were prespeciﬁed in the study proto-
col and included the radial artery inner lumen diameter, the total wall 
thickness, and the relative intima and media thickness at the puncture 
site. The region of interest around the puncture site was arbitrarily 
deﬁned 4 mm proximally and distally to the entry site (Figure III in 
the Data Supplement). The inner lumen diameter was measured in 
a longitudinal view and deﬁned as the distance between the leading 
edges of the intima–lumen interface of the near wall and the lumen–
intima interface of the far wall. Inner diameter was acquired at the 
entry site and at the distal and proximal landmark sites (Figure III in 
the Data Supplement). The total wall thickness, including the intima, 
the media, and the adventitia, was measured in a cross-sectional view 
within the puncture site region of interest in a frame showing a 3-lay-
er appearance of the vessel wall (Figure IV in the Data Supplement). 
Intima thickness was deﬁned as the distance from the leading edge of 
the lumen–intima interface to the interface between intima and media 
and separately measured as in previous report using the same technol-
ogy.8 The media thickness was calculated by subtracting the intima 
thickness from the intima–media thickness.
The deﬁnitions of speciﬁc acute wall injuries of the radial artery 
are provided in the Methods in the Data Supplement.
Clinical End Points
Clinical end points evaluated at 3-hour and 30-day follow-up were 
(1) radial artery pulsation loss (RAPL), deﬁned as any loss of radial 
artery pulsation at the puncture site, which was normally detected at 
baseline; (2) RAO, deﬁned as imaging conﬁrmed lack of anterograde 
ﬂow in the radial artery, that was present at baseline; (3) symptoms 
WHAT IS KNOWN
s Radial over femoral access provides less access site 
complications and potentially improved survival.
s Radial access complications include occlusion and 
spasm, which may increase the difﬁculty of repeat 
catheterizations from the same site.
WHAT THE STUDY ADDS
s Traumatic injuries to the radial artery, as assessed by 
high-resolution ultrasound imaging, were ubiquitous 
in patients undergoing transradial cannulation.
s Radial artery intima and total wall thickness in-
creased after cannulation.
s Radial artery size, calciﬁcation at baseline and num-
ber of puncture attempts, might have an impact on 
radial occlusion and pulse loss at follow-up.
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Figure 1. Study proﬁle.
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of pain or discomfort of the upper extremity reported by the patients 
at follow-up; (4) functional impairment, deﬁned as any kind of func-
tional compromise of the upper extremity reported by the patients at 
follow-up, that was likely related to the procedure.
Statistical Analysis
The sample size of this exploratory study was arbitrarily set at 100 
patients. Categorical variables were expressed as frequency (percent-
age), whereas continuous variables were expressed as mean±SD. 
Repeated measures ANOVA with a Greenhouse–Geisser correction 
was used to compare echographic measures at baseline with the re-
spective values at the 3-hour and 30-day follow-up. Post hoc test-
ing between the 3 timepoints was performed using the Bonferroni 
correction for multiple comparisons (2-sided α=0.05/3=0.0167). 
Mixed-design ANOVA was used to test the consistence of paired 
measurements results among subgroups (ie, sex, diabetes mellitus, 
current smoking, hypertension, dyslipidemia, previous myocardial 
infarction, and peripheral vascular disease).
Correlations between variables were assessed with the Pearson 
r correlation coefﬁcient. Univariate regression analysis was used to 
investigate the predictive value for the occurrence of clinical end 
points. Statistical signiﬁcance was set at a P<0.05.
Results
A total of 100 patients who were scheduled for coronary 
diagnostic angiography or intervention underwent ultrasound 
assessment of the radial artery in the R-RADAR study. Nine 
patients were eventually treated through the femoral artery 
and 1 through the contralateral radial artery. The preselected 
radial artery was successfully cannulated in 90 patients, who 
thus represent the ﬁnal population of this analysis (Figure 1). 
Eighty-eight and 77 patients completed the echographic eval-
uation at 3 hours and 30 days, respectively.
Baseline characteristics are displayed in Table 1. 
Procedure duration was on average 50 minutes (Table 2). 
RAPL was observed in 10 patients, 5 (6.1%) at 3 hours and 
7 (9.2%) at 30 days. Three patients (3.4%) developed RAO 
immediately after procedure, which persisted at 30-day 
follow-up. In total, 44 patients experienced pain or discom-
fort of the upper extremity, 32 (36.8%) at 3-hour follow-up 
and 24 (32.0%) at 30 days, whereas any kind of functional 
compromise occurred in 19 patients, 12 (14.1%) at 3-hour 
follow-up and 9 (12.0%) at 30-day follow-up. All patients 
having radial occlusion were symptomatic, but only 1 expe-
rienced functional compromise. Two patients with RAO at 
30 days also had loss of radial pulsation.
Ultrasound Findings
The mean radial artery lumen at puncture site was 2.25 mm. 
The presence of wall calciﬁcation and artery spasm at baseline 
was reported in 7% and 10% of patients, respectively.
After the procedure, acute wall injuries at the puncture site 
were ubiquitous (Figures 2 and 3; Movies I–VII in the Data 
Supplement). Eighty-six (97.7%) patients showed acute inju-
ries at 3 hours and 74 (96.1%) at 30 days. Radial dissection 
and wall hematoma were most frequent both at 3 hours (dis-
section, 89.8%; hematoma, 73.9%) and 30 days (dissection, 
83.1%; hematoma, 64.9%). More than half of the patients 
had lumen narrowing at any timepoint. Pseudoaneurysms was 
observed in 14.8% of patients at 3 hours, increasing to 55.8% 
at 30-day follow-up. Thrombus formation at any timepoint 
was seen in 4% of patients (Figure 4).
Radial artery inner lumen diameter in the region of inter-
est changed over time (Figure 5). At the entry site, it slightly 
decreased 3 hours after the procedure (baseline, 2.25±0.50 ver-
sus 3 hours, 2.02±0.66; P=0.01) and partially restored at 30-day 
follow-up (3 hours, 2.02±0.66 versus 30 days, 2.14±0.68; 
P=0.38; Table 3). The lumen diameter remained unchanged 
during follow-up proximally to the entry site, whereas it con-
sistently decreased over time distally (Figure 5; Table 3). No 
interaction was observed between the change in lumen diam-
eter overtime and the baseline characteristics explored (ie, sex, 
diabetes mellitus, current smoking, hypertension, dyslipidemia, 
previous myocardial infarction, and peripheral vascular disease).
The total wall thickness of the radial artery at the puncture 
site tripled 3 hours after cannulation, and further increased by 
28% at 30 days (Figure 5; Table 3). The artery intima thick-
ened at 3 hours and persisted at 30 days, whereas the media 
did not change signiﬁcantly over time (Figure 5; Table 3).
Impact of Ultrasound Findings and Procedural 
Characteristics on Clinical End Points
Injuries to the radial wall detected at 3-hour or 30-day follow-
up did not correlate with clinical end points (Table 4). RAO 
Table 1.  Patient Characteristics
Age, y 64.6±10.5
Male sex, n (%) 72.2% (65/90)
Body mass index, kg/m2 27.9±4.0
Diabetes mellitus, n (%) 15.6% (14/90)
Hypertension, n (%) 56.7% (51/90)
Hyperlipidemia, n (%) 60% (54/90)
Smoking, n (%) 20% (18/90)
Previous myocardial infarction, n (%) 20% (18/90)
Previous PCI or CABG, n (%) 41.1% (37/90)
Peripheral vascular disease, n (%) 20% (18/90)
CABG indicates coronary artery bypass graft; and PCI, percutaneous coronary 
intervention.
Table 2.  Procedural Characteristics
Allen test positive (%) 85.5% (65/76)
Spasm at baseline (%) 10% (9/90)
Punctures no. of attempts 1 (1–2)
  Range 1–4
  >1 attempt 16.1% (14/87)
Coronary angiography only (%) 56.7% (51/90)
PCI performed (%) 43.3% (39/90)
PCI no. of treated vessels 1 (1–2)
Procedure duration, min 50 (34–77)
Coronary angiography only 35 (27–46)
PCI performed 77 (62–104)
Heparin used, n (%) 93.3% (84/90)
Heparin total dose, IU 7500 (6250–10 000)
Bivalirudin used, n (%) 6.7% (6/90)
Bivalirudin total dose 265.5 (161.2–383.4)
Active coagulation time 284±104
PCI indicates percutaneous coronary intervention.
R-RADAR STUDY
119118
3
2  Costa et al  Radial Artery Ultrasound Within Catheterization 
were enrolled in this prospective single-center registry. Radial artery 
catheterization within 2 months or clinical instability (including pre-
sentation with ST-segment–elevation myocardial infarction) were the 
main exclusion criteria. The Erasmus Medical Center Review Board 
approved the trial, and all patients gave written informed consent to 
participate. Eventually, 90 patients were treated through the prese-
lected radial artery and constitute the ﬁnal population.
Ultrasound Evaluation
Ultrasound studies were performed by 2 experienced sonographers 
(K.W. and J.L.) with a Visualsonics MS550D and a 22 to 55-MHz 
probe (VisualSonics Inc., Toronto, Canada), a high-resolution ultra-
sound system with a spatial resolution of 30 to 50 μm.6–8 At baseline, 
an estimated puncture site with adequate radial pulsation was marked. 
The area was photographed and digitally stored as a reference for the 
evaluation at follow-up (Figure I in the Data Supplement). Ultrasound 
evaluation was then performed before radial cannulation, 3 hours af-
ter the procedure when the compressive device was removed, and 
again after 4 to 6 weeks. Longitudinal and cross-sectional views 
were acquired (Figure II in the Data Supplement). Interpretable ultra-
sound studies could be obtained in all patients. However, 10 patients 
were excluded from the analysis because the studied right radial ar-
tery was eventually not used for catheterization (Table I in the Data 
Supplement).
Transradial Coronary Catheterization
After local anesthesia of the puncture site with xylocaine 2%, a 6F 
sheath (Radifocus, Terumo, Japan; outer diameter, 2.45 mm) was in-
serted at or close to the previously marked site. The anterior wall 
technique was used to achieve artery cannulation in all patients of 
the study. Sheath insertion was followed by an intra-arterial bolus of 
2500 IU of unfractionated heparin in diagnostic procedures, whereas 
for percutaneous coronary intervention, 100 IU/kg body weight of 
unfractionated heparin or bivalirudin at the product-labeling dose was 
used. A mixture of 0.2-mg nitroglycerin and 2.5-mg verapamil for 
prevention of radial artery spasm was injected in all patients. At the 
end of the procedure, the radial sheath was removed and a dedicated 
compression device (TR BAND, Terumo, Japan) was applied. It was 
recommended to achieve nonocclusive compression by performing 
the reverse Barbeau test.9 In 30-minute intervals, air was released 
from the compression device until removal after 3 hours. All patients 
underwent physical and ultrasound examination of the radial artery at 
baseline before the catheterization, 3 hours after sheath removal, and 
4 to 6 weeks after the procedure.
Echographic End Points
The echographic measurements were prespeciﬁed in the study proto-
col and included the radial artery inner lumen diameter, the total wall 
thickness, and the relative intima and media thickness at the puncture 
site. The region of interest around the puncture site was arbitrarily 
deﬁned 4 mm proximally and distally to the entry site (Figure III in 
the Data Supplement). The inner lumen diameter was measured in 
a longitudinal view and deﬁned as the distance between the leading 
edges of the intima–lumen interface of the near wall and the lumen–
intima interface of the far wall. Inner diameter was acquired at the 
entry site and at the distal and proximal landmark sites (Figure III in 
the Data Supplement). The total wall thickness, including the intima, 
the media, and the adventitia, was measured in a cross-sectional view 
within the puncture site region of interest in a frame showing a 3-lay-
er appearance of the vessel wall (Figure IV in the Data Supplement). 
Intima thickness was deﬁned as the distance from the leading edge of 
the lumen–intima interface to the interface between intima and media 
and separately measured as in previous report using the same technol-
ogy.8 The media thickness was calculated by subtracting the intima 
thickness from the intima–media thickness.
The deﬁnitions of speciﬁc acute wall injuries of the radial artery 
are provided in the Methods in the Data Supplement.
Clinical End Points
Clinical end points evaluated at 3-hour and 30-day follow-up were 
(1) radial artery pulsation loss (RAPL), deﬁned as any loss of radial 
artery pulsation at the puncture site, which was normally detected at 
baseline; (2) RAO, deﬁned as imaging conﬁrmed lack of anterograde 
ﬂow in the radial artery, that was present at baseline; (3) symptoms 
WHAT IS KNOWN
s Radial over femoral access provides less access site 
complications and potentially improved survival.
s Radial access complications include occlusion and 
spasm, which may increase the difﬁculty of repeat 
catheterizations from the same site.
WHAT THE STUDY ADDS
s Traumatic injuries to the radial artery, as assessed by 
high-resolution ultrasound imaging, were ubiquitous 
in patients undergoing transradial cannulation.
s Radial artery intima and total wall thickness in-
creased after cannulation.
s Radial artery size, calciﬁcation at baseline and num-
ber of puncture attempts, might have an impact on 
radial occlusion and pulse loss at follow-up.
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of pain or discomfort of the upper extremity reported by the patients 
at follow-up; (4) functional impairment, deﬁned as any kind of func-
tional compromise of the upper extremity reported by the patients at 
follow-up, that was likely related to the procedure.
Statistical Analysis
The sample size of this exploratory study was arbitrarily set at 100 
patients. Categorical variables were expressed as frequency (percent-
age), whereas continuous variables were expressed as mean±SD. 
Repeated measures ANOVA with a Greenhouse–Geisser correction 
was used to compare echographic measures at baseline with the re-
spective values at the 3-hour and 30-day follow-up. Post hoc test-
ing between the 3 timepoints was performed using the Bonferroni 
correction for multiple comparisons (2-sided α=0.05/3=0.0167). 
Mixed-design ANOVA was used to test the consistence of paired 
measurements results among subgroups (ie, sex, diabetes mellitus, 
current smoking, hypertension, dyslipidemia, previous myocardial 
infarction, and peripheral vascular disease).
Correlations between variables were assessed with the Pearson 
r correlation coefﬁcient. Univariate regression analysis was used to 
investigate the predictive value for the occurrence of clinical end 
points. Statistical signiﬁcance was set at a P<0.05.
Results
A total of 100 patients who were scheduled for coronary 
diagnostic angiography or intervention underwent ultrasound 
assessment of the radial artery in the R-RADAR study. Nine 
patients were eventually treated through the femoral artery 
and 1 through the contralateral radial artery. The preselected 
radial artery was successfully cannulated in 90 patients, who 
thus represent the ﬁnal population of this analysis (Figure 1). 
Eighty-eight and 77 patients completed the echographic eval-
uation at 3 hours and 30 days, respectively.
Baseline characteristics are displayed in Table 1. 
Procedure duration was on average 50 minutes (Table 2). 
RAPL was observed in 10 patients, 5 (6.1%) at 3 hours and 
7 (9.2%) at 30 days. Three patients (3.4%) developed RAO 
immediately after procedure, which persisted at 30-day 
follow-up. In total, 44 patients experienced pain or discom-
fort of the upper extremity, 32 (36.8%) at 3-hour follow-up 
and 24 (32.0%) at 30 days, whereas any kind of functional 
compromise occurred in 19 patients, 12 (14.1%) at 3-hour 
follow-up and 9 (12.0%) at 30-day follow-up. All patients 
having radial occlusion were symptomatic, but only 1 expe-
rienced functional compromise. Two patients with RAO at 
30 days also had loss of radial pulsation.
Ultrasound Findings
The mean radial artery lumen at puncture site was 2.25 mm. 
The presence of wall calciﬁcation and artery spasm at baseline 
was reported in 7% and 10% of patients, respectively.
After the procedure, acute wall injuries at the puncture site 
were ubiquitous (Figures 2 and 3; Movies I–VII in the Data 
Supplement). Eighty-six (97.7%) patients showed acute inju-
ries at 3 hours and 74 (96.1%) at 30 days. Radial dissection 
and wall hematoma were most frequent both at 3 hours (dis-
section, 89.8%; hematoma, 73.9%) and 30 days (dissection, 
83.1%; hematoma, 64.9%). More than half of the patients 
had lumen narrowing at any timepoint. Pseudoaneurysms was 
observed in 14.8% of patients at 3 hours, increasing to 55.8% 
at 30-day follow-up. Thrombus formation at any timepoint 
was seen in 4% of patients (Figure 4).
Radial artery inner lumen diameter in the region of inter-
est changed over time (Figure 5). At the entry site, it slightly 
decreased 3 hours after the procedure (baseline, 2.25±0.50 ver-
sus 3 hours, 2.02±0.66; P=0.01) and partially restored at 30-day 
follow-up (3 hours, 2.02±0.66 versus 30 days, 2.14±0.68; 
P=0.38; Table 3). The lumen diameter remained unchanged 
during follow-up proximally to the entry site, whereas it con-
sistently decreased over time distally (Figure 5; Table 3). No 
interaction was observed between the change in lumen diam-
eter overtime and the baseline characteristics explored (ie, sex, 
diabetes mellitus, current smoking, hypertension, dyslipidemia, 
previous myocardial infarction, and peripheral vascular disease).
The total wall thickness of the radial artery at the puncture 
site tripled 3 hours after cannulation, and further increased by 
28% at 30 days (Figure 5; Table 3). The artery intima thick-
ened at 3 hours and persisted at 30 days, whereas the media 
did not change signiﬁcantly over time (Figure 5; Table 3).
Impact of Ultrasound Findings and Procedural 
Characteristics on Clinical End Points
Injuries to the radial wall detected at 3-hour or 30-day follow-
up did not correlate with clinical end points (Table 4). RAO 
Table 1.  Patient Characteristics
Age, y 64.6±10.5
Male sex, n (%) 72.2% (65/90)
Body mass index, kg/m2 27.9±4.0
Diabetes mellitus, n (%) 15.6% (14/90)
Hypertension, n (%) 56.7% (51/90)
Hyperlipidemia, n (%) 60% (54/90)
Smoking, n (%) 20% (18/90)
Previous myocardial infarction, n (%) 20% (18/90)
Previous PCI or CABG, n (%) 41.1% (37/90)
Peripheral vascular disease, n (%) 20% (18/90)
CABG indicates coronary artery bypass graft; and PCI, percutaneous coronary 
intervention.
Table 2.  Procedural Characteristics
Allen test positive (%) 85.5% (65/76)
Spasm at baseline (%) 10% (9/90)
Punctures no. of attempts 1 (1–2)
  Range 1–4
  >1 attempt 16.1% (14/87)
Coronary angiography only (%) 56.7% (51/90)
PCI performed (%) 43.3% (39/90)
PCI no. of treated vessels 1 (1–2)
Procedure duration, min 50 (34–77)
Coronary angiography only 35 (27–46)
PCI performed 77 (62–104)
Heparin used, n (%) 93.3% (84/90)
Heparin total dose, IU 7500 (6250–10 000)
Bivalirudin used, n (%) 6.7% (6/90)
Bivalirudin total dose 265.5 (161.2–383.4)
Active coagulation time 284±104
PCI indicates percutaneous coronary intervention.
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was caused by thrombus formation in one case, spiral dissec-
tion in another and to wall hematoma in the last. RAPL at 30 
days occurred in 2 of 3 patients with RAO, in 4 patients with 
radial artery spasm, and in 1 patient with slow-ﬂow and spon-
taneous contrast.
Smaller radial arteries at baseline had higher risk for 
RAPL both at 3-hour (odds ratio [OR], 1.42 per 0.1-mm 
reduction; 95% conﬁdence interval [CI], 1.08–1.88; P=0.013) 
and 30-day follow-up (OR, 1.23 per 0.1-mm reduction; 95% 
CI, 1.00–1.52; P=0.049), but no higher risk of RAO, pain and 
discomfort, or functional impairment (Table 4). Intima, media, 
or overall wall thickness did not affect clinical end points at 
any timepoint (Table 4). The presence of radial artery calciﬁ-
cation at baseline was associated with RAPL at 3 hours (OR, 
12.33; 95% CI, 1.58–96.0; P=0.016) with a consistent trend 
at 30 days (OR, 6.60; 95% CI, 0.96–45.3; P=0.055; Table 4). 
The number of puncture attempts required to achieve radial 
cannulation predicted the occurrence of RAPL (OR, 2.64; 
95% CI, 1.11–6.24; P=0.027), RAO (OR, 3.49; 95% CI, 
1.20–10.1; P=0.022), and pain and discomfort (OR, 2.24; 
95% CI, 1.00–5.04; P=0.05) at 30 days, with an increased risk 
after each further attempt (Figure 6). At 3 hours, the number 
of puncture attempts also correlated with RAO (OR, 3.49; 
95% CI, 1.22–9.96; P=0.020), with a similar trend for RAPL 
(OR, 2.17; 95% CI, 0.75–6.29; P=0.15), pain and discomfort 
(OR, 1.71; 95% CI, 0.84–3.49; P=0.14), but not for functional 
impairment (OR, 1.05; 95% CI, 0.40–2.76; P=0.91) at this 
timepoint. When we searched for correlation between the 
number of puncture attempts and ultrasound measurements, 
we observed a strong, negative correlation between the num-
ber of attempts and the radial lumen diameter at puncture site 
both at 3-hour and 30-day follow-up. We did not observe any 
correlation between the number of puncture attempts and the 
total wall, intima, and media thickness at 3-hour and 30-day 
follow-up (Table 5).
Discussion
In this prospective mechanistic study, we evaluated the radial 
artery by noninvasive high-resolution ultrasound after transra-
dial catheterization. We found that
1. The radial artery puncture site could be assessed, non-
invasively and in detail with high-resolution ultrasound.
2. The incidence of RAO and pulsation loss at 30 days was 
3.9% and 9.2%, respectively.
3. Traumatic injuries to the radial artery were ubiquitous, 
but did not result in any apparent clinical consequence.
4. The lumen of the radial artery at the puncture site mod-
estly varied during follow-up and was slightly reduced 
only in the distal part of the region of interest. Intima 
and overall arterial thickness increased at 3 hours, which 
persisted at 30 days.
Figure 2. Radial cannulation and injuries. In the upper part, sheath removal and consequent trauma. In the lower part, acute wall injuries 
of the radial artery after cannulation observed with high-resolution ultrasound: dissection (A), intramural hematoma (B), pseudoaneurysm 
(C), spasm (D), and thrombus formation (E).
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5. Smaller radial artery size and presence of wall calciﬁca-
tion at baseline predicted radial pulse loss at 3 hours and 
30 days.
6. A higher number of puncture attempts to cannulate the 
radial artery predicted radial occlusion, loss of pulsation, 
and symptoms at 30-day follow-up.
To the best of our knowledge, this is the ﬁrst study 
evaluating in vivo the radial artery puncture site, before 
and after cannulation, with a noninvasive high-resolution 
imaging technique. Invasive imaging studies already dem-
onstrated structural changes in the proximal segments of 
the radial artery after cannulation.10,11 However, an intrinsic 
limitation of intravascular imaging is the inability to exam-
ine vessel segments distal to the sheath tip, precluding a 
comprehensive evaluation of the puncture site. Noninvasive 
ultrasound was used to evaluate radial artery after cannu-
lation for coronary catheterization5 and in the emergency 
Figure 3. Ultrasound evidence of radial artery acute wall injuries at puncture site. Radial dissection: The arrowhead indicates the disrup-
tion of the vessel layers at the longitudinal view. Wall hematoma: the arrowhead indicates the hematoma with evidence of blood between 
the vessel layers. Pseudoaneurysm: arrowhead indicates the pseudoaneurysm at the longitudinal view, with evidence of blood outside the 
vessel wall. Lumen compromise: compromise of the arterial lumen caused by any injury. Spasm: the arrowhead indicates spasm, shown 
as vessel shrinkage and a thickened intima. Thrombus: arrowhead indicates the thrombus presenting as a still mass in the vessel lumen, 
characterized by the clear transition between its surface and the intima.
Figure 4. Incidence of radial artery acute wall 
injuries at puncture site. The histogram expresses 
the percentage of the population presenting each 
injury at 3-h and 30-d follow-up and overall. Injuries 
observed were not mutually exclusive.
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was caused by thrombus formation in one case, spiral dissec-
tion in another and to wall hematoma in the last. RAPL at 30 
days occurred in 2 of 3 patients with RAO, in 4 patients with 
radial artery spasm, and in 1 patient with slow-ﬂow and spon-
taneous contrast.
Smaller radial arteries at baseline had higher risk for 
RAPL both at 3-hour (odds ratio [OR], 1.42 per 0.1-mm 
reduction; 95% conﬁdence interval [CI], 1.08–1.88; P=0.013) 
and 30-day follow-up (OR, 1.23 per 0.1-mm reduction; 95% 
CI, 1.00–1.52; P=0.049), but no higher risk of RAO, pain and 
discomfort, or functional impairment (Table 4). Intima, media, 
or overall wall thickness did not affect clinical end points at 
any timepoint (Table 4). The presence of radial artery calciﬁ-
cation at baseline was associated with RAPL at 3 hours (OR, 
12.33; 95% CI, 1.58–96.0; P=0.016) with a consistent trend 
at 30 days (OR, 6.60; 95% CI, 0.96–45.3; P=0.055; Table 4). 
The number of puncture attempts required to achieve radial 
cannulation predicted the occurrence of RAPL (OR, 2.64; 
95% CI, 1.11–6.24; P=0.027), RAO (OR, 3.49; 95% CI, 
1.20–10.1; P=0.022), and pain and discomfort (OR, 2.24; 
95% CI, 1.00–5.04; P=0.05) at 30 days, with an increased risk 
after each further attempt (Figure 6). At 3 hours, the number 
of puncture attempts also correlated with RAO (OR, 3.49; 
95% CI, 1.22–9.96; P=0.020), with a similar trend for RAPL 
(OR, 2.17; 95% CI, 0.75–6.29; P=0.15), pain and discomfort 
(OR, 1.71; 95% CI, 0.84–3.49; P=0.14), but not for functional 
impairment (OR, 1.05; 95% CI, 0.40–2.76; P=0.91) at this 
timepoint. When we searched for correlation between the 
number of puncture attempts and ultrasound measurements, 
we observed a strong, negative correlation between the num-
ber of attempts and the radial lumen diameter at puncture site 
both at 3-hour and 30-day follow-up. We did not observe any 
correlation between the number of puncture attempts and the 
total wall, intima, and media thickness at 3-hour and 30-day 
follow-up (Table 5).
Discussion
In this prospective mechanistic study, we evaluated the radial 
artery by noninvasive high-resolution ultrasound after transra-
dial catheterization. We found that
1. The radial artery puncture site could be assessed, non-
invasively and in detail with high-resolution ultrasound.
2. The incidence of RAO and pulsation loss at 30 days was 
3.9% and 9.2%, respectively.
3. Traumatic injuries to the radial artery were ubiquitous, 
but did not result in any apparent clinical consequence.
4. The lumen of the radial artery at the puncture site mod-
estly varied during follow-up and was slightly reduced 
only in the distal part of the region of interest. Intima 
and overall arterial thickness increased at 3 hours, which 
persisted at 30 days.
Figure 2. Radial cannulation and injuries. In the upper part, sheath removal and consequent trauma. In the lower part, acute wall injuries 
of the radial artery after cannulation observed with high-resolution ultrasound: dissection (A), intramural hematoma (B), pseudoaneurysm 
(C), spasm (D), and thrombus formation (E).
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5. Smaller radial artery size and presence of wall calciﬁca-
tion at baseline predicted radial pulse loss at 3 hours and 
30 days.
6. A higher number of puncture attempts to cannulate the 
radial artery predicted radial occlusion, loss of pulsation, 
and symptoms at 30-day follow-up.
To the best of our knowledge, this is the ﬁrst study 
evaluating in vivo the radial artery puncture site, before 
and after cannulation, with a noninvasive high-resolution 
imaging technique. Invasive imaging studies already dem-
onstrated structural changes in the proximal segments of 
the radial artery after cannulation.10,11 However, an intrinsic 
limitation of intravascular imaging is the inability to exam-
ine vessel segments distal to the sheath tip, precluding a 
comprehensive evaluation of the puncture site. Noninvasive 
ultrasound was used to evaluate radial artery after cannu-
lation for coronary catheterization5 and in the emergency 
Figure 3. Ultrasound evidence of radial artery acute wall injuries at puncture site. Radial dissection: The arrowhead indicates the disrup-
tion of the vessel layers at the longitudinal view. Wall hematoma: the arrowhead indicates the hematoma with evidence of blood between 
the vessel layers. Pseudoaneurysm: arrowhead indicates the pseudoaneurysm at the longitudinal view, with evidence of blood outside the 
vessel wall. Lumen compromise: compromise of the arterial lumen caused by any injury. Spasm: the arrowhead indicates spasm, shown 
as vessel shrinkage and a thickened intima. Thrombus: arrowhead indicates the thrombus presenting as a still mass in the vessel lumen, 
characterized by the clear transition between its surface and the intima.
Figure 4. Incidence of radial artery acute wall 
injuries at puncture site. The histogram expresses 
the percentage of the population presenting each 
injury at 3-h and 30-d follow-up and overall. Injuries 
observed were not mutually exclusive.
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medicine setting.12 Yet, conventional ultrasound systems use 
vascular probes with a frequency between 7 and 10 MHz, 
producing a spatial resolution of 300 μm, thus incapable 
to discriminate subtle changes of the radial wall such as 
the intima/media thickness and local wall injuries observed 
with histopathology.13 In the current study, we used a high-
resolution ultrasound system with a frequency of 40 MHz, 
and a spatial resolution of 30 μm similar to intravascular 
ultrasound.6,7
We found a variety of radial wall injuries after radial cath-
eterization, occurring in all patients. These could be related 
to puncture trauma or to the mismatch between sheath size 
and artery diameter.14 The average inner diameter of the radial 
artery in our study (ie, 2.25 mm) was signiﬁcantly smaller than 
the outer diameter of the 6F sheath used (ie, 2.45 mm), hence 
producing an angioplasty-like effect during insertion. Yonetsu 
et al10 reported similar injuries—intimal tears in 44.1% of 
patients and radial dissection in 24.7%—with optical coher-
ence tomography in the proximal segment of the radial artery. 
In our data set, the acute wall injuries of the radial artery were 
not associated with RAO, RAPL, symptoms, or functional 
impairment. This may be related to a lack of statistical power 
caused by the relatively low occurrence of RAO and RAPL. 
In our study, the occurrence of RAO and RAPL was lower 
Figure 5. Evolution of radial artery measurements at the puncture site over time. A, Radial artery inner lumen diameter evolution at the 
puncture site region of interest at the 3 timepoints (ie, before cannulation, at 3-h and at 30-d follow-up). Box plots for the radial artery 
intima (B), media (C), and total wall (D) thickness at the 3 timepoints.
Table 3.  Radial Artery Ultrasound Measurements at the Puncture Site Region of Interest
Preprocedure (1)
Three-Hour  
Follow-Up (2)
Thirty-Day  
Follow-Up (3) P Value (1–2–3) P Value (1–2) P Value (2–3) P Value (1–3)
Mid lumen diameter, mm 2.25±0.50 2.02±0.66 2.14±0.68 0.016 0.01 0.38 0.57
Distal lumen diameter, mm 2.21±0.50 2.10±0.45 1.99±0.53 0.005 0.32 0.38 0.001
Proximal lumen diameter, mm 2.29±0.53 2.22±0.48 2.17±0.53 0.19 … … …
Total wall thickness, mm 0.32±0.10 1.01±0.49 1.28±0.41 <0.0001 <0.0001 <0.0001 <0.0001
Intima thickness, mm 0.11±0.09 0.16±0.06 0.16±0.08 <0.0001 0.001 1.00 0.004
Media thickness, mm 0.18±0.04 0.26±0.14 0.32±0.13 0.07 … … …
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Table 4.  Impact of Ultrasound Findings on Clinical End Points
Three-Hour Follow-Up Thirty-Day Follow-Up
End Point, 
n (%) Odds Ratio (95% CI) P Value
End Point, 
n (%) Odds Ratio (95% CI) P Value
Radial artery pulse loss 5/82 (6.1) … … 7/76 (9.2) … …
  Acute wall injuries*
   No dissection 0/7 (0) … … 1/7 (14.3) … …
   Dissection 5/75 (6.7) n.a. … 6/69 (8.7) 0.56 (0.06–5.48) 0.62
   No hematoma 2/21 (9.5) … … 3/21 (14.3) … …
   Hematoma 3/61 (4.9) 0.52 (0.08–3.23) 0.49 4/55 (7.3) 0.50 (0.10–2.43) 0.39
   No pseudoaneurysm 5/70 (7.1) … … 6/64 (9.4) … …
   Pseudoaneurysm 0/12 (0) n.a. … 1/12 (8.3) 0.89 (0.10–8.17) 0.92
   No lumen compromise 0/30 (0) … … 2/28 (7.1) … …
   Any lumen compromise 5/52 (9.6) n.a. … 5/48 (10.4) 1.48 (0.27–8.17) 0.65
   No spasm 3/57 (5.3) … … 4/51 (7.8) … …
   Spasm 2/25 (8.0) 1.50 (0.23–9.56) 0.67 3/25 (12.0) 1.53 (0.32–7.42) 0.60
   No thrombus 5/81 (6.2) … … 7/75 (9.3) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 3/76 (3.9) … … 5/70 (7.1) … …
   Calciﬁcations at baseline 2/6 (33.3) 12.33 (1.58–96.0) 0.016 2/6 (33.3) 6.60 (0.96–45.3) 0.055
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.42 (1.08–1.88) 0.013 … 1.23 (1.00–1.52) 0.049
   Total wall thickness at baseline (0.1-mm decrease) … 1.40 (0.71–2.77) 0.33 … 1.45 (0.55–3.84) 0.44
   Intima thickness at baseline (0.01-mm decrease) … 1.04 (0.98–1.10) 0.22 … 1.03 (0.88–1.20) 0.71
   Media thickness at baseline (0.01-mm decrease) … 0.90 (0.75–1.07) 0.24 … 1.11 (0.95–1.30) 0.20
Radial artery occlusion 3/87 (3.4) … … 3/76 (3.9) … …
  Acute wall injuries*
   No dissection 1/9 (11.1) … … 1/7 (14.3) … …
   Dissection 2/78 (2.6) 0.21 (0.02–2.55) 0.22 2/69 (2.9) 0.18 (0.01–2.24) 0.18
   No hematoma 1/22 (4.5) … … 1/21 (4.8) … …
   Hematoma 2/65 (3.1) 0.70 (0.06–8.08) 0.77 2/55 (3.6) 0.79 (0.07–9.21) 0.85
   No pseudoaneurysm 3/75 (4.0) … … 3/64 (4.7) … …
   Pseudoaneurysm 0/12 (0) n.a. … 0/12 (0) n.a. …
   No lumen compromise 1/33 (3.0) … … 1/28 (3.6) … …
   Any lumen compromise 2/54 (3.7) 1.21 (0.10–13.8) 0.88 2/48 (4.2) 1.15 (0.10–13.3) 0.91
   No spasm 1/60 (1.7) … … 1/51 (2.0) … …
   Spasm 2/27 (7.4) 4.53 (0.39–52.3) 0.22 2/25 (8.0) 4.17 (0.36–48.2) 0.25
   No thrombus 3/86 (3.5) … … 3/75 (4.0) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 3/81 (3.7) … … 3/70 (4.3) … …
   Calciﬁcations at baseline 0/6 (0) n.a. … 0/6 (0) n.a. …
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.20 (0.89–1.61) 0.24 … 1.19 (0.89–1.59) 0.24
   Total wall thickness at baseline (0.1-mm decrease) … 0.42 (0.07–2.38) 0.33 … 2.27 (0.41–12.5) 0.44
   Intima thickness at baseline (0.01-mm decrease) … 0.90 (0.61–1.31) 0.58 … 1.08 (0.76–1.56) 0.65
   Media thickness at baseline (0.01-mm decrease) … 0.90 (0.72–1.14) 0.39 … 1.11 (0.88–1.39) 0.39
Pain and discomfort 32/87 (36.8) … … 24/75 (32.0) … …
  Acute wall injuries*
   No dissection 3/9 (33.3) … … 2/7 (28.6) … …
   Dissection 29/78 (37.2) 1.16 (0.27–4.99) 0.84 22/68 (32.4) 1.17 (0.21–6.51) 0.86
(Continued )
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medicine setting.12 Yet, conventional ultrasound systems use 
vascular probes with a frequency between 7 and 10 MHz, 
producing a spatial resolution of 300 μm, thus incapable 
to discriminate subtle changes of the radial wall such as 
the intima/media thickness and local wall injuries observed 
with histopathology.13 In the current study, we used a high-
resolution ultrasound system with a frequency of 40 MHz, 
and a spatial resolution of 30 μm similar to intravascular 
ultrasound.6,7
We found a variety of radial wall injuries after radial cath-
eterization, occurring in all patients. These could be related 
to puncture trauma or to the mismatch between sheath size 
and artery diameter.14 The average inner diameter of the radial 
artery in our study (ie, 2.25 mm) was signiﬁcantly smaller than 
the outer diameter of the 6F sheath used (ie, 2.45 mm), hence 
producing an angioplasty-like effect during insertion. Yonetsu 
et al10 reported similar injuries—intimal tears in 44.1% of 
patients and radial dissection in 24.7%—with optical coher-
ence tomography in the proximal segment of the radial artery. 
In our data set, the acute wall injuries of the radial artery were 
not associated with RAO, RAPL, symptoms, or functional 
impairment. This may be related to a lack of statistical power 
caused by the relatively low occurrence of RAO and RAPL. 
In our study, the occurrence of RAO and RAPL was lower 
Figure 5. Evolution of radial artery measurements at the puncture site over time. A, Radial artery inner lumen diameter evolution at the 
puncture site region of interest at the 3 timepoints (ie, before cannulation, at 3-h and at 30-d follow-up). Box plots for the radial artery 
intima (B), media (C), and total wall (D) thickness at the 3 timepoints.
Table 3.  Radial Artery Ultrasound Measurements at the Puncture Site Region of Interest
Preprocedure (1)
Three-Hour  
Follow-Up (2)
Thirty-Day  
Follow-Up (3) P Value (1–2–3) P Value (1–2) P Value (2–3) P Value (1–3)
Mid lumen diameter, mm 2.25±0.50 2.02±0.66 2.14±0.68 0.016 0.01 0.38 0.57
Distal lumen diameter, mm 2.21±0.50 2.10±0.45 1.99±0.53 0.005 0.32 0.38 0.001
Proximal lumen diameter, mm 2.29±0.53 2.22±0.48 2.17±0.53 0.19 … … …
Total wall thickness, mm 0.32±0.10 1.01±0.49 1.28±0.41 <0.0001 <0.0001 <0.0001 <0.0001
Intima thickness, mm 0.11±0.09 0.16±0.06 0.16±0.08 <0.0001 0.001 1.00 0.004
Media thickness, mm 0.18±0.04 0.26±0.14 0.32±0.13 0.07 … … …
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Table 4.  Impact of Ultrasound Findings on Clinical End Points
Three-Hour Follow-Up Thirty-Day Follow-Up
End Point, 
n (%) Odds Ratio (95% CI) P Value
End Point, 
n (%) Odds Ratio (95% CI) P Value
Radial artery pulse loss 5/82 (6.1) … … 7/76 (9.2) … …
  Acute wall injuries*
   No dissection 0/7 (0) … … 1/7 (14.3) … …
   Dissection 5/75 (6.7) n.a. … 6/69 (8.7) 0.56 (0.06–5.48) 0.62
   No hematoma 2/21 (9.5) … … 3/21 (14.3) … …
   Hematoma 3/61 (4.9) 0.52 (0.08–3.23) 0.49 4/55 (7.3) 0.50 (0.10–2.43) 0.39
   No pseudoaneurysm 5/70 (7.1) … … 6/64 (9.4) … …
   Pseudoaneurysm 0/12 (0) n.a. … 1/12 (8.3) 0.89 (0.10–8.17) 0.92
   No lumen compromise 0/30 (0) … … 2/28 (7.1) … …
   Any lumen compromise 5/52 (9.6) n.a. … 5/48 (10.4) 1.48 (0.27–8.17) 0.65
   No spasm 3/57 (5.3) … … 4/51 (7.8) … …
   Spasm 2/25 (8.0) 1.50 (0.23–9.56) 0.67 3/25 (12.0) 1.53 (0.32–7.42) 0.60
   No thrombus 5/81 (6.2) … … 7/75 (9.3) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 3/76 (3.9) … … 5/70 (7.1) … …
   Calciﬁcations at baseline 2/6 (33.3) 12.33 (1.58–96.0) 0.016 2/6 (33.3) 6.60 (0.96–45.3) 0.055
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.42 (1.08–1.88) 0.013 … 1.23 (1.00–1.52) 0.049
   Total wall thickness at baseline (0.1-mm decrease) … 1.40 (0.71–2.77) 0.33 … 1.45 (0.55–3.84) 0.44
   Intima thickness at baseline (0.01-mm decrease) … 1.04 (0.98–1.10) 0.22 … 1.03 (0.88–1.20) 0.71
   Media thickness at baseline (0.01-mm decrease) … 0.90 (0.75–1.07) 0.24 … 1.11 (0.95–1.30) 0.20
Radial artery occlusion 3/87 (3.4) … … 3/76 (3.9) … …
  Acute wall injuries*
   No dissection 1/9 (11.1) … … 1/7 (14.3) … …
   Dissection 2/78 (2.6) 0.21 (0.02–2.55) 0.22 2/69 (2.9) 0.18 (0.01–2.24) 0.18
   No hematoma 1/22 (4.5) … … 1/21 (4.8) … …
   Hematoma 2/65 (3.1) 0.70 (0.06–8.08) 0.77 2/55 (3.6) 0.79 (0.07–9.21) 0.85
   No pseudoaneurysm 3/75 (4.0) … … 3/64 (4.7) … …
   Pseudoaneurysm 0/12 (0) n.a. … 0/12 (0) n.a. …
   No lumen compromise 1/33 (3.0) … … 1/28 (3.6) … …
   Any lumen compromise 2/54 (3.7) 1.21 (0.10–13.8) 0.88 2/48 (4.2) 1.15 (0.10–13.3) 0.91
   No spasm 1/60 (1.7) … … 1/51 (2.0) … …
   Spasm 2/27 (7.4) 4.53 (0.39–52.3) 0.22 2/25 (8.0) 4.17 (0.36–48.2) 0.25
   No thrombus 3/86 (3.5) … … 3/75 (4.0) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 3/81 (3.7) … … 3/70 (4.3) … …
   Calciﬁcations at baseline 0/6 (0) n.a. … 0/6 (0) n.a. …
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.20 (0.89–1.61) 0.24 … 1.19 (0.89–1.59) 0.24
   Total wall thickness at baseline (0.1-mm decrease) … 0.42 (0.07–2.38) 0.33 … 2.27 (0.41–12.5) 0.44
   Intima thickness at baseline (0.01-mm decrease) … 0.90 (0.61–1.31) 0.58 … 1.08 (0.76–1.56) 0.65
   Media thickness at baseline (0.01-mm decrease) … 0.90 (0.72–1.14) 0.39 … 1.11 (0.88–1.39) 0.39
Pain and discomfort 32/87 (36.8) … … 24/75 (32.0) … …
  Acute wall injuries*
   No dissection 3/9 (33.3) … … 2/7 (28.6) … …
   Dissection 29/78 (37.2) 1.16 (0.27–4.99) 0.84 22/68 (32.4) 1.17 (0.21–6.51) 0.86
(Continued )
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than previously reported and may result from a strict protocol 
including routine use of periprocedural anticoagulation, non-
occlusive compression, and relatively short total compression 
times.5,15,16
Our study conﬁrmed modest reductions of the radial 
artery lumen size after cannulation.5,10,11,13 This could be 
mechanistically explained by impaired vasomotion and by 
the increase in wall thickness. Impaired vasomotion after 
radial cannulation could be the result of endothelial dys-
function17 after endothelial stripping caused by sheath inser-
tion or smooth-muscle cell damage.18 We also conﬁrmed 
histopathology and imaging data that indicated a consistent 
increase in the intimal and total wall thickness.10,13 In our 
study, this was related to the development of acute wall 
   No hematoma 9/23 (39.1) … … 8/20 (40.0) … …
   Hematoma 23/64 (35.9) 0.93 (0.35–2.47) 0.89 16/55 (29.1) 0.67 (0.23–1.92) 0.45
   No pseudoaneurysm 29/74 (39.2) … … 22/63 (34.9) … …
   Pseudoaneurysm 3/13 (23.1) 0.48 (0.12–1.87) 0.29 2/12 (16.7) 0.38 (0.08–1.90) 0.24
   No lumen compromise 12/33 (36.4) … … 8/27 (29.6) … …
   Any lumen compromise 20/54 (37.0) 1.00 (0.41–2.45) 0.99 16/48 (33.3) 1.15 (0.42–3.19) 0.79
   No spasm 20/60 (33.3) … … 15/50 (30.0) … …
   Spasm 12/27 (44.4) 1.50 (0.60–3.77) 0.39 9/25 (36.0) 1.23 (0.45–3.39) 0.68
   No thrombus 32/86 (37.2) … … 24/74 (32.4) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 29/81 (35.8) … … 23/69 (33.3) … …
   Calciﬁcations at baseline 3/6 (50.0) 1.83 (0.35–9.64) 0.48 1/6 (16.7) 0.41 (0.04–3.70) 0.43
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.01 (0.92–1.11) 0.80 … 1.00 (0.90–1.10) 0.98
   Total wall thickness at baseline (0.1-mm decrease) … 1.21 (0.79–1.85) 0.39 … 1.16 (0.52–1.42) 0.55
   Intima thickness at baseline (0.01-mm decrease) … 1.02 (0.97–1.08) 0.39 … 1.02 (0.95–1.08) 0.65
   Media thickness at baseline (0.01-mm decrease) … 1.07 (0.99–1.15) 0.10 … 1.04 (0.95–1.14) 0.41
Functional impairment 12/85 (14.1) 9/75 (12.0)
  Acute wall injuries*
   No dissection 0/9 (0) … … 1/7 (14.3) … …
   Dissection 12/76 (15.8) n.a. … 8/68 (11.8) 0.79 (0.08–7.40) 0.83
   No hematoma 5/22 (22.7) … … 3/20 (15.0) … …
   Hematoma 7/63 (11.1) 0.45 (0.13–1.59) 0.22 6/55 (10.9) 0.73 (0.17–3.25) 0.68
   No pseudoaneurysm 10/72 (13.9) … … 8/63 (12.7) … …
   Pseudoaneurysm 2/13 (15.4) 1.14 (0.22–5.95) 0.87 1/12 (8.3) 0.64 (0.07–5.61) 0.68
   No lumen compromise 7/32 (21.9) … … 4/27 (14.8) … …
   Any lumen compromise 5/53 (9.4) 0.36 (0.10–1.26) 0.11 5/48 (10.4) 0.65 (0.16–2.67) 0.55
   No spasm 8/59 (13.6) … … 6/50 (12.0) … …
   Spasm 4/26 (15.4) 1.11 (0.30–4.05) 0.88 3/25 (12.0) 0.96 (0.22–4.18) 0.95
   No thrombus 12/84 (14.3) … … 9/74 (12.2) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 12/79 (15.2) … … 9/69 (13.0) … …
   Calciﬁcations at baseline 0/6 (0) n.a. … 0/6 (0) n.a. …
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.07 (0.93–1.25) 0.30 … 0.94 (0.83–1.07) 0.38
   Total wall thickness at baseline (0.1-mm decrease) … 0.93 (0.50–1.75) 0.82 … 1.19 (0.55–1.56) 0.66
   Intima thickness at baseline (0.01-mm decrease) … 0.93 (0.78–1.10) 0.40 … 1.10 (0.88–1.35) 0.41
   Media thickness at baseline (0.01-mm decrease) … 1.08 (0.96–1.19) 0.24 … 0.96 (0.84–1.09) 0.54
CI indicates conﬁdence interval.
*Acute wall injuries detected at 3-hour follow-up.
†Diameter at puncture site was considered at the mid-entry site.
Table 4. Continued
Three-Hour Follow-Up Thirty-Day Follow-Up
End Point, 
n (%) Odds Ratio (95% CI) P Value
End Point, 
n (%) Odds Ratio (95% CI) P Value
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injuries that increased the distance between the intimal and 
the adventitial layers. Over half of patients had pseudoaneu-
rysms at 30-day follow-up. This high rate can be explained 
by the unprecedented high spatial resolution of the nonin-
vasive 40-MHz ultrasound technology used. The majority 
of these pseudoaneurysms would not be visible by standard 
10-MHz vascular probes. Notably, we detected an increase 
in the rate of pseudoaneurysms from 3 hours to 30 days after 
the procedure. It could be speculated that early removal of 
the compressive device before complete hemostasis may 
result in continued blood accumulation into the arterial 
wall resulting in pseudoaneurysm formation. However, a 
previous study demonstrated, on the contrary, a reduction 
of RAO with an early deﬂation of the radial compressive 
device,15 suggesting an early deﬂation protocol may lead to 
pseudoaneurysm formation that, however, does not result 
in RAO. We observed a relatively high proportion of radial 
artery spasm occurrence at 30 days (44.2%), which has not 
been previously described. However, this ﬁnding should be 
interpreted with caution. Spasm implied a thickening of the 
vessel wall layers. Still, vessel wall thickening after can-
nulation could also be because of vessel remodeling. The 
exact pathophysiological mechanism cannot be discerned 
with current technology.
Multiple puncture attempts were associated with RAO, 
RAPL, and symptoms at 30 days. Previous reports already 
suggested that multiple puncture attempts might increase 
radial artery spasm,19 while reducing radial artery trauma by 
several means might reduce vascular complications.5,14,20 The 
application of subcutaneous nitrates and the implementation 
of ultrasound-guided puncture may facilitate radial artery can-
nulation and reduce the number of puncture attempts needed 
to achieve cannulation.21,22 In addition, we also observed a 
negative correlation between radial lumen at 30 days and the 
number of puncture attempts. This might have important con-
sequences for future catheterizations through the same radial 
access considering that smaller and less pulsatile arteries 
might be more difﬁcult to cannulate.
Limitations
This is a single-center mechanistic study with a relatively 
small sample size. To explore predictors of RAO or pulse 
loss, we developed a univariate predictive model, which was 
not adjusted for many potential confounders. As such, the 
clinical impact of the radial wall injuries observed with high-
resolution ultrasound should be tested in larger studies. The 
occurrence of symptoms and functional impairment was self 
reported by the patients, and as such could have been biased. 
However, these end points were secondary in our study, and 
recent reports conﬁrmed the lack of impact of radial catheter-
ization on the upper limb function.23
Radial spasm deﬁnition was prespeciﬁed in the study 
protocol according to accepted intravascular ultrasound con-
sensus.24 Still, radial spasm was evaluated only in the acute 
phase and the evidence of an image resembling spasm long 
after cannulation might be related with vessel remodeling. 
However, current technology does not allow a clear distinction 
between spasm and permanent vessel remodeling.
Noninvasive ultrasound evaluation exposes radial artery 
to an external compression, which might eventually affect 
measurements. However, the extent of this change is likely to 
be small because of the higher blood pressure of the arterial 
system.
Conclusions
The radial artery puncture site can be assessed noninvasively 
and in detail by high-resolution ultrasound. Arterial wall heal-
ing after transradial catheterization is a dynamic process char-
acterized by increased intimal and total wall thickness and 
a modest reduction in lumen size. Acute wall injuries of the 
radial artery were ubiquitous after cannulation, but contrary to 
repeated puncture attempts, did not seem to affect postproce-
dural radial occlusion or loss of pulsation.
Acknowledgments
We thank Ella Nitters for her contribution in the original design and 
production of Figure 2. To the memory of the late Professor Dr W. van 
der Giessen who codesigned the Rotterdam Radial Access Research 
(R-RADAR) study.
Disclosures
None.
Figure 6. Impact of the number of puncture 
attempts on clinical end points. Forest plot with 
odds ratio, conﬁdence interval (CI), and P value 
for the occurrence of each clinical end point at 30 
d is presented. An odds ratio >1 represent to an 
increase of the risk of each end point to occur at 
30 d.
Table 5.  Correlation Between Number of Punctures and 
Ultrasound Measurements at 3 Hours and 30 Days
Three-Hour Follow-Up Thirty-Day Follow-Up
Correlation 
Coefﬁcient P Value
Correlation 
Coefﬁcient P Value
Mid lumen diameter, mm −0.49 <0.0001 −0.45 <0.0001
Distal lumen diameter, mm −0.21 0.069 −0.25 0.037
Proximal lumen diameter, mm −0.37 0.001 −0.47 <0.0001
Total wall thickness, mm 0.10 0.356 0.02 0.871
Intima thickness, mm −0.02 0.829 −0.21 0.076
Media thickness, mm −0.18 0.431 −0.05 0.853
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than previously reported and may result from a strict protocol 
including routine use of periprocedural anticoagulation, non-
occlusive compression, and relatively short total compression 
times.5,15,16
Our study conﬁrmed modest reductions of the radial 
artery lumen size after cannulation.5,10,11,13 This could be 
mechanistically explained by impaired vasomotion and by 
the increase in wall thickness. Impaired vasomotion after 
radial cannulation could be the result of endothelial dys-
function17 after endothelial stripping caused by sheath inser-
tion or smooth-muscle cell damage.18 We also conﬁrmed 
histopathology and imaging data that indicated a consistent 
increase in the intimal and total wall thickness.10,13 In our 
study, this was related to the development of acute wall 
   No hematoma 9/23 (39.1) … … 8/20 (40.0) … …
   Hematoma 23/64 (35.9) 0.93 (0.35–2.47) 0.89 16/55 (29.1) 0.67 (0.23–1.92) 0.45
   No pseudoaneurysm 29/74 (39.2) … … 22/63 (34.9) … …
   Pseudoaneurysm 3/13 (23.1) 0.48 (0.12–1.87) 0.29 2/12 (16.7) 0.38 (0.08–1.90) 0.24
   No lumen compromise 12/33 (36.4) … … 8/27 (29.6) … …
   Any lumen compromise 20/54 (37.0) 1.00 (0.41–2.45) 0.99 16/48 (33.3) 1.15 (0.42–3.19) 0.79
   No spasm 20/60 (33.3) … … 15/50 (30.0) … …
   Spasm 12/27 (44.4) 1.50 (0.60–3.77) 0.39 9/25 (36.0) 1.23 (0.45–3.39) 0.68
   No thrombus 32/86 (37.2) … … 24/74 (32.4) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 29/81 (35.8) … … 23/69 (33.3) … …
   Calciﬁcations at baseline 3/6 (50.0) 1.83 (0.35–9.64) 0.48 1/6 (16.7) 0.41 (0.04–3.70) 0.43
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.01 (0.92–1.11) 0.80 … 1.00 (0.90–1.10) 0.98
   Total wall thickness at baseline (0.1-mm decrease) … 1.21 (0.79–1.85) 0.39 … 1.16 (0.52–1.42) 0.55
   Intima thickness at baseline (0.01-mm decrease) … 1.02 (0.97–1.08) 0.39 … 1.02 (0.95–1.08) 0.65
   Media thickness at baseline (0.01-mm decrease) … 1.07 (0.99–1.15) 0.10 … 1.04 (0.95–1.14) 0.41
Functional impairment 12/85 (14.1) 9/75 (12.0)
  Acute wall injuries*
   No dissection 0/9 (0) … … 1/7 (14.3) … …
   Dissection 12/76 (15.8) n.a. … 8/68 (11.8) 0.79 (0.08–7.40) 0.83
   No hematoma 5/22 (22.7) … … 3/20 (15.0) … …
   Hematoma 7/63 (11.1) 0.45 (0.13–1.59) 0.22 6/55 (10.9) 0.73 (0.17–3.25) 0.68
   No pseudoaneurysm 10/72 (13.9) … … 8/63 (12.7) … …
   Pseudoaneurysm 2/13 (15.4) 1.14 (0.22–5.95) 0.87 1/12 (8.3) 0.64 (0.07–5.61) 0.68
   No lumen compromise 7/32 (21.9) … … 4/27 (14.8) … …
   Any lumen compromise 5/53 (9.4) 0.36 (0.10–1.26) 0.11 5/48 (10.4) 0.65 (0.16–2.67) 0.55
   No spasm 8/59 (13.6) … … 6/50 (12.0) … …
   Spasm 4/26 (15.4) 1.11 (0.30–4.05) 0.88 3/25 (12.0) 0.96 (0.22–4.18) 0.95
   No thrombus 12/84 (14.3) … … 9/74 (12.2) … …
   Thrombus 0/1 (0) n.a. … 0/1 (0) n.a. …
  Measurements and characteristics
   No calciﬁcations at baseline 12/79 (15.2) … … 9/69 (13.0) … …
   Calciﬁcations at baseline 0/6 (0) n.a. … 0/6 (0) n.a. …
   Diameter at puncture site at baseline (0.1-mm decrease)† … 1.07 (0.93–1.25) 0.30 … 0.94 (0.83–1.07) 0.38
   Total wall thickness at baseline (0.1-mm decrease) … 0.93 (0.50–1.75) 0.82 … 1.19 (0.55–1.56) 0.66
   Intima thickness at baseline (0.01-mm decrease) … 0.93 (0.78–1.10) 0.40 … 1.10 (0.88–1.35) 0.41
   Media thickness at baseline (0.01-mm decrease) … 1.08 (0.96–1.19) 0.24 … 0.96 (0.84–1.09) 0.54
CI indicates conﬁdence interval.
*Acute wall injuries detected at 3-hour follow-up.
†Diameter at puncture site was considered at the mid-entry site.
Table 4. Continued
Three-Hour Follow-Up Thirty-Day Follow-Up
End Point, 
n (%) Odds Ratio (95% CI) P Value
End Point, 
n (%) Odds Ratio (95% CI) P Value
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injuries that increased the distance between the intimal and 
the adventitial layers. Over half of patients had pseudoaneu-
rysms at 30-day follow-up. This high rate can be explained 
by the unprecedented high spatial resolution of the nonin-
vasive 40-MHz ultrasound technology used. The majority 
of these pseudoaneurysms would not be visible by standard 
10-MHz vascular probes. Notably, we detected an increase 
in the rate of pseudoaneurysms from 3 hours to 30 days after 
the procedure. It could be speculated that early removal of 
the compressive device before complete hemostasis may 
result in continued blood accumulation into the arterial 
wall resulting in pseudoaneurysm formation. However, a 
previous study demonstrated, on the contrary, a reduction 
of RAO with an early deﬂation of the radial compressive 
device,15 suggesting an early deﬂation protocol may lead to 
pseudoaneurysm formation that, however, does not result 
in RAO. We observed a relatively high proportion of radial 
artery spasm occurrence at 30 days (44.2%), which has not 
been previously described. However, this ﬁnding should be 
interpreted with caution. Spasm implied a thickening of the 
vessel wall layers. Still, vessel wall thickening after can-
nulation could also be because of vessel remodeling. The 
exact pathophysiological mechanism cannot be discerned 
with current technology.
Multiple puncture attempts were associated with RAO, 
RAPL, and symptoms at 30 days. Previous reports already 
suggested that multiple puncture attempts might increase 
radial artery spasm,19 while reducing radial artery trauma by 
several means might reduce vascular complications.5,14,20 The 
application of subcutaneous nitrates and the implementation 
of ultrasound-guided puncture may facilitate radial artery can-
nulation and reduce the number of puncture attempts needed 
to achieve cannulation.21,22 In addition, we also observed a 
negative correlation between radial lumen at 30 days and the 
number of puncture attempts. This might have important con-
sequences for future catheterizations through the same radial 
access considering that smaller and less pulsatile arteries 
might be more difﬁcult to cannulate.
Limitations
This is a single-center mechanistic study with a relatively 
small sample size. To explore predictors of RAO or pulse 
loss, we developed a univariate predictive model, which was 
not adjusted for many potential confounders. As such, the 
clinical impact of the radial wall injuries observed with high-
resolution ultrasound should be tested in larger studies. The 
occurrence of symptoms and functional impairment was self 
reported by the patients, and as such could have been biased. 
However, these end points were secondary in our study, and 
recent reports conﬁrmed the lack of impact of radial catheter-
ization on the upper limb function.23
Radial spasm deﬁnition was prespeciﬁed in the study 
protocol according to accepted intravascular ultrasound con-
sensus.24 Still, radial spasm was evaluated only in the acute 
phase and the evidence of an image resembling spasm long 
after cannulation might be related with vessel remodeling. 
However, current technology does not allow a clear distinction 
between spasm and permanent vessel remodeling.
Noninvasive ultrasound evaluation exposes radial artery 
to an external compression, which might eventually affect 
measurements. However, the extent of this change is likely to 
be small because of the higher blood pressure of the arterial 
system.
Conclusions
The radial artery puncture site can be assessed noninvasively 
and in detail by high-resolution ultrasound. Arterial wall heal-
ing after transradial catheterization is a dynamic process char-
acterized by increased intimal and total wall thickness and 
a modest reduction in lumen size. Acute wall injuries of the 
radial artery were ubiquitous after cannulation, but contrary to 
repeated puncture attempts, did not seem to affect postproce-
dural radial occlusion or loss of pulsation.
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Figure 6. Impact of the number of puncture 
attempts on clinical end points. Forest plot with 
odds ratio, conﬁdence interval (CI), and P value 
for the occurrence of each clinical end point at 30 
d is presented. An odds ratio >1 represent to an 
increase of the risk of each end point to occur at 
30 d.
Table 5.  Correlation Between Number of Punctures and 
Ultrasound Measurements at 3 Hours and 30 Days
Three-Hour Follow-Up Thirty-Day Follow-Up
Correlation 
Coefﬁcient P Value
Correlation 
Coefﬁcient P Value
Mid lumen diameter, mm −0.49 <0.0001 −0.45 <0.0001
Distal lumen diameter, mm −0.21 0.069 −0.25 0.037
Proximal lumen diameter, mm −0.37 0.001 −0.47 <0.0001
Total wall thickness, mm 0.10 0.356 0.02 0.871
Intima thickness, mm −0.02 0.829 −0.21 0.076
Media thickness, mm −0.18 0.431 −0.05 0.853
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Background 
 
Platelet reactivity plays a pivotal role in the pathogenesis of ischemic 
cardiovascular disorders (1). It has been shown that both platelet activation and 
aggregation are heightened in acute coronary syndromes (ACS) and from current 
evidence emerges a strong and independent correlation between the propensity 
to clot formation (2) and the clinical outcome. Platelet aggregation blockade has 
been demonstrated to provide unequivocal benefit in a broad population of 
patients (3-5). The current parenteral anti platelet drugs act on different activation 
and aggregation pathways, including the P2Y12 ADP receptor, mediating 
upstream activation and the glycoprotein IIb/IIIa, the so called final common 
aggregation pathway. While no approved oral anti-platelet agent acts by inhibiting 
the final common pathway of platelet aggregation, there are currently numerous 
oral compounds inhibiting the P2Y12 receptor. As more extensively discussed 
below, the availability of parenteral platelet blockers remains of paramount 
importance when a prompt and predictable inhibitory effect is needed, especially 
in the acute setting of patients with acute coronary syndrome undergoing 
immediate coronary intervention.   
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This chapter aims at reviewing the currently approved parenteral glycoprotein 
IIb/IIIa inhibitors, including eptifibatide, tirofiban and abciximab, as well as 
discussing current evidence for the P2Y12 receptors cangrelor and elinogrel. The 
intravenous formulation of the acetylsalicylic acid has been widely described in 
literature and will not be part of this review.  
 
 
 
Glycoprotein IIb/IIIa inhibitors: 
 
Among the proposed pharmacologic targets for antiplatelet therapy, glycoprotein 
IIb/IIIa (GPIIb/IIIa) continues to be attractive as it represents the common final 
step in the pathway that leads to platelet aggregation (6). GPIIb/IIIa inhibitors 
(GPI), are currently considered the most powerful and specific platelet inhibitors 
in acute thrombosis. GPI inhibit also thrombin generation and fibrin clot formation 
(7). This explains why GPI display a moderate prolongation effect on activated 
clotting time (ACT) measurement and, moreover, why GPI interact with UFH, 
which dose should be lowered during PCI.  
The three GPIIb/IIIa inhibitors currently on the market have profoundly different 
characteristics despite binding to the same receptor. 
Abciximab is an anti-integrin Fab fragment of a human–mouse chimeric 
monoclonal antibody with high affinity and a slow dissociation rate from the 
GPIIb/IIIa platelet receptor (8, 9). Despite a short plasma half-life of 10–30 
minutes, Abciximab has a long biologic half-life, mainly due to its strong and 
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irreversible binding to the GPIIb/IIIa receptor. Platelet function returns to baseline 
days after therapy cessation, as platelet cellular turnover is required to overcome 
drug irreversible receptor blockade (8, 9). Complete receptor blockade is 
obtained at approximately 5μg/mL. The binding site of abciximab is located on 
the ß-chain of the GPIIb/IIIa receptor and is different from the binding site for the 
low molecular weight inhibitors eptifibatide and tirofiban (8, 9). Unlike other GPIs, 
abciximab has no renal clearance. Hence, no dose adjustment needs to be 
carried out in patients with renal dysfunction and it can be administered in 
patients with end stage renal disease. However abciximab has been shown to 
have a high antigenicity, with an increased risk of thrombocytopenia, especially 
after re-administration (10). This downside is possibly due to the size of the 
molecule or to the murine origin, and it has never been shown with the other 
GPIs (11). 
Tirofiban (9) is a small synthetic nonpeptide competitive GPI with high specificity 
and affinity for GPIIb/IIIa receptors conferred by a tyrosine analogue structurally 
similar to the RGD (arginine–glycine–aspartic acid)-loop of the GPIIb/IIIa 
receptor. Tirofiban has a long plasma half-life and short biologic half-life resulting 
in a rapid recovery of platelet activity approximately 3-4 hours following therapy 
cessation. It is about 35% unbound in the circulation with predominant renal 
clearance (65%) and can be hemodialyzed. Dosing adjustment needs to be 
implemented in patients with creatinine clearance below 30 ml/min. Different 
dosing regimens may be required based on the patient’s diagnosis and the timing 
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of PCI. A regimen with a loading infusion of 0.4 μg/kg/min run over 30 minutes 
followed by a 0.10 μg/kg/min maintenance infusion has proven to be quite 
effective in the management of patients with non- ST-elevation acute coronary 
syndromes when administered at least four hours prior to PCI. Otherwise a 
regimen including a high dose bolus of 25 μg/kg followed by a maintenance 
infusion of 0.15 μg/kg/min, has shown a higher platelet inhibition (12) then is 
deemed more appropriate when administered immediately before PCI. 
Eptifibatide is a small, cyclic heptapeptide, which has a modified lysine–glycine–
aspartate amino acid sequence. It is highly specific for the GPIIb/IIIa receptor, 
with a relatively low binding affinity and a rapid dissociation from its receptor, 
leading to early restoration of platelet function after discontinuation of the infusion 
(13, 14). Inhibition of platelet aggregation by eptifibatide is dose dependent. 
Regarding drug elimination, eptifibatide clearance largely occurs via renal 
mechanisms, with a half-life of 2.7 hours. As such, unlike abciximab or tirofiban, 
dose adjustment is required in patients with creatinine clearance below 50 ml/min 
and the drug is contra-indicated in patients with creatinine clearance below 30 
ml/min.  A double 180 μg/kg bolus followed by a 2.0 μg/kg/min infusion has been 
validated to provide a proper platelet inhibition when administered immediately 
before PCI (15) in patients with normal renal function. 
 
 
Clinical trials 
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All three drugs have been trialed in two different clinical scenarios: the 
downstream use, i.e., given immediately before PCI; and (b) upstream use, i.e., 
administered well before intervention and as early as possible after diagnosis in 
patients with ACS. While numerous studies have suggested that starting GPI 
upstream may further reduce ischemic events  both before and during PCI as 
compared to downstream administration (16, 17), this treatment strategy has 
always been associated to a definite bleeding hazard. Hence, American and 
European guidelines currently discourage the upstream utilization of this therapy 
whereas a downstream use, especially in patients at high ischemic risk and or 
with high thrombus burden remains a viable treatment option.  
Abciximab  
Given shortly before PCI, abciximab administered as a bolus followed by a 12-
hour infusion is superior to placebo on top of unfractionated heparin in reducing 
the acute risk of ischemic complications. This statement is mainly supported by 
three landmark studies: the EPIC trial (Evaluation of 7E3 for the Prevention of 
Ischemic Complications) (18), the EPILOG trial (Evaluation in Percutaneous 
Transcateter Coronary Angioplasty to Improve Long-term Outcome with 
Abciximab GP IIb/IIIa blockade), and the EPISTENT trial (Evaluation of Platelet 
IIb/IIIa Inhibitor for Stenting). A major limitation of these early landmark studies is 
the absence of pretreatment with clopidogrel on top of aspirin. 
The ISAR-REACT 2 study (Intracoronary Stenting and Antithrombotic Regimen: 
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Rapid Early Action for Coronary Treatment) (19), enrolling patients with 
NSTEACS, showed a 25% reduction in the risk of recurrent ischemic events 
among patients treated with Clopidogrel at a loading dose of 600 mg on top of 
aspirin and abciximab. Notably among patients with an elevated troponin level, 
the risk of recurrent ischemic events was considerably higher and was reduced 
by 29% by abciximab. 
Several trials have been conducted to test the effectiveness of abciximab in the 
setting of STEMI. A meta-analysis including 1101 patients presenting for primary 
PCI from ADMIRAL (Abciximab before Direct Angioplasty and Stenting in 
Myocardial Infarction regarding Acute and Long-term Follow-up) (20), ISAR 2 
(21), and ACE (Abciximab and Carbostent Evaluation) (22) trials, demonstrated a 
significant reduction of the primary end point of death or reinfarction with 
abciximab versus placebo (12.9% vs 19.0%). 
 
Tirofiban  
The RESTORE and TARGET trials tested the efficacy and safety of tirofiban, 
given at a bolus dose of 10 ugr/kg as compared to placebo or abciximab, 
respectively. The results of this studies indicated that tirofiban, when given at this 
bolus regimen, may be inadequate to suppress ischemic events and subsequent 
PK/PD studies showed that this regimen falls short in fully inhibiting ADP-induced 
platelet activation. An higher bolus regimen of 25 ugr/kg, the so called high dose 
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bolus (HDB) has been subsequently developed.  
In the ADVANCE trial, high-risk PCI patients pretreated with thienopyridines, 
were consecutively randomized to HDB tirofiban and infusion for 24–48 hours or 
placebo. The cumulative incidence of the primary composite end point death, MI, 
TVR, and bailout use of GPIIb/IIIa inhibitors was 35% and 20% in the placebo 
and HDB tirofiban groups respectively (23). Similarly On-TIME 2 trial (24) 
provided recent and further evidence of the added benefit of utilizing HDB 
tirofiban on top of dual antiplatelet therapy in STEMI patients.  Thus, taken 
together current evidence suggests that use of tirofiban in a single HDB is 
beneficial even on top of upstream use of aspirin and clopidogrel across the 
whole spectrum of ACS patients, spanning from NSTE- to STE-ACS. 
Eptifibatide  
The ESPRIT trial (25) compared eptifibatide to placebo in reducing ischemic 
complications in patients undergoing elective coronary stent implantation and 
concomitant thienopyridine therapy. The trial was stopped in February 2000 for 
efficacy when results showed a highly significant 37% reduction in the combined 
primary end point of death, MI, urgent TVR or "thrombotic bail-out. 
 
 
Are all three glycoprotein IIb/IIIa inhibitors equally effective and safe? 
The comparison between the three GPI have been described. The most studied 
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comparison was between tirofiban and abciximab, whereas data on the 
comparison abciximab vs eptifibatide is limited. Finally no randomized 
comparison exists between eptifibatide and tirofiban. 
Currently there are nine studies involving 7132 patients regarding the comparison 
between Abciximab and Tirofiban. The overall pooled effect estimate analysis 
showed that tirofiban at 30 days led to similar mortality rate (OR = 0.90; 95% CI, 
0.53–1.54; p = 0.70), but tended to increase the composite of death or MI (6.0% 
vs 5.1%; OR = 1.18; 95% CI, 0.96–1.45; p = 0.11) when compared to abciximab. 
However these results mainly mirrored the findings of the TARGET study (26) 
which, trialed a tirofiban 10 μg/kg 3 minute bolus and 0.15 μg/kg/min infusion 
regimen. Indeed, when tirofiban given as a high dose bolus,  mortality (OR = 
0.73; 95% CI, 0.36–1.47; p = 0.38), the composite of death or MI (OR = 0.87; 
95% CI 0.56–1.35; p = 0.54) or MACE rate (OR = 0.87; 95% CI, 0.57–1.32; p = 
0.51) were similar compared to abciximab. The rate of major bleeding did not 
differ in the two groups (OR= 1.24; 95% CI, 0.78–1.98; p = 0.35), whereas minor 
bleedings (3.1% vs 4.8%; OR = 0.64; 95% CI 0.50–0.82; p <0.001) and any 
thrombocytopenia (0.3% vs 2.4%; OR = 0.28; 95% CI, 0.08–0.94; p = 0.04) were 
both markedly reduced in the tirofiban group. 
 
Glycoprotein IIb/IIIa inhibitors and P2Y12 oral receptor blockers 
As GPI were largely trialed and developed in the pre-clopidogrel era, much of the 
evidence generated through their use was questioned after the advent of the oral 
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P2Y12 inhibitors. However emerging evidence suggests that inhibition of P2Y12 
and GPIIb/IIIa receptors may potentially play a complementary role in further 
reducing the incidence of ischemic events in patients with ACS. 
Currently, there are multi-single randomized controlled studies (19, 23, 24) as 
well as a meta- analysis (27) showing that the benefit of glycoprotein inhibitors 
seems to be at least maintained even in patients properly pretreated with both 
aspirin and clopidogrel. Conversely there is still limited evidence about the effect 
of GPI in patients treated with the more potent oral P2Y12 blockers prasugrel or 
ticagrelor (28) . 
 
 
Cangrelor: 
 
 
 
Cangrelor is an intravenous, non thienopyridine antagonist of the P2Y12 receptor. 
It’s unique pharmacological profile makes this molecule attractive, especially in 
the acute emergency setting such as ST segment elevated myocardial infarction 
(STEMI) and non-ST segment elevated myocardial infarction (NSTEMI) in which 
the time to cardiac catheterization is becoming shorter and a rapid onset of 
platelet inhibition is essential.  
In this setting, neither ticagrelor, nor prasugrel provided pharmacodynamic 
evidence of a rapid effect, in fact at 2 hours from the administration of the loading 
dose, one third to half of patients with STEMI had high platelet reactivity as 
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Glycoprotein IIb/IIIa inhibitors and P2Y12 oral receptor blockers 
As GPI were largely trialed and developed in the pre-clopidogrel era, much of the 
evidence generated through their use was questioned after the advent of the oral 
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P2Y12 inhibitors. However emerging evidence suggests that inhibition of P2Y12 
and GPIIb/IIIa receptors may potentially play a complementary role in further 
reducing the incidence of ischemic events in patients with ACS. 
Currently, there are multi-single randomized controlled studies (19, 23, 24) as 
well as a meta- analysis (27) showing that the benefit of glycoprotein inhibitors 
seems to be at least maintained even in patients properly pretreated with both 
aspirin and clopidogrel. Conversely there is still limited evidence about the effect 
of GPI in patients treated with the more potent oral P2Y12 blockers prasugrel or 
ticagrelor (28) . 
 
 
Cangrelor: 
 
 
 
Cangrelor is an intravenous, non thienopyridine antagonist of the P2Y12 receptor. 
It’s unique pharmacological profile makes this molecule attractive, especially in 
the acute emergency setting such as ST segment elevated myocardial infarction 
(STEMI) and non-ST segment elevated myocardial infarction (NSTEMI) in which 
the time to cardiac catheterization is becoming shorter and a rapid onset of 
platelet inhibition is essential.  
In this setting, neither ticagrelor, nor prasugrel provided pharmacodynamic 
evidence of a rapid effect, in fact at 2 hours from the administration of the loading 
dose, one third to half of patients with STEMI had high platelet reactivity as 
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assessed with the VerifyNow assay, irrespective of the drug used (28-30). 
Moreover, the administration of oral P2Y12  inhibitors imply a relatively long-term 
platelet inhibition for at least 3-5 days,  hence making problematic the immediate 
or urgent referral to surgery. In this case, the availability of a drug with a fast 
offset of action is of paramount importance.   
Furthermore is worth mentioning how the usefulness of oral P2Y12  can be 
impaired in patients who cannot swallow or absorb medications. This eventuality 
is particularly frequent in patients with acute coronary syndromes that often 
presents with vomit, shock or need for intubation. 
Cangrelor, when administered as a bolus of 30 μg/kg, achieves an almost 
complete and immediate inhibition of ADP-induced platelet aggregation, and his 
action is sustained on a high stable degree of inhibition during continuous 
infusion. The plasma half-life is approximately 3-5 minutes and the platelet 
function comes back to normal within one hour after the cessation of infusion. 
Cangrelor does not have a relevant hepatic and renal metabolism, unlike the 
current oral P2Y12 inhibitors. 
Cangrelor (N-2-methylthio-ethyl-2-(3,3,3-trilfluoropropylthiol)-5’-adenyl acid, is an 
analogue of adenosine triphosphate (ATP), the natural antagonist of the receptor 
P2Y12 .  
ATP has a low affinity to the P2Y12 because is rapidly metabolized by the 
ectonucleotidases (31).  
The design of cangrelor, with the replacement of anhydride with methylene 
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groups and an halogen, conferred to the molecule a higher affinity to the P2Y12 
receptor and a longer half life. Furthermore the modification at the adenine C2 
position with 3,3,3-trifluoropropylhio and N6 methylthioethyl groups increased 
potency six times with respect to ATP (32, 33). These structural changes brought 
important pharmacological advantages. 
Cangrelor interaction with oral P2Y12 inhibitors have been studied. A randomized 
study showed a competitive interaction between Clopidogrel and Cangrelor when 
clopidogrel was administered simultaneously or immediately after cangrelor 
discontinuation (bolus of 30 μg/kg and 1-h infusion of 4 μg/kg/min). The high 
affinity of Cangrelor to P2Y12 prevents the active metabolite of clopidogrel to bind 
to the receptor during or immediately after its administration, hindering 
clopidogrel induced platelet inhibition (34). The same effect was demonstrated 
after prasugrel administration. Conversely the use of Cangrelor after 
preincubation with active metabolites of clopidogrel or prasugrel led to a 
sustained platelet inhibition (35). 
Importantly these findings emphasize the need of a correct transition between 
cangrelor and oral P2Y12 receptor inhibitors. So far the most studied transition 
was between cangrelor and clopidogrel during the Champion trial: this study 
demonstrated how clopidogrel should be administered after cangrelor infusion 
discontinuation for the competitive interaction between the two drugs to be 
avoided. There is little evidence regarding the transition between cangrelor and 
both prasugrel and ticagrelor. Recently a small study reported the effects of the 
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transition between cangrelor and ticagrelor and vice-versa:  the authors 
demonstrated how ticagrelor given before or during infusion of cangrelor did not 
attenuate the pharmacodynamic effect of cangrelor. Furthermore the 
pharmacodynamic effects of ticagrelor were preserved when ticagrelor was 
administered during infusion of cangrelor. In fact the pharmacodynamic effect of 
ticagrelor are greater when the drug is given earlier, even if in this study the 
difference was not statistically significant (30 min vs 75 min after initiation of 
cangrelor infusion) (36).  
However bigger studies over the transition between cangrelor and novel oral 
P2Y12 inhibitors have yet to be reported. Two randomized trial, TRANSITION I 
and TRANSITION II, testing the transition to and from ticagrelor and prasugrel 
respectively, have been completed but not yet published.  
 
 
The promising results raised from the phase II studies of Cangrelor led to the 
foundation of the phase III program that consisted of two large parallel 
randomized trials, the Platelet Inhibition with Cangrelor in Patients Undergoing 
PCI (CHAMPION-PCI) trial (37) and the Intravenous Platelet Blockade with 
Cangrelor during PCI (CHAMPION-PLATFORM) trial (38). Both trials tested the 
hypothesis that Cangrelor, administered as a bolus of 30 μg/kg within 30 min to 
the PCI start and followed by a 4 μg/kg/min infusion (for at least 2 h and no 
longer than 4 h), could reduce the thrombotic events compared to Clopidogrel at 
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a loading dose of 600 mg. The primary end point for both studies was a 
composite of death from any cause, myocardial infarction (MI), and ischemia-
driven revascularization (IDR) at 48 h post randomization.  
In CHAMPION-PCI, patients were randomized to receive cangrelor plus loading 
dose of clopidogrel at the end of the infusion in the study arm, or loading dose of 
clopidogrel prior to the start of PCI in the comparator arm. 
In CHAMPION-PLATFORM patients were randomized to receive cangrelor plus 
clopidogrel at the end of the infusion or placebo plus clopidogrel at the end of 
PCI. 
In both trials, patients randomized to cangrelor, received their loading dose of 
clopidogrel after infusion discontinuation in order to avoid interaction between 
clopidogrel and cangrelor. Patients with STEMI and on prior clopidogrel therapy 
were eligible for CHAMPION-PCI but excluded from CHAMPION-PLATFORM.  
Enrollment was prematurely terminated for futility, given the low likelihood of 
achieving the primary end-point, and both trials failed to demonstrate the 
superiority of adjunctive cangrelor therapy.  At that moment, 98% patients were 
enrolled in CHAMPION-PCI and 86% in CHAMPION-PLATFORM, the primary 
end point rate was similar between cangrelor and control in both studies (7.5% 
for cangrelor, 7.1% for clopidogrel, odds ratio (OR) 1.05, 95% confidence interval 
(CI), 0.88 to 1.24; P=0.59; and 7.0% vs 8.0%, OR 0.87; 95% CI, 0.71 to 1.07; 
P=0.17 respectively).  
However a benefit of cangrelor was shown in secondary end points not 
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depending on biomarkers such as death, stent thrombosis and Q-wave 
myocardial infarction.  
In fact, the primary end point of the study was importantly driven by the 
occurrence of MI, which was difficult to assess in this population. Indeed post-
procedure MI is problematic when biomarkers are elevated before the procedure 
and importantly, in the CHAMPION trials population, the time from hospital 
admission to PCI was short (6.3 h mean in CHAMPION PCI and 7.9 h mean in 
CHAMPION PLATFORM). Furthermore the definition of MI of the CHAMPION 
studies preceded the Universal definition of MI (39) and the presence of stable or 
falling biomarkers at the time of PCI was not required to define PCI-related MI 
endpoint. Considering all this issues a pooled analysis of data from the 
CHAMPION trials using the universal definition of MI was performed (40). 
According to this definition, if the biomarkers before the procedure are elevated 
and not falling or stable, the diagnosis of periprocedural MI based on biomarkers 
is not recommended. With this analysis the authors demonstrated that at 48 h 
cangrelor significantly reduced the primary end point (3.1% vs 3.8%; OR 0.82; 
95% CI, 0.68-0.99 ; P = 0.037). These findings pushed the investigators to a new 
attempt, and the CHAMPION PHOENIX trial (41) was designed. The study 
design had many similarities with the previous PCI and PLATFORM, but some 
important differences. First the definition of MI endpoint followed the Universal 
definition of MI. Second, the dose of clopidogrel in the comparator arm changed 
from 600 mg to 300-600 mg at the investigator discretion and the enrollment was 
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restricted to clopidogrel naive patients. Third the primary endpoint was a 
composite of death, MI, IDR, or stent thrombosis at 48 hours.  
In the CHAMPION-PHOENIX trial, cangrelor significantly reduced the primary 
end point (4.7 vs 5.9; OR 0.78; 95 % CI, 0.66-0.93; P= 0.005). The result was 
mostly driven by a reduction in the rate of MI (3.8% vs 4.7%; OR 0.80; 95% CI 
0.67-0.97; P = 0.02) and was persistent at 30 days. Stent thrombosis, the key 
secondary endpoint, was also significantly reduced in the cangrelor group by 38 
% (OR 0.62, 95% CI, 0.43-0.90; P = 0.01). Finally, the rate of severe bleeding 
was not significantly increased in the cangrelor group with the GUSTO criteria 
(0.16% vs 0.11%; OR 1.50; 95% CI, 0.53-4.22; P= 0.44) nor with other bleeding 
definitions.  
Recently all the three CHAMPION trials, using the Universal MI definition, were 
included in a patient level meta-analysis (�25,000 patients)  that showed a 
significant reduction of the primary endpoint death, MI, ischemic driven 
revascularization (IDR), and stent thrombosis at 48 h with cangrelor by 19% 
(3.8% for cangrelor vs 4.7% for control; OR 0.81, 95% CI, 0.71-0.91, P = 0.0007) 
and a reduction of stent thrombosis by 41% (0.5% vs 0.8%, OR 0.59, 95% CI 
0.43-0.80, P = 0.0008). These results persisted at 30 days and the safety 
outcome, evaluated with the GUSTO criteria, was not significantly different in the 
two groups. (42) 
The potential benefit of cangrelor was tested also in a different scenario: the 
bridge to surgery. The BRIDGE trial, a small randomized phase II study, enrolled 
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210 patients already on thienopyridine therapy and scheduled for CABG surgery. 
The patients, after the thionopyridine therapy discontinuation, 2 to 7 days before 
surgery, were randomized in two arms that received cangrelor or placebo 
respectively. Cangrelor administered without bolus with an infusion of 0.75 
ug/kg/min was discontinued 1 to 6 hours before surgery. The primary efficacy 
endpoint expressed as the proportion of patients with a platelet reactivity < 240 
PRU during infusion prior to surgery, was significantly reduced in the cangrelor 
arm (98.8% vs 19%, RR 5.2, 95% CI, 3.3-8.1, P = 0.01), with no significant 
differences in CABG related bleeding and major bleeding prior to CABG surgery 
(43). 
 
 
Elinogrel: 
 
Elinogrel is a reversible, direct-acting agent, that competitively binds with platelet 
P2Y12 receptor (44). Elinogrel has a more rapid onset and offset effect 
compared to clopidogrel and is available in both the oral and intravenous ways of 
administration. 
The INNOVATE- PCI (A Randomised, Double-Blind, Active-Controlled Trial to 
Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 
Inhibitor, vs. Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing 
Non-Urgent PCI) phase II trial have shown that both intravenous and oral doses 
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of elinogrel (80–120 mg intravenous loading dose plus 50–150 mg twice daily) 
achieved more potent and rapid platelet inhibition than clopidogrel in patients 
undergoing elective PCI. This benefit was not associated with a significant 
increase in major or minor bleeding (45) (46). However, elinogrel was more 
commonly associated with elevation in liver enzymes than clopidogrel (45). At 
present time, there is no plan for Elinogrel to get engaged into a phase III 
program and thus to possible market approval.  
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Table 1 Pharmacology of the three available GPIIb/IIIa inhibitors  
 
 Abciximab Eptifibatide Tirofiban 
Molecular 
weight (Da) 47.615 831.96 495.08 
Molecular 
structure 
Monoclonal 
antibody 
Synthetic cyclic 
heptapeptide Synthetic nonpeptide 
Reversibility No Yes Yes 
Kd (nmol/L) 5 120                       15 
Affinity to 
GPIIb/IIIa High Low   High 
Antigenicity Yes No   No  
Duration of 
antiplatelet 
effect 
For life of platelet 5 hours after discontinuation 
 
4 hours after 
discontinuation 
 
Half-life 10–30 minutes 2.5 hours 1.8 hours 
Adjustment 
needed in 
renal 
insufficiency 
 
   Mild (Cr/Cl 
>60 mL/min)  
 
 
 
No 
 
 
 
No 
 
 
 
No 
Moderate 
(Cr/Cl <60 
mL/min)  
No Yes No 
Severe (Cr/Cl 
<30 mL/min or 
dialysis)  
No Contraindicated Yes 
Cost $$$$ / €€€€ $$$ / €€ $$ / €€ 
  
Kd, constant of dissociation. 
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Fig. 1: Kinetics of Platelet Inhibition Over Time After 20 μmol/l ADP after treatment with tirofiban or 
prasugrel alone. To note the late action of prasugrel compared with tirofiban.  
*p  0.05 versus %IPA measured in the prasugrel-alone group at post hoc analysis. Vertical bars 
represent SD of the mean value. Adapted with permission from Valgimigli M, Tebaldi M, Campo G, 
Gambetti S, Bristot L, Monti M, et al. Prasugrel versus tirofiban bolus with or without short post-
bolus infusion with or without concomitant prasugrel administration in patients with myocardial 
infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By 
drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction 
compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovascular interventions. 
2012;5(3):268-77. (28) 
IPA, inhibition of platelet aggregation 
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Fig. 2: Chemical structure of Cangrelor and ATP. Cangrelor is an analogue of ATP.  
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Fig. 2: Chemical structure of Cangrelor and ATP. Cangrelor is an analogue of ATP.  
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Fig. 3: Transition from Cangrelor to Ticagrelor 
Evaluation of platelet reactivity through VerifyNow P2Y12 assay, before and during infusion of 
cangrelor and after the transition to ticagrelor. On the left are results from patients given ticagrelor at 
1.25 h , and on the right are results from patients given ticagrelor at 0.5 h. Mean values plus the 
upper bound of the 95th percentile are shown. From Schneider DJ, Seecheran N, Raza SS, Keating 
FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. 
Coronary artery disease. 2014. (36) 
<f/N> PRU, platelet reactivity unit. 
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Fig. 3: Transition from Cangrelor to Ticagrelor 
Evaluation of platelet reactivity through VerifyNow P2Y12 assay, before and during infusion of 
cangrelor and after the transition to ticagrelor. On the left are results from patients given ticagrelor at 
1.25 h , and on the right are results from patients given ticagrelor at 0.5 h. Mean values plus the 
upper bound of the 95th percentile are shown. From Schneider DJ, Seecheran N, Raza SS, Keating 
FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. 
Coronary artery disease. 2014. (36) 
<f/N> PRU, platelet reactivity unit. 
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Phosphate- or Citrate-Buffered Tiroﬁban
Versus Unfractionated Heparin and its
Impact on Thrombocytopenia and
Clinical Outcomes in Patients With
Acute Coronary Syndrome
A Post Hoc Analysis From the PRISM Trial
Marianna Adamo, MD,a,b Sara Ariotti, MD,a,c Francesco Costa, MD,a,d Salvatore Curello, MD,b Aris Moschovitis, MD,c
Ton de Vries, MA,e Harvey D. White, DSC,f Stephan Windecker, MD, PHD,c Marco Valgimigli, MD, PHDa,c
ABSTRACT
OBJECTIVES The aim of this study was to investigate whether the 2 tiroﬁban formulations tested in the early and late
phases of the PRISM (Platelet Receptor Inhibitor in Ischemic Syndrome Management) trial might differ with respect to
risk for thrombocytopenia and clinical outcomes compared with unfractionated heparin (UFH).
BACKGROUND Citrate-buffered tiroﬁban is currently marketed as brand-name drug. However, tiroﬁban has recently
been promoted in some countries as a generic drug with different formulations, such as phosphate-buffered product.
METHODS In the PRISM trial 3,232 patients were randomly assigned to receive tiroﬁban or UFH. In the early phase, 879
patients were allocated to phosphate-buffered tiroﬁban and 874 patients to UFH group. After a protocol amendment due
to a study drug instability report, citrate-buffered tiroﬁban replaced the phosphate-buffered formulation. Therefore, in
the late phase, 737 and 742 patients were treated with citrate-buffered tiroﬁban and UFH, respectively.
RESULTS The relative risk for thrombocytopenia (nadir <90,000/mm3 or <100,000/mm3) was increased in patients
treated with phosphate-buffered tiroﬁban in the early phase (odds ratio [OR]: 3.51; 95% conﬁdence interval [CI]: 1.15 to
10.73; p ¼ 0.027; and OR: 2.83; 95% CI: 1.11 to 7.22; p ¼ 0.029, respectively) but not in patients treated with citrate-
buffered tiroﬁban in the late phase (OR: 1.01; 95% CI: 0.20 to 5.05; p ¼ 0.987; and OR: 0.99; 95% CI: 0.26 to 3.45; p ¼
0.991, respectively). Using a combined deﬁnition of thrombocytopenia (nadir <150,000/mm3 or a decrease $50%), the
randomization period signiﬁcantly modiﬁed the effect of the treatment (tiroﬁban vs. UFH) on platelet decrease (p for
interaction ¼ 0.024). Thrombocytopenia was associated with a 5- to 10-fold increased risk for TIMI (Thrombolysis In
Myocardial Infarction) bleeding and a 2-fold increased risk for net adverse cardiovascular events.
CONCLUSIONS Phosphate-buffered tiroﬁban, currently marketed as a generic drug, is associated with a higher rate of
thrombocytopeniawith a potentially increased risk for adverse clinical outcomes comparedwith citrate-buffered tiroﬁban.
(J Am Coll Cardiol Intv 2016;9:1667–76) © 2016 by the American College of Cardiology Foundation.
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P atients with acute coronary syn-dromes (ACS) are frequently treatedwith intravenous glycoprotein IIb/
IIIa inhibitors (GPI) (1,2). Among these
agents, tiroﬁban was ﬁrst approved by the
U.S. Food and Drug Administration in 1998.
Since initial approval, the dose has been
revised, and tiroﬁban given as a high-dose
bolus is currently the most frequently used
GPI (3,4).
PRISM (Platelet Receptor Inhibitor in
Ischemic Syndrome Management) was the
ﬁrst randomized clinical study investigating
the safety and efﬁcacy of tiroﬁban, and it
demonstrated a clinical beneﬁt of this GPI
compared with unfractionated heparin (UFH)
with respect to acute ischemic events and 30-day
mortality in the absence of an increased risk for
bleeding. At variance with all other placebo-
controlled studies, PRISM reported a signiﬁcant in-
crease in the rate of thrombocytopenia in the tiroﬁban
compared with UFH group (5).
Two different formulations of tiroﬁban were used
in the PRISM trial in a sequential manner. After a
protocol amendment due to a drug instability report,
the phosphate-buffered product, which was used as
the study drug during the early phase of the study,
was replaced by the citrate-buffered formulation,
which is currently marketed as a brand-name drug
(Aggrastat; Correvio Ltd. in the United Kingdom and
Medicure Pharma in the United States) (6). However,
tiroﬁban has been recently promoted as a generic
drug in several European countries with different
formulations, such as phosphate-buffered tiroﬁban.
In this post hoc analysis of the PRISM trial, we
sought to investigate whether the 2 tiroﬁban formu-
lations used during the early and late phases of the
study and currently marketed as generic and brand-
name drugs might differ with respect to rates of
thrombocytopenia and clinical outcomes compared
with UFH.
METHODS
The design and the main ﬁndings of the PRISM trial
were previously reported (5).
Brieﬂy, PRISM was a randomized, controlled,
multicenter, double-blind trial including patients
with non–ST-segment elevation ACS. Patients were
randomly assigned to receive tiroﬁban (bolus of 0.6
mg/kg/min over 30 min followed by 0.15 mg/kg/min
infusion for 48 h) or UFH (bolus of 5,000 IU followed
by infusion of 1,000 IU/h for 48 h, adjusted for acti-
vated partial thromboplastin time at 6 and 24 h).
During the early recruitment phase of the trial, tir-
oﬁban was administered as a phosphate-buffered
product that ranged in concentration from 0.17 to 0.5
mg/ml; sodium chloride was used to render the prod-
uct iso-osmotic. During the late recruitment phase,
this composition was abandoned and substituted by a
citrate-buffered product (10 mmol/l) containing so-
dium chloride. The change in compositionwas deemed
necessary because of instability report of the
phosphate-buffered composition and the ﬁnding of
precipitates in vials stored for 24 months or more (6).
Sodium porcine heparin was provided as 1,000 U/ml
(10-ml ﬁll) or as 10,000 U/ml (5-ml ﬁll) without differ-
ences through the early and late recruitment phases.
STUDY ENDPOINTS. To maintain the randomization
scheme, we primarily aimed to compare outcomes in
patients treated with phosphate-buffered tiroﬁban
versus UFH during the early phase and those treated
with citrate-buffered tiroﬁban versus UFH during the
late phase. As sensitivity analyses, we also compared
patients receiving the 2 tiroﬁban formulations
throughout the 2 different time periods.
Thrombocytopenia was deﬁned as platelet
nadir <90,000/mm3 (used in the PRISM trial [5]), as
platelet count <100,000/mm3 (the most frequent
cutoff used in previous studies [7–9]), and as a com-
bination of nadir value<150,000/mm3 and decrease of
platelet count $50% (used in a previous large registry
[10]). Severe thrombocytopenia was deﬁned as
platelet count <50,000/mm3.
We also investigated the 30-day ischemic endpoints
reported in the PRISM trial (2): death, myocardial
infarction (MI), refractory ischemia; readmission for
unstable angina, a composite of major adverse car-
diovascular events including all single endpoints pre-
viously mentioned and a composite of death and MI.
Bleeding events were deﬁned according to the
TIMI (Thrombolysis In Myocardial Infarction) classi-
ﬁcation (11).
Finally, a composite endpoint of net adverse car-
diovascular events (NACEs) including major adverse
cardiovascular events and major or minor TIMI
bleeding was assessed.
STATISTICAL ANALYSIS. Continuous variables were
expressed as mean  SD and were compared using the
Student t test. Categorical variables were expressed
as counts and percentages and were compared using
the chi-square or Fisher exact test, as appropriate.
The proportionality assumptions were checked by
visual estimation after plotting the log cumulative
hazard versus (log) time at follow-up after the index
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procedure and by applying a test for nonproportional
hazards using Schoenfeld residuals, which failed to
reject the null hypothesis that bleeding and ischemic
event rate was affected by time. Therefore, a multi-
variate Cox regression analysis stratiﬁed by center,
including baseline variables differently distributed at
an alpha level of 0.10, was performed to calculate the
relative risk of these endpoints and to evaluate
whether thrombocytopenia was an independent pre-
dictor of outcomes. Each result was expressed as
hazard ratio (HR) and corresponding 95% conﬁdence
interval (CI).
A stepwise logistic regression model was used to
calculate the relative risk for thrombocytopenia ac-
cording to the 3 different deﬁnitions and adjusted for
baseline imbalances. Each result was reported as odds
ratio (OR) and corresponding 95% CI.
Interaction tests between randomization period
(early vs. late) and treatment (tiroﬁban vs. UFH) were
done with likelihood ratio tests of the null hypothesis
that the interaction coefﬁcient was zero.
The Kaplan-Meier method was used to plot the
cumulative incidence of bleeding events according to
the presence of thrombocytopenia.
For all analyses, a 2-sided alpha value <0.05 was
considered to indicate statistical signiﬁcance. All
statistical analyses were performed using SPSS
version 21 (SPSS, Inc., Chicago, Illinois).
RESULTS
BASELINE CHARACTERISTICS AND DURATION OF
STUDY DRUG INFUSION. In the PRISM trial, 3,232
patients were randomly assigned to receive tiroﬁban
or UFH treatment. Before a formal study protocol
amendment, during the early recruitment phase,
1,753 patients were enrolled, of whom 879 (50.1%)
were allocated to the phosphate-buffered tiroﬁban
group and 874 (49.9%) to the UFH arm. During the
late recruitment phase, 737 of 1,479 patients (49.8%)
were treated with citrate-buffered tiroﬁban and 742
(50.2%) with UFH.
The baseline features within the randomized arms
during both the early and late recruitment periods are
shown in Table 1. During the early phase, patients
treated with UFH more frequently had prior coronary
artery bypass graft surgery compared with those
receiving phosphate-buffered tiroﬁban (20.4% vs.
16.5%, p ¼ 0.037), whereas during the late phase,
patients treated with UFH more commonly had non–
ST-segment elevation MI compared with those
receiving citrate-buffered tiroﬁban (27.4% vs. 21.4%,
p ¼ 0.008) (Table 1).
Among tiroﬁban-treated patients, those receiving
citrate-buffered tiroﬁban more commonly had
hypercholesterolemia (52% vs. 43.7%, p < 0.001) or
previous heart failure (14.8 vs. 10.4%, p ¼ 0.007),
TABLE 1 Baseline Features
M1
(n ¼ 879)
H1
(n ¼ 874)
p Value,
H1 vs. M1
M2
(n ¼ 737)
H2
(n ¼ 742)
p Value,
H2 vs. M2
p Value,
M1 vs. M2
Male 587 (66.8) 607 (69.5) 0.239 500 (67.8) 504 (68.4) 1.000 0.670
Age (yrs) 62 � 11 62 � 11 1.000 63 � 11 62 � 11 1.000 0.270
Race (white) 733 (83.4) 731 (83.6) 0.889 616 (83.6) 623 (84.5) 0.843 0.918
Smoking 234 (26.6) 243 (27.8) 0.359 185 (25.1) 180 (24.4) 0.880 0.646
Hypertension 477 (54.3) 470 (53.8) 0.848 399 (45.7) 412 (55.9) 0.602 0.960
Diabetes 182 (20.7) 199 (22.8) 0.298 147 (16.8) 159 (21.6) 0.521 0.710
Hypercholesterolemia 384 (43.7) 406 (46.5) 0.230 383 (52.0) 359 (48.7) 0.176 <0.001
Previous MI 416 (47.3) 405 (46.3) 0.679 340 (46.1) 356 (48.3) 0.498 0.652
Previous CABG 145 (16.5) 178 (20.4) 0.037 129 (17.5) 110 (14.9) 0.162 0.591
Previous PCI 125 (14.2) 144 (16.5) 0.190 104 (14.1) 107 (14.5) 0.941 0.950
History of heart failure 91 (10.4) 103 (11.8) 0.361 109 (14.8) 100 (13.5) 0.469 0.007
Clinical presentation 0.211 0.008 0.018
NSTEMI 223 (25.4) 209 (23.9) 158 (21.4) 203 (27.4)
Unstable angina 656 (74.6) 665 (76.1) 579 (78.6) 539 (72.6)
Multivessel disease* 373 (70.4) 364 (69.5) 0.747 277 (66.9) 311 (71.7) 0.134 0.253
Treatment
CABG 162 (18.4) 146 (16.7) 0.570 134 (18.2) 123 (16.6) 0.413 0.421
PCI 177 (20.1) 167 (19.1) 0.588 171 (23.2) 185 (24.9) 0.436 0.728
Medical therapy 555 (63.1) 568 (65.0) 0.420 437 (59.3) 439 (59.2) 0.959 0.114
Values are n (%) or mean � SD. *Calculated on patients who underwent coronary angiography (530 patients belonging to the phosphate-buffered group, 524 treated with
unfractionated heparin in the early period, 414 receiving citrate-buffered tiroﬁban, and 434 treated with unfractionated heparin in the late period).
CABG ¼ coronary artery bypass grafting; H1 ¼ unfractionated heparin in the early phase; H2 ¼ unfractionated heparin in the late phase; M1 ¼ phosphate-buffered tiroﬁban in
the early phase; M2 ¼ citrate-buffered tiroﬁban in the late phase; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous
coronary intervention.
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P atients with acute coronary syn-dromes (ACS) are frequently treatedwith intravenous glycoprotein IIb/
IIIa inhibitors (GPI) (1,2). Among these
agents, tiroﬁban was ﬁrst approved by the
U.S. Food and Drug Administration in 1998.
Since initial approval, the dose has been
revised, and tiroﬁban given as a high-dose
bolus is currently the most frequently used
GPI (3,4).
PRISM (Platelet Receptor Inhibitor in
Ischemic Syndrome Management) was the
ﬁrst randomized clinical study investigating
the safety and efﬁcacy of tiroﬁban, and it
demonstrated a clinical beneﬁt of this GPI
compared with unfractionated heparin (UFH)
with respect to acute ischemic events and 30-day
mortality in the absence of an increased risk for
bleeding. At variance with all other placebo-
controlled studies, PRISM reported a signiﬁcant in-
crease in the rate of thrombocytopenia in the tiroﬁban
compared with UFH group (5).
Two different formulations of tiroﬁban were used
in the PRISM trial in a sequential manner. After a
protocol amendment due to a drug instability report,
the phosphate-buffered product, which was used as
the study drug during the early phase of the study,
was replaced by the citrate-buffered formulation,
which is currently marketed as a brand-name drug
(Aggrastat; Correvio Ltd. in the United Kingdom and
Medicure Pharma in the United States) (6). However,
tiroﬁban has been recently promoted as a generic
drug in several European countries with different
formulations, such as phosphate-buffered tiroﬁban.
In this post hoc analysis of the PRISM trial, we
sought to investigate whether the 2 tiroﬁban formu-
lations used during the early and late phases of the
study and currently marketed as generic and brand-
name drugs might differ with respect to rates of
thrombocytopenia and clinical outcomes compared
with UFH.
METHODS
The design and the main ﬁndings of the PRISM trial
were previously reported (5).
Brieﬂy, PRISM was a randomized, controlled,
multicenter, double-blind trial including patients
with non–ST-segment elevation ACS. Patients were
randomly assigned to receive tiroﬁban (bolus of 0.6
mg/kg/min over 30 min followed by 0.15 mg/kg/min
infusion for 48 h) or UFH (bolus of 5,000 IU followed
by infusion of 1,000 IU/h for 48 h, adjusted for acti-
vated partial thromboplastin time at 6 and 24 h).
During the early recruitment phase of the trial, tir-
oﬁban was administered as a phosphate-buffered
product that ranged in concentration from 0.17 to 0.5
mg/ml; sodium chloride was used to render the prod-
uct iso-osmotic. During the late recruitment phase,
this composition was abandoned and substituted by a
citrate-buffered product (10 mmol/l) containing so-
dium chloride. The change in compositionwas deemed
necessary because of instability report of the
phosphate-buffered composition and the ﬁnding of
precipitates in vials stored for 24 months or more (6).
Sodium porcine heparin was provided as 1,000 U/ml
(10-ml ﬁll) or as 10,000 U/ml (5-ml ﬁll) without differ-
ences through the early and late recruitment phases.
STUDY ENDPOINTS. To maintain the randomization
scheme, we primarily aimed to compare outcomes in
patients treated with phosphate-buffered tiroﬁban
versus UFH during the early phase and those treated
with citrate-buffered tiroﬁban versus UFH during the
late phase. As sensitivity analyses, we also compared
patients receiving the 2 tiroﬁban formulations
throughout the 2 different time periods.
Thrombocytopenia was deﬁned as platelet
nadir <90,000/mm3 (used in the PRISM trial [5]), as
platelet count <100,000/mm3 (the most frequent
cutoff used in previous studies [7–9]), and as a com-
bination of nadir value<150,000/mm3 and decrease of
platelet count $50% (used in a previous large registry
[10]). Severe thrombocytopenia was deﬁned as
platelet count <50,000/mm3.
We also investigated the 30-day ischemic endpoints
reported in the PRISM trial (2): death, myocardial
infarction (MI), refractory ischemia; readmission for
unstable angina, a composite of major adverse car-
diovascular events including all single endpoints pre-
viously mentioned and a composite of death and MI.
Bleeding events were deﬁned according to the
TIMI (Thrombolysis In Myocardial Infarction) classi-
ﬁcation (11).
Finally, a composite endpoint of net adverse car-
diovascular events (NACEs) including major adverse
cardiovascular events and major or minor TIMI
bleeding was assessed.
STATISTICAL ANALYSIS. Continuous variables were
expressed as mean  SD and were compared using the
Student t test. Categorical variables were expressed
as counts and percentages and were compared using
the chi-square or Fisher exact test, as appropriate.
The proportionality assumptions were checked by
visual estimation after plotting the log cumulative
hazard versus (log) time at follow-up after the index
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procedure and by applying a test for nonproportional
hazards using Schoenfeld residuals, which failed to
reject the null hypothesis that bleeding and ischemic
event rate was affected by time. Therefore, a multi-
variate Cox regression analysis stratiﬁed by center,
including baseline variables differently distributed at
an alpha level of 0.10, was performed to calculate the
relative risk of these endpoints and to evaluate
whether thrombocytopenia was an independent pre-
dictor of outcomes. Each result was expressed as
hazard ratio (HR) and corresponding 95% conﬁdence
interval (CI).
A stepwise logistic regression model was used to
calculate the relative risk for thrombocytopenia ac-
cording to the 3 different deﬁnitions and adjusted for
baseline imbalances. Each result was reported as odds
ratio (OR) and corresponding 95% CI.
Interaction tests between randomization period
(early vs. late) and treatment (tiroﬁban vs. UFH) were
done with likelihood ratio tests of the null hypothesis
that the interaction coefﬁcient was zero.
The Kaplan-Meier method was used to plot the
cumulative incidence of bleeding events according to
the presence of thrombocytopenia.
For all analyses, a 2-sided alpha value <0.05 was
considered to indicate statistical signiﬁcance. All
statistical analyses were performed using SPSS
version 21 (SPSS, Inc., Chicago, Illinois).
RESULTS
BASELINE CHARACTERISTICS AND DURATION OF
STUDY DRUG INFUSION. In the PRISM trial, 3,232
patients were randomly assigned to receive tiroﬁban
or UFH treatment. Before a formal study protocol
amendment, during the early recruitment phase,
1,753 patients were enrolled, of whom 879 (50.1%)
were allocated to the phosphate-buffered tiroﬁban
group and 874 (49.9%) to the UFH arm. During the
late recruitment phase, 737 of 1,479 patients (49.8%)
were treated with citrate-buffered tiroﬁban and 742
(50.2%) with UFH.
The baseline features within the randomized arms
during both the early and late recruitment periods are
shown in Table 1. During the early phase, patients
treated with UFH more frequently had prior coronary
artery bypass graft surgery compared with those
receiving phosphate-buffered tiroﬁban (20.4% vs.
16.5%, p ¼ 0.037), whereas during the late phase,
patients treated with UFH more commonly had non–
ST-segment elevation MI compared with those
receiving citrate-buffered tiroﬁban (27.4% vs. 21.4%,
p ¼ 0.008) (Table 1).
Among tiroﬁban-treated patients, those receiving
citrate-buffered tiroﬁban more commonly had
hypercholesterolemia (52% vs. 43.7%, p < 0.001) or
previous heart failure (14.8 vs. 10.4%, p ¼ 0.007),
TABLE 1 Baseline Features
M1
(n ¼ 879)
H1
(n ¼ 874)
p Value,
H1 vs. M1
M2
(n ¼ 737)
H2
(n ¼ 742)
p Value,
H2 vs. M2
p Value,
M1 vs. M2
Male 587 (66.8) 607 (69.5) 0.239 500 (67.8) 504 (68.4) 1.000 0.670
Age (yrs) 62 � 11 62 � 11 1.000 63 � 11 62 � 11 1.000 0.270
Race (white) 733 (83.4) 731 (83.6) 0.889 616 (83.6) 623 (84.5) 0.843 0.918
Smoking 234 (26.6) 243 (27.8) 0.359 185 (25.1) 180 (24.4) 0.880 0.646
Hypertension 477 (54.3) 470 (53.8) 0.848 399 (45.7) 412 (55.9) 0.602 0.960
Diabetes 182 (20.7) 199 (22.8) 0.298 147 (16.8) 159 (21.6) 0.521 0.710
Hypercholesterolemia 384 (43.7) 406 (46.5) 0.230 383 (52.0) 359 (48.7) 0.176 <0.001
Previous MI 416 (47.3) 405 (46.3) 0.679 340 (46.1) 356 (48.3) 0.498 0.652
Previous CABG 145 (16.5) 178 (20.4) 0.037 129 (17.5) 110 (14.9) 0.162 0.591
Previous PCI 125 (14.2) 144 (16.5) 0.190 104 (14.1) 107 (14.5) 0.941 0.950
History of heart failure 91 (10.4) 103 (11.8) 0.361 109 (14.8) 100 (13.5) 0.469 0.007
Clinical presentation 0.211 0.008 0.018
NSTEMI 223 (25.4) 209 (23.9) 158 (21.4) 203 (27.4)
Unstable angina 656 (74.6) 665 (76.1) 579 (78.6) 539 (72.6)
Multivessel disease* 373 (70.4) 364 (69.5) 0.747 277 (66.9) 311 (71.7) 0.134 0.253
Treatment
CABG 162 (18.4) 146 (16.7) 0.570 134 (18.2) 123 (16.6) 0.413 0.421
PCI 177 (20.1) 167 (19.1) 0.588 171 (23.2) 185 (24.9) 0.436 0.728
Medical therapy 555 (63.1) 568 (65.0) 0.420 437 (59.3) 439 (59.2) 0.959 0.114
Values are n (%) or mean � SD. *Calculated on patients who underwent coronary angiography (530 patients belonging to the phosphate-buffered group, 524 treated with
unfractionated heparin in the early period, 414 receiving citrate-buffered tiroﬁban, and 434 treated with unfractionated heparin in the late period).
CABG ¼ coronary artery bypass grafting; H1 ¼ unfractionated heparin in the early phase; H2 ¼ unfractionated heparin in the late phase; M1 ¼ phosphate-buffered tiroﬁban in
the early phase; M2 ¼ citrate-buffered tiroﬁban in the late phase; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous
coronary intervention.
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whereas patients treated with phosphate-buffered
tiroﬁban were more frequently admitted for non–ST-
segment elevation MI (25.4% vs. 21.4%, p ¼ 0.018)
(Table 1).
Approximately 60% of patients underwent medical
management, and 70% of patients undergoing coro-
nary angiography had multivessel coronary artery
disease, which did not differ across groups (Table 1).
The duration of study drug infusion was well
matched across groups. Phosphate-buffered (early
phase) and citrate-buffered (late phase) tiroﬁban
formulations were infused for a mean of 45.1 � 10.6 h
and 44.8 � 10.5 h, respectively, whereas UFH was
administered for a mean of 45.5 � 9.5 h and 45.1 � 10.1
h during the early and late phases, respectively.
THROMBOCYTOPENIA. Baseline platelet counts did
not differ across groups. The rate of thrombocyto-
penia was signiﬁcantly higher during the early
recruitment phase, when phosphate-buffered tir-
oﬁban was compared with UFH, using a cutoff of
90,000/mm3 (1.7% vs. 0.5%, respectively, p ¼ 0.030)
or 100,000/mm3 (2.0% vs. 0.7%, respectively,
p ¼ 0.034) but not during the late recruitment phase,
when citrate-buffered tiroﬁban was compared with
UFH (0.3% vs. 0.1% [p ¼ 0.621] and 0.7% vs. 0.7%
[p ¼ 0.971]) (Figure 1A). The rate of thrombocytopenia
did not differ across groups on the basis of platelet
nadir value <150,000/mm3 or decrease in platelet
count $50% (Figure 1A).
Severe thrombocytopenia was observed in 4 pa-
tients treated with phosphate-buffered tiroﬁban
versus none treated with UFH during the early
recruitment phase (0.5% vs. 0%, p ¼ 0.046) and in 1
patient treated with citrate-buffered tiroﬁban versus
no patients allocated to the UFH group during the late
recruitment phase (0.1% vs. 0%, p ¼ 0.49).
Among tiroﬁban-treated patients, the rate of
thrombocytopenia (nadir <90,000/mm3 or <100,000/
mm3) was signiﬁcantly higher in those treated with
phosphate-buffered compared with those treated
with citrate-buffered tiroﬁban, and a trend toward a
more frequent platelet nadir <150,000/mm3 or a
decrease in platelet count $50% in patients receiving
phosphate-buffer tiroﬁban was observed (Figure 1A).
On multivariate-adjusted analysis, the relative
risk for thrombocytopenia (nadir <90,000/mm3 or
<100,000/mm3) was approximately 3-fold higher in
patients treated with tiroﬁban during the early (OR:
3.51; 95% CI: 1.15 to 10.73; p ¼ 0.027; and OR: 2.83;
95% CI: 1.11 to 7.22; p ¼ 0.029, respectively) but not
during the late recruitment phase, although formal
statistical testing for interaction did not reach con-
ventional thresholds of signiﬁcance (Figure 1B).
The randomization period, however, emerged as a
possible treatment modiﬁer with respect to the risk
for thrombocytopenia under the combined deﬁnition
of platelet nadir <150,000/mm3 or decrease in
platelet count $50% (p for interaction ¼ 0.024)
(Figure 1B).
Among patients receiving tiroﬁban, the phosphate-
buffered formulation was associated with an
increased risk for a platelet decrease <90,000/mm3
(OR: 3.99; 95% CI: 1.13 to 14.05; p ¼ 0.031) or 100,000/
mm3 (OR: 2.78; 95% CI: 1.02 to 7.63; p ¼ 0.047)
compared with citrate-buffered tiroﬁban.
CLINICAL ENDPOINTS AT 30 DAYS. After adjustment
for baseline differences, citrate-buffered tiroﬁban
was associated with a reduced risk for 30-day mor-
tality compared with UFH (HR: 0.49; 95% CI: 0.27 to
0.89; p ¼ 0.019), whereas no difference was observed
between phosphate-buffered tiroﬁban and UFH (HR:
0.87; 95% CI: 0.49 to 1.54; p ¼ 0.629). However, no
signiﬁcant interaction was observed between the
randomization period and treatment with respect to
the mortality endpoint (p for interaction ¼ 0.151)
(Figure 2). There were no differences between tir-
oﬁban and UFH with regard to other explored
ischemic or bleeding endpoints (Figure 2).
Among tiroﬁban treated patients, no signiﬁcant
differences were noted between the 2 tiroﬁban for-
mulations with respect to 30-day mortality and other
clinical endpoints. A trend toward a higher rate of
refractory ischemia in the citrate-buffered group was
observed (Online Table 1).
THROMBOCYTOPENIA EFFECT ON ISCHEMIC AND
BLEEDING OUTCOMES. Baseline characteristics of
patients who did compared with those who did not
develop thrombocytopenia according to different
deﬁnitions are reported in Table 2 and Online Table 2.
Premature study drug discontinuation was deemed
necessary in approximately 50% of patients among
those who developed thrombocytopenia (platelet
nadir <90,000/mm3 or 100,000/mm3), whereas this
was infrequent in patients without thrombocytopenia
(45.8% vs. 1.7% and 42.2% vs. 1.6%, respectively,
p < 0.001 for all).
After adjustment for differences in baseline char-
acteristics, thrombocytopenia was associated with a 5-
to 10-fold increased risk for TIMI minor or major
bleeding (Figure 3) and major bleeding (Table 3, Online
Table 3). Patients who experienced a platelet
nadir <100,000/mm3 also had a 2-fold increased risk
for NACEs (HR: 2.36; 95% CI: 1.31 to 4.23; p ¼ 0.004)
(Table 3). Under the combined deﬁnition, a trend
toward a higher risk for refractory ischemia was ob-
served in patients with thrombocytopenia (Table 3).
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DISCUSSION
The main ﬁndings of the present study can be sum-
marized as follows. 1) Patients treated with
phosphate-buffered tiroﬁban during the early
recruitment phase of the PRISM trial more frequently
experienced thrombocytopenia, with a 3-fold
increased risk for platelet decrease <90,000/mm3 or
100,000/mm3 compared with those receiving UFH
during the same randomization period. No difference
was observed between citrate-buffered tiroﬁban and
UFH during the late recruitment phase. 2) The
randomization period (early vs. late) signiﬁcantly
modiﬁed the effect of treatment (tiroﬁban vs. UFH)
with respect to the risk for thrombocytopenia
(platelet nadir <150,000/mm3 or decrease in platelet
count $50%). 3) Outside the randomization scheme,
phosphate-buffered tiroﬁban was associated with a
signiﬁcantly higher risk for thrombocytopenia
(platelet nadir <90,000/mm3 or 100,000/mm3)
compared with the corresponding citrate-buffered
product. 4) Thrombocytopenia was conﬁrmed to be
an independent predictor of adverse outcomes, with
a 5- to 10-fold increased risk for TIMI minor or major
bleeding and a 2-fold increased risk for NACEs. 5)
After adjustment for baseline differences, citrate-
FIGURE 1 Thrombocytopenia in Patients Treated With Tiroﬁban or Unfractionated Heparin in the Early and Late Phases According To
Different Deﬁnitions
(A) The incidence of thrombocytopenia (platelet nadir <90,000/mm3 or 100,000/mm3) was signiﬁcantly higher in patients receiving tiroﬁban
versus unfractionated heparin (UFH) in the early phase but not in the late phase. Among tiroﬁban-treated patients, a higher incidence of
thrombocytopenia was observed in the phosphate-buffered (early-phase) versus citrate-buffered (late-phase) group. (B) An increased relative
risk for thrombocytopenia (platelet nadir <90,000/mm3 or 100,000/mm3) was reported in patients treated with phosphate-buffered tiroﬁban
versus UFH in the early phase. The randomization period was a treatment modiﬁer with respect to the risk for platelet decrease <150,000/mm3
or $50%. CI ¼ conﬁdence interval; OR ¼ odds ratio; PTL ¼ platelet.
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whereas patients treated with phosphate-buffered
tiroﬁban were more frequently admitted for non–ST-
segment elevation MI (25.4% vs. 21.4%, p ¼ 0.018)
(Table 1).
Approximately 60% of patients underwent medical
management, and 70% of patients undergoing coro-
nary angiography had multivessel coronary artery
disease, which did not differ across groups (Table 1).
The duration of study drug infusion was well
matched across groups. Phosphate-buffered (early
phase) and citrate-buffered (late phase) tiroﬁban
formulations were infused for a mean of 45.1 � 10.6 h
and 44.8 � 10.5 h, respectively, whereas UFH was
administered for a mean of 45.5 � 9.5 h and 45.1 � 10.1
h during the early and late phases, respectively.
THROMBOCYTOPENIA. Baseline platelet counts did
not differ across groups. The rate of thrombocyto-
penia was signiﬁcantly higher during the early
recruitment phase, when phosphate-buffered tir-
oﬁban was compared with UFH, using a cutoff of
90,000/mm3 (1.7% vs. 0.5%, respectively, p ¼ 0.030)
or 100,000/mm3 (2.0% vs. 0.7%, respectively,
p ¼ 0.034) but not during the late recruitment phase,
when citrate-buffered tiroﬁban was compared with
UFH (0.3% vs. 0.1% [p ¼ 0.621] and 0.7% vs. 0.7%
[p ¼ 0.971]) (Figure 1A). The rate of thrombocytopenia
did not differ across groups on the basis of platelet
nadir value <150,000/mm3 or decrease in platelet
count $50% (Figure 1A).
Severe thrombocytopenia was observed in 4 pa-
tients treated with phosphate-buffered tiroﬁban
versus none treated with UFH during the early
recruitment phase (0.5% vs. 0%, p ¼ 0.046) and in 1
patient treated with citrate-buffered tiroﬁban versus
no patients allocated to the UFH group during the late
recruitment phase (0.1% vs. 0%, p ¼ 0.49).
Among tiroﬁban-treated patients, the rate of
thrombocytopenia (nadir <90,000/mm3 or <100,000/
mm3) was signiﬁcantly higher in those treated with
phosphate-buffered compared with those treated
with citrate-buffered tiroﬁban, and a trend toward a
more frequent platelet nadir <150,000/mm3 or a
decrease in platelet count $50% in patients receiving
phosphate-buffer tiroﬁban was observed (Figure 1A).
On multivariate-adjusted analysis, the relative
risk for thrombocytopenia (nadir <90,000/mm3 or
<100,000/mm3) was approximately 3-fold higher in
patients treated with tiroﬁban during the early (OR:
3.51; 95% CI: 1.15 to 10.73; p ¼ 0.027; and OR: 2.83;
95% CI: 1.11 to 7.22; p ¼ 0.029, respectively) but not
during the late recruitment phase, although formal
statistical testing for interaction did not reach con-
ventional thresholds of signiﬁcance (Figure 1B).
The randomization period, however, emerged as a
possible treatment modiﬁer with respect to the risk
for thrombocytopenia under the combined deﬁnition
of platelet nadir <150,000/mm3 or decrease in
platelet count $50% (p for interaction ¼ 0.024)
(Figure 1B).
Among patients receiving tiroﬁban, the phosphate-
buffered formulation was associated with an
increased risk for a platelet decrease <90,000/mm3
(OR: 3.99; 95% CI: 1.13 to 14.05; p ¼ 0.031) or 100,000/
mm3 (OR: 2.78; 95% CI: 1.02 to 7.63; p ¼ 0.047)
compared with citrate-buffered tiroﬁban.
CLINICAL ENDPOINTS AT 30 DAYS. After adjustment
for baseline differences, citrate-buffered tiroﬁban
was associated with a reduced risk for 30-day mor-
tality compared with UFH (HR: 0.49; 95% CI: 0.27 to
0.89; p ¼ 0.019), whereas no difference was observed
between phosphate-buffered tiroﬁban and UFH (HR:
0.87; 95% CI: 0.49 to 1.54; p ¼ 0.629). However, no
signiﬁcant interaction was observed between the
randomization period and treatment with respect to
the mortality endpoint (p for interaction ¼ 0.151)
(Figure 2). There were no differences between tir-
oﬁban and UFH with regard to other explored
ischemic or bleeding endpoints (Figure 2).
Among tiroﬁban treated patients, no signiﬁcant
differences were noted between the 2 tiroﬁban for-
mulations with respect to 30-day mortality and other
clinical endpoints. A trend toward a higher rate of
refractory ischemia in the citrate-buffered group was
observed (Online Table 1).
THROMBOCYTOPENIA EFFECT ON ISCHEMIC AND
BLEEDING OUTCOMES. Baseline characteristics of
patients who did compared with those who did not
develop thrombocytopenia according to different
deﬁnitions are reported in Table 2 and Online Table 2.
Premature study drug discontinuation was deemed
necessary in approximately 50% of patients among
those who developed thrombocytopenia (platelet
nadir <90,000/mm3 or 100,000/mm3), whereas this
was infrequent in patients without thrombocytopenia
(45.8% vs. 1.7% and 42.2% vs. 1.6%, respectively,
p < 0.001 for all).
After adjustment for differences in baseline char-
acteristics, thrombocytopenia was associated with a 5-
to 10-fold increased risk for TIMI minor or major
bleeding (Figure 3) and major bleeding (Table 3, Online
Table 3). Patients who experienced a platelet
nadir <100,000/mm3 also had a 2-fold increased risk
for NACEs (HR: 2.36; 95% CI: 1.31 to 4.23; p ¼ 0.004)
(Table 3). Under the combined deﬁnition, a trend
toward a higher risk for refractory ischemia was ob-
served in patients with thrombocytopenia (Table 3).
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marized as follows. 1) Patients treated with
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experienced thrombocytopenia, with a 3-fold
increased risk for platelet decrease <90,000/mm3 or
100,000/mm3 compared with those receiving UFH
during the same randomization period. No difference
was observed between citrate-buffered tiroﬁban and
UFH during the late recruitment phase. 2) The
randomization period (early vs. late) signiﬁcantly
modiﬁed the effect of treatment (tiroﬁban vs. UFH)
with respect to the risk for thrombocytopenia
(platelet nadir <150,000/mm3 or decrease in platelet
count $50%). 3) Outside the randomization scheme,
phosphate-buffered tiroﬁban was associated with a
signiﬁcantly higher risk for thrombocytopenia
(platelet nadir <90,000/mm3 or 100,000/mm3)
compared with the corresponding citrate-buffered
product. 4) Thrombocytopenia was conﬁrmed to be
an independent predictor of adverse outcomes, with
a 5- to 10-fold increased risk for TIMI minor or major
bleeding and a 2-fold increased risk for NACEs. 5)
After adjustment for baseline differences, citrate-
FIGURE 1 Thrombocytopenia in Patients Treated With Tiroﬁban or Unfractionated Heparin in the Early and Late Phases According To
Different Deﬁnitions
(A) The incidence of thrombocytopenia (platelet nadir <90,000/mm3 or 100,000/mm3) was signiﬁcantly higher in patients receiving tiroﬁban
versus unfractionated heparin (UFH) in the early phase but not in the late phase. Among tiroﬁban-treated patients, a higher incidence of
thrombocytopenia was observed in the phosphate-buffered (early-phase) versus citrate-buffered (late-phase) group. (B) An increased relative
risk for thrombocytopenia (platelet nadir <90,000/mm3 or 100,000/mm3) was reported in patients treated with phosphate-buffered tiroﬁban
versus UFH in the early phase. The randomization period was a treatment modiﬁer with respect to the risk for platelet decrease <150,000/mm3
or $50%. CI ¼ conﬁdence interval; OR ¼ odds ratio; PTL ¼ platelet.
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buffered tiroﬁban was associated with a reduced risk
for death compared with UFH, whereas no difference
in mortality was observed between phosphate-
buffered tiroﬁban and UFH.
TIROFIBAN USE AND FORMULATIONS. American
College of Cardiology and American Heart Association
guidelines suggest the administration of GPIs in high-
risk patients with non–ST-segment elevation ACS
undergoing percutaneous coronary intervention
irrespective of pre-treatment status with P2Y12 in-
hibitors (12,13). European Society of Cardiology
guidelines recommend GPIs for patients with ACS in
bailout situations or with thrombotic complications
(14,15). As a result, these drugs are frequently used in
clinical practice in patients with ACS undergoing
invasive management, and tiroﬁban is currently the
most frequently used GPI worldwide.
Citrate-buffered tiroﬁban is marketed as brand-
name product (Aggrastat, Correvio [UK] Ltd. and
Medicure Pharma [US]). In several European coun-
tries, tiroﬁban is marketed as a generic drug with
formulations different from the citrate-buffered,
including phosphate-buffered tiroﬁban (Hexal,
Hikma, and MEDAC). No generic tiroﬁban products
are currently marketed in the United States. Seven
generic versions are available in India; at least 1 of
these is a citrate-buffered product (Gland Pharma).
No information regarding the excipients is in the
public domain for the remaining 6 products.
THROMBOCYTOPENIA AND OUTCOMES. The associ-
ation between thrombocytopenia and adverse clinical
outcomes in the setting of ACS is well established,
and patients receiving GPIs should be carefully scru-
tinized for changes in platelet count during and
FIGURE 2 Clinical Outcomes at 30 Days in Patients Treated With Tiroﬁban Versus Unfractionated Heparin According to Randomization Phase
The relative risk for death was 50% reduced in patients treated with tiroﬁban versus unfractionated heparin (UFH) in the late but not in the
early phase. CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular event; MI ¼ myocardial infarction; NACE ¼ net
adverse cardiovascular event.
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immediately after drug administration. Patients who
experience signiﬁcant platelet decreases after GPI
administration are at increased risk for bleeding,
recurrent MI, and death (7–10). In the Global Reg-
istry of Acute Coronary Events (GRACE) population,
thrombocytopenia after GPI treatment was associ-
ated with a 4-fold increased risk for in-hospital
mortality and a 2- to 3-fold increased risk for
stroke and recurrent infarction (16). In the
CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines)
registry, patients who developed thrombocytopenia
had a 3- and 4-fold increased risk for mortality and
bleeding, respectively (10). In the PRISM popula-
tion, thrombocytopenia emerged as an independent
predictor of both bleeding and ischemic clinical
outcomes, with a 5- to 10-fold increased risk
for TIMI bleeding, a 2-fold increased risk for
NACEs, and a trend toward an increased risk for
refractory ischemia at 30-day follow-up. The lack of
an association between thrombocytopenia and
mortality in our cohort of patients may reﬂect a
type II error.
MECHANISM OF THROMBOCYTOPENIA. Drug-induced
immune thrombocytopenia is a common hematologic
problem. More than 200 drugs have been reported to
TABLE 2 Baseline Characteristics of Patients With or Without Thrombocytopenia According to Different Deﬁnitions (Platelet Nadir
<100,000/mm3 and Platelets Decrease <150,000/mm3 or $50%)
TCP*
(n ¼ 33)
Non-TCP
(n ¼ 3,056) p Value
TCP†
(n ¼ 312)
Non-TCP
(n ¼ 2,777) p Value
Male 24 (72.7) 2,085 (68.2) 0.581 235 (75.3) 1,874 (67.5) 0.005
Age (yrs) 64.0 � 11.0 62.4 � 11.1 0.405 64.5 � 10.9 62.2 � 11.1 <0.001
Race (white) 28 (84.8) 2,561 (83.8) 0.871 264 (84.6) 2,325 (83.7) 0.746
Smoking 7 (21.2) 795 (26.0) 0.531 65 (20.8) 737 (26.5) 0.029
Hypertension 21 (63.6) 1,656 (54.2) 0.279 178 (57.1) 1,499 (54.0) 0.309
Diabetes mellitus 12 (36.4) 641 (21.0) 0.031 90 (28.8) 563 (20.3) 0.001
Hypercholesterolemia 12 (36.4) 1,458 (47.7) 0.194 131 (42.0) 1,339 (48.2) 0.042
Previous MI 18 (54.5) 1,441 (47.2) 0.398 156 (50.0) 1,303 (46.9) 0.310
Previous CABG 7 (21.2) 533 (17.4) 0.571 72 (23.1) 468 (16.9) 0.007
Previous PCI 5 (15.2) 454 (14.9) 0.962 51 (16.3) 408 (14.7) 0.450
History of heart failure 6 (18.2) 377 (12.3) 0.311 48 (15.4) 335 (12.1) 0.102
Baseline PTL (n/mm3) 194.5 � 56.0 240.2 � 60.4 <0.001 246.4 � 58.4 180.5 � 46 <0.001
Clinical presentation (MI) 12 (36.4) 758 (24.8) 0.127 96 (30.8) 674 (24.3) 0.013
Values are n (%) or mean � SD. *TCP was deﬁned as platelet nadir <100,000/mm3. †TCP was deﬁned as platelet nadir <150,000/mm3 or platelet decrease $50%.
PTL ¼ platelets; TCP ¼ thrombocytopenia; other abbreviations as in Table 1.
FIGURE 3 Effect of Thrombocytopenia on Bleeding
The cumulative incidence of minor or major TIMI (Thrombolysis in Myocardial Infarction) bleeding was signiﬁcantly higher in patients who did compared with those who
did not experience thrombocytopenia, regardless of deﬁnition. *Thrombocytopenia with platelet nadir <90,000/mm3. †Thrombocytopenia with platelet
nadir <100,000/mm3. ‡Thrombocytopenia with platelet nadir <150,000/mm3 or decrease $50%. CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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buffered tiroﬁban was associated with a reduced risk
for death compared with UFH, whereas no difference
in mortality was observed between phosphate-
buffered tiroﬁban and UFH.
TIROFIBAN USE AND FORMULATIONS. American
College of Cardiology and American Heart Association
guidelines suggest the administration of GPIs in high-
risk patients with non–ST-segment elevation ACS
undergoing percutaneous coronary intervention
irrespective of pre-treatment status with P2Y12 in-
hibitors (12,13). European Society of Cardiology
guidelines recommend GPIs for patients with ACS in
bailout situations or with thrombotic complications
(14,15). As a result, these drugs are frequently used in
clinical practice in patients with ACS undergoing
invasive management, and tiroﬁban is currently the
most frequently used GPI worldwide.
Citrate-buffered tiroﬁban is marketed as brand-
name product (Aggrastat, Correvio [UK] Ltd. and
Medicure Pharma [US]). In several European coun-
tries, tiroﬁban is marketed as a generic drug with
formulations different from the citrate-buffered,
including phosphate-buffered tiroﬁban (Hexal,
Hikma, and MEDAC). No generic tiroﬁban products
are currently marketed in the United States. Seven
generic versions are available in India; at least 1 of
these is a citrate-buffered product (Gland Pharma).
No information regarding the excipients is in the
public domain for the remaining 6 products.
THROMBOCYTOPENIA AND OUTCOMES. The associ-
ation between thrombocytopenia and adverse clinical
outcomes in the setting of ACS is well established,
and patients receiving GPIs should be carefully scru-
tinized for changes in platelet count during and
FIGURE 2 Clinical Outcomes at 30 Days in Patients Treated With Tiroﬁban Versus Unfractionated Heparin According to Randomization Phase
The relative risk for death was 50% reduced in patients treated with tiroﬁban versus unfractionated heparin (UFH) in the late but not in the
early phase. CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular event; MI ¼ myocardial infarction; NACE ¼ net
adverse cardiovascular event.
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immediately after drug administration. Patients who
experience signiﬁcant platelet decreases after GPI
administration are at increased risk for bleeding,
recurrent MI, and death (7–10). In the Global Reg-
istry of Acute Coronary Events (GRACE) population,
thrombocytopenia after GPI treatment was associ-
ated with a 4-fold increased risk for in-hospital
mortality and a 2- to 3-fold increased risk for
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Early Implementation of the ACC/AHA Guidelines)
registry, patients who developed thrombocytopenia
had a 3- and 4-fold increased risk for mortality and
bleeding, respectively (10). In the PRISM popula-
tion, thrombocytopenia emerged as an independent
predictor of both bleeding and ischemic clinical
outcomes, with a 5- to 10-fold increased risk
for TIMI bleeding, a 2-fold increased risk for
NACEs, and a trend toward an increased risk for
refractory ischemia at 30-day follow-up. The lack of
an association between thrombocytopenia and
mortality in our cohort of patients may reﬂect a
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Values are n (%) or mean � SD. *TCP was deﬁned as platelet nadir <100,000/mm3. †TCP was deﬁned as platelet nadir <150,000/mm3 or platelet decrease $50%.
PTL ¼ platelets; TCP ¼ thrombocytopenia; other abbreviations as in Table 1.
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The cumulative incidence of minor or major TIMI (Thrombolysis in Myocardial Infarction) bleeding was signiﬁcantly higher in patients who did compared with those who
did not experience thrombocytopenia, regardless of deﬁnition. *Thrombocytopenia with platelet nadir <90,000/mm3. †Thrombocytopenia with platelet
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cause immune thrombocytopenia (17); these include
commonly used drugs such as antibiotics, anticon-
vulsants, and arginine-glycine-aspartic acid (RGD)
mimetic agents such as tiroﬁban and eptiﬁbatide.
Immune thrombocytopenia can occur on ﬁrst expo-
sure to an RGD mimetic agent, and the platelet count
usually drops abruptly within hours of commence-
ment of drug administration (18), suggesting the
presence of a naturally occurring antiplatelet anti-
body. Binding of ﬁbrinogen, RGD peptides, or RGD
mimetic drugs to the RGD recognition site of aIIbb3
induces conformational changes and the emergence
of cryptic epitopes previously “unseen” by the im-
mune system (18). In the majority of patients with
eptiﬁbatide- and tiroﬁban-induced thrombocyto-
penia, antibody binding was found to be drug speciﬁc
(19,20).
Extrapolating these ﬁndings to our analysis, it may
be speculated that conformational changes in aIIbb3
induced by phosphate-buffered tiroﬁban are more
frequently recognized by naturally occurring anti-
platelet antibodies compared with citrate-buffered
tiroﬁban, thereby being more frequently associated
with thrombocytopenia.
Our ﬁndings conﬁrm previous observations that
thrombocytopenia appears to be more a drug- than a
class-speciﬁc side effect (21–23). The current obser-
vation that 2 distinct tiroﬁban formulations, which
exert comparable antiplatelet effects, are associated
with a remarkable difference in terms of drug safety,
notably thrombocytopenia, reinforces the notion that
the chemical structure of a given drug more than its
anticipated target effect is associated with the risk for
thrombocytopenia.
GENERIC DRUGS AND SIDE EFFECTS. Our current
observation should also raise a word of caution with
respect to current regulations for generic drug
approval. The main principle underpinning the safe
and effective use of generic drugs is the concept of
bioequivalence (24).
The purpose of establishing bioequivalence is to
demonstrate equivalence between a generic medicine
and the original medicine in order to allow extrapo-
lation of the pre-clinical and clinical testing per-
formed with the original drug.
Although the active pharmaceutical ingredient
does not differ between original and generic medi-
cines, other (supposedly inactive) ingredients, known
as excipients, may differ, and a number of pharma-
ceutical excipients are known to cause adverse effects
or result in contraindications (25). As excipients may
differ between originator medicines and generic
preparations, which have been shown to be bio-
equivalent and therefore substitutable, there needs to
be an awareness in the medical and health care
community of differences in excipients and thus, the
potential for generic formulations to induce safety
issues. This may be particularly relevant when treat-
ing life-threatening disease such as ACS. Evidence
has been published that differences in excipients
between originator medications and their generic
counterparts can cause problems (26,27); our present
ﬁndings expand on previous observations (28).
STUDY LIMITATIONS. First, the analysis was not pre-
speciﬁed, and the small number of events, in partic-
ular with regard to thrombocytopenia, may have
affected the results. However, sensitivity analyses
TABLE 3 Clinical Outcomes in Patients With or Without Thrombocytopenia According to Different Deﬁnitions (Platelet Nadir
<100,000/mm3 and Platelet Decrease <150,000/mm3 or $50%)
TCP*
(n ¼ 33)
Non-TCP
(n ¼ 3,056)
Adjusted HR†
(95% CI) p Value
TCP‡
(n ¼ 312)
Non-TCP
(n ¼ 2,777)
Adjusted HR§
(95% CI) p Value
Death 1 (3.0) 89 (2.9) 1.10 (0.15–8.08) 0.924 13 (4.2) 77 (2.8) 1.34 (0.70–2.53) 0.376
MI 3 (9.0) 128 (4.2) 2.48 (0.77–8.00) 0.128 16 (5.1) 115 (4.1) 1.18 (0.67–2.07) 0.570
Refractory ischemia 5 (15.2) 326 (10.7) 1.55 (0.63–3.78) 0.341 45 (14.4) 286 (10.3) 1.40 (1.00–1.97) 0.052
Readmission for UA 2 (0.6) 119 (3.9) 1.87 (0.45–7.76) 0.387 10 (3.2) 111 (4.0) 0.72 (0.36–1.45) 0.363
Death or MI 4 (12.1) 195 (6.4) 2.01 (0.73–5.51) 0.176 25 (8.0) 174 (6.3) 1.13 (0.72–1.77) 0.605
MACEs 9 (27.3) 504 (16.5) 1.71 (0.87–3.34) 0.118 60 (19.2) 453 (16.3) 1.11 (0.83–1.48) 0.493
Minor or major bleeding 5 (15.2) 61 (2) 9.84 (3.80–25.5) <0.001 19 (6.1) 47 (1.7) 4.96 (2.71–9.09) <0.001
Major bleeding 1 (3.0) 12 (0.4) 11.2 (1.42–87.5) 0.022 4 (1.3) 9 (0.3) 6.40 (1.81–22.6) 0.004
NACEs 12 (36.4) 542 (17.7) 2.36 (1.31–4.23) 0.004 71 (22.8) 483 (17.4) 1.27 (0.97–1.67) 0.087
*TCP was deﬁned as platelet nadir <100,000/mm3. †Variables used for the adjustment were diabetes mellitus and baseline platelet value. ‡TCP was deﬁned as platelet
nadir <150,000/mm3 or platelet decrease $50%. §Variables used for the adjustment were age, male sex, smoking, diabetes mellitus, hypercholesterolemia, prior coronary
artery bypass graft surgery, non–ST-segment elevation MI, and baseline platelet value.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major cardiovascular adverse event; NACE ¼ net cardiovascular adverse events; UA ¼ unstable angina; other
abbreviations as in Tables 1 and 2.
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performed using different deﬁnitions of thrombocy-
topenia and comparing patients treated with tiroﬁban
versus UFH during the early versus late recruitment
phases and patients receiving the 2 tiroﬁban formu-
lations throughout the 2 different periods provided
consistent results.
Second, in the PRISM trial, tiroﬁban was used as
upstream treatment, which is discouraged in cur-
rent guidelines, and was administered at a bolus
dose of 0.6 mg/kg/min for 30 min followed by 0.15
mg/kg/min infusion for 48 h. This treatment mo-
dality differs from the approved high-dose bolus
regimen of 25 mg/kg over 3 min, followed by 0.15
mg/kg/min infusion up to 48 h, which is currently
used in clinical practice. However, the difference in
the total dose of tiroﬁban administered according to
the PRISM regimen versus the one currently in use
is negligible. In a patient weighing 70 kg with
normal renal function undergoing 48-h post-bolus
infusion, the total drug exposure is 31.5 mg in
48.5 h for the PRISM scheme and 32 mg in 48.05 h
for current use.
Third, the bleeding events were classiﬁed using the
TIMI criteria because at the time of study recruit-
ment, the Bleeding Academic Research Consortium
classiﬁcation was not available.
CONCLUSIONS
Phosphate-buffered tiroﬁban, currently marketed as a
generic drug in several countries, is associated with a
higher risk for thrombocytopenia and potentially
increased risk for adverse clinical outcomes
compared with a citrate-buffered tiroﬁban formula-
tion. Careful post-marketing surveillance of both the
brand-name and generic formulations of tiroﬁban is
warranted.
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PERSPECTIVES
WHAT IS KNOWN? Citrate-buffered tiroﬁban is currently
marketed as a brand-name drug, whereas a phosphate-buffered
product has recently been promoted as a generic drug in several
European countries. In the PRISM trial, the 2 tiroﬁban formula-
tions were used in the late and early phases of the study,
respectively.
WHAT IS NEW? Phosphate-buffered tiroﬁban is associated
with a higher rate of thrombocytopenia with potentially
increased risk for adverse outcomes compared with citrate-
buffered formulation.
WHAT IS NEXT? Post-marketing surveillance of the different
tiroﬁban formulations is needed to ascertain whether brand-
name tiroﬁban has a better safety proﬁle compared with the
generic products.
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cause immune thrombocytopenia (17); these include
commonly used drugs such as antibiotics, anticon-
vulsants, and arginine-glycine-aspartic acid (RGD)
mimetic agents such as tiroﬁban and eptiﬁbatide.
Immune thrombocytopenia can occur on ﬁrst expo-
sure to an RGD mimetic agent, and the platelet count
usually drops abruptly within hours of commence-
ment of drug administration (18), suggesting the
presence of a naturally occurring antiplatelet anti-
body. Binding of ﬁbrinogen, RGD peptides, or RGD
mimetic drugs to the RGD recognition site of aIIbb3
induces conformational changes and the emergence
of cryptic epitopes previously “unseen” by the im-
mune system (18). In the majority of patients with
eptiﬁbatide- and tiroﬁban-induced thrombocyto-
penia, antibody binding was found to be drug speciﬁc
(19,20).
Extrapolating these ﬁndings to our analysis, it may
be speculated that conformational changes in aIIbb3
induced by phosphate-buffered tiroﬁban are more
frequently recognized by naturally occurring anti-
platelet antibodies compared with citrate-buffered
tiroﬁban, thereby being more frequently associated
with thrombocytopenia.
Our ﬁndings conﬁrm previous observations that
thrombocytopenia appears to be more a drug- than a
class-speciﬁc side effect (21–23). The current obser-
vation that 2 distinct tiroﬁban formulations, which
exert comparable antiplatelet effects, are associated
with a remarkable difference in terms of drug safety,
notably thrombocytopenia, reinforces the notion that
the chemical structure of a given drug more than its
anticipated target effect is associated with the risk for
thrombocytopenia.
GENERIC DRUGS AND SIDE EFFECTS. Our current
observation should also raise a word of caution with
respect to current regulations for generic drug
approval. The main principle underpinning the safe
and effective use of generic drugs is the concept of
bioequivalence (24).
The purpose of establishing bioequivalence is to
demonstrate equivalence between a generic medicine
and the original medicine in order to allow extrapo-
lation of the pre-clinical and clinical testing per-
formed with the original drug.
Although the active pharmaceutical ingredient
does not differ between original and generic medi-
cines, other (supposedly inactive) ingredients, known
as excipients, may differ, and a number of pharma-
ceutical excipients are known to cause adverse effects
or result in contraindications (25). As excipients may
differ between originator medicines and generic
preparations, which have been shown to be bio-
equivalent and therefore substitutable, there needs to
be an awareness in the medical and health care
community of differences in excipients and thus, the
potential for generic formulations to induce safety
issues. This may be particularly relevant when treat-
ing life-threatening disease such as ACS. Evidence
has been published that differences in excipients
between originator medications and their generic
counterparts can cause problems (26,27); our present
ﬁndings expand on previous observations (28).
STUDY LIMITATIONS. First, the analysis was not pre-
speciﬁed, and the small number of events, in partic-
ular with regard to thrombocytopenia, may have
affected the results. However, sensitivity analyses
TABLE 3 Clinical Outcomes in Patients With or Without Thrombocytopenia According to Different Deﬁnitions (Platelet Nadir
<100,000/mm3 and Platelet Decrease <150,000/mm3 or $50%)
TCP*
(n ¼ 33)
Non-TCP
(n ¼ 3,056)
Adjusted HR†
(95% CI) p Value
TCP‡
(n ¼ 312)
Non-TCP
(n ¼ 2,777)
Adjusted HR§
(95% CI) p Value
Death 1 (3.0) 89 (2.9) 1.10 (0.15–8.08) 0.924 13 (4.2) 77 (2.8) 1.34 (0.70–2.53) 0.376
MI 3 (9.0) 128 (4.2) 2.48 (0.77–8.00) 0.128 16 (5.1) 115 (4.1) 1.18 (0.67–2.07) 0.570
Refractory ischemia 5 (15.2) 326 (10.7) 1.55 (0.63–3.78) 0.341 45 (14.4) 286 (10.3) 1.40 (1.00–1.97) 0.052
Readmission for UA 2 (0.6) 119 (3.9) 1.87 (0.45–7.76) 0.387 10 (3.2) 111 (4.0) 0.72 (0.36–1.45) 0.363
Death or MI 4 (12.1) 195 (6.4) 2.01 (0.73–5.51) 0.176 25 (8.0) 174 (6.3) 1.13 (0.72–1.77) 0.605
MACEs 9 (27.3) 504 (16.5) 1.71 (0.87–3.34) 0.118 60 (19.2) 453 (16.3) 1.11 (0.83–1.48) 0.493
Minor or major bleeding 5 (15.2) 61 (2) 9.84 (3.80–25.5) <0.001 19 (6.1) 47 (1.7) 4.96 (2.71–9.09) <0.001
Major bleeding 1 (3.0) 12 (0.4) 11.2 (1.42–87.5) 0.022 4 (1.3) 9 (0.3) 6.40 (1.81–22.6) 0.004
NACEs 12 (36.4) 542 (17.7) 2.36 (1.31–4.23) 0.004 71 (22.8) 483 (17.4) 1.27 (0.97–1.67) 0.087
*TCP was deﬁned as platelet nadir <100,000/mm3. †Variables used for the adjustment were diabetes mellitus and baseline platelet value. ‡TCP was deﬁned as platelet
nadir <150,000/mm3 or platelet decrease $50%. §Variables used for the adjustment were age, male sex, smoking, diabetes mellitus, hypercholesterolemia, prior coronary
artery bypass graft surgery, non–ST-segment elevation MI, and baseline platelet value.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major cardiovascular adverse event; NACE ¼ net cardiovascular adverse events; UA ¼ unstable angina; other
abbreviations as in Tables 1 and 2.
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performed using different deﬁnitions of thrombocy-
topenia and comparing patients treated with tiroﬁban
versus UFH during the early versus late recruitment
phases and patients receiving the 2 tiroﬁban formu-
lations throughout the 2 different periods provided
consistent results.
Second, in the PRISM trial, tiroﬁban was used as
upstream treatment, which is discouraged in cur-
rent guidelines, and was administered at a bolus
dose of 0.6 mg/kg/min for 30 min followed by 0.15
mg/kg/min infusion for 48 h. This treatment mo-
dality differs from the approved high-dose bolus
regimen of 25 mg/kg over 3 min, followed by 0.15
mg/kg/min infusion up to 48 h, which is currently
used in clinical practice. However, the difference in
the total dose of tiroﬁban administered according to
the PRISM regimen versus the one currently in use
is negligible. In a patient weighing 70 kg with
normal renal function undergoing 48-h post-bolus
infusion, the total drug exposure is 31.5 mg in
48.5 h for the PRISM scheme and 32 mg in 48.05 h
for current use.
Third, the bleeding events were classiﬁed using the
TIMI criteria because at the time of study recruit-
ment, the Bleeding Academic Research Consortium
classiﬁcation was not available.
CONCLUSIONS
Phosphate-buffered tiroﬁban, currently marketed as a
generic drug in several countries, is associated with a
higher risk for thrombocytopenia and potentially
increased risk for adverse clinical outcomes
compared with a citrate-buffered tiroﬁban formula-
tion. Careful post-marketing surveillance of both the
brand-name and generic formulations of tiroﬁban is
warranted.
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Marco Valgimigli, Bern University Hospital, Depart-
ment of Cardiology, CH-3010 Bern, Switzerland.
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WHAT IS KNOWN? Citrate-buffered tiroﬁban is currently
marketed as a brand-name drug, whereas a phosphate-buffered
product has recently been promoted as a generic drug in several
European countries. In the PRISM trial, the 2 tiroﬁban formula-
tions were used in the late and early phases of the study,
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WHAT IS NEW? Phosphate-buffered tiroﬁban is associated
with a higher rate of thrombocytopenia with potentially
increased risk for adverse outcomes compared with citrate-
buffered formulation.
WHAT IS NEXT? Post-marketing surveillance of the different
tiroﬁban formulations is needed to ascertain whether brand-
name tiroﬁban has a better safety proﬁle compared with the
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 CURRENTOPINION Coronary stent selection and optimal course of
dual antiplatelet therapy in patients at high
bleeding or thrombotic risk: navigating between
limited evidence and clinical concerns
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Purpose of review
Optimal duration of dual antiplatelet therapy (DAPT) after coronary revascularization, in particular after
drug-eluting stent (DES) implantation, is a matter of ongoing debate.
Recent findings
First generation of DES, as compared with bare metal stents (BMS), reduce restenosis rates but increase
very late stent thrombosis rates, thus requiring a prolonged course of DAPT. As a consequence, patients
with high thrombotic and/or bleeding risk: have been systematically excluded from randomized trials
comparing DES versus BMS; remain ‘uncertain’ DES candidates; should preferentially undergo BMS
implantation at the time of percutaneous coronary intervention instead of DES. The Zotarolimus-eluting
Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) trial is the first randomized study that
demonstrated the superiority of the Zotarolimus-eluting Endeavor Sprint versus BMS in uncertain DES
candidates who followed a personalized DAPT duration, which was tailored to patients’s, not stent’s,
characteristics.
Summary
The results of the ZEUS trial may support a paradigm shift in our current understanding of the most proper
use of DES in practice and should trigger further research in patients at high bleeding or thrombotic risk,
who have been so far largely deprived of the potential benefit provided by DES.
Keywords
drug-eluting stents, dual antiplatelet therapy, high bleeding risk, high thrombotic risk, Zotarolimus-eluting stent
INTRODUCTION
Cardiovascular disease is the main cause of death in
industrialized countries and coronary artery disease
(CAD) is the most common cause of cardiovascular
events, and is associated with high morbidity and
mortality due to myocardial infarction (MI), heart
failure, and ventricular arrhythmias [1]. The majority
of patients admitted to the hospital with diagnosis of
CAD, whether silent ischemia, stable angina (SCAD),
unstable angina, non ST-segment elevation myo-
cardial infarction (NSTEMI) or ST-segment elevation
myocardial infarction (STEMI), undergo percutane-
ous revascularization with stent implantation.
STENT THROMBOSIS AND DUAL
ANTIPLATELET THERAPY: FROM
INCEPTION TO MAINSTREAM
The threat of acute or subacute (i.e., within the
first 30 days) stent thrombosis has accompanied
percutaneous coronary intervention since the early
days of stent intervention [2]. The initial attempts to
mitigate that risk with aspirin, a single antiplatelet
therapy, in conjunction with parenteral and oral
anticoagulant medications, paved the way for the
dual antiplatelet therapy (DAPT) regimen consisting
of a P2Y12 inhibitor, at that time, ticlopidine, and
aspirin, an irreversible cyclooxygenase-1 (COX-1)
inhibitor [3,4]. This dual-pathway antiplatelet
therapy was shown to be more effective and well
tolerated than aspirin in combination with other
previously explored antithrombotic medications,
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including vitamin K antagonists [3,4]. As the
majority of stent thrombosis cases were noted to
occur within the first weeks after stent implantation,
an arbitrary 30-day [3,4] to 6 weeks [5] duration of
DAPT has been investigated in studies, and as a
consequence a 30-day duration of therapy has
become the standard of care approach after bare
metal stent (BMS) implantation.
Yet, proper stent expansion was also acknowl-
edged in these early days as a key factor to minimize
the risk of stent reocclusion [6], and optimal stent
expansion in some DAPT studies even as a prereq-
uisite for patients’ eligibility [3,4]. Since then, the
multifactorial nature of stent thrombosis has been
well characterized across literature [7].
The advent of first-generation drug-eluting
stents (DES) has triggered renewed interest in reas-
sessing optimal DAPT duration after stent place-
ment. In the absence of complete supportive
evidence, DES per se have been initially regarded
as more thrombogenic devices. This was due to their
intrinsic capability to minimize late loss and as such
potentially compromise stent coverage. Inflam-
mation was also noted in experimental animal
models. In the pivotal studies designed for stent
approval, DAPT was recommended for 2 [8] or 3
[9] months after sirolimus-eluting stent implan-
tation or 6 months [10] after paclitaxel-eluting stent
studies. No safety issues were noted early on, up to at
least 1 year, as compared with the uncoated stents
[8–10].
Following the observation that first-generation
DES were associated with higher mortality as com-
pared with traditional BMS [11], the community
reacted by endorsing a long-term, or even an indef-
inite, DAPT regimen after DES implantation, and
also continued the development of novel materials,
designs, and delivery systems, with biocompatible
polymers, and new antiproliferative agents com-
pared with their predecessors.
The mechanistic interpretation behind the
postulated higher mortality hazard after first-gener-
ation DES was centered on the perceived higher risk
of stent thrombosis associated with these devices
[11]. An extraordinary amount of scientific scrutiny
has been devoted to the safety profile of first-
generation DES, which has populated general
medicine and more specialized journals since their
introduction into themarket. Although results from
registries have been inconsistent (perhaps not sur-
prisingly, given the relatively low incidence of stent
thrombosis and the presence of residual unmeas-
ured confounders), there has not been a single
randomized controlled study or meta-analysis of
randomized studies showing that the risk of early,
including either acute or subacute, as well as late
(from 30 days to 1 year) stent thrombosis is higher
after first-generation DES as compared with BMS
[12]. Meta-analysis has actually provided evidence
that the risk of stent thrombosis within the first year
may be lower after first-generation DES as compared
with BMS [13].
On the contrary, first-generation DES were con-
sistently shown later on to be associated with four-
fold to five-fold higher risk of very late (i.e., after the
first year) stent thrombosis as compared with BMS
[12,13]. This observation corroborated the percep-
tion of increased thrombogenicity of DES as com-
pared with BMS and fueled ‘the longer the better
notion’ for DAPT duration in DES-treated patients
[14]. Although underpowered for stent thrombosis,
at least two controlled studies, randomizing patients
to different DES platforms and DAPT duration regi-
mens, conveyed signals in support of the need for
prolonged DAPT after first-generation devices
[15,16]. These findings have now been established
by the results of the DAPT trial [17
&&
], which clearly
showed ischemic benefit in terms of stent throm-
bosis and MI reduction in patients receiving first-
generation DES.
The high bleeding risk and high thrombotic risk
population represents a sizable proportion of CAD
patients undergoing coronary stent implantation.
Managing these patients in terms of stent type
selection (i.e., BMS or DES) and decision on the
KEY POINTS
 Drug-eluting stents (DES) per se are regarded as more
thrombogenic devices and as such they should not be
implanted in patients who cannot tolerate or undergo a
prolonged course of dual antiplatelet therapy (DAPT).
 Patients at high bleeding or thrombotic risk, including
advanced age, requiring anticoagulation therapy,
recent or previous bleeding requiring medical attention,
presenting allergy/intolerance to aspirin or any
available P2Y12-inhibitor, planned surgery within
12 months of percutaneous coronary intervention, or
cancer have been so far excluded from trials, and
international guidelines still today recommend bare
metal stents (BMS) preferentially over DES.
 The recent Zotarolimus-eluting Endeavor Sprint Stent in
Uncertain DES Candidates (ZEUS) trial provided new
evidence that patients at high bleeding or thrombotic
risk may have improved outcomes after Zotarolimus-
eluting Endeavor Sprint implantation followed by a
personalized short DAPT duration as compared
with BMS.
 Further research in the field is awaited to confirm and
extend current findings to other new generation,
potentially more efficacious DES platforms.
Clinical trials
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most appropriate course of DAPT after stent implan-
tation remains a clinical challenge. The uncertainty
largely reflects the fact that these patients have been
systematically excluded from major randomized
controlled trials testing and contrasting various
stent types. Accordingly, it is still today generally
recommended that these patients should be treated
with traditional BMS implantation. The aim of this
review is to discuss current evidence on the relation-
ship among stent type, individual clinical features,
and optimal DAPT duration, with particular regard
to patients who have been traditionally regarded
as uncertain DES candidates, that is, those at high
bleeding and/or thrombotic risk.
OPTIMAL DAPT DURATION AFTER DRUG-
ELUTING STENT IMPLANTATION: ARE ALL
PATIENTS ALIKE?
In spite of the current recommendations, the
optimal duration of DAPT after coronary stenting
in general and DES in particular remains unclear
[18]. The recent DAPT trial [17
&&
], which compared
30-month versus 12-month duration of DAPT
after first-generation or second-generation DES in
patients with stable or unstable CAD, confirmed
a significant decrease of definite very late stent
thrombosis and major adverse cardiovascular and
cerebrovascular events at 30 months after stent
implantation in the long-term DAPT arm (12 and
18 months) but with a borderline and significant
increase in overall mortality at 30 and 33 months,
respectively. The reasons why a significant and clear
reduction in stent thrombosis and MI failed to cor-
respondingly lower cardiovascular mortality remain
unclear. A distinct increase of bleeding events,
which have been systematically associated with
prolonged DAPT regimen in this as well as almost
all previous studies, may potentially at least partially
explain this unexpected finding. Among the
patients enrolled, a total of 954 patients had a
history of cancer prior to enrollment, 45 patients
developed a cancer prior to randomization and 182
patients developed a cancer after randomization.
The number of cancer-related deaths was signifi-
cantly higher in the prolonged DAPT arm
(31 patients) as compared with the placebo arm
(14 patients; P¼0.02) and bleeding-mediated
deaths occurred in three patients of the first group.
Among the main exclusion criteria were hypersen-
sitivity or allergy to aspirin or P2Y12-inhibitors,
planned surgerywith discontinuation of DAPTmore
than 14 days, switch among thienopyridines in the
first 12 months, indication for long-term anticoa-
gulant therapy, and absence of bleeding or throm-
botic events in the first 12 months of DAPT
administration. Hence, patients at high bleeding
or thrombotic risk were excluded from theDAPT trial.
HIGH THROMBOTIC RISK POPULATION
Allergy/intolerance to aspirin or any available
P2Y12-inhibitor, planned surgery within 12months
of percutaneous coronary intervention (PCI),
cancer and thrombotic diathesis (coagulopathy or
immunological disorders) confer high thrombotic
risk to patients undergoing coronary stent insertion.
In patients with acetyl salicylic acid (ASA) hyper-
sensitivity, the current guidelines [19] recommend
the execution of a rapid desensitization attempt,
ideally to take place before PCI, or long-term
therapy with clopidogrel as an alternative. The
new P2Y12 inhibitors, prasugrel and ticagrelor,
may be preferred as single antiplatelet therapy
for a limited duration (1–6 months) after PCI, as
they provide more reliable and predictable platelet
inhibition. In patients with planned cardiac or
noncardiac surgery under DAPT, current recom-
mendations [19] are to proceed to surgery in case
of emergency, to consider the discontinuation of
one or none of the two antiplatelet agents on the
basis of bleeding and thrombotic risk, in semielec-
tive and urgent surgery, and to wait until com-
pletion of the mandatory dual antiplatelet regime
when the surgery is elective, without discontinu-
ation of aspirin if possible. In patients with cancer
there are no definite recommendations for optimal
DAPT duration. In the DAPT trial, an increase of
fatalities in patients with cancer in the 30-month
DAPT arm was observed, and this contributed to a
significant increase in noncardiovascular death, par-
tially due to bleeding events. Obviously, this sub-
group of patients presents a group with a worse
prognosis per se but a prolonged DAPT might
increase the bleeding risk as a consequence of
immunological and coagulation disorders related
to the underlying disease. The choice of optimal
type and duration of antiplatelet therapy remains
a challenge in these subsets of patients.
HIGH BLEEDING RISK POPULATION
The criteria that confer higher bleeding risk are:
advanced age; clinical indication for anticoagula-
tion therapy; recent or previous bleeding requiring
hospitalization or medical attention; systemic
conditions associated with increased bleeding risk
(i.e., coagulopathy or thrombocytopenia <100000/
mm3); known anemia (hemoglobin repetitively
<10g/dl); and need for chronic treatment with
steroids or nonsteroidal anti-inflammatory drugs.
Among these conditions, patients with clinical
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indication for oral anticoagulants (OAC) have been
investigated in multiple retrospective and few pro-
spective studies. Long-term OAC is currently recom-
mended (class I) in patients with atrial fibrillation
and at least one risk factor for stroke [20], in those
with mechanical heart valves [21] and in those with
deep venous thrombosis and/or pulmonary embo-
lism [22]. A significant proportion of these patients
have concomitant CAD and need antiplatelet
therapy. It is well known that the risk of bleeding
increases when aspirin, clopidogrel or both are
added to OAC [23
&
]. The recent use of clopidogrel
with or without aspirin in patients taking oral anti-
coagulant therapy and undergoing percutaneous
coronary intervention (WOEST) trial [24
&&
] was
the first randomized clinical trial to study the
possibility of reducing the risk of bleeding in
patients receiving OAC and undergoing PCI. A total
of 573 patients receiving OAC (�70% due to atrial
fibrillation) were randomly assigned to clopidogrel
alone (experimental treatment) or clopidogrel and
aspirin (control treatment) for a period of 1 month
after BMS and 12 months after DES implantation.
The primary endpoint, Thrombolysis In Myocardial
Infarction (TIMI) bleeding, was significantly lower
in the dual therapy group (even if there was no
difference in terms of major bleeding), without an
increase in MI, target vessel revascularization (TVR),
stroke, or stent thrombosis. Even all-cause mortality
was significantly reduced in the dual therapy arm,
but this observation requires caution due to the
modest sample size. Patients with history of intra-
cranial bleeding, peptic ulcer in the previous 6
months, TIMI major bleeding in the previous year,
thrombocytopenia (<50000/mm3), and age greater
than 80 years were excluded. At present, current
guidelines [20] and the 2014 consensus document
[25
&&
] recommend 4 weeks of triple therapy in
patients with atrial fibrillation, stable or unstable
CAD, and high bleeding risk (HAS-BLED bleeding
risk score �3; Class IIa, level of evidence C), except
patients with low thrombotic risk (SCAD and
CHA2DS2-VASC¼1 in men), in whom dual therapy
withOAC and clopidogrel may be considered on the
basis of the WOEST trial results. As of the publica-
tion of the 2014 consensus document new studies
are available. The Intracoronary Stenting and
Antithrombotic Regimen-Testing of a six-week ver-
sus a six-month clopidogrel treatment Regimen In
Patients with concomitant aspirin and oraL anti-
coagulant therapy following drug-Eluting stenting
(ISAR-TRIPLE) trial [26
&
] is the largest randomized
trial investigating triple therapy after stenting and
the first trial that compared different durations of
triple therapy after DES positioning in patients with
clinical indication for OAC (�85% due to atrial
fibrillation). A total of 614 patients were randomly
assigned to 6-week clopidogrel therapy (n¼307) or
6-month clopidogrel therapy (n¼307). The null
hypothesis was that 6-week was superior to 6-month
triple therapy in this patient population. The
primary end-point, a composite of death, MI, stent
thrombosis, stroke, or TIMI major bleeding, did not
significantly differ between groups. Among differ-
ent components, there was a significant increase of
MI in the 6-week group (n¼6) as compared with the
6-month group (n¼0) but five events occurred in
the first 6 weeks, when both groups were in triple
therapy, and one event occurred at 7 months, when
clopidogrel was stopped in both groups. This trial
demonstrated that shortening the duration of triple
therapy neither reduced the incidence of major
bleeding nor increased the incidence of ischemic
events (Sarafoff et al. presented at: Transcatheter
Cardiovascular therapeutics; 15 September 2014;
Washington, DC, USA). Major exclusion criteria
were previous stent thrombosis and DES in the left
main coronary artery.
THE ZOTAROLIMUS-ELUTING ENDEAVOR
SPRINT STENT IN UNCERTAIN DES
CANDIDATES TRIAL
Randomized controlled trials, which have so far
compared DES versus BMS, have recommended
either a longer DAPT regimen in the DES arm or a
similarly prolonged course of DAPT in BMS patients
so to match the extended course of therapy after
DES. Hence, no study has so far disentangled the
effects of DES versus BMS from those offered by
long-term DAPT.
The Zotarolimus-eluting Endeavor Sprint Stent
in Uncertain DES Candidates (ZEUS) was a multina-
tional, randomized, single-blinded trial [27,28
&&
],
conducted at 20 sites in four European countries
designed to evaluate whether Zotarolimus-eluting
Endeavor Sprint (E-ZES) implantation followed by a
shorter than currently recommended course of
DAPT, that is, based on the clinical profile of the
patient (tailored DAPT), would decrease the inci-
dence of 12-month major adverse cardiovascular
events as compared with BMS in uncertain DES
candidates. Eligible patients were those at high
bleeding risk and/or high thrombotic risk and/or
low restenosis risk (Table 1) admitted to the hospital
because of SCAD or acute coronary syndrome (ACS).
It was the first trial that prospectively studied these
subpopulations of patients. A total of 1606 patients
undergoing elective, urgent, or emergent PCI were
randomly assigned to E-ZES or a thin-strut BMS.
E-ZES is a hydrophilic polymer-based second-gener-
ation device with a unique drug fast-release profile.
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Unlike other DES on the market, including the
Resolute stent, Zotarolimus is eluted 100% from
the stent within 14 days of implantation and no
drug is detectable in the arterial tissue 28 days after
stent implantation; although the rapid release pro-
file results in less powerful inhibition of intimal
hyperplasia, it also leads tomore rapid and complete
stent coverage compared with other DES, raising the
possibility of shorter DAPT duration. Moreover, the
phosphorylcholine coating has been shown to
reduce thrombus formation as compared with
BMS. Patients with high bleeding risk criteria were
51.6%, predominantly elderly (26.5%) and/or need-
ing OAC (19.4%); patients with high thrombotic
risk criteria were 17.7%, predominantly waiting
for planned cardiac or noncardiac surgery (7.3%),
neoplastic (5.2%) or intolerant to aspirin or any
P2Y12-inhibitor (4.6%); patients with low restenosis
Table 1. Inclusion criteria for eligible patients
Elective, urgent, or emergent PCI with intended stent implantation in patients with at least one of the following:
High bleeding risk High thrombotic risk Low restenosis risk
Need for OAC Intolerance to aspirin Planned stent at least 3.0mm, apart from
LMCA and SVG intervention or for ISR lesions
Previous or recent bleeding requiring
hospitalization or medical attention
Intolerance to any available
P2Y12-inhibitor
Age more than 80 years Planned surgery (other than skin) within
12 months after PCI
Bleeding diathesis (including coagulopathy and
thrombocytopenia less than 100000/mm3)
Malignancy with life expectancy more
than 1 year
Known anemia (Hb repeatedly less than 10g/dl) Thrombotic diathesis (coagulopathy and
immunological disorders)
Need for chronic treatment with steroids or NSAID
Hb, hemoglobin; ISR, in-stent restenosis; LMCA, left main coronary artery; NSAID, nonsteroidal anti-inflammatory drug; OAC, oral anticoagulant; PCI,
percutaneous coronary intervention; SVG, saphenous vein graft.
High bleeding risk High thrombotic risk Low restenosis risk
Stable CAD: DAPT duration for 30 days
Unstable CAD: DAPT duration up to 6 months
Intolerance to ASA: indefinite monotherapy with P2Y12-inhibitor
Intolerance to P2Y12-inhibitor: indefinite monotherapy with ASA
Planned surgery: DAPT duration up to surgical intervention
Cancer: DAPT duration up to 6 months
Thrombotic diathesis: DAPT duration up to 6 months
30-day DAPT
51.6% 17.7%
1606 patients
58.6%
E-ZES BMS
802 patients 804 patients
FIGURE 1. Tailored dual antiplatelet therapy in the Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates
(ZEUS) trial. figure shows the prespecified duration of dual antiplatelet therapy in relation to different inclusion criteria and the
percentage of patients included in each main category. Each patient could have one or more inclusion criteria in one or more
of the main categories. DES, drug-eluting stents.
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indication for oral anticoagulants (OAC) have been
investigated in multiple retrospective and few pro-
spective studies. Long-term OAC is currently recom-
mended (class I) in patients with atrial fibrillation
and at least one risk factor for stroke [20], in those
with mechanical heart valves [21] and in those with
deep venous thrombosis and/or pulmonary embo-
lism [22]. A significant proportion of these patients
have concomitant CAD and need antiplatelet
therapy. It is well known that the risk of bleeding
increases when aspirin, clopidogrel or both are
added to OAC [23
&
]. The recent use of clopidogrel
with or without aspirin in patients taking oral anti-
coagulant therapy and undergoing percutaneous
coronary intervention (WOEST) trial [24
&&
] was
the first randomized clinical trial to study the
possibility of reducing the risk of bleeding in
patients receiving OAC and undergoing PCI. A total
of 573 patients receiving OAC (�70% due to atrial
fibrillation) were randomly assigned to clopidogrel
alone (experimental treatment) or clopidogrel and
aspirin (control treatment) for a period of 1 month
after BMS and 12 months after DES implantation.
The primary endpoint, Thrombolysis In Myocardial
Infarction (TIMI) bleeding, was significantly lower
in the dual therapy group (even if there was no
difference in terms of major bleeding), without an
increase in MI, target vessel revascularization (TVR),
stroke, or stent thrombosis. Even all-cause mortality
was significantly reduced in the dual therapy arm,
but this observation requires caution due to the
modest sample size. Patients with history of intra-
cranial bleeding, peptic ulcer in the previous 6
months, TIMI major bleeding in the previous year,
thrombocytopenia (<50000/mm3), and age greater
than 80 years were excluded. At present, current
guidelines [20] and the 2014 consensus document
[25
&&
] recommend 4 weeks of triple therapy in
patients with atrial fibrillation, stable or unstable
CAD, and high bleeding risk (HAS-BLED bleeding
risk score �3; Class IIa, level of evidence C), except
patients with low thrombotic risk (SCAD and
CHA2DS2-VASC¼1 in men), in whom dual therapy
withOAC and clopidogrel may be considered on the
basis of the WOEST trial results. As of the publica-
tion of the 2014 consensus document new studies
are available. The Intracoronary Stenting and
Antithrombotic Regimen-Testing of a six-week ver-
sus a six-month clopidogrel treatment Regimen In
Patients with concomitant aspirin and oraL anti-
coagulant therapy following drug-Eluting stenting
(ISAR-TRIPLE) trial [26
&
] is the largest randomized
trial investigating triple therapy after stenting and
the first trial that compared different durations of
triple therapy after DES positioning in patients with
clinical indication for OAC (�85% due to atrial
fibrillation). A total of 614 patients were randomly
assigned to 6-week clopidogrel therapy (n¼307) or
6-month clopidogrel therapy (n¼307). The null
hypothesis was that 6-week was superior to 6-month
triple therapy in this patient population. The
primary end-point, a composite of death, MI, stent
thrombosis, stroke, or TIMI major bleeding, did not
significantly differ between groups. Among differ-
ent components, there was a significant increase of
MI in the 6-week group (n¼6) as compared with the
6-month group (n¼0) but five events occurred in
the first 6 weeks, when both groups were in triple
therapy, and one event occurred at 7 months, when
clopidogrel was stopped in both groups. This trial
demonstrated that shortening the duration of triple
therapy neither reduced the incidence of major
bleeding nor increased the incidence of ischemic
events (Sarafoff et al. presented at: Transcatheter
Cardiovascular therapeutics; 15 September 2014;
Washington, DC, USA). Major exclusion criteria
were previous stent thrombosis and DES in the left
main coronary artery.
THE ZOTAROLIMUS-ELUTING ENDEAVOR
SPRINT STENT IN UNCERTAIN DES
CANDIDATES TRIAL
Randomized controlled trials, which have so far
compared DES versus BMS, have recommended
either a longer DAPT regimen in the DES arm or a
similarly prolonged course of DAPT in BMS patients
so to match the extended course of therapy after
DES. Hence, no study has so far disentangled the
effects of DES versus BMS from those offered by
long-term DAPT.
The Zotarolimus-eluting Endeavor Sprint Stent
in Uncertain DES Candidates (ZEUS) was a multina-
tional, randomized, single-blinded trial [27,28
&&
],
conducted at 20 sites in four European countries
designed to evaluate whether Zotarolimus-eluting
Endeavor Sprint (E-ZES) implantation followed by a
shorter than currently recommended course of
DAPT, that is, based on the clinical profile of the
patient (tailored DAPT), would decrease the inci-
dence of 12-month major adverse cardiovascular
events as compared with BMS in uncertain DES
candidates. Eligible patients were those at high
bleeding risk and/or high thrombotic risk and/or
low restenosis risk (Table 1) admitted to the hospital
because of SCAD or acute coronary syndrome (ACS).
It was the first trial that prospectively studied these
subpopulations of patients. A total of 1606 patients
undergoing elective, urgent, or emergent PCI were
randomly assigned to E-ZES or a thin-strut BMS.
E-ZES is a hydrophilic polymer-based second-gener-
ation device with a unique drug fast-release profile.
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Unlike other DES on the market, including the
Resolute stent, Zotarolimus is eluted 100% from
the stent within 14 days of implantation and no
drug is detectable in the arterial tissue 28 days after
stent implantation; although the rapid release pro-
file results in less powerful inhibition of intimal
hyperplasia, it also leads tomore rapid and complete
stent coverage compared with other DES, raising the
possibility of shorter DAPT duration. Moreover, the
phosphorylcholine coating has been shown to
reduce thrombus formation as compared with
BMS. Patients with high bleeding risk criteria were
51.6%, predominantly elderly (26.5%) and/or need-
ing OAC (19.4%); patients with high thrombotic
risk criteria were 17.7%, predominantly waiting
for planned cardiac or noncardiac surgery (7.3%),
neoplastic (5.2%) or intolerant to aspirin or any
P2Y12-inhibitor (4.6%); patients with low restenosis
Table 1. Inclusion criteria for eligible patients
Elective, urgent, or emergent PCI with intended stent implantation in patients with at least one of the following:
High bleeding risk High thrombotic risk Low restenosis risk
Need for OAC Intolerance to aspirin Planned stent at least 3.0mm, apart from
LMCA and SVG intervention or for ISR lesions
Previous or recent bleeding requiring
hospitalization or medical attention
Intolerance to any available
P2Y12-inhibitor
Age more than 80 years Planned surgery (other than skin) within
12 months after PCI
Bleeding diathesis (including coagulopathy and
thrombocytopenia less than 100000/mm3)
Malignancy with life expectancy more
than 1 year
Known anemia (Hb repeatedly less than 10g/dl) Thrombotic diathesis (coagulopathy and
immunological disorders)
Need for chronic treatment with steroids or NSAID
Hb, hemoglobin; ISR, in-stent restenosis; LMCA, left main coronary artery; NSAID, nonsteroidal anti-inflammatory drug; OAC, oral anticoagulant; PCI,
percutaneous coronary intervention; SVG, saphenous vein graft.
High bleeding risk High thrombotic risk Low restenosis risk
Stable CAD: DAPT duration for 30 days
Unstable CAD: DAPT duration up to 6 months
Intolerance to ASA: indefinite monotherapy with P2Y12-inhibitor
Intolerance to P2Y12-inhibitor: indefinite monotherapy with ASA
Planned surgery: DAPT duration up to surgical intervention
Cancer: DAPT duration up to 6 months
Thrombotic diathesis: DAPT duration up to 6 months
30-day DAPT
51.6% 17.7%
1606 patients
58.6%
E-ZES BMS
802 patients 804 patients
FIGURE 1. Tailored dual antiplatelet therapy in the Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates
(ZEUS) trial. figure shows the prespecified duration of dual antiplatelet therapy in relation to different inclusion criteria and the
percentage of patients included in each main category. Each patient could have one or more inclusion criteria in one or more
of the main categories. DES, drug-eluting stents.
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risk criteria were 21% with stable CAD and 37.6%
with unstable CAD. Finally, 318 patients (19.8%)
had inclusion criteria included in two or three differ-
ent categories; in particular, 94 patients (5.9%) were
at the same time at high bleeding and thrombotic
risk, and each patient could have two or more
inclusion criteria in each category. DAPT duration
was prespecified considering the patient’s inclusion
criteria instead of the stent type (Fig. 1) and was
administered in 1532 patients, whereas 74 patients
(4.6%) received a monotherapy due to intolerance
to aspirin or P2Y12-inhibitor. The primary endpoint
was a composite of all-cause death, nonfatal MI,
or any TVR. Secondary endpoints included each
component of the primary endpoint, cardiac death,
Academic Research Consortium defined stent
thrombosis, all-cause or ischemic stroke, target
lesion revascularization, and bleeding. With a
median DAPT duration of about 32 days in both
groups, the primary endpoint at 12 months was
significantly lower in the E-ZES arm as compared
with the BMS arm due to a significant reduction in
MI and TVR (Fig. 2). Although all-cause and cardi-
ovascular mortality did not differ between groups,
the composite of any death or nonfatal MI as well
as of cardiovascular death or nonfatal MI was sig-
nificantly reduced in the E-ZES population. With a
declining trend in definite stent thrombosis, the
composite of definite or probable stent thrombosis
was significantly lower after E-ZES implantation
(Fig. 3), whereas TIMI or Bleeding Academic
Research Consortium (BARC) [29] classification
bleeding did not differ between groups. No signal
for by-treatment interaction was shown for the
primary endpoint based on age, sex, presence of
diabetes mellitus, indication for the procedure, pre-
defined duration of DAPT, and location or complex-
ity of treated lesion(s). In conclusion, the ZEUS
study demonstrated that in patients with high
bleeding and/or high thrombotic and/or low reste-
nosis risk E-ZES implantation followed by a tailored
DAPT, including no (monotherapy in patients intol-
erant to aspirin or any available P2Y12) or a 30-day
(high bleeding risk population) DAPT course of
therapy, reduced the rate of major adverse cardio-
vascular events as compared with BMS. Given the
unique properties of E-ZES, these results should not
be extrapolated to other newer-generation DES
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FIGURE 2. Primary endpoint in the Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) trial.
(a) The significant difference in the composite primary endpoint between the BMS and E-ZES groups. Panels (b) to (d) show
the incidence of each component of the primary endpoint between the two different arms and the corresponding P value:
(b) myocardial infarction; (c) target vessel revascularization; (d) all-cause death the BMS, bare metal stent; DES, drug-eluting
stent; E-ZES, Zotarolimus-eluting Endeavor Sprint.
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coated with the same or other antiproliferative
agents and diverse polymers. As the E-ZES has been
associatedwith a lower efficacy in preventing TVR as
compared with other more potent first-generation
or second-generation DES [30], it remains unclear
whether other DES may offer similar advantages,
especially in patients at high-bleeding or throm-
botic risk.
Further research is needed to ascertain whether
the tailored DAPT regimen tested in our study can be
safely implemented in patients receiving other DES.
The ongoing BioFreedom drug-coated stent vs the
Gazelle bare metal stent in patients at high bleeding
risk using a short (1 month) course of dual antipla-
telet therapy (LEADERS-FREE) trial [31], which com-
pares the BioFreedom drug-coated stent with the
Gazelle BMS (i.e., the corresponding BMS platform)
in high bleeding risk patients under 1-month DAPT,
is awaited to further extend available treatment
options for this challenging patient subset.
CONCLUSION
Although several studies provided some reassurance
that a short course of DAPT might be well tolerated
in certain patients treated with a particular type
of DES, the optimal duration of DAPT remains
uncertain, particularly in patients with high risk
of bleeding or thrombotic events. Importantly, in
the DAPT trial, the majority of screened patients
(15761 out of 25682) at the time of intervention
were not subsequently randomized to stop or con-
tinue DAPT beyond 1 year, including 616 patients
who were subsequently excluded due to the occur-
rence of moderate-to-severe Global Utilization
Of Streptokinase And Tpa For Occluded Arteries
(GUSTO) bleeding within the first 12 months. The
ZEUS trial provides for the very first time data show-
ing that a BMS-like DAPT regimen (30 days or even
shorter) in the E-ZES group did not pose safety
concerns while achieving superior clinical efficacy
in patients with high bleeding risk, extending and
confirming the results of the ISAR-TRIPLE trial, and
suggesting that long-term DAPT should be reserved
for patients without significant risk of bleeding
events, as observed in the DAPT trial. Moreover,
in patients with planned surgery and in neoplastic
patients, a course of DAPT up to surgery or up to
6 months, respectively, was shown to be well tol-
erated and apparently more effective than BMS in
patients assigned to E-ZES implantation. Although
the current guidelines recommend the use of BMS,
wherein a long course of DAPT is contraindicated
[19,32], this study suggests that E-ZES may become
the device of choice also in patients who cannot
tolerate a prolonged DAPT regimen or in those with
indication for indefinite monotherapy. This study
had paradigm-shift potential, as it suggested that,
contrary to original belief, the optimal duration of
DAPT after stent implantation should be guided by a
careful assessment of the balance between the ische-
mic and bleeding risks independently of the type of
stent used (BMS or DES). Further randomized trials
are needed to confirm or refute these findings for
other types of DES.
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risk criteria were 21% with stable CAD and 37.6%
with unstable CAD. Finally, 318 patients (19.8%)
had inclusion criteria included in two or three differ-
ent categories; in particular, 94 patients (5.9%) were
at the same time at high bleeding and thrombotic
risk, and each patient could have two or more
inclusion criteria in each category. DAPT duration
was prespecified considering the patient’s inclusion
criteria instead of the stent type (Fig. 1) and was
administered in 1532 patients, whereas 74 patients
(4.6%) received a monotherapy due to intolerance
to aspirin or P2Y12-inhibitor. The primary endpoint
was a composite of all-cause death, nonfatal MI,
or any TVR. Secondary endpoints included each
component of the primary endpoint, cardiac death,
Academic Research Consortium defined stent
thrombosis, all-cause or ischemic stroke, target
lesion revascularization, and bleeding. With a
median DAPT duration of about 32 days in both
groups, the primary endpoint at 12 months was
significantly lower in the E-ZES arm as compared
with the BMS arm due to a significant reduction in
MI and TVR (Fig. 2). Although all-cause and cardi-
ovascular mortality did not differ between groups,
the composite of any death or nonfatal MI as well
as of cardiovascular death or nonfatal MI was sig-
nificantly reduced in the E-ZES population. With a
declining trend in definite stent thrombosis, the
composite of definite or probable stent thrombosis
was significantly lower after E-ZES implantation
(Fig. 3), whereas TIMI or Bleeding Academic
Research Consortium (BARC) [29] classification
bleeding did not differ between groups. No signal
for by-treatment interaction was shown for the
primary endpoint based on age, sex, presence of
diabetes mellitus, indication for the procedure, pre-
defined duration of DAPT, and location or complex-
ity of treated lesion(s). In conclusion, the ZEUS
study demonstrated that in patients with high
bleeding and/or high thrombotic and/or low reste-
nosis risk E-ZES implantation followed by a tailored
DAPT, including no (monotherapy in patients intol-
erant to aspirin or any available P2Y12) or a 30-day
(high bleeding risk population) DAPT course of
therapy, reduced the rate of major adverse cardio-
vascular events as compared with BMS. Given the
unique properties of E-ZES, these results should not
be extrapolated to other newer-generation DES
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coated with the same or other antiproliferative
agents and diverse polymers. As the E-ZES has been
associatedwith a lower efficacy in preventing TVR as
compared with other more potent first-generation
or second-generation DES [30], it remains unclear
whether other DES may offer similar advantages,
especially in patients at high-bleeding or throm-
botic risk.
Further research is needed to ascertain whether
the tailored DAPT regimen tested in our study can be
safely implemented in patients receiving other DES.
The ongoing BioFreedom drug-coated stent vs the
Gazelle bare metal stent in patients at high bleeding
risk using a short (1 month) course of dual antipla-
telet therapy (LEADERS-FREE) trial [31], which com-
pares the BioFreedom drug-coated stent with the
Gazelle BMS (i.e., the corresponding BMS platform)
in high bleeding risk patients under 1-month DAPT,
is awaited to further extend available treatment
options for this challenging patient subset.
CONCLUSION
Although several studies provided some reassurance
that a short course of DAPT might be well tolerated
in certain patients treated with a particular type
of DES, the optimal duration of DAPT remains
uncertain, particularly in patients with high risk
of bleeding or thrombotic events. Importantly, in
the DAPT trial, the majority of screened patients
(15761 out of 25682) at the time of intervention
were not subsequently randomized to stop or con-
tinue DAPT beyond 1 year, including 616 patients
who were subsequently excluded due to the occur-
rence of moderate-to-severe Global Utilization
Of Streptokinase And Tpa For Occluded Arteries
(GUSTO) bleeding within the first 12 months. The
ZEUS trial provides for the very first time data show-
ing that a BMS-like DAPT regimen (30 days or even
shorter) in the E-ZES group did not pose safety
concerns while achieving superior clinical efficacy
in patients with high bleeding risk, extending and
confirming the results of the ISAR-TRIPLE trial, and
suggesting that long-term DAPT should be reserved
for patients without significant risk of bleeding
events, as observed in the DAPT trial. Moreover,
in patients with planned surgery and in neoplastic
patients, a course of DAPT up to surgery or up to
6 months, respectively, was shown to be well tol-
erated and apparently more effective than BMS in
patients assigned to E-ZES implantation. Although
the current guidelines recommend the use of BMS,
wherein a long course of DAPT is contraindicated
[19,32], this study suggests that E-ZES may become
the device of choice also in patients who cannot
tolerate a prolonged DAPT regimen or in those with
indication for indefinite monotherapy. This study
had paradigm-shift potential, as it suggested that,
contrary to original belief, the optimal duration of
DAPT after stent implantation should be guided by a
careful assessment of the balance between the ische-
mic and bleeding risks independently of the type of
stent used (BMS or DES). Further randomized trials
are needed to confirm or refute these findings for
other types of DES.
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ABSTRACT
OBJECTIVES This study sought to investigate the ischemic and bleeding outcomes of patients fulﬁlling high bleeding
risk (HBR) criteria who were randomized to zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent
(BMS) implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration for stable or unstable
coronary artery disease.
BACKGROUND DES instead of BMS use remains controversial in HBR patients, in whom long-term DAPT poses safety
concerns.
METHODS The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) is a multinational, ran-
domized single-blinded trial that randomized among others, in a stratiﬁed manner, 828 patients fulﬁlling pre-deﬁned
clinical or biochemical HBR criteria—including advanced age, indication to oral anticoagulants or other pro-hemorrhagic
medications, history of bleeding and known anemia—to receive E-ZES or BMS followed by a protocol-mandated 30-day
DAPT regimen. The primary endpoint of the study was the 12-month major adverse cardiovascular event rate, consisting
of death, myocardial infarction, or target vessel revascularization.
RESULTS Compared with patients without, those with 1 or more HBR criteria had worse outcomes, owing to higher
ischemic and bleeding risks. Among HBR patients, major adverse cardiovascular events occurred in 22.6% of the E-ZES
and 29% of the BMS patients (hazard ratio: 0.75; 95% conﬁdence interval: 0.57 to 0.98; p ¼ 0.033), driven by lower
myocardial infarction (3.5% vs. 10.4%; p < 0.001) and target vessel revascularization (5.9% vs. 11.4%; p ¼ 0.005) rates
in the E-ZES arm. The composite of deﬁnite or probable stent thrombosis was signiﬁcantly reduced in E-ZES recipients,
whereas bleeding events did not differ between stent groups.
CONCLUSIONS Among HBR patients with stable or unstable coronary artery disease, E-ZES implantation provides
superior efﬁcacy and safety as compared with conventional BMS. (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain
DES Candidates [ZEUS]; NCT01385319) (J Am Coll Cardiol Intv 2016;9:426–36) © 2016 by the American College of
Cardiology Foundation.
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ABSTRACT
OBJECTIVES This study sought to investigate the ischemic and bleeding outcomes of patients fulﬁlling high bleeding
risk (HBR) criteria who were randomized to zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent
(BMS) implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration for stable or unstable
coronary artery disease.
BACKGROUND DES instead of BMS use remains controversial in HBR patients, in whom long-term DAPT poses safety
concerns.
METHODS The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) is a multinational, ran-
domized single-blinded trial that randomized among others, in a stratiﬁed manner, 828 patients fulﬁlling pre-deﬁned
clinical or biochemical HBR criteria—including advanced age, indication to oral anticoagulants or other pro-hemorrhagic
medications, history of bleeding and known anemia—to receive E-ZES or BMS followed by a protocol-mandated 30-day
DAPT regimen. The primary endpoint of the study was the 12-month major adverse cardiovascular event rate, consisting
of death, myocardial infarction, or target vessel revascularization.
RESULTS Compared with patients without, those with 1 or more HBR criteria had worse outcomes, owing to higher
ischemic and bleeding risks. Among HBR patients, major adverse cardiovascular events occurred in 22.6% of the E-ZES
and 29% of the BMS patients (hazard ratio: 0.75; 95% conﬁdence interval: 0.57 to 0.98; p ¼ 0.033), driven by lower
myocardial infarction (3.5% vs. 10.4%; p < 0.001) and target vessel revascularization (5.9% vs. 11.4%; p ¼ 0.005) rates
in the E-ZES arm. The composite of deﬁnite or probable stent thrombosis was signiﬁcantly reduced in E-ZES recipients,
whereas bleeding events did not differ between stent groups.
CONCLUSIONS Among HBR patients with stable or unstable coronary artery disease, E-ZES implantation provides
superior efﬁcacy and safety as compared with conventional BMS. (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain
DES Candidates [ZEUS]; NCT01385319) (J Am Coll Cardiol Intv 2016;9:426–36) © 2016 by the American College of
Cardiology Foundation.
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D rug-eluting stents (DES) reduce the reste-nosis rates as compared to bare-metalstents (BMS) (1–3). However, an excessive
inhibition of neointimal formation with incomplete
endothelialization, observed in the ﬁrst-generation
devices, has been associated with an increased risk
of very-late stent thrombosis (ST) after dual anti-
platelet therapy (DAPT) discontinuation (4,5).
Second-generation DES have been developed to over-
come safety concerns and maintain the efﬁcacy
similar to ﬁrst-generation DES. Yet, a minimum
course of 3- or 12-month DAPT duration is currently
mandated after implantation of newer-generation
DES according to current European or American
guidelines, respectively (6,7). As a consequence, the
use of DES instead of BMS remains controversial in
high bleeding risk (HBR) patients, in whom long-
term DAPT poses safety concerns.
The zotarolimus-eluting Endeavor Sprint stent
(E-ZES) is a hydrophilic polymer-based second-
generation device with a unique drug fast-release
proﬁle (8), resulting in less powerful inhibition of
intimal hyperplasia, but also in a rapid and/or com-
plete stent strut coverage. This characteristic raises
the possibility that it might be feasible to shorten
DAPT duration while maintaining superior efﬁcacy
compared with BMS (9). The ZEUS (Zotarolimus-
Eluting Endeavor Sprint Stent in Uncertain DES Can-
didates) study, which mandated a tailored DAPT
duration based on patients’ characteristics, showed a
lower incidence of major adverse cardiovascular
events (MACE) after E-ZES as compared with BMS in
uncertain DES recipients. More than 50% of the pa-
tients fulﬁlled at least 1 HBR criterion in this study,
and they were to be treated with a 30-day course of
DAPT only.
We sought to investigate: 1) the ischemic and
bleeding outcomes in relation to the presence or
absence of at least 1 HBR criterion within the
study population; and 2) assess the efﬁcacy
and safety of E-ZES or BMS implantation in
HBR patients.
METHODS
STUDY POPULATION. The design and main
study ﬁndings, including consistency of
study results across inclusion criteria, of the
ZEUS trial were previously reported (10,11).
Brieﬂy, it was a multinational, randomized
single-blinded trial including patients with
at least 1 qualifying criterion among the
pre-speciﬁed uncertain DES recipients un-
dergoing elective, urgent, or emergent
percutaneous coronary intervention with
intended stent implantation. They were
randomly allocated 1:1 to receive E-ZES or a
thin-strut (thickness <100 mm) BMS followed
by a DAPT regimen independent of stent
type, but clinical-proﬁle–driven. Randomiza-
tion was stratiﬁed based upon the presence or absence
of HBR status. Patients were deemed at HBR provided
they fulﬁl at least 1 of the pre-speciﬁed criteria,
including: age older than 80 years; clinical indication
for treatment with oral anticoagulant agents; recent
bleeding episode(s) that required medical attention or
hospitalization if the bleeding diathesis has not been
completely resolved; systemic conditions associated
with increased bleeding risk (e.g., hematological
disorders or any known coagulopathy determining
bleeding-diathesis, including prior or current throm-
bocytopenia, which was deﬁned as platelet count
<100,000/mm3); known anemia, deﬁned as repeatedly
documented hemoglobin <10 g/dl; and need for
long-term treatment with steroids or nonsteroidal
anti-inﬂammatory drugs.
The study was conducted in accordance with the
principles of the Declaration of Helsinki. The ethics
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committees of all participating centers independently
approved the protocol, and all participants gave
written informed consent.
DEVICES AND THERAPY. The Endeavor stent (Med-
tronic Vascular, Minneapolis, Minnesota) is consti-
tuted by a cobalt-based alloy platform (91-mm strut
thickness) and a phosphorylcholine-polymer (4.8-mm)
loaded with zotarolimus at the dose concentration of
10-mg/mm stent length. The drug is eluted within
15 days of implantation, and concentration within
surrounding vascular tissue is not detected already at
30 days after stent deployment (8,9).
All commercially available thin-strut BMS were
allowed by the protocol. All patients received aspirin
and clopidogrel (300 to 600 mg orally as loading dose
followed by 75 mg/day), or prasugrel (60 mg as
loading dose followed by 10 or 5 mg/day) or ticagrelor
(180 mg as loading dose followed by 90 mg twice a
day). All HBR patients were treated with DAPT for a
pre-speciﬁed 30-day period after stent implantation.
In case of a staged procedure, DAPT had to be pro-
longed or restarted for 30 additional days. Patients
who were not eligible for DAPT were treated
with aspirin or P2Y12 inhibitor monotherapy. Unfrac-
tionated heparin or bivalirudin was used during
percutaneous coronary procedure according to
guideline-recommended regimens.
STUDY ENDPOINTS AND FOLLOW-UP. The primary
endpoint of the ZEUS trial was MACE at 12 months,
deﬁned as a composite of all-cause death, nonfatal
MI, and any target vessel revascularization (TVR).
Secondary efﬁcacy endpoints were the composite
of death and MI; the composite of cardiovascular
death and MI; each component of the primary
endpoint; target lesion revascularization, ischemic
stroke; deﬁnite, probable, possible ST and the com-
posite of deﬁnite and probable ST. Secondary safety
endpoints comprised bleeding events according to
both Bleeding Academic Research Consortium (BARC)
and Thrombolysis In Myocardial Infarction (TIMI)
classiﬁcations. All study endpoint deﬁnitions were
previously reported (11).
Thirty-day and 6- and 12-month follow-up visits
were performed according to study protocol in order
to assess potential adverse events and compliance
with medications and to record a 12-lead
electrocardiogram.
All endpoints were conﬁrmed on the basis of the
documentation collected at each site and were cen-
trally adjudicated by the clinical events committee,
whose members were unaware of treatment
assignment.
STATISTICAL ANALYSIS. In this pre-speciﬁed anal-
ysis of the ZEUS trial, categorical variables were
FIGURE 1 HBR Criteria in the Study Population
The number of patients fulﬁlling each high bleeding risk (HBR) criterion is shown in decreasing order. There was a considerable overlap among
HBR criteria, with 643 patients (78%) fulﬁlling 1, 330 (40%) 2, and 65 (8%) $3 HBR qualifying features. NSAID ¼ nonsteroidal anti-
inﬂammatory drugs.
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committees of all participating centers independently
approved the protocol, and all participants gave
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tuted by a cobalt-based alloy platform (91-mm strut
thickness) and a phosphorylcholine-polymer (4.8-mm)
loaded with zotarolimus at the dose concentration of
10-mg/mm stent length. The drug is eluted within
15 days of implantation, and concentration within
surrounding vascular tissue is not detected already at
30 days after stent deployment (8,9).
All commercially available thin-strut BMS were
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STUDY ENDPOINTS AND FOLLOW-UP. The primary
endpoint of the ZEUS trial was MACE at 12 months,
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posite of deﬁnite and probable ST. Secondary safety
endpoints comprised bleeding events according to
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classiﬁcations. All study endpoint deﬁnitions were
previously reported (11).
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were performed according to study protocol in order
to assess potential adverse events and compliance
with medications and to record a 12-lead
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All endpoints were conﬁrmed on the basis of the
documentation collected at each site and were cen-
trally adjudicated by the clinical events committee,
whose members were unaware of treatment
assignment.
STATISTICAL ANALYSIS. In this pre-speciﬁed anal-
ysis of the ZEUS trial, categorical variables were
FIGURE 1 HBR Criteria in the Study Population
The number of patients fulﬁlling each high bleeding risk (HBR) criterion is shown in decreasing order. There was a considerable overlap among
HBR criteria, with 643 patients (78%) fulﬁlling 1, 330 (40%) 2, and 65 (8%) $3 HBR qualifying features. NSAID ¼ nonsteroidal anti-
inﬂammatory drugs.
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expressed as frequency and percentage, and compared
using the Fisher exact test, whereas continuous vari-
ables were expressed as median and interquartile
range, and compared with theWilcoxon rank sum test.
Estimation of the cumulative incidence of events
was performed by the Kaplan-Meier method, and
hazard ratios (HRs) with 95% conﬁdence intervals
(CIs) and p values were calculated using the stratiﬁed
Cox regression model. The proportionality assump-
tions were checked by visual estimation after plotting
the log cumulative hazard versus (log) time at follow-
up after index procedure and by applying a test for
nonproportional hazards using the Schoenfeld re-
siduals, which failed to reject the null hypothesis that
event rate was affected by time (p ¼ 0.48). Sensitivity
analyses were performed testing the consistency of
study results in patients with only 1 or at least 2 HBR
criteria, as well as investigating the effect of allocated
stent type on outcomes according to each HBR crite-
rion when separately appraised.
A 2-sided p value <0.05 was considered signiﬁcant.
All analyses were performed on the basis of the
intention-to-treat principle using SPSS version 21.0
(SPSS, Chicago, Illinois).
RESULTS
STUDY POPULATION. From June 2011 to September
2012, a total of 5,288 patients were screened and
1,606 were ﬁnally randomized. A total of 828 patients
fulﬁlled 1 or more HBR criteria, of whom 425 (51.3%)
age >80 years, 311 (37.6%) had clinical indication
to oral anticoagulant (Online Table 1), 113 (13.6%)
reported previous or recent bleeding requiring hos-
pitalization or medical attention, 95 (11.5%) presented
bleeding diathesis, 68 (8.2%) had known anemia, and
25 (3.0%) were in need of long-term treatment with
steroids or nonsteroidal anti-inﬂammatory drugs.
There was a considerable overlap among HBR criteria,
with 643 patients (78%) fulﬁlling 1, 330 (40%) 2. and
65 (8%) $3 HBR qualifying features (Figure 1).
Baseline patient characteristics stratiﬁed according
to the presence or absence of HBR status are shown in
Online Tables 2 and 3.
Among HBR patients, of whom 424 (51.2%) were
randomized to receive E-ZES, and 404 (48.8%) to
BMS, baseline clinical and angiographic features were
well-matched between stent groups (Tables 1 and 2).
The median age was 80 years; diabetes was observed
in roughly one-third of the population, hypertension
in more than 80%, impaired kidney function in
approximately 60% of the patients, and 65% of pa-
tients had acute coronary syndrome at presentation
(Table 1). One third of the patients underwent multi-
vessel intervention, and at least 1 complex lesion was
treated in approximately three-fourths of the patients
(Table 2).
DUAL ANTIPLATELET THERAPY. The duration of
DAPT—which largely consisted of aspirin and clopi-
dogrel—was almost 5-fold shorter in patients with HBR
criteria (median [interquartile range]: 30 [20 to 30]
days) as compared with those without HBR criteria
(median [interquartile range]: 174 [30 to 190] days;
p < 0.0001).
TABLE 1 Baseline Characteristics of Patients at HBR
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424) p Value
Age, yrs
Median 80.5 80.4 0.83
Interquartile range 72.3–84.4 72.8–84.9
Female 145 (35.9) 150 (35.4) 0.89
Body mass index, kg/m2
Median 26 26 0.96
Interquartile range 24–29 24–29
Diabetes 117 (29.0) 137 (32.3) 0.33
Hypertension 336 (83.2) 344 (81.1) 0.47
Hyperlipidemia 193 (47.8) 191 (45.0) 0.44
Current cigarettes use 45 (11.1) 44 (10.4) 0.36
Creatinine clearance, ml/min*
Median 54.3 54.8 0.90
Interquartile range 39.1–69.9 38.7–69.9
Patients with GFR <60 ml/min* 242 (61.3) 241 (59.5) 0.61
Patients with GFR <30 ml/min* 51 (12.9) 52 (12.8) >0.99
Patients on dialysis 6 (1.5) 14 (3.3) 0.11
Prior MI 114 (28.2) 117 (27.6) 0.88
Prior PCI 83 (20.5) 90 (21.2) 0.86
Prior CABG 38 (9.4) 39 (9.2) >0.99
Prior stroke or TIA 34 (8.4) 32 (7.5) 0.70
COPD 43 (10.6) 32 (7.5) 0.15
PAD 94 (23.3) 76 (17.9) 0.06
Left ventricular ejection fraction†
Median 49 48 0.59
Interquartile range 40–55 40–55
Clinical presentation
Stable angina pectoris 140 (34.7) 147 (34.7) >0.99
Acute coronary syndrome
Unstable angina 69 (17.1) 72 (17.0) >0.99
Non–ST-segment elevation MI 133 (32.9) 140 (33.0) >0.99
ST-segment elevation MI 62 (15.3) 65 (15.3) >0.99
Angiographic features
Single-vessel disease 125 (30.9) 138 (32.5) 0.716
Double-vessel disease 144 (35.6) 146 (34.4)
Triple-vessel disease 132 (32.7) 139 (32.8)
Values are n (%), unless indicated otherwise. *Calculated in 395 patients in the BMS arm and in 405 patients in
the E-ZES arm. †Calculated in 380 patients in the BMS arm and in 397 patients in the E-ZES arm.
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular
ﬁltrate rate; HBR ¼ high bleeding risk; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼
percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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Among HBR patients, 14 (3%) patients in each stent
group received treatment with a single antiplatelet
agent after stent implantation; among those who
received DAPT, treatment was stopped within the ﬁrst
15, 30, and 60 days in 5 (1.2%), 151 (37.4%), and 291
(72.0%) patients in the BMS and 10 (2.4%), 245 (57.8%),
and 323 (76.2%) in the E-ZES group, respectively (p <
0.001). Reasons for prolonging DAPT beyond 30 days
included planned or unplanned procedures in de novo
lesions, which were evenly distributed between stent
groups, or need for reintervention in previously
instrumented coronary segments, which explained
the longer DAPT duration in the BMS group.
BLEEDING RISK CRITERIA AND OUTCOMES. Any
actionable BARC bleeding was almost 2-fold higher in
patients with (7.7%) as compared with those without
(3.9%; HR: 2.32; 95% CI: 1.49 to 3.62; p < 0.001) at
least 1 HBR criterion whereas major BARC (4.2% vs.
1.5%; HR: 2.93; 95% CI: 1.51 to 5.70; p ¼ 0.001) and
major or minor TIMI bleeding (2.8% vs. 1.0%; HR:
2.87; 95% CI: 1.28 to 6.41; p ¼ 0.011) were almost
three-fold greater in the former group. There was
evidence of an additive effect on bleeding outcomes
with respect to the presence of only 1 or more than 1
HBR features (Figure 2).
The cumulative risk of death, MI or TVR was
doubled in HBR (25.7% vs. 13.5%; p < 0.001) as
compared with other patients, driven by higher rates
of death (16.5% vs. 5.7%; p < 0.001) or MI (6.9% vs.
4.0%; p ¼ 0.012). Deﬁnite or probable ST was also
increased in HBR patients (4.3% vs. 1.7%; p ¼ 0.002).
When adjustment was implemented for baseline
imbalances, residual bleeding (BARC type 2, 3, or 5
HR: 1.33, 95% CI: 0.75 to 2.36, p ¼ 0.332; BARC type 3
or 5 HR: 2.05, 95% CI: 0.84 to 4.98, p ¼ 0.114; TIMI
major or minor HR: 2.15, 95% CI: 0.73 to 6.29,
p ¼ 0.163) and mortality (adjusted HR: 1.46; 95% CI:
0.95 to 2.25; p ¼ 0.083) risks no longer differed.
STENT TYPES AND OUTCOMES IN HBR PATIENTS.
At 12 months, the primary endpoint occurred in 96
(22.6%) patients in the E-ZES and in 117 (29%) patients
in the BMS group (HR: 0.75; 95% CI: 0.57 to 0.98;
p ¼ 0.033), owing to lower MI (3.5% vs. 10.4%;
HR: 0.33; 95% CI: 0.18 to 0.60; p < 0.001) and TVR
(5.9% vs. 11.4%; HR: 0.50; 95% CI: 0.30 to 0.80; p ¼
0.005) rates in the E-ZES compared with BMS cohort
(Figure 3, Table 3). The composite of death and MI
(18.4% vs. 24.8%; HR: 0.72; 95% CI: 0.53 to 0.96;
p ¼ 0.027) as well as cardiovascular death or MI
(14.6% vs. 20.3%; HR: 0.70; 95% CI: 0.50 to 0.97;
p ¼ 0.032) were lower in the E-ZES group, whereas
mortality did not differ (Table 3). Deﬁnite or probable
ST (2.6% vs. 6.2%; HR: 0.42; 95% CI: 0.21 to 0.85;
p ¼ 0.016) and deﬁnite, probable or possible ST (6.6%
vs. 10.6%; HR: 0.61; 95% CI: 0.38 to 0.98; p ¼ 0.042)
were respectively more than halved or reduced by
almost 40% in E-ZES–treated patients (Table 3).
TABLE 2 Procedural Results and Use of Medications During the Trial in Patients at HBR
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424) p Value
Treated lesions, n
Median 1 1 0.82
Interquartile range 1–2 1–2
$2 Treated lesions* 154 (38.1) 151 (35.7) 0.47
Multivessel intervention 130 (32.2) 141 (33.3) 0.77
LAD treated 196 (48.5) 234 (55.2) 0.06
CFX treated 155 (38.4) 141 (33.3) 0.13
RCA treated 161 (39.9) 162 (38.2) 0.67
LMCA treated 27 (6.7) 26 (6.1) 0.78
SVG treated 6 (1.5) 8 (1.9) 0.79
At least 1 complex (type B2 or C) lesion 310 (76.7) 321 (75.7) 0.75
Total ACC/AHA score†
Median 7 7 0.94
Interquartile range 4–11 4–11
Stents implanted, n
Median 1 1 >0.99
Interquartile range 1–2 1–2
Length of stent, mm
Median 28 30 0.96
Interquartile range 18–46 18–44
Mean stent diameter, mm‡
Median 3 3 0.14
Interquartile range 2.75–3.50 2.75–3.25
Patients receiving $2 stents 182 (45.0) 191 (45.0) >0.99
Patients receiving $3 stents 73 (18.1) 77 (18.2) >0.99
Patients with overlapping stents 103 (25.5) 106 (25.0) 0.87
Quantitative coronary analysis
Lesion length, mm§ 16.88 � 10.44 16.44 � 10.64 0.28
Reference vessel diameter, before, mm§ 2.65 � 0.59 2.67 � 0.61 0.90
Minimal lumen diameter, before, mm§ 0.89 � 0.48 0.88 � 0.51 0.28
Stenosis, before, %§ 66 � 15 68 � 16 0.23
Reference vessel diameter, after, mm‡ 2.86 � 0.50 2.86 � 0.51 0.89
Minimal lumen diameter, after, mm§ 2.65 � 0.52 2.64 � 0.55 0.81
Stenosis, after, %§ 7.4 � 8.6 7.5 � 11.4 0.47
Drug therapy at discharge
Aspirin 377 (93.3) 386 (91.0) 0.25
P2Y12 inhibitor 387 (95.8) 410 (96.7) 0.58
ACE inhibitor 234 (57.9) 240 (56.6) 0.73
Beta-blocker 307 (76.0) 299 (70.5) 0.08
Statin 321 (79.5) 347 (81.8) 0.43
Oral anticoagulation 96 (23.8) 100 (23.6) >0.99
Proton pump inhibitork 290 (71.8) 293 (69.4) 0.49
Drug therapy at 30 days
Aspirin 373 (92.3) 383 (90.3) 0.33
P2Y12 inhibitor 364 (90.1) 389 (91.7) 0.47
ACE inhibitor¶ 213 (52.7) 242 (57.1) 0.40
Beta-blocker¶ 297 (73.5) 297 (70.0) 0.54
Statin¶ 303 (75.0) 336 (79.2) 0.25
Oral anticoagulation 100 (24.8) 97 (22.9) 0.81
Proton pump inhibitor# 267 (69.0) 270 (66.5) 0.49
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expressed as frequency and percentage, and compared
using the Fisher exact test, whereas continuous vari-
ables were expressed as median and interquartile
range, and compared with theWilcoxon rank sum test.
Estimation of the cumulative incidence of events
was performed by the Kaplan-Meier method, and
hazard ratios (HRs) with 95% conﬁdence intervals
(CIs) and p values were calculated using the stratiﬁed
Cox regression model. The proportionality assump-
tions were checked by visual estimation after plotting
the log cumulative hazard versus (log) time at follow-
up after index procedure and by applying a test for
nonproportional hazards using the Schoenfeld re-
siduals, which failed to reject the null hypothesis that
event rate was affected by time (p ¼ 0.48). Sensitivity
analyses were performed testing the consistency of
study results in patients with only 1 or at least 2 HBR
criteria, as well as investigating the effect of allocated
stent type on outcomes according to each HBR crite-
rion when separately appraised.
A 2-sided p value <0.05 was considered signiﬁcant.
All analyses were performed on the basis of the
intention-to-treat principle using SPSS version 21.0
(SPSS, Chicago, Illinois).
RESULTS
STUDY POPULATION. From June 2011 to September
2012, a total of 5,288 patients were screened and
1,606 were ﬁnally randomized. A total of 828 patients
fulﬁlled 1 or more HBR criteria, of whom 425 (51.3%)
age >80 years, 311 (37.6%) had clinical indication
to oral anticoagulant (Online Table 1), 113 (13.6%)
reported previous or recent bleeding requiring hos-
pitalization or medical attention, 95 (11.5%) presented
bleeding diathesis, 68 (8.2%) had known anemia, and
25 (3.0%) were in need of long-term treatment with
steroids or nonsteroidal anti-inﬂammatory drugs.
There was a considerable overlap among HBR criteria,
with 643 patients (78%) fulﬁlling 1, 330 (40%) 2. and
65 (8%) $3 HBR qualifying features (Figure 1).
Baseline patient characteristics stratiﬁed according
to the presence or absence of HBR status are shown in
Online Tables 2 and 3.
Among HBR patients, of whom 424 (51.2%) were
randomized to receive E-ZES, and 404 (48.8%) to
BMS, baseline clinical and angiographic features were
well-matched between stent groups (Tables 1 and 2).
The median age was 80 years; diabetes was observed
in roughly one-third of the population, hypertension
in more than 80%, impaired kidney function in
approximately 60% of the patients, and 65% of pa-
tients had acute coronary syndrome at presentation
(Table 1). One third of the patients underwent multi-
vessel intervention, and at least 1 complex lesion was
treated in approximately three-fourths of the patients
(Table 2).
DUAL ANTIPLATELET THERAPY. The duration of
DAPT—which largely consisted of aspirin and clopi-
dogrel—was almost 5-fold shorter in patients with HBR
criteria (median [interquartile range]: 30 [20 to 30]
days) as compared with those without HBR criteria
(median [interquartile range]: 174 [30 to 190] days;
p < 0.0001).
TABLE 1 Baseline Characteristics of Patients at HBR
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424) p Value
Age, yrs
Median 80.5 80.4 0.83
Interquartile range 72.3–84.4 72.8–84.9
Female 145 (35.9) 150 (35.4) 0.89
Body mass index, kg/m2
Median 26 26 0.96
Interquartile range 24–29 24–29
Diabetes 117 (29.0) 137 (32.3) 0.33
Hypertension 336 (83.2) 344 (81.1) 0.47
Hyperlipidemia 193 (47.8) 191 (45.0) 0.44
Current cigarettes use 45 (11.1) 44 (10.4) 0.36
Creatinine clearance, ml/min*
Median 54.3 54.8 0.90
Interquartile range 39.1–69.9 38.7–69.9
Patients with GFR <60 ml/min* 242 (61.3) 241 (59.5) 0.61
Patients with GFR <30 ml/min* 51 (12.9) 52 (12.8) >0.99
Patients on dialysis 6 (1.5) 14 (3.3) 0.11
Prior MI 114 (28.2) 117 (27.6) 0.88
Prior PCI 83 (20.5) 90 (21.2) 0.86
Prior CABG 38 (9.4) 39 (9.2) >0.99
Prior stroke or TIA 34 (8.4) 32 (7.5) 0.70
COPD 43 (10.6) 32 (7.5) 0.15
PAD 94 (23.3) 76 (17.9) 0.06
Left ventricular ejection fraction†
Median 49 48 0.59
Interquartile range 40–55 40–55
Clinical presentation
Stable angina pectoris 140 (34.7) 147 (34.7) >0.99
Acute coronary syndrome
Unstable angina 69 (17.1) 72 (17.0) >0.99
Non–ST-segment elevation MI 133 (32.9) 140 (33.0) >0.99
ST-segment elevation MI 62 (15.3) 65 (15.3) >0.99
Angiographic features
Single-vessel disease 125 (30.9) 138 (32.5) 0.716
Double-vessel disease 144 (35.6) 146 (34.4)
Triple-vessel disease 132 (32.7) 139 (32.8)
Values are n (%), unless indicated otherwise. *Calculated in 395 patients in the BMS arm and in 405 patients in
the E-ZES arm. †Calculated in 380 patients in the BMS arm and in 397 patients in the E-ZES arm.
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; GFR ¼ glomerular
ﬁltrate rate; HBR ¼ high bleeding risk; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; PCI ¼
percutaneous coronary intervention; TIA ¼ transient ischemic attack.
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Among HBR patients, 14 (3%) patients in each stent
group received treatment with a single antiplatelet
agent after stent implantation; among those who
received DAPT, treatment was stopped within the ﬁrst
15, 30, and 60 days in 5 (1.2%), 151 (37.4%), and 291
(72.0%) patients in the BMS and 10 (2.4%), 245 (57.8%),
and 323 (76.2%) in the E-ZES group, respectively (p <
0.001). Reasons for prolonging DAPT beyond 30 days
included planned or unplanned procedures in de novo
lesions, which were evenly distributed between stent
groups, or need for reintervention in previously
instrumented coronary segments, which explained
the longer DAPT duration in the BMS group.
BLEEDING RISK CRITERIA AND OUTCOMES. Any
actionable BARC bleeding was almost 2-fold higher in
patients with (7.7%) as compared with those without
(3.9%; HR: 2.32; 95% CI: 1.49 to 3.62; p < 0.001) at
least 1 HBR criterion whereas major BARC (4.2% vs.
1.5%; HR: 2.93; 95% CI: 1.51 to 5.70; p ¼ 0.001) and
major or minor TIMI bleeding (2.8% vs. 1.0%; HR:
2.87; 95% CI: 1.28 to 6.41; p ¼ 0.011) were almost
three-fold greater in the former group. There was
evidence of an additive effect on bleeding outcomes
with respect to the presence of only 1 or more than 1
HBR features (Figure 2).
The cumulative risk of death, MI or TVR was
doubled in HBR (25.7% vs. 13.5%; p < 0.001) as
compared with other patients, driven by higher rates
of death (16.5% vs. 5.7%; p < 0.001) or MI (6.9% vs.
4.0%; p ¼ 0.012). Deﬁnite or probable ST was also
increased in HBR patients (4.3% vs. 1.7%; p ¼ 0.002).
When adjustment was implemented for baseline
imbalances, residual bleeding (BARC type 2, 3, or 5
HR: 1.33, 95% CI: 0.75 to 2.36, p ¼ 0.332; BARC type 3
or 5 HR: 2.05, 95% CI: 0.84 to 4.98, p ¼ 0.114; TIMI
major or minor HR: 2.15, 95% CI: 0.73 to 6.29,
p ¼ 0.163) and mortality (adjusted HR: 1.46; 95% CI:
0.95 to 2.25; p ¼ 0.083) risks no longer differed.
STENT TYPES AND OUTCOMES IN HBR PATIENTS.
At 12 months, the primary endpoint occurred in 96
(22.6%) patients in the E-ZES and in 117 (29%) patients
in the BMS group (HR: 0.75; 95% CI: 0.57 to 0.98;
p ¼ 0.033), owing to lower MI (3.5% vs. 10.4%;
HR: 0.33; 95% CI: 0.18 to 0.60; p < 0.001) and TVR
(5.9% vs. 11.4%; HR: 0.50; 95% CI: 0.30 to 0.80; p ¼
0.005) rates in the E-ZES compared with BMS cohort
(Figure 3, Table 3). The composite of death and MI
(18.4% vs. 24.8%; HR: 0.72; 95% CI: 0.53 to 0.96;
p ¼ 0.027) as well as cardiovascular death or MI
(14.6% vs. 20.3%; HR: 0.70; 95% CI: 0.50 to 0.97;
p ¼ 0.032) were lower in the E-ZES group, whereas
mortality did not differ (Table 3). Deﬁnite or probable
ST (2.6% vs. 6.2%; HR: 0.42; 95% CI: 0.21 to 0.85;
p ¼ 0.016) and deﬁnite, probable or possible ST (6.6%
vs. 10.6%; HR: 0.61; 95% CI: 0.38 to 0.98; p ¼ 0.042)
were respectively more than halved or reduced by
almost 40% in E-ZES–treated patients (Table 3).
TABLE 2 Procedural Results and Use of Medications During the Trial in Patients at HBR
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424) p Value
Treated lesions, n
Median 1 1 0.82
Interquartile range 1–2 1–2
$2 Treated lesions* 154 (38.1) 151 (35.7) 0.47
Multivessel intervention 130 (32.2) 141 (33.3) 0.77
LAD treated 196 (48.5) 234 (55.2) 0.06
CFX treated 155 (38.4) 141 (33.3) 0.13
RCA treated 161 (39.9) 162 (38.2) 0.67
LMCA treated 27 (6.7) 26 (6.1) 0.78
SVG treated 6 (1.5) 8 (1.9) 0.79
At least 1 complex (type B2 or C) lesion 310 (76.7) 321 (75.7) 0.75
Total ACC/AHA score†
Median 7 7 0.94
Interquartile range 4–11 4–11
Stents implanted, n
Median 1 1 >0.99
Interquartile range 1–2 1–2
Length of stent, mm
Median 28 30 0.96
Interquartile range 18–46 18–44
Mean stent diameter, mm‡
Median 3 3 0.14
Interquartile range 2.75–3.50 2.75–3.25
Patients receiving $2 stents 182 (45.0) 191 (45.0) >0.99
Patients receiving $3 stents 73 (18.1) 77 (18.2) >0.99
Patients with overlapping stents 103 (25.5) 106 (25.0) 0.87
Quantitative coronary analysis
Lesion length, mm§ 16.88 � 10.44 16.44 � 10.64 0.28
Reference vessel diameter, before, mm§ 2.65 � 0.59 2.67 � 0.61 0.90
Minimal lumen diameter, before, mm§ 0.89 � 0.48 0.88 � 0.51 0.28
Stenosis, before, %§ 66 � 15 68 � 16 0.23
Reference vessel diameter, after, mm‡ 2.86 � 0.50 2.86 � 0.51 0.89
Minimal lumen diameter, after, mm§ 2.65 � 0.52 2.64 � 0.55 0.81
Stenosis, after, %§ 7.4 � 8.6 7.5 � 11.4 0.47
Drug therapy at discharge
Aspirin 377 (93.3) 386 (91.0) 0.25
P2Y12 inhibitor 387 (95.8) 410 (96.7) 0.58
ACE inhibitor 234 (57.9) 240 (56.6) 0.73
Beta-blocker 307 (76.0) 299 (70.5) 0.08
Statin 321 (79.5) 347 (81.8) 0.43
Oral anticoagulation 96 (23.8) 100 (23.6) >0.99
Proton pump inhibitork 290 (71.8) 293 (69.4) 0.49
Drug therapy at 30 days
Aspirin 373 (92.3) 383 (90.3) 0.33
P2Y12 inhibitor 364 (90.1) 389 (91.7) 0.47
ACE inhibitor¶ 213 (52.7) 242 (57.1) 0.40
Beta-blocker¶ 297 (73.5) 297 (70.0) 0.54
Statin¶ 303 (75.0) 336 (79.2) 0.25
Oral anticoagulation 100 (24.8) 97 (22.9) 0.81
Proton pump inhibitor# 267 (69.0) 270 (66.5) 0.49
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Interestingly, the occurrence of ST appeared evenly
distributed in the BMS group when considering the on
versus off-DAPT follow-up duration, whereas only 1
of 11 ST cases in patients allocated to E-ZES occurred
while patients were off DAPT.
A trend towards a lower bleeding risk was noted
in the E-ZES cohort with respect to BARC 2, 3, or 5
events (6.1% vs. 9.4%; HR: 0.65; 95% CI: 0.39 to 1.07;
p¼0.089),whereasmajor BARCor TIMImajor orminor
events did not differ between stent groups (Table 3).
ADDITIONAL ANALYSES. The consistency of out-
comes with respect to the presence of a single or mul-
tiple HBR features is shown in Figure 4. The primary
endpoint outcomes in relation to each HBR criterion
are shown in Online Figure 1. A further sensitivity
analysis focusing on patients with atrial ﬁbrillation
showed consistent ﬁndings (Online Figure 2).
DISCUSSION
Patients at HBR represent a well sizable portion of
coronary artery disease population undergoing
percutaneous coronary stenting. However, these pa-
tients have been largely excluded from major ran-
domized controlled trials evaluating different stent
types. Although multiple bleeding risk scores or sin-
gle individual risk factors for bleeding exist (12–14),
HBR status is rarely deﬁned according to objective
risk criteria (15–17). The lack of standardized algo-
rithms for the identiﬁcation of HBR patients hampers
comparability across studies and limit their external
validity in clinical practice.
As a reﬂection of limited evidence for the use of
DES in this population, 6 of 10 (576 of 946) partici-
pants preferred BMS whereas only 1 out of 20 (44 of
946) responders vouched for the value of newer-
generation DES for HBR patients in a recent Euro-
pean survey (18).
MAIN STUDY FINDINGS. In the ZEUS trial, 828 pa-
tients fulﬁlling at least 1 pre-speciﬁed HBR criterion
were randomized to receive BMS or E-ZES, which is a
hydrophilic polymer-based second-generation device
with a unique drug, fast-release proﬁle. In this
selected high-risk patient population, the study pro-
tocol mandated 30-day DAPT irrespective of the stent
type. The results of our study can be summarized as
follows:
� Patients at HBR, who have been selected according
to pre-speciﬁed objective criteria, displayed higher
TABLE 2 Continued
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424) p Value
Dual antiplatelet therapy duration
Median 31 30 0.009
Interquartile range 30–177 30–53
Range 0–365 0–365
Values are n (%) or mean � SD, unless indicated otherwise. *Calculated in 404 patients in the BMS arm and in
423 in the E-ZES arm. †Calculated in 402 patients in the BMS arm and in the 422 in the E-ZES arm. ‡Calculated in
395 patients in the BMS arm and in the 416 patients in the E-ZES arm. §Calculated in 396 patients in the BMS arm
and in 422 patients in the E-ZES arm. kCalculated in 404 patients in the BMS arm and in 422 in the E-ZES arm.
¶Calculated in 389 patients in the BMS arm and in 407 patients in the E-ZES arm. #Calculated in 387 patients in
the BMS arm and in the 406 patients in the E-ZES arm.
ACC/AHA ¼ American College of Cardiology/American Heart Association; ACE ¼ angiotensin-converting
enzyme; HBR ¼ high bleeding risk; LAD ¼ left anterior descending coronary artery, CFX ¼ circumﬂex coronary
artery, RCA ¼ right coronary artery, LMCA ¼ left main coronary artery, SVG ¼ saphenous vein graft.
FIGURE 2 Bleeding Event Rates According to The Presence and Number of HBR Criteria
There was evidence of an additive effect on bleeding outcomes with respect to the presence of only 1 or more than 1 high bleeding risk (HBR)
features; p value for trend <0.001. Vertical bars represent 95% conﬁdence intervals. BARC ¼ Bleeding Academic Research Consortium; TIMI ¼
Thrombolysis In Myocardial infarction.
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risk of bleeding, consistently across all assessed
bleeding scales, which was proportionally greater
depending on the number of HBR criteria simul-
taneously fulﬁlled as compared with patients
without HBR features.
� Patients at HBR were also at higher MACE risk
as compared with patients who were not at HBR
status, driven by higher death and MI rates. ST was
almost 3-fold greater in patients with as compared
with those without HBR criteria. This observation
reinforces the notion that bleeding predictors
largely overlap with risk factors for ischemic com-
plications and highlights the challenge of identi-
fying a safe and effective anti-thrombotic treatment
in this patient population in clinical practice.
� HBR patients derived beneﬁts in terms of
reductions of MACE, MI, TVR, and ST when treated
with E-ZES as compared with BMS, which is
consistent with study results observed in the over-
all population (11). At sensitivity analyses, results
remained entirely consistent focusing on patients
who displayed 2 or more HBR features, or evalu-
ating each HBR criterion separately. A further
analysis restricted to patients with atrial ﬁbrilla-
tion, which was the most frequent indication to oral
anticoagulation, conﬁrmed overall study ﬁndings.
� Despite comparable protocol-mandated DAPT du-
rations in both stent groups, cumulative treatment
duration with aspirin and P2Y12 inhibitor was
signiﬁcantly longer in BMS as compared with E-ZES
FIGURE 3 Clinical Outcomes in the HBR Population Treated With Zotarolimus-Eluting Stents Versus BMS
Rate of events for primary composite endpoint of death, myocardial infarction (MI), and target vessel revascularization (TVR) (A), MI (B), TVR
(C), or deﬁnite or probable stent thrombosis (D) at 12 months. BMS ¼ bare-metal stent(s); E-ZES ¼ zotarolimus-eluting Endeavor Sprint
stent(s); HBR ¼ high bleeding risk; HR ¼ hazard ratio.
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Interestingly, the occurrence of ST appeared evenly
distributed in the BMS group when considering the on
versus off-DAPT follow-up duration, whereas only 1
of 11 ST cases in patients allocated to E-ZES occurred
while patients were off DAPT.
A trend towards a lower bleeding risk was noted
in the E-ZES cohort with respect to BARC 2, 3, or 5
events (6.1% vs. 9.4%; HR: 0.65; 95% CI: 0.39 to 1.07;
p¼0.089),whereasmajor BARCor TIMImajor orminor
events did not differ between stent groups (Table 3).
ADDITIONAL ANALYSES. The consistency of out-
comes with respect to the presence of a single or mul-
tiple HBR features is shown in Figure 4. The primary
endpoint outcomes in relation to each HBR criterion
are shown in Online Figure 1. A further sensitivity
analysis focusing on patients with atrial ﬁbrillation
showed consistent ﬁndings (Online Figure 2).
DISCUSSION
Patients at HBR represent a well sizable portion of
coronary artery disease population undergoing
percutaneous coronary stenting. However, these pa-
tients have been largely excluded from major ran-
domized controlled trials evaluating different stent
types. Although multiple bleeding risk scores or sin-
gle individual risk factors for bleeding exist (12–14),
HBR status is rarely deﬁned according to objective
risk criteria (15–17). The lack of standardized algo-
rithms for the identiﬁcation of HBR patients hampers
comparability across studies and limit their external
validity in clinical practice.
As a reﬂection of limited evidence for the use of
DES in this population, 6 of 10 (576 of 946) partici-
pants preferred BMS whereas only 1 out of 20 (44 of
946) responders vouched for the value of newer-
generation DES for HBR patients in a recent Euro-
pean survey (18).
MAIN STUDY FINDINGS. In the ZEUS trial, 828 pa-
tients fulﬁlling at least 1 pre-speciﬁed HBR criterion
were randomized to receive BMS or E-ZES, which is a
hydrophilic polymer-based second-generation device
with a unique drug, fast-release proﬁle. In this
selected high-risk patient population, the study pro-
tocol mandated 30-day DAPT irrespective of the stent
type. The results of our study can be summarized as
follows:
� Patients at HBR, who have been selected according
to pre-speciﬁed objective criteria, displayed higher
TABLE 2 Continued
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424) p Value
Dual antiplatelet therapy duration
Median 31 30 0.009
Interquartile range 30–177 30–53
Range 0–365 0–365
Values are n (%) or mean � SD, unless indicated otherwise. *Calculated in 404 patients in the BMS arm and in
423 in the E-ZES arm. †Calculated in 402 patients in the BMS arm and in the 422 in the E-ZES arm. ‡Calculated in
395 patients in the BMS arm and in the 416 patients in the E-ZES arm. §Calculated in 396 patients in the BMS arm
and in 422 patients in the E-ZES arm. kCalculated in 404 patients in the BMS arm and in 422 in the E-ZES arm.
¶Calculated in 389 patients in the BMS arm and in 407 patients in the E-ZES arm. #Calculated in 387 patients in
the BMS arm and in the 406 patients in the E-ZES arm.
ACC/AHA ¼ American College of Cardiology/American Heart Association; ACE ¼ angiotensin-converting
enzyme; HBR ¼ high bleeding risk; LAD ¼ left anterior descending coronary artery, CFX ¼ circumﬂex coronary
artery, RCA ¼ right coronary artery, LMCA ¼ left main coronary artery, SVG ¼ saphenous vein graft.
FIGURE 2 Bleeding Event Rates According to The Presence and Number of HBR Criteria
There was evidence of an additive effect on bleeding outcomes with respect to the presence of only 1 or more than 1 high bleeding risk (HBR)
features; p value for trend <0.001. Vertical bars represent 95% conﬁdence intervals. BARC ¼ Bleeding Academic Research Consortium; TIMI ¼
Thrombolysis In Myocardial infarction.
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risk of bleeding, consistently across all assessed
bleeding scales, which was proportionally greater
depending on the number of HBR criteria simul-
taneously fulﬁlled as compared with patients
without HBR features.
� Patients at HBR were also at higher MACE risk
as compared with patients who were not at HBR
status, driven by higher death and MI rates. ST was
almost 3-fold greater in patients with as compared
with those without HBR criteria. This observation
reinforces the notion that bleeding predictors
largely overlap with risk factors for ischemic com-
plications and highlights the challenge of identi-
fying a safe and effective anti-thrombotic treatment
in this patient population in clinical practice.
� HBR patients derived beneﬁts in terms of
reductions of MACE, MI, TVR, and ST when treated
with E-ZES as compared with BMS, which is
consistent with study results observed in the over-
all population (11). At sensitivity analyses, results
remained entirely consistent focusing on patients
who displayed 2 or more HBR features, or evalu-
ating each HBR criterion separately. A further
analysis restricted to patients with atrial ﬁbrilla-
tion, which was the most frequent indication to oral
anticoagulation, conﬁrmed overall study ﬁndings.
� Despite comparable protocol-mandated DAPT du-
rations in both stent groups, cumulative treatment
duration with aspirin and P2Y12 inhibitor was
signiﬁcantly longer in BMS as compared with E-ZES
FIGURE 3 Clinical Outcomes in the HBR Population Treated With Zotarolimus-Eluting Stents Versus BMS
Rate of events for primary composite endpoint of death, myocardial infarction (MI), and target vessel revascularization (TVR) (A), MI (B), TVR
(C), or deﬁnite or probable stent thrombosis (D) at 12 months. BMS ¼ bare-metal stent(s); E-ZES ¼ zotarolimus-eluting Endeavor Sprint
stent(s); HBR ¼ high bleeding risk; HR ¼ hazard ratio.
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patients (Table 2), reﬂecting a higher TVR rate in
the former group of patients. Bleeding events
trended higher in the BMS compared with the
E-ZES groups, reﬂecting the longer DAPT after BMS
implantation.
COMPARISON WITH OTHER STUDIES. Randomized
controlled trials, which have so far compared DES
versus BMS, have recommended either a longer DAPT
regimen in the DES arm or a similarly prolonged
course of DAPT in BMS patients so to match the
extended course of therapy after DES (19,20). Hence,
no study has so far disentangled the effects of DES
versus BMS from those offered by long-term DAPT.
The recent DAPT trial (21) that compared 30- versus
12-month duration of DAPT after stent implantation
in patients with stable or unstable coronary artery
disease, showed a signiﬁcant decrease of very late
stent thrombosis and major adverse cardiovascular
and cerebrovascular events at 30 months after stent
implantation in the long-term DAPT arm. Yet, pa-
tients exposed to long-term DAPT also experienced a
borderline and signiﬁcant increase in overall mortal-
ity at 30 and 33 months, respectively (21). Patients
TABLE 3 Outcome Rates at 12 Months According to Treatment Group in Patients at HBR
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424)
Hazard Ratio
(95% Conﬁdence Interval) p Value
Primary efﬁcacy endpoint
Death for any cause, myocardial infarction,
or target vessel revascularization
117 (29.0) 96 (22.6) 0.745 (0.568–0.977) 0.033
Secondary efﬁcacy endpoints
Death for any cause or myocardial infarction 100 (24.8) 78 (18.4) 0.715 (0.531–0.963) 0.027
Death for cardiovascular cause or myocardial infarction 82 (20.3) 62 (14.6) 0.695 (0.499–0.968) 0.032
Death for any cause 70 (17.3) 67 (15.8) 0.913 (0.652–1.278) 0.595
Death for cardiovascular cause 51 (12.6) 50 (11.8) 0.931 (0.629–1.378) 0.720
Myocardial infarction 42 (10.4) 15 (3.5) 0.331 (0.184–0.598) <0.001
Target vessel revascularization 46 (11.4) 25 (5.9) 0.495 (0.304–0.806) 0.005
Target lesion revascularization 45 (11.1) 22 (5.2) 0.443 (0.266–0.739) 0.002
Ischemic stroke 11 (2.7) 5 (1.2) 0.432 (0.150–1.245) 0.120
Deﬁnite stent thrombosis* 10 (2.5) 4 (0.9) 0.381 (0.119–1.217) 0.103
Probable stent thrombosis* 15 (3.7) 7 (1.7) 0.448 (0.182–1.099) 0.079
Possible stent thrombosis* 18 (4.5) 17 (4.0) 0.870 (0.448–1.689) 0.681
Deﬁnite or probable stent thrombosis* 25 (6.2) 11 (2.6) 0.419 (0.206–0.853) 0.016
Deﬁnite, probable, or possible stent thrombosis* 43 (10.6) 28 (6.6) 0.610 (0.379–0.983) 0.042
Safety endpoints
TIMI classiﬁcation
Major or minor 13 (3.2) 10 (2.4) 0.734 (0.322–1.674) 0.462
Major 10 (2.5) 6 (1.4) 0.318
Minor 3 (0.7) 4 (0.9) >0.99
Requiring medical attention 25 (6.2) 16 (3.8) 0.148
BARC classiﬁcation†
Type 5 or 3 20 (5.0) 15 (3.5) 0.718 (0.368–1.404) 0.333
Type 5, 3, or 2 38 (9.4) 26 (6.1) 0.648 (0.393–1.068) 0.089
Type 5 4 (1.0) 2 (0.5) 0.441
Type 5A 3 (0.7) 1 (0.2) 0.362
Type 5B 1 (0.2) 1 (0.2) >0.99
Type 4 0 0 —
Type 3 16 (4.0) 13 (3.1) 0.572
Type 3A 5 (1.2) 2 (0.5) 0.276
Type 3B 9 (2.2) 10 (2.4) >0.99
Type 3C 2 (0.5) 1 (0.2) 0.616
Type 2 18 (4.5) 11 (2.6) 0.185
Values are n (%), unless indicated otherwise. *Stent thrombosis was deﬁned according to the criteria of the Academic Research Consortium. †Type 5 refers to fatal bleeding;
Type 4 are coronary artery bypass–related bleedings; Type 3 bleedings are divided into 3A: overt bleeding plus hemoglobin drop of 3 to <5 g/dl or any transfusion with overt
bleeding, 3B: overt bleeding plus hemoglobin drop $5 g/dl or cardiac tamponed or bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemor-
rhoid) or bleeding requiring intravenous inotropes, 3C: intracranial hemorrhage or intraocular bleed compromising vision; Type 2 are any overt, actionable sign of hemorrhage
that does not ﬁt the criteria for Types 3, 4, or 5, but does meet at least 1 of the following criteria: 1) requiring nonsurgical, medical intervention by a health care professional;
2) leading to hospitalization or increased level of care; and 3) prompting evaluation.
BARC ¼ Bleeding Academic Research Consortium; HBR ¼ high bleeding risk; TIMI ¼ Thrombolysis In Myocardial Infarction.
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who received BMS implantation, at discretion of the
treating physician were excluded from primary anal-
ysis, whereas only patients who were free from
ischemic and bleeding events after 12-month DAPT
were included in the study. Hence, patients at HBR
were excluded from the DAPT trial, and this study
was not designed to answer the question as to which
type of stent should be better used at the time of
intervention in patients fulﬁlling 1 or more HBR
criteria.
The WOEST (What is the Optimal antiplatElet &
Anticoagulant Therapy in Patients With Oral Anti-
coagulation and Coronary StenTing) trial (22)
included a total of total of 573 patients receiving oral
anticoagulant (w70% due to atrial ﬁbrillation) who
were randomly assigned to clopidogrel alone
(experimental treatment) or clopidogrel plus aspirin
(control treatment) for a period of 1 month after BMS
and 12 months after DES implantation. The primary
endpoint, consisting of any TIMI bleeding, was
signiﬁcantly lower in the dual therapy group, largely
driven by minimal or minor bleeding, without an
increase in MI, TVR, stroke or stent thrombosis.
The ISAR-TRIPLE (Intracoronary Stenting and
Antithrombotic Regimen–Testing of a Six-WeekVersus
a six-Month Clopidogrel Treatment Regimen in Pa-
tients With Concomitant Aspirin and Oral Anticoagu-
lant Therapy Following Drug-Eluting Stenting) trial
(23) is the largest randomized trial investigating triple
therapy after DES implantation in patientswith clinical
indication to oral anticoagulant (w85% due to atrial
ﬁbrillation). A total of 614 patients were randomly
FIGURE 4 Clinical Outcomes in Zotarolimus-Eluting Stents Versus BMS According to the Absence or Presence of a
Single or Multiple HBR Features
Patients without HBR criteria (No HBR), fulﬁlling 1 (HBR 1) or more than 1 (HBR>1) HBR criteria are shown, with HR and 95% conﬁdence
intervals (CI), for the primary endpoint of all-cause death, MI, and TVR; death or MI; cardiovascular (CV) death or MI; MI; TVR; deﬁnite,
probable, or possible stent thrombosis and BARC type 2, 3, or 5 bleeding events among patients randomly assigned to either E-ZES or BMS
group. P-int ¼ p value for interaction. Abbreviations as in Figures 2 and 3.
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patients (Table 2), reﬂecting a higher TVR rate in
the former group of patients. Bleeding events
trended higher in the BMS compared with the
E-ZES groups, reﬂecting the longer DAPT after BMS
implantation.
COMPARISON WITH OTHER STUDIES. Randomized
controlled trials, which have so far compared DES
versus BMS, have recommended either a longer DAPT
regimen in the DES arm or a similarly prolonged
course of DAPT in BMS patients so to match the
extended course of therapy after DES (19,20). Hence,
no study has so far disentangled the effects of DES
versus BMS from those offered by long-term DAPT.
The recent DAPT trial (21) that compared 30- versus
12-month duration of DAPT after stent implantation
in patients with stable or unstable coronary artery
disease, showed a signiﬁcant decrease of very late
stent thrombosis and major adverse cardiovascular
and cerebrovascular events at 30 months after stent
implantation in the long-term DAPT arm. Yet, pa-
tients exposed to long-term DAPT also experienced a
borderline and signiﬁcant increase in overall mortal-
ity at 30 and 33 months, respectively (21). Patients
TABLE 3 Outcome Rates at 12 Months According to Treatment Group in Patients at HBR
Bare-Metal Stent
(n ¼ 404)
Endeavor Stent
(n ¼ 424)
Hazard Ratio
(95% Conﬁdence Interval) p Value
Primary efﬁcacy endpoint
Death for any cause, myocardial infarction,
or target vessel revascularization
117 (29.0) 96 (22.6) 0.745 (0.568–0.977) 0.033
Secondary efﬁcacy endpoints
Death for any cause or myocardial infarction 100 (24.8) 78 (18.4) 0.715 (0.531–0.963) 0.027
Death for cardiovascular cause or myocardial infarction 82 (20.3) 62 (14.6) 0.695 (0.499–0.968) 0.032
Death for any cause 70 (17.3) 67 (15.8) 0.913 (0.652–1.278) 0.595
Death for cardiovascular cause 51 (12.6) 50 (11.8) 0.931 (0.629–1.378) 0.720
Myocardial infarction 42 (10.4) 15 (3.5) 0.331 (0.184–0.598) <0.001
Target vessel revascularization 46 (11.4) 25 (5.9) 0.495 (0.304–0.806) 0.005
Target lesion revascularization 45 (11.1) 22 (5.2) 0.443 (0.266–0.739) 0.002
Ischemic stroke 11 (2.7) 5 (1.2) 0.432 (0.150–1.245) 0.120
Deﬁnite stent thrombosis* 10 (2.5) 4 (0.9) 0.381 (0.119–1.217) 0.103
Probable stent thrombosis* 15 (3.7) 7 (1.7) 0.448 (0.182–1.099) 0.079
Possible stent thrombosis* 18 (4.5) 17 (4.0) 0.870 (0.448–1.689) 0.681
Deﬁnite or probable stent thrombosis* 25 (6.2) 11 (2.6) 0.419 (0.206–0.853) 0.016
Deﬁnite, probable, or possible stent thrombosis* 43 (10.6) 28 (6.6) 0.610 (0.379–0.983) 0.042
Safety endpoints
TIMI classiﬁcation
Major or minor 13 (3.2) 10 (2.4) 0.734 (0.322–1.674) 0.462
Major 10 (2.5) 6 (1.4) 0.318
Minor 3 (0.7) 4 (0.9) >0.99
Requiring medical attention 25 (6.2) 16 (3.8) 0.148
BARC classiﬁcation†
Type 5 or 3 20 (5.0) 15 (3.5) 0.718 (0.368–1.404) 0.333
Type 5, 3, or 2 38 (9.4) 26 (6.1) 0.648 (0.393–1.068) 0.089
Type 5 4 (1.0) 2 (0.5) 0.441
Type 5A 3 (0.7) 1 (0.2) 0.362
Type 5B 1 (0.2) 1 (0.2) >0.99
Type 4 0 0 —
Type 3 16 (4.0) 13 (3.1) 0.572
Type 3A 5 (1.2) 2 (0.5) 0.276
Type 3B 9 (2.2) 10 (2.4) >0.99
Type 3C 2 (0.5) 1 (0.2) 0.616
Type 2 18 (4.5) 11 (2.6) 0.185
Values are n (%), unless indicated otherwise. *Stent thrombosis was deﬁned according to the criteria of the Academic Research Consortium. †Type 5 refers to fatal bleeding;
Type 4 are coronary artery bypass–related bleedings; Type 3 bleedings are divided into 3A: overt bleeding plus hemoglobin drop of 3 to <5 g/dl or any transfusion with overt
bleeding, 3B: overt bleeding plus hemoglobin drop $5 g/dl or cardiac tamponed or bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemor-
rhoid) or bleeding requiring intravenous inotropes, 3C: intracranial hemorrhage or intraocular bleed compromising vision; Type 2 are any overt, actionable sign of hemorrhage
that does not ﬁt the criteria for Types 3, 4, or 5, but does meet at least 1 of the following criteria: 1) requiring nonsurgical, medical intervention by a health care professional;
2) leading to hospitalization or increased level of care; and 3) prompting evaluation.
BARC ¼ Bleeding Academic Research Consortium; HBR ¼ high bleeding risk; TIMI ¼ Thrombolysis In Myocardial Infarction.
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who received BMS implantation, at discretion of the
treating physician were excluded from primary anal-
ysis, whereas only patients who were free from
ischemic and bleeding events after 12-month DAPT
were included in the study. Hence, patients at HBR
were excluded from the DAPT trial, and this study
was not designed to answer the question as to which
type of stent should be better used at the time of
intervention in patients fulﬁlling 1 or more HBR
criteria.
The WOEST (What is the Optimal antiplatElet &
Anticoagulant Therapy in Patients With Oral Anti-
coagulation and Coronary StenTing) trial (22)
included a total of total of 573 patients receiving oral
anticoagulant (w70% due to atrial ﬁbrillation) who
were randomly assigned to clopidogrel alone
(experimental treatment) or clopidogrel plus aspirin
(control treatment) for a period of 1 month after BMS
and 12 months after DES implantation. The primary
endpoint, consisting of any TIMI bleeding, was
signiﬁcantly lower in the dual therapy group, largely
driven by minimal or minor bleeding, without an
increase in MI, TVR, stroke or stent thrombosis.
The ISAR-TRIPLE (Intracoronary Stenting and
Antithrombotic Regimen–Testing of a Six-WeekVersus
a six-Month Clopidogrel Treatment Regimen in Pa-
tients With Concomitant Aspirin and Oral Anticoagu-
lant Therapy Following Drug-Eluting Stenting) trial
(23) is the largest randomized trial investigating triple
therapy after DES implantation in patientswith clinical
indication to oral anticoagulant (w85% due to atrial
ﬁbrillation). A total of 614 patients were randomly
FIGURE 4 Clinical Outcomes in Zotarolimus-Eluting Stents Versus BMS According to the Absence or Presence of a
Single or Multiple HBR Features
Patients without HBR criteria (No HBR), fulﬁlling 1 (HBR 1) or more than 1 (HBR>1) HBR criteria are shown, with HR and 95% conﬁdence
intervals (CI), for the primary endpoint of all-cause death, MI, and TVR; death or MI; cardiovascular (CV) death or MI; MI; TVR; deﬁnite,
probable, or possible stent thrombosis and BARC type 2, 3, or 5 bleeding events among patients randomly assigned to either E-ZES or BMS
group. P-int ¼ p value for interaction. Abbreviations as in Figures 2 and 3.
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assigned to therapy with clopidogrel for 6 weeks (n ¼
307) or 6 months (n ¼ 307). The primary endpoint, a
composite of death, MI, ST, stroke, or TIMI major
bleeding, failed to show the anticipated superiority of
short- versus long-term triple therapy duration.
The ZEUS study is therefore the ﬁrst randomized
controlled trial comparing 2 different stent types in
HBR patients after mandating a similarly short course
of DAPT. An interesting observation was that BMS
patients received a longer cumulative DAPT duration
as compared with those assigned to E-ZES, reﬂecting
the more frequent need to re-start DAPT after rein-
tervention for in-stent restenosis or ST. Given the
observation that long-term DAPT duration may be
paramount in patients receiving DES implantation for
the treatment of an in-stent restenosis (24), our cur-
rent ﬁndings may further justify the selection of a
safe DES over a BMS in this patient population to
minimize the risk of in-stent restenosis, which would
then require reintervention followed by a prolonged
course of DAPT.
The lower risk of MI or ST observed in patients
treated with E-ZES as compared to BMS, despite a
similarly short DAPT duration in both stent groups, is
consistent with the mounting evidence that lower
in-stent intimal hyperplasia may carry not only
greater efﬁcacy (e.g., lower TVR), but also improved
safety (e.g., lower ST or stent-related MIs) (4, 25,26).
STUDY LIMITATIONS. By design, our study does not
address the topic of optimal DAPT duration after
stenting. On the other hand, the results of our
investigation challenge the current wisdom that BMS
is per se a safer coronary device as compared with
DES under a similarly short DAPT duration. Because
of the unique properties of the E-ZES, our results
should not be extrapolated to newer-generation DES
coated with the same or other antiproliferative agents
and diverse or no polymers. As for all substudies, type
I and type II errors are not corrected for. Hence, our
results should be hypothesis-generating. Further
research is needed to ascertain whether the tailored
DAPT regimen tested in our study can be safely
implemented in patients receiving other DES. The
recently reported LEADERS-FREE (A Randomized
Clinical Evaluation of the BioFreedom Stent) trial
(27) largely reproduced our study ﬁndings in terms of
both better efﬁcacy and safety in an HBR population
after the use of a drug-coated stent as compared with
the corresponding BMS. Therefore, it remains to be
seen whether other permanent or bioresorbable
polymer-based DES could be safely employed after a
30-day DAPT regimen.
CONCLUSIONS
Our study provides proof of concept that in HBR pa-
tients who undergo stent implantation, E-ZES as
compared with conventional BMS followed by 30-day
DAPT regimen provides superior efﬁcacy and safety.
Future studies are needed to assess the tolerability
and safety of more contemporary DES when followed
by an abbreviated DAPT duration in this challenging
patient population.
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assigned to therapy with clopidogrel for 6 weeks (n ¼
307) or 6 months (n ¼ 307). The primary endpoint, a
composite of death, MI, ST, stroke, or TIMI major
bleeding, failed to show the anticipated superiority of
short- versus long-term triple therapy duration.
The ZEUS study is therefore the ﬁrst randomized
controlled trial comparing 2 different stent types in
HBR patients after mandating a similarly short course
of DAPT. An interesting observation was that BMS
patients received a longer cumulative DAPT duration
as compared with those assigned to E-ZES, reﬂecting
the more frequent need to re-start DAPT after rein-
tervention for in-stent restenosis or ST. Given the
observation that long-term DAPT duration may be
paramount in patients receiving DES implantation for
the treatment of an in-stent restenosis (24), our cur-
rent ﬁndings may further justify the selection of a
safe DES over a BMS in this patient population to
minimize the risk of in-stent restenosis, which would
then require reintervention followed by a prolonged
course of DAPT.
The lower risk of MI or ST observed in patients
treated with E-ZES as compared to BMS, despite a
similarly short DAPT duration in both stent groups, is
consistent with the mounting evidence that lower
in-stent intimal hyperplasia may carry not only
greater efﬁcacy (e.g., lower TVR), but also improved
safety (e.g., lower ST or stent-related MIs) (4, 25,26).
STUDY LIMITATIONS. By design, our study does not
address the topic of optimal DAPT duration after
stenting. On the other hand, the results of our
investigation challenge the current wisdom that BMS
is per se a safer coronary device as compared with
DES under a similarly short DAPT duration. Because
of the unique properties of the E-ZES, our results
should not be extrapolated to newer-generation DES
coated with the same or other antiproliferative agents
and diverse or no polymers. As for all substudies, type
I and type II errors are not corrected for. Hence, our
results should be hypothesis-generating. Further
research is needed to ascertain whether the tailored
DAPT regimen tested in our study can be safely
implemented in patients receiving other DES. The
recently reported LEADERS-FREE (A Randomized
Clinical Evaluation of the BioFreedom Stent) trial
(27) largely reproduced our study ﬁndings in terms of
both better efﬁcacy and safety in an HBR population
after the use of a drug-coated stent as compared with
the corresponding BMS. Therefore, it remains to be
seen whether other permanent or bioresorbable
polymer-based DES could be safely employed after a
30-day DAPT regimen.
CONCLUSIONS
Our study provides proof of concept that in HBR pa-
tients who undergo stent implantation, E-ZES as
compared with conventional BMS followed by 30-day
DAPT regimen provides superior efﬁcacy and safety.
Future studies are needed to assess the tolerability
and safety of more contemporary DES when followed
by an abbreviated DAPT duration in this challenging
patient population.
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Aim: Chronic kidney disease (CKD) is a powerful predictor of major cardiovascular events and stent thrombosis
(ST) in patients undergoing percutaneous coronary interventions (PCI). No randomized data are available to
compare, and guide the selection of type of stent between bare metal (BMS) or drug eluting stent (DES) in this
population.
Methods and results: We performed a post-hoc analysis of the PROlonging Dual antiplatelet treatment after
Grading stent-induced Intimal hyperplasia studY (PRODIGY) trial, in which stable or unstable patients with
coronary artery disease undergoing PCI were randomized 1:1:1:1 to receive BMS, paclitaxel- (PES),
zotarolimus- (ZES-S), or everolimus- (EES) eluting stent. A total of 2003 patients were randomized, and 22
patients were excluded for missing serum creatinine leading to a ﬁnal population of 1981 patients. Primary out-
comewas deﬁnite or probable ST.We also assessedMACE (myocardial infarction, stroke, or death), and all-cause
death, as secondary outcome.
CKD, deﬁned with estimated glomerular ﬁltration rate b60 ml/min/1.73 m2, was found in 373 patients (18.8%).
The incidence of ST at 2 years was 5.1% in CKD and 2.1% in non-CKD patients (HR 2.57, 95% conﬁdence interval
(CI) 1.46 to 4.52, p b 0.001). At multivariable regression we found that patients randomized to EES or ZES-S,
but not PES, had lower risk of ST at two years as compared with BMS: adjusted HR = 0.288, 95% CI [0.107–
0.778, p= 0.014] and HR= 0.394, 95% CI [0.164–0.947, p= 0.037] respectively. The number of patients needed
to be treated to prevent 1 STwith an EES vs BMSwas 20 in CKD and 50 in patients without CKD. EES patients had
the lowest incidentMACE events 26.4% as compared to BMS 35.1%, ZES-S 33.0%, or PES 35.7% patients, p= 0.551.
All-cause deathwas lowest in ZES-S group 10.6% as compared to BMS 18.1%, PES 25.5% and EES 14.9%, p= 0.040.
We found no signiﬁcant interaction between DAPT duration (6 vs 24 months) and stent type on primary outcome,
PINT = 0.47 for BMS, PINT = 0.57 for PES, PINT = 0.41 for ZES-S and PINT = 0.28 for EES.
Conclusions: In an all-comer population of patients with stable and unstable CAD, CKD at baseline was associated
with a double risk of ST and MACE. CKD patients receiving EES had less than half risk of ST 2 years after PCI as
compared with BMS and PES. Our analysis suggests that 2nd generation limus-based stent should be favored over
paclitaxel-based DES or BMS to reduce ST and MACE in CKD patients.
© 2016 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Chronic kidney disease (CKD) is common in patients undergoing
percutaneous coronary interventions (PCI), especially in those present-
ing with acute coronary syndromes [1–3], and has been consistently
associated with an increased risk of ischemic events, including stent
thrombosis (ST) [4]. CKD is a powerful predictor of subsequent ST with
more than 6-fold increased risk [5] thus raising possible concerns of
using of drug eluting stents (DES) in these patients [6]. The European
Guidelines for myocardial revascularization (2010) have recommended
that DES should not be preferred and used indiscriminately over bare
metal stents (BMS) in patients with CKD [7] although this recommenda-
tion was reformulated in the subsequent edition.
While randomized data are lacking in this setting, observations on
safety and efﬁcacy of DES in CKD patients have not supported these
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Chronic kidney disease (CKD) is common in patients undergoing
percutaneous coronary interventions (PCI), especially in those present-
ing with acute coronary syndromes [1–3], and has been consistently
associated with an increased risk of ischemic events, including stent
thrombosis (ST) [4]. CKD is a powerful predictor of subsequent ST with
more than 6-fold increased risk [5] thus raising possible concerns of
using of drug eluting stents (DES) in these patients [6]. The European
Guidelines for myocardial revascularization (2010) have recommended
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concerns and showed similar safety [8–10] or potential reduction of
major adverse cardiovascular events (MACE) of DES compared with
BMS [3,11]. These data however have several limitations: i) Stent type
(DES or BMS) was left at operator's preference [3,8–11], ii) ﬁrst-
generation DES, which are known to be more susceptible to ST, were
used [3,8–11] and iii) ST was not systematically collected using the
Academic Research Consortium (ARC) criteria [3,10,11].
To overcome in part these limitations we performed a post-hoc
analysis of the PROlonging Dual antiplatelet treatment after Grading
stent-induced Intimal hyperplasia studY (PRODIGY trial) [12,13] with
the primary purpose to assess, in an all-comer population of patients
with stable or unstable coronary artery disease undergoing PCI, long
term outcome of patients with CKD at presentation who were random-
ized to receive BMS, paclitaxel-eluting stent (PES), zotarolimus-eluting
stent (ZES-S) or everolimus-eluting stent (EES) at the time of PCI.
2. Methods
2.1. Study design and population
The design of the PRODIGY trial has been published [14]. PRODIGY
was an open label, 2 by 4 randomized, multicenter, controlled trial, test-
ing the hypothesis that 24 months of dual antiplatelet therapy (DAPT)
with aspirin and clopidogrel could reduce the composite of all-cause
death, stroke, or MI as compared with 6 months DAPT in an all-comer
population undergoing PCI [12]. At day 0 patients with an indication
to coronary stenting randomly underwent implantation BMS (no active
late loss inhibition), Endeavor Sprint ZES-S (mild late loss inhibition),
PES (moderate late loss inhibition), or Xience V EES (high late loss inhi-
bition). At 30 days, patients within each stent group were randomly
assigned to receive 6 months or up to 24 months of DAPT (80 to
160 mg aspirin orally and 75 mg clopidogrel orally). The key inclusion
criterion was the presence of coronary atherosclerosis requiring PCI,
thus including patients with stable coronary artery disease (CAD),
non-ST-segment elevation acute coronary syndrome (NSTE-ACS), or
ST-segment elevation acute coronary syndrome (STE-ACS). Key exclusion
criteriawere: known acetylsalicylic acid or clopidogrel allergy;major sur-
gery within 15 days; planned surgery in the following 24 months, active
bleeding or bleeding diathesis; and concomitant or foreseeable oral anti-
coagulant treatment. All patients received an ofﬁce visit at 30 days,
6 months, and 24 months after randomization.
2.2. Deﬁnitions
CKD was deﬁned by glomerular ﬁltration rate (eGFR) b60 ml/min/
1.73 m2. The modiﬁcation of diet in renal disease formula was used to
compute eGFR:
eGFR [ml/min/1.73 m2] = 186 ∗ baseline SCr [mg/dl]− 1.154 ∗ Age
[years]− 0.203 ∗ (0.742 if Female) ∗ (1.21 if African descent).
Our primary endpoint was the incidence of deﬁnite or probable ST
based on the ARC criteria [15]. Secondary endpoints considered were:
the composite of all-cause death, stroke or myocardial infarction; all-
cause death;myocardial infarction; stroke; and target lesion revascular-
ization. All endpoints were assessed at 24 months. All potential end-
points were individually adjudicated by a clinical event committee
blinded to randomized treatment allocation.
2.3. Statistical analysis
Baseline categorical variables were expressed as count (percentage)
and compared with the χ2 test. Baseline continuous variables were
expressed as median (interquartile range) and compared with the
Wilcoxon rank sum between the groups deﬁned by CKD (binary)
and ANOVA rank sum test between the groups deﬁned by stent
type (four levels).
The hazard ratios (HR) and 95% conﬁdence interval (CI) of the four
randomized groups of patients deﬁned by stent type on outcome were
estimated by ﬁtting a Cox proportional hazard regression model with
the bare metal stent group set as reference category. The association
between stent type and clinical outcomewas adjusted for potential con-
founders and established risk factors of stent thrombosis [5]. In addition
to CKD (as deﬁned above), the following covariates were included a
priori into the model for risk adjustment: age, left ventricular ejection
fraction (LVEF), diabetes mellitus, ACS at presentation (vs stable angi-
na), and total stent length. Additionally, the experimental treatments
6 vs 24 month duration of dual antiplatelet therapy and stent type
were included in the model.
There were no missing observations for all the covariates except for
LVEF (N=139, 6.9%) and stent length (N=6, 0.3%). Sensitivity analysis
using case-deletion and the exclusion of the aforementioned covariates
were used to address the role of missingness. Sensitivity analysis by in-
cluding eGFR as a continuous variable was also performed. The propor-
tionality assumptionwas checked either by visual estimation of the log-
cumulative hazard versus log-time (sFigure 1) or by using Schoenfeld
residuals which failed to reject the null hypothesis that event rate was
affected by time (p = 0.46). A 2-sided probability value p ≤ 0.05 was
considered signiﬁcant. Data were analyzed in the R version 3.1.3 soft-
ware environment [16] and “Survival” package.
3. Results
3.1. Patients
From December 2006 to December 2008, 2789 patients were
screened for eligibility, 2013 were randomized to one of four different
stent types [12,13]. Ten patients, who withdrawn informed consent
within 30 days of visit, and 22 patients who had incomplete baseline
SCr data, were excluded (Fig. 1). This led to a ﬁnal population of 1981
patients. Baseline variables are outlined in Table 1; 1833 were censored
at 2 years of follow-up.
Overall, 373 (18.8%) patients had CKD at baseline. Within this group
of patients, baseline (Table 1) and procedural (Table 2) characteristics
were fairly balanced across the four stent arms. Patients allocated
to the BMS group were older 78 [71–82] years compared with the
ZES-S group 72 [66–79] years, PES group 76 [70–81] years and EES 75
Fig. 1. Patient ﬂow.
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concerns and showed similar safety [8–10] or potential reduction of
major adverse cardiovascular events (MACE) of DES compared with
BMS [3,11]. These data however have several limitations: i) Stent type
(DES or BMS) was left at operator's preference [3,8–11], ii) ﬁrst-
generation DES, which are known to be more susceptible to ST, were
used [3,8–11] and iii) ST was not systematically collected using the
Academic Research Consortium (ARC) criteria [3,10,11].
To overcome in part these limitations we performed a post-hoc
analysis of the PROlonging Dual antiplatelet treatment after Grading
stent-induced Intimal hyperplasia studY (PRODIGY trial) [12,13] with
the primary purpose to assess, in an all-comer population of patients
with stable or unstable coronary artery disease undergoing PCI, long
term outcome of patients with CKD at presentation who were random-
ized to receive BMS, paclitaxel-eluting stent (PES), zotarolimus-eluting
stent (ZES-S) or everolimus-eluting stent (EES) at the time of PCI.
2. Methods
2.1. Study design and population
The design of the PRODIGY trial has been published [14]. PRODIGY
was an open label, 2 by 4 randomized, multicenter, controlled trial, test-
ing the hypothesis that 24 months of dual antiplatelet therapy (DAPT)
with aspirin and clopidogrel could reduce the composite of all-cause
death, stroke, or MI as compared with 6 months DAPT in an all-comer
population undergoing PCI [12]. At day 0 patients with an indication
to coronary stenting randomly underwent implantation BMS (no active
late loss inhibition), Endeavor Sprint ZES-S (mild late loss inhibition),
PES (moderate late loss inhibition), or Xience V EES (high late loss inhi-
bition). At 30 days, patients within each stent group were randomly
assigned to receive 6 months or up to 24 months of DAPT (80 to
160 mg aspirin orally and 75 mg clopidogrel orally). The key inclusion
criterion was the presence of coronary atherosclerosis requiring PCI,
thus including patients with stable coronary artery disease (CAD),
non-ST-segment elevation acute coronary syndrome (NSTE-ACS), or
ST-segment elevation acute coronary syndrome (STE-ACS). Key exclusion
criteriawere: known acetylsalicylic acid or clopidogrel allergy;major sur-
gery within 15 days; planned surgery in the following 24 months, active
bleeding or bleeding diathesis; and concomitant or foreseeable oral anti-
coagulant treatment. All patients received an ofﬁce visit at 30 days,
6 months, and 24 months after randomization.
2.2. Deﬁnitions
CKD was deﬁned by glomerular ﬁltration rate (eGFR) b60 ml/min/
1.73 m2. The modiﬁcation of diet in renal disease formula was used to
compute eGFR:
eGFR [ml/min/1.73 m2] = 186 ∗ baseline SCr [mg/dl]− 1.154 ∗ Age
[years]− 0.203 ∗ (0.742 if Female) ∗ (1.21 if African descent).
Our primary endpoint was the incidence of deﬁnite or probable ST
based on the ARC criteria [15]. Secondary endpoints considered were:
the composite of all-cause death, stroke or myocardial infarction; all-
cause death;myocardial infarction; stroke; and target lesion revascular-
ization. All endpoints were assessed at 24 months. All potential end-
points were individually adjudicated by a clinical event committee
blinded to randomized treatment allocation.
2.3. Statistical analysis
Baseline categorical variables were expressed as count (percentage)
and compared with the χ2 test. Baseline continuous variables were
expressed as median (interquartile range) and compared with the
Wilcoxon rank sum between the groups deﬁned by CKD (binary)
and ANOVA rank sum test between the groups deﬁned by stent
type (four levels).
The hazard ratios (HR) and 95% conﬁdence interval (CI) of the four
randomized groups of patients deﬁned by stent type on outcome were
estimated by ﬁtting a Cox proportional hazard regression model with
the bare metal stent group set as reference category. The association
between stent type and clinical outcomewas adjusted for potential con-
founders and established risk factors of stent thrombosis [5]. In addition
to CKD (as deﬁned above), the following covariates were included a
priori into the model for risk adjustment: age, left ventricular ejection
fraction (LVEF), diabetes mellitus, ACS at presentation (vs stable angi-
na), and total stent length. Additionally, the experimental treatments
6 vs 24 month duration of dual antiplatelet therapy and stent type
were included in the model.
There were no missing observations for all the covariates except for
LVEF (N=139, 6.9%) and stent length (N=6, 0.3%). Sensitivity analysis
using case-deletion and the exclusion of the aforementioned covariates
were used to address the role of missingness. Sensitivity analysis by in-
cluding eGFR as a continuous variable was also performed. The propor-
tionality assumptionwas checked either by visual estimation of the log-
cumulative hazard versus log-time (sFigure 1) or by using Schoenfeld
residuals which failed to reject the null hypothesis that event rate was
affected by time (p = 0.46). A 2-sided probability value p ≤ 0.05 was
considered signiﬁcant. Data were analyzed in the R version 3.1.3 soft-
ware environment [16] and “Survival” package.
3. Results
3.1. Patients
From December 2006 to December 2008, 2789 patients were
screened for eligibility, 2013 were randomized to one of four different
stent types [12,13]. Ten patients, who withdrawn informed consent
within 30 days of visit, and 22 patients who had incomplete baseline
SCr data, were excluded (Fig. 1). This led to a ﬁnal population of 1981
patients. Baseline variables are outlined in Table 1; 1833 were censored
at 2 years of follow-up.
Overall, 373 (18.8%) patients had CKD at baseline. Within this group
of patients, baseline (Table 1) and procedural (Table 2) characteristics
were fairly balanced across the four stent arms. Patients allocated
to the BMS group were older 78 [71–82] years compared with the
ZES-S group 72 [66–79] years, PES group 76 [70–81] years and EES 75
Fig. 1. Patient ﬂow.
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[71–80] years, (p b 0.017). Diabeteswas less prevalent in EES 22 (25.3%)
as comparedwith the ZES-S group 25 (26.6%), BMS 33 (35.1%) or PES 52
(53.1%), p b 0.001. ACS at admission was more prevalent in the BMS
group 81 (86.2%) compared to ZES-S 74 (78.7%), PES 68 (69.4%)
and EES 71 (81.6%), p = 0.02. LVEF was lower in the BMS group 43
[40–55] % compared to ZES-S 51 [45–60] %, PES 45 [35–55] % and EES
50 [40–55] %, p = 0.01.
3.2. Stent thrombosis
Deﬁnite and probable ST incidence in CKD patients after a 2 year
follow-upwas 5.1%. As comparedwith patients with normal renal func-
tion, CKDpatients had an increased risk of ST at two yearswith a hazard
ratio of 2.57, 95% conﬁdence interval (CI) [1.46–4.52] Table 3; Fig. 2a,b.
After adjusting for established risk factors and potential con-
founders, we observed that CKD patients randomized to EES or ZES-S,
but not PES, had lower risk of ST at two years of follow-up as compared
with BMS, adjusted HR = 0.288, 95% CI [0.107–0.778, p = 0.014] andTa
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Fig. 2. Cumulative incidence of deﬁnite or probable stent thrombosis (Academic Research
Consortium deﬁnition) in non-CKD patients (panel A) and CKD patients (panel B), vertical
lines represent single event. Abbreviations as in Table 1.
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[71–80] years, (p b 0.017). Diabeteswas less prevalent in EES 22 (25.3%)
as comparedwith the ZES-S group 25 (26.6%), BMS 33 (35.1%) or PES 52
(53.1%), p b 0.001. ACS at admission was more prevalent in the BMS
group 81 (86.2%) compared to ZES-S 74 (78.7%), PES 68 (69.4%)
and EES 71 (81.6%), p = 0.02. LVEF was lower in the BMS group 43
[40–55] % compared to ZES-S 51 [45–60] %, PES 45 [35–55] % and EES
50 [40–55] %, p = 0.01.
3.2. Stent thrombosis
Deﬁnite and probable ST incidence in CKD patients after a 2 year
follow-upwas 5.1%. As comparedwith patients with normal renal func-
tion, CKDpatients had an increased risk of ST at two yearswith a hazard
ratio of 2.57, 95% conﬁdence interval (CI) [1.46–4.52] Table 3; Fig. 2a,b.
After adjusting for established risk factors and potential con-
founders, we observed that CKD patients randomized to EES or ZES-S,
but not PES, had lower risk of ST at two years of follow-up as compared
with BMS, adjusted HR = 0.288, 95% CI [0.107–0.778, p = 0.014] andTa
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Fig. 2. Cumulative incidence of deﬁnite or probable stent thrombosis (Academic Research
Consortium deﬁnition) in non-CKD patients (panel A) and CKD patients (panel B), vertical
lines represent single event. Abbreviations as in Table 1.
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HR = 0.394, 95% CI [0.164–0.947, p = 0.037] respectively, Table 4.
Similar patterns of reduced incidence of deﬁnite or probable ST were
observed in patients without CKD Table 3. Other independent predic-
tors of ST were: eGFR b 60 ml/min/1.73 m2, HR = 2.218 95% CI
[1.189–4.138, p = 0.012], LVEF (%), HR = 0.969 95% CI [0.945–0.994,
p = 0.015] and ACS at presentation vs stable CAD, HR = 3.981 95% CI
[1.219–13.9 p = 0.022].
The number of patients needed to be treated with an EES vs BMS to
prevent 1 deﬁnite or probable ST at 2 yearswas 20 in patients with CKD
and 50 in patients without CKD.
We found no signiﬁcant interaction between either DAPT duration
(6 vs 24 months) PINT = 0.47 for BMS, PINT = 0.57 for PES, PINT = 0.41
for ZES-S and PINT = 0.28 for EES, or eGFR level (b60 vs ≥60 ml/min/
1.73 m2) pint = 0.78 for BMS, pint = 0.63 for PES, pint = 0.20 for ZES-S
and pint = 0.79 for EES on ST outcome.
Both EES and ZES-S were associated with lower adjusted ST risk also
when compared with PES, Table 5.
3.3. Major adverse cardiovascular events
Patients with CKD at baseline had an increased risk of MACE at two
years of follow-upwith a hazard ratio of 2.04, 95%CI [1.65–2.52] as com-
pared with patients with eGFR N 60 ml/min/1.73 m2, Table 3; Fig. 3a,b.
CKD patients randomized to EES had lower incident MACE events
26.4% as compared to patients randomized to BMS 35.1%, ZES-S 33.0%,
or PES 35.7%, p = 0.551 (Fig. 3b). The individual components of the
composite endpointwere signiﬁcantly different among the stent alloca-
tion arms (Table 3): all-cause deathwas lowest in the ZES-S group10.6%
as compared with BMS 18.1%, PES 25.5% and EES 14.9%, p = 0.040, Fig.
4b. At multivariable analysis age, eGFR b 60ml/min/1.73, LVEF, diabetes
and total stent length, but not stent type were independent predictors
of MACE after two years of follow-up, sTable 1, the result was main-
tained by including eGFR as a continuous variable. Consistently age,
eGFR b 60 ml/min/1.73 and LVEF, but not stent type were independent
predictors of all-cause death, sTable 2.
3.4. Target lesion revascularization
Patients with CKD had non-signiﬁcantly more TLR at two years of
follow-up as compared with patients without CKD, with a hazard ratio
of 1.330, 95% CI [0.957–1.840, p = 0.089]. TLR was not signiﬁcantly dif-
ferent among the four stent arms in CKD patients Table 3, sFigure 2b.
However, the use of drug eluting stents including either ZES-S, or PES
or EES signiﬁcantly reduced TLR as comparedwith BMS atmultivariable
analysis, sTable 3, sFigure 2a,b.
4. Discussion
In an all-comer population of patients with stable and unstable CAD,
CKDwas observed in≈ one out of ﬁve patients andwas associatedwith
doubled risk of MACE and ST.
Similar to prior observations in PRODIGY patients without CKD [12,
13], we observed that CKD patients randomized to receive EES or ZES-
S had lower adjusted risk of deﬁnite or probable ST as compared with
patients receiving BMS or PES, with an adjusted hazard ratio of 0.409
[0.209–0.797] for EES, which was directionally consistent for ZES-S
0.789 [0.459–1.357] as compared with BMS. Patients who received
EES had also lower adjusted risk of ST as compared with patients who
received PES 0.360 [0.187–0.969], but not ZES-S 0.518 [0.257–1.041],
Table 5. This association was not modiﬁed by DAPT duration (6 vs
24 months) as the interaction test was non-signiﬁcant for each stent
type.
CKD patients who were randomized to receive EES had the lowest
numerical MACE and all-cause death incidence after two years of
follow-up as compared with BMS, ZES-S or PES patients. However, un-
like ST, the association between reduced MACE and speciﬁcally all-
cause death with EES was not maintained after adjusting for con-
founders and covariates with multivariable analysis. This suggests that
it may be either a spurious association or β type error. In fact ST inci-
dence in CKD patients may only explain part of the worse outcome of
these patients which were older and associated with several baseline
variables of increased risk (Table 1).
CKD patients had a trend toward higher TLR after two years of fol-
low-up, however, there was no difference between BMS, and either
1st or 2nd generation DES. This ﬁnding may be explained by a numeri-
cally higher TLR incidence in the DES group (both 1st and 2nd genera-
tion), while TLR with BMS was numerically similar in both CKD and
non-CKD patients (Table 3, sTable 3, sFigure 2a,b).
There may be several possible reasons to explain increased ST inci-
dence in CKD patients as compared to patients without CKD patients.
First, CKD is associatedwith systemic persistent inﬂammation endo-
thelial dysfunction [17,18], which may interact differently in patients
receiving BMS as compared with 1st and 2nd generation DES. This
may eventually amplify the coronary inﬂammation process after stent
deployment and delay strut re-endothelialization. In this regard EES
with its thinner strut design, more biocompatible polymers, less poly-
mer mass and limus-based antiproliferative drugs may induce lower
local inﬂammatory response and explain lower ST incidence as com-
pared to both BMS and ﬁrst generation DES. Our ﬁndings in CKD pa-
tients are aligned with recent trials [19,20] and meta-analysis [21]
which showed that second generation DES is associated with lower ST
rate than BMS and ﬁrst generation DES. Importantly in CKD population
the number needed to treat with EES vs BMS to prevent one ST (NNT =
20) was much lower than the non-CKD population (NNT= 50), indicat-
ing a much higher absolute beneﬁt.
Second, the presence of CKD is associatedwith higher atherosclerot-
ic burden, diffuse coronary disease and coronary calciﬁcation which
may in turn favor stent malapposition, under-expansion, eventually
leading to ST. Of note, reduced ST with EES was maintained even after
adjusting for total stent length, which may partly account for this
issue. Coronary calciﬁcation and diffuse disease are also well-known
risk factors for in-stent restenosis and TLR. Both 1st and 2nd generation
DES, which have lower late loss than BMS, did not signiﬁcantly reduce
TLR in our population (sFigure 2ab) as previously reported [3,4]. This
ﬁnding reinforces the inﬂammation hypothesis as a predominant expla-
nation of the lower STwith EES, on the other side raises thedoubt on the
efﬁcacy of DES in preventing TLR in calciﬁed vessels like those found in
CKD patients and needs further investigations (sFigure 2b).
Finally, CKD patients may be poor responders to DAPT. It was dem-
onstrated that diabetic patients with eGFR b 60ml/min/1.73 m2 receiv-
ing aspirin and clopidogrel had much higher platelet reactivity after
ADP stimuli and a 2-fold increase in high platelet reactivity after ADP
Table 4
Cox proportional hazard regression. Patients included N = 1845, patients excluded for
missing data N= 158. Deﬁnite and probable stent thrombosis events = 51. Abbreviation
as in Tables 1 and 2.
y = ST
(deﬁnite or probable)
Hazard
ratio
Lower
95% CI
Upper
95% CI
p-Value
Age (years) 1.000 0.976 1.026 0.973
eGFR b 60 ml/min/1.73 m2 2.218 1.189 4.138 0.012
LVEF (%) 0.969 0.945 0.994 0.015
Diabetes 1.121 0.604 2.081 0.718
ACS vs stable CAD 3.981 1.219 13.00 0.022
6 vs 24 months DAPT 1.398 0.798 2.448 0.241
Total stent length (mm) 1.000 0.990 1.009 0.973
Stent type
BMS (reference)
ZES-S 0.394 0.164 0.947 0.037
PES 1.180 0.626 2.226 0.608
EES 0.288 0.107 0.778 0.014
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stimuli [22] as compared to patients without these conditions. These
ﬁndings may indicate a dysfunctional purinergic signaling mediated
ADP receptor, but also of the presence of a hyper-reactive platelet phe-
notype. In our analysis, the lack of signiﬁcant interaction between DAPT
duration (6 vs 24 months) and either eGFR or each stent on ST primary
outcome, suggests that DAPT prolongation with clopidogrel may not be
sufﬁcient to reduce the occurrence of ST in CKD patients (like in non-
CKD patients) consistently with the previously reported post-hoc anal-
ysis of CREDO [23] and CHARISMA [24]. These considerations may not
apply for novel P2Y12 inhibitors like prasugrel and ticagrelor (which
were not used in the PRODIGY trial) and have showed to reduce cardio-
vascular events in ACS patients [25,26].
Table 5
Multivariable adjusted hazard ratios and 95% conﬁdence intervals for deﬁnite and probable stent thrombosis. Covariate included in the model as in Table 4, abbreviations as in Table 1.
Covariate BMS (ref.) ZES-S (ref.) PES (ref.) EES (ref.)
BMS 1 2.535 [1.056–6.088] 0.847 [0.449–1.598] 3.467 [1.285–9.352]
ZES-S 0.394 [0.164–0.947] 1 0.334 [0.141–0.789] 1.367 [0.434–4.312]
PES 1.180 [0.626–2.226] 2.993 [1.268–7.062] 1 4.092 [1.539–10.88]
EES 0.288 [0.107–0.778] 0.731 [0.232–2.306] 0.244 [0.092–0.650] 1
Fig. 3. Cumulative incidence of death, recurrent myocardial infarction, or stroke in
non-CKD patients (panel A) and CKD patients (panel B). Abbreviation as in Table 1.
Fig. 4. Cumulative incidence of all-cause death in non-CKD patients (panel A) and CKD
patients (panel B). Abbreviations as in Table 1.
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HR = 0.394, 95% CI [0.164–0.947, p = 0.037] respectively, Table 4.
Similar patterns of reduced incidence of deﬁnite or probable ST were
observed in patients without CKD Table 3. Other independent predic-
tors of ST were: eGFR b 60 ml/min/1.73 m2, HR = 2.218 95% CI
[1.189–4.138, p = 0.012], LVEF (%), HR = 0.969 95% CI [0.945–0.994,
p = 0.015] and ACS at presentation vs stable CAD, HR = 3.981 95% CI
[1.219–13.9 p = 0.022].
The number of patients needed to be treated with an EES vs BMS to
prevent 1 deﬁnite or probable ST at 2 yearswas 20 in patients with CKD
and 50 in patients without CKD.
We found no signiﬁcant interaction between either DAPT duration
(6 vs 24 months) PINT = 0.47 for BMS, PINT = 0.57 for PES, PINT = 0.41
for ZES-S and PINT = 0.28 for EES, or eGFR level (b60 vs ≥60 ml/min/
1.73 m2) pint = 0.78 for BMS, pint = 0.63 for PES, pint = 0.20 for ZES-S
and pint = 0.79 for EES on ST outcome.
Both EES and ZES-S were associated with lower adjusted ST risk also
when compared with PES, Table 5.
3.3. Major adverse cardiovascular events
Patients with CKD at baseline had an increased risk of MACE at two
years of follow-upwith a hazard ratio of 2.04, 95%CI [1.65–2.52] as com-
pared with patients with eGFR N 60 ml/min/1.73 m2, Table 3; Fig. 3a,b.
CKD patients randomized to EES had lower incident MACE events
26.4% as compared to patients randomized to BMS 35.1%, ZES-S 33.0%,
or PES 35.7%, p = 0.551 (Fig. 3b). The individual components of the
composite endpointwere signiﬁcantly different among the stent alloca-
tion arms (Table 3): all-cause deathwas lowest in the ZES-S group10.6%
as compared with BMS 18.1%, PES 25.5% and EES 14.9%, p = 0.040, Fig.
4b. At multivariable analysis age, eGFR b 60ml/min/1.73, LVEF, diabetes
and total stent length, but not stent type were independent predictors
of MACE after two years of follow-up, sTable 1, the result was main-
tained by including eGFR as a continuous variable. Consistently age,
eGFR b 60 ml/min/1.73 and LVEF, but not stent type were independent
predictors of all-cause death, sTable 2.
3.4. Target lesion revascularization
Patients with CKD had non-signiﬁcantly more TLR at two years of
follow-up as compared with patients without CKD, with a hazard ratio
of 1.330, 95% CI [0.957–1.840, p = 0.089]. TLR was not signiﬁcantly dif-
ferent among the four stent arms in CKD patients Table 3, sFigure 2b.
However, the use of drug eluting stents including either ZES-S, or PES
or EES signiﬁcantly reduced TLR as comparedwith BMS atmultivariable
analysis, sTable 3, sFigure 2a,b.
4. Discussion
In an all-comer population of patients with stable and unstable CAD,
CKDwas observed in≈ one out of ﬁve patients andwas associatedwith
doubled risk of MACE and ST.
Similar to prior observations in PRODIGY patients without CKD [12,
13], we observed that CKD patients randomized to receive EES or ZES-
S had lower adjusted risk of deﬁnite or probable ST as compared with
patients receiving BMS or PES, with an adjusted hazard ratio of 0.409
[0.209–0.797] for EES, which was directionally consistent for ZES-S
0.789 [0.459–1.357] as compared with BMS. Patients who received
EES had also lower adjusted risk of ST as compared with patients who
received PES 0.360 [0.187–0.969], but not ZES-S 0.518 [0.257–1.041],
Table 5. This association was not modiﬁed by DAPT duration (6 vs
24 months) as the interaction test was non-signiﬁcant for each stent
type.
CKD patients who were randomized to receive EES had the lowest
numerical MACE and all-cause death incidence after two years of
follow-up as compared with BMS, ZES-S or PES patients. However, un-
like ST, the association between reduced MACE and speciﬁcally all-
cause death with EES was not maintained after adjusting for con-
founders and covariates with multivariable analysis. This suggests that
it may be either a spurious association or β type error. In fact ST inci-
dence in CKD patients may only explain part of the worse outcome of
these patients which were older and associated with several baseline
variables of increased risk (Table 1).
CKD patients had a trend toward higher TLR after two years of fol-
low-up, however, there was no difference between BMS, and either
1st or 2nd generation DES. This ﬁnding may be explained by a numeri-
cally higher TLR incidence in the DES group (both 1st and 2nd genera-
tion), while TLR with BMS was numerically similar in both CKD and
non-CKD patients (Table 3, sTable 3, sFigure 2a,b).
There may be several possible reasons to explain increased ST inci-
dence in CKD patients as compared to patients without CKD patients.
First, CKD is associatedwith systemic persistent inﬂammation endo-
thelial dysfunction [17,18], which may interact differently in patients
receiving BMS as compared with 1st and 2nd generation DES. This
may eventually amplify the coronary inﬂammation process after stent
deployment and delay strut re-endothelialization. In this regard EES
with its thinner strut design, more biocompatible polymers, less poly-
mer mass and limus-based antiproliferative drugs may induce lower
local inﬂammatory response and explain lower ST incidence as com-
pared to both BMS and ﬁrst generation DES. Our ﬁndings in CKD pa-
tients are aligned with recent trials [19,20] and meta-analysis [21]
which showed that second generation DES is associated with lower ST
rate than BMS and ﬁrst generation DES. Importantly in CKD population
the number needed to treat with EES vs BMS to prevent one ST (NNT =
20) was much lower than the non-CKD population (NNT= 50), indicat-
ing a much higher absolute beneﬁt.
Second, the presence of CKD is associatedwith higher atherosclerot-
ic burden, diffuse coronary disease and coronary calciﬁcation which
may in turn favor stent malapposition, under-expansion, eventually
leading to ST. Of note, reduced ST with EES was maintained even after
adjusting for total stent length, which may partly account for this
issue. Coronary calciﬁcation and diffuse disease are also well-known
risk factors for in-stent restenosis and TLR. Both 1st and 2nd generation
DES, which have lower late loss than BMS, did not signiﬁcantly reduce
TLR in our population (sFigure 2ab) as previously reported [3,4]. This
ﬁnding reinforces the inﬂammation hypothesis as a predominant expla-
nation of the lower STwith EES, on the other side raises thedoubt on the
efﬁcacy of DES in preventing TLR in calciﬁed vessels like those found in
CKD patients and needs further investigations (sFigure 2b).
Finally, CKD patients may be poor responders to DAPT. It was dem-
onstrated that diabetic patients with eGFR b 60ml/min/1.73 m2 receiv-
ing aspirin and clopidogrel had much higher platelet reactivity after
ADP stimuli and a 2-fold increase in high platelet reactivity after ADP
Table 4
Cox proportional hazard regression. Patients included N = 1845, patients excluded for
missing data N= 158. Deﬁnite and probable stent thrombosis events = 51. Abbreviation
as in Tables 1 and 2.
y = ST
(deﬁnite or probable)
Hazard
ratio
Lower
95% CI
Upper
95% CI
p-Value
Age (years) 1.000 0.976 1.026 0.973
eGFR b 60 ml/min/1.73 m2 2.218 1.189 4.138 0.012
LVEF (%) 0.969 0.945 0.994 0.015
Diabetes 1.121 0.604 2.081 0.718
ACS vs stable CAD 3.981 1.219 13.00 0.022
6 vs 24 months DAPT 1.398 0.798 2.448 0.241
Total stent length (mm) 1.000 0.990 1.009 0.973
Stent type
BMS (reference)
ZES-S 0.394 0.164 0.947 0.037
PES 1.180 0.626 2.226 0.608
EES 0.288 0.107 0.778 0.014
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stimuli [22] as compared to patients without these conditions. These
ﬁndings may indicate a dysfunctional purinergic signaling mediated
ADP receptor, but also of the presence of a hyper-reactive platelet phe-
notype. In our analysis, the lack of signiﬁcant interaction between DAPT
duration (6 vs 24 months) and either eGFR or each stent on ST primary
outcome, suggests that DAPT prolongation with clopidogrel may not be
sufﬁcient to reduce the occurrence of ST in CKD patients (like in non-
CKD patients) consistently with the previously reported post-hoc anal-
ysis of CREDO [23] and CHARISMA [24]. These considerations may not
apply for novel P2Y12 inhibitors like prasugrel and ticagrelor (which
were not used in the PRODIGY trial) and have showed to reduce cardio-
vascular events in ACS patients [25,26].
Table 5
Multivariable adjusted hazard ratios and 95% conﬁdence intervals for deﬁnite and probable stent thrombosis. Covariate included in the model as in Table 4, abbreviations as in Table 1.
Covariate BMS (ref.) ZES-S (ref.) PES (ref.) EES (ref.)
BMS 1 2.535 [1.056–6.088] 0.847 [0.449–1.598] 3.467 [1.285–9.352]
ZES-S 0.394 [0.164–0.947] 1 0.334 [0.141–0.789] 1.367 [0.434–4.312]
PES 1.180 [0.626–2.226] 2.993 [1.268–7.062] 1 4.092 [1.539–10.88]
EES 0.288 [0.107–0.778] 0.731 [0.232–2.306] 0.244 [0.092–0.650] 1
Fig. 3. Cumulative incidence of death, recurrent myocardial infarction, or stroke in
non-CKD patients (panel A) and CKD patients (panel B). Abbreviation as in Table 1.
Fig. 4. Cumulative incidence of all-cause death in non-CKD patients (panel A) and CKD
patients (panel B). Abbreviations as in Table 1.
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5. Study limitations
There are limitations to acknowledge in this study. Serum creatinine
was used for the calculation of GFR, however GFR estimation with the
modiﬁcation of diet in renal disease formula is mostly used in clinical
practice especially in patients undergoing urgent PCI.
Although stent type was randomized in the overall PRODIGY popu-
lation, the selection of CKD population may have introduced some
bias. To overcome this potential limitation we adjusted the association
between stent type and outcome with multivariable regression includ-
ing a priori established risk factors and confounders.
The population with eGFR b30ml/min/1.73 m2 and dialysis was rel-
atively underrepresented in the PRODIGY trial and the ﬁnal population
may be slightly underpowered to test clinical outcome. However, given
the high incidence of stent thrombosis in those population, the long
term follow-up (up two years) and the lack of randomized ad-hoc stud-
ieswe believe that this analysismay add to the current evidence in favor
of 2nd generation DES use in higher risk population to reduce stent
thrombosis.
6. Conclusions
In an all-comer population of patients with stable and unstable CAD,
the presence of CKD at baseline was associated with a double risk of ST
and MACE. CKD patients randomized to receive EES had less than half
the risk of developing incident deﬁnite or probable ST at 2 years as com-
pared with patients who received BMS and 1st generation DES. These
data suggest that 2nd generation limus-based stent should be favored
over paclitaxel-based DES and BMS to reduce MACE and ST in CKD
patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2016.03.033.
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5. Study limitations
There are limitations to acknowledge in this study. Serum creatinine
was used for the calculation of GFR, however GFR estimation with the
modiﬁcation of diet in renal disease formula is mostly used in clinical
practice especially in patients undergoing urgent PCI.
Although stent type was randomized in the overall PRODIGY popu-
lation, the selection of CKD population may have introduced some
bias. To overcome this potential limitation we adjusted the association
between stent type and outcome with multivariable regression includ-
ing a priori established risk factors and confounders.
The population with eGFR b30ml/min/1.73 m2 and dialysis was rel-
atively underrepresented in the PRODIGY trial and the ﬁnal population
may be slightly underpowered to test clinical outcome. However, given
the high incidence of stent thrombosis in those population, the long
term follow-up (up two years) and the lack of randomized ad-hoc stud-
ieswe believe that this analysismay add to the current evidence in favor
of 2nd generation DES use in higher risk population to reduce stent
thrombosis.
6. Conclusions
In an all-comer population of patients with stable and unstable CAD,
the presence of CKD at baseline was associated with a double risk of ST
and MACE. CKD patients randomized to receive EES had less than half
the risk of developing incident deﬁnite or probable ST at 2 years as com-
pared with patients who received BMS and 1st generation DES. These
data suggest that 2nd generation limus-based stent should be favored
over paclitaxel-based DES and BMS to reduce MACE and ST in CKD
patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2016.03.033.
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ABSTRACT
OBJECTIVE
To assess the benefits and risks of short term (<12 
months) or extended (>12 months) dual antiplatelet 
therapy (DAPT) versus standard 12 month therapy, 
following percutaneous coronary intervention with 
drug eluting stents.
DESIGN
Meta-analysis of randomised controlled trials.
DATA SOURCES 
PubMed, Embase, Cumulative Index to Nursing and 
Allied Health Literature, Scopus, Web of Science, 
Cochrane Library, and major congress proceedings, 
searched from 1 January 2002 to 16 February 2015.
REVIEW METHODS
Trials comparing short term (<12 months) or extended 
(>12 months) DAPT regimens with standard 12 month 
duration of therapy. Primary outcomes were 
cardiovascular mortality, myocardial infarction, stent 
thrombosis, major bleeding, and all cause mortality.
RESULTS
10 randomised controlled trials (n=32 287) were 
included. Compared to 12 month DAPT, a short term 
course of therapy was associated with a significant 
reduction in major bleeding (odds ratio 0.58 (95% 
confidence interval 0.36 to 0.92); P=0.02) with no 
significant differences in ischaemic or thrombotic 
outcomes. Extended versus 12 month DAPT yielded a 
significant reduction in the odds of myocardial 
infarction (0.53 (0.42 to 0.66); P<0.001) and stent 
thrombosis (0.33 (0.21 to 0.51); P<0.001), but more 
major bleeding (1.62 (1.26 to 2.09); P<0.001). All cause 
but not cardiovascular death was also significantly 
increased (1.30 (1.02 to 1.66); P=0.03).
CONCLUSIONS
Compared with a standard 12 month duration, short 
term DAPT (<12 months) after drug eluting stent 
implementation yields reduced bleeding with no 
apparent increase in ischaemic complications, and 
could be considered for most patients. In selected 
patients with low bleeding risk and very high ischaemic 
risk, extended DAPT (>12 months) could be considered. 
The increase in all cause but not cardiovascular death 
with extended DAPT requires further investigation.
Introduction
Drug eluting stents have consistently improved the safety 
and eﬃcacy of percutaneous coronary intervention as 
compared with bare metal stents.1-4  While drug eluting 
stents have reduced in-stent restenosis, uncertainty has 
arisen regarding the risk of associated late and very late 
stent thrombosis. Dual antiplatelet therapy consisting of 
aspirin plus a P2Y12 receptor antagonist is recommended 
after drug eluting stent implantation for at least 
12 months by the American College of Cardiology/Ameri-
can Heart Association and for six to 12 months by Euro-
pean guidelines,5 6 followed by aspirin monotherapy. 
Current recommendations, however, are based largely on 
observational data with few randomised controlled trials. 
The most recent trials and meta-analyses have sug-
gested comparable eﬃcacy of short term dual antiplate-
let therapy versus therapy of at least 12 months, 
especially with newer generation drug eluting stents,7-9 
but these studies are underpowered to draw deﬁnitive 
conclusions. On the other hand, very late stent throm-
bosis still occurs with drug eluting stents, especially 
after ﬁrst generation devices, raising the question of 
whether prolongation of dual antiplatelet therapy oﬀers 
clinical benefit. One randomised controlled trial 
recently showed a signiﬁcant reduction of stent throm-
bosis with dual antiplatelet therapy extended beyond 
12 months at the price of increased bleeding.10 Thus, the 
optimal duration of dual antiplatelet therapy is 
debated, with short term and extended protocols not 
yet compared to standard 12 month treatment within 
the same trial. We aimed to perform a meta-analysis of 
randomised controlled trials to compare the eﬃcacy 
and safety of short term and extended dual antiplatelet 
therapy with standard 12 month therapy.
Methods
Data sources and search strategy
Established methods were used in compliance with the 
Preferred Reporting Items for Systematic reviews and 
WHAT IS ALREADY KNOWN ON THIS TOPIC
Dual antiplatelet therapy is currently recommended after the implantation of drug 
eluting stents, but the optimal duration is a matter of debate
The currently recommended 12 month duration is of uncertain value
WHAT THIS STUDY ADDS
Compared with a 12 month duration, short term (<12 months) dual antiplatelet 
therapy yields reduced bleeding without increasing ischaemic complications
Dual antiplatelet therapy extended beyond 12 months reduces ischaemic and 
thrombotic events compared with a 12 month regimen, but at the price of greater 
risk of major bleeding and all cause death
The increase in all cause but not cardiovascular death seen with extended therapy 
requires further investigation
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aspirin plus a P2Y12 receptor antagonist is recommended 
after drug eluting stent implantation for at least 
12 months by the American College of Cardiology/Ameri-
can Heart Association and for six to 12 months by Euro-
pean guidelines,5 6 followed by aspirin monotherapy. 
Current recommendations, however, are based largely on 
observational data with few randomised controlled trials. 
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gested comparable eﬃcacy of short term dual antiplate-
let therapy versus therapy of at least 12 months, 
especially with newer generation drug eluting stents,7-9 
but these studies are underpowered to draw deﬁnitive 
conclusions. On the other hand, very late stent throm-
bosis still occurs with drug eluting stents, especially 
after ﬁrst generation devices, raising the question of 
whether prolongation of dual antiplatelet therapy oﬀers 
clinical benefit. One randomised controlled trial 
recently showed a signiﬁcant reduction of stent throm-
bosis with dual antiplatelet therapy extended beyond 
12 months at the price of increased bleeding.10 Thus, the 
optimal duration of dual antiplatelet therapy is 
debated, with short term and extended protocols not 
yet compared to standard 12 month treatment within 
the same trial. We aimed to perform a meta-analysis of 
randomised controlled trials to compare the eﬃcacy 
and safety of short term and extended dual antiplatelet 
therapy with standard 12 month therapy.
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Meta-Analyses (PRISMA) statement in healthcare inter-
ventions.11 We screened Medline, Embase, the Cumula-
tive Index to Nursing and Allied Health Literature, 
Scopus, Web of Science, the Cochrane Register of Con-
trolled Clinical Trials, as well as congress proceedings 
from major cardiac societies, for randomised data com-
paring diﬀerent durations of dual antiplatelet therapy. 
Dual antiplatelet therapy was deﬁned as aspirin plus a 
P2Y12 receptor inhibitor, after percutaneous coronary 
intervention with implantation of a drug eluting stent. 
The search period took place from 1 January 2002 to 16 
February 2015. 
Search terms according to medical subjects headings 
were: “DAPT”, “dual antiplatelet therapy”, “clopidogrel”, 
“Plavix”, “prasugrel”, “Eﬁent”, “ticagrelor”, “Brilinta”, 
“thienopyridine”, “P2Y12”, “shortened DAPT”, “pro-
longed DAPT”, “extended DAPT”, “premature cessation”, 
“early discontinuation”, “randomised trial”, and “trial”. 
No language or publication status restriction was 
imposed. The most updated or inclusive data for each 
study were used for abstraction. In addition, landmark 
analysis data at 12 months were available from the origi-
nal PROlonging Dual antIplatelet treatment after Grading 
stent-induced intimal hyperplasia studY (PRODIGY)7 and 
were therefore incorporated into the present article.
Study design and selection criteria
The design of the current meta-analysis compared two 
strategies of dual antiplatelet therapy involving three 
durations after percutaneous coronary intervention 
with drug eluting stent implantation. The ﬁrst compar-
ison was between a short term (<12 months) and 
12 month therapy, and the second between an extended 
duration (>12 months) and 12 month therapy. The origi-
nal PRODIGY randomised controlled trial7 assigned 
patients to either six or 24 month durations. Because 
the randomisation process in PRODIGY began one 
month after the index percutaneous coronary interven-
tion, the availability of landmark data at 12 months 
allowed inclusion of the study in the short term versus 
12 month comparison, after censoring events that 
occurred after 12 months and keeping the original ran-
domisation design. We did additional sensitivity analy-
ses by including PRODIGY trial data in the extended 
duration versus 12 month comparison. The analyses 
included only events that occurred beyond 12 months in 
both study arms (postrandomisation subgroups). 
The main exclusion criteria for this meta-analysis 
were: observational design, patients without docu-
mented coronary artery disease or patients with periph-
eral or cerebrovascular disease, percutaneous coronary 
intervention without stents or with bare metal stents 
only, and duration timeframes of dual antiplatelet ther-
apy selected by the meta-analysis not reported. Two 
independent reviewers (VS and MK) selected the stud-
ies for inclusion and extracted the study characteristics 
and relevant outcomes; divergences were solved by con-
sensus after discussion with a third reviewer (EPN). Three 
authors (EPN, MK, and VS) independently reassessed the 
trials’ eligibility and ranked their risk of bias. Risk of bias 
was graded using the components recommended by the 
Cochrane Collaboration—that is, random sequence 
generation; allocation concealment; blinding of partic-
ipants, personnel, and outcome assessors; incomplete 
outcome data; selective outcome reporting; and other 
sources of bias.12
Outcome measures
Primary clinical endpoints were cardiovascular mortal-
ity, myocardial infarction, stent thrombosis, major 
bleeding, and overall mortality; secondary endpoints 
were repeat revascularisation, and cerebrovascular acci-
dent, and the combination of cardiac and cerebrovascu-
lar accidents. We classiﬁed stent thrombosis as deﬁnite/
probable, deﬁnite, late (between 30 days and one year 
after percutaneous coronary intervention), and very late 
(>one year after percutaneous coronary intervention) 
according to criteria from the Academic Research Con-
sortium.13  For major bleeding, trial deﬁnitions were 
applied. Major bleeding according to TIMI criteria,14 and 
a composite endpoint of major adverse cardiac and cere-
brovascular accidents were also assessed.
Statistical analyses
Data were analysed according to the intention to treat 
principle. Odds ratios and 95% conﬁdence intervals 
were used as summary statistics. Heterogeneity was 
assessed by Cochran’s Q test.15 We also used the statisti-
cal inconsistency test (I2=(Q−df)/Q×100%, where Q=χ2 
statistic and df=its degrees of freedom) to overcome the 
low statistical power of Cochran’s Q test. Pooled odds 
ratios were calculated using a ﬁxed eﬀect model with 
the Mantel-Haenszel method, because of the absence of 
moderate or signiﬁcant inconsistency (>50%) across 
studies. We also did prespeciﬁed sensitivity analyses 
using a random eﬀects model. Potential publication 
bias was examined by constructing funnel plots for the 
clinical outcomes in which the standard error of the log 
of the odds ratio was plotted against the odds ratio. The 
asymmetry of the plot was estimated both visually and 
by Harbord’s regression test.16 Prespeciﬁed analyses 
assessed the eﬀect of diﬀerent durations of dual anti-
platelet therapy in the following subgroups: age older 
than 65 years or younger than 65 years, patients with or 
without acute coronary syndrome, and those treated 
with either clopidogrel or new P2Y12 inhibitors (prasu-
grel and ticagrelor). P<0.05 was considered signiﬁcant 
and reported as two sided.
Results
Studies and patients
The PRISMA statement ﬂowchart (web ﬁg 1) describes 
the literature screening, study selection, and reasons for 
exclusion. From 338 initial studies, 295 were discarded 
at title or abstract level. Another 33 studies did not meet 
the prespeciﬁed inclusion criteria and were therefore 
excluded. A total of 10 randomised controlled trials 
(n=32 287)7 8 10 17-28  were ﬁnally included in the meta-anal-
ysis. Tables 1  and 2  list the characteristics and refer-
ences of the included studies. Web ﬁg 2 summarises the 
quality of included studies, along with potential sources 
of bias. Web table 1 outlines the full electronic Medline 
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Meta-Analyses (PRISMA) statement in healthcare inter-
ventions.11 We screened Medline, Embase, the Cumula-
tive Index to Nursing and Allied Health Literature, 
Scopus, Web of Science, the Cochrane Register of Con-
trolled Clinical Trials, as well as congress proceedings 
from major cardiac societies, for randomised data com-
paring diﬀerent durations of dual antiplatelet therapy. 
Dual antiplatelet therapy was deﬁned as aspirin plus a 
P2Y12 receptor inhibitor, after percutaneous coronary 
intervention with implantation of a drug eluting stent. 
The search period took place from 1 January 2002 to 16 
February 2015. 
Search terms according to medical subjects headings 
were: “DAPT”, “dual antiplatelet therapy”, “clopidogrel”, 
“Plavix”, “prasugrel”, “Eﬁent”, “ticagrelor”, “Brilinta”, 
“thienopyridine”, “P2Y12”, “shortened DAPT”, “pro-
longed DAPT”, “extended DAPT”, “premature cessation”, 
“early discontinuation”, “randomised trial”, and “trial”. 
No language or publication status restriction was 
imposed. The most updated or inclusive data for each 
study were used for abstraction. In addition, landmark 
analysis data at 12 months were available from the origi-
nal PROlonging Dual antIplatelet treatment after Grading 
stent-induced intimal hyperplasia studY (PRODIGY)7 and 
were therefore incorporated into the present article.
Study design and selection criteria
The design of the current meta-analysis compared two 
strategies of dual antiplatelet therapy involving three 
durations after percutaneous coronary intervention 
with drug eluting stent implantation. The ﬁrst compar-
ison was between a short term (<12 months) and 
12 month therapy, and the second between an extended 
duration (>12 months) and 12 month therapy. The origi-
nal PRODIGY randomised controlled trial7 assigned 
patients to either six or 24 month durations. Because 
the randomisation process in PRODIGY began one 
month after the index percutaneous coronary interven-
tion, the availability of landmark data at 12 months 
allowed inclusion of the study in the short term versus 
12 month comparison, after censoring events that 
occurred after 12 months and keeping the original ran-
domisation design. We did additional sensitivity analy-
ses by including PRODIGY trial data in the extended 
duration versus 12 month comparison. The analyses 
included only events that occurred beyond 12 months in 
both study arms (postrandomisation subgroups). 
The main exclusion criteria for this meta-analysis 
were: observational design, patients without docu-
mented coronary artery disease or patients with periph-
eral or cerebrovascular disease, percutaneous coronary 
intervention without stents or with bare metal stents 
only, and duration timeframes of dual antiplatelet ther-
apy selected by the meta-analysis not reported. Two 
independent reviewers (VS and MK) selected the stud-
ies for inclusion and extracted the study characteristics 
and relevant outcomes; divergences were solved by con-
sensus after discussion with a third reviewer (EPN). Three 
authors (EPN, MK, and VS) independently reassessed the 
trials’ eligibility and ranked their risk of bias. Risk of bias 
was graded using the components recommended by the 
Cochrane Collaboration—that is, random sequence 
generation; allocation concealment; blinding of partic-
ipants, personnel, and outcome assessors; incomplete 
outcome data; selective outcome reporting; and other 
sources of bias.12
Outcome measures
Primary clinical endpoints were cardiovascular mortal-
ity, myocardial infarction, stent thrombosis, major 
bleeding, and overall mortality; secondary endpoints 
were repeat revascularisation, and cerebrovascular acci-
dent, and the combination of cardiac and cerebrovascu-
lar accidents. We classiﬁed stent thrombosis as deﬁnite/
probable, deﬁnite, late (between 30 days and one year 
after percutaneous coronary intervention), and very late 
(>one year after percutaneous coronary intervention) 
according to criteria from the Academic Research Con-
sortium.13  For major bleeding, trial deﬁnitions were 
applied. Major bleeding according to TIMI criteria,14 and 
a composite endpoint of major adverse cardiac and cere-
brovascular accidents were also assessed.
Statistical analyses
Data were analysed according to the intention to treat 
principle. Odds ratios and 95% conﬁdence intervals 
were used as summary statistics. Heterogeneity was 
assessed by Cochran’s Q test.15 We also used the statisti-
cal inconsistency test (I2=(Q−df)/Q×100%, where Q=χ2 
statistic and df=its degrees of freedom) to overcome the 
low statistical power of Cochran’s Q test. Pooled odds 
ratios were calculated using a ﬁxed eﬀect model with 
the Mantel-Haenszel method, because of the absence of 
moderate or signiﬁcant inconsistency (>50%) across 
studies. We also did prespeciﬁed sensitivity analyses 
using a random eﬀects model. Potential publication 
bias was examined by constructing funnel plots for the 
clinical outcomes in which the standard error of the log 
of the odds ratio was plotted against the odds ratio. The 
asymmetry of the plot was estimated both visually and 
by Harbord’s regression test.16 Prespeciﬁed analyses 
assessed the eﬀect of diﬀerent durations of dual anti-
platelet therapy in the following subgroups: age older 
than 65 years or younger than 65 years, patients with or 
without acute coronary syndrome, and those treated 
with either clopidogrel or new P2Y12 inhibitors (prasu-
grel and ticagrelor). P<0.05 was considered signiﬁcant 
and reported as two sided.
Results
Studies and patients
The PRISMA statement ﬂowchart (web ﬁg 1) describes 
the literature screening, study selection, and reasons for 
exclusion. From 338 initial studies, 295 were discarded 
at title or abstract level. Another 33 studies did not meet 
the prespeciﬁed inclusion criteria and were therefore 
excluded. A total of 10 randomised controlled trials 
(n=32 287)7 8 10 17-28  were ﬁnally included in the meta-anal-
ysis. Tables 1  and 2  list the characteristics and refer-
ences of the included studies. Web ﬁg 2 summarises the 
quality of included studies, along with potential sources 
of bias. Web table 1 outlines the full electronic Medline 
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search process. No publication bias was suggested by 
the funnel plots (web ﬁgs 3-8) and by Harbord’s regres-
sion test (web table 7). Seven studies tested short term 
regimens (<12 months) of dual antiplatelet therapy against 
12 months’ duration (table 1),7 8 22–28  and three studies 
tested extended regimens (>12 months; table 2).10 17-21
Clopidogrel and aspirin was the most frequent drug 
combination in dual antiplatelet therapy; prasugrel or 
ticagrelor were available in three8 10 17-19  and two8-28 
studies, respectively. Of 32 287 patients, 7975 were ran-
domly allocated to short term regimens and 8196 to 
extended regimens of dual antiplatelet therapy; 16 116 
patients constituted the 12 month control group. Web 
table 2 lists the patients’ baseline characteristics. 
Patients presented evenly, with either stable angina/
silent ischaemia or non-ST segment elevation acute cor-
onary syndrome (48% and 45%, respectively); fewer than 
10% presented with ST segment elevation myocardial 
infarction. Web table 3 lists procedural characteristics 
of each study. Web table 4 lists deﬁnitions of major 
adverse cardiac and cerebrovascular events.
Cardiovascular mortality and myocardial infarction
Eight studies including 26 996 patients provided data 
for cardiovascular mortality. Cardiovascular mortality 
after short term and 12 month dual antiplatelet therapy 
did not diﬀer signiﬁcantly (event rate 1.13% (68/5997 
patients) v 1.20% (72/6013); odds ratio 0.95 (95% conﬁ-
dence interval 0.68 to 1.33); P=0.76; I2=0%; ﬁg 1). Simi-
larly, cardiovascular mortality did not differ 
signiﬁcantly between extended dual antiplatelet ther-
apy and 12 month therapy (1.03% (78/7551) v 0.95% 
(71/7455); 1.09 (0.79 to 1.50); P=0.62; I2=34%; ﬁg 1).
All 10 randomised controlled trials (n=32 287) were 
included in the myocardial infarction analysis. Myocar-
dial infarction rates were similar in patients ran-
domised to either short term or 12 month dual 
antiplatelet  therapy (1.65% (132/7975 patients) v 1.50% 
(120/8020); odds ratio 1.11 (95% conﬁdence interval 0.87 
to 1.43); P=0.40; I2=0%; ﬁg 1). We saw a reduction of 
roughly 50% in the odds of myocardial infarction with 
extended dual antiplatelet therapy, compared with 12 
month therapy (1.55% (127/8196) v 2.89% (234/8096); 
0.53 (0.42 to 0.66); P<0.001; I2=37%; ﬁg 1).
Stent thrombosis
All 10 studies (n=32 287) contributed to the analysis of 
deﬁnite/probable stent thrombosis (ﬁg 2). We saw no sig-
niﬁcant diﬀerence in the rates of stent thrombosis when 
comparing short term dual antiplatelet therapy with 
12 month therapy (0.53% (42/7975 patients) v 0.40% 
(32/8020); odds ratio 1.32 (95% conﬁdence interval 0.83 
to 2.08); P=0.24; I2=0%). Similarly, the analysis of deﬁ-
nite stent thrombosis demonstrated identical rates 
(0.3%) for both short term and 12 month dual antiplate-
let therapy (1.00 (0.40 to 2.53); P=0.99; I2=0%; ﬁg 2).
By contrast, a 67% reduction in the odds of deﬁnite/
probable stent thrombosis was observed with extended 
versus 12 month dual antiplatelet therapy (odds ratio 0.33 
(95% conﬁdence interval 0.21 to 0.51); P<0.001; I2=18%; 
ﬁg 2). The corresponding rates were 0.32% (26/8196 
patients) versus 0.98% (79/8096), with a number needed 
Table 2 | Characteristics of included studies comparing extended (>12 month) versus 12 month dual antiplatelet therapy 
Inclusion criteria Exclusion criteria Primary endpoints Secondary endpoints
Time to 
randomisation
ARCTIC Interruption17 18 (2014), n=1286, 12 months v 18 months of DAPT duration*
≥18 years and eligible for 
PCI with planned use of 
≥1 DES; without use of a 
GPIIb/IIIa inhibitor at 
randomisation; able to 
understand study 
requirements and comply 
with study procedures 
and protocol
Anticoagulation with vitamin K antagonists; contraindication 
to aspirin or clopidogrel, GPIIb/IIIa inhibitors, or increased 
dose regimen of aspirin/clopidogrel; ongoing or recent 
bleeding or major surgery <3 weeks; severe liver insufficiency; 
thrombocytopenia <80 000/μL; GPIIb/IIIa inhibitor before 
randomisation; primary PCI for STEMI; history of major 
bleeding with contraindication to APT; scheduled surgery <12 
months; high risk feature of poor compliance to DAPT
Composite of all 
cause death, MI, 
stroke or TIA, urgent 
coronary 
revascularisation, 
and ST
Composite of ST (whether 
revascularised or not) and urgent 
revascularisation, all cause death, MI, 
stroke or TIA, urgent coronary 
revascularisation, and ST; main safety 
endpoint was STEEPLE major bleeding
12 months after 
index PCI
DAPT10 19 (2014), n=9961, 12 months v 30 months of DAPT duration
>18 years old, 
undergoing 
percutaneous 
intervention with stent 
deployment
Index procedure stent placement with stent diameter <2.25 
mm or >4.0 mm; pregnancy; planned surgery necessitating 
discontinuation of APT within 30 months after enrollment; life 
expectancy of <3 years; enrollment in another device or drug 
study whose protocol specifically rules out concurrent 
enrollment or involves blinded placement of a DES or BMS 
other than those included as DAPT study devices; warfarin or 
similar anticoagulant therapy; hypersensitivity or allergies to 
one of the drugs or DES components; patient treated with 
both DES and BMS during index procedure
Definite/probable ST 
and MACCE defined 
as composite of 
death, MI or stroke
Moderate or severe bleeding according 
to GUSTO14 classification; clinically 
actionable non-CABG related bleeding 
according to BARC (type 2, 3, and 5); MI, 
stroke, cardiac and vascular mortality
12 months after 
index PCI
DES LATE20 21 (2010), n=5045, 12 months v 24 months of DAPT duration
<12 months DES 
implantation; no MACE 
(MI, stroke, repeat PCI) or 
major bleeding since PCI; 
DAPT on board
DAPT contraindications due to bleeding diathesis or major 
bleeding history; long term DAPT indication due to 
concomitant vascular disease or recent ACS
MI or cardiac death All cause death; MI, stroke; ST; repeat 
revascularisation; composite of MI or all 
cause death; composite of MI, stroke, or 
all cause death; composite of MI, stroke, 
or cardiac death; TIMI14 major bleeding
12 months after 
index PCI
Data classified by study name (year), no of patients, and comparison of DAPT durations after index percutaneous coronary intervention. DAPT=dual antiplatelet therapy; PCI=percutaneous 
coronary intervention; DES=drug eluting stent; GP=glycoprotein; STEMI=ST segment elevation myocardial infarction; APT=antiplatelet therapy; MI=myocardial infarction; ST=stent thrombosis; 
TIA=transient ischaemic attack; STEEPLE=the safety and efficacy of enoxaparin in PCI patients, an international randomized evaluation; BMS=bare-metal stent; MACCE=major adverse cardiac 
and cerebrovascular events; GUSTO=global utilization of streptokinase and TPA for occluded arteries; CABG=coronary artery bypass grafting; BARC=Bleeding Academic Research Consortium; 
MACE=major adverse cardiovascular events; ACS=acute coronary syndrome.
*Available landmark data at 12 and 12-24 months.
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to treat of 152. Similarly, the analysis of deﬁnite stent 
thrombosis showed a 70% reduction in the odds of stent 
thombosis with extended versus 12 month dual antiplate-
let therapy (0.30 (0.19 to 0.49); P<0.001; I2=32%; corre-
sponding rates 0.27% (22/8196) v 0.89% (72/8096; ﬁg 2).
Timing of stent thrombosis
We saw similar rates of late stent thrombosis when com-
paring short term with 12 month dual antiplatelet therapy 
(0.36% (20/5501 patients) v 0.31% (16/5089); odds ratio 
1.24 (95% conﬁdence interval 0.65 to 2.36); P=0.50; 
I2=40%). By contrast, the odds of very late stent thrombo-
sis were signiﬁcantly reduced by 67% when comparing 
extended with 12 month therapy (0.32% (26/8196) v 0.98% 
(79/8096); 0.33 (0.21 to 0.51); P<0.001; I2=18%; ﬁg 2).
Major bleeding
Major bleeding rates were available in all studies 
(n=32 287). Short term versus 12 month dual 
 antiplatelet therapy was associated with a roughly 
40% reduction in the odds of major bleeding (event 
rate 0.35% (28/7975 patients) v 0.61% (49/8020); odds 
ratio 0.58 (95% conﬁdence interval 0.36 to 0.92); 
P=0.02; I2=0%); the corresponding number needed to 
treat to prevent a major bleed was 385. Conversely, 
continuation of dual antiplatelet therapy beyond 12 
months signiﬁcantly increased the odds of major 
bleeding by 62% (1.95% (160/8196) v 1.21% (98/8096); 
1.62 (1.26 to 2.09); P<0.001; I2=7%; ﬁg 3); the corre-
sponding number needed to harm by causing a major 
bleed was 135.
All cause mortality
All 10 randomised controlled trials (n=32 287) provided 
data for all cause death. We found no signiﬁcant diﬀer-
ences in all cause mortality between short term and 
12 month dual antiplatelet therapy (event rate 1.43% 
(114/7975 patients) v 1.56% (125/8020); odds ratio 0.91 
Cardiovascular mortality
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Test for overall effect: z=0.50, P=0.62
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Fig 1 | Individual and summary odds ratios for the endpoints of cardiovascular mortality and myocardial infarction. 
M-H=Mantel-Haenszel. Data stratified by duration of dual antiplatelet therapy: short term (<12 months) versus 12 months, 
and extended (>12 months) versus 12 months
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search process. No publication bias was suggested by 
the funnel plots (web ﬁgs 3-8) and by Harbord’s regres-
sion test (web table 7). Seven studies tested short term 
regimens (<12 months) of dual antiplatelet therapy against 
12 months’ duration (table 1),7 8 22–28  and three studies 
tested extended regimens (>12 months; table 2).10 17-21
Clopidogrel and aspirin was the most frequent drug 
combination in dual antiplatelet therapy; prasugrel or 
ticagrelor were available in three8 10 17-19  and two8-28 
studies, respectively. Of 32 287 patients, 7975 were ran-
domly allocated to short term regimens and 8196 to 
extended regimens of dual antiplatelet therapy; 16 116 
patients constituted the 12 month control group. Web 
table 2 lists the patients’ baseline characteristics. 
Patients presented evenly, with either stable angina/
silent ischaemia or non-ST segment elevation acute cor-
onary syndrome (48% and 45%, respectively); fewer than 
10% presented with ST segment elevation myocardial 
infarction. Web table 3 lists procedural characteristics 
of each study. Web table 4 lists deﬁnitions of major 
adverse cardiac and cerebrovascular events.
Cardiovascular mortality and myocardial infarction
Eight studies including 26 996 patients provided data 
for cardiovascular mortality. Cardiovascular mortality 
after short term and 12 month dual antiplatelet therapy 
did not diﬀer signiﬁcantly (event rate 1.13% (68/5997 
patients) v 1.20% (72/6013); odds ratio 0.95 (95% conﬁ-
dence interval 0.68 to 1.33); P=0.76; I2=0%; ﬁg 1). Simi-
larly, cardiovascular mortality did not differ 
signiﬁcantly between extended dual antiplatelet ther-
apy and 12 month therapy (1.03% (78/7551) v 0.95% 
(71/7455); 1.09 (0.79 to 1.50); P=0.62; I2=34%; ﬁg 1).
All 10 randomised controlled trials (n=32 287) were 
included in the myocardial infarction analysis. Myocar-
dial infarction rates were similar in patients ran-
domised to either short term or 12 month dual 
antiplatelet  therapy (1.65% (132/7975 patients) v 1.50% 
(120/8020); odds ratio 1.11 (95% conﬁdence interval 0.87 
to 1.43); P=0.40; I2=0%; ﬁg 1). We saw a reduction of 
roughly 50% in the odds of myocardial infarction with 
extended dual antiplatelet therapy, compared with 12 
month therapy (1.55% (127/8196) v 2.89% (234/8096); 
0.53 (0.42 to 0.66); P<0.001; I2=37%; ﬁg 1).
Stent thrombosis
All 10 studies (n=32 287) contributed to the analysis of 
deﬁnite/probable stent thrombosis (ﬁg 2). We saw no sig-
niﬁcant diﬀerence in the rates of stent thrombosis when 
comparing short term dual antiplatelet therapy with 
12 month therapy (0.53% (42/7975 patients) v 0.40% 
(32/8020); odds ratio 1.32 (95% conﬁdence interval 0.83 
to 2.08); P=0.24; I2=0%). Similarly, the analysis of deﬁ-
nite stent thrombosis demonstrated identical rates 
(0.3%) for both short term and 12 month dual antiplate-
let therapy (1.00 (0.40 to 2.53); P=0.99; I2=0%; ﬁg 2).
By contrast, a 67% reduction in the odds of deﬁnite/
probable stent thrombosis was observed with extended 
versus 12 month dual antiplatelet therapy (odds ratio 0.33 
(95% conﬁdence interval 0.21 to 0.51); P<0.001; I2=18%; 
ﬁg 2). The corresponding rates were 0.32% (26/8196 
patients) versus 0.98% (79/8096), with a number needed 
Table 2 | Characteristics of included studies comparing extended (>12 month) versus 12 month dual antiplatelet therapy 
Inclusion criteria Exclusion criteria Primary endpoints Secondary endpoints
Time to 
randomisation
ARCTIC Interruption17 18 (2014), n=1286, 12 months v 18 months of DAPT duration*
≥18 years and eligible for 
PCI with planned use of 
≥1 DES; without use of a 
GPIIb/IIIa inhibitor at 
randomisation; able to 
understand study 
requirements and comply 
with study procedures 
and protocol
Anticoagulation with vitamin K antagonists; contraindication 
to aspirin or clopidogrel, GPIIb/IIIa inhibitors, or increased 
dose regimen of aspirin/clopidogrel; ongoing or recent 
bleeding or major surgery <3 weeks; severe liver insufficiency; 
thrombocytopenia <80 000/μL; GPIIb/IIIa inhibitor before 
randomisation; primary PCI for STEMI; history of major 
bleeding with contraindication to APT; scheduled surgery <12 
months; high risk feature of poor compliance to DAPT
Composite of all 
cause death, MI, 
stroke or TIA, urgent 
coronary 
revascularisation, 
and ST
Composite of ST (whether 
revascularised or not) and urgent 
revascularisation, all cause death, MI, 
stroke or TIA, urgent coronary 
revascularisation, and ST; main safety 
endpoint was STEEPLE major bleeding
12 months after 
index PCI
DAPT10 19 (2014), n=9961, 12 months v 30 months of DAPT duration
>18 years old, 
undergoing 
percutaneous 
intervention with stent 
deployment
Index procedure stent placement with stent diameter <2.25 
mm or >4.0 mm; pregnancy; planned surgery necessitating 
discontinuation of APT within 30 months after enrollment; life 
expectancy of <3 years; enrollment in another device or drug 
study whose protocol specifically rules out concurrent 
enrollment or involves blinded placement of a DES or BMS 
other than those included as DAPT study devices; warfarin or 
similar anticoagulant therapy; hypersensitivity or allergies to 
one of the drugs or DES components; patient treated with 
both DES and BMS during index procedure
Definite/probable ST 
and MACCE defined 
as composite of 
death, MI or stroke
Moderate or severe bleeding according 
to GUSTO14 classification; clinically 
actionable non-CABG related bleeding 
according to BARC (type 2, 3, and 5); MI, 
stroke, cardiac and vascular mortality
12 months after 
index PCI
DES LATE20 21 (2010), n=5045, 12 months v 24 months of DAPT duration
<12 months DES 
implantation; no MACE 
(MI, stroke, repeat PCI) or 
major bleeding since PCI; 
DAPT on board
DAPT contraindications due to bleeding diathesis or major 
bleeding history; long term DAPT indication due to 
concomitant vascular disease or recent ACS
MI or cardiac death All cause death; MI, stroke; ST; repeat 
revascularisation; composite of MI or all 
cause death; composite of MI, stroke, or 
all cause death; composite of MI, stroke, 
or cardiac death; TIMI14 major bleeding
12 months after 
index PCI
Data classified by study name (year), no of patients, and comparison of DAPT durations after index percutaneous coronary intervention. DAPT=dual antiplatelet therapy; PCI=percutaneous 
coronary intervention; DES=drug eluting stent; GP=glycoprotein; STEMI=ST segment elevation myocardial infarction; APT=antiplatelet therapy; MI=myocardial infarction; ST=stent thrombosis; 
TIA=transient ischaemic attack; STEEPLE=the safety and efficacy of enoxaparin in PCI patients, an international randomized evaluation; BMS=bare-metal stent; MACCE=major adverse cardiac 
and cerebrovascular events; GUSTO=global utilization of streptokinase and TPA for occluded arteries; CABG=coronary artery bypass grafting; BARC=Bleeding Academic Research Consortium; 
MACE=major adverse cardiovascular events; ACS=acute coronary syndrome.
*Available landmark data at 12 and 12-24 months.
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to treat of 152. Similarly, the analysis of deﬁnite stent 
thrombosis showed a 70% reduction in the odds of stent 
thombosis with extended versus 12 month dual antiplate-
let therapy (0.30 (0.19 to 0.49); P<0.001; I2=32%; corre-
sponding rates 0.27% (22/8196) v 0.89% (72/8096; ﬁg 2).
Timing of stent thrombosis
We saw similar rates of late stent thrombosis when com-
paring short term with 12 month dual antiplatelet therapy 
(0.36% (20/5501 patients) v 0.31% (16/5089); odds ratio 
1.24 (95% conﬁdence interval 0.65 to 2.36); P=0.50; 
I2=40%). By contrast, the odds of very late stent thrombo-
sis were signiﬁcantly reduced by 67% when comparing 
extended with 12 month therapy (0.32% (26/8196) v 0.98% 
(79/8096); 0.33 (0.21 to 0.51); P<0.001; I2=18%; ﬁg 2).
Major bleeding
Major bleeding rates were available in all studies 
(n=32 287). Short term versus 12 month dual 
 antiplatelet therapy was associated with a roughly 
40% reduction in the odds of major bleeding (event 
rate 0.35% (28/7975 patients) v 0.61% (49/8020); odds 
ratio 0.58 (95% conﬁdence interval 0.36 to 0.92); 
P=0.02; I2=0%); the corresponding number needed to 
treat to prevent a major bleed was 385. Conversely, 
continuation of dual antiplatelet therapy beyond 12 
months signiﬁcantly increased the odds of major 
bleeding by 62% (1.95% (160/8196) v 1.21% (98/8096); 
1.62 (1.26 to 2.09); P<0.001; I2=7%; ﬁg 3); the corre-
sponding number needed to harm by causing a major 
bleed was 135.
All cause mortality
All 10 randomised controlled trials (n=32 287) provided 
data for all cause death. We found no signiﬁcant diﬀer-
ences in all cause mortality between short term and 
12 month dual antiplatelet therapy (event rate 1.43% 
(114/7975 patients) v 1.56% (125/8020); odds ratio 0.91 
Cardiovascular mortality
  EXCELLENT22
  ITALIC28
  OPTIMIZE24
  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=1.40, df=5, P=0.92, I2=0%
Test for overall effect: z=0.31, P=0.76
  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=1.50, df=1, P=0.22, I2=34%
Test for overall effect: z=0.50, P=0.62
Myocardial infarction
  EXCELLENT22
  ISAR-SAFE23
  ITALIC28
  OPTIMIZE24
  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=3.00, df=6, P=0.81, I2=0%
Test for overall effect: z=0.84, P=0.40
  ARCTIC-Interruption17,18
  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=3.16, df=2, P=0.21, I2=37%
Test for overall effect: z=5.75, P<0.001
0.66 (0.11 to 3.99)
1.67 (0.40 to 6.99)
0.91 (0.54 to 1.50)
1.00 (0.57 to 1.78)
0.50 (0.09 to 2.73)
1.05 (0.34 to 3.28)
0.95 (0.68 to 1.33)
0.95 (0.64 to 1.40)
1.47 (0.82 to 2.64)
1.09 (0.79 to 1.50)
1.87 (0.74 to 4.72)
0.93 (0.44 to 1.99)
1.50 (0.42 to 5.33)
1.17 (0.77 to 1.78)
0.94 (0.55 to 1.58)
0.50 (0.09 to 2.73)
1.17 (0.62 to 2.19)
1.11 (0.87 to 1.43)
0.99 (0.39 to 2.52)
0.48 (0.38 to 0.62)
0.70 (0.39 to 1.26)
0.53 (0.42 to 0.66)
4.2
4.2
44.5
33.1
5.7
8.2
100.0
73.4
26.6
100.0
5.9
11.9
3.4
34.9
25.0
3.4
15.4
100.0
3.8
84.5
11.6
100.0
0.01 0.1 1 10 100
Study
Favours short term
or extended DAPT
Favours
12 month DAPT
Odds ratio (95% CI)
M-H, fixed
Odds ratio (95% CI)
M-H, fixed
Weight
(%)
2/722
5/926
29/1605
24/983
2/1059
6/682
68/5977
Extended
50/5020
28/2531
78/7551
Short term
13/722
13/1998
6/926
49/1605
28/983
2/1059
21/682
132/7975
Extended
9/645
99/5020
19/2531
127/8196
Short term
3/721
3/924
32/1606
24/987
4/1058
6/717
72/6013
12 month
52/4941
19/2514
71/7455
12 month
7/721
14/2007
4/924
42/1606
30/987
4/1058
19/717
120/8020
12 month
9/641
198/4941
27/2514
234/8096
12 month
No of events/total
Fig 1 | Individual and summary odds ratios for the endpoints of cardiovascular mortality and myocardial infarction. 
M-H=Mantel-Haenszel. Data stratified by duration of dual antiplatelet therapy: short term (<12 months) versus 12 months, 
and extended (>12 months) versus 12 months
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(95% conﬁdence interval 0.71 to 1.18); P=0.49; I2=0%; 
ﬁg 4). By contrast, extended versus 12 month dual anti-
platelet therapy was associated with a higher risk of all 
cause death (1.84% (151/8196) v 1.42% (115/8096); 1.30 
(1.02 to 1.66); P=0.03; I2=0%; ﬁg 4). The number needed 
to harm was 238.
Repeat revascularisation and cerebrovascular 
accidents
Repeat revascularisation data were available from 
seven studies (n=16 351). Short term duration of dual 
antiplatelet therapy yielded similar results compared 
with 12 month duration (event rate 3.06% (153/4994 
Definite or probable stent thrombosis
  EXCELLENT22
  ISAR-SAFE23
  ITALIC28
  OPTIMIZE24
  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=4.20, df=6, P=0.65, I2=0%
Test for overall effect: z=1.18, P=0.24
  ARCTIC-Interruption17,18
  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=2.43, df=2, P=0.30, I2=18%
Test for overall effect: z=4.98, P<0.001
Definite stent thrombosis
  ISAR-SAFE23
  PRODIGY7,26
Total (95% CI)
Test for heterogeneity: χ2=0.89, df=1, P=0.35, I2=0%
Test for overall effect: z=0.01, P=0.99
  ARCTIC-Interruption17,18
  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=2.94, df=2, P=0.23, I2=32%
Test for overall effect: z=4.92, P<0.001
Late stent thrombosis
  EXCELLENT22
  OPTIMIZE24
  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=6.66, df=4, P=0.16, I2=40%
Test for overall effect: z=0.67, P=0.50
Very late stent thrombosis
  ARCTIC-Interruption17,18
  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=2.43, df=2, P=0.30, I2=18%
Test for overall effect: z=4.98, P<0.001
6.03 (0.72 to 50.24)
1.26 (0.34 to 4.69)
7.01 (0.36 to 135.85)
1.08 (0.49 to 2.38)
1.12 (0.45 to 2.76)
0.67 (0.11 to 3.99)
1.05 (0.21 to 5.23)
1.32 (0.83 to 2.08)
0.14 (0.01 to 2.74)
0.29 (0.17 to 0.48)
0.63 (0.24 to 1.63)
0.33 (0.21 to 0.51)
1.68 (0.40 to 7.02)
0.67 (0.19 to 2.37)
1.00 (0.40 to 2.53)
0.14 (0.01 to 2.74)
0.25 (0.14 to 0.45)
0.63 (0.24 to 1.63)
0.30 (0.19 to 0.49)
6.03 (0.72 to 50.24)
4.01 (0.45 to 35.92)
1.12 (0.45 to 2.76)
0.14 (0.01 to 2.76)
0.21 (0.01 to 4.38)
1.24 (0.65 to 2.36)
0.14 (0.01 to 2.74)
0.29 (0.17 to 0.48)
0.63 (0.24 to 1.63)
0.33 (0.21 to 0.51)
3.1
12.4
1.6
37.0
27.6
9.3
9.1
100.0
4.4
81.8
13.8
100.0
33.4
66.6
100.0
4.8
80.1
15.1
100.0
5.9
5.9
52.9
20.8
14.5
100.0
4.4
81.8
13.8
100.0
0.01 0.1 1 10 100
Study
Favours short term
or extended DAPT
Favours
12 month DAPT
Odds ratio (95% CI)
M-H, fixed
Odds ratio (95% CI)
M-H, fixed
Weight
(%)
6/722
5/1998
3/926
13/1605
10/983
2/1059
3/682
42/7975
Extended
0/645
19/5020
7/2531
26/8196
Short term
5/1998
4/983
9/2981
Extended
0/645
15/5020
7/2531
22/8196
Short term
6/722
4/1605
10/983
0/1059
0/682
20/5051
Extended
0/645
19/5020
7/2531
26/8196
Short term
1/721
4/2007
0/924
12/1606
9/987
3/1058
3/717
32/8020
12 month
3/641
65/4941
11/2514
79/8096
12 month
3/2007
6/987
9/2994
12 month
3/641
58/4941
11/2514
72/8096
12 month
1/721
1/1606
9/987
3/1058
2/717
16/5089
12 month
3/641
65/4941
11/2514
79/8096
12 month
No of events/total
Fig 2 | Individual and summary odds ratios for the endpoints of definite/probable stent thrombosis and definite stent 
thrombosis, and analysis of late and very late stent thrombosis. Data stratified by duration of dual antiplatelet therapy: 
short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months 
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patients) v 2.63% (132/5026); odds ratio 1.17 (95% conﬁ-
dence interval 0.92 to 1.48); P=0.20; I2=0%). Results 
with extended dual antiplatelet therapy were compara-
ble to those with 12 month therapy (2.80% (89/3176) v 
2.35% (74/3155); 1.20 (0.88 to 1.64); P=0.25; I2=0%; ﬁg 5).
All studies (n=32 287) provided data for cerebrovascu-
lar accidents. These events occurred in 0.45% of 
patients (36/7975) with short term dual antiplatelet 
therapy versus 0.49% (39/8020) with 12 month therapy 
(odds ratio 0.93 (95% conﬁdence interval 0.59 to 1.46); 
P=0.75; I2=0%). Similarly, we did not see any signiﬁcant 
diﬀerences in cerebrovascular accidents when compar-
ing extended duration with 12 month duration (0.78% v 
0.84%; 0.93 (0.66 to 1.31); P=0.67; I2=0%; web ﬁg 9).
Sensitivity analyses
The results obtained by repeating the analyses using 
random eﬀects models were highly consistent with the 
 EXCELLENT22
 ISAR-SAFE23
 ITALIC28
 OPTIMIZE24
 PRODIGY7,26
 RESET27
 SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=1.90, df=6, P=0.93, I2=0%
Test for overall effect: z=2.21, P=0.02
 ARCTIC-Interruption17,18
 DAPT10,19
 DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=2.14, df=2, P=0.34, I2=7%
Test for overall effect: z=3.75, P<0.001
0.50 (0.09 to 2.73)
0.80 (0.22 to 3.00)
0.14 (0.01 to 2.75)
0.71 (0.32 to 1.61)
0.56 (0.19 to 1.66)
0.33 (0.07 to 1.65)
0.65 (0.21 to 2.01)
0.58 (0.36 to 0.92)
7.02 (0.86 to 57.24)
1.62 (1.21 to 2.17)
1.41 (0.84 to 2.39)
1.62 (1.26 to 2.09)
8.1
10.2
7.1
28.4
18.2
12.2
15.8
100.0
1.0
74.4
24.6
100.0
0.01 0.1 1 10 100
Study
Favours short term
or extended DAPT
Favours
12 month DAPT
Odds ratio (95% CI)
M-H, fixed
Odds ratio (95% CI)
M-H, fixed
Weight
(%)
2/722
4/1998
0/926
10/1605
5/983
2/1059
5/682
28/7975
Extended
7/645
119/5020
34/2531
160/8196
Short term
4/721
5/2007
3/924
14/1606
9/987
6/1058
8/717
49/8020
12 month
1/641
73/4941
24/2514
98/8096
12 month
No of events/total
Fig 3 | Individual and summary odds ratios for the endpoint of major bleeding. Data stratified by duration of dual 
antiplatelet therapy: short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months
  EXCELLENT22
  ISAR-SAFE23
  ITALIC28
  OPTIMIZE24
  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=1.99, df=6, P=0.92, I2=0%
Test for overall effect: z=0.69, P=0.49
  ARCTIC-Interruption17,18
  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=1.25, df=2, P=0.54, I2=0%
Test for overall effect: z=2.12, P=0.03
0.57 (0.17 to 1.95)
0.67 (0.27 to 1.64)
1.14 (0.41 to 3.16)
0.95 (0.63 to 1.46)
1.03 (0.66 to 1.62)
0.62 (0.20 to 1.91)
0.90 (0.30 to 2.69)
0.91 (0.71 to 1.18)
0.77 (0.29 to 2.08)
1.31 (0.97 to 1.78)
1.44 (0.91 to 2.26)
1.30 (1.02 to 1.66)
5.7
9.8
5.7
36.0
30.7
6.5
5.6
100.0
7.9
64.4
27.8
100.0
0.01 0.1 1 10 100
Study
Favours short term
or extended DAPT
Favours
12 month DAPT
Odds ratio (95% CI)
M-H, fixed
Odds ratio (95% CI)
M-H, fixed
Weight
(%)
4/722
8/1998
8/926
43/1605
40/983
5/1059
6/682
114/7975
Extended
7/645
98/5020
46/2531
151/8196
Short term
7/721
12/2007
7/924
45/1606
39/987
8/1058
7/717
125/8020
12 month
9/641
74/4941
32/2514
115/8096
12 month
No of events/total
Fig 4 | Individual and summary odds ratios for the endpoint of all cause mortality. Data stratified by duration of dual 
antiplatelet therapy: short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months
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(95% conﬁdence interval 0.71 to 1.18); P=0.49; I2=0%; 
ﬁg 4). By contrast, extended versus 12 month dual anti-
platelet therapy was associated with a higher risk of all 
cause death (1.84% (151/8196) v 1.42% (115/8096); 1.30 
(1.02 to 1.66); P=0.03; I2=0%; ﬁg 4). The number needed 
to harm was 238.
Repeat revascularisation and cerebrovascular 
accidents
Repeat revascularisation data were available from 
seven studies (n=16 351). Short term duration of dual 
antiplatelet therapy yielded similar results compared 
with 12 month duration (event rate 3.06% (153/4994 
Definite or probable stent thrombosis
  EXCELLENT22
  ISAR-SAFE23
  ITALIC28
  OPTIMIZE24
  PRODIGY7,26
  RESET27
  SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=4.20, df=6, P=0.65, I2=0%
Test for overall effect: z=1.18, P=0.24
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  DAPT10,19
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Total (95% CI)
Test for heterogeneity: χ2=2.43, df=2, P=0.30, I2=18%
Test for overall effect: z=4.98, P<0.001
Definite stent thrombosis
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Test for heterogeneity: χ2=0.89, df=1, P=0.35, I2=0%
Test for overall effect: z=0.01, P=0.99
  ARCTIC-Interruption17,18
  DAPT10,19
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Total (95% CI)
Test for heterogeneity: χ2=2.94, df=2, P=0.23, I2=32%
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Late stent thrombosis
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Test for heterogeneity: χ2=6.66, df=4, P=0.16, I2=40%
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Very late stent thrombosis
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  DAPT10,19
  DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=2.43, df=2, P=0.30, I2=18%
Test for overall effect: z=4.98, P<0.001
6.03 (0.72 to 50.24)
1.26 (0.34 to 4.69)
7.01 (0.36 to 135.85)
1.08 (0.49 to 2.38)
1.12 (0.45 to 2.76)
0.67 (0.11 to 3.99)
1.05 (0.21 to 5.23)
1.32 (0.83 to 2.08)
0.14 (0.01 to 2.74)
0.29 (0.17 to 0.48)
0.63 (0.24 to 1.63)
0.33 (0.21 to 0.51)
1.68 (0.40 to 7.02)
0.67 (0.19 to 2.37)
1.00 (0.40 to 2.53)
0.14 (0.01 to 2.74)
0.25 (0.14 to 0.45)
0.63 (0.24 to 1.63)
0.30 (0.19 to 0.49)
6.03 (0.72 to 50.24)
4.01 (0.45 to 35.92)
1.12 (0.45 to 2.76)
0.14 (0.01 to 2.76)
0.21 (0.01 to 4.38)
1.24 (0.65 to 2.36)
0.14 (0.01 to 2.74)
0.29 (0.17 to 0.48)
0.63 (0.24 to 1.63)
0.33 (0.21 to 0.51)
3.1
12.4
1.6
37.0
27.6
9.3
9.1
100.0
4.4
81.8
13.8
100.0
33.4
66.6
100.0
4.8
80.1
15.1
100.0
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5.9
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14.5
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42/7975
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5/1998
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9/2981
Extended
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7/2531
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10/983
0/1059
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20/5051
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Fig 2 | Individual and summary odds ratios for the endpoints of definite/probable stent thrombosis and definite stent 
thrombosis, and analysis of late and very late stent thrombosis. Data stratified by duration of dual antiplatelet therapy: 
short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months 
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patients) v 2.63% (132/5026); odds ratio 1.17 (95% conﬁ-
dence interval 0.92 to 1.48); P=0.20; I2=0%). Results 
with extended dual antiplatelet therapy were compara-
ble to those with 12 month therapy (2.80% (89/3176) v 
2.35% (74/3155); 1.20 (0.88 to 1.64); P=0.25; I2=0%; ﬁg 5).
All studies (n=32 287) provided data for cerebrovascu-
lar accidents. These events occurred in 0.45% of 
patients (36/7975) with short term dual antiplatelet 
therapy versus 0.49% (39/8020) with 12 month therapy 
(odds ratio 0.93 (95% conﬁdence interval 0.59 to 1.46); 
P=0.75; I2=0%). Similarly, we did not see any signiﬁcant 
diﬀerences in cerebrovascular accidents when compar-
ing extended duration with 12 month duration (0.78% v 
0.84%; 0.93 (0.66 to 1.31); P=0.67; I2=0%; web ﬁg 9).
Sensitivity analyses
The results obtained by repeating the analyses using 
random eﬀects models were highly consistent with the 
 EXCELLENT22
 ISAR-SAFE23
 ITALIC28
 OPTIMIZE24
 PRODIGY7,26
 RESET27
 SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=1.90, df=6, P=0.93, I2=0%
Test for overall effect: z=2.21, P=0.02
 ARCTIC-Interruption17,18
 DAPT10,19
 DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=2.14, df=2, P=0.34, I2=7%
Test for overall effect: z=3.75, P<0.001
0.50 (0.09 to 2.73)
0.80 (0.22 to 3.00)
0.14 (0.01 to 2.75)
0.71 (0.32 to 1.61)
0.56 (0.19 to 1.66)
0.33 (0.07 to 1.65)
0.65 (0.21 to 2.01)
0.58 (0.36 to 0.92)
7.02 (0.86 to 57.24)
1.62 (1.21 to 2.17)
1.41 (0.84 to 2.39)
1.62 (1.26 to 2.09)
8.1
10.2
7.1
28.4
18.2
12.2
15.8
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1.0
74.4
24.6
100.0
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main ﬁndings (web table 5). Seven studies (n=17 716) 
reported major bleeding events by TIMI criteria.14 Short 
term dual antiplatelet therapy compared with 12 month 
therapy was associated with a signiﬁcantly reduced rate 
of TIMI major bleeding (odds ratio 0.49 (95% conﬁ-
dence interval 0.26 to 0.94); P=0.03; I2=0%). Converse 
results were found with therapy continuation beyond 12 
months compared with 12 month therapy (1.60 (0.97 to 
2.64); P=0.07; I2=42%; web ﬁg 10).
Nine studies reported the incidence of major adverse 
cardiac and cerebrovascular accidents. No signiﬁcant 
diﬀerences were seen with short term versus 12 month 
dual antiplatelet therapy (odds ratio 1.02 (0.86 to 1.22); 
P=0.81; I2=0%). The odds of major adverse cardiac and 
cerebrovascular accidents were signiﬁcantly reduced 
by 22%, when extended therapy was compared with 12 
month therapy (0.78 (0.67 to 0.92); P=0.002; I2=47%; 
web ﬁg 11). Analyses in patients with and without acute 
coronary syndrome, younger or older than 65 years, and 
treated with diﬀerent P2Y12 inhibitors (web table 6) 
showed no signiﬁcant outcome diﬀerences among 
those subgroups. Sensitivity analyses for the extended 
versus 12 month regimen comparison after inclusion of 
the PRODIGY landmark analysis are in web ﬁgs 12-18. 
These analyses showed highly consistent ﬁndings with 
the main results, except for all cause mortality, which 
became of borderline significance (P=0.05) in the 
extended versus 12 month regimen comparison.
Discussion
The current meta-analysis compares the eﬃcacy and 
safety of three diﬀerent durations of dual antiplatelet 
therapy in patients undergoing percutaneous coronary 
intervention with drug eluting stents. To our knowl-
edge, by its unique design, it is the ﬁrst report focusing 
on outcomes with either short term or extended (beyond 
12 months) duration of dual antiplatelet therapy versus 
12 month therapy. By incorporating the most recent 
 evidence from randomised controlled trials, this report 
forms the largest database on duration of dual anti-
platelet therapy ever analysed (n=32 287). 
There were two main ﬁndings. First, short term dual 
antiplatelet therapy, when compared to 12 month ther-
apy, was associated with a similar rate of stent throm-
bosis or myocardial infarction, with a reduced risk of 
major bleeding. Second, extended therapy, compared 
with a 12 month regimen, reduced the odds of deﬁnite/
probable stent thrombosis, very late stent thrombosis, 
and myocardial infarction, but increased the odds of 
major bleeding. While all cause mortality also increased 
in the extended versus 12 month regimen comparison, 
driven by non-cardiovascular events, this study ﬁnding 
becomes mitigated by the inclusion of the landmark 
analysis at 12 months of patients enrolled in the PROD-
IGY trial. Nevertheless, given the potential profound 
implications of this observation if conﬁrmed to be true, 
further studies are needed to validate or confute this 
preliminary ﬁnding.
Coronary drug eluting stents—by inhibiting in-stent 
neointimal proliferation—have eﬀectively reduced the 
need for repeat revascularisation compared with bare 
metal stents and have achieved widespread use 
worldwide.4  Concerns about drug eluting stents have 
arisen, however, regarding the propensity for throm-
botic events occurring more than one year after 
implantation.1 2
Based on these considerations, current guidelines 
from the American College of Cardiology/American 
Heart Association advocate at least 12 months of dual 
antiplatelet therapy after implantation of drug eluting 
stents.5  The European Society of Cardiology endorses 
six to 12 months of dual therapy after implantation, and 
12 months for all patients with acute coronary syn-
drome irrespective of revascularisation strategy.6  Pro-
longed dual antiplatelet therapy (beyond 12 months), 
while protecting against thrombosis, will invariably 
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increase the risk of major bleeding with an uncertain 
net impact on patient outcomes after percutaneous cor-
onary intervention.29-31 This beneﬁt-risk dualism has 
raised controversies around the optimal duration of 
dual antiplatelet therapy that would maximise the 
eﬀect against stent thrombosis while minimising the 
associated bleeding risk. As a result, recent randomised 
controlled trials have adopted a triad of duration mod-
els: short term, 12 months, and beyond 12 months.
Short term (<12 month) versus 12 month dual 
antiplatelet therapy
We did not observe any signiﬁcant diﬀerences in myo-
cardial infarction and stent thrombosis outcomes with 
short term dual antiplatelet therapy as compared with 
12 month therapy, in the face of reduced bleeding com-
plications. This neutral eﬀect on ischaemic endpoints 
testiﬁes for a similar eﬃcacy and a greater safety proﬁle 
with shortened therapy as compared with 12 month 
therapy. Our ﬁndings are consistent with those of recent 
trials (which were, however, limited in sample size) and 
two previous meta-analyses of four trials comparing 
short term with longer durations.9 32 The two analyses, 
however, included fewer studies that were, in addition, 
heterogeneous as to duration of prolonged dual anti-
platelet therapy, spanning 12-24 months.
Extended (>12 month) versus 12 month dual 
antiplatelet therapy
Although previous studies had suggested that short 
term dual antiplatelet therapy is eﬀective and safe, 
especially with the availability of modern interven-
tional techniques and new generation drug eluting 
stents, the beneﬁt to harm ratio of therapy beyond one 
year had remained largely unknown. Registry data had 
suggested improvements in ischaemic outcomes with 
prolonged dual antiplatelet therapy; however, registries 
are prone to bias owing to their observational design.33 34 
An important ﬁnding was the 67% reduction in cumula-
tive odds of deﬁnite/probable stent thrombosis and, 
speciﬁcally, of very late (>1 year) stent thrombosis with 
extended dual antiplatelet therapy when compared 
with 12 month therapy, at the price of higher major 
bleeding and all cause mortality. In practical terms, the 
numbers needed to treat and to harm were similar for 
thrombotic (number needed to treat 152) and bleeding 
(number needed to harm 135) events, highlighting the 
importance of balancing the patients’ thrombotic pro-
ﬁle against their bleeding risk in case of prolonged dual 
antiplatelet therapy. 
The pathophysiology of very late stent thrombosis 
has been attributed to incomplete re-endothelialisation 
caused by drug or scaﬀold induced inhibition of endo-
thelial cell proliferation, belated stent malapposition, 
neoatherosclerosis, and inﬂammation induced by the 
durable polymers, which occur over time after drug 
eluting stent implantation.35 36  The results of the pres-
ent meta-analysis suggest that in a subgroup of 
patients, both patient and stent related factors can 
interact adversely over time through retarded endothe-
lialisation and persistent inﬂammation, culminating in 
very late stent thrombosis37 once dual antiplatelet ther-
apy is withdrawn. On the other hand, major bleeding 
and apparently also all cause deaths (number needed to 
harm 238) were more common with prolonged dual 
antiplatelet therapy. It remains unclear whether this 
observation on total mortality is real and whether it 
might be explained by the eﬀect of bleeding on fatal 
outcomes.
The DAPT trial,10 19 which is the largest to explore the 
eﬀect of extended versus 12 month dual antiplatelet 
therapy, found ischaemic protection with extended 
therapy at the price of increased bleeding risk. In the 
present meta-analysis, a large number of myocardial 
infarctions were derived from the DAPT trial, which was 
only partly justiﬁed by the trial’s bigger sample size 
than the other trials. Indeed, the annual incidence of 
myocardial infarction in the DAPT trial was more than 
twice that reported by other studies. On the other hand, 
the annual incidence of other thrombotic complications 
(such as stent thrombosis) or of bleeding events in the 
DAPT trial seemed more consistent with those observed 
in the other included trials. Reasons for the marked dif-
ference in myocardial infarction rates—in the range of 
three extra events per 100 aspirin treated patients per 
year in the control group of the DAPT trial as compared 
to the other studies—remain unclear. Moreover, the 
consistency of direction of estimates testiﬁed by the 
very low heterogeneity across trials in our pooled anal-
ysis suggests that the overall eﬀect of this meta-analysis 
is robust and can be interpreted with conﬁdence. In 
view of the residual uncertainty on overall mortality 
and the clear bleeding liability associated with pro-
longed dual antiplatelet therapy, a long term regimen 
should probably be reserved to patients at high 
 ischaemic risk and low bleeding risk, in whom such 
treatment would have been well tolerated for the ﬁrst 
12 months.
Implications for clinical practice
There are distinct eﬀects associated with short term and 
extended dual antiplatelet therapy. Shorter duration 
yields fewer bleeding events than a longer duration, 
with comparable eﬃcacy against ischaemic complica-
tions. Furthermore, extended therapy leads to a marked 
reduction of thrombotic complications at the price of 
increased bleeding rates with a signal towards increased 
all cause mortality. The currently recommended 12 
month duration of dual antiplatelet therapy after drug 
eluting stent implementation is a compromise between 
ischaemic and bleeding risks. However, based on this 
meta-analysis, the 12 month recommendation seems to 
be a less appealing strategy to minimise bleeding risk or 
maximise ischaemic beneﬁt than a short term or an 
extended therapy regimen, respectively.
The lack of clear-cut beneﬁts observed with the 12 
month strategy raises the question of whether this aver-
age duration of dual antiplatelet therapy might be 
replaced by a shorter or longer duration in patients at 
high or low bleeding risk, respectively.
The apparently discordant ﬁnding of similar isch-
aemic risks in trials comparing a short term versus 
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main ﬁndings (web table 5). Seven studies (n=17 716) 
reported major bleeding events by TIMI criteria.14 Short 
term dual antiplatelet therapy compared with 12 month 
therapy was associated with a signiﬁcantly reduced rate 
of TIMI major bleeding (odds ratio 0.49 (95% conﬁ-
dence interval 0.26 to 0.94); P=0.03; I2=0%). Converse 
results were found with therapy continuation beyond 12 
months compared with 12 month therapy (1.60 (0.97 to 
2.64); P=0.07; I2=42%; web ﬁg 10).
Nine studies reported the incidence of major adverse 
cardiac and cerebrovascular accidents. No signiﬁcant 
diﬀerences were seen with short term versus 12 month 
dual antiplatelet therapy (odds ratio 1.02 (0.86 to 1.22); 
P=0.81; I2=0%). The odds of major adverse cardiac and 
cerebrovascular accidents were signiﬁcantly reduced 
by 22%, when extended therapy was compared with 12 
month therapy (0.78 (0.67 to 0.92); P=0.002; I2=47%; 
web ﬁg 11). Analyses in patients with and without acute 
coronary syndrome, younger or older than 65 years, and 
treated with diﬀerent P2Y12 inhibitors (web table 6) 
showed no signiﬁcant outcome diﬀerences among 
those subgroups. Sensitivity analyses for the extended 
versus 12 month regimen comparison after inclusion of 
the PRODIGY landmark analysis are in web ﬁgs 12-18. 
These analyses showed highly consistent ﬁndings with 
the main results, except for all cause mortality, which 
became of borderline significance (P=0.05) in the 
extended versus 12 month regimen comparison.
Discussion
The current meta-analysis compares the eﬃcacy and 
safety of three diﬀerent durations of dual antiplatelet 
therapy in patients undergoing percutaneous coronary 
intervention with drug eluting stents. To our knowl-
edge, by its unique design, it is the ﬁrst report focusing 
on outcomes with either short term or extended (beyond 
12 months) duration of dual antiplatelet therapy versus 
12 month therapy. By incorporating the most recent 
 evidence from randomised controlled trials, this report 
forms the largest database on duration of dual anti-
platelet therapy ever analysed (n=32 287). 
There were two main ﬁndings. First, short term dual 
antiplatelet therapy, when compared to 12 month ther-
apy, was associated with a similar rate of stent throm-
bosis or myocardial infarction, with a reduced risk of 
major bleeding. Second, extended therapy, compared 
with a 12 month regimen, reduced the odds of deﬁnite/
probable stent thrombosis, very late stent thrombosis, 
and myocardial infarction, but increased the odds of 
major bleeding. While all cause mortality also increased 
in the extended versus 12 month regimen comparison, 
driven by non-cardiovascular events, this study ﬁnding 
becomes mitigated by the inclusion of the landmark 
analysis at 12 months of patients enrolled in the PROD-
IGY trial. Nevertheless, given the potential profound 
implications of this observation if conﬁrmed to be true, 
further studies are needed to validate or confute this 
preliminary ﬁnding.
Coronary drug eluting stents—by inhibiting in-stent 
neointimal proliferation—have eﬀectively reduced the 
need for repeat revascularisation compared with bare 
metal stents and have achieved widespread use 
worldwide.4  Concerns about drug eluting stents have 
arisen, however, regarding the propensity for throm-
botic events occurring more than one year after 
implantation.1 2
Based on these considerations, current guidelines 
from the American College of Cardiology/American 
Heart Association advocate at least 12 months of dual 
antiplatelet therapy after implantation of drug eluting 
stents.5  The European Society of Cardiology endorses 
six to 12 months of dual therapy after implantation, and 
12 months for all patients with acute coronary syn-
drome irrespective of revascularisation strategy.6  Pro-
longed dual antiplatelet therapy (beyond 12 months), 
while protecting against thrombosis, will invariably 
 EXCELLENT22
 ITALIC28
 OPTIMIZE24
 RESET27
 SECURITY8
Total (95% CI)
Test for heterogeneity: χ2=1.49, df=4, P=0.83, I2=0%
Test for overall effect: z=1.28, P=0.20
 ARCTIC-Interruption17,18
 DES LATE20,21
Total (95% CI)
Test for heterogeneity: χ2=0.45, df=1, P=0.50, I2=0%
Test for overall effect: z=1.15, P=0.25
1.00 (0.65 to 1.54)
2.50 (0.48 to 12.93)
1.24 (0.87 to 1.77)
1.15 (0.68 to 1.94)
1.40 (0.31 to 6.30)
1.17 (0.92 to 1.48)
0.88 (0.34 to 2.30)
1.25 (0.89 to 1.73)
1.20 (0.88 to 1.64)
32.1
1.6
43.2
20.8
2.3
100.0
12.4
87.6
100.0
0.01 0.1 1 10 100
Study
Favours short term
or extended DAPT
Favours
12 month DAPT
Odds ratio (95% CI)
M-H, fixed
Odds ratio (95% CI)
M-H, fixed
Weight
(%)
43/722
5/926
70/1605
31/1059
4/682
153/4994
Extended
8/645
81/2531
89/3176
Short term
43/721
2/924
57/1606
27/1058
3/717
132/5026
12 month
9/641
65/2514
74/3155
12 month
No of events/total
Fig 5 | Individual and summary odds ratios for the endpoint of repeat revascularisation. Data stratified by duration of dual 
antiplatelet therapy: short term (<12 months) versus 12 months, and extended (>12 months) versus 12 months
Chapter 5.1
RESEARCH
9the bmj | BMJ 2015;350:h1618 | doi: 10.1136/bmj.h1618
increase the risk of major bleeding with an uncertain 
net impact on patient outcomes after percutaneous cor-
onary intervention.29-31 This beneﬁt-risk dualism has 
raised controversies around the optimal duration of 
dual antiplatelet therapy that would maximise the 
eﬀect against stent thrombosis while minimising the 
associated bleeding risk. As a result, recent randomised 
controlled trials have adopted a triad of duration mod-
els: short term, 12 months, and beyond 12 months.
Short term (<12 month) versus 12 month dual 
antiplatelet therapy
We did not observe any signiﬁcant diﬀerences in myo-
cardial infarction and stent thrombosis outcomes with 
short term dual antiplatelet therapy as compared with 
12 month therapy, in the face of reduced bleeding com-
plications. This neutral eﬀect on ischaemic endpoints 
testiﬁes for a similar eﬃcacy and a greater safety proﬁle 
with shortened therapy as compared with 12 month 
therapy. Our ﬁndings are consistent with those of recent 
trials (which were, however, limited in sample size) and 
two previous meta-analyses of four trials comparing 
short term with longer durations.9 32 The two analyses, 
however, included fewer studies that were, in addition, 
heterogeneous as to duration of prolonged dual anti-
platelet therapy, spanning 12-24 months.
Extended (>12 month) versus 12 month dual 
antiplatelet therapy
Although previous studies had suggested that short 
term dual antiplatelet therapy is eﬀective and safe, 
especially with the availability of modern interven-
tional techniques and new generation drug eluting 
stents, the beneﬁt to harm ratio of therapy beyond one 
year had remained largely unknown. Registry data had 
suggested improvements in ischaemic outcomes with 
prolonged dual antiplatelet therapy; however, registries 
are prone to bias owing to their observational design.33 34 
An important ﬁnding was the 67% reduction in cumula-
tive odds of deﬁnite/probable stent thrombosis and, 
speciﬁcally, of very late (>1 year) stent thrombosis with 
extended dual antiplatelet therapy when compared 
with 12 month therapy, at the price of higher major 
bleeding and all cause mortality. In practical terms, the 
numbers needed to treat and to harm were similar for 
thrombotic (number needed to treat 152) and bleeding 
(number needed to harm 135) events, highlighting the 
importance of balancing the patients’ thrombotic pro-
ﬁle against their bleeding risk in case of prolonged dual 
antiplatelet therapy. 
The pathophysiology of very late stent thrombosis 
has been attributed to incomplete re-endothelialisation 
caused by drug or scaﬀold induced inhibition of endo-
thelial cell proliferation, belated stent malapposition, 
neoatherosclerosis, and inﬂammation induced by the 
durable polymers, which occur over time after drug 
eluting stent implantation.35 36  The results of the pres-
ent meta-analysis suggest that in a subgroup of 
patients, both patient and stent related factors can 
interact adversely over time through retarded endothe-
lialisation and persistent inﬂammation, culminating in 
very late stent thrombosis37 once dual antiplatelet ther-
apy is withdrawn. On the other hand, major bleeding 
and apparently also all cause deaths (number needed to 
harm 238) were more common with prolonged dual 
antiplatelet therapy. It remains unclear whether this 
observation on total mortality is real and whether it 
might be explained by the eﬀect of bleeding on fatal 
outcomes.
The DAPT trial,10 19 which is the largest to explore the 
eﬀect of extended versus 12 month dual antiplatelet 
therapy, found ischaemic protection with extended 
therapy at the price of increased bleeding risk. In the 
present meta-analysis, a large number of myocardial 
infarctions were derived from the DAPT trial, which was 
only partly justiﬁed by the trial’s bigger sample size 
than the other trials. Indeed, the annual incidence of 
myocardial infarction in the DAPT trial was more than 
twice that reported by other studies. On the other hand, 
the annual incidence of other thrombotic complications 
(such as stent thrombosis) or of bleeding events in the 
DAPT trial seemed more consistent with those observed 
in the other included trials. Reasons for the marked dif-
ference in myocardial infarction rates—in the range of 
three extra events per 100 aspirin treated patients per 
year in the control group of the DAPT trial as compared 
to the other studies—remain unclear. Moreover, the 
consistency of direction of estimates testiﬁed by the 
very low heterogeneity across trials in our pooled anal-
ysis suggests that the overall eﬀect of this meta-analysis 
is robust and can be interpreted with conﬁdence. In 
view of the residual uncertainty on overall mortality 
and the clear bleeding liability associated with pro-
longed dual antiplatelet therapy, a long term regimen 
should probably be reserved to patients at high 
 ischaemic risk and low bleeding risk, in whom such 
treatment would have been well tolerated for the ﬁrst 
12 months.
Implications for clinical practice
There are distinct eﬀects associated with short term and 
extended dual antiplatelet therapy. Shorter duration 
yields fewer bleeding events than a longer duration, 
with comparable eﬃcacy against ischaemic complica-
tions. Furthermore, extended therapy leads to a marked 
reduction of thrombotic complications at the price of 
increased bleeding rates with a signal towards increased 
all cause mortality. The currently recommended 12 
month duration of dual antiplatelet therapy after drug 
eluting stent implementation is a compromise between 
ischaemic and bleeding risks. However, based on this 
meta-analysis, the 12 month recommendation seems to 
be a less appealing strategy to minimise bleeding risk or 
maximise ischaemic beneﬁt than a short term or an 
extended therapy regimen, respectively.
The lack of clear-cut beneﬁts observed with the 12 
month strategy raises the question of whether this aver-
age duration of dual antiplatelet therapy might be 
replaced by a shorter or longer duration in patients at 
high or low bleeding risk, respectively.
The apparently discordant ﬁnding of similar isch-
aemic risks in trials comparing a short term versus 
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12  month duration of dual antiplatelet therapy—as 
opposed to an ischaemic protection conferred by an 
extended versus 12 month duration—may reﬂect diﬀer-
ences in the selection of patient populations included 
in the studies. In trials randomising patients to a 
12  month versus short term regimen, those at high 
bleeding risk were not excluded, and randomisation 
occurred relatively early after stent implantation (that is, 
immediately, or after one, three, or six months). Studies 
comparing 12 month with extended regimens randomised 
patients only after several months of dual antiplatelet 
therapy provided that no major bleeding episodes had 
occurred in the preceding months. These studies most 
likely selected, by design, a patient population at rela-
tively lower risk of bleeding while receiving therapy. 
In view of the possible association between bleeding 
and subsequent ischaemic and fatal events, it may be 
hypothesised that in less carefully selected populations 
(such as those patients included in short term v 12 
month studies), the detrimental eﬀect of bleeding on 
ischaemic endpoints and death would have counterbal-
anced the ischaemic protection potentially oﬀered by 
dual antiplatelet therapy. On the other hand, prolong-
ing therapy in the long term in patients at relatively 
lower bleeding risk (that is, those who tolerate this ther-
apy for at least 12 months) could result in a more favour-
able reduction of ischaemic events, at the cost of some 
major haemorrhagic complications.
From an individual patient’s perspective, the results 
of this article suggest that the 12 month cut-oﬀ for dual 
antiplatelet therapy should not necessarily be consid-
ered as the optimal standard of care choice. Rather, 
durations shorter or longer than 12 months should be 
calibrated, taking into consideration the patient’s 
bleeding and ischaemic risk proﬁle, in addition to pro-
cedural variables and acuity of presentation. Further, 
well powered trials are warranted to test the clinical 
eﬀect of tailored dual antiplatelet therapy. A practical 
approach for clinicians, given the results of our pooled 
analysis, would be to oﬀer to many patients, especially 
those at high bleeding risk, a duration of less than one 
year after coronary implantation of a drug eluting stent. 
Prolonged dual antiplatelet therapy beyond one year 
could represent an option for selected patients who 
present very high ischaemic and low bleeding risks.
Effect of dual antiplatelet therapy on all cause 
mortality
In the present article, all cause but not cardiovascular 
mortality was found to be increased with extended dual 
antiplatelet therapy as compared with 12 month regi-
mens. These ﬁndings were at variance with a recent 
Bayesian non-standard meta-analysis, in which no dif-
ference in all cause, cardiovascular, and non-cardiovas-
cular mortality was found between treatment 
durations.38  The Bayesian meta-analysis focused only 
on the mortality outcome and had broad inclusion crite-
ria. It comprised patients with coronary artery disease 
undergoing medical management (that is, without coro-
nary stent implantation) and patients without coronary 
artery disease, who qualiﬁed for inclusion based on 
multiple atherothrombotic risk factors, peripheral artery 
disease, or presence of atrial ﬁbrillation. This recent 
pooled analysis also included a highly heterogeneous 
duration of regimens. Dual antiplatelet therapy spanned 
from six to 40 months in the so-called “extended DAPT” 
arm, which was compared to a similarly heterogeneous 
shorter “DAPT duration” group; this second group 
included not only a shortened regimen but also no dual 
antiplatelet therapy at all. Hence, while the ﬁnding of 
the mortality increase in our meta-analysis might be due 
to chance, it could also indicate an excess of deaths 
attributed to non-cardiovascular causes (for example, 
cancer related deaths, as observed in the large DAPT 
trial10 19) or to major bleeding.
Limitations
The results were analysed on trial level data and not on 
patient level data; individual patient information 
would have added further insights to the analysis. Fur-
thermore, the criteria for inclusion of patients in this 
meta-analysis were broad, comprising both stable low 
risk and unstable high risk patients, according to the 
original trial designs, and reﬂecting more closely the 
case mix encountered in clinical practice. Diﬀerent 
types of P2Y12 antagonists (clopidogrel, prasugrel, and 
ticagrelor) and drug eluting stents were used across and 
within trials. These data should be viewed as reﬂecting 
real world routine practice in all patients treated with 
diﬀerent antiplatelet drugs and drug eluting stents, 
based on clinical settings, operator choices, and drug 
availability.
On the other hand, all the main and sensitivity anal-
yses performed were consistent, suggesting that the 
eﬀects of the diﬀerent durations of dual antiplatelet 
therapy were robust and justiﬁed. Since most ran-
domised trials were performed under clopidogrel, and 
ﬁrst generation drug eluting stents were implanted in a 
sizable fraction of patients, further randomised con-
trolled trials are needed to explore the eﬀect of novel 
P2Y12 inhibitors and new stents on the duration of dual 
antiplatelet therapy. Finally, no data were available to 
speciﬁcally test the interaction of diﬀerent stents and 
diﬀerent DAPT durations.
Conclusions
Discontinuation of dual antiplatelet therapy before the 
recommended 12 month period following percutaneous 
coronary intervention with drug eluting stents yields 
signiﬁcantly reduced bleeding without increasing isch-
aemic outcomes. By contrast, dual antiplatelet therapy 
maintained well beyond 12 months (that is, up to 24 or 
30 months) reduces the incidence of thrombotic com-
plications, in particular stent thrombosis and myocar-
dial infarction, at the price of increased major bleeding 
and possibly all cause death. The eﬀect of extended 
dual antiplatelet therapy on mortality rates observed in 
the DAPT trial10 19 and conﬁrmed in this meta-analysis 
remains preliminary, as a play of chance cannot be 
excluded. However, this observation warrants further 
investigation as, if true, could have profound conse-
quences on public health.
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12  month duration of dual antiplatelet therapy—as 
opposed to an ischaemic protection conferred by an 
extended versus 12 month duration—may reﬂect diﬀer-
ences in the selection of patient populations included 
in the studies. In trials randomising patients to a 
12  month versus short term regimen, those at high 
bleeding risk were not excluded, and randomisation 
occurred relatively early after stent implantation (that is, 
immediately, or after one, three, or six months). Studies 
comparing 12 month with extended regimens randomised 
patients only after several months of dual antiplatelet 
therapy provided that no major bleeding episodes had 
occurred in the preceding months. These studies most 
likely selected, by design, a patient population at rela-
tively lower risk of bleeding while receiving therapy. 
In view of the possible association between bleeding 
and subsequent ischaemic and fatal events, it may be 
hypothesised that in less carefully selected populations 
(such as those patients included in short term v 12 
month studies), the detrimental eﬀect of bleeding on 
ischaemic endpoints and death would have counterbal-
anced the ischaemic protection potentially oﬀered by 
dual antiplatelet therapy. On the other hand, prolong-
ing therapy in the long term in patients at relatively 
lower bleeding risk (that is, those who tolerate this ther-
apy for at least 12 months) could result in a more favour-
able reduction of ischaemic events, at the cost of some 
major haemorrhagic complications.
From an individual patient’s perspective, the results 
of this article suggest that the 12 month cut-oﬀ for dual 
antiplatelet therapy should not necessarily be consid-
ered as the optimal standard of care choice. Rather, 
durations shorter or longer than 12 months should be 
calibrated, taking into consideration the patient’s 
bleeding and ischaemic risk proﬁle, in addition to pro-
cedural variables and acuity of presentation. Further, 
well powered trials are warranted to test the clinical 
eﬀect of tailored dual antiplatelet therapy. A practical 
approach for clinicians, given the results of our pooled 
analysis, would be to oﬀer to many patients, especially 
those at high bleeding risk, a duration of less than one 
year after coronary implantation of a drug eluting stent. 
Prolonged dual antiplatelet therapy beyond one year 
could represent an option for selected patients who 
present very high ischaemic and low bleeding risks.
Effect of dual antiplatelet therapy on all cause 
mortality
In the present article, all cause but not cardiovascular 
mortality was found to be increased with extended dual 
antiplatelet therapy as compared with 12 month regi-
mens. These ﬁndings were at variance with a recent 
Bayesian non-standard meta-analysis, in which no dif-
ference in all cause, cardiovascular, and non-cardiovas-
cular mortality was found between treatment 
durations.38  The Bayesian meta-analysis focused only 
on the mortality outcome and had broad inclusion crite-
ria. It comprised patients with coronary artery disease 
undergoing medical management (that is, without coro-
nary stent implantation) and patients without coronary 
artery disease, who qualiﬁed for inclusion based on 
multiple atherothrombotic risk factors, peripheral artery 
disease, or presence of atrial ﬁbrillation. This recent 
pooled analysis also included a highly heterogeneous 
duration of regimens. Dual antiplatelet therapy spanned 
from six to 40 months in the so-called “extended DAPT” 
arm, which was compared to a similarly heterogeneous 
shorter “DAPT duration” group; this second group 
included not only a shortened regimen but also no dual 
antiplatelet therapy at all. Hence, while the ﬁnding of 
the mortality increase in our meta-analysis might be due 
to chance, it could also indicate an excess of deaths 
attributed to non-cardiovascular causes (for example, 
cancer related deaths, as observed in the large DAPT 
trial10 19) or to major bleeding.
Limitations
The results were analysed on trial level data and not on 
patient level data; individual patient information 
would have added further insights to the analysis. Fur-
thermore, the criteria for inclusion of patients in this 
meta-analysis were broad, comprising both stable low 
risk and unstable high risk patients, according to the 
original trial designs, and reﬂecting more closely the 
case mix encountered in clinical practice. Diﬀerent 
types of P2Y12 antagonists (clopidogrel, prasugrel, and 
ticagrelor) and drug eluting stents were used across and 
within trials. These data should be viewed as reﬂecting 
real world routine practice in all patients treated with 
diﬀerent antiplatelet drugs and drug eluting stents, 
based on clinical settings, operator choices, and drug 
availability.
On the other hand, all the main and sensitivity anal-
yses performed were consistent, suggesting that the 
eﬀects of the diﬀerent durations of dual antiplatelet 
therapy were robust and justiﬁed. Since most ran-
domised trials were performed under clopidogrel, and 
ﬁrst generation drug eluting stents were implanted in a 
sizable fraction of patients, further randomised con-
trolled trials are needed to explore the eﬀect of novel 
P2Y12 inhibitors and new stents on the duration of dual 
antiplatelet therapy. Finally, no data were available to 
speciﬁcally test the interaction of diﬀerent stents and 
diﬀerent DAPT durations.
Conclusions
Discontinuation of dual antiplatelet therapy before the 
recommended 12 month period following percutaneous 
coronary intervention with drug eluting stents yields 
signiﬁcantly reduced bleeding without increasing isch-
aemic outcomes. By contrast, dual antiplatelet therapy 
maintained well beyond 12 months (that is, up to 24 or 
30 months) reduces the incidence of thrombotic com-
plications, in particular stent thrombosis and myocar-
dial infarction, at the price of increased major bleeding 
and possibly all cause death. The eﬀect of extended 
dual antiplatelet therapy on mortality rates observed in 
the DAPT trial10 19 and conﬁrmed in this meta-analysis 
remains preliminary, as a play of chance cannot be 
excluded. However, this observation warrants further 
investigation as, if true, could have profound conse-
quences on public health.
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To the editor:
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor
inhibitor is currently recommended for one year after coronary stent
implantation or an episode of acute coronary syndrome. Recently two
large clinical trials demonstrated beneﬁts in reducing stent- and non-
stent related myocardial infarction extending DAPT with the use of
thienopyridines (i.e. clopidogrel or prasugrel) or ticagrelor beyond the
recommended 12-month period [1,2]. However, a greater than 12-
month course of DAPT with thienopyridines was also associated with
higher mortality in the DAPT trial [1], which was conﬁrmed by subse-
quent meta-analyses [3]. It remains unclear if this effect on mortality
is class- or thienopyridine-speciﬁc.We therefore performed a systemat-
ic revision of the literature and meta-analysis of the available clinical
trials that randomized patients to 12-month vs. greater than 12-
month DAPT duration based on thienopyridines or ticagrelor, to explore
the differential impact of P2Y12 inhibitor type on all-cause mortality,
cardiovascular and non-cardiovascular mortality.
The studywas conducted according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) statement
(Supplemental material) [4]. We selected for our analysis randomized
clinical trials that assigned patients to a standard 12-month DAPT vs.
extended DAPT beyond 12 months. The ﬁnal search was performed on
May 2, 2015. Statistical pooling of odds ratios (OR) was performed
with random effects. A 2-tailed alpha of 5% was used for hypothesis
testing. Statistical interaction was assessed with Cochran Q via a chi-
square test and quantiﬁed with the I2 test.
We identiﬁed 4 relevant studies, of which 3 tested the effect of
thienopyridines (i.e. clopidogrel/prasugrel) and one of ticagrelor [1,
2,5,6]. Data extraction was limited to all-cause, cardiovascular and
non-cardiovascular mortality. On-treatment events and those
occurring at the longest available follow-up were appraised in the
main and sensitivity analyses, respectively. All analyses were
intention-to-treat and performed with RevMan v5.3.5 (the Cochrane
Collaboration).
Among 37,427 patients, all-cause mortality after an extended DAPT
course was increased by 30% in patients receiving thienopyridines (OR
1.30; 95% CI 1.02–1.66), but not in those treated with ticagrelor (OR
0.94; 95% CI 0.82–1.08) with signiﬁcant interaction between duration
and type of treatment (Pint: 0.02) (Fig. 1A). The differential impact of
thienopyridines vs. ticagrelor on all-cause mortality was driven by
both cardiovascular and non-cardiovascular death. Cardiovascularmor-
tality trended lower with an extended use of ticagrelor beyond 12
months (OR: 0.85; 95% CI 0.72–1.01), whereas no such effect was ob-
served with thienopyridines (OR: 1.08; 95% CI 0.79–1.49) (Pint: 0.19)
(Fig. 1B). At sensitivity analysis, interaction became more pronounced
(Pint: 0.10)when events at longest available follow-upwere considered.
Non-cardiovascular mortality was increased from an extended treat-
ment with thienopyridines (OR: 1.85; 95% CI 1.23–2.79) but not after
prolonged treatment with ticagrelor (OR: 1.14; 95% CI 0.92–1.42)
(Pint: 0.04) (Fig. 1C). To further corroborate our ﬁndings we evaluated
the differential impact on cardiovascular and non-cardiovascular
mortality on each treatment group. An extended course of DAPT with
thienopyridines had a different impact on cardiovascular mortality as
compared to non-cardiovascular mortality (Pint: 0.04), characterized
by a null-effect on the former and a signiﬁcant 87% increase on the latter
International Journal of Cardiology 201 (2015) 179–181
⁎ Corresponding author at: Swiss Cardiovascular Center Bern, Bern, University Hospital,
CH-3010, Bern, Switzerland.
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To the editor:
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month course of DAPT with thienopyridines was also associated with
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quent meta-analyses [3]. It remains unclear if this effect on mortality
is class- or thienopyridine-speciﬁc.We therefore performed a systemat-
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trials that randomized patients to 12-month vs. greater than 12-
month DAPT duration based on thienopyridines or ticagrelor, to explore
the differential impact of P2Y12 inhibitor type on all-cause mortality,
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The studywas conducted according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) statement
(Supplemental material) [4]. We selected for our analysis randomized
clinical trials that assigned patients to a standard 12-month DAPT vs.
extended DAPT beyond 12 months. The ﬁnal search was performed on
May 2, 2015. Statistical pooling of odds ratios (OR) was performed
with random effects. A 2-tailed alpha of 5% was used for hypothesis
testing. Statistical interaction was assessed with Cochran Q via a chi-
square test and quantiﬁed with the I2 test.
We identiﬁed 4 relevant studies, of which 3 tested the effect of
thienopyridines (i.e. clopidogrel/prasugrel) and one of ticagrelor [1,
2,5,6]. Data extraction was limited to all-cause, cardiovascular and
non-cardiovascular mortality. On-treatment events and those
occurring at the longest available follow-up were appraised in the
main and sensitivity analyses, respectively. All analyses were
intention-to-treat and performed with RevMan v5.3.5 (the Cochrane
Collaboration).
Among 37,427 patients, all-cause mortality after an extended DAPT
course was increased by 30% in patients receiving thienopyridines (OR
1.30; 95% CI 1.02–1.66), but not in those treated with ticagrelor (OR
0.94; 95% CI 0.82–1.08) with signiﬁcant interaction between duration
and type of treatment (Pint: 0.02) (Fig. 1A). The differential impact of
thienopyridines vs. ticagrelor on all-cause mortality was driven by
both cardiovascular and non-cardiovascular death. Cardiovascularmor-
tality trended lower with an extended use of ticagrelor beyond 12
months (OR: 0.85; 95% CI 0.72–1.01), whereas no such effect was ob-
served with thienopyridines (OR: 1.08; 95% CI 0.79–1.49) (Pint: 0.19)
(Fig. 1B). At sensitivity analysis, interaction became more pronounced
(Pint: 0.10)when events at longest available follow-upwere considered.
Non-cardiovascular mortality was increased from an extended treat-
ment with thienopyridines (OR: 1.85; 95% CI 1.23–2.79) but not after
prolonged treatment with ticagrelor (OR: 1.14; 95% CI 0.92–1.42)
(Pint: 0.04) (Fig. 1C). To further corroborate our ﬁndings we evaluated
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mortality on each treatment group. An extended course of DAPT with
thienopyridines had a different impact on cardiovascular mortality as
compared to non-cardiovascular mortality (Pint: 0.04), characterized
by a null-effect on the former and a signiﬁcant 87% increase on the latter
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outcome (Fig. 2A). On the other hand, an extendedDAPTwith ticagrelor
was associated to a trend towards cardiovascular mortality reduction
and a null-effect on non-cardiovascular fatality (Fig. 2B).
Our pooled analysis suggests that the type of P2Y12 inhibitor used in
combination with aspirin may exert a differential effect on mortality
and type thereof after an extended DAPT duration beyond 12 months.
While a prolonged treatmentwith thienopyridines increased fatality
risk, in keepingwith previous reports [3], ticagrelor provided amore fa-
vorable impact onmortality. This was driven by a trend towards cardio-
vascular mortality reduction and a null-effect on non-cardiovascular
death.While it may be argued that ticagrelor did not reduce signiﬁcant-
ly cardiovascular mortality in PEGASUS, this ﬁnding is highly consistent
Fig. 1. The odds ratio for standard vs. extended DAPT duration regarding all-cause (A), cardiovascular (B) and non-cardiovascular (C) mortality is presented among the studies
implementing thienopyridines and ticagrelor.
180 Letter to the Editor
Chapter 5.2
with the PLATO trial [7], where all-cause and cardiovascular mortality
were both signiﬁcantly lower after ticagrelor as compared to
clopidogrel. On this other hand, no contemporary study has reported
mortality reduction after treatment with clopidogrel as compared to
placebo or after prasugrel as compared to placebo or clopidogrel.
The putative reasons behind the differential effect of ticagrelor vs.
clopidogrel/prasugrel on non-cardiovascular mortality remain spec-
ulative. It is tempting to speculate that while ticagrelor exerts a more
powerful inhibition of platelet activity compared to clopidogrel and
as such be more protective towards ischemic recurrences, its revers-
ible inhibition of the P2Y12 receptor may mitigate the detrimental
consequences of bleeding on mortality and type thereof. In keeping
with this, in both the PEGASUS and PLATO, no excess of fatal bleeding
was observed with ticagrelor despite overall higher bleeding risks [2,
7]. Off-target effects exerted by ticagrelor, mainly related to the
inhibition of the ENT-1 receptor, may also concur explaining our
ﬁndings.
Our study suffers of several limitations. The effect of an extended
course of ticagrelor beyond 12 months was studied only in a single,
yet large-scale trial, which recruited patients with history of myocardial
infarction [2]. Differently, the three studies that appraised a similar
treatment extensionwith thienopyridines included patients with stable
coronary artery disease at presentation. However, it seems unlikely that
clinical presentation alonemay explain the observed effect onmortality
considering that none of the studies so far performed demonstrated
interaction between clinical presentation and duration of DAPT on
mortality [8,9]. In addition, among thienopyridines studies, the DAPT
trial was the only in which a portion of patients received a treatment
with prasugrel, thus it may be questioned if our ﬁndings are
clopidogrel-speciﬁc or they may also apply to prasugrel [1,5,6]. Howev-
er, Garratt et al. reported nomortality beneﬁt with 30-month treatment
with prasugrel as compared to standard 12-month treatment [10].
In conclusion, an extended treatment with ticagrelor, as compared
to a similar strategy with thienopyridines, exerted a more favorable
effect on all-cause mortality due to a trend towards reduction of
cardiovascular death and a null-effect on non-cardiovascular death.
Our analysis suggests that type of P2Y12 inhibitor used in combination
with aspirin may be a treatment modiﬁer onmortality and type thereof
in patients undergoing N12-month therapy.
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powerful inhibition of platelet activity compared to clopidogrel and
as such be more protective towards ischemic recurrences, its revers-
ible inhibition of the P2Y12 receptor may mitigate the detrimental
consequences of bleeding on mortality and type thereof. In keeping
with this, in both the PEGASUS and PLATO, no excess of fatal bleeding
was observed with ticagrelor despite overall higher bleeding risks [2,
7]. Off-target effects exerted by ticagrelor, mainly related to the
inhibition of the ENT-1 receptor, may also concur explaining our
ﬁndings.
Our study suffers of several limitations. The effect of an extended
course of ticagrelor beyond 12 months was studied only in a single,
yet large-scale trial, which recruited patients with history of myocardial
infarction [2]. Differently, the three studies that appraised a similar
treatment extensionwith thienopyridines included patients with stable
coronary artery disease at presentation. However, it seems unlikely that
clinical presentation alonemay explain the observed effect onmortality
considering that none of the studies so far performed demonstrated
interaction between clinical presentation and duration of DAPT on
mortality [8,9]. In addition, among thienopyridines studies, the DAPT
trial was the only in which a portion of patients received a treatment
with prasugrel, thus it may be questioned if our ﬁndings are
clopidogrel-speciﬁc or they may also apply to prasugrel [1,5,6]. Howev-
er, Garratt et al. reported nomortality beneﬁt with 30-month treatment
with prasugrel as compared to standard 12-month treatment [10].
In conclusion, an extended treatment with ticagrelor, as compared
to a similar strategy with thienopyridines, exerted a more favorable
effect on all-cause mortality due to a trend towards reduction of
cardiovascular death and a null-effect on non-cardiovascular death.
Our analysis suggests that type of P2Y12 inhibitor used in combination
with aspirin may be a treatment modiﬁer onmortality and type thereof
in patients undergoing N12-month therapy.
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available with the full text of the article at 
NEJM.org). Similar findings have been reported 
by Mauri et al.1 with an extended use of thieno-
pyridines beyond 1 year.
A pooled analysis of these two studies sug-
gests a significant relative increase of 41% in the 
number of cancer-related deaths among patients 
who were treated with extended dual antiplatelet 
therapy (Fig. 1). In this analysis, the number of 
patients who would need to be treated to cause 
one cancer death was 322. Could the author in-
dicate whether there was an imbalance in the 
diagnosis of cancer before and after randomiza-
tion in the two study groups? If this is not the 
case, the reason for an increase in cancer-related 
deaths with an extended duration of dual anti-
platelet therapy should be investigated.
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To the Editor: Bonaca et al. are missing the 
most important finding of the PEGASUS-TIMI 54 
study — namely, that drugs that cause excess 
bleeding also increase the risk of solid cancers. 
This study showed an increasing dose–response 
relationship for deaths from cancer: 77 in the 
group receiving 90 mg of ticagrelor and 64 in 
those receiving 60 mg of ticagrelor, as compared 
with 53 receiving placebo. In the Study of Platelet 
Inhibition and Patient Outcomes (PLATO), the 
administration of ticagrelor was too short and 
the follow-up was too incomplete to provide reli-
able data about cancer.1
A review of prasugrel by the Food and Drug 
Administration (FDA)2 first reported the associ-
ation between bleeding and solid cancers. In the 
Trial to Assess Improvement in Therapeutic 
Outcomes by Optimizing Platelet Inhibition with 
Prasugrel–Thrombolysis in Myocardial Infarction 
38 (TRITON-TIMI 38),3 the hazard ratios in the 
prasugrel group, as compared with the clopido-
grel group, for the incidence of solid cancers and 
death were both approximately 1.6 (P = 0.001). 
An FDA review 4 of the DAPT study documented 
that the relative risk of the incidence of a solid 
cancer was about 1.2 with clopidogrel and 1.3 with 
prasugrel, as compared with placebo. The rates 
of cancer-related death (relative risk, 2.2; P = 0.02) 
were higher with continued use of thienopyri-
dines.5 The latter FDA review4 also provides an 
0.50.2 1.0 10.05.02.0
Standard Therapy BetterExtended Therapy Better
Mauri et al.
Bonaca et al.
All patients
Heterogeneity, I2=0%
Extended Therapy Hazard Ratio (95% CI)Standard TherapyStudy
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P Value
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53/7067
  67/12,007 0.02
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Figure 1. Pooled Analysis of Cancer-Related Deaths among Patients Receiving Extended Dual Antiplatelet Therapy, 
as Compared with Standard Therapy, in Two Studies.
In the trial by Mauri et al. (Dual Antiplatelet Therapy [DAPT] study), patients who had received 1 year of treatment 
with a thienopyridine (clopidogrel or prasugrel) were randomly assigned to continue receiving a thienopyridine or to 
receive a placebo for another 18 months. In the trial by Bonaca et al. (PEGASUS-TIMI 54), all patients were followed 
for a median of 33 months, including those receiving ticagrelor (who are included in the extended-therapy group in 
the pooled analysis) and those receiving placebo (who are included in the standard-therapy group). The size of the 
squares is proportional to the size of the study. The diamond incorporates the overall hazard ratio and 95% confi-
dence interval.
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major antiplatelet and anticoagulant trials sub-
mitted to the FDA. The most serious hazard of 
long-term antiplatelet use is cancer, not bleeding.
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To the Editor: The PEGASUS-TIMI 54 and 
DAPT1 trials have both shown that intensified 
platelet inhibition with dual antiplatelet therapy 
(P2Y12 antagonist plus aspirin) after 1 year effec-
tively reduces the risk of ischemic events in pa-
tients with high-risk coronary artery disease at 
the expense of clinically serious bleeding. 
Therefore, a personalized antiplatelet strategy 
that is based on a risk-profile analysis including 
a therapeutic-window concept for platelet reac-
tivity may improve the balance between efficacy 
and safety during long-term dual antiplatelet 
therapy.2
East Asians have less thrombophilia and a 
greater bleeding tendency than do Western popu-
lations during antiplatelet therapy.3,4 Further-
more, active metabolite concentrations of prasu-
grel and ticagrelor are up to 50% greater among 
East Asians than among white patients, findings 
that translate into more potent platelet inhibi-
tion among East Asians.4 In PEGASUS-TIMI 54, 
the net clinical benefit of the addition of long-
term ticagrelor among Asian patients appears to 
be less favorable than among white patients 
(Fig. 1). (East Asians made up approximately three 
quarters of the Asian cohort.) A more judicious 
approach in adapting the strategy outlined in the 
PEGASUS-TIMI 54 trial for Asians without fur-
ther dedicated studies in the Asian population 
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Figure 1. Net Clinical Benefit for Asian Patients, as Compared with All Patients, in the PEGASUS-TIMI 54 Trial.
Shown are the percentages of Asian patients, as compared with all patients, who had a composite cardiovascular 
event (death from cardiovascular causes, myocardial infarction, or stroke at 3 years) or who had a major bleeding 
episode (as defined by the Thrombolysis in Myocardial Infarction [TIMI] criteria at 3 years), according to the dose of 
ticagrelor or placebo. The values below the graph show the number of patients who would need to be treated to pre-
vent one cardiovascular event and the number of patients who would need to be harmed to cause one cardiovascular 
or bleeding event. Among Asian patients, the numbers needed to harm for ticagrelor (60 mg) are 400.0 for a cardio-
vascular event and 43.5 for a major bleeding event. NA denotes not applicable.
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In the trial by Mauri et al. (Dual Antiplatelet Therapy [DAPT] study), patients who had received 1 year of treatment 
with a thienopyridine (clopidogrel or prasugrel) were randomly assigned to continue receiving a thienopyridine or to 
receive a placebo for another 18 months. In the trial by Bonaca et al. (PEGASUS-TIMI 54), all patients were followed 
for a median of 33 months, including those receiving ticagrelor (who are included in the extended-therapy group in 
the pooled analysis) and those receiving placebo (who are included in the standard-therapy group). The size of the 
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dence interval.
The New England Journal of Medicine 
Downloaded from nejm.org on September 24, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Chapter 5.3
correspondence
n engl j med 373;13 nejm.org september 24, 2015 1273
overview of bleeding and cancer results for all 
major antiplatelet and anticoagulant trials sub-
mitted to the FDA. The most serious hazard of 
long-term antiplatelet use is cancer, not bleeding.
Thomas A. Marciniak, M.D.
6400 Windermere Cir. 
North Bethesda, MD 
thomas.a.marciniak@gmail.com
No potential conflict of interest relevant to this letter was re-
ported.
1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus 
clopidogrel in patients with acute coronary syndromes. N Engl J 
Med 2009;361:1045-57.
2. Marciniak TA. FDA secondary review of cancer adverse 
events and risk benefit: NDA 22-307 prasugrel. 2008 (http://
www.accessdata.fda.gov/drugsatfda_docs/nda/2009/ 
022307s000_MedR_P26.pdf).
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus 
clopidogrel in patients with acute coronary syndromes. N Engl J 
Med 2007;357:2001-15. 
4. Marciniak TA. FDA clinical review: antiplatelet and antico-
agulant drugs cancer risk. 2014 (http://www.accessdata.fda.gov/
drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf).
5. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of 
dual antiplatelet therapy after drug-eluting stents. N Engl J Med 
2014;371:2155-66.
DOI: 10.1056/NEJMc1508692
To the Editor: The PEGASUS-TIMI 54 and 
DAPT1 trials have both shown that intensified 
platelet inhibition with dual antiplatelet therapy 
(P2Y12 antagonist plus aspirin) after 1 year effec-
tively reduces the risk of ischemic events in pa-
tients with high-risk coronary artery disease at 
the expense of clinically serious bleeding. 
Therefore, a personalized antiplatelet strategy 
that is based on a risk-profile analysis including 
a therapeutic-window concept for platelet reac-
tivity may improve the balance between efficacy 
and safety during long-term dual antiplatelet 
therapy.2
East Asians have less thrombophilia and a 
greater bleeding tendency than do Western popu-
lations during antiplatelet therapy.3,4 Further-
more, active metabolite concentrations of prasu-
grel and ticagrelor are up to 50% greater among 
East Asians than among white patients, findings 
that translate into more potent platelet inhibi-
tion among East Asians.4 In PEGASUS-TIMI 54, 
the net clinical benefit of the addition of long-
term ticagrelor among Asian patients appears to 
be less favorable than among white patients 
(Fig. 1). (East Asians made up approximately three 
quarters of the Asian cohort.) A more judicious 
approach in adapting the strategy outlined in the 
PEGASUS-TIMI 54 trial for Asians without fur-
ther dedicated studies in the Asian population 
Pa
tie
nt
s 
(%
) 9
12
6
3
0
Placebo Ticagrelor,
60 mg
Ticagrelor,
90 mg
No. Needed to Treat
No. Needed to Harm
78.7
80.6
84.0
64.9
Placebo Ticagrelor,
60 mg
Ticagrelor,
90 mg
NA
400.0; 43.5
128.2
65.4
Death from cardiovascular
causes, myocardial
infarction, or stroke
TIMI major bleeding
All Patients
(N=21,162)
Asian Patients
(N=2369)
 
9.04
7.77 7.85 6.86 7.11 6.08
1.06
2.30 2.60
1.44
3.74
2.97
  
Figure 1. Net Clinical Benefit for Asian Patients, as Compared with All Patients, in the PEGASUS-TIMI 54 Trial.
Shown are the percentages of Asian patients, as compared with all patients, who had a composite cardiovascular 
event (death from cardiovascular causes, myocardial infarction, or stroke at 3 years) or who had a major bleeding 
episode (as defined by the Thrombolysis in Myocardial Infarction [TIMI] criteria at 3 years), according to the dose of 
ticagrelor or placebo. The values below the graph show the number of patients who would need to be treated to pre-
vent one cardiovascular event and the number of patients who would need to be harmed to cause one cardiovascular 
or bleeding event. Among Asian patients, the numbers needed to harm for ticagrelor (60 mg) are 400.0 for a cardio-
vascular event and 43.5 for a major bleeding event. NA denotes not applicable.
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will be an essential challenge, given these obser-
vations.
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To the Editor: There is uncertainty about the 
balance between bleeding and efficacy in the 
PEGASUS-TIMI 54 trial, since the absolute reduc-
tion of approximately 1 percentage point in the 
composite of death from cardiovascular causes, 
myocardial infarction, or stroke seems to be off-
set by a similar elevation in the risk of major 
bleeding. To help apply these results to practice, 
first, we need more details about major bleeding 
events, especially whether these events were 
spontaneous or related to surgical or interven-
tional procedures. Second, a formal analysis of 
efficacy and safety on the basis of baseline clini-
cal and bleeding risk would be helpful to guide 
treatment — for example, using adapted scores 
from the Global Registry of Acute Coronary 
Events (GRACE)1 study and the HAS-BLED (Hyper-
tension, Abnormal Renal/Liver Function, Stroke, 
Bleeding History or Predisposition, Labile INR, 
Elderly, Drugs/Alcohol Concomitantly)2 study. 
Third, no information is presented on platelet-
function studies that might provide important 
insights into risks of bleeding.3 Finally, the re-
sults provide no information on cost-effective-
ness. Investigators are to be congratulated on a 
landmark trial, but global economic and health-
policy constraints mean that providing all rele-
vant information on new treatments as early as 
possible will help increase adoption into practice.
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The authors reply: In response to the com-
ments of Sharma and colleagues: we agree that 
the intensity of long-term antiplatelet therapy 
that best balances benefit and risk may be lower 
for patients who are further removed from their 
myocardial infarction, as we discussed in our ar-
ticle on the design of the PEGASUS-TIMI 54 trial.1 
For that reason, we tested two doses of ticagrelor 
and indeed found similar efficacy and a tendency 
toward a better safety and side-effect profile 
with the lower dose. Whether even lesser degrees 
of platelet inhibition would be as effective for 
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secondary prevention in this population is a hy-
pothesis that remains to be proved but should be 
tested.
Costa and Valgimigli as well as Marciniak 
raise the issue of an association between long-
term antiplatelet therapy and an increase in the 
risk of cancer and cite data from the DAPT trial. 
However, with the exclusion of DAPT, in a meta-
analysis involving more than 50,000 patients in 
trials of prolonged P2Y12 inhibition, as compared 
with placebo, in which more than 1000 patients 
died from noncardiovascular causes, the hazard 
ratio for noncardiovascular death was 0.98 for 
patients receiving P2Y12 inhibitors.
2 Marciniak 
cites his previous analysis noting an excess of 
cancers with prasugrel, as compared with clopid-
ogrel, in TRITON-TIMI 38. However, in review-
ing the totality of evidence, the FDA concluded 
that causality of cancer was unlikely and that the 
chance of a false positive finding was high.3 
That conclusion was later supported by the pro-
spective assessment of cancer in the Targeted 
Platelet Inhibition to Clarify the Optimal Strat-
egy to Medically Manage Acute Coronary Syn-
dromes (TRILOGY ACS) trial, which showed no 
excess with prasugrel versus clopiogrel.4 Simi-
larly, with ticagrelor, although there was a nu-
meric imbalance in PEGASUS-TIMI 54, there was 
no excess of cancers with the 90-mg dose of 
ticagrelor, as compared with clopidogrel, in 
PLATO.5 Imbalances that were seen in some 
studies may be due to ascertainment bias, with 
bleeding leading to imaging studies that reveal 
cancers, so deaths of patients are classified as 
being from these cancers. Ongoing analyses 
should help shed light on this matter.
Jeong et al. raise the issue of a different re-
sponse to antiplatelet therapy among Asian pa-
tients. However, as we noted in our article, there 
was no heterogeneity with ticagrelor for ischemic 
or bleeding events among Asians as compared 
with other populations. We agree that larger, 
dedicated studies in Asia would be valuable, 
rather than attempting to perform risk–benefit 
assessments by extrapolating event rates from 
small subgroups of patients in whom the num-
ber of events in some groups was only eight.
We appreciate the enthusiasm of Flather and 
colleagues to see more secondary analyses. In-
deed, we agree that the analyses they mention 
are of value.
Marc P. Bonaca, M.D., M.P.H. 
Eugene Braunwald, M.D. 
Marc S. Sabatine, M.D., M.P.H.
Brigham and Women’s Hospital 
Boston, MA 
mbonaca@partners.org
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and ration-
ale for the Prevention of Cardiovascular Events in Patients With 
Prior Heart Attack Using Ticagrelor Compared to Placebo on a 
Background of Aspirin–Thrombolysis in Myocardial Infarction 
54 (PEGASUS-TIMI 54) trial. Am Heart J 2014;167:437-44.
2. Elmariah S, Mauri L, Doros G, et al. Extended duration dual 
antiplatelet therapy and mortality: a systematic review and meta-
analysis. Lancet 2015;385:792-8.
3. Unger EF. Weighing benefits and risks — the FDA’s review 
of prasugrel. N Engl J Med 2009;361:942-5.
4. Roe MT, Ohman EM. Prasugrel versus clopidogrel for acute 
coronary syndromes. N Engl J Med 2013;368:188-9.
5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus 
clopidogrel in patients with acute coronary syndromes. N Engl J 
Med 2009;361:1045-57.
DOI: 10.1056/NEJMc1508692
Advanced Dementia
To the Editor: Mitchell (June 25 issue)1 de-
scribes a patient in whom aspiration pneumonia 
develops because he is dying of advanced demen-
tia. She recommends careful discussions about 
the goals of care but stops short of what is truly 
needed: a recommendation to transition to com-
fort care or, ideally, a skilled, compassionate ex-
planation of why comfort care will be provided. 
The alternatives are burdensome and reasonable 
to withhold even if cost were not a factor. But it 
is: America spends too much on care that does 
not translate into improved health outcomes2; we 
are already rationing care, and it is time for a 
serious discussion about doing a better job of it.3
In my practice, I hold goals-of-care discussions 
early in the course of a patient’s illness, recom-
mend hospice whenever appropriate, and take 
intensive care off the table for patients who are 
obviously dying. An ethics consultation is help-
ful,4 but I usually only need to listen, show 
compassion, and use a “let’s do everything pos-
sible . . . that would be beneficial” framework. 
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will be an essential challenge, given these obser-
vations.
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To the Editor: There is uncertainty about the 
balance between bleeding and efficacy in the 
PEGASUS-TIMI 54 trial, since the absolute reduc-
tion of approximately 1 percentage point in the 
composite of death from cardiovascular causes, 
myocardial infarction, or stroke seems to be off-
set by a similar elevation in the risk of major 
bleeding. To help apply these results to practice, 
first, we need more details about major bleeding 
events, especially whether these events were 
spontaneous or related to surgical or interven-
tional procedures. Second, a formal analysis of 
efficacy and safety on the basis of baseline clini-
cal and bleeding risk would be helpful to guide 
treatment — for example, using adapted scores 
from the Global Registry of Acute Coronary 
Events (GRACE)1 study and the HAS-BLED (Hyper-
tension, Abnormal Renal/Liver Function, Stroke, 
Bleeding History or Predisposition, Labile INR, 
Elderly, Drugs/Alcohol Concomitantly)2 study. 
Third, no information is presented on platelet-
function studies that might provide important 
insights into risks of bleeding.3 Finally, the re-
sults provide no information on cost-effective-
ness. Investigators are to be congratulated on a 
landmark trial, but global economic and health-
policy constraints mean that providing all rele-
vant information on new treatments as early as 
possible will help increase adoption into practice.
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EDITORIAL
Duration of dual antiplatelet therapy after
drug-eluting stent implantation: will we ever
reach a consensus?
Marco Valgimigli*, Sara Ariotti, and Francesco Costa
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
This editorial refers to ‘ISAR-SAFE: a randomized, double-
blind,placebo-controlledtrialof6vs.12 monthsofclopidogrel
therapy after drug-eluting stenting’, by S. Schulz-Schu¨pke
et al., on page doi:10.1093/eurheartj/ehu523.
‘Well? Shall we go?’—‘Yes, let’s go’. ‘They do not move.’
Waiting for Godot, by Samuel Beckett,
Combined treatmentwith aspirin and aP2Y12 inhibitor, the so-called
dual antiplatelet therapy (DAPT) regimen, exerts protection against
ischaemic myocardial recurrences via a double mechanism of action.
First, it prevents sudden thrombotic occlusion of previously
implanted stent(s) in the coronary arteries, thereby reducing the
risk of stent thrombosis that occurs as a result of inﬂammation
during healing.1,2 Since the vast majority of stent thrombosis cases
are known to occur within the ﬁrst weeks after stent implantation,
an arbitrary 30 day to 6 weeks duration of DAPT has been investi-
gated and a 30 day duration of therapy has become the standard of
care approach after uncoated stent implantation.
Secondly, DAPThas also been shown tomitigate the risk of subse-
quent myocardial infarction in patients not previously treated with
coronary stents or arising fromnon-previously stented coronary seg-
ments.3,4 While the capability of DAPT to limit the progression of
atherosclerosis per se has never been demonstrated, it remains
likely—even if not proven—that DAPT protects the patient from
the consequences of spontaneous coronary plaque rupture.
The reasons why long-term prolongation of DAPT is debated,
despite its unquestionable value, are two-fold. Long-term DAPT
carries a time-dependent riskofmajor and clinically relevant bleeding
complications, which affects morbidity andmortality at least as much
as ischaemic recurrences.4–7
Moreover, the advent of drug-eluting stents (DES) has prompted
attention to be paid to delayed healing and persistent polymer-
induced inﬂammation at the sites of stent placement, thereby poten-
tially requiring long-standing DAPT continuation.
First-generation DES were associated with a four- to ﬁve-fold
higher risk of very late (i.e. after the ﬁrst year) stent thrombosis as
compared with bare metal stents (BMS).8,9 This observation corro-
borated the perception of increased thrombogenicity of DES as
compared with BMS and fuelled ‘the longer the better’ notion
for DAPT duration in DES-treated patients.10
Yet, stent thrombogenicity is a multifactorial process and the
drug-elution capability per se does not appear nowadays (i.e. at
variance with the original belief) clearly related to it.11
Emerging evidence of superior safety with respect to stent throm-
bosis and target vessel myocardial infarction has been generated for
some of the newly introduced devices when compared with ﬁrst-
generation DES.12–14 Moreover, there is a growing literature sug-
gesting that at least some second-generation devices may be safer
when compared not only with ﬁrst-generation devices but also
with the corresponding BMS counterparts.14–16 Therefore, the
original belief according to which a DES per se should trigger a pro-
longed course of DAPT does not seem to be supported by currently
available comparative safety and efﬁcacy data amongst different
stent platforms.
The complexity and importanceof the topic canonly be addressed
by properly performed randomized clinical trials. Yet, after multiple
dedicated randomized controlled studies, the issue of the optimal
duration of DAPT after DES implantation remains apparently
unsettled.
In this issue of the journal, Schulz-Schu¨pke and colleagues report
on the long awaited primary ﬁndings of the Intracoronary Stenting
and Antithrombotic Regimen: Safety And EFﬁcacy of 6 Months
Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE)
trial, which randomized 4000 patients, out of the previously
planned 6000, to undergo 6- vs. 12-month therapy with aspirin and
clopidogrel, largely after second-generation DES implantation.17
Beyond the speciﬁc clinical and scientiﬁc value of the study, this
trial does represent a major academic achievement, in light of its
global representativeness, and investigator-initiated and placebo-
controlled design. The hurdles of conducting such a study, which
led investigators to stop inclusion prematurely, reinforce the
notion that it is becoming increasinglymore challenging for physicians
(and also expert trialists!) to provide answers to clinically relevant
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questionswithout the direct involvement of industries. This observa-
tion should prompt aprofound reﬂectionwithin themedical commu-
nity on the sustainability of spontaneous research in the future and
highlights the value of this speciﬁc study despite its inherent limita-
tions, largely related to limited study power, which arewell acknowl-
edged by the authors.
Waiting for Godot?
In the tragicomedy entitledWaiting for Godot, by Samuel Becket, Vlad-
imir and the struggling Estragon wait for the mysterious Mr Godot,
who never shows up. The ISAR-SAFE along with the DAPT trials
have been eagerly awaited by the community as the studies are sup-
posed to bring a ﬁnal word on the optimal DAPT duration afterDES.
Unlike Mr Godot, ISAR-SAFE and DAPT trials ﬁnally arrived.
However, similarly to Mr Godot, both studies, for very different
reasons, did not entirely fulﬁl the expectations set by the community.
The incidence of the primary endpoint of the ISAR-SAFE study, con-
sisting of death, myocardial infarction, stent thrombosis (deﬁnite or
probable), stroke, or Thrombolysis in Myocardial Infarction (TIMI)
major bleeding, was virtually identical in both groups at 9 months
after randomization, fulﬁlling the pre-speciﬁed non-inferiority cri-
teria. Absolute non-inferiority delta between the two treatment
groups was set at 2%, corresponding to 20% of the anticipated back-
groundevent rate (i.e. 10%).While theoriginallyplanned relative20%
non-inferiority boundary was appropriately stringent, the ﬁve-fold
lower than expected observed event rate resulted in non-inferiority
criteria being even greater than the actual event rate observed in the
study. As a result, the ISAR-SAFE trial cannot be regarded as a conclu-
sive investigation per se. The selection of mainly stable patients at the
time of percutaeous coronary intervention (,20% myocardial in-
farction patients), the relatively short treatment duration difference
(6 months) and follow-up (9 months), the application of a noise
avoidance strategy, i.e. setting randomization at the time the treat-
ment started to diverge in the two study groups, and perhaps the
need to stick to clopidogrel instead of newer P2Y12 inhibitors may
account for such an unexpected low event rate. It may be argued
that in the era of more potent and consistent P2Y12 inhibitors, the
restriction to their use in the ISAR-SAFE trial, which mandated the
use of clopidogrel only, may have led to the exclusion of patients at
highest risk of adverse events after stenting. A parallel registry,
describing reasons for patients’ exclusion in the study and their
outcomes, would have proven extremely helpful to understand
conclusively the external validity of this trial.
No difference in TIMI major bleeding was also noted in the two
study groups. Yet, TIMI minor bleeding trended in favour of the
6-month DAPT regimen [0.1% vs. 0.4%; hazard ratio (HR) 0.25,
95% conﬁdence interval (CI) 0.05–1.17; P ¼ 0.08] and when the
BARC (Bleeding Academic Research Consortium) classiﬁcation
was applied, which captures any type of actionable or non-actionable
bleeding complications, the 6-month DAPT regimen was associated
with 50% lower risk of events (1.4% vs. 2.8%; HR 0.49, 95% CI 0.31–
0.77; P ¼ 0.002). An interesting observation arising from the ISAR-
SAFE trial is the complete lack of rebound phenomenon after
DAPT discontinuation, both at 6 (experimental arm) and at 12
(control group) months. This is in agreement with the results of
the patterns of non-adherence to anti-platelet regimens in stented
patients (PARIS) registry,18 where only patients who discontinued
DAPT due to a bleeding episode or non-compliance experienced
an increased risk of adverse events thereafter. Yet, this observation
appears in contrast to the resultsof theDAPT trialwherea three-fold
increased risk ofmyocardial infarction in the 90 days followingDAPT
discontinuation has been reported at both 12 (control group) and
30 months (experimental arm). The inspection of the 95% CIs of
the HRs capturing events in the 90 days after DAPT discontinuation
in ISAR-SAFE and DAPT trials suggests that this discrepant ﬁnding
with respect to rebound effect after stopping DAPT cannot easily
be attributed to a type II error. Moreover, no single randomized
controlled trial (RCT) testing different DAPT durations has so
far reported this observation, apart from the DAPT trial. Hence, a
proper explanation for the observed rebound effect, or lack
thereof, of protocol-mandated DAPT discontinuation in the DAPT
trial vs. ISAR-SAFE and other RCTs remain elusive and warrants
further investigation.
Pooled snalysis
Including ISAR-SAFE, seven studies, recruiting 15 378 patients have
so far compared ,12-month DAPT duration (ranging from 3 to
6 months), with 12-month (5 studies)19–22 or 24-month (two
studies)5,23 DAPT duration. Three additional studies, including the
DAPT trial, evaluated the value of prolonging vs.stopping DAPT
beyond 12 months. While multiple meta-analyses exist pooling to-
gether all available evidence, irrespective of actual DAPT duration
in the control and experimental arm, this generates amethodological
issue as it would lead to inclusion of the 12-month DAPT duration in
both study arms. As the aimof ISAR-SAFE is to assesswhetherDAPT
can be safely stopped at 6 as compared with 12 months, only includ-
ing studies comparing a shorter than 12-month vs. a ≥12-month
regimen may add clarity to the results provided now by ISAR-SAFE
itself. The mean age was comparable across these seven studies,
ranging from 62 to 68 years, and the prevalence of diabetes mellitus
ranged from25%up to39%. Theprevalenceof ST-segment elevation
myocardial infarction at presentation varied widely amongst the
included studies. Importantly, in all trials, DAPT consisted of aspirin
and clopidogrel. Loss at follow-up was variable across studies: SE-
CURITY19 and the ISAR-SAFE trials had the highest loss at follow-up,
while in the EXCELLENT22, RESET21, PRODIGY,5 and ITALIC23
trials, loss at follow-up was minimal. ISAR-SAFE is the only study
among those included basedon a double-blind design.Nodetectable
heterogeneity for the explored endpoints, as assessed by the Q x2
test was found, and I2 was consistently equal to 0. We speciﬁcally
looked into the four endpoints, which were combined, in the
primary endpoint of the ISAR-SAFE Trial.
Comparedwith at least 12-monthDAPTduration, patients receiv-
ing ,12 months DAPT therapy had a similar risk of death from all
cause [odds ratio (OR) 0.89; 95% CI 0.68–1.15; P ¼ 0.37,
ﬁxed-effects] (Figure 1), myocardial infarction (OR 1.14; 95% CI
0.89–1.47; P ¼ 0.30, ﬁxed-effects) (Figure 1), deﬁnite or probable
stent thrombosis (OR 1.36; 95% CI 0.85–2.16; P ¼ 0.19,
ﬁxed-effects) (Figure 1), and stroke (OR 0.84; 95% CI 0.53–1.31;
P ¼ 0.30, ﬁxed-effects) (Figure 1), and lower risk of major bleeding
(OR 0.53; 95% CI 0.34–0.84; P ¼ 0.007, ﬁxed-effects) (Figure 1).
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In summary, despite the fact that ISAR-SAFE has limited power to
answer the original study question (i.e. is it safe to stop DAPT at
6 months after DES as compared with 12 month therapy?) the
results of this pooled analysis of all studies so far conducted compar-
ing shorter than 12 months vs. at least 12 months or longer DAPT
duration after DES implantation are consistent with the overall
study results. It suggests that a shorter DAPT regimen halves the
risk of major bleeding and does not seem to be associated, in
return, with extra ischaemic risk. This observation is in keeping
with the PARIS registry, where patients who discontinued DAPT
under medical guidance were not exposed to a higher risk of major
adverse cardiovascular events or stent thrombosis as compared
with patients who remained on DAPT for 2 years.18
What does the future hold?
The lack of clear ischaemic beneﬁt associated with an at least
12-month DAPT regimen arising from the pooled analysis of all
studies comparing shorter than vs. at least 12-monthDAPT duration
contrastswith the results of theDAPT trial.4 In that study, an unques-
tionable beneﬁt in terms of both stent- and patient-oriented ischae-
mic endpoints has been reported, even if the excess of bleeding risk
and the increase of non-cardiovascular mortality remain a matter of
concern.4 Reconciliation of these apparently contrasting ﬁndings in
clinical practice remains challenging. Difference in patient selection,
timing of randomization, proportion of patients receiving newer as
compared with ﬁrst-generation DES,24,25 and use of newer P2Y12
inhibitors are elements which may at least partially account for
these different results.
Hence, after 10 randomized controlled studies including .30 000
patients, the only possible conclusion to be drawn by the clinician is
that one standardDAPT regimen does not seem to beneﬁt all patients
equally. A personalizedDAPT duration based on the individual bleed-
inghazardorthebalanceofbleedingand ischaemic risk seemsthemost
logical way for the future, which will require dedicated studies.26
The selection of which single antiplatelet agent to carry forward
after DAPT discontinuation, i.e. aspirin as conventionally recom-
mended27 or the P2Y12 inhibitor and type thereof, remains an area
of research for the future, but they hold promise to shorten overall
DAPT duration without compromising efﬁcacy.
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questionswithout the direct involvement of industries. This observa-
tion should prompt aprofound reﬂectionwithin themedical commu-
nity on the sustainability of spontaneous research in the future and
highlights the value of this speciﬁc study despite its inherent limita-
tions, largely related to limited study power, which arewell acknowl-
edged by the authors.
Waiting for Godot?
In the tragicomedy entitledWaiting for Godot, by Samuel Becket, Vlad-
imir and the struggling Estragon wait for the mysterious Mr Godot,
who never shows up. The ISAR-SAFE along with the DAPT trials
have been eagerly awaited by the community as the studies are sup-
posed to bring a ﬁnal word on the optimal DAPT duration afterDES.
Unlike Mr Godot, ISAR-SAFE and DAPT trials ﬁnally arrived.
However, similarly to Mr Godot, both studies, for very different
reasons, did not entirely fulﬁl the expectations set by the community.
The incidence of the primary endpoint of the ISAR-SAFE study, con-
sisting of death, myocardial infarction, stent thrombosis (deﬁnite or
probable), stroke, or Thrombolysis in Myocardial Infarction (TIMI)
major bleeding, was virtually identical in both groups at 9 months
after randomization, fulﬁlling the pre-speciﬁed non-inferiority cri-
teria. Absolute non-inferiority delta between the two treatment
groups was set at 2%, corresponding to 20% of the anticipated back-
groundevent rate (i.e. 10%).While theoriginallyplanned relative20%
non-inferiority boundary was appropriately stringent, the ﬁve-fold
lower than expected observed event rate resulted in non-inferiority
criteria being even greater than the actual event rate observed in the
study. As a result, the ISAR-SAFE trial cannot be regarded as a conclu-
sive investigation per se. The selection of mainly stable patients at the
time of percutaeous coronary intervention (,20% myocardial in-
farction patients), the relatively short treatment duration difference
(6 months) and follow-up (9 months), the application of a noise
avoidance strategy, i.e. setting randomization at the time the treat-
ment started to diverge in the two study groups, and perhaps the
need to stick to clopidogrel instead of newer P2Y12 inhibitors may
account for such an unexpected low event rate. It may be argued
that in the era of more potent and consistent P2Y12 inhibitors, the
restriction to their use in the ISAR-SAFE trial, which mandated the
use of clopidogrel only, may have led to the exclusion of patients at
highest risk of adverse events after stenting. A parallel registry,
describing reasons for patients’ exclusion in the study and their
outcomes, would have proven extremely helpful to understand
conclusively the external validity of this trial.
No difference in TIMI major bleeding was also noted in the two
study groups. Yet, TIMI minor bleeding trended in favour of the
6-month DAPT regimen [0.1% vs. 0.4%; hazard ratio (HR) 0.25,
95% conﬁdence interval (CI) 0.05–1.17; P ¼ 0.08] and when the
BARC (Bleeding Academic Research Consortium) classiﬁcation
was applied, which captures any type of actionable or non-actionable
bleeding complications, the 6-month DAPT regimen was associated
with 50% lower risk of events (1.4% vs. 2.8%; HR 0.49, 95% CI 0.31–
0.77; P ¼ 0.002). An interesting observation arising from the ISAR-
SAFE trial is the complete lack of rebound phenomenon after
DAPT discontinuation, both at 6 (experimental arm) and at 12
(control group) months. This is in agreement with the results of
the patterns of non-adherence to anti-platelet regimens in stented
patients (PARIS) registry,18 where only patients who discontinued
DAPT due to a bleeding episode or non-compliance experienced
an increased risk of adverse events thereafter. Yet, this observation
appears in contrast to the resultsof theDAPT trialwherea three-fold
increased risk ofmyocardial infarction in the 90 days followingDAPT
discontinuation has been reported at both 12 (control group) and
30 months (experimental arm). The inspection of the 95% CIs of
the HRs capturing events in the 90 days after DAPT discontinuation
in ISAR-SAFE and DAPT trials suggests that this discrepant ﬁnding
with respect to rebound effect after stopping DAPT cannot easily
be attributed to a type II error. Moreover, no single randomized
controlled trial (RCT) testing different DAPT durations has so
far reported this observation, apart from the DAPT trial. Hence, a
proper explanation for the observed rebound effect, or lack
thereof, of protocol-mandated DAPT discontinuation in the DAPT
trial vs. ISAR-SAFE and other RCTs remain elusive and warrants
further investigation.
Pooled snalysis
Including ISAR-SAFE, seven studies, recruiting 15 378 patients have
so far compared ,12-month DAPT duration (ranging from 3 to
6 months), with 12-month (5 studies)19–22 or 24-month (two
studies)5,23 DAPT duration. Three additional studies, including the
DAPT trial, evaluated the value of prolonging vs.stopping DAPT
beyond 12 months. While multiple meta-analyses exist pooling to-
gether all available evidence, irrespective of actual DAPT duration
in the control and experimental arm, this generates amethodological
issue as it would lead to inclusion of the 12-month DAPT duration in
both study arms. As the aimof ISAR-SAFE is to assesswhetherDAPT
can be safely stopped at 6 as compared with 12 months, only includ-
ing studies comparing a shorter than 12-month vs. a ≥12-month
regimen may add clarity to the results provided now by ISAR-SAFE
itself. The mean age was comparable across these seven studies,
ranging from 62 to 68 years, and the prevalence of diabetes mellitus
ranged from25%up to39%. Theprevalenceof ST-segment elevation
myocardial infarction at presentation varied widely amongst the
included studies. Importantly, in all trials, DAPT consisted of aspirin
and clopidogrel. Loss at follow-up was variable across studies: SE-
CURITY19 and the ISAR-SAFE trials had the highest loss at follow-up,
while in the EXCELLENT22, RESET21, PRODIGY,5 and ITALIC23
trials, loss at follow-up was minimal. ISAR-SAFE is the only study
among those included basedon a double-blind design.Nodetectable
heterogeneity for the explored endpoints, as assessed by the Q x2
test was found, and I2 was consistently equal to 0. We speciﬁcally
looked into the four endpoints, which were combined, in the
primary endpoint of the ISAR-SAFE Trial.
Comparedwith at least 12-monthDAPTduration, patients receiv-
ing ,12 months DAPT therapy had a similar risk of death from all
cause [odds ratio (OR) 0.89; 95% CI 0.68–1.15; P ¼ 0.37,
ﬁxed-effects] (Figure 1), myocardial infarction (OR 1.14; 95% CI
0.89–1.47; P ¼ 0.30, ﬁxed-effects) (Figure 1), deﬁnite or probable
stent thrombosis (OR 1.36; 95% CI 0.85–2.16; P ¼ 0.19,
ﬁxed-effects) (Figure 1), and stroke (OR 0.84; 95% CI 0.53–1.31;
P ¼ 0.30, ﬁxed-effects) (Figure 1), and lower risk of major bleeding
(OR 0.53; 95% CI 0.34–0.84; P ¼ 0.007, ﬁxed-effects) (Figure 1).
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In summary, despite the fact that ISAR-SAFE has limited power to
answer the original study question (i.e. is it safe to stop DAPT at
6 months after DES as compared with 12 month therapy?) the
results of this pooled analysis of all studies so far conducted compar-
ing shorter than 12 months vs. at least 12 months or longer DAPT
duration after DES implantation are consistent with the overall
study results. It suggests that a shorter DAPT regimen halves the
risk of major bleeding and does not seem to be associated, in
return, with extra ischaemic risk. This observation is in keeping
with the PARIS registry, where patients who discontinued DAPT
under medical guidance were not exposed to a higher risk of major
adverse cardiovascular events or stent thrombosis as compared
with patients who remained on DAPT for 2 years.18
What does the future hold?
The lack of clear ischaemic beneﬁt associated with an at least
12-month DAPT regimen arising from the pooled analysis of all
studies comparing shorter than vs. at least 12-monthDAPT duration
contrastswith the results of theDAPT trial.4 In that study, an unques-
tionable beneﬁt in terms of both stent- and patient-oriented ischae-
mic endpoints has been reported, even if the excess of bleeding risk
and the increase of non-cardiovascular mortality remain a matter of
concern.4 Reconciliation of these apparently contrasting ﬁndings in
clinical practice remains challenging. Difference in patient selection,
timing of randomization, proportion of patients receiving newer as
compared with ﬁrst-generation DES,24,25 and use of newer P2Y12
inhibitors are elements which may at least partially account for
these different results.
Hence, after 10 randomized controlled studies including .30 000
patients, the only possible conclusion to be drawn by the clinician is
that one standardDAPT regimen does not seem to beneﬁt all patients
equally. A personalizedDAPT duration based on the individual bleed-
inghazardorthebalanceofbleedingand ischaemic risk seemsthemost
logical way for the future, which will require dedicated studies.26
The selection of which single antiplatelet agent to carry forward
after DAPT discontinuation, i.e. aspirin as conventionally recom-
mended27 or the P2Y12 inhibitor and type thereof, remains an area
of research for the future, but they hold promise to shorten overall
DAPT duration without compromising efﬁcacy.
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Aims We investigated if acute coronary syndrome (ACS) rather than stable coronary artery disease (SCAD) presentation
is an outcomemodiﬁerwith respect to the duration of dual-antiplatelet therapy (DAPT) in patients undergoing coronary
stenting.
Methods and
results
In the ProlongingDual-Antiplatelet TreatmentAfterGrading Stent-Induced IntimalHyperplasia (PRODIGY) trial, a total of
1465 (74.3%) patients presentedACSwhereas 505 (25.7%) had SCADandwere randomized to 6- or 24-monthDAPT. At
24 months, the composite of death, myocardial infarction (MI), or cerebrovascular accident (CVA) did not differ between
the long- and short-term DAPT arms in both ACS (11.1 vs. 11.7%; P ¼ 0.67) and SCAD (7.5 vs. 4.8%; P ¼ 0.21) patients,
respectively. Long-term DAPT was associated with a 75% increase of Bleeding Academic Research Consortium
(BARC)-class 2, 3, or 5 bleeding in ACS [7.1 vs. 4.1%; hazard ratio (HR) 1.75, 95% conﬁdence interval (CI) 1.11–2.74,
P ¼ 0.015; number needed to treat for harm (NNTH): 33.3] and a ﬁve-fold increase in SCAD (8.2 vs. 1.6%; HR 5.37,
95% CI 1.84–15.74, P ¼ 0.002; NNTH: 15.1) patients, with a borderline quantitative interaction (PINT ¼ 0.056). As a
result, net adverse cardiovascular events (death, MI, CVA, BARC class 2, 3, or 5 bleeding) were more than doubled in
SCAD patients receiving 24-month DAPT, whereas they did not differ in ACS patients (PINT ¼ 0.024).
Conclusions This analysis suggests that clinical presentationmay be a treatmentmodiﬁerwith respect toDAPTduration after stenting
consistent with the hypothesis that SCAD—but not ACS—patients are exposed to a signiﬁcant increase in bleeding and
net adverse clinical events when treated with 24-month compared with 6-month therapy.
Trial registration clinicaltrials.gov Identiﬁer: NCT00611286. http://clinicaltrials.gov/ct2/show/NCT00611286?term=prodigy&rank=2.
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24-month duration of dual-antiplatelet therapy
after stent implantation: a pre-speciﬁed analysis
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Aims We investigated if acute coronary syndrome (ACS) rather than stable coronary artery disease (SCAD) presentation
is an outcomemodiﬁerwith respect to the duration of dual-antiplatelet therapy (DAPT) in patients undergoing coronary
stenting.
Methods and
results
In the ProlongingDual-Antiplatelet TreatmentAfterGrading Stent-Induced IntimalHyperplasia (PRODIGY) trial, a total of
1465 (74.3%) patients presentedACSwhereas 505 (25.7%) had SCADandwere randomized to 6- or 24-monthDAPT. At
24 months, the composite of death, myocardial infarction (MI), or cerebrovascular accident (CVA) did not differ between
the long- and short-term DAPT arms in both ACS (11.1 vs. 11.7%; P ¼ 0.67) and SCAD (7.5 vs. 4.8%; P ¼ 0.21) patients,
respectively. Long-term DAPT was associated with a 75% increase of Bleeding Academic Research Consortium
(BARC)-class 2, 3, or 5 bleeding in ACS [7.1 vs. 4.1%; hazard ratio (HR) 1.75, 95% conﬁdence interval (CI) 1.11–2.74,
P ¼ 0.015; number needed to treat for harm (NNTH): 33.3] and a ﬁve-fold increase in SCAD (8.2 vs. 1.6%; HR 5.37,
95% CI 1.84–15.74, P ¼ 0.002; NNTH: 15.1) patients, with a borderline quantitative interaction (PINT ¼ 0.056). As a
result, net adverse cardiovascular events (death, MI, CVA, BARC class 2, 3, or 5 bleeding) were more than doubled in
SCAD patients receiving 24-month DAPT, whereas they did not differ in ACS patients (PINT ¼ 0.024).
Conclusions This analysis suggests that clinical presentationmay be a treatmentmodiﬁerwith respect toDAPTduration after stenting
consistent with the hypothesis that SCAD—but not ACS—patients are exposed to a signiﬁcant increase in bleeding and
net adverse clinical events when treated with 24-month compared with 6-month therapy.
Trial registration clinicaltrials.gov Identiﬁer: NCT00611286. http://clinicaltrials.gov/ct2/show/NCT00611286?term=prodigy&rank=2.
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Introduction
A 30-day course of therapy with a P2Y12 inhibitor in addition to
aspirin (i.e. dual-antiplatelet therapy, DAPT) is the current standard
for the prevention of stent thrombosis (ST) after bare metal stent
implantation.1 Similarly, 12-month of DAPT is recommended for
acute coronary syndrome (ACS) patients, irrespective of the revas-
cularization strategy.1–3 The advent of ﬁrst generation drug-eluting
stent (DES) has prompted renewed interest in re-assessing optimal
DAPT duration after stent placement. Drug-eluting stent per se has
been initially regarded as more thrombogenic devices.4,5 Hence,
without compelling evidence, an at least 6- or 12-month DAPT dur-
ation regimen has been recommended in patients receiving DES
irrespective of clinical presentation.2,3
Interestingly, themost recent ESC guidelines onmyocardial revas-
cularizationprovideadifferential setof recommendations afterDES,1
based upon the stability of clinical presentation, whereas the ACC/
AHA guidelines uniformly support at least 12-monthDAPT duration
after DES, irrespective of the indication to percutaneous coronary
intervention (PCI).2,3
Multiple randomized trials have investigated the optimal DAPT
duration after stent placement but given the relatively low number
of ACS patients included in many of those studies, it remains
unclear whether ACS is a treatment modiﬁer of DAPT duration
after coronary stenting.6,7
Hence, we aimed at investigating whether clinical presentation
(SCAD vs. ACS) in the setting of an all-comer PCI population may
modify the effect of DAPT duration with regard to ischaemic and
bleeding events in patients undergoing a short or a prolonged
course of DAPT after coronary stenting.
Methods
The design and main study ﬁndings for the Prolonging Dual-
Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperpla-
sia Study (PRODIGY) were previously reported.6,8 In brief, all-comer
patients receiving a balanced mixture of stents with varying anti-intimal
hyperplasia potency and belonging to both ﬁrst- and second-
generation DES at three Italian sites were randomly allocated at 30
days to either 6 or 24 months of dual-antiplatelet treatment. Selection
criteria were broad, reﬂecting routine clinical practice. Randomization
to 6- or 24-month DAPT was performed at 30 days and it was strati-
ﬁed by centre, ongoing ST-segment-elevation myocardial infarction
(MI), the presence of diabetes mellitus, and need for intervening on
at least one in-stent restenotic lesion. The study was conducted in
accordance with the principles of the Declaration of Helsinki. The
Ethics Committees of the three participating centres independently
approved the protocol, and all participants gave written informed
consent.
Treatment protocol
All patients received aspirin (80–160 mg orally indeﬁnitely) and clo-
pidogrel (75 mg/day) according to the randomization scheme as
follows: for either 6 months in the short dual-antiplatelet group or
24 months in the prolonged dual-antiplatelet arm irrespective of
the previously implanted stent type or indication for the coronary
procedure.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 1 Baseline characteristics of the patients
Characteristic Acute coronary syndrome Stable coronary artery disease
24-Month
clopidogrel
(n 5 732)
6-Month
clopidogrel
(n 5 733)
P-value 24-Month
clopidogrel
(n5 255)
6-Month
clopidogrel
(n5 250)
P-value
Age (year) 67.7+11.8 68.2+11.8 0.38 68.2+8.8 67.04+9.8 0.15
Male sex, no. (%) 555 (75.8) 550 (75.0) 0.73 209 (82.0) 197 (78.8) 0.37
Body mass index (kg/m2) 26.1 26.4 0.36 27.3 27.1 0.53
Diabetes, no. (%) 165 (22.5) 162 (22.1) 0.51 78 (30.5) 70 (28.0) 0.68
Hypertension, no. (%) 510 (69.7) 499 (68.1) 0.51 211 (82.7) 194 (77.6) 0.16
Hyperlipidaemia, no. (%) 370 (50.5) 354 (48.3) 0.39 183 (71.8) 171 (68.4) 0.45
Current cigarette use, no. (%) 185 (25.3) 207 (28.2) 0.45 36 (14.1) 40 (16.0) 0.51
Creatinine clearance (mL/min) 75.0 73.5 0.50 73.9 77.8 0.38
Prior myocardial infarction, no. (%) 179 (24.4) 187 (25.5) 0.38 91 (35.6) 69 (27.6) 0.13
Left ventricular ejection fraction 50.0 50.0 0.13 60 60 0.57
Clinical presentation, no. (%)
Non-ST-elevation acute coronary syndrome 411 (56.1) 406 (55.4) 0.77 – – –
Unstable angina 185 (25.3) 182 (24.8) 0.84 – – –
Non-ST-elevation MI 226 (30.9) 224 (30.6) 0.90 – – –
ST-segment-elevation MI 321 (43.9) 327 (44.6) 0.77 – – –
Bleedscore
CRUSADE score 26 25 0.97 22.5 24 0.46
ACUITY score 17 16 0.38 11 11 0.75
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Introduction
A 30-day course of therapy with a P2Y12 inhibitor in addition to
aspirin (i.e. dual-antiplatelet therapy, DAPT) is the current standard
for the prevention of stent thrombosis (ST) after bare metal stent
implantation.1 Similarly, 12-month of DAPT is recommended for
acute coronary syndrome (ACS) patients, irrespective of the revas-
cularization strategy.1–3 The advent of ﬁrst generation drug-eluting
stent (DES) has prompted renewed interest in re-assessing optimal
DAPT duration after stent placement. Drug-eluting stent per se has
been initially regarded as more thrombogenic devices.4,5 Hence,
without compelling evidence, an at least 6- or 12-month DAPT dur-
ation regimen has been recommended in patients receiving DES
irrespective of clinical presentation.2,3
Interestingly, themost recent ESC guidelines onmyocardial revas-
cularizationprovideadifferential setof recommendations afterDES,1
based upon the stability of clinical presentation, whereas the ACC/
AHA guidelines uniformly support at least 12-monthDAPT duration
after DES, irrespective of the indication to percutaneous coronary
intervention (PCI).2,3
Multiple randomized trials have investigated the optimal DAPT
duration after stent placement but given the relatively low number
of ACS patients included in many of those studies, it remains
unclear whether ACS is a treatment modiﬁer of DAPT duration
after coronary stenting.6,7
Hence, we aimed at investigating whether clinical presentation
(SCAD vs. ACS) in the setting of an all-comer PCI population may
modify the effect of DAPT duration with regard to ischaemic and
bleeding events in patients undergoing a short or a prolonged
course of DAPT after coronary stenting.
Methods
The design and main study ﬁndings for the Prolonging Dual-
Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperpla-
sia Study (PRODIGY) were previously reported.6,8 In brief, all-comer
patients receiving a balanced mixture of stents with varying anti-intimal
hyperplasia potency and belonging to both ﬁrst- and second-
generation DES at three Italian sites were randomly allocated at 30
days to either 6 or 24 months of dual-antiplatelet treatment. Selection
criteria were broad, reﬂecting routine clinical practice. Randomization
to 6- or 24-month DAPT was performed at 30 days and it was strati-
ﬁed by centre, ongoing ST-segment-elevation myocardial infarction
(MI), the presence of diabetes mellitus, and need for intervening on
at least one in-stent restenotic lesion. The study was conducted in
accordance with the principles of the Declaration of Helsinki. The
Ethics Committees of the three participating centres independently
approved the protocol, and all participants gave written informed
consent.
Treatment protocol
All patients received aspirin (80–160 mg orally indeﬁnitely) and clo-
pidogrel (75 mg/day) according to the randomization scheme as
follows: for either 6 months in the short dual-antiplatelet group or
24 months in the prolonged dual-antiplatelet arm irrespective of
the previously implanted stent type or indication for the coronary
procedure.
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Table 1 Baseline characteristics of the patients
Characteristic Acute coronary syndrome Stable coronary artery disease
24-Month
clopidogrel
(n 5 732)
6-Month
clopidogrel
(n 5 733)
P-value 24-Month
clopidogrel
(n5 255)
6-Month
clopidogrel
(n5 250)
P-value
Age (year) 67.7+11.8 68.2+11.8 0.38 68.2+8.8 67.04+9.8 0.15
Male sex, no. (%) 555 (75.8) 550 (75.0) 0.73 209 (82.0) 197 (78.8) 0.37
Body mass index (kg/m2) 26.1 26.4 0.36 27.3 27.1 0.53
Diabetes, no. (%) 165 (22.5) 162 (22.1) 0.51 78 (30.5) 70 (28.0) 0.68
Hypertension, no. (%) 510 (69.7) 499 (68.1) 0.51 211 (82.7) 194 (77.6) 0.16
Hyperlipidaemia, no. (%) 370 (50.5) 354 (48.3) 0.39 183 (71.8) 171 (68.4) 0.45
Current cigarette use, no. (%) 185 (25.3) 207 (28.2) 0.45 36 (14.1) 40 (16.0) 0.51
Creatinine clearance (mL/min) 75.0 73.5 0.50 73.9 77.8 0.38
Prior myocardial infarction, no. (%) 179 (24.4) 187 (25.5) 0.38 91 (35.6) 69 (27.6) 0.13
Left ventricular ejection fraction 50.0 50.0 0.13 60 60 0.57
Clinical presentation, no. (%)
Non-ST-elevation acute coronary syndrome 411 (56.1) 406 (55.4) 0.77 – – –
Unstable angina 185 (25.3) 182 (24.8) 0.84 – – –
Non-ST-elevation MI 226 (30.9) 224 (30.6) 0.90 – – –
ST-segment-elevation MI 321 (43.9) 327 (44.6) 0.77 – – –
Bleedscore
CRUSADE score 26 25 0.97 22.5 24 0.46
ACUITY score 17 16 0.38 11 11 0.75
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Follow-up
All randomized patients returned for study visits at 30 days, and then
every 6 months up to 2 years. During follow-up visits, patients were
examined and assessed for adverse events, asked for the antiplatelet
therapy compliance and 12-lead electrocardiogram recordings were
obtained.
Study endpoints
The primary efﬁcacy endpoint of the PRODIGY trial was the composite
of death, MI, or cerebrovascular accident (CVA), whereas the key safety
endpoint included Bleeding Academic Research Consortium (BARC)
type 2, 3, or 5 bleeding. To appraise the net effect of DAPT duration
in the stratiﬁed ACS and SCAD populations on the combined ischaemic
and bleeding complications, two net adverse clinical event (NACE) end-
points were generated by combining the primary efﬁcacy endpoint of
death, MI, or CVA with either the primary safety endpoint of BARC
type 2, 3, or 5 bleeding or with BARC type 3 or 5 events. Other
endpoints included each component of the primary efﬁcacy endpoint,
cardiovascular death, ST deﬁned on the basis of the Academic Research
Consortium criteria,9 and BARC type 3 or 5 bleeding. Other safety
endpoints included bleeding events adjudicated according to the TIMI
and GUSTO scales. All study endpoint deﬁnitions were previously
reported.8
All endpointswere conﬁrmedon thebasis of documentation collected
at eachhospital andwere centrally adjudicatedby the clinical events com-
mittee, whose members were unaware of the patients’ treatment-group
assignments. The time frame of interest for the primary endpoint was
from 30 days (i.e. after the primary endpoint randomization) to 24
months.
Statistical analysis
In this pre-speciﬁed analysis of the PRODIGY trial,8 categorical variables
were expressed as frequency (percentage), whereas continuous variables
were expressed as median (interquartile range). Continuous variables
were compared between randomized groups using the Wilcoxon’s rank
sums test, whereas for binary variables the x2 test was used.
Estimationof the cumulative incidenceof eventswasperformedby the
Kaplan–Meier method and events were compared by the log-rank test.
Hazard ratios (HRs)with 95% conﬁdence intervals (CIs)were calculated
for long-term clopidogrel vs. short-term clopidogrel (i.e. values.1 indi-
cated increased hazard in the long-term group) with a proportional
hazards model. The number needed to treat for harm (NNTH) was
appraised as 1/absolute risk reduction. The proportionality hazard
assumptions were visually checked and veriﬁed by plotting the log cumu-
lative hazard vs. (log) time at follow-up after the index procedure and
by applying a test for non-proportional hazards using the Schoenfeld resi-
duals.WeperformedaCoxregression analysiswith interaction testing to
determine whether the effect of duration of dual-antiplatelet therapy on
the primaryefﬁcacyendpoint, on the key safety endpoint of BARC2, 3, or
5 and on BARC 3 or 5 bleeding was consistent across important pre-
speciﬁed subgroups. Interaction tests were performed with likelihood
ratio tests of the null hypothesis that the interaction coefﬁcient was
zero. A two-sided probability value of ,0.05 was considered signiﬁcant.
All analyses, performed on the basis of the intention-to-treat principle,
were performed with SPSS, version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
From December 2006 to December 2008, a total of 2789 patients
underwent screening and 2013 were ﬁnally recruited into the study.
Figure 1 Ischaemic endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome)
subgroups are shown,with hazard ratios and 95%conﬁdence intervals, for theprimary endpoint of death for any cause,myocardial infarction (MI), or
cerebrovascular accident (CVA), cardiovascular (CV) death ormyocardial infarction, death for any cause andmyocardial infarction (Death/MI), def-
inite stent thrombosis (def ST) anddeﬁnite/probable stent thrombosis (Def/probST) amongpatients randomlyassigned toeither the6-monthor the
24-month dual-antiplatelet therapy.
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Thirty-three (1.6%) patients died within 30 days and 10 patients with-
drew consent, therefore, 1970 patients— of which approximately
three-quarters (n ¼ 1465) presented with ACS and 505 with
SCAD—were randomly allocated at 30 days to receive 6-month
(733 ACS and 250 SCAD) or 24-month (732 ACS and 255 SCAD)
duration of clopidogrel therapy (see Supplementary material online,
Figure S1).
Clinical andangiographic characteristicswerebalanced in the long-
vs. short-term DAPT duration arms within both the SCAD and ACS
strata (Table 1 and Supplementary material online, Table S2). Adher-
ence to protocol-mandated antiplatelet regimens was high and did
not differ in SCAD or ACS patient populations (see Supplementary
material online, Figure S2).
Clinical follow-up at 2 years was complete for 99.6% of patients in
both ACS and SCAD arms.
Ischaemic outcomes
At 24 months, the primary efﬁcacy endpoint (death, MI, or CVA)
occurred in 167 (11.4%) patients in the ACS group and in 32
(5.8%) patients in the SCAD group (Table 2).
The primary endpoint event rate did not differ with respect to
DAPT duration in both ACS (11.1% in the 24-month vs. 11.7% in the
6-month DAPT arms; HR 0.936, 95% CI 0.691–1.268; P ¼ 0.67) and
SCAD groups (7.5% in the 24-month vs. 4.8% in the 6-month DAPT
arms; HR 1.591, 95% CI 0.773–3.278; P ¼ 0.21), with no evidence of
interaction between clinical presentation and randomized duration
of therapy (PINT ¼ 0.189) (Figures 1 and 2A). Consistent ﬁndings
were noted when each component of the primary endpoint was
examined separately (see Supplementary material online, Table S2
and Figure 1). Other patient-oriented ischaemic events including
cardiovascular death alone or in combination with other non-fatal
Figure 2 Cumulative incidence of ischaemic and bleeding events. Cumulative incidence curves are shown. (A) Death for any cause, myocardial
infarction, or cerebrovascular accident in the stable and unstable groupof the two treatment arms. (B) Bleeding according to the Bleeding Academic
Research Consortium 2, 3, 5 criteria, in the stable and unstable group of the two treatment arms.
Impact of stability of disease on risks and beneﬁts of DAPT Page 5 of 10
by guest on February 27, 2015
Downloaded from 
IMPACT OF CLINICAL PRESENTATION ON DAPT DURATION
251250
5
Follow-up
All randomized patients returned for study visits at 30 days, and then
every 6 months up to 2 years. During follow-up visits, patients were
examined and assessed for adverse events, asked for the antiplatelet
therapy compliance and 12-lead electrocardiogram recordings were
obtained.
Study endpoints
The primary efﬁcacy endpoint of the PRODIGY trial was the composite
of death, MI, or cerebrovascular accident (CVA), whereas the key safety
endpoint included Bleeding Academic Research Consortium (BARC)
type 2, 3, or 5 bleeding. To appraise the net effect of DAPT duration
in the stratiﬁed ACS and SCAD populations on the combined ischaemic
and bleeding complications, two net adverse clinical event (NACE) end-
points were generated by combining the primary efﬁcacy endpoint of
death, MI, or CVA with either the primary safety endpoint of BARC
type 2, 3, or 5 bleeding or with BARC type 3 or 5 events. Other
endpoints included each component of the primary efﬁcacy endpoint,
cardiovascular death, ST deﬁned on the basis of the Academic Research
Consortium criteria,9 and BARC type 3 or 5 bleeding. Other safety
endpoints included bleeding events adjudicated according to the TIMI
and GUSTO scales. All study endpoint deﬁnitions were previously
reported.8
All endpointswere conﬁrmedon thebasis of documentation collected
at eachhospital andwere centrally adjudicatedby the clinical events com-
mittee, whose members were unaware of the patients’ treatment-group
assignments. The time frame of interest for the primary endpoint was
from 30 days (i.e. after the primary endpoint randomization) to 24
months.
Statistical analysis
In this pre-speciﬁed analysis of the PRODIGY trial,8 categorical variables
were expressed as frequency (percentage), whereas continuous variables
were expressed as median (interquartile range). Continuous variables
were compared between randomized groups using the Wilcoxon’s rank
sums test, whereas for binary variables the x2 test was used.
Estimationof the cumulative incidenceof eventswasperformedby the
Kaplan–Meier method and events were compared by the log-rank test.
Hazard ratios (HRs)with 95% conﬁdence intervals (CIs)were calculated
for long-term clopidogrel vs. short-term clopidogrel (i.e. values.1 indi-
cated increased hazard in the long-term group) with a proportional
hazards model. The number needed to treat for harm (NNTH) was
appraised as 1/absolute risk reduction. The proportionality hazard
assumptions were visually checked and veriﬁed by plotting the log cumu-
lative hazard vs. (log) time at follow-up after the index procedure and
by applying a test for non-proportional hazards using the Schoenfeld resi-
duals.WeperformedaCoxregression analysiswith interaction testing to
determine whether the effect of duration of dual-antiplatelet therapy on
the primaryefﬁcacyendpoint, on the key safety endpoint of BARC2, 3, or
5 and on BARC 3 or 5 bleeding was consistent across important pre-
speciﬁed subgroups. Interaction tests were performed with likelihood
ratio tests of the null hypothesis that the interaction coefﬁcient was
zero. A two-sided probability value of ,0.05 was considered signiﬁcant.
All analyses, performed on the basis of the intention-to-treat principle,
were performed with SPSS, version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
From December 2006 to December 2008, a total of 2789 patients
underwent screening and 2013 were ﬁnally recruited into the study.
Figure 1 Ischaemic endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome)
subgroups are shown,with hazard ratios and 95%conﬁdence intervals, for theprimary endpoint of death for any cause,myocardial infarction (MI), or
cerebrovascular accident (CVA), cardiovascular (CV) death ormyocardial infarction, death for any cause andmyocardial infarction (Death/MI), def-
inite stent thrombosis (def ST) anddeﬁnite/probable stent thrombosis (Def/probST) amongpatients randomlyassigned toeither the6-monthor the
24-month dual-antiplatelet therapy.
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Thirty-three (1.6%) patients died within 30 days and 10 patients with-
drew consent, therefore, 1970 patients— of which approximately
three-quarters (n ¼ 1465) presented with ACS and 505 with
SCAD—were randomly allocated at 30 days to receive 6-month
(733 ACS and 250 SCAD) or 24-month (732 ACS and 255 SCAD)
duration of clopidogrel therapy (see Supplementary material online,
Figure S1).
Clinical andangiographic characteristicswerebalanced in the long-
vs. short-term DAPT duration arms within both the SCAD and ACS
strata (Table 1 and Supplementary material online, Table S2). Adher-
ence to protocol-mandated antiplatelet regimens was high and did
not differ in SCAD or ACS patient populations (see Supplementary
material online, Figure S2).
Clinical follow-up at 2 years was complete for 99.6% of patients in
both ACS and SCAD arms.
Ischaemic outcomes
At 24 months, the primary efﬁcacy endpoint (death, MI, or CVA)
occurred in 167 (11.4%) patients in the ACS group and in 32
(5.8%) patients in the SCAD group (Table 2).
The primary endpoint event rate did not differ with respect to
DAPT duration in both ACS (11.1% in the 24-month vs. 11.7% in the
6-month DAPT arms; HR 0.936, 95% CI 0.691–1.268; P ¼ 0.67) and
SCAD groups (7.5% in the 24-month vs. 4.8% in the 6-month DAPT
arms; HR 1.591, 95% CI 0.773–3.278; P ¼ 0.21), with no evidence of
interaction between clinical presentation and randomized duration
of therapy (PINT ¼ 0.189) (Figures 1 and 2A). Consistent ﬁndings
were noted when each component of the primary endpoint was
examined separately (see Supplementary material online, Table S2
and Figure 1). Other patient-oriented ischaemic events including
cardiovascular death alone or in combination with other non-fatal
Figure 2 Cumulative incidence of ischaemic and bleeding events. Cumulative incidence curves are shown. (A) Death for any cause, myocardial
infarction, or cerebrovascular accident in the stable and unstable groupof the two treatment arms. (B) Bleeding according to the Bleeding Academic
Research Consortium 2, 3, 5 criteria, in the stable and unstable group of the two treatment arms.
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ischaemicendpointswerehomogenouslydistributedacrosstreatment
arms (see Supplementarymaterial online, Table S2). Similarly, no signal
of heterogeneity was noted for stent-oriented endpoints, including
deﬁnite (PINT ¼ 0.93) and deﬁnite or probable ST (PINT ¼ 0.89),
with respect to DAPT duration (Figure 1).
At further sensitivity analysis, the primary endpoint proved to
be consistent across all pre-speciﬁed clinical or angiographic covari-
ates within the ACS population (see Supplementary material online,
Figure S3).
Bleeding outcomes
The key safety endpoint, consisting of BARC classiﬁcation 2, 3, or 5
bleeding, occurred in 82 (5.6%) and 25 (4.5%) patients of the ACS
and SCAD groups, respectively. Patients treated with longer DAPT
experienced higher rate of bleeding events in both ACS (7.1 vs.
4.1%;HR1.75, 95%CI 1.11–2.74, P ¼ 0.015;NNTH: 33.3) and espe-
cially SCAD (8.2 vs. 1.6%; HR 5.371, 95% CI 1.84–15.74, P ¼ 0.002;
NNTH: 15.1) groups (Table 2 and Figure 2B). When bleeding was
restricted to BARC 3 or 5 criteria, there was an increase of bleeding
complications in patients treated with 24-month when compared
with 6-month DAPT in the SCAD (4.3 vs. 0.8%; HR 5.53, 95% CI
1.2–24.9, P ¼ 0.026; NNTH: 28.6) but not in the ACS group (3.1
vs. 2.3%; HR 1.35, 95% CI 0.72–2.53; P ¼ 0.34). Consistent ﬁndings
were observed with TIMI and GUSTO bleeding scales (see Supple-
mentary material online, Table S2).
There was a borderline quantitative interaction between clinical
presentations and bleeding outcomes (P-values for interaction ¼
0.056 for BARC 2, 3, or 5; P ¼ 0.091 for BARC 3 or 5), suggesting a
higher hazard of bleeding in the 24-month DAPT when compared
with the 6-month arm in the SCAD, which was not observed in the
ACS patients (Figures 2B and 3).
To further explore the consistency of increased bleedings in ACS
patients, sensitivity analyses were performed for BARC 2, 3, or 5 as
well as 3 or 5 events across various subgroups, with no clear signal
for interaction between any of the tested covariates and bleeding
outcomes (see Supplementary material online, Figures S4 and S5).
Net adverse cardiac events
The risk of NACE, consisting of the death, MI, CVA, or BARC 2, 3, or
5 bleeding, was signiﬁcantly increased in the 24-month vs. 6-month
DAPT arm in SCAD patients (13.3 vs. 5.6%; HR 2.5, 95% CI 1.35–
4.69, P ¼ 0.004; NNTH: 13) but not in the ACS population (16.1
vs. 14.1%; HR 1.15, 95%CI 0.88–1.50, P ¼ 0.29), with positive quan-
titative interaction testing (P value for interaction ¼ 0.024) (Figures 4
and 5). When BARC 3 or 5 was used in the combined ischaemic and
bleeding endpoint, results remained consistent; despite interaction
testing did not reach formal statistical signiﬁcance (P ¼ 0.089)
(Figure 4 and Supplementary material online, Figure S6).
Discussion
The main ﬁndings of our analysis of the PRODIGY trial can be sum-
marized as follows:
(1) The lack of ischaemic beneﬁt in favour of a 24-month course of
DAPT, which was previously reported in the overall patient
population, was conﬁrmed in both SCAD and ACS patients,
with no signal of heterogeneity across strata.
(2) Both SCAD and ACS patients displayed a signiﬁcant increase in
bleeding in the 24-month DAPT arm according to the key
safety endpoint of BARC 2, 3, or 5 bleeding. Yet, the magnitude
of such increase appeared relatively greater in the SCAD when
Figure 3 Bleeding endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome)
subgroups are shown, with hazard ratios and 95% conﬁdence intervals, for the key safety endpoint of Bleeding Academic Research Consortium
2, 3, 5 bleeding, and further safety outcomes of Bleeding Academic Research Consortium 3 or 5, TIMI major and minor (TIMI MA/MIN), and
GUSTOmoderate and severe (GUSTOMOD/SEV) bleeding among patients randomly assigned to either the 6-month or the 24-month clopidogrel
therapy.
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compared wih the ACS groups, with a borderline interaction
(P ¼ 0.056). The NNTH with a 24-month DAPT was halved in
SCAD patients when compared with ACS patients. When
more stringent criteria for bleeding were applied, excluding
BARC 2 events, there was a signiﬁcant increase in bleeding end-
points in the SCAD but not in the ACS populations receiving
24-month vs. 6-month DAPT.
(3) The NACE rates, including the primary efﬁcacy and the key sec-
ondary endpoint, were signiﬁcantly increased only in SCAD
patients allocated to the24-month group,whereas no such an in-
crease was noted in the ACS population (PINT ¼ 0.024). After
excluding BARC 2 bleeding, which was recently shown to lack
prognostic implications in terms of overall mortality,10 there
appeared a numerical increase of NACE in SCAD patients
only, with interaction testing providing consistent borderline
results (P ¼ 0.089).
The PRODIGY trial was designed to detect a 40% reduction of the
composite endpoint of death, MI, or CVA in the prolonged DAPT
arm. Our goal was to explore this conservative estimate of beneﬁt
in favour of prolonged DAPT that was previously shown by registry
data, which informed guidelines and daily practice across the world
since 2006.11,12 Our study ultimately failed to provide evidence of a
beneﬁt of a prolonged course of DAPT in largely unselected patients
receiving a balancedmixtureof stentswith varying anti-intimal hyper-
plasia potency and belonging to both ﬁrst- and second-generation
DES.6 The lack of a clear beneﬁt in favour of a prolonged course of
DAPT after DES implantation has been conﬁrmed by 9 of 10 rando-
mized studies so far performed, which were all designed assuming
prolonged DAPT to be associated with a considerable expected
beneﬁt.7 In the recent DAPT trial, a 30-month DAPT duration
resulted in a signiﬁcant reduction of both ST and major adverse
cardiovascular events (MACE). While no formal interaction testing
was noted with respect to the beneﬁt observed for ST across stent
types, patients receiving zotarolimus- or everolimus-eluting stents
did not show a clear and signiﬁcant MACE reduction, with positive
interaction test (P ¼ 0.048). Yet, the 95% upper boundary for
MACE reduction after second-generation DES did not exclude a
possible overall beneﬁt in the 30-month when compared with
12-month DAPT.13
Similarly, the boundary of the 95% conﬁdence interval of primary
endpoint in the PRODIGY trial entailed the possibility that a pro-
longed duration of clopidogrel therapy is associated with up to
26% reduction of patient-oriented ischaemic endpoints. Ultimately,
the possible beneﬁt of a very prolonged DAPT regimen has to be
weighed against an increased bleeding risk. Multiple individual
studies aswell as all pooled analyses so far performedhaveconﬁrmed
a distinct increase bleeding risk in patients undergoing long-term
DAPT,6,7 including the DAPT trial. Despite including only patients
who were free from bleeding events at 12 months, this latter study
reported a possible increase of non-cardiovascular mortality in the
30-month DAPT arm, which remains a matter of concern.
Among thedeaths fromnon-cardiovascular causes, bleeding related
deaths accounted for 11 deaths in the group that continued to receive
thienopyridine vs. 3 deaths in the placebo group, P ¼ 0.057).13
We remain convinced that the balance between risks and benef-
its of prolonged DAPT may largely reﬂect intrinsic bleeding vs.
ischaemic risk in the single individual patient.
Figure 4 Net adverse clinical event. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syn-
drome) subgroups are shown,with hazard ratios and 95% conﬁdence intervals, for the net adverse clinical events of death for any cause, myocardial
infarction, cardiovascular accident, orBleedingAcademicResearchConsortiumclass2, 3, 5bleeding (NACEBARC2–5), and fordeath foranycause,
myocardial infarction, cardiovascular accident, or Bleeding Academic Research Consortium class 3, 5 bleeding (NACE BARC 3–5) among patients
randomly assigned to either the 6-month or the 24-month clopidogrel therapy.
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ischaemicendpointswerehomogenouslydistributedacrosstreatment
arms (see Supplementarymaterial online, Table S2). Similarly, no signal
of heterogeneity was noted for stent-oriented endpoints, including
deﬁnite (PINT ¼ 0.93) and deﬁnite or probable ST (PINT ¼ 0.89),
with respect to DAPT duration (Figure 1).
At further sensitivity analysis, the primary endpoint proved to
be consistent across all pre-speciﬁed clinical or angiographic covari-
ates within the ACS population (see Supplementary material online,
Figure S3).
Bleeding outcomes
The key safety endpoint, consisting of BARC classiﬁcation 2, 3, or 5
bleeding, occurred in 82 (5.6%) and 25 (4.5%) patients of the ACS
and SCAD groups, respectively. Patients treated with longer DAPT
experienced higher rate of bleeding events in both ACS (7.1 vs.
4.1%;HR1.75, 95%CI 1.11–2.74, P ¼ 0.015;NNTH: 33.3) and espe-
cially SCAD (8.2 vs. 1.6%; HR 5.371, 95% CI 1.84–15.74, P ¼ 0.002;
NNTH: 15.1) groups (Table 2 and Figure 2B). When bleeding was
restricted to BARC 3 or 5 criteria, there was an increase of bleeding
complications in patients treated with 24-month when compared
with 6-month DAPT in the SCAD (4.3 vs. 0.8%; HR 5.53, 95% CI
1.2–24.9, P ¼ 0.026; NNTH: 28.6) but not in the ACS group (3.1
vs. 2.3%; HR 1.35, 95% CI 0.72–2.53; P ¼ 0.34). Consistent ﬁndings
were observed with TIMI and GUSTO bleeding scales (see Supple-
mentary material online, Table S2).
There was a borderline quantitative interaction between clinical
presentations and bleeding outcomes (P-values for interaction ¼
0.056 for BARC 2, 3, or 5; P ¼ 0.091 for BARC 3 or 5), suggesting a
higher hazard of bleeding in the 24-month DAPT when compared
with the 6-month arm in the SCAD, which was not observed in the
ACS patients (Figures 2B and 3).
To further explore the consistency of increased bleedings in ACS
patients, sensitivity analyses were performed for BARC 2, 3, or 5 as
well as 3 or 5 events across various subgroups, with no clear signal
for interaction between any of the tested covariates and bleeding
outcomes (see Supplementary material online, Figures S4 and S5).
Net adverse cardiac events
The risk of NACE, consisting of the death, MI, CVA, or BARC 2, 3, or
5 bleeding, was signiﬁcantly increased in the 24-month vs. 6-month
DAPT arm in SCAD patients (13.3 vs. 5.6%; HR 2.5, 95% CI 1.35–
4.69, P ¼ 0.004; NNTH: 13) but not in the ACS population (16.1
vs. 14.1%; HR 1.15, 95%CI 0.88–1.50, P ¼ 0.29), with positive quan-
titative interaction testing (P value for interaction ¼ 0.024) (Figures 4
and 5). When BARC 3 or 5 was used in the combined ischaemic and
bleeding endpoint, results remained consistent; despite interaction
testing did not reach formal statistical signiﬁcance (P ¼ 0.089)
(Figure 4 and Supplementary material online, Figure S6).
Discussion
The main ﬁndings of our analysis of the PRODIGY trial can be sum-
marized as follows:
(1) The lack of ischaemic beneﬁt in favour of a 24-month course of
DAPT, which was previously reported in the overall patient
population, was conﬁrmed in both SCAD and ACS patients,
with no signal of heterogeneity across strata.
(2) Both SCAD and ACS patients displayed a signiﬁcant increase in
bleeding in the 24-month DAPT arm according to the key
safety endpoint of BARC 2, 3, or 5 bleeding. Yet, the magnitude
of such increase appeared relatively greater in the SCAD when
Figure 3 Bleeding endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome)
subgroups are shown, with hazard ratios and 95% conﬁdence intervals, for the key safety endpoint of Bleeding Academic Research Consortium
2, 3, 5 bleeding, and further safety outcomes of Bleeding Academic Research Consortium 3 or 5, TIMI major and minor (TIMI MA/MIN), and
GUSTOmoderate and severe (GUSTOMOD/SEV) bleeding among patients randomly assigned to either the 6-month or the 24-month clopidogrel
therapy.
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compared wih the ACS groups, with a borderline interaction
(P ¼ 0.056). The NNTH with a 24-month DAPT was halved in
SCAD patients when compared with ACS patients. When
more stringent criteria for bleeding were applied, excluding
BARC 2 events, there was a signiﬁcant increase in bleeding end-
points in the SCAD but not in the ACS populations receiving
24-month vs. 6-month DAPT.
(3) The NACE rates, including the primary efﬁcacy and the key sec-
ondary endpoint, were signiﬁcantly increased only in SCAD
patients allocated to the24-month group,whereas no such an in-
crease was noted in the ACS population (PINT ¼ 0.024). After
excluding BARC 2 bleeding, which was recently shown to lack
prognostic implications in terms of overall mortality,10 there
appeared a numerical increase of NACE in SCAD patients
only, with interaction testing providing consistent borderline
results (P ¼ 0.089).
The PRODIGY trial was designed to detect a 40% reduction of the
composite endpoint of death, MI, or CVA in the prolonged DAPT
arm. Our goal was to explore this conservative estimate of beneﬁt
in favour of prolonged DAPT that was previously shown by registry
data, which informed guidelines and daily practice across the world
since 2006.11,12 Our study ultimately failed to provide evidence of a
beneﬁt of a prolonged course of DAPT in largely unselected patients
receiving a balancedmixtureof stentswith varying anti-intimal hyper-
plasia potency and belonging to both ﬁrst- and second-generation
DES.6 The lack of a clear beneﬁt in favour of a prolonged course of
DAPT after DES implantation has been conﬁrmed by 9 of 10 rando-
mized studies so far performed, which were all designed assuming
prolonged DAPT to be associated with a considerable expected
beneﬁt.7 In the recent DAPT trial, a 30-month DAPT duration
resulted in a signiﬁcant reduction of both ST and major adverse
cardiovascular events (MACE). While no formal interaction testing
was noted with respect to the beneﬁt observed for ST across stent
types, patients receiving zotarolimus- or everolimus-eluting stents
did not show a clear and signiﬁcant MACE reduction, with positive
interaction test (P ¼ 0.048). Yet, the 95% upper boundary for
MACE reduction after second-generation DES did not exclude a
possible overall beneﬁt in the 30-month when compared with
12-month DAPT.13
Similarly, the boundary of the 95% conﬁdence interval of primary
endpoint in the PRODIGY trial entailed the possibility that a pro-
longed duration of clopidogrel therapy is associated with up to
26% reduction of patient-oriented ischaemic endpoints. Ultimately,
the possible beneﬁt of a very prolonged DAPT regimen has to be
weighed against an increased bleeding risk. Multiple individual
studies aswell as all pooled analyses so far performedhaveconﬁrmed
a distinct increase bleeding risk in patients undergoing long-term
DAPT,6,7 including the DAPT trial. Despite including only patients
who were free from bleeding events at 12 months, this latter study
reported a possible increase of non-cardiovascular mortality in the
30-month DAPT arm, which remains a matter of concern.
Among thedeaths fromnon-cardiovascular causes, bleeding related
deaths accounted for 11 deaths in the group that continued to receive
thienopyridine vs. 3 deaths in the placebo group, P ¼ 0.057).13
We remain convinced that the balance between risks and benef-
its of prolonged DAPT may largely reﬂect intrinsic bleeding vs.
ischaemic risk in the single individual patient.
Figure 4 Net adverse clinical event. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syn-
drome) subgroups are shown,with hazard ratios and 95% conﬁdence intervals, for the net adverse clinical events of death for any cause, myocardial
infarction, cardiovascular accident, orBleedingAcademicResearchConsortiumclass2, 3, 5bleeding (NACEBARC2–5), and fordeath foranycause,
myocardial infarction, cardiovascular accident, or Bleeding Academic Research Consortium class 3, 5 bleeding (NACE BARC 3–5) among patients
randomly assigned to either the 6-month or the 24-month clopidogrel therapy.
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In this sub-analysis,we stratiﬁed all-comerPCI patients recruited in
the PRODIGY study-based clinical presentation as an accepted
proxy towards both ischaemic and bleeding risk. Indeed, ACS
patients have been previously shown to suffer from a heightened
risk of both ischaemic and bleeding events.14,15 This was conﬁrmed
in our study, as event rates for both endpoints were higher in ACS
compared with SCAD patients. Yet, our analysis suggested that clin-
ical presentation might be a treatment modiﬁer with respect to the
value of prolonged vs. shortened DAPT duration. Stable coronary
artery disease—but not ACS patients—showed notable trends
towards higher bleeding and combined ischaemic and bleeding
risks based on the BARC 3–5 scale. Ischaemic events per se were
also numerically higher in SCAD patients undergoing 24-month
therapy. Equally, therewas an increase of bleeding complications dis-
favouring the 24-monthDAPT regimen, whichwas consistent across
BARC, TIMI, andGUSTObleeding scales. Acute coronary syndrome
patients display higher platelet reactivitywhen comparedwith SCAD
patients.14 Hence, a more potent or prolonged course of platelet in-
hibitionmay have a greater efﬁcacy with a lower bleeding trade-off in
the former than the latter.Accordingly, our stratiﬁed analysis showed
a numerical advantage on ischaemic endpoints and a relatively lower
bleeding hazard in ACS patients undergoing 24-month DAPT dur-
ation. This hypothesis ﬁnds additional support in the results of
TRITON TIMI 38 trial, where particularly high ischaemic risk sub-
groups, such as STEMI or diabetic ACS patients showed no apparent
bleeding liability when treated with prasugrel when compared with
clopidogrel.16 In the CHARISMA trial, patients at lower ischaemic
risk—the so-called ‘asymptomatic’ patient cohort—showed a rela-
tively greater propensity to and a highly signiﬁcant increase in
severe GUSTO bleeding complications, whereas bleeding liability
was apparently lower and not signiﬁcant in patients at higher-risk
ischaemic risk proﬁle.17
Figure5 Cumulative incidence of net adverse clinical event. Cumulative incidence curves are shown for the net adverse clinical events consisting
of death for any cause,myocardial infarction, cerebrovascular accident, andBleedingAcademicResearchConsortiumclass 2, 3, 5 bleeding. (A)Acute
coronary syndrome subgroup and (B) stable coronary artery disease subgroup.
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Bleeding itselfmay predispose to ischaemic complication.10,18 This
provides a potential explanation for the trend towards higher ischae-
mic events in SCAD patients treated with 24-month DAPT. In CHA-
RISMA, patients recruited with a lower cardiovascular risk, showed a
68% increase in GUSTO severe bleeding in the DAPT group and a
concomitant 30 and 44% relative risk increase of mortality and car-
diovascular mortality, respectively.17 Whether this reﬂects a direct
effect of bleeding events on ischaemic risk or it is explained by tem-
porarily or permanently discontinuation of secondary prevention
medications after bleeding is not entirely clear.
Moreover, it has been hypothesized that a more potent or pro-
longed antiplatelet therapy could induce haemorrhage of the athero-
sclerotic plaque, driving to an accelerated progression of the
coronary artery disease.19,20 This may become clinically relevant in
patients at low propensity for spontaneous plaque rupture, such as
SCAD patients.
To conﬁrm or refute the less is more hypothesis, the GLOBAL
LEADERS trial (NCT01813435) is prospectively comparing if a
30-day course of DAPT, followed by ticagrelor monotherapy leads
to superior ischaemic outcomes when compared with 1-year
DAPT followed by aspirin monotherapy in an all-comer PCI popula-
tion including both ACS and SCAD patients.
Study limitations
Despite the current analysiswas pre-speciﬁed, no assessment apriori
of thepower for subgroupswascomputed.Hence, our results should
be interpreted bearing inmind the possibility of a type II error. In add-
ition, the relatively small number of SCAD patients included, pre-
cluded meaningful analysis of the role of stent type within each
presentation stratum. No formal correction was in place for the
number of statistical tests performed, thereby potentially inﬂating
type 1 error.
Randomization in PRODIGY was stratiﬁed based on the
presence or absence of STEMI, but not for any ACS vs. SCADpres-
entation at entry. Hence, despite all baseline clinical and angio-
graphic covariates were well matched within the SCAD and ACS
strata in the long vs. short DAPT arms, our present analysis is
based on post-randomization subgroups. In the PRODIGY trial,
the antiplatelet agent evaluated was clopidogrel, accordingly the
results of this analysis cannot be extrapolated tomore potent anti-
platelet agents. In addition, the original design of the PRODIGY
trial did not include a randomization to 12-month DAPT, which
is currently the recommended therapy duration in ACS patients.1
The PRODIGY trial was underpowered to assess the effect of
different DAPT duration on ST endpoints. Conﬁdence intervals
for deﬁnite or deﬁnite and probable ST are therefore wide and
inconclusive.
In conclusion, our study suggests that clinical presentation is a po-
tential treatmentmodiﬁerwith respect to thedurationofDAPTafter
stenting, consistent with the hypothesis that SCAD—but not ACS—
patients are exposed to a signiﬁcant increase in bleeding and NACE
when treated with 24-month when compared with 6-month
therapy. Our ﬁndings lend support to the recently released ESC
guidelines on myocardial revascularization, which recommends
6-month DAPT duration after DES implantation in SCAD but not
ACS patients.
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In this sub-analysis,we stratiﬁed all-comerPCI patients recruited in
the PRODIGY study-based clinical presentation as an accepted
proxy towards both ischaemic and bleeding risk. Indeed, ACS
patients have been previously shown to suffer from a heightened
risk of both ischaemic and bleeding events.14,15 This was conﬁrmed
in our study, as event rates for both endpoints were higher in ACS
compared with SCAD patients. Yet, our analysis suggested that clin-
ical presentation might be a treatment modiﬁer with respect to the
value of prolonged vs. shortened DAPT duration. Stable coronary
artery disease—but not ACS patients—showed notable trends
towards higher bleeding and combined ischaemic and bleeding
risks based on the BARC 3–5 scale. Ischaemic events per se were
also numerically higher in SCAD patients undergoing 24-month
therapy. Equally, therewas an increase of bleeding complications dis-
favouring the 24-monthDAPT regimen, whichwas consistent across
BARC, TIMI, andGUSTObleeding scales. Acute coronary syndrome
patients display higher platelet reactivitywhen comparedwith SCAD
patients.14 Hence, a more potent or prolonged course of platelet in-
hibitionmay have a greater efﬁcacy with a lower bleeding trade-off in
the former than the latter.Accordingly, our stratiﬁed analysis showed
a numerical advantage on ischaemic endpoints and a relatively lower
bleeding hazard in ACS patients undergoing 24-month DAPT dur-
ation. This hypothesis ﬁnds additional support in the results of
TRITON TIMI 38 trial, where particularly high ischaemic risk sub-
groups, such as STEMI or diabetic ACS patients showed no apparent
bleeding liability when treated with prasugrel when compared with
clopidogrel.16 In the CHARISMA trial, patients at lower ischaemic
risk—the so-called ‘asymptomatic’ patient cohort—showed a rela-
tively greater propensity to and a highly signiﬁcant increase in
severe GUSTO bleeding complications, whereas bleeding liability
was apparently lower and not signiﬁcant in patients at higher-risk
ischaemic risk proﬁle.17
Figure5 Cumulative incidence of net adverse clinical event. Cumulative incidence curves are shown for the net adverse clinical events consisting
of death for any cause,myocardial infarction, cerebrovascular accident, andBleedingAcademicResearchConsortiumclass 2, 3, 5 bleeding. (A)Acute
coronary syndrome subgroup and (B) stable coronary artery disease subgroup.
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Bleeding itselfmay predispose to ischaemic complication.10,18 This
provides a potential explanation for the trend towards higher ischae-
mic events in SCAD patients treated with 24-month DAPT. In CHA-
RISMA, patients recruited with a lower cardiovascular risk, showed a
68% increase in GUSTO severe bleeding in the DAPT group and a
concomitant 30 and 44% relative risk increase of mortality and car-
diovascular mortality, respectively.17 Whether this reﬂects a direct
effect of bleeding events on ischaemic risk or it is explained by tem-
porarily or permanently discontinuation of secondary prevention
medications after bleeding is not entirely clear.
Moreover, it has been hypothesized that a more potent or pro-
longed antiplatelet therapy could induce haemorrhage of the athero-
sclerotic plaque, driving to an accelerated progression of the
coronary artery disease.19,20 This may become clinically relevant in
patients at low propensity for spontaneous plaque rupture, such as
SCAD patients.
To conﬁrm or refute the less is more hypothesis, the GLOBAL
LEADERS trial (NCT01813435) is prospectively comparing if a
30-day course of DAPT, followed by ticagrelor monotherapy leads
to superior ischaemic outcomes when compared with 1-year
DAPT followed by aspirin monotherapy in an all-comer PCI popula-
tion including both ACS and SCAD patients.
Study limitations
Despite the current analysiswas pre-speciﬁed, no assessment apriori
of thepower for subgroupswascomputed.Hence, our results should
be interpreted bearing inmind the possibility of a type II error. In add-
ition, the relatively small number of SCAD patients included, pre-
cluded meaningful analysis of the role of stent type within each
presentation stratum. No formal correction was in place for the
number of statistical tests performed, thereby potentially inﬂating
type 1 error.
Randomization in PRODIGY was stratiﬁed based on the
presence or absence of STEMI, but not for any ACS vs. SCADpres-
entation at entry. Hence, despite all baseline clinical and angio-
graphic covariates were well matched within the SCAD and ACS
strata in the long vs. short DAPT arms, our present analysis is
based on post-randomization subgroups. In the PRODIGY trial,
the antiplatelet agent evaluated was clopidogrel, accordingly the
results of this analysis cannot be extrapolated tomore potent anti-
platelet agents. In addition, the original design of the PRODIGY
trial did not include a randomization to 12-month DAPT, which
is currently the recommended therapy duration in ACS patients.1
The PRODIGY trial was underpowered to assess the effect of
different DAPT duration on ST endpoints. Conﬁdence intervals
for deﬁnite or deﬁnite and probable ST are therefore wide and
inconclusive.
In conclusion, our study suggests that clinical presentation is a po-
tential treatmentmodiﬁerwith respect to thedurationofDAPTafter
stenting, consistent with the hypothesis that SCAD—but not ACS—
patients are exposed to a signiﬁcant increase in bleeding and NACE
when treated with 24-month when compared with 6-month
therapy. Our ﬁndings lend support to the recently released ESC
guidelines on myocardial revascularization, which recommends
6-month DAPT duration after DES implantation in SCAD but not
ACS patients.
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Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT) in a variety of patient populations,
with heterogeneous results regarding beneﬁt and safety, speciﬁcally with regard to cardiovascular and non-cardiovas-
cular mortality. We performed a meta-analysis of randomized trials comparing more than a year of DAPT with aspirin
alone in high-risk patients with a history of prior myocardial infarction (MI).
Methods
and results
A total of 33 435 patients were followed over a mean 31months among one trial of patients with priorMI (63.3% of total)
and ﬁve trials with a subgroup of patients that presented with, or had a history of, a prior MI (36.7% of total). Extended
DAPT decreased the risk of major adverse cardiovascular events compared with aspirin alone (6.4 vs. 7.5%; risk ratio, RR
0.78, 95% conﬁdence intervals, CI, 0.67–0.90; P ¼ 0.001) and reduced cardiovascular death (2.3 vs. 2.6%; RR 0.85, 95% CI
0.74–0.98; P ¼ 0.03), with no increase in non-cardiovascular death (RR 1.03, 95% CI 0.86–1.23; P ¼ 0.76). The resultant
effect on all-cause mortality was an RR of 0.92 (95% CI 0.83–1.03; P ¼ 0.13). Extended DAPT also reduced MI (RR 0.70,
95% CI 0.55–0.88; P ¼ 0.003), stroke (RR 0.81, 95% CI 0.68–0.97; P ¼ 0.02), and stent thrombosis (RR 0.50, 95% CI
0.28–0.89; P ¼ 0.02). There was an increased risk of major bleeding (1.85 vs. 1.09%; RR 1.73, 95% CI 1.19–2.50;
P ¼ 0.004) but not fatal bleeding (0.14 vs. 0.17%; RR 0.91, 95% CI 0.53–1.58; P ¼ 0.75).
Conclusion Compared with aspirin alone, DAPT beyond 1 year among stabilized high-risk patients with prior MI decreases ischae-
mic events, including signiﬁcant reductions in the individual endpoints of cardiovascular death, recurrent MI, and stroke.
Dual antiplatelet therapy beyond 1 year increases major bleeding, but not fatal bleeding or non-cardiovascular death.
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Introduction
Patients with myocardial infarction (MI) have heightened platelet
activation and aggregation resulting in atherothrombosis following
the rupture or ﬁssuring of an unstable atherosclerotic plaque com-
pared with patients with stable ischaemic heart disease (SIHD).1 – 3
A higher predisposition to atherothrombosis may persist for years
following an MI,3 – 6 and SIHD patients with a history of an MI are
at high risk for major adverse cardiovascular events (MACE).7 – 9 As
such, following MI, patients may have a persistent pathobiology
that predisposes them to beneﬁt more from therapies that
intensely inhibit platelet activation and aggregation than patients
following percutaneous coronary intervention (PCI) for stable
ischaemia.10
However, dual antiplatelet therapy (DAPT)with a platelet adeno-
sine diphosphate (ADP) antagonist in addition to aspirin is strongly
recommended for only up to 1 year for reduction of cardiovascular
events in patients with a prior MI, with a weak recommendation to
continue thereafter in patients who underwent PCI based on expert
consensus.11 – 15 In the absence of deﬁnitive longer-term data,
DAPT is often stopped after completion of 1 year of treatment in
half of all patients.16 Recently, two large randomized controlled
trials (RCTs) demonstrated that extended duration of DAPT signiﬁ-
cantly reduced atherothrombotic events in patients 1 year or more
following an MI17 or a PCI18 at the expense of higher bleeding and, in
the case of the PCI trial,18 potentially a higher risk of death from
non-cardiovascular causes. Given these ﬁndings, and the heterogen-
eity in results of other trials testing extended duration DAPT, we
sought to better understand the cardiovascular beneﬁts and risks
of DAPT beyond 1 year for secondary prevention in high-risk pa-
tients with a prior MI.
Methods
Study design
This systematic review and meta-analysis was conducted in accordance
with the recommendations of the Cochrane Collaboration and the Pre-
ferred Reporting Items for Systematic reviews andMeta-Analyses guide-
lines.19 The previously published study protocol is available at the
PROSPERO registry (www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42015019657) and Supplementary material online,
Appendix.
Eligibility criteria and trial selection
We considered prospective RCTs of secondary prevention eligible
for inclusion if they followed patients beyond 1 year that either pre-
sented with or had a history of a prior MI and were randomized to a
strategy of extended duration (beyond 12 months) DAPT compared
with aspirin alone (with or without the use of a placebo for blinding).
Eligible RCTs were considered irrespective of language, blinding, and
publication status. We excluded observational studies. We excluded
trials of DAPT among patients presenting with MI who were followed
no longer than 12 months; if such trials followed patients longer, we
considered 1-year landmark results of MI patients randomized to
DAPT beyond 12 months as a sensitivity analysis. We also excluded
trials of patients with SIHD alone undergoing PCI and trials of oral anti-
coagulant therapies.
Search strategy and data extraction
We conducted a literature search of OVID Medline (1950 to 2 April
2015) and the Cochrane central register of controlled trials databases,
utilizing keyword search terms including: ‘antiplatelet’, ‘DAPT’, ‘thieno-
pyridine’, ‘secondary prevention’, ‘MI’, ‘acute coronary syndrome’,
‘major adverse cardiovascular events’, ‘death’, ‘mortality’, and ‘survival’
(see Supplementary material online, Search Strategy). We reviewed
Supplementary material online, Appendices and reference lists of eli-
gible papers, cardiovascular conference abstracts between 2014 and
2015, and clinicaltrials.gov, to ensure identiﬁcation of relevant published
and unpublished studies. If published data were not available, we con-
tacted the study principal investigator (PI) for input to maximize contri-
bution to, and harmonize outcomes.
Baseline characteristics data and outcomes were abstracted for each
study from the published manuscripts, appendices, or unpublished data
by two investigators (J.A.U. and D.L.B.) independently. Baseline charac-
teristics included patient data and study design characteristics [year, clin-
ical setting (major inclusion and exclusion criteria) sample size,
randomized intervention and control, duration of difference in interven-
tion, duration of follow-up, blinding, and primary endpoint]. Results
were compared and any disagreements were resolved by consensus.
Quality assessment
Quality was graded based on documentation of trial conduct criteria
such as method of randomization, allocation concealment and blinding,
blinded outcome adjudication, extent of outcome reporting and ascer-
tainment, participant attrition and adherence metrics.20 Studies were
categorized as high quality if criteria were clearly described and ac-
counted for, low quality if any aspect of the ﬁrst three criteria was un-
accounted for, or otherwise of uncertain risk of bias.
Outcomes
The primary endpoint for this analysis was the incidence of MACE,
which was deﬁned as a composite of cardiovascular death, non-fatal
MI, and non-fatal stroke. Secondary endpoints included individual com-
ponents of the composite primary endpoint, all-cause death, non-
cardiovascular death, major bleeding events, and when relevant stent
thrombosis. All cardiovascular endpoints were adjudicated and deﬁned
within the individual trials according to standard criteria. Major bleeding
events were considered according to standardized bleeding endpoint
deﬁnitions reported in each trial (see Supplementary material online, Ta-
ble S1 describes individual trial endpoint deﬁnitions).21
Statistical analysis
Data for patients that either presented with or had a history of a quali-
fying MI at baseline were extracted and descriptive characteristics were
summarized using means (standard deviation), medians (interquartile
range), or rates from each study weighted according to individual sample
sizes.We extracted the originally reported hazard ratios (HRs) and 95%
conﬁdence intervals (CI) from each study when available and otherwise
calculated risk ratios (RRs) and 95% CI from the reported number of
events and patients at risk per treatment arm. Data from each trial
were considered as per the intention-to-treat principle with pooled
summary RR and 95% CI derived using a random effects meta-analysis
model with weighting based on inverse variance. If a particular endpoint
was not reported in a trial, and it could not be deduced from other out-
comes or provided by the study PI, it was excluded only from that spe-
ciﬁc endpoint’s pooled analysis. A correction factor of 0.5 was added to
values of a treatment armwhen no events were observed for calculation
of the RR for an endpoint and its variance. We used the Cochran Q stat-
istic and the I2 measure to assess heterogeneity for treatment effects
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across trials, with an I2 . 75% considered representative of high hetero-
geneity. We performed sensitivity analyses including sequentially re-
moving studies from the pooled effect estimates and adding studies
with applicable 1-year landmark analyses. Heterogeneity among se-
lected subgroups was also explored according to age, sex, DAPT regi-
men, type of index myocardial event, time from the index MI, and in
patients with and without a history of PCI, diabetes, additional MI, stroke
or transient ischaemic attack (TIA), or chronic kidney disease. An inter-
action term representing each category was introduced into the model
for MACE and major bleeding to test for differences in treatment effect
between subgroups. Publication bias was evaluated by visual inspection
of funnel plots, without further statistical testing given these tests have
limited speciﬁcity and power when ,10 studies are analysed.22 Two-
sided P-values were calculated with ,0.05 considered signiﬁcant for
all analyses. Statistical analyses were performed with Review Manager
version 5.3.5 (Nordic Cochrane Centre, Denmark) and Comprehensive
Meta-Analysis version 3.0 (Biostat Inc., Englewood, NJ, USA).
Role of the funding source
There was no funding source for this study. J.A.U. and D.L.B. had full ac-
cess to all the data in the study and had ﬁnal responsibility for the deci-
sion to submit for publication. All included studies complied with the
Declaration of Helsinki and individual ethics committees approved the
research protocols and informed consent was obtained from subjects in
each respective trial.
Results
Among 1342 records screened, we identiﬁed 36 RCTs to review in
detail (see Supplementary material online, Results and Figure S1).
After exclusions, the remaining six trials met criteria for eligibility
in the primary meta-analysis.17,18,23 – 29 These trials, which com-
prised 33 435 participants randomized to a strategy of extended
DAPT (n ¼ 20 203) vs. aspirin alone (n ¼ 13 232), are summarized
in Table 1. One trial exclusively randomized patients with a history
of MI (n ¼ 21 162; 63.3% of the pooled population),17 one rando-
mized a subgroup of patients with prior MI (n ¼ 3846; 11.5%),23,24
while the remaining four trials randomized patients that recently
underwent PCI and included a subgroup whose indication was an
acute coronary syndrome (n ¼ 8427; 25.2%).18,25–29 Various ADP
antagonists were studied across the six trials as outlined in Table 1,
including clopidogrel, prasugrel, and ticagrelor.
At baseline, overall, the mean age of participants was 64.0 years,
mean weight was 81.4 kg, 7900 (23.6%) were women, 28 064
(83.9%) underwent or had a history of PCI, 9888 (29.6%) had dia-
betes, 5439 (18.6%) had chronic kidney disease, and 16 340
(48.9%) presented with or had a history of ST-elevation or
Q-wave MI (see Supplementary material online, Table S2). Enrolled
patients infrequently presented with unstable angina (n ¼ 2384;
7.1%), with a history of stroke/TIA (n ¼ 866; 2.6%), or with a history
of revascularization by coronary artery bypass grafting (n ¼ 2477;
7.4%). The mean duration of follow-up of 31 months and the
mean difference in the achieved duration of DAPT was 30 months
(range 17–36 months).
Quality metrics of trial conduct, participant attrition, and thera-
peutic adherence across trials are summarized (see Supplementary
material online, Table S3) and were reasonably comparable for trials
that varied in length of follow-up, timing of randomization, and type
of intervention. Three trials were double blind and placebo-
controlled,17,18,23,24,29 while three were unmasked open-label
trials with blinded endpoint adjudication and standard care as the
control.25–28 Forgiving unblinded study designs, all trials were con-
sidered high quality. All trials reported or provided results for
MACE, CV death, MI, stroke, major bleeding, non-CV death, and
all-cause mortality (see Supplementary material online, Table S1).
Cardiovascular endpoints, cause of death, andmajor bleeding events
were deﬁned in each trial according to standard diagnostic criteria
and were adjudicated by a blinded endpoints committee in each trial
allowing for comparisons across trials. Four of six trials provided
data for stent thrombosis.18,25–29 Causes of major bleeding events
were also provided by all trials (see Supplementary material online,
Table S4).
Major adverse cardiovascular events
Among the six trials, the individual and pooled HR/RRs for the com-
posite primary endpoint of the 2273 MACE are provided in Figure 1.
Among the 20 203 participants with a prior MI treated with DAPT
beyond 1 year, 1286 (6.37%) patients developed a MACE compared
with 987 of 13 232 (7.46%) patients treated with aspirin alone [RR
0.78 (95%CI 0.67–0.90); P ¼ 0.001; Figure 1]. This risk reduction re-
presented an absolute risk difference (ARD) of 1.09% (95% CI
0.53–1.65) or a number needed to treat (NNT) of 91 (95% CI
61–189) to prevent one MACE over a mean 31 months of
follow-up.
Cardiovascular mortality
Extended DAPT for more than a year following an MI signiﬁcantly
reduced cardiovascular death (which comprised 60% of all observed
deaths) (Figure 2), as 472 of 20 203 patients (2.3%) died from cardio-
vascular causes while treated with extended DAPT compared with
344 of 13 232 patients (2.6%) treated with aspirin alone [RR 0.85
(95%CI 0.74–0.98); P ¼ 0.03; ARD ¼ 0.26%; NNT ¼ 380; see Sup-
plementary material online, Figure S2].
Other individual cardiovascular endpoints
Extended DAPT also signiﬁcantly reduced the risk of MI [RR 0.70
(95% CI 0.55–0.88); P ¼ 0.003; ARD ¼ 0.84%; NNT ¼ 120; see
Supplementary material online, Figure S3] and stroke [RR 0.81
(95% CI 0.68–0.97); P ¼ 0.02 ARD ¼ 0.31%; NNT ¼ 324; see Sup-
plementary material online, Figure S4]. Among trials that enrolled
only PCI-treated patients, deﬁnite or probable stent thrombosis
events were infrequent. Yet the risk of late stent thrombosis
more than a year following an MI was signiﬁcantly reduced with ex-
tended DAPT [RR 0.50 (95% CI 0.28–0.89); P ¼ 0.02; ARD ¼
0.73%; NNT ¼ 137; see Supplementary material online, Figure S5].
Major bleeding events and safety
These results occurred in the context of an increased risk of major
bleeding events with extended DAPT [1.85 vs. 1.09%; RR 1.73 (95%
CI 1.19–2.50); P ¼ 0.004; ARD ¼ 0.76%; NNH ¼ 132; Figure 2 and
see Supplementary material online, Figure S6]. However, intracranial
haemorrhage (ICH) [0.41 vs. 0.31%; RR 1.34 (95% CI 0.89–2.02);
P ¼ 0.17] and fatal bleeding events [0.14 vs. 0.17%; RR 0.91 (95%
CI 0.53–1.58); P ¼ 0.75] were infrequent and were not signiﬁcantly
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Introduction
Patients with myocardial infarction (MI) have heightened platelet
activation and aggregation resulting in atherothrombosis following
the rupture or ﬁssuring of an unstable atherosclerotic plaque com-
pared with patients with stable ischaemic heart disease (SIHD).1 – 3
A higher predisposition to atherothrombosis may persist for years
following an MI,3 – 6 and SIHD patients with a history of an MI are
at high risk for major adverse cardiovascular events (MACE).7 – 9 As
such, following MI, patients may have a persistent pathobiology
that predisposes them to beneﬁt more from therapies that
intensely inhibit platelet activation and aggregation than patients
following percutaneous coronary intervention (PCI) for stable
ischaemia.10
However, dual antiplatelet therapy (DAPT)with a platelet adeno-
sine diphosphate (ADP) antagonist in addition to aspirin is strongly
recommended for only up to 1 year for reduction of cardiovascular
events in patients with a prior MI, with a weak recommendation to
continue thereafter in patients who underwent PCI based on expert
consensus.11 – 15 In the absence of deﬁnitive longer-term data,
DAPT is often stopped after completion of 1 year of treatment in
half of all patients.16 Recently, two large randomized controlled
trials (RCTs) demonstrated that extended duration of DAPT signiﬁ-
cantly reduced atherothrombotic events in patients 1 year or more
following an MI17 or a PCI18 at the expense of higher bleeding and, in
the case of the PCI trial,18 potentially a higher risk of death from
non-cardiovascular causes. Given these ﬁndings, and the heterogen-
eity in results of other trials testing extended duration DAPT, we
sought to better understand the cardiovascular beneﬁts and risks
of DAPT beyond 1 year for secondary prevention in high-risk pa-
tients with a prior MI.
Methods
Study design
This systematic review and meta-analysis was conducted in accordance
with the recommendations of the Cochrane Collaboration and the Pre-
ferred Reporting Items for Systematic reviews andMeta-Analyses guide-
lines.19 The previously published study protocol is available at the
PROSPERO registry (www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42015019657) and Supplementary material online,
Appendix.
Eligibility criteria and trial selection
We considered prospective RCTs of secondary prevention eligible
for inclusion if they followed patients beyond 1 year that either pre-
sented with or had a history of a prior MI and were randomized to a
strategy of extended duration (beyond 12 months) DAPT compared
with aspirin alone (with or without the use of a placebo for blinding).
Eligible RCTs were considered irrespective of language, blinding, and
publication status. We excluded observational studies. We excluded
trials of DAPT among patients presenting with MI who were followed
no longer than 12 months; if such trials followed patients longer, we
considered 1-year landmark results of MI patients randomized to
DAPT beyond 12 months as a sensitivity analysis. We also excluded
trials of patients with SIHD alone undergoing PCI and trials of oral anti-
coagulant therapies.
Search strategy and data extraction
We conducted a literature search of OVID Medline (1950 to 2 April
2015) and the Cochrane central register of controlled trials databases,
utilizing keyword search terms including: ‘antiplatelet’, ‘DAPT’, ‘thieno-
pyridine’, ‘secondary prevention’, ‘MI’, ‘acute coronary syndrome’,
‘major adverse cardiovascular events’, ‘death’, ‘mortality’, and ‘survival’
(see Supplementary material online, Search Strategy). We reviewed
Supplementary material online, Appendices and reference lists of eli-
gible papers, cardiovascular conference abstracts between 2014 and
2015, and clinicaltrials.gov, to ensure identiﬁcation of relevant published
and unpublished studies. If published data were not available, we con-
tacted the study principal investigator (PI) for input to maximize contri-
bution to, and harmonize outcomes.
Baseline characteristics data and outcomes were abstracted for each
study from the published manuscripts, appendices, or unpublished data
by two investigators (J.A.U. and D.L.B.) independently. Baseline charac-
teristics included patient data and study design characteristics [year, clin-
ical setting (major inclusion and exclusion criteria) sample size,
randomized intervention and control, duration of difference in interven-
tion, duration of follow-up, blinding, and primary endpoint]. Results
were compared and any disagreements were resolved by consensus.
Quality assessment
Quality was graded based on documentation of trial conduct criteria
such as method of randomization, allocation concealment and blinding,
blinded outcome adjudication, extent of outcome reporting and ascer-
tainment, participant attrition and adherence metrics.20 Studies were
categorized as high quality if criteria were clearly described and ac-
counted for, low quality if any aspect of the ﬁrst three criteria was un-
accounted for, or otherwise of uncertain risk of bias.
Outcomes
The primary endpoint for this analysis was the incidence of MACE,
which was deﬁned as a composite of cardiovascular death, non-fatal
MI, and non-fatal stroke. Secondary endpoints included individual com-
ponents of the composite primary endpoint, all-cause death, non-
cardiovascular death, major bleeding events, and when relevant stent
thrombosis. All cardiovascular endpoints were adjudicated and deﬁned
within the individual trials according to standard criteria. Major bleeding
events were considered according to standardized bleeding endpoint
deﬁnitions reported in each trial (see Supplementary material online, Ta-
ble S1 describes individual trial endpoint deﬁnitions).21
Statistical analysis
Data for patients that either presented with or had a history of a quali-
fying MI at baseline were extracted and descriptive characteristics were
summarized using means (standard deviation), medians (interquartile
range), or rates from each study weighted according to individual sample
sizes.We extracted the originally reported hazard ratios (HRs) and 95%
conﬁdence intervals (CI) from each study when available and otherwise
calculated risk ratios (RRs) and 95% CI from the reported number of
events and patients at risk per treatment arm. Data from each trial
were considered as per the intention-to-treat principle with pooled
summary RR and 95% CI derived using a random effects meta-analysis
model with weighting based on inverse variance. If a particular endpoint
was not reported in a trial, and it could not be deduced from other out-
comes or provided by the study PI, it was excluded only from that spe-
ciﬁc endpoint’s pooled analysis. A correction factor of 0.5 was added to
values of a treatment armwhen no events were observed for calculation
of the RR for an endpoint and its variance. We used the Cochran Q stat-
istic and the I2 measure to assess heterogeneity for treatment effects
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across trials, with an I2 . 75% considered representative of high hetero-
geneity. We performed sensitivity analyses including sequentially re-
moving studies from the pooled effect estimates and adding studies
with applicable 1-year landmark analyses. Heterogeneity among se-
lected subgroups was also explored according to age, sex, DAPT regi-
men, type of index myocardial event, time from the index MI, and in
patients with and without a history of PCI, diabetes, additional MI, stroke
or transient ischaemic attack (TIA), or chronic kidney disease. An inter-
action term representing each category was introduced into the model
for MACE and major bleeding to test for differences in treatment effect
between subgroups. Publication bias was evaluated by visual inspection
of funnel plots, without further statistical testing given these tests have
limited speciﬁcity and power when ,10 studies are analysed.22 Two-
sided P-values were calculated with ,0.05 considered signiﬁcant for
all analyses. Statistical analyses were performed with Review Manager
version 5.3.5 (Nordic Cochrane Centre, Denmark) and Comprehensive
Meta-Analysis version 3.0 (Biostat Inc., Englewood, NJ, USA).
Role of the funding source
There was no funding source for this study. J.A.U. and D.L.B. had full ac-
cess to all the data in the study and had ﬁnal responsibility for the deci-
sion to submit for publication. All included studies complied with the
Declaration of Helsinki and individual ethics committees approved the
research protocols and informed consent was obtained from subjects in
each respective trial.
Results
Among 1342 records screened, we identiﬁed 36 RCTs to review in
detail (see Supplementary material online, Results and Figure S1).
After exclusions, the remaining six trials met criteria for eligibility
in the primary meta-analysis.17,18,23 – 29 These trials, which com-
prised 33 435 participants randomized to a strategy of extended
DAPT (n ¼ 20 203) vs. aspirin alone (n ¼ 13 232), are summarized
in Table 1. One trial exclusively randomized patients with a history
of MI (n ¼ 21 162; 63.3% of the pooled population),17 one rando-
mized a subgroup of patients with prior MI (n ¼ 3846; 11.5%),23,24
while the remaining four trials randomized patients that recently
underwent PCI and included a subgroup whose indication was an
acute coronary syndrome (n ¼ 8427; 25.2%).18,25–29 Various ADP
antagonists were studied across the six trials as outlined in Table 1,
including clopidogrel, prasugrel, and ticagrelor.
At baseline, overall, the mean age of participants was 64.0 years,
mean weight was 81.4 kg, 7900 (23.6%) were women, 28 064
(83.9%) underwent or had a history of PCI, 9888 (29.6%) had dia-
betes, 5439 (18.6%) had chronic kidney disease, and 16 340
(48.9%) presented with or had a history of ST-elevation or
Q-wave MI (see Supplementary material online, Table S2). Enrolled
patients infrequently presented with unstable angina (n ¼ 2384;
7.1%), with a history of stroke/TIA (n ¼ 866; 2.6%), or with a history
of revascularization by coronary artery bypass grafting (n ¼ 2477;
7.4%). The mean duration of follow-up of 31 months and the
mean difference in the achieved duration of DAPT was 30 months
(range 17–36 months).
Quality metrics of trial conduct, participant attrition, and thera-
peutic adherence across trials are summarized (see Supplementary
material online, Table S3) and were reasonably comparable for trials
that varied in length of follow-up, timing of randomization, and type
of intervention. Three trials were double blind and placebo-
controlled,17,18,23,24,29 while three were unmasked open-label
trials with blinded endpoint adjudication and standard care as the
control.25–28 Forgiving unblinded study designs, all trials were con-
sidered high quality. All trials reported or provided results for
MACE, CV death, MI, stroke, major bleeding, non-CV death, and
all-cause mortality (see Supplementary material online, Table S1).
Cardiovascular endpoints, cause of death, andmajor bleeding events
were deﬁned in each trial according to standard diagnostic criteria
and were adjudicated by a blinded endpoints committee in each trial
allowing for comparisons across trials. Four of six trials provided
data for stent thrombosis.18,25–29 Causes of major bleeding events
were also provided by all trials (see Supplementary material online,
Table S4).
Major adverse cardiovascular events
Among the six trials, the individual and pooled HR/RRs for the com-
posite primary endpoint of the 2273 MACE are provided in Figure 1.
Among the 20 203 participants with a prior MI treated with DAPT
beyond 1 year, 1286 (6.37%) patients developed a MACE compared
with 987 of 13 232 (7.46%) patients treated with aspirin alone [RR
0.78 (95%CI 0.67–0.90); P ¼ 0.001; Figure 1]. This risk reduction re-
presented an absolute risk difference (ARD) of 1.09% (95% CI
0.53–1.65) or a number needed to treat (NNT) of 91 (95% CI
61–189) to prevent one MACE over a mean 31 months of
follow-up.
Cardiovascular mortality
Extended DAPT for more than a year following an MI signiﬁcantly
reduced cardiovascular death (which comprised 60% of all observed
deaths) (Figure 2), as 472 of 20 203 patients (2.3%) died from cardio-
vascular causes while treated with extended DAPT compared with
344 of 13 232 patients (2.6%) treated with aspirin alone [RR 0.85
(95%CI 0.74–0.98); P ¼ 0.03; ARD ¼ 0.26%; NNT ¼ 380; see Sup-
plementary material online, Figure S2].
Other individual cardiovascular endpoints
Extended DAPT also signiﬁcantly reduced the risk of MI [RR 0.70
(95% CI 0.55–0.88); P ¼ 0.003; ARD ¼ 0.84%; NNT ¼ 120; see
Supplementary material online, Figure S3] and stroke [RR 0.81
(95% CI 0.68–0.97); P ¼ 0.02 ARD ¼ 0.31%; NNT ¼ 324; see Sup-
plementary material online, Figure S4]. Among trials that enrolled
only PCI-treated patients, deﬁnite or probable stent thrombosis
events were infrequent. Yet the risk of late stent thrombosis
more than a year following an MI was signiﬁcantly reduced with ex-
tended DAPT [RR 0.50 (95% CI 0.28–0.89); P ¼ 0.02; ARD ¼
0.73%; NNT ¼ 137; see Supplementary material online, Figure S5].
Major bleeding events and safety
These results occurred in the context of an increased risk of major
bleeding events with extended DAPT [1.85 vs. 1.09%; RR 1.73 (95%
CI 1.19–2.50); P ¼ 0.004; ARD ¼ 0.76%; NNH ¼ 132; Figure 2 and
see Supplementary material online, Figure S6]. However, intracranial
haemorrhage (ICH) [0.41 vs. 0.31%; RR 1.34 (95% CI 0.89–2.02);
P ¼ 0.17] and fatal bleeding events [0.14 vs. 0.17%; RR 0.91 (95%
CI 0.53–1.58); P ¼ 0.75] were infrequent and were not signiﬁcantly
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different between extended DAPT-treated patients and aspirin
alone. Treatment with extended DAPT had no signiﬁcant effect
on non-CV death [RR 1.03 (95% CI 0.86–1.23); P ¼ 0.76; see Sup-
plementary material online, Figure S7]. The net effect was
a non-signiﬁcant RR of 0.92 (95% CI 0.83–1.03; P ¼ 0.13; see
Supplementary material online, Figure S8) for all-cause mortality.
Sensitivity analyses
There was no meaningful heterogeneity in results across trials for
either the primary or the secondary endpoints. No evidence of pub-
lication bias was suggested by visual inspection of the funnel plots for
MACE (see Supplementary material online, Figure S9) or secondary
endpoints. Results for the primary endpoint analysis remained
signiﬁcant after removal of any one trial from the pooled result
(see Supplementary material online, Table S5). More so, after simul-
taneous removal of both the PEGASUS-TIMI 54 and DAPT results,
the primary endpoint remained signiﬁcant among the remaining four
trials [RR 0.82 (95%CI 0.70–0.97); P ¼ 0.02; ARD ¼ 1.11% (95%CI
0.09–2.13)]. The addition of 1-year landmark results from two trials
testing other strategies of more intensive antiplatelet therapy for
secondary prevention among stabilized patients .1 year from an
MI,30,31 also did not materially change the results [RR 0.79 (95%
CI 0.72–0.87); P, 0.00001; see Supplementary material online, Ap-
pendix Figure S10]. Finally, results did not signiﬁcantly differ among
any subgroup for MACE or major bleeding (all P-interactions ≥0.09;
see Supplementary material online, Tables S6 and S7).
Figure 1 Risk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers re-
present risk ratios and horizontal lines the 95% conﬁdence intervals with marker size reﬂecting the statistical weight of the study using inverse
variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% conﬁdence intervals for major adverse
cardiovascular events. There was no signiﬁcant between-trial heterogeneity (Q statistic ¼ 8.36, d.f. ¼ 5; P ¼ 0.14; I2 ¼ 40%).
Figure 2 Risk of individual cardiovascular and bleeding endpoints comparing extended dual antiplatelet therapy vs. aspirin alone. Square data
markers represent risk ratios and horizontal lines the 95% conﬁdence intervals using inverse variance random effects meta-analysis.
J.A. Udell et al.Page 6 of 10
by guest on August 31, 2015
Downloaded from
 
Chapter 5.6
Discussion
Our meta-analysis of .33 000 high-risk patients stabilized following
an MI found that, overall compared with aspirin alone, extended
DAPT beyond 1 year resulted in a 22% relative and 1.1% absolute
risk reduction for major adverse cardiovascular events over a
mean 31 months of follow-up. The magnitude of this relative risk re-
duction was consistent, with no signiﬁcant heterogeneity, or sensi-
tivity to removing any one trial from the pooled results. The pooled
data in our meta-analysis show for the ﬁrst time that there is a sig-
niﬁcant 15% reduction in cardiovascular death in post-MI patients
receiving long-term DAPT. There was a 0.8% absolute increase in
the risk of major bleeding, but without signiﬁcant excess of ICH
or fatal bleeding and no impact on non-cardiovascular causes of
death.
This meta-analysis differs in important ways from prior re-
ports.32 –36 We elected to focus on stabilized patients with a his-
tory of prior MI since these patients are known to be at higher
atherothrombotic risk compared with patients with SIHD treated
with elective PCI.9,24,37,38 As such, we reasoned that these patients
would be expected to demonstrate a more favourable
beneﬁt-to-risk proﬁle when treated with long-term DAPT com-
pared with patients without a prior MI. We also focused on trials
that randomized at least one arm of this population to a strategy
of DAPT .1 year following a qualifying MI vs. aspirin alone. We
did this in order to address the unresolved question of whether
treatment of patients with a history of MI with DAPT beyond the
currently recommended 1-year duration results in signiﬁcant and
clinically meaningful reductions in atherothrombotic events. As
well, we leveraged the power of a larger population to better quan-
tify the magnitude of bleeding risk with this strategy and reﬁne risk
estimates for cardiovascular and non-cardiovascular causes of
death. Finally, we analysed eligible trials irrespective of whether,
when, and how patients were treated with PCI, since data support
up to a year of DAPT post-MI regardless of whether patients
underwent PCI. Patients with MI treated with PCI have
stent-related factors that may modify the beneﬁt–risk trade-off
of extended DAPT, including the timing and propensity for late
stent thrombosis39,40; however, the beneﬁt of extended DAPT
was consistent regardless of whether trials exclusively enrolled pa-
tients undergoing PCI or not.
Our ﬁndings of reduced atherothrombotic risk with extended
DAPT irrespective of whether trials enrolled only PCI-treated pa-
tients support prior research that suggests the mechanism of long-
term cardiovascular beneﬁt with extended DAPT in patients with a
history of prior MI is likely an extension of the beneﬁts seen follow-
ing early treatment of an MI, and distinct from simply preventing
stent thrombosis in patients with prior PCI. For instance, long
term, the majority of ruptured coronary plaques that result in recur-
rent MI appear to occur in lesions other than earlier culprits treated
with PCI in patients with coronary heart disease.18,29,41 After an in-
farction, patients have a more susceptible coronary milieu and are
more prone to recurrent plaque rupturewith prolonged platelet ac-
tivation and aggregation1 – 3,42 and higher circulating markers of
myonecrosis and inﬂammation43 compared with stable patients
which may mediate a preferential beneﬁt from extended DAPT.
Furthermore, prolonged DAPT in patients with a history of prior
MI appeared to reduce ischaemic events in other arterial territories,
in accordance with our observed results for stroke.
Coronary heart disease treatment guidelines recommend 1 year
of DAPT in patients following MI, based simply on the original dur-
ation of pivotal secondary prevention RCTs,11 –15 although land-
mark analyses from these trials suggested continued divergence of
event curves with time.44 –46 This recommendation was extended
to patients treated with coronary revascularization by PCI,15,47
based on expert consensus and observational studies suggesting a
delayed propensity for complete endothelialization and subsequent
risk of late stent thrombosis following discontinuation of DAPT in
patients treated with early generation drug-eluting stents.48,49 Sub-
sequently, a number of small RCTs have randomized patients trea-
ted with PCI to shorter durations of DAPT and concluded that
1-year duration of DAPTmay offer no beneﬁt compared with short-
er courses of therapy.50 – 55 However, none of these prior trials
were powered to study this question, each enrolled limited numbers
of subjects with MI, and prior meta-analyses have not distinguished
treatment effects between acute and stable coronary patients.32–36
To the best of our knowledge, there are at least eight ongoing out-
comes trials comparing experimental with traditional DAPT strat-
egies enrolling patients following PCI (see Supplementary material
online, Table S8). These trials will greatly inform the care of patients
receiving stents. However, each of these trials is primarily focused
on PCI, whereas our meta-analysis results pertain to the patient’s
underlying history of MI irrespective of PCI status.
Considering the inclusion and exclusion criteria of the trials we
studied certain characteristics that may deﬁne stabilized high-risk
patients with previous MI at low risk of bleeding that beneﬁt from
extended DAPT. The majority of patients studied were considered
high risk for recurrent atherothrombotic events with 93% having a
history of biomarker positive acute coronary syndrome often in the
presence of additional risk factors such as older age, diabetes, or
established atherosclerosis. Studies typically excluded patients
with a bleeding diathesis such as a coagulation disorder or long-term
anticoagulation therapy, recent (within 6–12 months) or active
major bleeding such as gastrointestinal bleeding, recent (within
1 month) major surgery, or any history of ICH. In addition, very
few patients enrolled had a history of a prior stroke or TIA
(,3%). As such, our ﬁndings may not be generalizable to all acute
coronary syndrome patients,56 such as patients with unstable angina
or a history of stroke, but may bemost accurately applied to patients
with a prior history of MI who have tolerated 1 year of DAPT
without development of, or ongoing risk for, signiﬁcant bleeding.
There are certain limitations to this study. First, we pooled trials
with heterogeneous populations that varied in treatment strategy,
study design, intended primary outcome, and major bleeding deﬁni-
tions. For logistical reasons, we did not evaluate individual patient-
level data, but unpublished data for several endpoints were provided
by individual PIs to compare standard endpoints among similar pa-
tients across trials. Second, some of the RCTs were unblinded,
which may bias reporting of non-fatal adverse cardiovascular and
bleeding events. However, these unblinded trials provided ,15%
of the total population studied and all trials utilized blinded central
committee endpoint adjudication. Third, ﬁve of the six included
trials focused on subgroups, as they were not prospectively de-
signed to determine whether extended DAPT was beneﬁcial in
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different between extended DAPT-treated patients and aspirin
alone. Treatment with extended DAPT had no signiﬁcant effect
on non-CV death [RR 1.03 (95% CI 0.86–1.23); P ¼ 0.76; see Sup-
plementary material online, Figure S7]. The net effect was
a non-signiﬁcant RR of 0.92 (95% CI 0.83–1.03; P ¼ 0.13; see
Supplementary material online, Figure S8) for all-cause mortality.
Sensitivity analyses
There was no meaningful heterogeneity in results across trials for
either the primary or the secondary endpoints. No evidence of pub-
lication bias was suggested by visual inspection of the funnel plots for
MACE (see Supplementary material online, Figure S9) or secondary
endpoints. Results for the primary endpoint analysis remained
signiﬁcant after removal of any one trial from the pooled result
(see Supplementary material online, Table S5). More so, after simul-
taneous removal of both the PEGASUS-TIMI 54 and DAPT results,
the primary endpoint remained signiﬁcant among the remaining four
trials [RR 0.82 (95%CI 0.70–0.97); P ¼ 0.02; ARD ¼ 1.11% (95%CI
0.09–2.13)]. The addition of 1-year landmark results from two trials
testing other strategies of more intensive antiplatelet therapy for
secondary prevention among stabilized patients .1 year from an
MI,30,31 also did not materially change the results [RR 0.79 (95%
CI 0.72–0.87); P, 0.00001; see Supplementary material online, Ap-
pendix Figure S10]. Finally, results did not signiﬁcantly differ among
any subgroup for MACE or major bleeding (all P-interactions ≥0.09;
see Supplementary material online, Tables S6 and S7).
Figure 1 Risk of major adverse cardiovascular events comparing extended dual antiplatelet therapy vs. aspirin alone. Square data markers re-
present risk ratios and horizontal lines the 95% conﬁdence intervals with marker size reﬂecting the statistical weight of the study using inverse
variance random effects meta-analysis. A diamond data marker represents the overall risk ratios and 95% conﬁdence intervals for major adverse
cardiovascular events. There was no signiﬁcant between-trial heterogeneity (Q statistic ¼ 8.36, d.f. ¼ 5; P ¼ 0.14; I2 ¼ 40%).
Figure 2 Risk of individual cardiovascular and bleeding endpoints comparing extended dual antiplatelet therapy vs. aspirin alone. Square data
markers represent risk ratios and horizontal lines the 95% conﬁdence intervals using inverse variance random effects meta-analysis.
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Discussion
Our meta-analysis of .33 000 high-risk patients stabilized following
an MI found that, overall compared with aspirin alone, extended
DAPT beyond 1 year resulted in a 22% relative and 1.1% absolute
risk reduction for major adverse cardiovascular events over a
mean 31 months of follow-up. The magnitude of this relative risk re-
duction was consistent, with no signiﬁcant heterogeneity, or sensi-
tivity to removing any one trial from the pooled results. The pooled
data in our meta-analysis show for the ﬁrst time that there is a sig-
niﬁcant 15% reduction in cardiovascular death in post-MI patients
receiving long-term DAPT. There was a 0.8% absolute increase in
the risk of major bleeding, but without signiﬁcant excess of ICH
or fatal bleeding and no impact on non-cardiovascular causes of
death.
This meta-analysis differs in important ways from prior re-
ports.32 –36 We elected to focus on stabilized patients with a his-
tory of prior MI since these patients are known to be at higher
atherothrombotic risk compared with patients with SIHD treated
with elective PCI.9,24,37,38 As such, we reasoned that these patients
would be expected to demonstrate a more favourable
beneﬁt-to-risk proﬁle when treated with long-term DAPT com-
pared with patients without a prior MI. We also focused on trials
that randomized at least one arm of this population to a strategy
of DAPT .1 year following a qualifying MI vs. aspirin alone. We
did this in order to address the unresolved question of whether
treatment of patients with a history of MI with DAPT beyond the
currently recommended 1-year duration results in signiﬁcant and
clinically meaningful reductions in atherothrombotic events. As
well, we leveraged the power of a larger population to better quan-
tify the magnitude of bleeding risk with this strategy and reﬁne risk
estimates for cardiovascular and non-cardiovascular causes of
death. Finally, we analysed eligible trials irrespective of whether,
when, and how patients were treated with PCI, since data support
up to a year of DAPT post-MI regardless of whether patients
underwent PCI. Patients with MI treated with PCI have
stent-related factors that may modify the beneﬁt–risk trade-off
of extended DAPT, including the timing and propensity for late
stent thrombosis39,40; however, the beneﬁt of extended DAPT
was consistent regardless of whether trials exclusively enrolled pa-
tients undergoing PCI or not.
Our ﬁndings of reduced atherothrombotic risk with extended
DAPT irrespective of whether trials enrolled only PCI-treated pa-
tients support prior research that suggests the mechanism of long-
term cardiovascular beneﬁt with extended DAPT in patients with a
history of prior MI is likely an extension of the beneﬁts seen follow-
ing early treatment of an MI, and distinct from simply preventing
stent thrombosis in patients with prior PCI. For instance, long
term, the majority of ruptured coronary plaques that result in recur-
rent MI appear to occur in lesions other than earlier culprits treated
with PCI in patients with coronary heart disease.18,29,41 After an in-
farction, patients have a more susceptible coronary milieu and are
more prone to recurrent plaque rupturewith prolonged platelet ac-
tivation and aggregation1 – 3,42 and higher circulating markers of
myonecrosis and inﬂammation43 compared with stable patients
which may mediate a preferential beneﬁt from extended DAPT.
Furthermore, prolonged DAPT in patients with a history of prior
MI appeared to reduce ischaemic events in other arterial territories,
in accordance with our observed results for stroke.
Coronary heart disease treatment guidelines recommend 1 year
of DAPT in patients following MI, based simply on the original dur-
ation of pivotal secondary prevention RCTs,11 –15 although land-
mark analyses from these trials suggested continued divergence of
event curves with time.44 –46 This recommendation was extended
to patients treated with coronary revascularization by PCI,15,47
based on expert consensus and observational studies suggesting a
delayed propensity for complete endothelialization and subsequent
risk of late stent thrombosis following discontinuation of DAPT in
patients treated with early generation drug-eluting stents.48,49 Sub-
sequently, a number of small RCTs have randomized patients trea-
ted with PCI to shorter durations of DAPT and concluded that
1-year duration of DAPTmay offer no beneﬁt compared with short-
er courses of therapy.50 – 55 However, none of these prior trials
were powered to study this question, each enrolled limited numbers
of subjects with MI, and prior meta-analyses have not distinguished
treatment effects between acute and stable coronary patients.32–36
To the best of our knowledge, there are at least eight ongoing out-
comes trials comparing experimental with traditional DAPT strat-
egies enrolling patients following PCI (see Supplementary material
online, Table S8). These trials will greatly inform the care of patients
receiving stents. However, each of these trials is primarily focused
on PCI, whereas our meta-analysis results pertain to the patient’s
underlying history of MI irrespective of PCI status.
Considering the inclusion and exclusion criteria of the trials we
studied certain characteristics that may deﬁne stabilized high-risk
patients with previous MI at low risk of bleeding that beneﬁt from
extended DAPT. The majority of patients studied were considered
high risk for recurrent atherothrombotic events with 93% having a
history of biomarker positive acute coronary syndrome often in the
presence of additional risk factors such as older age, diabetes, or
established atherosclerosis. Studies typically excluded patients
with a bleeding diathesis such as a coagulation disorder or long-term
anticoagulation therapy, recent (within 6–12 months) or active
major bleeding such as gastrointestinal bleeding, recent (within
1 month) major surgery, or any history of ICH. In addition, very
few patients enrolled had a history of a prior stroke or TIA
(,3%). As such, our ﬁndings may not be generalizable to all acute
coronary syndrome patients,56 such as patients with unstable angina
or a history of stroke, but may bemost accurately applied to patients
with a prior history of MI who have tolerated 1 year of DAPT
without development of, or ongoing risk for, signiﬁcant bleeding.
There are certain limitations to this study. First, we pooled trials
with heterogeneous populations that varied in treatment strategy,
study design, intended primary outcome, and major bleeding deﬁni-
tions. For logistical reasons, we did not evaluate individual patient-
level data, but unpublished data for several endpoints were provided
by individual PIs to compare standard endpoints among similar pa-
tients across trials. Second, some of the RCTs were unblinded,
which may bias reporting of non-fatal adverse cardiovascular and
bleeding events. However, these unblinded trials provided ,15%
of the total population studied and all trials utilized blinded central
committee endpoint adjudication. Third, ﬁve of the six included
trials focused on subgroups, as they were not prospectively de-
signed to determine whether extended DAPT was beneﬁcial in
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post-MI patients. However, meta-analysis of randomized compari-
sons within each subgroup of patients with a history of MI remain
valid. Finally, although three-quarters of the primary outcome
events analysed were contributed from the PEGASUS-TIMI
54 and DAPT trials, our primary endpoint results were robust
and remained signiﬁcant after removal of both trials from the pooled
result. Additionally, for the ﬁrst time, pooling of these trials allowed
detection of a signiﬁcant reduction in cardiovascular death.
In summary, compared with aspirin alone, extended DAPT
beyond 1 year among stabilized high-risk patients with previous
MI decreased the risk of MACE, including cardiovascular death
alone, as well as recurrent MI and stroke. There was an increase
in the risk of major bleeding, but not fatal bleeding, with no excess
of non-cardiovascular causes of death. These ﬁndings now clarify
that in patients with prior MI who are at low risk of bleeding, con-
tinuation of DAPT beyond a year offers a substantial reduction in
important cardiovascular outcomes and should be considered.
Supplementary material
Supplementary material is available at European Heart Journal online.
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post-MI patients. However, meta-analysis of randomized compari-
sons within each subgroup of patients with a history of MI remain
valid. Finally, although three-quarters of the primary outcome
events analysed were contributed from the PEGASUS-TIMI
54 and DAPT trials, our primary endpoint results were robust
and remained signiﬁcant after removal of both trials from the pooled
result. Additionally, for the ﬁrst time, pooling of these trials allowed
detection of a signiﬁcant reduction in cardiovascular death.
In summary, compared with aspirin alone, extended DAPT
beyond 1 year among stabilized high-risk patients with previous
MI decreased the risk of MACE, including cardiovascular death
alone, as well as recurrent MI and stroke. There was an increase
in the risk of major bleeding, but not fatal bleeding, with no excess
of non-cardiovascular causes of death. These ﬁndings now clarify
that in patients with prior MI who are at low risk of bleeding, con-
tinuation of DAPT beyond a year offers a substantial reduction in
important cardiovascular outcomes and should be considered.
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Left main or proximal left anterior descending coronary artery 
disease location identifies high-risk patients deriving 
potentially greater benefit from prolonged dual antiplatelet 
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Left main or proximal left anterior descending coronary artery 
disease location identifies high-risk patients deriving 
potentially greater benefit from prolonged dual antiplatelet 
therapy duration
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Impact of coronary disease location on DAPT duration
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Table 1. Baseline characteristics.
Characteristic
Patients with LM/pLAD lumen narrowing Patients without LM/pLAD lumen narrowing
p-value*24-month 
clopidogrel 
(n=471)
6-month 
clopidogrel 
(n=482)
p-value
24-month 
clopidogrel 
(n=405)
6-month 
clopidogrel 
(n=396)
p-value
Age, yrs 69.6 (70-77) 69.9 (60-77) 0.59 67.4 (59-74) 66.7 (59-75) 0.91 0.03
Male sex, % (n) 74.5 (351) 74.7 (360) 0.95 77.3 (313) 75.8 (300) 0.61 0.35
Body mass index, kg/m2 26.2 (24-29) 26.6 (24-29) 0.82 27.3 (25-30) 26.4 (24-29) 0.39 0.27
Diabetes, % (n) 24.2 (114) 21.8 (105) 0.38 23.5 (95) 24.2 (96) 0.79 0.68
Insulin-dependent, % (n) 5.9 (28) 4.6 (22) 4.0 (16) 6.1 (24)
Hypertension, % (n) 70.7 (333) 70.7 (341) 0.99 72.6 (294) 67.9 (269) 0.15 0.84
Hyperlipidaemia, % (n) 54.1 (255) 51.9 (250) 0.48 53.6 (217) 51.5 (204) 0.56 0.86
Current cigarette use, % (n) 23.1 (109) 23.2 (112) 0.59 26.2 (105) 30.3 (120) 0.14 0.02
Creatinine clearance, ml/min 74.4 (54-100) 73.3 (56-95) 0.71 79.0 (59-102) 77.7 (60-97) 0.28 0.005
Prior myocardial infarction, % (n) 21.4 (101) 20.7 (100) 0.41 24.4 (99) 22.5 (89) 0.49 0.21
Prior percutaneous coronary 
intervention, % (n) 13.6 (64) 14.9 (72) 0.17 20.2 (82) 16.2 (64) 0.10 0.02
Left ventricular ejection fraction 55 (40-60) 53 (45-60) 0.82 55 (45-60) 51 (45-60) 0.44 0.53
Clinical presentation, % (n)
Stable angina pectoris 23.8 (112) 25.1 (121) 0.63 26.2 (106) 26.0 (103) 0.95 0.43
Acute coronary syndrome 76.2 (359) 74.9 (361) 73.8 (299) 74.0 (293)
Unstable angina 17.2 (81) 19.5 (94) 0.35 16.5 (67) 14.6 (58) 0.46 0.14
Non-ST-elevation MI 26.8 (126) 20.5 (99) 0.02 18.8 (76) 23.5 (93) 0.10 0.21
ST-segment elevation MI 32.3 (152) 34.9 (168) 0.40 38.5 (156) 35.9 (142) 0.43 0.12
* p-value for the comparison between patients with and without LM/pLAD lumen narrowing.
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Table 2. Outcome rates at 24 months according to the treatment group.
Patients with LM/pLAD lumen narrowing Patients without LM/pLAD lumen narrowing
p-int.24-month 
clopidogrel 
(n=471)
6-month 
clopidogrel 
(n=482)
Hazard ratio 
(95% CI)
p-value
24-month 
clopidogrel 
(n=405)
6-month 
clopidogrel 
(n=396)
Hazard ratio 
(95% CI)
p-value
Patient-oriented outcomes
Death from any cause, myocardial infarction 
or cerebrovascular accident 52 (11.0) 53 (11.0) 0.96 (0.65-1.41) 0.84 38 (9.4) 27 (6.8) 1.45 (0.88-2.38) 0.14 0.20
Death from any cause or myocardial infarction 44 (9.3) 51 (10.6) 0.83 (0.56-1.25) 0.38 34 (8.4) 26 (6.6) 1.33 (0.80 -2.22) 0.27 0.16
Death from cardiovascular cause or 
myocardial infarction 31 (6.6) 40 (8.3) 0.74 (0.46-1.18) 0.21 25 (6.2) 16 (4.0) 1.59 (0.85-2.97) 0.15 0.056
Death from any cause 33 (7.0) 36 (7.5) 0.88 (0.55-1.43) 0.62 27 (6.7) 20 (5.1) 1.39 (0.78-2.48) 0.26 0.24
Death from cardiovascular cause 18 (3.8) 23 (4.8) 0.74 (0.40-1.37) 0.34 16 (4.0) 10 (2.5) 1.66 (0.75-3.66) 0.21 0.12
Myocardial infarction 21 (4.5) 22 (4.6) 0.91 (0.50-1.66) 0.76 12 (3.0) 10 (2.5) 1.18 (0.51-2.74) 0.69 0.61
Stent-oriented outcomes
Definite stent 
thrombosis
Late 1 (0.2) 3 (0.6) 0.35 (0.03-3.25) 0.35 4 (1.0) 1 (0.3) 3.98 (0.44-35.6) 0.22 0.12
Very late 0 (0.0) 1 (0.2) n.a. 0.59 1 (0.3) 0 (0.0) n.a. 0.61 –
Cumulative 1 (0.2) 4 (0.8) 0.24 (0.03-2.13) 0.20 5 (1.2) 1 (0.3) 4.93 (0.57-42.3) 0.15 0.054
Definite or probable 
stent thrombosis
Late 2 (0.4) 5 (1.0) 0.38 (0.07-1.96) 0.25 6 (1.5) 3 (0.8) 1.99 (0.50-7.99). 0.33 0.13
Very late 1 (0.2) 2 (0.4) 0.43 (0.04-4.75) 0.49 1 (0.3) 1 (0.3) 1.06 (0.07-17.1) 0.96 0.63
Cumulative 3 (0.6) 7 (1.5) 0.39 (0.10-1.52) 0.17 7 (1.7) 4 (1.0) 1.75 (0.51-5.99) 0.37 0.11
Definite, probable or 
possible stent 
thrombosis
Late 7 (1.5) 15 (3.1) 0.44 (0.18-1.09) 0.08 17 (4.2) 8 (2.0) 2.17 (0.94-5.04) 0.07 0.01
Very late 6 (1.3) 12 (2.6) 0.46 (0.17-1.24) 0.12 4 (1.0) 2 (0.5) 2.05 (0.37-11.24) 0.41 0.13
Cumulative 13 (2.8) 27 (5.6) 0.45 (0.23-0.89) 0.02 21 (5.2) 10 (2.5) 2.15 (1.01-4.58) 0.046 0.002
Modified definite, probable or possible stent 
thrombosis 5 (1.1) 12 (2.5) 0.40 (0.14-1.15) 0.09 7 (1.7) 2 (0.5) 3.61 (0.75-17.4) 0.11 0.02
Bleeding outcomes
BARC type 2, 3 or 5 41 (8.7) 17 (3.5) 2.51 (1.43-4.42) 0.003 27 (6.7) 14 (3.5) 1.94 (1.01-3.69) 0.04 0.65
BARC type 3 or 5 23 (4.9) 10 (2.1) 2.26 (1.08-4.78) 0.03 9 (2.2) 8 (2.0) 1.17 (0.45-3.04) 0.74 0.28
Adjusted for non-ST-segment elevation myocardial infarction. BARC: Bleeding Academic Research Consortium
Hazard ratio (95% CI) p-values
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LM/pLAD lumen narrowing 0.96 (0.65-1.41) 0.84
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0.056
No LM/pLAD lumen narrowing 1.59 (0.85-2.97) 0.15
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LM/pLAD lumen narrowing 0.88 (0.55-1.43) 0.62
0.24
No LM/pLAD lumen narrowing 1.39 (0.78-2.48) 0.26
CV death
LM/pLAD lumen narrowing 0.74 (0.40-1.37) 0.34
0.12
No LM/pLAD lumen narrowing 1.66 (0.75-3.66) 0.21
Ml
LM/pLAD lumen narrowing 0.91 (0.50-1.66) 0.76
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10 1 0.1
6-month DAPT better 24-month DAPT better
Figure 2.#*<2.7<8:2.7<.-8=<,86.;&1.;=+0:8=9;?2<1*7-?2<18=< 95=6.77*::8?270*:.;18?7/8:<1.9*<2.7<8:2.7<.-
2;,1*.62,.7-9827<;*68709*<2.7<;:*7-862;.-<8;2@687<18:687<1#&
LM OR PROXIMAL LAD AND DAPT DURATION
275274
5
e1225
EuroIntervention 2
0
16
;11
:e
12
2
2-e
12
3
0
Impact of coronary disease location on DAPT duration

<AG;8F<K@BAG;)-4E@!+
"

C
 BE G;BF8 J<G;BHG %&	C% ?H@8A A4EEBJ<A:  <A
G;8 @BAG; IF  <A G;8 F<K@BAG; )- 4E@ !+ 
"
C
(Table 2, Figure 2),<@<?4E9<A7<A:F
J8E8B5F8EI87J;8A846;6B@CBA8AGB9G;8CE<@4EL8A7CB<AGJ4F
4CCE4<F87F8C4E4G8?L-;8E8J4F;BJ8I8E4GE8A7GBJ4E7F<AG8E46
G<BA)"'-

J<G;E8FC86GGB)-7HE4G<BA4A7G;8CE8F8A68
B9%&	C%?H@8AA4EEBJ<A:FH::8FG<A::E84G8E<F6;48@<6CEB
G86G<BAGBJ4E7FG;86B@CBF<G88A7CB<AGB964E7<BI4F6H?4E784G;BE
@LB64E7<4?<A94E6G<BA&"<AC4G<8AGFGE84G87J<G;4F6B@C4E87
GBF<K@BAG;)-(Table 2, Figure 2)
+8FH?GF E8@4<A87 6BAF<FG8AG E8:4E7?8FF B9 J;8G;8E FG8AG<A:
J4F (Appendix Table 2) BEJ4F ABG (Appendix Table 3) 466B@
C?<F;87 <A G;8 %& 4A7	BE C% 'B F<:A4? B9 ;8G8EB:8A8<GL <A
G;8 FH5:EBHCF B9 C4G<8AGF HA78E:B<A: FG8AG<A: I8EFHF G;BF8 J;B
7<7ABGE868<I8FG8AG<@C?4AG4G<BA<AG;8%&	C%J4FB5F8EI87
9BE C4G<8AGBE<8AG87 BHG6B@8F J<G; E8FC86G GB )- 7HE4G<BA
(Appendix Figure 1)
0;8AG;8:EBHCB9C4G<8AGFCE8F8AG<A:J<G;46HG86BEBA4ELFLA
7EB@8,J4F4CCE4<F87F8C4E4G8?LG;8E8FH?GFJ8E8<A?<A8J<G;
G;BF8B5F8EI87<AG;8BI8E4??C4G<8AGCBCH?4G<BA(Appendix Table 4)
STENT-ORIENTED OUTCOMES
-;8 E<F> B9 789<A<G8 789<A<G8 BE CEB545?8 4A7789<A<G8 CEB545?8
BECBFF<5?8,-J4FABG<A6E84F87<AC4G<8AGFJ<G;4F6B@C4E87GB
G;BF8J<G;BHG%&	C%?H@8AA4EEBJ<A:,<@<?4E?LG;86H@H
?4G<I8E<F>B9789<A<G8FG8AGG;EB@5BF<F7<7ABG7<998EJ<G;E8FC86G
GB )- 7HE4G<BA <A C4G<8AGF J<G; 
 <A G;8 @BAG; IF

<AG;8F<K@BAG;)-4E@!+
"


C

 BE G;BF8J<G;BHG%&	C% ?H@8AA4EEBJ<A:  <A
G;8 @BAG; IF 
 <A G;8 F<K@BAG; )- 4E@ !+ 
 " 
 C
 J<G; 4 GE8A7 GBJ4E7F <AG8E46G<BA
58GJ88A G;8 CE8F8A68 B9 %&	C% ?H@8A A4EEBJ<A: 4A7 G;8
7HE4G<BA B9 GE84G@8AG )"'-

 (Figure 3) BAF<FG8AG 9<A7
<A:F J8E8 ABG87 9BE G;8 6B@CBF<G8 B9 789<A<G8 BE CEB545?8 ,-
(Figure 3, Figure 4)
89<A<G8 CEB545?8 BE CBFF<5?8 ,-J4F F<:A<9<64AG?L E87H687 5L
@BAG;4F6B@C4E87GBF<K@BAG;GE84G@8AG4@BA:C4G<8AGFJ<G;
%&	C% ?H@8A A4EEBJ<A:  <A G;8 @BAG; IF  <A
G;8 F<K@BAG; )- 4E@ !+ 
  " 

 C


J;8E84F<GJ4F<A6E84F87<AC4G<8AGFJ<G;BHG%&	C%?H@8AA4E
EBJ<A:  <A G;8 @BAG; IF  <A G;8 F<K@BAG; )-
4E@ !+  " 
 C

 J<G; ;<:;?L F<:A<9<
64AG<AG8E46G<BAG8FG<A:)"'-


(Figure 3, Figure 4)+8FH?GF
E8@4<A87 6BAF<FG8AG J;8A G;8 N@B7<9<87O FG8AG G;EB@5BF<F 8A7
CB<AGJ4F4CCE4<F87<A6BA=HA6G<BAJ<G;789<A<G8BECEB545?88I8AGF
(Figure 3, Figure 5)G?4A7@4E>4A4?LF<F49G8E68AFBE<A:4??8I8AGF
B66HEE<A:589BE8F<K@BAG;F G;8G<@84GJ;<6;G;8GJBC;4E@46B
?B:<64?4E@FFG4EG877<I8E:<A:J8FG<??B5F8EI874E87H6G<BAB9789<
A<G8 CEB545?8 BE CBFF<5?8 FG8AG G;EB@5BF<F J<G;  IF F<K@BAG;
)-<AC4G<8AGFJ<G;%&	C%?H@8AA4EEBJ<A:!+

" 


 C

 J;8E84F <GF <A6E84F8 <A C4G<8AGF J<G;BHG
%&	C%?H@8AA4EEBJ<A:J4FAB?BA:8ECE8F8AG!+
" 
 C
 6BAF<FG8AG F<:A<9<64AG <AG8E46G<BA 89986G
Table 1. Baseline characteristics.
Characteristic
Patients with LM/pLAD lumen narrowing Patients without LM/pLAD lumen narrowing
p-value*24-month 
clopidogrel 
(n=471)
6-month 
clopidogrel 
(n=482)
p-value
24-month 
clopidogrel 
(n=405)
6-month 
clopidogrel 
(n=396)
p-value
Age, yrs 69.6 (70-77) 69.9 (60-77) 0.59 67.4 (59-74) 66.7 (59-75) 0.91 0.03
Male sex, % (n) 74.5 (351) 74.7 (360) 0.95 77.3 (313) 75.8 (300) 0.61 0.35
Body mass index, kg/m2 26.2 (24-29) 26.6 (24-29) 0.82 27.3 (25-30) 26.4 (24-29) 0.39 0.27
Diabetes, % (n) 24.2 (114) 21.8 (105) 0.38 23.5 (95) 24.2 (96) 0.79 0.68
Insulin-dependent, % (n) 5.9 (28) 4.6 (22) 4.0 (16) 6.1 (24)
Hypertension, % (n) 70.7 (333) 70.7 (341) 0.99 72.6 (294) 67.9 (269) 0.15 0.84
Hyperlipidaemia, % (n) 54.1 (255) 51.9 (250) 0.48 53.6 (217) 51.5 (204) 0.56 0.86
Current cigarette use, % (n) 23.1 (109) 23.2 (112) 0.59 26.2 (105) 30.3 (120) 0.14 0.02
Creatinine clearance, ml/min 74.4 (54-100) 73.3 (56-95) 0.71 79.0 (59-102) 77.7 (60-97) 0.28 0.005
Prior myocardial infarction, % (n) 21.4 (101) 20.7 (100) 0.41 24.4 (99) 22.5 (89) 0.49 0.21
Prior percutaneous coronary 
intervention, % (n) 13.6 (64) 14.9 (72) 0.17 20.2 (82) 16.2 (64) 0.10 0.02
Left ventricular ejection fraction 55 (40-60) 53 (45-60) 0.82 55 (45-60) 51 (45-60) 0.44 0.53
Clinical presentation, % (n)
Stable angina pectoris 23.8 (112) 25.1 (121) 0.63 26.2 (106) 26.0 (103) 0.95 0.43
Acute coronary syndrome 76.2 (359) 74.9 (361) 73.8 (299) 74.0 (293)
Unstable angina 17.2 (81) 19.5 (94) 0.35 16.5 (67) 14.6 (58) 0.46 0.14
Non-ST-elevation MI 26.8 (126) 20.5 (99) 0.02 18.8 (76) 23.5 (93) 0.10 0.21
ST-segment elevation MI 32.3 (152) 34.9 (168) 0.40 38.5 (156) 35.9 (142) 0.43 0.12
* p-value for the comparison between patients with and without LM/pLAD lumen narrowing.
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Table 2. Outcome rates at 24 months according to the treatment group.
Patients with LM/pLAD lumen narrowing Patients without LM/pLAD lumen narrowing
p-int.24-month 
clopidogrel 
(n=471)
6-month 
clopidogrel 
(n=482)
Hazard ratio 
(95% CI)
p-value
24-month 
clopidogrel 
(n=405)
6-month 
clopidogrel 
(n=396)
Hazard ratio 
(95% CI)
p-value
Patient-oriented outcomes
Death from any cause, myocardial infarction 
or cerebrovascular accident 52 (11.0) 53 (11.0) 0.96 (0.65-1.41) 0.84 38 (9.4) 27 (6.8) 1.45 (0.88-2.38) 0.14 0.20
Death from any cause or myocardial infarction 44 (9.3) 51 (10.6) 0.83 (0.56-1.25) 0.38 34 (8.4) 26 (6.6) 1.33 (0.80 -2.22) 0.27 0.16
Death from cardiovascular cause or 
myocardial infarction 31 (6.6) 40 (8.3) 0.74 (0.46-1.18) 0.21 25 (6.2) 16 (4.0) 1.59 (0.85-2.97) 0.15 0.056
Death from any cause 33 (7.0) 36 (7.5) 0.88 (0.55-1.43) 0.62 27 (6.7) 20 (5.1) 1.39 (0.78-2.48) 0.26 0.24
Death from cardiovascular cause 18 (3.8) 23 (4.8) 0.74 (0.40-1.37) 0.34 16 (4.0) 10 (2.5) 1.66 (0.75-3.66) 0.21 0.12
Myocardial infarction 21 (4.5) 22 (4.6) 0.91 (0.50-1.66) 0.76 12 (3.0) 10 (2.5) 1.18 (0.51-2.74) 0.69 0.61
Stent-oriented outcomes
Definite stent 
thrombosis
Late 1 (0.2) 3 (0.6) 0.35 (0.03-3.25) 0.35 4 (1.0) 1 (0.3) 3.98 (0.44-35.6) 0.22 0.12
Very late 0 (0.0) 1 (0.2) n.a. 0.59 1 (0.3) 0 (0.0) n.a. 0.61 –
Cumulative 1 (0.2) 4 (0.8) 0.24 (0.03-2.13) 0.20 5 (1.2) 1 (0.3) 4.93 (0.57-42.3) 0.15 0.054
Definite or probable 
stent thrombosis
Late 2 (0.4) 5 (1.0) 0.38 (0.07-1.96) 0.25 6 (1.5) 3 (0.8) 1.99 (0.50-7.99). 0.33 0.13
Very late 1 (0.2) 2 (0.4) 0.43 (0.04-4.75) 0.49 1 (0.3) 1 (0.3) 1.06 (0.07-17.1) 0.96 0.63
Cumulative 3 (0.6) 7 (1.5) 0.39 (0.10-1.52) 0.17 7 (1.7) 4 (1.0) 1.75 (0.51-5.99) 0.37 0.11
Definite, probable or 
possible stent 
thrombosis
Late 7 (1.5) 15 (3.1) 0.44 (0.18-1.09) 0.08 17 (4.2) 8 (2.0) 2.17 (0.94-5.04) 0.07 0.01
Very late 6 (1.3) 12 (2.6) 0.46 (0.17-1.24) 0.12 4 (1.0) 2 (0.5) 2.05 (0.37-11.24) 0.41 0.13
Cumulative 13 (2.8) 27 (5.6) 0.45 (0.23-0.89) 0.02 21 (5.2) 10 (2.5) 2.15 (1.01-4.58) 0.046 0.002
Modified definite, probable or possible stent 
thrombosis 5 (1.1) 12 (2.5) 0.40 (0.14-1.15) 0.09 7 (1.7) 2 (0.5) 3.61 (0.75-17.4) 0.11 0.02
Bleeding outcomes
BARC type 2, 3 or 5 41 (8.7) 17 (3.5) 2.51 (1.43-4.42) 0.003 27 (6.7) 14 (3.5) 1.94 (1.01-3.69) 0.04 0.65
BARC type 3 or 5 23 (4.9) 10 (2.1) 2.26 (1.08-4.78) 0.03 9 (2.2) 8 (2.0) 1.17 (0.45-3.04) 0.74 0.28
Adjusted for non-ST-segment elevation myocardial infarction. BARC: Bleeding Academic Research Consortium
Hazard ratio (95% CI) p-values
Sup. Int.
Death. Ml or CVA
LM/pLAD lumen narrowing 0.96 (0.65-1.41) 0.84
0.20
No LM/pLAD lumen narrowing 1.45 (0.88-2.38) 0.14
Death or Ml
LM/pLAD lumen narrowing 0.83 (0.56-1.25) 0.38
0.16
No LM/pLAD lumen narrowing 1.33 (0.80-2.22) 0.27
CV Eeath or Ml
LM/pLAD lumen narrowing 0.74 (0.46-1.18) 0.21
0.056
No LM/pLAD lumen narrowing 1.59 (0.85-2.97) 0.15
Death
LM/pLAD lumen narrowing 0.88 (0.55-1.43) 0.62
0.24
No LM/pLAD lumen narrowing 1.39 (0.78-2.48) 0.26
CV death
LM/pLAD lumen narrowing 0.74 (0.40-1.37) 0.34
0.12
No LM/pLAD lumen narrowing 1.66 (0.75-3.66) 0.21
Ml
LM/pLAD lumen narrowing 0.91 (0.50-1.66) 0.76
0.61
No LM/pLAD lumen narrowing 1.18 (0.51-2.74) 0.69
10 1 0.1
6-month DAPT better 24-month DAPT better
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Impact of coronary disease location on DAPT duration
Hazard ratio (95% CI) p-values
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DEF ST
LM/pLAD lumen narrowing 0.24 (0.03-2.13) 0.20
0.054
No LM/pLAD lumen narrowing 4.93 (0.57-42.3) 0.15
DEF/PROB ST
LM/pLAD lumen narrowing 0.39 (0.10-1.52) 0.17
0.11
No LM/pLAD lumen narrowing 1.75 (0.51-5.99) 0.37
DEF/PROB/POSS ST
LM/pLAD lumen narrowing 0.45 (0.23-0.89) 0.02
0.002
No LM/pLAD lumen narrowing 2.15 (1.01-4.58) 0.046
MOD DEF/PROB/POSS ST
LM/pLAD lumen narrowing 0.40 (0.14-1.15) 0.09
0.02
No LM/pLAD lumen narrowing 3.61 (0.75-17.4) 0.11
 100 10 1 0.1
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Pharmacodynamics studies reported a greater inhibition of platelet
aggregation among clopidogrel treated patients in smokers compared
with non-smokers [1]. Cigarette smoking increases the catalytic activity
of CYP1A2, which mediates the ﬁrst oxidative step in the conversion
of pro-drug clopidogrel to its active metabolite [2]. Therefore, in
clopidogrel treated patients smoking habit may increase the effect of
treatment, potentially leading to a higher protection against ischaemic
events, but also to a higher bleeding risk. Based on available evidence,
the impact of smoking habit on outcomes remains unclear [3–8].
We investigatedwhether smoking statusmay inﬂuence the effect of
dual antiplatelet therapy (DAPT) durationwith respect to ischaemic and
bleeding events in an all-comer PCI population who were randomized
either 6-month (short-term) or 24-month (long-term) treatment with
clopidogrel on top of aspirin after coronary stenting.
The design of the Prolonging Dual Antiplatelet Treatment After
Grading Stent Induced Intimal Hyperplasia Study (PRODIGY)was previ-
ously reported [9,10].
The study was conducted according to the ethical guidelines of the
Declaration of Helsinki. The Ethics Committee approved the protocol;
the informed consent was achieved from each patient.
Out of 2013 patients enrolled into the study, 33 died within 30 days
and 10 withdrew consent. Smoking status was recorded in all but 8 pa-
tients who were excluded from this analysis.
The ﬁnal population included 1962 patients: 984 were allocated
to receive 24-month DAPT (222 smokers and 762 non-smokers)
and 978 were assigned to 6-month DAPT (247 smokers and 731 non-
smokers).
Compared with non-smokers, smokers were younger, less frequent-
ly had history of hypertension, myocardial infarction (MI) or coronary
revascularization and more frequently presented with STEMI or had
higher creatinine clearance. Demographic, clinical and procedural fea-
tures were well balanced in the patients treated with long-term versus
short-term DAPTwithin both smoker and non-smoker groups (Table 1).
The primary efﬁcacy end-point (all-cause death, MI or cerebrovas-
cular accident – CVA – at 2 years) occurred in 165 (11.1%) non-
smokers and in 32 (6.8%) smokers without signiﬁcant differences
between the two groups after adjustment for variables which were
differently distributed at an alpha of 5% (HR 1.03 with CI 95% of
0.67–1.50; p = 0.989).
Among patients allocated to the long-term DAPT arm compared
with those assigned to receive the short-term DAPT, no signiﬁcant
differences of primary end-point rate were noted in both smokers
(5.9% in the long-term vs 7.7% in the short-term DAPT arms; HR 0.70,
95% CI 0.34–1.45; p = 0.339) and non-smokers (11.3% in the long-
term vs 10.8% in the short-term DAPT arms; HR 1.04, 95% CI 0.77–
1.41; p = 0.793) with no evidence of interaction between smoking
habit and DAPT duration (PINT = 0.426) (Fig. 1). Similarly, no differ-
ences between short and long-term DAPT groups in terms of both
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with non-smokers [1]. Cigarette smoking increases the catalytic activity
of CYP1A2, which mediates the ﬁrst oxidative step in the conversion
of pro-drug clopidogrel to its active metabolite [2]. Therefore, in
clopidogrel treated patients smoking habit may increase the effect of
treatment, potentially leading to a higher protection against ischaemic
events, but also to a higher bleeding risk. Based on available evidence,
the impact of smoking habit on outcomes remains unclear [3–8].
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bleeding events in an all-comer PCI population who were randomized
either 6-month (short-term) or 24-month (long-term) treatment with
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The study was conducted according to the ethical guidelines of the
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Out of 2013 patients enrolled into the study, 33 died within 30 days
and 10 withdrew consent. Smoking status was recorded in all but 8 pa-
tients who were excluded from this analysis.
The ﬁnal population included 1962 patients: 984 were allocated
to receive 24-month DAPT (222 smokers and 762 non-smokers)
and 978 were assigned to 6-month DAPT (247 smokers and 731 non-
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Compared with non-smokers, smokers were younger, less frequent-
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revascularization and more frequently presented with STEMI or had
higher creatinine clearance. Demographic, clinical and procedural fea-
tures were well balanced in the patients treated with long-term versus
short-term DAPTwithin both smoker and non-smoker groups (Table 1).
The primary efﬁcacy end-point (all-cause death, MI or cerebrovas-
cular accident – CVA – at 2 years) occurred in 165 (11.1%) non-
smokers and in 32 (6.8%) smokers without signiﬁcant differences
between the two groups after adjustment for variables which were
differently distributed at an alpha of 5% (HR 1.03 with CI 95% of
0.67–1.50; p = 0.989).
Among patients allocated to the long-term DAPT arm compared
with those assigned to receive the short-term DAPT, no signiﬁcant
differences of primary end-point rate were noted in both smokers
(5.9% in the long-term vs 7.7% in the short-term DAPT arms; HR 0.70,
95% CI 0.34–1.45; p = 0.339) and non-smokers (11.3% in the long-
term vs 10.8% in the short-term DAPT arms; HR 1.04, 95% CI 0.77–
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relative risk and interaction with smoking were observed for all-cause-
death and cardiovascular (CV) death or MI (Fig. 1).
The key safety end-point (BleedingAcademic Research Consortium−
BARC− type 2, 3 or 5) occurred in 22 (4.7%) smokers and 85 (5.7%) non-
smokers without signiﬁcant differences between two groups (Adjusted
HR 1.18; 95% CI 0.71–1.95; p = 0.532).
Patients who received long-term DAPT had a greater rate of
BARC type 2, 3 or 5 events compared with those treated with short-
term DAPT among non-smokers (8.0% vs 3.3%; HR 2.48, 95% CI 1.55–
3.97; p b 0.001), whereas no formal signiﬁcant difference was observed
within smokers (5.4% vs 4.0%; HR 1.36, 95% CI 0.59–3.14; p = 0.474);
however, the p-value for interaction between smoking status and
DAPT duration was not signiﬁcant (PINT = 0.220) (Fig. 1), suggesting
that smoking habit isn't a treatmentmodiﬁer with respect to the bleed-
ing risk in patients receiving different DAPT durations.
Sensitivity analysis on the per-protocol population was consistent
in direction and magnitude with those derived from the intention-
to-treat analysis (Fig. 1). Additional analysis performed dividing
population in smokers, never-smokers and former-smokers con-
ﬁrmed absence of interaction between smoking status and DAPT
duration for both death (PINT = 0.821), death, MI or CVA (PINT =
0.367), CV death or MI (PINT = 0.877) and BARC type 2,3 or
5 (PINT = 0.889).
There is conﬂicting evidence on the interaction between clopidogrel
therapy and smoking status. In a selected STEMI population treated
with ﬁbrinolysis, smoking habit improved the effect of clopidogrel on
TIMI-ﬂow grade [3] and in a cohort of patients with acute coronary syn-
drome (ACS), it increased the effect of clopidogrel when double was
compared to standard dose [4].
A large ACS registry reported similar efﬁcacy and safety of early
clopidogrel use in smokers and non-smoker patients [5]. Moreover, ran-
domized trials comparing clopidogrel with other P2Y12 inhibitors ob-
served a higher efﬁcacy of prasugrel and ticagrelor compared with
clopidogrel regardless of the smoking status [6,7]. Recently, a large
trial failed to demonstrate a clinical advantage in smokers versus
never-smokers in a clopidogrel versus aspirin treated population with
stable coronary artery disease [8].
We analyzed an all-comer population including both stable and
unstable patients undergoing PCI who were randomly allocated to
different DAPT durations after coronary stenting. No signiﬁcant inter-
action was observed for both efﬁcacy and safety end-points between
cigarette smoking and DAPT duration. A lower incidence of death,
MI or CVA was observed in smokers compared with non-smokers
in both long and short-term arms. Moreover, a trend toward a
lower bleeding rate was noted in smokers compared with non-
smokers in the long-term DAPT group. The better outcome of
smokers with respect to both ischaemic and bleeding events was
probably due to younger age and lower co-morbidity compared
with non-smokers. This difference was less evident in short-term
group, which may reﬂect a better matching in baseline risk factors
between smokers and non-smokers observed in this arm. These re-
sults support the hypothesis that smoking status doesn't impact on
clinical outcome of clopidogrel treated population. Smoking habit
may just be a marker of lower global risk rather than a risk modiﬁer
in these patients.
This analysis was not pre-speciﬁed and the small number of
patients included in the smoker group could affect the results; on
the other hand, the several overall and sensitivity analyses performed
converge in showing that the estimates can be interpreted with
conﬁdence.
In conclusion, smoking habit doesn't modify the impact of
clopidogrel therapy duration on ischaemic and bleeding outcomes of
patients undergoing coronary stenting.
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Table 1
Baseline and procedural features.
All population Non-smokers Smokers
Non-smokers
(1493)
Smokers
(469)
6-Month DAPT
(731)
24-Month DAPT
(762)
6-Month DAPT
(247)
24-Month DAPT
(222)
Sex (male), n (%) 1122 (75.2) 385 (82.1)§ 548 (75) 547 (75) 197 (79.8) 188 (84.7)
Age (years) median (IQR) 71.4 (63.8–77.5) 60.3 (53.0–68.6)⁎ 71.3 (64.1–77.8) 71.5 (62.9–77.2) 60.0 (53.8–68.4) 61.3 (52.1–68.6)
BMI (kg/m2) median (IQR) 26.7 (24.5–29.4) 26.2 (24.2–29.0) 26.8 (24.4–29.4) 26.6 (24.6–29.4) 26.1 (24.0–28.7) 26.6 (24.5–29.4)
Hypercholesterolemia, n (%) 850 (56.9) 222 (47.3)⁎ 402 (55.0) 448 (58.8) 119 (48.2) 103 (46.4)
Hypertension, n (%) 1144 (76.6) 266 (56.7)⁎ 545 (74.6) 599 (78.6) 146 (59.1) 120 (54.1)
Diabetes, n (%) 394 (26.4) 80 (17.1)⁎ 183 (25.1) 211 (27.7) 48 (19.4) 32 (14.4)
Previous stroke, n (%) 13 (1.1) 1 (0.3) 8 (1.4) 5 (0.9) 0 (0.0) 1 (0.6)
Previous MI, n (%) 444 (29.7) 81 (17.3)⁎ 210 (28.7) 234 (30.7) 46 (18.6) 35 (15.8)
Previous PCI, n (%) 313 (21.0) 45 (9.6)⁎ 145 (19.8) 168 (22.0) 25 (0.1) 20 (9.0)
Previous CABG, n (%) 191 (12.8) 22 (4.7)⁎ 88 (12.0) 103 (13.5) 15 (6.1) 7 (3.2)
Creatinine clearance (ml/min), median (IQR) 69.4 (54.2–90.2) 93.4 (69.5–112.6)⁎ 69.6 (53.8–89.3) 69.3 (54.2–92.0) 91.6 (69.3–112.6) 96.4 (70.7–112.7)
STEMI, n (%) 419 (28.1) 226 (48.2)⁎ 205 (28.0) 214 (28.1) 19 (48.2) 107 (48.2)
NSTACS, n (%) 649 (43.5) 167 (35.6)§ 318 (43.5) 331 (43.4) 88 (35.6) 79 (35.6)
SCAD, n (%) 425 (28.5) 76 (16.2)⁎ 208 (28.5) 217 (28.5) 40 (16.2) 36 (16.2)
LVEF (%), median (IQR) 52.0 (45.0–60.0) 51.0 (44.0–60.0) 50.0 (43.3–60.0) 55.0 (45.0–60.0) 50.0 (43.5–60.0) 52.0 (44.0–60.0)
Multivessel disease, n (%) 1064 (71.3) 307 (65.5)§ 518 (70.9) 546 (71.7) 161 (65.2) 146 (65.8)
At least 1 b2/c lesion, n (%) 978 (65.5) 323 (68.9) 486 (66.5) 492 (64.6) 176 (71.3) 147 (66.2)
Stent type BMS, n (%) 356 (24.4) 124 (26.4) 182 (24.9) 184 (24.1) 63 (25.5) 61 (27.5)
Stent type ENDEAVOR, n (%) 366 (24.5) 378 (25.3) 176 (24.1) 190 (24.9) 67 (27.1) 58 (26.1)
Stent type TAXUS, n (%) 378 (25.3) 109 (23.2) 183 (25.0) 195 (25.6) 60 (24.3) 49 (22.1)
Stent type XIENCE, n (%) 384 (25.7) 111 (23.7) 190 (26.0) 193 (25.3) 57 (23.1) 54 (24.3)
BMI= bodymass index; BMS= bare metal stent, CABG= coronary artery bypass graft; IQR= interquartile range; LVEF= left ventricular ejection fraction;MI=myocardial infarction;
NSTEACS= non ST-elevation acute coronary syndrome; PCI= percutaneous coronary intervention; SCAD= stable coronary artery disease; STEMI= ST-elevationmyocardial infarction.
§ P b 0.05.
⁎ P b 0.001.
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relative risk and interaction with smoking were observed for all-cause-
death and cardiovascular (CV) death or MI (Fig. 1).
The key safety end-point (BleedingAcademic Research Consortium−
BARC− type 2, 3 or 5) occurred in 22 (4.7%) smokers and 85 (5.7%) non-
smokers without signiﬁcant differences between two groups (Adjusted
HR 1.18; 95% CI 0.71–1.95; p = 0.532).
Patients who received long-term DAPT had a greater rate of
BARC type 2, 3 or 5 events compared with those treated with short-
term DAPT among non-smokers (8.0% vs 3.3%; HR 2.48, 95% CI 1.55–
3.97; p b 0.001), whereas no formal signiﬁcant difference was observed
within smokers (5.4% vs 4.0%; HR 1.36, 95% CI 0.59–3.14; p = 0.474);
however, the p-value for interaction between smoking status and
DAPT duration was not signiﬁcant (PINT = 0.220) (Fig. 1), suggesting
that smoking habit isn't a treatmentmodiﬁer with respect to the bleed-
ing risk in patients receiving different DAPT durations.
Sensitivity analysis on the per-protocol population was consistent
in direction and magnitude with those derived from the intention-
to-treat analysis (Fig. 1). Additional analysis performed dividing
population in smokers, never-smokers and former-smokers con-
ﬁrmed absence of interaction between smoking status and DAPT
duration for both death (PINT = 0.821), death, MI or CVA (PINT =
0.367), CV death or MI (PINT = 0.877) and BARC type 2,3 or
5 (PINT = 0.889).
There is conﬂicting evidence on the interaction between clopidogrel
therapy and smoking status. In a selected STEMI population treated
with ﬁbrinolysis, smoking habit improved the effect of clopidogrel on
TIMI-ﬂow grade [3] and in a cohort of patients with acute coronary syn-
drome (ACS), it increased the effect of clopidogrel when double was
compared to standard dose [4].
A large ACS registry reported similar efﬁcacy and safety of early
clopidogrel use in smokers and non-smoker patients [5]. Moreover, ran-
domized trials comparing clopidogrel with other P2Y12 inhibitors ob-
served a higher efﬁcacy of prasugrel and ticagrelor compared with
clopidogrel regardless of the smoking status [6,7]. Recently, a large
trial failed to demonstrate a clinical advantage in smokers versus
never-smokers in a clopidogrel versus aspirin treated population with
stable coronary artery disease [8].
We analyzed an all-comer population including both stable and
unstable patients undergoing PCI who were randomly allocated to
different DAPT durations after coronary stenting. No signiﬁcant inter-
action was observed for both efﬁcacy and safety end-points between
cigarette smoking and DAPT duration. A lower incidence of death,
MI or CVA was observed in smokers compared with non-smokers
in both long and short-term arms. Moreover, a trend toward a
lower bleeding rate was noted in smokers compared with non-
smokers in the long-term DAPT group. The better outcome of
smokers with respect to both ischaemic and bleeding events was
probably due to younger age and lower co-morbidity compared
with non-smokers. This difference was less evident in short-term
group, which may reﬂect a better matching in baseline risk factors
between smokers and non-smokers observed in this arm. These re-
sults support the hypothesis that smoking status doesn't impact on
clinical outcome of clopidogrel treated population. Smoking habit
may just be a marker of lower global risk rather than a risk modiﬁer
in these patients.
This analysis was not pre-speciﬁed and the small number of
patients included in the smoker group could affect the results; on
the other hand, the several overall and sensitivity analyses performed
converge in showing that the estimates can be interpreted with
conﬁdence.
In conclusion, smoking habit doesn't modify the impact of
clopidogrel therapy duration on ischaemic and bleeding outcomes of
patients undergoing coronary stenting.
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LVEF (%), median (IQR) 52.0 (45.0–60.0) 51.0 (44.0–60.0) 50.0 (43.3–60.0) 55.0 (45.0–60.0) 50.0 (43.5–60.0) 52.0 (44.0–60.0)
Multivessel disease, n (%) 1064 (71.3) 307 (65.5)§ 518 (70.9) 546 (71.7) 161 (65.2) 146 (65.8)
At least 1 b2/c lesion, n (%) 978 (65.5) 323 (68.9) 486 (66.5) 492 (64.6) 176 (71.3) 147 (66.2)
Stent type BMS, n (%) 356 (24.4) 124 (26.4) 182 (24.9) 184 (24.1) 63 (25.5) 61 (27.5)
Stent type ENDEAVOR, n (%) 366 (24.5) 378 (25.3) 176 (24.1) 190 (24.9) 67 (27.1) 58 (26.1)
Stent type TAXUS, n (%) 378 (25.3) 109 (23.2) 183 (25.0) 195 (25.6) 60 (24.3) 49 (22.1)
Stent type XIENCE, n (%) 384 (25.7) 111 (23.7) 190 (26.0) 193 (25.3) 57 (23.1) 54 (24.3)
BMI= bodymass index; BMS= bare metal stent, CABG= coronary artery bypass graft; IQR= interquartile range; LVEF= left ventricular ejection fraction;MI=myocardial infarction;
NSTEACS= non ST-elevation acute coronary syndrome; PCI= percutaneous coronary intervention; SCAD= stable coronary artery disease; STEMI= ST-elevationmyocardial infarction.
§ P b 0.05.
⁎ P b 0.001.
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Impact of proton pump inhibitors on clinical
outcomes in patients treated with a 6- or
24-month dual-antiplatelet therapy duration:
Insights from the PROlongingDual-antiplatelet
treatment after Grading stent-induced Intimal
hyperplasia studY trial
GiuseppeGargiulo, MD, a,b Francesco Costa, MD, c,d Sara Ariotti, MD, a SimoneBiscaglia, MD, e Gianluca Campo,MD, e
Giovanni Esposito, MD, PhD, b Sergio Leonardi, MD, f Pascal Vranckx, MD, PhD, g Stephan Windecker, MD, a and
Marco Valgimigli, MD, PhDa,c Bern, Switzerland; Naples, Messina, Ferrara, Pavia, Italy; Ferrara, Italy; Rotterdam,
The Netherlands; and Hasselt, Belgium
Background Proton pump inhibitors (PPIs) are frequently prescribed in combination with clopidogrel, but conflicting data
exist as to whether PPIs diminish the efficacy of clopidogrel.We assessed the association between PPI use and clinical outcomes for
patients treated with percutaneous coronary intervention (PCI) and dual-antiplatelet therapy (DAPT) with clopidogrel plus aspirin.
Methods and results In the PRODIGY trial, 1,970 patients were randomized to 6- or 24-month DAPT at 30 days
from index procedure. Among them, 738 patients (37.5%) received PPI (mainly lansoprazole; 90.1%) at the time of
randomization. Proton pump inhibitor users were older, were most likely to be woman, had a lower creatinine clearance,
presented more frequently with acute coronary syndrome, and had a higher CRUSADE bleeding score. After adjustment, the
primary efficacy end point (composite of all-cause death, myocardial infarction, and cerebrovascular accident) was similar
between no PPI and PPI users (9.2% vs 11.5%, adjusted hazard ratio [HR] 1.051, 95% CI 0.788-1.400, P = .736). Bleeding
rates did not differ between the 2 groups (Bleeding Academic Research Consortium type 2, 3, or 5: adjusted HR 0.996, 95%
CI 0.672-1.474, P = .980). Net clinical adverse events were also similar in no PPI and PPI patients (12.9% vs 14.9%, adjusted
HR 0.99, 95% CI 0.772-1.268, P = .93). Results remained consistent at sensitivity analysis when focusing on the 548 patients
who remained on PPI for the whole study duration.
Conclusions The current findings suggest that the concomitant use of PPIs, when clinically indicated, in patients
receiving clopidogrel is not associated with adverse clinical outcome. (Am Heart J 2016;174:95-102.)
Dual-antiplatelet therapy (DAPT) is the cornerstone of
antithrombotic treatment in patients undergoing percu-
taneous coronary intervention (PCI), although its optimal
duration still remains debated.1-3 Notably, these patients
are frequently treated with a proton pump inhibitor (PPI)
to prevent gastrointestinal (GI) complications such as
ulceration and bleeding or due to preexisting gastric
disease.4-7 However, clopidogrel is a prodrug that requires
metabolic transformation in the liver by cytochrome P-450
isoenzyme (mainly CYP2C19) to elicit its antiplatelet effect.
Proton pump inhibitors are also metabolized by CYP
enzymes, leading to a potential inhibition of CYP2C19
(mainly omeprazole and esomeprazole) translating into
reduced metabolic activation of clopidogrel when taken
together. Indeed, some pharmacodynamic studies dem-
onstrated a reduction of clopidogrel-induced antiplatelet
effect when a PPI, mainly omeprazole, was concomi-
tantly administered.8-11 The Food and Drug Administra-
tion and the European Medicine Agency discourage the
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concomitant use of omeprazole and clopidogrel.12,13
The clinical impact of the combined administration has
been studied, but results have been discordant, with some
studies reporting an increased risk of cardiovascular
adverse events, whereas others did not confirm this
concern.5-7,11,14-23 Pooled analyses also provided inconclu-
sive results, owing to the risk ofmisinterpretation related to
poor-quality observational studies, thus supporting the
need for high-quality studies.14,15
Therefore, the purpose of the present subanalysis of
the PRODIGY randomized trial is to assess whether
medical therapy with PPI compared to that without PPI
may impact clinical outcomes in the setting of an all-comer
population undergoing PCI and with a randomly allocated
short (6months) or prolonged (24months) DAPT regimen,
consisting of clopidogrel and aspirin.
Methods
The design andmain findings of the PRODIGYhave been
previously reported.1,24 Briefly, all-comer PCI patients
receiving a balanced mixture of stents with varying
anti-intimal hyperplasia potency and belonging to both
first- and second-generation drug-eluting stent (DES) at
3 Italian sites were randomly allocated at 30 days to either
6 or 24 months of DAPT. Selection criteria were broad,
reflecting routine clinical practice. Randomization to
6- or 24-month DAPT was stratified by center, ongoing
ST-segment elevation myocardial infarction (MI), the
presence of diabetes mellitus, and need for intervening of
at least 1 in-stent restenotic lesion. The studywas conducted
in accordance with the principles of the Declaration of
Helsinki. The Ethics Committees of the 3 participating
centers independently approved the protocol, and all
participants gave written informed consent.
Treatment protocol
All patients received aspirin (75-100mg orally indefinitely)
and clopidogrel (75 mg/d) according to the randomization
scheme as follows: for either 6 months in the short DAPT
armor 24months in theprolongedDAPTarm irrespective of
the previously implanted stent type or indication for PCI.
Follow-up
The randomized patients returned for study visits at
30 days and then every 6 months up to 2 years. During
follow-up visits, patients were examined and assessed for
adverse events and asked for the antiplatelet therapy
compliance, and 12-lead electrocardiogram recordings
were obtained.
Proton pump inhibitor use
The decision to start the treatment with a PPI as well as
the type of PPI to be used was left at the physician's
discretion and was not randomly assigned or mandated
by protocol. Proton pump inhibitor use was identified
both at study baseline and at each study follow-up visit,
along with other concomitant medication use. For the
present analysis, patients were defined as PPI users if on
treatment at 30-day follow-up visit, at the time point
when the randomization to short- versus long-term DAPT
was performed. We performed sensitivity analyses to
investigate the effect of PPI versus no PPI on clinical
outcomes after excluding patients who had changed their
initial status (no PPI or PPI) during the follow-up.
Study end points
The primary efficacy end point of the PRODIGY trial was
the composite of death, MI, or cerebrovascular accident
(CVA), whereas the key safety end point included Bleeding
Academic Research Consortium (BARC) type 2, 3, or 5
bleeding. The net effect on the combined ischemic and
bleeding complications was obtained by 2 net adverse
clinical event (NACE) end points that were generated by
Table I. Baseline characteristics in PPI-treated versus
non–PPI-treated patients
No PPI
(n = 1232)
PPI
(n = 738) P
Age (y) 68.1 (59.0-75.4) 71.2 (63.2-77.3) b.0001
Male sex 79.2% (976) 72.5% (535) .001
Bodymass index (kg/m2) 26.9 (24.7-29.4) 26.2 (24.2-29.3) .923
Diabetes 24.8% (305) 23.3% (172) .461
Insulin dependent 5.7% (70) 6.0% (44)
Hypertension 71.3% (879) 72.5% (535) .486
Hyperlipidemia 55.3% (681) 53.8% (397) .596
Current cigarette use 24.4% (301) 22.6% (167) .380
Creatinine clearance
(mL/min)
77.7 (58.3-99.2) 69.5 (53.3-91.0) b.0001
Prior MI 26.1% (321) 27.0% (199) .520
Prior PCI 18.6% (229) 16.1% (119) .180
LVEF 55.0 (45-60) 50.0 (43-60) .080
Clinical presentation
Stable angina pectoris 30.5% (376) 17.5% (129) b.0001
ACS 69.5% (856) 82.5% (609)
STEMI 30.2% (372) 37.4% (276) .001
NSTEMI 21.3% (262) 25.5% (188) .031
Unstable angina 18.0% (222) 19.6% (145) .369
Multivessel disease 70.5% (868) 69.2% (511) .569
No. of treated lesions 1 (1-2) 1 (1-2) .370
≥2 treated lesions 37.3% (459) 37.5% (277) .900
≥3 treated lesions 11.8% (145) 10.6% (78)
Multivessel intervention 26.5% (327) 27.0% (199) .837
At least 1 complex lesion
(type B2 or C)⁎
67.0% (825) 65.2% (481) .416
Total ACC/AHA score† 3 (2-5) 3 (2-4) .600
CRUSADE score 24 (16-34) 27 (18-38) b.0001
Aspirin 100% (1232) 100% (738) N.999
Clopidogrel 98.8% (1230) 99.9% (737) .882
Statin 90.3% (1093) 90.9% (671) .627
Abbreviations: LVEF, Left ventricular ejection fraction; STEMI, ST-segment elevation
myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction;
ACC, American College of Cardiology; AHA, American Heart Association.
⁎According to the American College of Cardiology/American Heart Association
coronary lesion classification.
† Type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses,
3 points; and type C stenoses, 4 points.
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combining the primary efficacy end point of death, MI, or
CVAwith either the primary safety endpoint of BARC type2,
3, or 5 bleeding or with BARC type 3 or 5 events. Other end
points included each component of the primary efficacy end
point, cardiovascular death, stent thrombosis (ST) defined
based on the Academic Research Consortium criteria, and
BARC type 3 or 5 bleeding. Other safety end points included
bleeding events adjudicated according to the Thrombolysis
in Myocardial Infarction (TIMI) and Global Use of Strategies
to Open Occluded Coronary Arteries scales. All study end
point definitions were previously reported.
All end points were confirmed based on documentation
collected at each hospital and were centrally adjudicated
by the clinical events committee, whose members were
unaware of the patients' treatment-group assignments. The
time frame of interest for the primary end point was from
30 days (ie, after the primary endpoint randomization)
to 24 months.
Statistical analysis
Categorical variables were expressed as frequency
(percentage),whereas continuous variableswere expressed
as median (interquartile range). Continuous variables were
compared between randomized groups using theWilcoxon
rank sum test, whereas for binary variables the χ2 test
was used.
Hazard ratios (HRs) with 95% CIs were calculated for no
PPI versus PPI treated patients (ie, values N1 indicated
increased hazard in the PPI group) with a proportional
hazards model. Cox regression was used for multivariate
analysis. Clinical and angiographic characteristics that were
imbalanced at a nominal 5% significance level between the
2 groups treated or not treated with PPI were identified and
included the final adjusted model; these included sex, age,
creatinine clearance, clinical presentation, and CRUSADE
score. As sensitivity analyses, adjusted outcomes were also
evaluated after excluding patients who had modified their
PPI status (assumption of PPI in thosewith no PPI therapy at
30 days or interruption of PPI in those with PPI therapy at
30 days) during follow-up. Further sensitivity analyses
included the assessment of adjusted outcomes with
landmark analysis at 6 to 24 months and the analysis
restricted to those patients treated with lansoprazole as PPI
type (exclusion of other PPI types).
Table II. Baseline characteristics in PPI versus no PPI treated patients stratified for the randomly allocated DAPT duration
24-m clopidogrel 6-m clopidogrel
No PPI (n = 612) PPI (n = 375) P No PPI (n = 620) PPI (n = 363) P
Age (y) 67.9 (58.9-74.5) 71.8 (63.8-77.7) b.0001 68.1 (59.2-76.6) 70.1 (61.7-76.9) .04
Male sex 80.6% (493) 72.3% (271) .003 77.9% (483) 72.7% (264) .070
Body mass index (kg/m2) 27.0 (24.9-29.4) 26.0 (23.9-29.3) .450 26.8 (24.2-29.2) 26.4 (24.2-29.3) .200
Diabetes 24.7% (151) 24.8% (93) .900 24.9% (154) 21.8% (79) .290
Insulin dependent 6.2% (38) 5.6% (21) 5.2% (32) 6.3% (23)
Hypertension 71.4% (437) 75.7% (284) .140 71.3% (442) 69.1% (251) .410
Hyperlipidemia 56.5% (346) 55.2% (207) .680 54.0% (335) 52.3% (190) .640
Current cigarette use 23.9% (146) 20.3% (176) .200 25.3% (156) 25.1% (91) .450
Creatinine clearance (mL/min) 77.7 (58.1-102.7) 68.9 (53.0-91.9) .001 77.8 (58.4-96.5) 70.7 (53.8-90.6) .002
Prior MI 28.3% (173) 25.9% (97) .410 24.8% (154) 28.1% (102) .300
Prior PCI 20.9% (128) 16.3% (61) .070 17.7% (110) 16.5% (60) .490
LVEF 54.0 (43-60) 55.0 (45-60) .520 55.0 (45-60) 50.0 (40-60) .002
Clinical presentation
Stable angina pectoris 31.2% (191) 17.1% (64) b.0001 29.8% (185) 17.9% (65) b.0001
ACS 68.8% (421) 82.9% (311) 70.2% (435) 82.1% (298)
STEMI 31.0% (190) 34.9% (131) .210 29.4% (182) 39.9% (145) .001
NSTEMI 21.1% (129) 25.9% (97) .080 21.5% (133) 25.1% (91) .190
Unstable Angina 16.7% (102) 22.1% (83) .03 19.4% (120) 17.1% (62) .370
Multivessel disease 70.4% (431) 70.4% (264) .990 70.5% (437) 68.0% (247) .420
No. of treated lesions 1 (1-2) 1 (1-2) .320 1 (1-2) 1 (1-2) .780
≥2 treated lesions 37.4% (229) 36.3% (136) .720 37.1% (230) 38.8% (141) .590
≥3 treated lesions 11.4% (70) 10.1% (38) .520 12.1% (75) 11.0% (40) .610
Multivessel intervention 25.8% (158) 25.3% (95) .870 27.3% (169) 28.7% (104) .640
At least 1 complex lesion (type B2 or C)⁎ 67.3% (412) 61.3% (230) .060 66.6% (413) 69.1% (251) .410
Total ACC/AHA score† 3 (2-4) 3 (2-4) .600 3 (2-5) 3 (2-5) .840
CRUSADE score 24 (15-35) 28 (19-38) b.0001 24 (18-33) 27 (18-38) .004
Aspirin 100% (612) 100% (375) N.999 100% (620) 100% (365) N.999
Clopidogrel 99.8% (611) 99.7% (374) .726 99.8% (619) 100% (363) .444
Statin 89.2% (539) 90.4% (339) .560 91.3% (554) 91.5% (332) .920
⁎According to the ACC/AHA coronary lesion classification.
† Type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses, 3 points; and type C stenoses, 4 points.
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concomitant use of omeprazole and clopidogrel.12,13
The clinical impact of the combined administration has
been studied, but results have been discordant, with some
studies reporting an increased risk of cardiovascular
adverse events, whereas others did not confirm this
concern.5-7,11,14-23 Pooled analyses also provided inconclu-
sive results, owing to the risk ofmisinterpretation related to
poor-quality observational studies, thus supporting the
need for high-quality studies.14,15
Therefore, the purpose of the present subanalysis of
the PRODIGY randomized trial is to assess whether
medical therapy with PPI compared to that without PPI
may impact clinical outcomes in the setting of an all-comer
population undergoing PCI and with a randomly allocated
short (6months) or prolonged (24months) DAPT regimen,
consisting of clopidogrel and aspirin.
Methods
The design andmain findings of the PRODIGYhave been
previously reported.1,24 Briefly, all-comer PCI patients
receiving a balanced mixture of stents with varying
anti-intimal hyperplasia potency and belonging to both
first- and second-generation drug-eluting stent (DES) at
3 Italian sites were randomly allocated at 30 days to either
6 or 24 months of DAPT. Selection criteria were broad,
reflecting routine clinical practice. Randomization to
6- or 24-month DAPT was stratified by center, ongoing
ST-segment elevation myocardial infarction (MI), the
presence of diabetes mellitus, and need for intervening of
at least 1 in-stent restenotic lesion. The studywas conducted
in accordance with the principles of the Declaration of
Helsinki. The Ethics Committees of the 3 participating
centers independently approved the protocol, and all
participants gave written informed consent.
Treatment protocol
All patients received aspirin (75-100mg orally indefinitely)
and clopidogrel (75 mg/d) according to the randomization
scheme as follows: for either 6 months in the short DAPT
armor 24months in theprolongedDAPTarm irrespective of
the previously implanted stent type or indication for PCI.
Follow-up
The randomized patients returned for study visits at
30 days and then every 6 months up to 2 years. During
follow-up visits, patients were examined and assessed for
adverse events and asked for the antiplatelet therapy
compliance, and 12-lead electrocardiogram recordings
were obtained.
Proton pump inhibitor use
The decision to start the treatment with a PPI as well as
the type of PPI to be used was left at the physician's
discretion and was not randomly assigned or mandated
by protocol. Proton pump inhibitor use was identified
both at study baseline and at each study follow-up visit,
along with other concomitant medication use. For the
present analysis, patients were defined as PPI users if on
treatment at 30-day follow-up visit, at the time point
when the randomization to short- versus long-term DAPT
was performed. We performed sensitivity analyses to
investigate the effect of PPI versus no PPI on clinical
outcomes after excluding patients who had changed their
initial status (no PPI or PPI) during the follow-up.
Study end points
The primary efficacy end point of the PRODIGY trial was
the composite of death, MI, or cerebrovascular accident
(CVA), whereas the key safety end point included Bleeding
Academic Research Consortium (BARC) type 2, 3, or 5
bleeding. The net effect on the combined ischemic and
bleeding complications was obtained by 2 net adverse
clinical event (NACE) end points that were generated by
Table I. Baseline characteristics in PPI-treated versus
non–PPI-treated patients
No PPI
(n = 1232)
PPI
(n = 738) P
Age (y) 68.1 (59.0-75.4) 71.2 (63.2-77.3) b.0001
Male sex 79.2% (976) 72.5% (535) .001
Bodymass index (kg/m2) 26.9 (24.7-29.4) 26.2 (24.2-29.3) .923
Diabetes 24.8% (305) 23.3% (172) .461
Insulin dependent 5.7% (70) 6.0% (44)
Hypertension 71.3% (879) 72.5% (535) .486
Hyperlipidemia 55.3% (681) 53.8% (397) .596
Current cigarette use 24.4% (301) 22.6% (167) .380
Creatinine clearance
(mL/min)
77.7 (58.3-99.2) 69.5 (53.3-91.0) b.0001
Prior MI 26.1% (321) 27.0% (199) .520
Prior PCI 18.6% (229) 16.1% (119) .180
LVEF 55.0 (45-60) 50.0 (43-60) .080
Clinical presentation
Stable angina pectoris 30.5% (376) 17.5% (129) b.0001
ACS 69.5% (856) 82.5% (609)
STEMI 30.2% (372) 37.4% (276) .001
NSTEMI 21.3% (262) 25.5% (188) .031
Unstable angina 18.0% (222) 19.6% (145) .369
Multivessel disease 70.5% (868) 69.2% (511) .569
No. of treated lesions 1 (1-2) 1 (1-2) .370
≥2 treated lesions 37.3% (459) 37.5% (277) .900
≥3 treated lesions 11.8% (145) 10.6% (78)
Multivessel intervention 26.5% (327) 27.0% (199) .837
At least 1 complex lesion
(type B2 or C)⁎
67.0% (825) 65.2% (481) .416
Total ACC/AHA score† 3 (2-5) 3 (2-4) .600
CRUSADE score 24 (16-34) 27 (18-38) b.0001
Aspirin 100% (1232) 100% (738) N.999
Clopidogrel 98.8% (1230) 99.9% (737) .882
Statin 90.3% (1093) 90.9% (671) .627
Abbreviations: LVEF, Left ventricular ejection fraction; STEMI, ST-segment elevation
myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction;
ACC, American College of Cardiology; AHA, American Heart Association.
⁎According to the American College of Cardiology/American Heart Association
coronary lesion classification.
† Type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses,
3 points; and type C stenoses, 4 points.
96 Gargiulo et al
American Heart Journal
April 2016
Chapter 5.9
combining the primary efficacy end point of death, MI, or
CVAwith either the primary safety endpoint of BARC type2,
3, or 5 bleeding or with BARC type 3 or 5 events. Other end
points included each component of the primary efficacy end
point, cardiovascular death, stent thrombosis (ST) defined
based on the Academic Research Consortium criteria, and
BARC type 3 or 5 bleeding. Other safety end points included
bleeding events adjudicated according to the Thrombolysis
in Myocardial Infarction (TIMI) and Global Use of Strategies
to Open Occluded Coronary Arteries scales. All study end
point definitions were previously reported.
All end points were confirmed based on documentation
collected at each hospital and were centrally adjudicated
by the clinical events committee, whose members were
unaware of the patients' treatment-group assignments. The
time frame of interest for the primary end point was from
30 days (ie, after the primary endpoint randomization)
to 24 months.
Statistical analysis
Categorical variables were expressed as frequency
(percentage),whereas continuous variableswere expressed
as median (interquartile range). Continuous variables were
compared between randomized groups using theWilcoxon
rank sum test, whereas for binary variables the χ2 test
was used.
Hazard ratios (HRs) with 95% CIs were calculated for no
PPI versus PPI treated patients (ie, values N1 indicated
increased hazard in the PPI group) with a proportional
hazards model. Cox regression was used for multivariate
analysis. Clinical and angiographic characteristics that were
imbalanced at a nominal 5% significance level between the
2 groups treated or not treated with PPI were identified and
included the final adjusted model; these included sex, age,
creatinine clearance, clinical presentation, and CRUSADE
score. As sensitivity analyses, adjusted outcomes were also
evaluated after excluding patients who had modified their
PPI status (assumption of PPI in thosewith no PPI therapy at
30 days or interruption of PPI in those with PPI therapy at
30 days) during follow-up. Further sensitivity analyses
included the assessment of adjusted outcomes with
landmark analysis at 6 to 24 months and the analysis
restricted to those patients treated with lansoprazole as PPI
type (exclusion of other PPI types).
Table II. Baseline characteristics in PPI versus no PPI treated patients stratified for the randomly allocated DAPT duration
24-m clopidogrel 6-m clopidogrel
No PPI (n = 612) PPI (n = 375) P No PPI (n = 620) PPI (n = 363) P
Age (y) 67.9 (58.9-74.5) 71.8 (63.8-77.7) b.0001 68.1 (59.2-76.6) 70.1 (61.7-76.9) .04
Male sex 80.6% (493) 72.3% (271) .003 77.9% (483) 72.7% (264) .070
Body mass index (kg/m2) 27.0 (24.9-29.4) 26.0 (23.9-29.3) .450 26.8 (24.2-29.2) 26.4 (24.2-29.3) .200
Diabetes 24.7% (151) 24.8% (93) .900 24.9% (154) 21.8% (79) .290
Insulin dependent 6.2% (38) 5.6% (21) 5.2% (32) 6.3% (23)
Hypertension 71.4% (437) 75.7% (284) .140 71.3% (442) 69.1% (251) .410
Hyperlipidemia 56.5% (346) 55.2% (207) .680 54.0% (335) 52.3% (190) .640
Current cigarette use 23.9% (146) 20.3% (176) .200 25.3% (156) 25.1% (91) .450
Creatinine clearance (mL/min) 77.7 (58.1-102.7) 68.9 (53.0-91.9) .001 77.8 (58.4-96.5) 70.7 (53.8-90.6) .002
Prior MI 28.3% (173) 25.9% (97) .410 24.8% (154) 28.1% (102) .300
Prior PCI 20.9% (128) 16.3% (61) .070 17.7% (110) 16.5% (60) .490
LVEF 54.0 (43-60) 55.0 (45-60) .520 55.0 (45-60) 50.0 (40-60) .002
Clinical presentation
Stable angina pectoris 31.2% (191) 17.1% (64) b.0001 29.8% (185) 17.9% (65) b.0001
ACS 68.8% (421) 82.9% (311) 70.2% (435) 82.1% (298)
STEMI 31.0% (190) 34.9% (131) .210 29.4% (182) 39.9% (145) .001
NSTEMI 21.1% (129) 25.9% (97) .080 21.5% (133) 25.1% (91) .190
Unstable Angina 16.7% (102) 22.1% (83) .03 19.4% (120) 17.1% (62) .370
Multivessel disease 70.4% (431) 70.4% (264) .990 70.5% (437) 68.0% (247) .420
No. of treated lesions 1 (1-2) 1 (1-2) .320 1 (1-2) 1 (1-2) .780
≥2 treated lesions 37.4% (229) 36.3% (136) .720 37.1% (230) 38.8% (141) .590
≥3 treated lesions 11.4% (70) 10.1% (38) .520 12.1% (75) 11.0% (40) .610
Multivessel intervention 25.8% (158) 25.3% (95) .870 27.3% (169) 28.7% (104) .640
At least 1 complex lesion (type B2 or C)⁎ 67.3% (412) 61.3% (230) .060 66.6% (413) 69.1% (251) .410
Total ACC/AHA score† 3 (2-4) 3 (2-4) .600 3 (2-5) 3 (2-5) .840
CRUSADE score 24 (15-35) 28 (19-38) b.0001 24 (18-33) 27 (18-38) .004
Aspirin 100% (612) 100% (375) N.999 100% (620) 100% (365) N.999
Clopidogrel 99.8% (611) 99.7% (374) .726 99.8% (619) 100% (363) .444
Statin 89.2% (539) 90.4% (339) .560 91.3% (554) 91.5% (332) .920
⁎According to the ACC/AHA coronary lesion classification.
† Type A stenoses were coded 1 point; type B1 stenoses, 2 points; type B2 stenoses, 3 points; and type C stenoses, 4 points.
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Interaction testing was performed to determine whether
the effect of DAPT duration was consistent irrespective of
PPI treatment on the primary and secondary end points of
the study. This was performedwith likelihood ratio tests of
the null hypothesis that the interaction coefficient was
zero. A 2-sided P value of b.05 was considered significant.
All analyses were based on the intention-to-treat principle
and were performed with SPSS, version 21.0 (SPSS, Inc,
Chicago, IL).
For the present analysis, no extramural fundingwas used
to support this work. The authors are solely responsible for
the design and conduct of this study, all study analyses, and
drafting and editing of the manuscript.
Results
Among 1,970 patients randomized to 6- versus 24-month
DAPT at 30 days from the PCI, 738 patients (37.5%) were
receiving a PPI. Most of them were treated with
lansoprazole (671 patients, 90.9%), whereas the others
received pantoprazole (56 patients, 7.6%) and few patients
received other PPI types (omeprazole, esomeprazole, and
rabeprazole, 1.5%).
Baseline characteristics of population with PPI and
without PPI are summarized in Table I, whereas Table II
describes their characteristics in the setting of the 2
randomized arms of DAPT regimens (24 vs 6 months).
Compared with patients who did not receive PPI, those
receiving PPI were older, were more likely female, had a
lower creatinine clearance, presented more frequently
with acute coronary syndrome (ACS), and had a higher
CRUSADE bleeding score (Tables I and II). The primary
efficacy end point (composite of all-cause death, MI, and
CVA) was similar between patients with PPI and without
PPI use (9.2% vs 11.5%, adjusted HR 1.051, 95% CI
0.788-1.400, P = .736) (Figure 1). Results were consistent
across other secondary end points as reported in Table III.
Safety end points of bleeding did not differ between the
2 groups (BARC type 2, 3, or 5: adjusted HR 0.996, 95% CI
0.672-1.474,P = .980; BARC type 3 or 5: adjustedHR 1.478,
95% CI 0.856-2.553, P = .160) (Figure 1 and Table III).
Overall, major bleeding evaluatedwith different definitions
was more frequent in PPI users compared with those
without PPI (BARC 3 or 5: 3.7% vs 2.1%, TIMImajor 1.5% vs
0.9%, GUSTO moderate or severe 3.7% vs 1.9%); however,
after adjustment for confounding factors, none of them
remained significant (Table III). The composite of efficacy
and safety end points in the NACEwas also similar in no PPI
and PPI patients (12.9% vs 14.9%, adjusted HR 0.99, 95% CI
0.772-1.268, P = .93) (Figure 1 and Table III).
Finally, there was no signal for heterogeneity between
PPI use and explored clinical end points with respect to
randomized DAPT duration (Figure 2, Supplementary
Figure 1, Table IV, and Supplementary Tables I-III).
At sensitivity analyses, PPI therapy during follow-up
was taken into account (1 month: 738 PPI patients 37%,
6 months: 685 PPI patients 35%, 12 months: 690 PPI
patients 35%, 18months: 709 PPI patients 36%, 24months:
734 PPI patients 37%). A specific analysis of clinical
outcomes was also performed in patients who remained
consistently on a PPI throughout the follow-up period
and excluding those who had started or interrupted PPI
Figure 1
C 
P = .042 
P = .566 
P = .043 
P = .161 
A 
P = .094 
P = .736 
B 
Survival free from ischemic and bleeding events according to PPI
treatment. Cox proportional model plot for the primary end point of
death for all causes, MI, and CVA (A), bleeding defined as BARC
class 3 or 5 (B), and NACEs (C) in patients treated or not treated with
PPI. Dashed lines represent the unadjusted risk model. Solid lines
represent the adjusted risk model.
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therapy. Results remained robust showing the absence
of significant differences for ischemic and bleeding
events (Supplementary Table IV). This was further
confirmed by landmark analyses (Supplementary Table V)
and by restriction of analysis to lansoprazole as PPI
(Supplementary Table VI).
Discussion
The present post hoc analysis from the PRODIGY
randomized trial investigated the impact of concomitant
PPI use on clinical outcomes in all-comer patients
undergoing PCI and receiving DAPT with clopidogrel as
thienopyridine component.
Although, at univariate analysis, PPI use was associated
with an increased risk of ischemic and bleeding events, after
multivariate adjustment, PPI therapy was no longer related
to different rates of ischemic events, bleeding, or NACE at
2 years irrespective of the short or prolonged regimen of
DAPT. The findings of our study are consistent with the
results of the COGENT trial, showing thus no association of
PPI use with increased risk of ischemic events.
Several studies assessing the inhibition of platelet
aggregation suggested that PPIs may significantly reduce
the antiplatelet effect of clopidogrel when the 2 drugs are
coadministered.8-11 In particular, some PPIs (omeprazole
and esomeprazole) highly inhibit CYP2C19 isoenzyme,
whereas other PPIs are weak inhibitors (lansoprazole) or
do not inhibit this isoenzyme (pantoprazole). However,
the findings from pharmacodynamic studies may not
necessarily translate into differences in clinical outcomes,
and the design and quality of studies might be the major
determinant of such contrasting evidence.14,15 Indeed,
most studies supporting an increased risk of cardiovas-
cular ischemic events when using any type of PPI in
patients on clopidogrel are observational studies. Con-
versely, randomized trials and propensity score–matched
studies did not support such concerns. Nonetheless, new
evidence from a recent US analysis of N60,000 patients
with gastroesophageal reflux disease exposed to PPIs
raised new questions by reporting a 1.2-fold increased
risk of MI and a 2-fold increased risk of cardiovascular
mortality, irrespective of clopidogrel use.20
Protonpump inhibitorusewas associatedwith an increased
risk of Major Adverse Cardiovascular Events and MI but not
death and target vessel revascularization in the subgroup
analysis of the BASKET trial.22 Similarly, the CAPRIE trial
showed a higher rate of ischemic events among patients
treated with PPIs and clopidogrel, whereas the most recent
subanalysis from the ADAPT-DES trial showed increased rate
of Major Adverse Cardiovascular Events due to death and
target vessel revascularization rather than MI or ST.17,23
In contrast, the dedicated COGENT trial did not support
these findings.16 This trial randomly assigned patients with
an indication for DAPT to receive clopidogrel in combina-
tion with either omeprazole or placebo, in addition to
Table III. Clinical outcomes in PPI-treated versus non–PPI-treated patients
No PPI (n = 1232) PPI (n = 738) UnadjustedHR (95%CI) P Adjusted HR (95% CI) P
Primary efficacy end point
Death for any cause, MI, or CVA 113 (9.2) 85 (11.5) 1.272 (0.960-1.685) .094 1.051 (0.788-1.400) .736
Secondary efficacy end points
Death for any cause or MI 107 (8.7) 75 (10.2) 1.178 (0.877-1.582) .278 0.957 (0.708-1.293) .773
Death for any cause 77 (6.2) 53 (7.2) 1.150 (0.811-1.632) .433 0.918 (0.642-1.311) .636
Death for cardiovascular cause 44 (3.6) 29 (3.9) 1.101 (0.689-1.759) .688 0.865 (0.534-1.400) .554
MI 48 (3.9) 32 (4.3) 1.115 (0.713-1.744) .633 0.941 (0.597-1.485) .790
Definite or probable ST 19 (1.5) 9 (1.2) 0.780 (0.353-1.723) .539 0.682 (0.306-1.523) .350
Definite, probable, or possible ST 47 (3.8) 37 (5.0) 1.320 (0.858-2.030) .207 1.028 (0.662-1.597) .900
Safety end points
BARC classification
Key safety end point (type 2, 3, or 5) 64 (5.2) 43 (5.8) 1.127 (0.766-1.659) .545 0.996 (0.672-1.474) .980
Type 3 or 5 26 (2.1) 27 (3.7) 1.746 (1.019-2.992) .043 1.478 (0.856-2.553) .161
TIMI classification
Minor 10 (0.8) 10 (1.4) 1.680 (0.699-4.036) .246 1.434 (0.589-3.492) .428
Major 11 (0.9) 11 (1.5) 1.679 (0.728-3.873) .224 1.465 (0.627-3.421) .378
Minor or major 21 (1.7) 21 (2.8) 1.684 (0.920-3.084) .091 1.453 (0.786-2.687) .234
GUSTO classification
Moderate 13 (1.1) 14 (1.9) 1.803 (0.848-3.836) .126 1.449 (0.676-3.110) .341
Severe 12 (1.0) 13 (1.8) 1.820 (0.830-3.988) .135 1.626 (0.732-3.613) .232
Moderate or severe 24 (1.9) 27 (3.7) 1.893 (1.092-3.281) .023 1.582 (0.905-2.763) .107
NACE
Death for any cause;MI; CVA; or BARC 2, 3, or 5 bleeding 159 (12.9) 110 (14.9) 1.172 (0.919-1.494) .202 0.989 (0.772-1.268) .933
Death for any cause, MI, CVA, or BARC 3 or 5 bleeding 125 (10.1) 97 (13.1) 1.317 (1.010-1.717) .042 1.083 (0.826-1.419) .566
Abbreviations: GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries.
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Interaction testing was performed to determine whether
the effect of DAPT duration was consistent irrespective of
PPI treatment on the primary and secondary end points of
the study. This was performedwith likelihood ratio tests of
the null hypothesis that the interaction coefficient was
zero. A 2-sided P value of b.05 was considered significant.
All analyses were based on the intention-to-treat principle
and were performed with SPSS, version 21.0 (SPSS, Inc,
Chicago, IL).
For the present analysis, no extramural fundingwas used
to support this work. The authors are solely responsible for
the design and conduct of this study, all study analyses, and
drafting and editing of the manuscript.
Results
Among 1,970 patients randomized to 6- versus 24-month
DAPT at 30 days from the PCI, 738 patients (37.5%) were
receiving a PPI. Most of them were treated with
lansoprazole (671 patients, 90.9%), whereas the others
received pantoprazole (56 patients, 7.6%) and few patients
received other PPI types (omeprazole, esomeprazole, and
rabeprazole, 1.5%).
Baseline characteristics of population with PPI and
without PPI are summarized in Table I, whereas Table II
describes their characteristics in the setting of the 2
randomized arms of DAPT regimens (24 vs 6 months).
Compared with patients who did not receive PPI, those
receiving PPI were older, were more likely female, had a
lower creatinine clearance, presented more frequently
with acute coronary syndrome (ACS), and had a higher
CRUSADE bleeding score (Tables I and II). The primary
efficacy end point (composite of all-cause death, MI, and
CVA) was similar between patients with PPI and without
PPI use (9.2% vs 11.5%, adjusted HR 1.051, 95% CI
0.788-1.400, P = .736) (Figure 1). Results were consistent
across other secondary end points as reported in Table III.
Safety end points of bleeding did not differ between the
2 groups (BARC type 2, 3, or 5: adjusted HR 0.996, 95% CI
0.672-1.474,P = .980; BARC type 3 or 5: adjustedHR 1.478,
95% CI 0.856-2.553, P = .160) (Figure 1 and Table III).
Overall, major bleeding evaluatedwith different definitions
was more frequent in PPI users compared with those
without PPI (BARC 3 or 5: 3.7% vs 2.1%, TIMImajor 1.5% vs
0.9%, GUSTO moderate or severe 3.7% vs 1.9%); however,
after adjustment for confounding factors, none of them
remained significant (Table III). The composite of efficacy
and safety end points in the NACEwas also similar in no PPI
and PPI patients (12.9% vs 14.9%, adjusted HR 0.99, 95% CI
0.772-1.268, P = .93) (Figure 1 and Table III).
Finally, there was no signal for heterogeneity between
PPI use and explored clinical end points with respect to
randomized DAPT duration (Figure 2, Supplementary
Figure 1, Table IV, and Supplementary Tables I-III).
At sensitivity analyses, PPI therapy during follow-up
was taken into account (1 month: 738 PPI patients 37%,
6 months: 685 PPI patients 35%, 12 months: 690 PPI
patients 35%, 18months: 709 PPI patients 36%, 24months:
734 PPI patients 37%). A specific analysis of clinical
outcomes was also performed in patients who remained
consistently on a PPI throughout the follow-up period
and excluding those who had started or interrupted PPI
Figure 1
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P = .161 
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P = .094 
P = .736 
B 
Survival free from ischemic and bleeding events according to PPI
treatment. Cox proportional model plot for the primary end point of
death for all causes, MI, and CVA (A), bleeding defined as BARC
class 3 or 5 (B), and NACEs (C) in patients treated or not treated with
PPI. Dashed lines represent the unadjusted risk model. Solid lines
represent the adjusted risk model.
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therapy. Results remained robust showing the absence
of significant differences for ischemic and bleeding
events (Supplementary Table IV). This was further
confirmed by landmark analyses (Supplementary Table V)
and by restriction of analysis to lansoprazole as PPI
(Supplementary Table VI).
Discussion
The present post hoc analysis from the PRODIGY
randomized trial investigated the impact of concomitant
PPI use on clinical outcomes in all-comer patients
undergoing PCI and receiving DAPT with clopidogrel as
thienopyridine component.
Although, at univariate analysis, PPI use was associated
with an increased risk of ischemic and bleeding events, after
multivariate adjustment, PPI therapy was no longer related
to different rates of ischemic events, bleeding, or NACE at
2 years irrespective of the short or prolonged regimen of
DAPT. The findings of our study are consistent with the
results of the COGENT trial, showing thus no association of
PPI use with increased risk of ischemic events.
Several studies assessing the inhibition of platelet
aggregation suggested that PPIs may significantly reduce
the antiplatelet effect of clopidogrel when the 2 drugs are
coadministered.8-11 In particular, some PPIs (omeprazole
and esomeprazole) highly inhibit CYP2C19 isoenzyme,
whereas other PPIs are weak inhibitors (lansoprazole) or
do not inhibit this isoenzyme (pantoprazole). However,
the findings from pharmacodynamic studies may not
necessarily translate into differences in clinical outcomes,
and the design and quality of studies might be the major
determinant of such contrasting evidence.14,15 Indeed,
most studies supporting an increased risk of cardiovas-
cular ischemic events when using any type of PPI in
patients on clopidogrel are observational studies. Con-
versely, randomized trials and propensity score–matched
studies did not support such concerns. Nonetheless, new
evidence from a recent US analysis of N60,000 patients
with gastroesophageal reflux disease exposed to PPIs
raised new questions by reporting a 1.2-fold increased
risk of MI and a 2-fold increased risk of cardiovascular
mortality, irrespective of clopidogrel use.20
Protonpump inhibitorusewas associatedwith an increased
risk of Major Adverse Cardiovascular Events and MI but not
death and target vessel revascularization in the subgroup
analysis of the BASKET trial.22 Similarly, the CAPRIE trial
showed a higher rate of ischemic events among patients
treated with PPIs and clopidogrel, whereas the most recent
subanalysis from the ADAPT-DES trial showed increased rate
of Major Adverse Cardiovascular Events due to death and
target vessel revascularization rather than MI or ST.17,23
In contrast, the dedicated COGENT trial did not support
these findings.16 This trial randomly assigned patients with
an indication for DAPT to receive clopidogrel in combina-
tion with either omeprazole or placebo, in addition to
Table III. Clinical outcomes in PPI-treated versus non–PPI-treated patients
No PPI (n = 1232) PPI (n = 738) UnadjustedHR (95%CI) P Adjusted HR (95% CI) P
Primary efficacy end point
Death for any cause, MI, or CVA 113 (9.2) 85 (11.5) 1.272 (0.960-1.685) .094 1.051 (0.788-1.400) .736
Secondary efficacy end points
Death for any cause or MI 107 (8.7) 75 (10.2) 1.178 (0.877-1.582) .278 0.957 (0.708-1.293) .773
Death for any cause 77 (6.2) 53 (7.2) 1.150 (0.811-1.632) .433 0.918 (0.642-1.311) .636
Death for cardiovascular cause 44 (3.6) 29 (3.9) 1.101 (0.689-1.759) .688 0.865 (0.534-1.400) .554
MI 48 (3.9) 32 (4.3) 1.115 (0.713-1.744) .633 0.941 (0.597-1.485) .790
Definite or probable ST 19 (1.5) 9 (1.2) 0.780 (0.353-1.723) .539 0.682 (0.306-1.523) .350
Definite, probable, or possible ST 47 (3.8) 37 (5.0) 1.320 (0.858-2.030) .207 1.028 (0.662-1.597) .900
Safety end points
BARC classification
Key safety end point (type 2, 3, or 5) 64 (5.2) 43 (5.8) 1.127 (0.766-1.659) .545 0.996 (0.672-1.474) .980
Type 3 or 5 26 (2.1) 27 (3.7) 1.746 (1.019-2.992) .043 1.478 (0.856-2.553) .161
TIMI classification
Minor 10 (0.8) 10 (1.4) 1.680 (0.699-4.036) .246 1.434 (0.589-3.492) .428
Major 11 (0.9) 11 (1.5) 1.679 (0.728-3.873) .224 1.465 (0.627-3.421) .378
Minor or major 21 (1.7) 21 (2.8) 1.684 (0.920-3.084) .091 1.453 (0.786-2.687) .234
GUSTO classification
Moderate 13 (1.1) 14 (1.9) 1.803 (0.848-3.836) .126 1.449 (0.676-3.110) .341
Severe 12 (1.0) 13 (1.8) 1.820 (0.830-3.988) .135 1.626 (0.732-3.613) .232
Moderate or severe 24 (1.9) 27 (3.7) 1.893 (1.092-3.281) .023 1.582 (0.905-2.763) .107
NACE
Death for any cause;MI; CVA; or BARC 2, 3, or 5 bleeding 159 (12.9) 110 (14.9) 1.172 (0.919-1.494) .202 0.989 (0.772-1.268) .933
Death for any cause, MI, CVA, or BARC 3 or 5 bleeding 125 (10.1) 97 (13.1) 1.317 (1.010-1.717) .042 1.083 (0.826-1.419) .566
Abbreviations: GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries.
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aspirin. The composite of cardiovascular death, MI,
revascularization, or stroke did not differ, but GI events
were less frequent in the omeprazole group.16
In the subgroup analyses of the PRINCIPLE and
TRITON-TIMI 38 trials, a significant impact of PPI
therapy on reducing the effect of clopidogrel on platelet
aggregation was further substantiated. However, the
pharmacodynamic changes did not translate into adverse
clinical outcomes.11
Our study is in linewith and importantly adds to previous
evidence indicating that the use of PPIs, largely consisting
of lansoprazole, in conjunction with clopidogrel is safe. In
addition, this observation held true in the 2 randomized
groups of short- versus long-term DAPT, indicating that PPI
therapy does not increase ischemic events irrespective
of whether clopidogrel is administered for short periods
(ie, 6 months) or prolonged times (ie, 24 months). The
incidence of ST was low and did not differ in patients with
or without concomitant PPI use.
In the subgroup analysis of the PLATO trial on PPI use,
the association between PPI use and clinical adverse events
in patients treated with clopidogrel was likely due to
confounding (observed also in those receiving ticagrelor
and in those receiving non-PPI GI drugs), with PPI use
emerging as amarker for, rather than a cause of higher rates
of cardiovascular adverse events.18 Interestingly, the role
of confounding factors appeared to also be relevant in the
present study as the PPI population showed an increased
risk of both ischemic and bleeding events. However, after
multivariate adjustment, differences in outcomes were no
longer present.
Proton pump inhibitors are often prescribed in patients
with DAPT to reduce bleeding complications or due to
specific clinical indication (ie, gastric disease). Generally,
the PPI use is left to the discretion of clinicians, and often, a
selection of patients is performed with those receiving PPI
being at increased risk for ischemic and bleeding events.
This explains at least in part the results of observational
Figure 2
No PPI 
PPI 
Adj. Log HR (95% CI) Adj. HR (95% CI)   p value P int. 
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Forest plots for clinical outcomes in short versus prolonged DAPT duration according to PPI treatment. Proton pump inhibitor and no-PPI subgroups are
shown, with HRs and 95% CIs, for the primary end point of death for any cause, MI, or CVA; death for any cause; cardiovascular death; MI; definite or
probable stent thrombosis; BARC type 3 or 5 bleeding; and NACEs among patients randomly assigned to either the 6- or 24-month DAPT.
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studies on PPI use and increased ischemic risk. In the
present study, PPIs were prescribed to patients with a
greater bleeding risk, as indicated by a more advanced age,
more female patients, and ACS, a worse renal function and
a higher CRUSADE score. However, after adjustment for
these confounding factors, the differences between PPI
and no-PPI populations were not clinically relevant for
most clinical outcomes. Although the COGENT trial
excluded patients with prior indication for PPI use or
H2-receptor antagonists and patients at higher risk for GI
bleeding, the results of the present study can be extended
to an all-comer population of patients undergoing PCI and
DAPT therapy.
Limitations
This is a post hoc not randomized and not prespecified
analysis of the PRODIGY trial, and the prescription of a
PPI was left to the physician's discretion.
Rates of overall but not specifically GI bleeding were
evaluated and available for this analysis, so potential benefits
of PPI on reducingGI bleeding events could not be analyzed.
Although multivariate adjustment was performed, it
cannot be excluded that unknown/unmeasured factors
may have impacted findings.
Data on PPI dosage were not prospectively collected,
so it was not possible to make specific analysis on
dose-dependent effects.
“In the PRODIGY, lansoprazole was by far the most
frequently used PPI. Hence, it remains unclear whether
our findings may be extrapolated to other PPIs such as
omeprazole or esmoprazole.”
Genetic analysis to test the predisposition for reduced
clopidogrel responsiveness was not available. Therefore,
it cannot be excluded that PPIs may have a different
impact on outcomes in this subgroup of patients.
Conclusion
Overall, PPI use was not associated with an increased
risk of cardiovascular events in all-comer patients
undergoing PCI and receiving DAPT. Our findings do
not support the need to avoid concomitant use of PPIs
and DAPT with aspirin plus clopidogrel, when
clinically indicated.
Appendix. Supplementary data
Supplementary data to this article can be found online
at http://dx.doi.org/10.1016/j.ahj.2016.01.015.
Table IV. Adjusted clinical outcomes in PPI-treated versus non–PPI-treated patients stratified for the randomly allocated DAPT duration
24-m clopidogrel 6-m clopidogrel
No PPI
(n = 612)
PPI
(n = 375)
Adjusted HR
(95% CI) P
No PPI
(n = 620)
PPI
(n = 363)
Adjusted HR
(95% CI) P Pint
Primary efficacy end point
Death for any cause, MI, or CVA 52 (8.5) 48 (12.8) 1.375 (0.916-2.064) .125 61 (9.8) 38 (10.2) 0.852 (0.562-1.291) .449 .19
Secondary efficacy end points
Death for any cause or MI 48 (7.8) 40 (10.7) 1.218 (0.789-1.881) .372 59 (9.5) 35 (9.6) 0.824 (0.538 -1.261) .372 .33
Death for any cause 37 (6.0) 28 (7.5) 1.070 (0.645-1.777) .792 40 (6.5) 25 (6.9) 0.865 (0.519-1.441) .578 .74
Death for cardiovascular cause 22 (3.6) 14 (3.7) 0.877 (0.437-1.757) .711 22 (3.5) 15 (4.1) 0.974 (0.494-1.923) .941 .80
MI 23 (3.8) 16 (4.3) 0.980 (0.505-1.904) .953 25 (4.0) 16 (4.4) 0.923 (0.490-1.739) .803 .99
Definite or probable ST 8 (1.3) 5 (1.3) 0.718 (0.231-2.225) .566 11 (1.8) 4 (1.1) 0.652 (0.204-2.085) .471 .63
Definite, probable, or possible ST 19 (3.1) 19 (5.1) 1.431 (0.743-2.755) .283 28 (4.5) 18 (5.0) 0.868 (0.473-1.593) .647 .34
Safety end points
BARC classification
Key safety end point (type 2, 3, or 5) 41 (6.7) 32 (8.5) 1.227 (0.762-1.977) .400 23 (3.7) 11 (3.0) 0.661 (0.321-1.362) .261 .34
Type 3 or 5 15 (2.5) 19 (5.1) 1.881 (0.937-3.777) .076 11 (1.8) 8 (2.2) 1.048 (0.418-2.627) .920 .44
TIMI classification
Minor 7 (1.1) 4 (1.1) 0.741 (0.212-2.592) .639 3 (0.5) 6 (1.7) 3.572 (0.861-14.827) .080 .15
Major 6 (1.0) 10 (2.7) 2.569 (0.905-7.290) .076 5 (0.8) 1 (0.3) 0.264 (0.031-2.265) .225 .11
Minor or major 13 (2.1) 14 (3.7) 1.559 (0.717-3.391) .262 8 (1.3) 7 (1.9) 1.388 (0.479-3.739) .579 .91
GUSTO classification
Moderate 8 (1.3) 9 (2.4) 1.487 (0.562-3.934) .424 5 (0.8) 5 (1.4) 1.488 (0.424-5.222) .535 .96
Severe 6 (1.0) 10 (2.7) 2.569 (0.905-7.288) .076 6 (1.0) 3 (0.8) 0.705 (0.175-2.843) .623 .26
Moderate or severe 13 (2.1) 19 (5.1) 2.079 (1.007-4.292) .048 11 (1.8) 8 (2.2) 1.050 (0.419-2.633) .917 .31
NACE
Death for any cause; MI; CVA;
or BARC 2, 3, or 5 bleeding
87 (14.2) 65 (17.3) 1.140 (0.818-1.589) .440 72 (11.6) 45 (12.4) 0.875 (0.599-1.277) .489 .60
Death for any cause, MI, CVA,
or BARC 3 or 5 bleeding
61 (10.0) 55 (14.7) 1.329 (0.911-1.939) .141 64 (10.3) 42 (11.6) 0.928 (0.625-1.379) .712 .34
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aspirin. The composite of cardiovascular death, MI,
revascularization, or stroke did not differ, but GI events
were less frequent in the omeprazole group.16
In the subgroup analyses of the PRINCIPLE and
TRITON-TIMI 38 trials, a significant impact of PPI
therapy on reducing the effect of clopidogrel on platelet
aggregation was further substantiated. However, the
pharmacodynamic changes did not translate into adverse
clinical outcomes.11
Our study is in linewith and importantly adds to previous
evidence indicating that the use of PPIs, largely consisting
of lansoprazole, in conjunction with clopidogrel is safe. In
addition, this observation held true in the 2 randomized
groups of short- versus long-term DAPT, indicating that PPI
therapy does not increase ischemic events irrespective
of whether clopidogrel is administered for short periods
(ie, 6 months) or prolonged times (ie, 24 months). The
incidence of ST was low and did not differ in patients with
or without concomitant PPI use.
In the subgroup analysis of the PLATO trial on PPI use,
the association between PPI use and clinical adverse events
in patients treated with clopidogrel was likely due to
confounding (observed also in those receiving ticagrelor
and in those receiving non-PPI GI drugs), with PPI use
emerging as amarker for, rather than a cause of higher rates
of cardiovascular adverse events.18 Interestingly, the role
of confounding factors appeared to also be relevant in the
present study as the PPI population showed an increased
risk of both ischemic and bleeding events. However, after
multivariate adjustment, differences in outcomes were no
longer present.
Proton pump inhibitors are often prescribed in patients
with DAPT to reduce bleeding complications or due to
specific clinical indication (ie, gastric disease). Generally,
the PPI use is left to the discretion of clinicians, and often, a
selection of patients is performed with those receiving PPI
being at increased risk for ischemic and bleeding events.
This explains at least in part the results of observational
Figure 2
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Forest plots for clinical outcomes in short versus prolonged DAPT duration according to PPI treatment. Proton pump inhibitor and no-PPI subgroups are
shown, with HRs and 95% CIs, for the primary end point of death for any cause, MI, or CVA; death for any cause; cardiovascular death; MI; definite or
probable stent thrombosis; BARC type 3 or 5 bleeding; and NACEs among patients randomly assigned to either the 6- or 24-month DAPT.
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studies on PPI use and increased ischemic risk. In the
present study, PPIs were prescribed to patients with a
greater bleeding risk, as indicated by a more advanced age,
more female patients, and ACS, a worse renal function and
a higher CRUSADE score. However, after adjustment for
these confounding factors, the differences between PPI
and no-PPI populations were not clinically relevant for
most clinical outcomes. Although the COGENT trial
excluded patients with prior indication for PPI use or
H2-receptor antagonists and patients at higher risk for GI
bleeding, the results of the present study can be extended
to an all-comer population of patients undergoing PCI and
DAPT therapy.
Limitations
This is a post hoc not randomized and not prespecified
analysis of the PRODIGY trial, and the prescription of a
PPI was left to the physician's discretion.
Rates of overall but not specifically GI bleeding were
evaluated and available for this analysis, so potential benefits
of PPI on reducingGI bleeding events could not be analyzed.
Although multivariate adjustment was performed, it
cannot be excluded that unknown/unmeasured factors
may have impacted findings.
Data on PPI dosage were not prospectively collected,
so it was not possible to make specific analysis on
dose-dependent effects.
“In the PRODIGY, lansoprazole was by far the most
frequently used PPI. Hence, it remains unclear whether
our findings may be extrapolated to other PPIs such as
omeprazole or esmoprazole.”
Genetic analysis to test the predisposition for reduced
clopidogrel responsiveness was not available. Therefore,
it cannot be excluded that PPIs may have a different
impact on outcomes in this subgroup of patients.
Conclusion
Overall, PPI use was not associated with an increased
risk of cardiovascular events in all-comer patients
undergoing PCI and receiving DAPT. Our findings do
not support the need to avoid concomitant use of PPIs
and DAPT with aspirin plus clopidogrel, when
clinically indicated.
Appendix. Supplementary data
Supplementary data to this article can be found online
at http://dx.doi.org/10.1016/j.ahj.2016.01.015.
Table IV. Adjusted clinical outcomes in PPI-treated versus non–PPI-treated patients stratified for the randomly allocated DAPT duration
24-m clopidogrel 6-m clopidogrel
No PPI
(n = 612)
PPI
(n = 375)
Adjusted HR
(95% CI) P
No PPI
(n = 620)
PPI
(n = 363)
Adjusted HR
(95% CI) P Pint
Primary efficacy end point
Death for any cause, MI, or CVA 52 (8.5) 48 (12.8) 1.375 (0.916-2.064) .125 61 (9.8) 38 (10.2) 0.852 (0.562-1.291) .449 .19
Secondary efficacy end points
Death for any cause or MI 48 (7.8) 40 (10.7) 1.218 (0.789-1.881) .372 59 (9.5) 35 (9.6) 0.824 (0.538 -1.261) .372 .33
Death for any cause 37 (6.0) 28 (7.5) 1.070 (0.645-1.777) .792 40 (6.5) 25 (6.9) 0.865 (0.519-1.441) .578 .74
Death for cardiovascular cause 22 (3.6) 14 (3.7) 0.877 (0.437-1.757) .711 22 (3.5) 15 (4.1) 0.974 (0.494-1.923) .941 .80
MI 23 (3.8) 16 (4.3) 0.980 (0.505-1.904) .953 25 (4.0) 16 (4.4) 0.923 (0.490-1.739) .803 .99
Definite or probable ST 8 (1.3) 5 (1.3) 0.718 (0.231-2.225) .566 11 (1.8) 4 (1.1) 0.652 (0.204-2.085) .471 .63
Definite, probable, or possible ST 19 (3.1) 19 (5.1) 1.431 (0.743-2.755) .283 28 (4.5) 18 (5.0) 0.868 (0.473-1.593) .647 .34
Safety end points
BARC classification
Key safety end point (type 2, 3, or 5) 41 (6.7) 32 (8.5) 1.227 (0.762-1.977) .400 23 (3.7) 11 (3.0) 0.661 (0.321-1.362) .261 .34
Type 3 or 5 15 (2.5) 19 (5.1) 1.881 (0.937-3.777) .076 11 (1.8) 8 (2.2) 1.048 (0.418-2.627) .920 .44
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Minor 7 (1.1) 4 (1.1) 0.741 (0.212-2.592) .639 3 (0.5) 6 (1.7) 3.572 (0.861-14.827) .080 .15
Major 6 (1.0) 10 (2.7) 2.569 (0.905-7.290) .076 5 (0.8) 1 (0.3) 0.264 (0.031-2.265) .225 .11
Minor or major 13 (2.1) 14 (3.7) 1.559 (0.717-3.391) .262 8 (1.3) 7 (1.9) 1.388 (0.479-3.739) .579 .91
GUSTO classification
Moderate 8 (1.3) 9 (2.4) 1.487 (0.562-3.934) .424 5 (0.8) 5 (1.4) 1.488 (0.424-5.222) .535 .96
Severe 6 (1.0) 10 (2.7) 2.569 (0.905-7.288) .076 6 (1.0) 3 (0.8) 0.705 (0.175-2.843) .623 .26
Moderate or severe 13 (2.1) 19 (5.1) 2.079 (1.007-4.292) .048 11 (1.8) 8 (2.2) 1.050 (0.419-2.633) .917 .31
NACE
Death for any cause; MI; CVA;
or BARC 2, 3, or 5 bleeding
87 (14.2) 65 (17.3) 1.140 (0.818-1.589) .440 72 (11.6) 45 (12.4) 0.875 (0.599-1.277) .489 .60
Death for any cause, MI, CVA,
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Background-—Multiple scores have been proposed to stratify bleeding risk, but their value to guide dual antiplatelet therapy
duration has never been appraised. We compared the performance of the CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines), ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy), and HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke,
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) scores in 1946 patients recruited in the
Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) and assessed
hemorrhagic and ischemic events in the 24- and 6-month dual antiplatelet therapy groups.
Methods and Results-—Bleeding score performance was assessed with a Cox regression model and C statistics. Discriminative
and reclassiﬁcation power was assessed with net reclassiﬁcation improvement and integrated discrimination improvement. The C
statistic was similar between the CRUSADE score (area under the curve 0.71) and ACUITY (area under the curve 0.68), and higher
than HASBLED (area under the curve 0.63). CRUSADE, but not ACUITY, improved reclassiﬁcation (net reclassiﬁcation index 0.39,
P=0.005) and discrimination (integrated discrimination improvement index 0.0083, P=0.021) of major bleeding compared with
HAS-BLED. Major bleeding and transfusions were higher in the 24- versus 6-month dual antiplatelet therapy groups in patients with
a CRUSADE score >40 (hazard ratio for bleeding 2.69, P=0.035; hazard ratio for transfusions 4.65, P=0.009) but not in those with
CRUSADE score ≤40 (hazard ratio for bleeding 1.50, P=0.25; hazard ratio for transfusions 1.37, P=0.44), with positive interaction
(Pint=0.05 and Pint=0.01, respectively). The number of patients with high CRUSADE scores needed to treat for harm for major
bleeding and transfusion were 17 and 15, respectively, with 24-month rather than 6-month dual antiplatelet therapy; corresponding
ﬁgures in the overall population were 67 and 71, respectively.
Conclusions-—Our analysis suggests that the CRUSADE score predicts major bleeding similarly to ACUITY and better than HAS
BLED in an all-comer population with percutaneous coronary intervention and potentially identiﬁes patients at higher risk of
hemorrhagic complications when treated with a long-term dual antiplatelet therapy regimen.
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B leeding is a common adverse event after percutaneouscoronary intervention and is associated with increased
morbidity and mortality.1–4 Bleeding predictors have been
described extensively; they are related mostly to the patient’s
clinical characteristics, the invasiveness of the procedure, and
the potency of the antithrombotic regimen. Antithrombotic
therapies after coronary intervention reduce ischemic events
but invariably increase bleeding risk, which in turn may
adversely affect short- and long-term outcomes.5,6 Interna-
tional guidelines recommend careful evaluation of both
ischemic and bleeding risk based on the patient’s clinical
characteristics7,8; however, evidence supporting the individ-
ualization of antithrombotic therapy is still limited. In partic-
ular, the potency and duration of dual antiplatelet therapy
(DAPT) after coronary stenting are currently based mainly on
the patient’s clinical presentation (ie, acute coronary syn-
drome or stable coronary artery disease) and the type of stent
used (ie, drug-eluting or bare metal stent), with evanescent
indications based on the patient’s bleeding risk.7–9 Many
bleeding risk scores have been validated for the prediction of
early and late bleeding events, and some have been tested on
large cohorts with acute coronary syndrome, demonstrating
reasonably good performance.10–12 Among them, the CRU-
SADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA [American College of Cardiology/
American Heart Association] Guidelines) score has been
validated in 17 857 patients with non–ST-segment elevation
myocardial infarction (MI), and its predictive capability was
consistent in terms of hemorrhagic risks in patients taking ≥2
antithrombotic medications.10 Our study sought to compare
the predictive performance of the CRUSADE, ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy), and
HAS-BLED (Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile INR [inter-
national normalized ratio], Elderly, Drugs/Alcohol Concomi-
tantly) risk scores with respect to major bleeding events in an
all-comer population treated with coronary stent. We also
intended to determine the incidence of major bleeding after
24-month rather than 6-month DAPT in the subgroups of
patients with high and low to intermediate bleeding risk.
Methods
The design and main study ﬁndings for the Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia Study (PRODIGY) were reported previously.5 In
brief, all patients receiving a balanced mixture of stents with
varying anti–intimal hyperplasia potency and including both
ﬁrst- and second-generation drug-eluting stents at 3 Italian
sites were randomly allocated at 30 days to either 6 or
24 months of DAPT. Selection criteria were broad, reﬂecting
routine clinical practice. Randomization to 6- or 24-month
DAPT was performed at 30 days and stratiﬁed by center,
ongoing ST-segment elevation MI, presence of diabetes
mellitus, and need for intervention on at least 1 in-stent
restenotic lesion. The study was conducted in accordance
with the principles of the Declaration of Helsinki. The ethics
committees of the 3 participating centers independently
approved the protocol, and all participants gave written
informed consent.
Treatment Protocol
All patients received aspirin (80–160 mg orally, indeﬁnitely)
and clopidogrel (75 mg/day) according to the following
randomization scheme: either 6 months in the short DAPT
group or 24 months in the prolonged DAPT arm, regardless of
the previously implanted stent type or indication for the
coronary procedure.
Follow-up
All randomized patients returned for study visits at 30 days
and then every 6 months for up to 2 years. During follow-up
visits, patients were examined and assessed for adverse
events and asked about antiplatelet therapy compliance; in
addition, 12-lead ECG recordings were obtained.
Study End Points
The primary objective of this analysis was to compare the
predictive performance of the CRUSADE, ACUITY, and HAS-
BLED bleeding risk scores with respect to major bleeding
events, adjudicated according to Bleeding Academic Research
Consortium (BARC) class 3 or 5, among patients recruited to
the PRODIGY trial. Further sensitivity analysis evaluated the
consistency of the results obtained with the BARC classiﬁca-
tion with other widely accepted bleeding deﬁnitions, including
the Thrombolysis in Myocardial Infarction (TIMI) and Global
Use of Strategies to Open Occluded Arteries (GUSTO) scales.
The CRUSADE, ACUITY, and HAS-BLED bleeding risk scores
were calculated, as reported previously,10–12 taking into
account the following exceptions: For the ACUITY score, given
the exclusive use of unfractionated heparin as an anticoag-
ulant in the PRODIGY trial, the “antithrombotic medication”
variable was set to zero; for the HAS-BLED score, given that
patients with an indication for long-term anticoagulation were
not included in the PRODIGY trial, the “labile INR” variable was
set to zero.
To assess the effect of high bleeding risk status in the 24-
and 6-month DAPT treatment arms, we selected the high-risk
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cutoff value of 40 for the CRUSADE score, as reported
previously.10 The incidence of major bleeding, red blood cell
transfusion, and major adverse cardiac events—a composite
of all-cause death, MI, and cerebrovascular accident—was
appraised in the subgroup of patients with high CRUSADE
scores (HCSs; >40) versus those with low to intermediate
scores (≤40) in the 2 DAPT duration arms. All study end point
deﬁnitions were reported previously,13 conﬁrmed on the basis
of documentation collected at each hospital, and centrally
adjudicated by the clinical events committee, the members of
which were unaware of the patients’ treatment-group
assignments. The time frame of interest for the primary end
point was from randomization (ie, 30 days after index
procedure) to 24 months.
Statistical Analysis
Categorical variables were expressed as frequency (percent-
age), whereas continuous variables were expressed as median
(interquartile range). Continuous variables were compared
between randomized groups using the Wilcoxon rank sum
test, whereas for binary variables, the v2 test was used.
Table 1. Baseline Characteristics
Characteristic Major Bleeding (n=53) No Major Bleeding (n=1893) P Value
Age, y 76.3 (71.3–81.3) 68.9 (59.8–76.1) <0.0001
Female sex 28.3% (15/53) 23.1% (438/1893) 0.38
Body mass index, kg/m2 25.4 (24.0–28.7) 26.6 (24.3–29.4) 0.30
Diabetes 34.0% (18/53) 24.0% (455/1893) 0.09
Insulin dependent 7.5% (4/53) 5.8% (110/1893)
Hypertension 77.4% (41/53) 71.7% (1358/1893) 0.37
Hyperlipidemia 52.8% (28/53) 54.9% (1039/1893) 0.76
Current cigarette use 13.2% (7/53) 24.3% (459/1893) 0.06
Creatinine clearance, mL/min 49.5 (36.3–65.5) 75.7 (57.0–96.5) <0.0001
Prior myocardial infarction 41.5% (22/53) 25.9% (491/1893) 0.01
Prior PCI 24.2% (13/53) 18.3% (343/1893) 0.23
Prior CABG 5.7% (3/53) 11.0% (208/1893) 0.21
LVEF 45.0 (35.75–55.0) 52.0 (45–60.0) 0.001
Clinical presentation
Stable angina pectoris 24.5% (13/53) 25.6% (485/1893) 0.85
Acute coronary syndrome 80.6% (40/53) 74.4% (1408/1893)
Multivessel disease 79.2% (42/53) 69.7% (1319/1893) 0.17
No. of treated lesions 1 (1–2) 1 (1–2) 0.30
≥2 treated lesions 35.8% (19/53) 37.6% (712/1893) 0.76
≥3 treated lesions 7.5% (4/53) 11.5% (218/1893)
Multivessel intervention 24.5% (13/53) 26.9% (509/1893) 0.70
At least 1 complex lesion (type B2 or C)* 66.0% (35/53) 66.0% (1250/1893) 0.99
Total ACC/AHA score† 3 (2–5) 3 (2–5) 0.48
Bleeding risk score
CRUSADE score 38 (24–43) 25 (18–35) <0.0001
ACUITY score 20 (14–28) 15 (9–20) <0.0001
HAS-BLED score 2 (1–2) 1 (1–2) <0.0001
ACC indicates American College of Cardiology; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; AHA, American Heart Association; CABG, coronary artery bypass
grafting; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED,
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; LVEF, left ventricular ejection fraction; PCI,
percutaneous coronary intervention.
*According to the ACC/AHA coronary lesion classiﬁcation.
†Type A stenoses were coded as 1 point, type B1 stenoses were coded as 2 points, type B2 stenoses were coded as 3 points, and type C stenoses were coded as 4 points.
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B leeding is a common adverse event after percutaneouscoronary intervention and is associated with increased
morbidity and mortality.1–4 Bleeding predictors have been
described extensively; they are related mostly to the patient’s
clinical characteristics, the invasiveness of the procedure, and
the potency of the antithrombotic regimen. Antithrombotic
therapies after coronary intervention reduce ischemic events
but invariably increase bleeding risk, which in turn may
adversely affect short- and long-term outcomes.5,6 Interna-
tional guidelines recommend careful evaluation of both
ischemic and bleeding risk based on the patient’s clinical
characteristics7,8; however, evidence supporting the individ-
ualization of antithrombotic therapy is still limited. In partic-
ular, the potency and duration of dual antiplatelet therapy
(DAPT) after coronary stenting are currently based mainly on
the patient’s clinical presentation (ie, acute coronary syn-
drome or stable coronary artery disease) and the type of stent
used (ie, drug-eluting or bare metal stent), with evanescent
indications based on the patient’s bleeding risk.7–9 Many
bleeding risk scores have been validated for the prediction of
early and late bleeding events, and some have been tested on
large cohorts with acute coronary syndrome, demonstrating
reasonably good performance.10–12 Among them, the CRU-
SADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA [American College of Cardiology/
American Heart Association] Guidelines) score has been
validated in 17 857 patients with non–ST-segment elevation
myocardial infarction (MI), and its predictive capability was
consistent in terms of hemorrhagic risks in patients taking ≥2
antithrombotic medications.10 Our study sought to compare
the predictive performance of the CRUSADE, ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy), and
HAS-BLED (Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile INR [inter-
national normalized ratio], Elderly, Drugs/Alcohol Concomi-
tantly) risk scores with respect to major bleeding events in an
all-comer population treated with coronary stent. We also
intended to determine the incidence of major bleeding after
24-month rather than 6-month DAPT in the subgroups of
patients with high and low to intermediate bleeding risk.
Methods
The design and main study ﬁndings for the Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia Study (PRODIGY) were reported previously.5 In
brief, all patients receiving a balanced mixture of stents with
varying anti–intimal hyperplasia potency and including both
ﬁrst- and second-generation drug-eluting stents at 3 Italian
sites were randomly allocated at 30 days to either 6 or
24 months of DAPT. Selection criteria were broad, reﬂecting
routine clinical practice. Randomization to 6- or 24-month
DAPT was performed at 30 days and stratiﬁed by center,
ongoing ST-segment elevation MI, presence of diabetes
mellitus, and need for intervention on at least 1 in-stent
restenotic lesion. The study was conducted in accordance
with the principles of the Declaration of Helsinki. The ethics
committees of the 3 participating centers independently
approved the protocol, and all participants gave written
informed consent.
Treatment Protocol
All patients received aspirin (80–160 mg orally, indeﬁnitely)
and clopidogrel (75 mg/day) according to the following
randomization scheme: either 6 months in the short DAPT
group or 24 months in the prolonged DAPT arm, regardless of
the previously implanted stent type or indication for the
coronary procedure.
Follow-up
All randomized patients returned for study visits at 30 days
and then every 6 months for up to 2 years. During follow-up
visits, patients were examined and assessed for adverse
events and asked about antiplatelet therapy compliance; in
addition, 12-lead ECG recordings were obtained.
Study End Points
The primary objective of this analysis was to compare the
predictive performance of the CRUSADE, ACUITY, and HAS-
BLED bleeding risk scores with respect to major bleeding
events, adjudicated according to Bleeding Academic Research
Consortium (BARC) class 3 or 5, among patients recruited to
the PRODIGY trial. Further sensitivity analysis evaluated the
consistency of the results obtained with the BARC classiﬁca-
tion with other widely accepted bleeding deﬁnitions, including
the Thrombolysis in Myocardial Infarction (TIMI) and Global
Use of Strategies to Open Occluded Arteries (GUSTO) scales.
The CRUSADE, ACUITY, and HAS-BLED bleeding risk scores
were calculated, as reported previously,10–12 taking into
account the following exceptions: For the ACUITY score, given
the exclusive use of unfractionated heparin as an anticoag-
ulant in the PRODIGY trial, the “antithrombotic medication”
variable was set to zero; for the HAS-BLED score, given that
patients with an indication for long-term anticoagulation were
not included in the PRODIGY trial, the “labile INR” variable was
set to zero.
To assess the effect of high bleeding risk status in the 24-
and 6-month DAPT treatment arms, we selected the high-risk
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cutoff value of 40 for the CRUSADE score, as reported
previously.10 The incidence of major bleeding, red blood cell
transfusion, and major adverse cardiac events—a composite
of all-cause death, MI, and cerebrovascular accident—was
appraised in the subgroup of patients with high CRUSADE
scores (HCSs; >40) versus those with low to intermediate
scores (≤40) in the 2 DAPT duration arms. All study end point
deﬁnitions were reported previously,13 conﬁrmed on the basis
of documentation collected at each hospital, and centrally
adjudicated by the clinical events committee, the members of
which were unaware of the patients’ treatment-group
assignments. The time frame of interest for the primary end
point was from randomization (ie, 30 days after index
procedure) to 24 months.
Statistical Analysis
Categorical variables were expressed as frequency (percent-
age), whereas continuous variables were expressed as median
(interquartile range). Continuous variables were compared
between randomized groups using the Wilcoxon rank sum
test, whereas for binary variables, the v2 test was used.
Table 1. Baseline Characteristics
Characteristic Major Bleeding (n=53) No Major Bleeding (n=1893) P Value
Age, y 76.3 (71.3–81.3) 68.9 (59.8–76.1) <0.0001
Female sex 28.3% (15/53) 23.1% (438/1893) 0.38
Body mass index, kg/m2 25.4 (24.0–28.7) 26.6 (24.3–29.4) 0.30
Diabetes 34.0% (18/53) 24.0% (455/1893) 0.09
Insulin dependent 7.5% (4/53) 5.8% (110/1893)
Hypertension 77.4% (41/53) 71.7% (1358/1893) 0.37
Hyperlipidemia 52.8% (28/53) 54.9% (1039/1893) 0.76
Current cigarette use 13.2% (7/53) 24.3% (459/1893) 0.06
Creatinine clearance, mL/min 49.5 (36.3–65.5) 75.7 (57.0–96.5) <0.0001
Prior myocardial infarction 41.5% (22/53) 25.9% (491/1893) 0.01
Prior PCI 24.2% (13/53) 18.3% (343/1893) 0.23
Prior CABG 5.7% (3/53) 11.0% (208/1893) 0.21
LVEF 45.0 (35.75–55.0) 52.0 (45–60.0) 0.001
Clinical presentation
Stable angina pectoris 24.5% (13/53) 25.6% (485/1893) 0.85
Acute coronary syndrome 80.6% (40/53) 74.4% (1408/1893)
Multivessel disease 79.2% (42/53) 69.7% (1319/1893) 0.17
No. of treated lesions 1 (1–2) 1 (1–2) 0.30
≥2 treated lesions 35.8% (19/53) 37.6% (712/1893) 0.76
≥3 treated lesions 7.5% (4/53) 11.5% (218/1893)
Multivessel intervention 24.5% (13/53) 26.9% (509/1893) 0.70
At least 1 complex lesion (type B2 or C)* 66.0% (35/53) 66.0% (1250/1893) 0.99
Total ACC/AHA score† 3 (2–5) 3 (2–5) 0.48
Bleeding risk score
CRUSADE score 38 (24–43) 25 (18–35) <0.0001
ACUITY score 20 (14–28) 15 (9–20) <0.0001
HAS-BLED score 2 (1–2) 1 (1–2) <0.0001
ACC indicates American College of Cardiology; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; AHA, American Heart Association; CABG, coronary artery bypass
grafting; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED,
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; LVEF, left ventricular ejection fraction; PCI,
percutaneous coronary intervention.
*According to the ACC/AHA coronary lesion classiﬁcation.
†Type A stenoses were coded as 1 point, type B1 stenoses were coded as 2 points, type B2 stenoses were coded as 3 points, and type C stenoses were coded as 4 points.
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In its original derivation, the CRUSADE score assigned
patients to 5 risk strata (very low risk ≤20, low risk 21–30,
moderate risk 31–40, high risk 41–50, very high risk >50).
The ACUITY score deﬁned 4 risk strata (low risk <10,
moderate risk 10–14, high risk 15–19, very high risk ≥20),
whereas HAS-BLED stratiﬁed patients into 3 risk strata (low
risk <2, intermediate risk 2, high risk >2). For the purpose of
this analysis, patients were categorized into 3 bleeding risk
strata across all scores by jointly considering the very high risk
and high risk (high risk) and low risk and very low risk
categories (low risk) as 1 each. A detailed report of the
components of each score is presented in Table S1.
The predictive value of CRUSADE, ACUITY, and HAS-BLED
scores was assessed in Cox regression models and with
receiver operating characteristics area under the curve (AUC)
and category-free net reclassiﬁcation improvement and
integrated discrimination improvement.14 The calibration of
the models was evaluated using the Hosmer–Lemeshow
goodness-of-ﬁt statistical analysis. Net reclassiﬁcation
improvement and integrated discrimination improvement
were calculated by analyzing the differences in patients’
individual estimated probability of experiencing major bleed-
ing events after the addition of the CRUSADE score result to
the models containing the aforementioned bleeding risk
scores. Net reclassiﬁcation improvement represents the
average weighted improvement in discrimination. Integrated
discrimination improvement considers the change in the
estimated prediction probabilities as a continuous variable
and represents the average improvement in predicted
probability.
Estimation of the cumulative incidence of events was
performed using the Kaplan–Meier method, and events were
compared with the log-rank test. Absolute risk difference with
95% CI was calculated for long-term versus short-term
clopidogrel with the Newcombe–Wilson method without
continuity correction. The Mantel–Haenszel v2 test was used
Figure 1. Distribution of bleeding risk scores and major bleeding events in the PRODIGY population. The Venn diagram (center) shows the
patients included in the high bleeding risk category by each score. The ACUITY score had broader inclusion in the high-risk category, whereas
CRUSADE and HAS-BLED were more restrictive (bottom right corner). Bleeding risk score distribution is presented for CRUSADE (top left
corner), ACUITY (top right corner), and HAS-BLED (bottom left corner), with the number of patients with major bleeding in the high-risk category
(gray section) and in the low- to intermediate-risk category according to 3 bleeding deﬁnitions. ACUITY indicates Acute Catheterization and
Urgent Intervention Triage Strategy; BARC, Bleeding Academic Research Consortium; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open
Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly,
Drugs/Alcohol Concomitantly; PRODIGY, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; TIMI,
Thrombolysis in Myocardial Infarction.
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to assess the evidence of statistical interaction on an additive
scale between randomized DAPT duration and bleeding risk
status, according to CRUSADE. The number needed to treat
for harm (NNTH) was calculated as 1 divided by the absolute
risk difference (ARD). All analyses were performed on the
basis of the intention-to-treat principle with Review Manager
version 5.3 (RevMan; Cochrane Collaboration) and SPSS
version 21.0 (IBM Corp).
Results
In the PRODIGY trial, a total of 1970 patients were randomly
allocated at 30 days postprocedure to receive clopidogrel
therapy for 6 or 24 months. Complete data regarding the 3
bleeding risk scores were available in 1946 patients (98.8%).
The 2-year cumulative risk of major bleeding and need for
red blood cell transfusion was 2.7% and 2.0%, respectively
Table 3. Incidence of TIMI Minor and Major Bleeding Among Bleeding Risk Categories
Events (n/N) Hazard Ratio (95% CI) P Value
All patients 2.1% (42/1946) — —
CRUSADE score
Low (≤30) 1.2% (16/1282) Reference —
Intermediate (31–40) 3.0% (11/357) 2.50 (1.16–5.39) 0.019
High (>40) 4.9% (15/307) 4.20 (2.08–8.51) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.1% (10/475) 2.56 (0.80–8.17) 0.112
High (>14) 2.8% (28/991) 3.47 (1.22–9.89) 0.02
HAS-BLED score
Low (<2) 1.3% (13/977) Reference —
Intermediate (2) 2.8% (26/914) 2.17 (1.11–4.22) 0.023
High (>2) 5.4% (3/55) 4.79 (1.36–16.83) 0.015
Each hazard ratio is considered as compared to the reference low bleeding risk category. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; TIMI, Thrombolysis in Myocardial Infarction.
Table 2. Incidence of Major Bleeding Among Bleeding Risk Categories
Major Bleeding Hazard Ratio (95% CI) P Value
All patients 2.7% (53/1946) — —
CRUSADE score
Low (≤30) 1.4% (18/1282) Reference —
Intermediate (31–40) 4.2% (15/357) 3.10 (1.56–6.15) 0.001
High (>40) 6.5% (20/307) 5.62 (2.99–10.55) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.5% (12/475) 3.08 (0.99–9.54) 0.052
High (>14) 3.7% (37/991) 4.93 (1.76–13.82) 0.002
HAS-BLED score
Low (<2) 1.5% (15/977) Reference —
Intermediate (2) 3.7% (34/914) 2.56 (1.40–4.69) 0.002
High (>2) 7.3% (4/55) 5.45 (1.81–16.43) 0.003
Each hazard ratio is considered as compared with the reference low bleeding risk category. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
DOI: 10.1161/JAHA.115.002524 Journal of the American Heart Association 5
Risk Stratiﬁcation in Long or Short DAPT Costa et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on December 9, 2015http://jaha.ahajournals.org/Downloaded from 
CLINICAL RISK SCORES  AND DAPT DURATION
303302
5
In its original derivation, the CRUSADE score assigned
patients to 5 risk strata (very low risk ≤20, low risk 21–30,
moderate risk 31–40, high risk 41–50, very high risk >50).
The ACUITY score deﬁned 4 risk strata (low risk <10,
moderate risk 10–14, high risk 15–19, very high risk ≥20),
whereas HAS-BLED stratiﬁed patients into 3 risk strata (low
risk <2, intermediate risk 2, high risk >2). For the purpose of
this analysis, patients were categorized into 3 bleeding risk
strata across all scores by jointly considering the very high risk
and high risk (high risk) and low risk and very low risk
categories (low risk) as 1 each. A detailed report of the
components of each score is presented in Table S1.
The predictive value of CRUSADE, ACUITY, and HAS-BLED
scores was assessed in Cox regression models and with
receiver operating characteristics area under the curve (AUC)
and category-free net reclassiﬁcation improvement and
integrated discrimination improvement.14 The calibration of
the models was evaluated using the Hosmer–Lemeshow
goodness-of-ﬁt statistical analysis. Net reclassiﬁcation
improvement and integrated discrimination improvement
were calculated by analyzing the differences in patients’
individual estimated probability of experiencing major bleed-
ing events after the addition of the CRUSADE score result to
the models containing the aforementioned bleeding risk
scores. Net reclassiﬁcation improvement represents the
average weighted improvement in discrimination. Integrated
discrimination improvement considers the change in the
estimated prediction probabilities as a continuous variable
and represents the average improvement in predicted
probability.
Estimation of the cumulative incidence of events was
performed using the Kaplan–Meier method, and events were
compared with the log-rank test. Absolute risk difference with
95% CI was calculated for long-term versus short-term
clopidogrel with the Newcombe–Wilson method without
continuity correction. The Mantel–Haenszel v2 test was used
Figure 1. Distribution of bleeding risk scores and major bleeding events in the PRODIGY population. The Venn diagram (center) shows the
patients included in the high bleeding risk category by each score. The ACUITY score had broader inclusion in the high-risk category, whereas
CRUSADE and HAS-BLED were more restrictive (bottom right corner). Bleeding risk score distribution is presented for CRUSADE (top left
corner), ACUITY (top right corner), and HAS-BLED (bottom left corner), with the number of patients with major bleeding in the high-risk category
(gray section) and in the low- to intermediate-risk category according to 3 bleeding deﬁnitions. ACUITY indicates Acute Catheterization and
Urgent Intervention Triage Strategy; BARC, Bleeding Academic Research Consortium; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open
Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly,
Drugs/Alcohol Concomitantly; PRODIGY, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; TIMI,
Thrombolysis in Myocardial Infarction.
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to assess the evidence of statistical interaction on an additive
scale between randomized DAPT duration and bleeding risk
status, according to CRUSADE. The number needed to treat
for harm (NNTH) was calculated as 1 divided by the absolute
risk difference (ARD). All analyses were performed on the
basis of the intention-to-treat principle with Review Manager
version 5.3 (RevMan; Cochrane Collaboration) and SPSS
version 21.0 (IBM Corp).
Results
In the PRODIGY trial, a total of 1970 patients were randomly
allocated at 30 days postprocedure to receive clopidogrel
therapy for 6 or 24 months. Complete data regarding the 3
bleeding risk scores were available in 1946 patients (98.8%).
The 2-year cumulative risk of major bleeding and need for
red blood cell transfusion was 2.7% and 2.0%, respectively
Table 3. Incidence of TIMI Minor and Major Bleeding Among Bleeding Risk Categories
Events (n/N) Hazard Ratio (95% CI) P Value
All patients 2.1% (42/1946) — —
CRUSADE score
Low (≤30) 1.2% (16/1282) Reference —
Intermediate (31–40) 3.0% (11/357) 2.50 (1.16–5.39) 0.019
High (>40) 4.9% (15/307) 4.20 (2.08–8.51) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.1% (10/475) 2.56 (0.80–8.17) 0.112
High (>14) 2.8% (28/991) 3.47 (1.22–9.89) 0.02
HAS-BLED score
Low (<2) 1.3% (13/977) Reference —
Intermediate (2) 2.8% (26/914) 2.17 (1.11–4.22) 0.023
High (>2) 5.4% (3/55) 4.79 (1.36–16.83) 0.015
Each hazard ratio is considered as compared to the reference low bleeding risk category. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; TIMI, Thrombolysis in Myocardial Infarction.
Table 2. Incidence of Major Bleeding Among Bleeding Risk Categories
Major Bleeding Hazard Ratio (95% CI) P Value
All patients 2.7% (53/1946) — —
CRUSADE score
Low (≤30) 1.4% (18/1282) Reference —
Intermediate (31–40) 4.2% (15/357) 3.10 (1.56–6.15) 0.001
High (>40) 6.5% (20/307) 5.62 (2.99–10.55) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.5% (12/475) 3.08 (0.99–9.54) 0.052
High (>14) 3.7% (37/991) 4.93 (1.76–13.82) 0.002
HAS-BLED score
Low (<2) 1.5% (15/977) Reference —
Intermediate (2) 3.7% (34/914) 2.56 (1.40–4.69) 0.002
High (>2) 7.3% (4/55) 5.45 (1.81–16.43) 0.003
Each hazard ratio is considered as compared with the reference low bleeding risk category. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
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(2.2% and 2.6% for TIMI minor or major and GUSTO moderate
to severe bleeding, respectively). Patients randomized to
24-month DAPT duration, compared with those allocated to
6-month DAPT, experienced a signiﬁcant increase in major
bleeding (3.5% versus 2.0%, P=0.042; NNTH 66.7) and
received blood transfusions more frequently (2.7% versus
1.3%, P=0.041; NNTH 71.4). No bleeding event occurred in
the 24 patients for whom bleeding scores were missing.
The median CRUSADE score was 25 (interquartile range
18–35; meanSD: 26.512.8), whereas the median ACUITY
and HAS-BLED scores were 15 (interquartile range 10–21;
meanSD: 15.87.9) and 1 (interquartile range 1–2;
meanSD: 1.30.7), respectively (Table 1 and Figure 1).
By applying previously validated cutoffs, 307 patients (15.8%)
based on CRUSADE, 991 patients (50.9%) based on ACUITY,
and 55 patients (2.8%) based on HAS-BLED met the threshold
for the high or very high bleeding risk category. Most patients
with HCS also satisﬁed high bleeding risk criteria according to
both HAS-BLED and ACUITY, whereas the vast majority of
patients at high bleeding risk according to ACUITY did not
reach the same risk category for the other 2 scores
(Figure 1).
Table 4. Incidence of GUSTO Moderate and Severe Bleeding Among Bleeding Risk Categories
Events (n/N) Hazard Ratio (95% CI) P Value
All patients 2.6% (52/1946) — —
CRUSADE score
Low (≤30) 1.3% (18/1282) Reference —
Intermediate (31–40) 3.6% (13/357) 2.80 (1.36–5.76) 0.005
High (>40) 6.8% (21/307) 5.58 (2.94–10.58) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.5% (12/475) 3.08 (0.99–9.56) 0.052
High (>14) 3.5% (35/991) 4.35 (1.55–12.24) 0.005
HAS-BLED score
Low (<2) 1.4% (14/977) Reference —
Intermediate (2) 3.4% (31/914) 2.40 (1.28–4.52) 0.006
High (>2) 10.9% (6/55) 9.05 (3.47–23.60) <0.0001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
Table 5. Risk Classiﬁcation of Major Bleeding According to the 3 Bleeding Risk Scores
CRUSADE ACUITY HAS-BLED
CRUSADE vs ACUITY ACUITY vs HAS-BLED CRUSADE vs HAS-BLED
Difference P Value Difference P Value Difference P Value
True-positive rate* 37.7% (20/53) 69.8% (37/53) 7.5% (4/53) 32.1 <0.0001 62.3 <0.0001 30.2 <0.0001
False-positive rate† 15.2% (287/1893) 50.3% (954/
1893)
2.7% (51/1893) 35.1 <0.0001 47.6 <0.0001 12.5 <0.0001
False-negative
rate‡
34.0% (18/53) 7.5% (4/53) 28.3% (15/53) 26.5 <0.0001 20.8 <0.0001 5.7 <0.0001
True-negative rate§ 66.7% (1264/
1893)
25.1% (476/
1893)
50.8% (962/
1893)
41.6 <0.0001 25.7 <0.0001 15.9 <0.0001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly.
*Proportion of events categorized as CRUSADE >40, ACUITY >14, and HAS-BLED>2.
†Proportion of events categorized as CRUSADE >40, ACUITY >14, and HAS-BLED>2.
‡Proportion of events categorized as CRUSADE ≤30, ACUITY <10, and HAS-BLED<2.
§Proportion of events categorized as CRUSADE ≤30, ACUITY <10, and HAS-BLED<2.
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The patients who bled were older, had reduced renal
function and left ventricular ejection fraction, had more
frequent history of MI and diabetes mellitus, and underwent
left main coronary artery intervention more frequently. All 3
bleeding risk scores were signiﬁcantly higher for patients with
hemorrhagic events at follow-up compared with those with-
out, consistently across bleeding deﬁnitions (Table 1).
Predictive Performance of the Bleeding Risk
Scores
The transition from a lower to a higher risk category carried a
signiﬁcant increase in bleeding rates across bleeding risk
scores (Table 2). This result was consistent among all
explored bleeding deﬁnitions (Tables 3 and 4) and in the
6- and 24-month DAPT groups when assessed separately. The
ACUITY score best classiﬁed patients with major bleeding in
the high-risk group (higher sensitivity), but it was also the
least speciﬁc, classifying only 25% of patients without events
to the low-risk group. In contrast, the HAS-BLED score
showed the lowest sensitivity, classifying 7.5% of those who
Figure 2. Calibration plots comparing the expected and observed probabilities of major bleeding. A, CRUSADE score. B, ACUITY score. C,
HAS-BLED score. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of
Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
Table 6. ROC: Predictive Performance of Major Bleeding With
the 3 Risk Scores Used as Continuous Variables and as 3 Risk
Score Categories (Low, Intermediate, and High Risk)
Major Bleeding
AUC (95% CI) P Value
CRUSADE score
Continuous parameter 0.71 (0.64–0.77) <0.0001
3 Categories 0.68 (0.60–0.75) <0.0001
ACUITY score
Continuous parameter 0.68 (0.61–0.75) <0.0001
3 Categories 0.61 (0.55–0.68) 0.004
HAS-BLED score
Continuous parameter 0.63 (0.56–0.70) 0.001
3 Categories 0.62 (0.55–0.70) 0.002
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; AUC,
area under the curve; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA
Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; ROC,
receiver operating characteristics.
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(2.2% and 2.6% for TIMI minor or major and GUSTO moderate
to severe bleeding, respectively). Patients randomized to
24-month DAPT duration, compared with those allocated to
6-month DAPT, experienced a signiﬁcant increase in major
bleeding (3.5% versus 2.0%, P=0.042; NNTH 66.7) and
received blood transfusions more frequently (2.7% versus
1.3%, P=0.041; NNTH 71.4). No bleeding event occurred in
the 24 patients for whom bleeding scores were missing.
The median CRUSADE score was 25 (interquartile range
18–35; meanSD: 26.512.8), whereas the median ACUITY
and HAS-BLED scores were 15 (interquartile range 10–21;
meanSD: 15.87.9) and 1 (interquartile range 1–2;
meanSD: 1.30.7), respectively (Table 1 and Figure 1).
By applying previously validated cutoffs, 307 patients (15.8%)
based on CRUSADE, 991 patients (50.9%) based on ACUITY,
and 55 patients (2.8%) based on HAS-BLED met the threshold
for the high or very high bleeding risk category. Most patients
with HCS also satisﬁed high bleeding risk criteria according to
both HAS-BLED and ACUITY, whereas the vast majority of
patients at high bleeding risk according to ACUITY did not
reach the same risk category for the other 2 scores
(Figure 1).
Table 4. Incidence of GUSTO Moderate and Severe Bleeding Among Bleeding Risk Categories
Events (n/N) Hazard Ratio (95% CI) P Value
All patients 2.6% (52/1946) — —
CRUSADE score
Low (≤30) 1.3% (18/1282) Reference —
Intermediate (31–40) 3.6% (13/357) 2.80 (1.36–5.76) 0.005
High (>40) 6.8% (21/307) 5.58 (2.94–10.58) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.5% (12/475) 3.08 (0.99–9.56) 0.052
High (>14) 3.5% (35/991) 4.35 (1.55–12.24) 0.005
HAS-BLED score
Low (<2) 1.4% (14/977) Reference —
Intermediate (2) 3.4% (31/914) 2.40 (1.28–4.52) 0.006
High (>2) 10.9% (6/55) 9.05 (3.47–23.60) <0.0001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
Table 5. Risk Classiﬁcation of Major Bleeding According to the 3 Bleeding Risk Scores
CRUSADE ACUITY HAS-BLED
CRUSADE vs ACUITY ACUITY vs HAS-BLED CRUSADE vs HAS-BLED
Difference P Value Difference P Value Difference P Value
True-positive rate* 37.7% (20/53) 69.8% (37/53) 7.5% (4/53) 32.1 <0.0001 62.3 <0.0001 30.2 <0.0001
False-positive rate† 15.2% (287/1893) 50.3% (954/
1893)
2.7% (51/1893) 35.1 <0.0001 47.6 <0.0001 12.5 <0.0001
False-negative
rate‡
34.0% (18/53) 7.5% (4/53) 28.3% (15/53) 26.5 <0.0001 20.8 <0.0001 5.7 <0.0001
True-negative rate§ 66.7% (1264/
1893)
25.1% (476/
1893)
50.8% (962/
1893)
41.6 <0.0001 25.7 <0.0001 15.9 <0.0001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly.
*Proportion of events categorized as CRUSADE >40, ACUITY >14, and HAS-BLED>2.
†Proportion of events categorized as CRUSADE >40, ACUITY >14, and HAS-BLED>2.
‡Proportion of events categorized as CRUSADE ≤30, ACUITY <10, and HAS-BLED<2.
§Proportion of events categorized as CRUSADE ≤30, ACUITY <10, and HAS-BLED<2.
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The patients who bled were older, had reduced renal
function and left ventricular ejection fraction, had more
frequent history of MI and diabetes mellitus, and underwent
left main coronary artery intervention more frequently. All 3
bleeding risk scores were signiﬁcantly higher for patients with
hemorrhagic events at follow-up compared with those with-
out, consistently across bleeding deﬁnitions (Table 1).
Predictive Performance of the Bleeding Risk
Scores
The transition from a lower to a higher risk category carried a
signiﬁcant increase in bleeding rates across bleeding risk
scores (Table 2). This result was consistent among all
explored bleeding deﬁnitions (Tables 3 and 4) and in the
6- and 24-month DAPT groups when assessed separately. The
ACUITY score best classiﬁed patients with major bleeding in
the high-risk group (higher sensitivity), but it was also the
least speciﬁc, classifying only 25% of patients without events
to the low-risk group. In contrast, the HAS-BLED score
showed the lowest sensitivity, classifying 7.5% of those who
Figure 2. Calibration plots comparing the expected and observed probabilities of major bleeding. A, CRUSADE score. B, ACUITY score. C,
HAS-BLED score. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of
Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
Table 6. ROC: Predictive Performance of Major Bleeding With
the 3 Risk Scores Used as Continuous Variables and as 3 Risk
Score Categories (Low, Intermediate, and High Risk)
Major Bleeding
AUC (95% CI) P Value
CRUSADE score
Continuous parameter 0.71 (0.64–0.77) <0.0001
3 Categories 0.68 (0.60–0.75) <0.0001
ACUITY score
Continuous parameter 0.68 (0.61–0.75) <0.0001
3 Categories 0.61 (0.55–0.68) 0.004
HAS-BLED score
Continuous parameter 0.63 (0.56–0.70) 0.001
3 Categories 0.62 (0.55–0.70) 0.002
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; AUC,
area under the curve; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA
Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; ROC,
receiver operating characteristics.
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eventually bled as high risk. The CRUSADE score provided
reasonable sensitivity and speciﬁcity, correctly classifying
67% of patients without events in the low-risk category
(Table 5).
At the C statistic analysis, the point estimate of the AUC
for the prediction of major bleeding was similar between the
CRUSADE risk score (AUC 0.71, 95% CI 0.64–0.77) and
ACUITY (AUC 0.68, 95% CI 0.61–0.75) and numerically higher
than HAS-BLED (AUC 0.63, 95% CI 0.56–0.70), as both
continuous and 3-risk categories, although 95% CIs remained
partially overlapping among the 3 bleeding scores (Table 6).
All 3 risk models were well calibrated according to the
Hosmer–Lemershow test for goodness of ﬁt (CRUSADE
P=0.27; ACUITY P=0.33; HAS-BLED P=0.69) (Figure 2). These
observations remained consistent when TIMI and GUSTO
bleeding deﬁnitions were applied (Table 7). CRUSADE, but not
ACUITY, successfully reclassiﬁed the risk of major bleeding
compared with HAS-BLED, with better discriminatory power.
When compared with ACUITY, CRUSADE was not signiﬁcantly
superior on net reclassiﬁcation improvement and integrated
discrimination improvement (Table 8 and Figure 3). These
results were largely consistent across different bleeding
scales (Table 9). In addition, the bleeding risk scores,
especially CRUSADE, showed reasonably good discriminatory
capability for ischemic events, including the composite of
death, MI, or cerebrovascular accident; for MI alone; and for
stent thrombosis alone (Table 10).
CRUSADE Score and DAPT Duration
Bleeding events
Patients meeting the threshold for HCS showed an almost 3-
fold greater rate of major bleeding when treated with 24-
versus 6-month DAPT (9.7% versus 3.7%; ARD 6%; 95% CI
0.4% to 12.3%; P=0.04); patients with low to intermediate
Table 7. ROC: Predictive Performance of TIMI Minor or Major and GUSTO Moderate or Severe Bleeding for the 3 Risk Scores Used
as Continuous Variables and as 3 Risk Score Categories (Low, Intermediate, and High Risk)
TIMI Minor or Major GUSTO Moderate or Severe
AUC (95% CI) P Value AUC (95% CI) P Value
CRUSADE score
Continuous parameter 0.68 (0.60–0.76) <0.0001 0.71 (0.63–0.82) <0.0001
3 Categories 0.65 (0.56–0.74) 0.001 0.68 (0.58–0.79) <0.0001
ACUITY score
Continuous parameter 0.65 (0.57–0.73) 0.001 0.67 (0.58–0.77) <0.0001
3 Categories 0.59 (0.52–0.67) 0.036 0.61 (0.51–0.69) 0.009
HAS-BLED score
Continuous parameter 0.62 (0.53–0.69) 0.010 0.65 (0.55–0.73) <0.0001
3 Categories 0.61 (0.52–0.69) 0.019 0.64 (0.53–0.73) 0.001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; AUC, area under the curve; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; ROC, receiver operating characteristics; TIMI, Thrombolysis in Myocardial Infarction.
Table 8. Risk Reclassiﬁcation and Integrated Discriminatory Improvement for Major Bleeding
Bleeding Correctly
Reclassiﬁed, P (n1)
No Bleeding Correctly
Reclassiﬁed, P (n2)
Net Reclassiﬁcation
Improvement† P Value
Integrated Discriminatory
Improvement‡ P Value
CRUSADE vs ACUITY* 0.57 (30) 0.49 (921) 0.12 0.49 0.0015 0.488
ACUITY vs HAS-BLED* 0.49 (26) 0.57 (1076) 0.12 0.40 0.0067 0.069
CRUSADE vs HAS-BLED* 0.62 (33) 0.57 (1087) 0.39 0.005 0.0083 0.021
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly.
*The model considered each bleeding risk score as a reference value for the others.
†The net reclassiﬁcation improvement was deﬁned as (A+B)�([1�A]+[1�B]), in which A is the probability of bleeding correctly reclassiﬁed and B is the probability of no bleeding correctly
reclassiﬁed.
‡The integrated discrimination improvement was deﬁned as
ð
P
i
in bleeders ½pnewð1Þ�poldð1Þ �Þ
n1 �
ð
P
i
in non-bleeders ½pnewð2Þ�poldð2Þ �Þ
n2 :
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CRUSADE scores did not experience a signiﬁcant increase in
major bleeding when treated with long versus short DAPT
duration (2.4% versus 1.6%; ARD 0.8%; 95% CI �0.6% to 2.2%;
P=0.25) (Figure 4A and Table 11). A quantitative interaction
was noted between bleeding risk and duration of antiplatelet
therapy with respect to major bleeding (Pint=0.05) (Figure 5).
The NNTH to experience major bleeding with prolonged DAPT
in the HCS group was 17 (Figure 6). These ﬁndings remained
Figure 3. Reclassiﬁcation tables. The 3 bleeding risk scores are compared using each score as reference
for the others: The ﬁrst score mentioned is the score to be tested, the second is considered the reference.
The percentage of patients correctly reclassiﬁed by each score is displayed in green, whereas the
percentage of patients not correctly reclassiﬁed is in red. ACUITY indicates Acute Catheterization and
Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED,
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR,
Elderly, Drugs/Alcohol Concomitantly.
Table 9. Risk Reclassiﬁcation and Integrated Discriminatory Improvement for TIMI Minor or Major and GUSTO Moderate or Severe
Bleeding
Bleeding Correctly
Reclassiﬁed P (n1)
No Bleeding Correctly
Reclassiﬁed, P (n2)
Net Reclassiﬁcation
Improvement† P Value
Integrated Discriminatory
Improvement ‡ P Value
TIMI Minor or Major
CRUSADE vs ACUITY* 0.55 (23) 0.51 (974) 0.12 0.53 0.0022 0.198
ACUITY vs HAS-BLED* 0.45 (19) 0.55 (1055) 0.012 1.00 0.0031 0.256
CRUSADE vs HAS-BLED* 0.62 (26) 0.56 (1065) 0.37 0.03 0.0053 0.069
GUSTO Moderate or Severe
CRUSADE vs ACUITY* 0.53 (27) 0.55 (1044) 0.16 0.26 0.004 0.11
ACUITY vs HAS-BLED* 0.47 (24) 0.53 (998) �0.004 1.00 0.002 0.62
CRUSADE vs HAS-BLED* 0.59 (30) 0.54 (1029) 0.26 0.066 0.006 0.11
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; TIMI, Thrombolysis in Myocardial Infarction.
*The model considered each bleeding risk score as a reference value for the others.
†The net reclassiﬁcation improvement was deﬁned as (A+B)�([1�A]+[1�B]), in which A is the probability of bleeding correctly reclassiﬁed and B is the probability of no bleeding correctly
reclassiﬁed.
‡The integrated discrimination improvement was deﬁned as
ð
P
i
in bleeders ½pnewð1Þ�poldð1Þ �Þ
n1 �
ð
P
i
in non-bleeders ½pnewð2Þ�poldð2Þ �Þ
n2 :
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5eventually bled as high risk. The CRUSADE score provided
reasonable sensitivity and speciﬁcity, correctly classifying
67% of patients without events in the low-risk category
(Table 5).
At the C statistic analysis, the point estimate of the AUC
for the prediction of major bleeding was similar between the
CRUSADE risk score (AUC 0.71, 95% CI 0.64–0.77) and
ACUITY (AUC 0.68, 95% CI 0.61–0.75) and numerically higher
than HAS-BLED (AUC 0.63, 95% CI 0.56–0.70), as both
continuous and 3-risk categories, although 95% CIs remained
partially overlapping among the 3 bleeding scores (Table 6).
All 3 risk models were well calibrated according to the
Hosmer–Lemershow test for goodness of ﬁt (CRUSADE
P=0.27; ACUITY P=0.33; HAS-BLED P=0.69) (Figure 2). These
observations remained consistent when TIMI and GUSTO
bleeding deﬁnitions were applied (Table 7). CRUSADE, but not
ACUITY, successfully reclassiﬁed the risk of major bleeding
compared with HAS-BLED, with better discriminatory power.
When compared with ACUITY, CRUSADE was not signiﬁcantly
superior on net reclassiﬁcation improvement and integrated
discrimination improvement (Table 8 and Figure 3). These
results were largely consistent across different bleeding
scales (Table 9). In addition, the bleeding risk scores,
especially CRUSADE, showed reasonably good discriminatory
capability for ischemic events, including the composite of
death, MI, or cerebrovascular accident; for MI alone; and for
stent thrombosis alone (Table 10).
CRUSADE Score and DAPT Duration
Bleeding events
Patients meeting the threshold for HCS showed an almost 3-
fold greater rate of major bleeding when treated with 24-
versus 6-month DAPT (9.7% versus 3.7%; ARD 6%; 95% CI
0.4% to 12.3%; P=0.04); patients with low to intermediate
Table 7. ROC: Predictive Performance of TIMI Minor or Major and GUSTO Moderate or Severe Bleeding for the 3 Risk Scores Used
as Continuous Variables and as 3 Risk Score Categories (Low, Intermediate, and High Risk)
TIMI Minor or Major GUSTO Moderate or Severe
AUC (95% CI) P Value AUC (95% CI) P Value
CRUSADE score
Continuous parameter 0.68 (0.60–0.76) <0.0001 0.71 (0.63–0.82) <0.0001
3 Categories 0.65 (0.56–0.74) 0.001 0.68 (0.58–0.79) <0.0001
ACUITY score
Continuous parameter 0.65 (0.57–0.73) 0.001 0.67 (0.58–0.77) <0.0001
3 Categories 0.59 (0.52–0.67) 0.036 0.61 (0.51–0.69) 0.009
HAS-BLED score
Continuous parameter 0.62 (0.53–0.69) 0.010 0.65 (0.55–0.73) <0.0001
3 Categories 0.61 (0.52–0.69) 0.019 0.64 (0.53–0.73) 0.001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; AUC, area under the curve; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; ROC, receiver operating characteristics; TIMI, Thrombolysis in Myocardial Infarction.
Table 8. Risk Reclassiﬁcation and Integrated Discriminatory Improvement for Major Bleeding
Bleeding Correctly
Reclassiﬁed, P (n1)
No Bleeding Correctly
Reclassiﬁed, P (n2)
Net Reclassiﬁcation
Improvement† P Value
Integrated Discriminatory
Improvement‡ P Value
CRUSADE vs ACUITY* 0.57 (30) 0.49 (921) 0.12 0.49 0.0015 0.488
ACUITY vs HAS-BLED* 0.49 (26) 0.57 (1076) 0.12 0.40 0.0067 0.069
CRUSADE vs HAS-BLED* 0.62 (33) 0.57 (1087) 0.39 0.005 0.0083 0.021
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly.
*The model considered each bleeding risk score as a reference value for the others.
†The net reclassiﬁcation improvement was deﬁned as (A+B)�([1�A]+[1�B]), in which A is the probability of bleeding correctly reclassiﬁed and B is the probability of no bleeding correctly
reclassiﬁed.
‡The integrated discrimination improvement was deﬁned as
ð
P
i
in bleeders ½pnewð1Þ�poldð1Þ �Þ
n1 �
ð
P
i
in non-bleeders ½pnewð2Þ�poldð2Þ �Þ
n2 :
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CRUSADE scores did not experience a signiﬁcant increase in
major bleeding when treated with long versus short DAPT
duration (2.4% versus 1.6%; ARD 0.8%; 95% CI �0.6% to 2.2%;
P=0.25) (Figure 4A and Table 11). A quantitative interaction
was noted between bleeding risk and duration of antiplatelet
therapy with respect to major bleeding (Pint=0.05) (Figure 5).
The NNTH to experience major bleeding with prolonged DAPT
in the HCS group was 17 (Figure 6). These ﬁndings remained
Figure 3. Reclassiﬁcation tables. The 3 bleeding risk scores are compared using each score as reference
for the others: The ﬁrst score mentioned is the score to be tested, the second is considered the reference.
The percentage of patients correctly reclassiﬁed by each score is displayed in green, whereas the
percentage of patients not correctly reclassiﬁed is in red. ACUITY indicates Acute Catheterization and
Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED,
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR,
Elderly, Drugs/Alcohol Concomitantly.
Table 9. Risk Reclassiﬁcation and Integrated Discriminatory Improvement for TIMI Minor or Major and GUSTO Moderate or Severe
Bleeding
Bleeding Correctly
Reclassiﬁed P (n1)
No Bleeding Correctly
Reclassiﬁed, P (n2)
Net Reclassiﬁcation
Improvement† P Value
Integrated Discriminatory
Improvement ‡ P Value
TIMI Minor or Major
CRUSADE vs ACUITY* 0.55 (23) 0.51 (974) 0.12 0.53 0.0022 0.198
ACUITY vs HAS-BLED* 0.45 (19) 0.55 (1055) 0.012 1.00 0.0031 0.256
CRUSADE vs HAS-BLED* 0.62 (26) 0.56 (1065) 0.37 0.03 0.0053 0.069
GUSTO Moderate or Severe
CRUSADE vs ACUITY* 0.53 (27) 0.55 (1044) 0.16 0.26 0.004 0.11
ACUITY vs HAS-BLED* 0.47 (24) 0.53 (998) �0.004 1.00 0.002 0.62
CRUSADE vs HAS-BLED* 0.59 (30) 0.54 (1029) 0.26 0.066 0.006 0.11
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; TIMI, Thrombolysis in Myocardial Infarction.
*The model considered each bleeding risk score as a reference value for the others.
†The net reclassiﬁcation improvement was deﬁned as (A+B)�([1�A]+[1�B]), in which A is the probability of bleeding correctly reclassiﬁed and B is the probability of no bleeding correctly
reclassiﬁed.
‡The integrated discrimination improvement was deﬁned as
ð
P
i
in bleeders ½pnewð1Þ�poldð1Þ �Þ
n1 �
ð
P
i
in non-bleeders ½pnewð2Þ�poldð2Þ �Þ
n2 :
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consistent across bleeding scales (Table 11). Patients with
HCS experienced an almost 5-fold increase in red blood cell
transfusion in the 24- versus 6-month DAPT duration arms
(8.3% versus 1.8%; ARD 6.5%; 95% CI 1.6% to 12.3%; P=0.02;
NNTH: 15.4), whereas this did not differ in patients with low
to intermediate CRUSADE score (1.7% versus 1.2%; ARD 0.5%;
95% CI 0.6% to 1.7%; P=0.45) (Figure 4B and Table 11), with
positive interaction testing (Pint=0.01) (Figure 5).
Figure 4. Kaplan–Meier curves during follow-up for hemorrhagic and ischemic events in the high and low to intermediate CRUSADE score
categories after 24- or 6-month DAPT. A, Major bleeding. B, Red blood cell transfusion. C, Major adverse cardiovascular events including death
for all causes, myocardial infarction, and cerebrovascular accident. CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy; HAS-BLED, Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; HR, hazard ratio.
Table 11. Hemorrhagic and Ischemic Outcomes in the High and Low to Intermediate CRUSADE Score Groups After 24- or
6-Month Dual Antiplatelet Therapy
HCS (>40) LICS (≤40)
Pint
24-Month
DAPT (n=144)
6-Month DAPT
(n=163) ARD (95% CI)
P
Value
24-Month
DAPT (n=831)
6-Month DAPT
(n=808) ARD (95% CI)
P
Value
Major Bleeding* 9.7% (14) 3.7% (6) 6% (0.4%, 12.3%) 0.04 2.4% (20) 1.6% (13) 0.8% (0.6%, 2.2%) 0.25 0.05
Red blood cell
transfusion
8.3% (12) 1.8% (3) 6.5% (1.6%, 12.3%) 0.02 1.7% (14) 1.2% (10) 0.5% (0.6%, 1.7%) 0.45 0.01
MACE 28.5% (41) 25.8% (42) 2.7% (7.2%, 12.6%) 0.59 6.7% (56) 6.7% (54) 0.0% (2.5, 2.4%) 0.96 0.58
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; ARD, absolute risk difference; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-
BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; HCS, high CRUSADE score; int,
interaction; LICS, low to intermediate CRUSADE score; MACE, major adverse cardiovascular events consistent with death from all causes, myocardial infarction, and cerebrovascular
accident; TIMI, Thrombolysis in Myocardial Infarction.
*Results consistent among other bleeding deﬁnitions: TIMI minor or major and HCS (7.6% vs 2.4%; ARD 5.2%; 95% CI 0.2% to 10.9%; P: 0.05) and LICS (1.9% vs 1.4%; ARD 0.5%; 95% CI
0.6% to 1.9%; P=0.37) (Pint=0.02). GUSTO moderate or severe and HCS (9.7% vs 4.3%; ARD 5.4%; 95% CI 0.3% to 11.8%; P=0.08) and LICS (2.2% vs 1.5%; ARD 0.7%; 95% CI 0.6% to
2.1%; P=0.30) (Pint=0.08).
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consistent across bleeding scales (Table 11). Patients with
HCS experienced an almost 5-fold increase in red blood cell
transfusion in the 24- versus 6-month DAPT duration arms
(8.3% versus 1.8%; ARD 6.5%; 95% CI 1.6% to 12.3%; P=0.02;
NNTH: 15.4), whereas this did not differ in patients with low
to intermediate CRUSADE score (1.7% versus 1.2%; ARD 0.5%;
95% CI 0.6% to 1.7%; P=0.45) (Figure 4B and Table 11), with
positive interaction testing (Pint=0.01) (Figure 5).
Figure 4. Kaplan–Meier curves during follow-up for hemorrhagic and ischemic events in the high and low to intermediate CRUSADE score
categories after 24- or 6-month DAPT. A, Major bleeding. B, Red blood cell transfusion. C, Major adverse cardiovascular events including death
for all causes, myocardial infarction, and cerebrovascular accident. CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy; HAS-BLED, Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; HR, hazard ratio.
Table 11. Hemorrhagic and Ischemic Outcomes in the High and Low to Intermediate CRUSADE Score Groups After 24- or
6-Month Dual Antiplatelet Therapy
HCS (>40) LICS (≤40)
Pint
24-Month
DAPT (n=144)
6-Month DAPT
(n=163) ARD (95% CI)
P
Value
24-Month
DAPT (n=831)
6-Month DAPT
(n=808) ARD (95% CI)
P
Value
Major Bleeding* 9.7% (14) 3.7% (6) 6% (0.4%, 12.3%) 0.04 2.4% (20) 1.6% (13) 0.8% (0.6%, 2.2%) 0.25 0.05
Red blood cell
transfusion
8.3% (12) 1.8% (3) 6.5% (1.6%, 12.3%) 0.02 1.7% (14) 1.2% (10) 0.5% (0.6%, 1.7%) 0.45 0.01
MACE 28.5% (41) 25.8% (42) 2.7% (7.2%, 12.6%) 0.59 6.7% (56) 6.7% (54) 0.0% (2.5, 2.4%) 0.96 0.58
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; ARD, absolute risk difference; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-
BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; HCS, high CRUSADE score; int,
interaction; LICS, low to intermediate CRUSADE score; MACE, major adverse cardiovascular events consistent with death from all causes, myocardial infarction, and cerebrovascular
accident; TIMI, Thrombolysis in Myocardial Infarction.
*Results consistent among other bleeding deﬁnitions: TIMI minor or major and HCS (7.6% vs 2.4%; ARD 5.2%; 95% CI 0.2% to 10.9%; P: 0.05) and LICS (1.9% vs 1.4%; ARD 0.5%; 95% CI
0.6% to 1.9%; P=0.37) (Pint=0.02). GUSTO moderate or severe and HCS (9.7% vs 4.3%; ARD 5.4%; 95% CI 0.3% to 11.8%; P=0.08) and LICS (2.2% vs 1.5%; ARD 0.7%; 95% CI 0.6% to
2.1%; P=0.30) (Pint=0.08).
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Ischemic events
The risk of death, MI, or cerebrovascular accident did not
differ in the 24- versus 6-month DAPT groups, both in patients
with HCS (28.5% versus 25.8%; ARD 2.7%; 95% CI 7.2% to
12.6%; P=0.59) and with low to intermediate CRUSADE score
(6.7% versus 6.7%; ARD 0%; 95% CI 2.5% to 2.4%; P=0.96)
(Pint=0.58). (Figure 4C and Table 11) Similarly, when sepa-
rately assessed, the risk of all-cause death, MI, or deﬁnite or
probable stent thrombosis remained homogeneously dis-
tributed between DAPT groups in patients with and without
HCS (Table 12).
Discussion
The main ﬁndings of this study can be summarized as follows.
First, the CRUSADE, HAS-BLED, and ACUITY risk scores
demonstrated reasonably good predictive value with respect
to major bleeding in the PRODIGY all-comer population,
regardless of the bleeding deﬁnition used. Second, bleeding
risk scores also displayed a signiﬁcant capability to predict
ischemic events in terms of major adverse cardiac events, MI,
or stent thrombosis. Third, the CRUSADE risk score, predicted
bleeding signiﬁcantly better than HAS-BLED, with improved
reclassiﬁcation and discrimination performance. Fourth,
patients with HCS treated with 24-month DAPT experienced
a 3-fold higher risk of major bleeding and a 5-fold risk of red
blood cell transfusion compared with 6-month DAPT, without
clear evidence of beneﬁt. The NNTH with an HCS was as low
as 17 for major bleeding and 15 for red blood cell transfusion;
these values were lower than corresponding values in the
unselected patient cohort, suggesting that long-term DAPT
has a narrow therapeutic window and high potential for harm
in this selected patient population with high bleeding risk.
Fifth, conversely, patients not meeting the threshold for the
HCS category—corresponding to as many as 84.2% of the
patients originally included in our study—did not have higher
Figure 5. Hemorrhagic and ischemic outcomes in patients with
high and low to intermediate CRUSADE scores. The forest plot
shows the absolute risk difference and the P value of the
interaction effect for major bleeding, red blood cell transfusion,
and MACE after 24- versus 6-month DAPT in the groups of
patients with high and low to intermediate CRUSADE scores.
CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Imple-
mentation of the ACC/AHA Guidelines; DAPT, dual antiplatelet
therapy; int, interaction; MACE, major adverse cardiovascular
events.
Figure 6. Effects of long- and short-term DAPT on patients with a high CRUSADE score and in the overall
population. The number of patients needed to treat to experience major bleeding or red blood cell
transfusion after 24-month DAPT compared with 6-month treatment is signiﬁcantly lower in the group of
patients with a high CRUSADE score (>40) than in the overall study population. CRUSADE indicates Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy.
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bleeding risk, consistently across bleeding risk scales, if
treated with 24- versus 6-month DAPT duration.
There is consensus currently about the need to choose
intensity and/or duration of potent antithrombotic therapy
after percutaneous coronary intervention through the assess-
ment of actual individual bleeding risk. Nevertheless, it
remains undeﬁned how bleeding risk should be properly
assessed and whether it should truly inﬂuence therapeutic
decisions in clinical practice. The ultimate goal of this
analysis was to select 1 bleeding risk score that could guide
duration of DAPT in clinical practice to maximize beneﬁts
over risks. Among the risk scores explored, we found
CRUSADE to have a better predictive proﬁle for major
bleeding compared with HAS-BLED and a similar proﬁle
compared to ACUITY. This observation is consistent with
some previous studies and with the European Society of
Cardiology guidelines that recommended the CRUSADE
score for bleeding risk stratiﬁcation in non–ST-segment
elevation MI.9,15,16 It might be speculated that the set of
covariates used to predict bleeding risk for the CRUSADE
score better reﬂects the bleeding risk in patients undergoing
stent implantation and subsequent DAPT. Accordingly, we
stratiﬁed the PRODIGY patient population into high versus
nonhigh bleeding risk status based on CRUSADE and
assessed whether a priori bleeding risk could be a treatment
modiﬁer with respect to DAPT duration. We failed to identify
a speciﬁc patient population (eg, those at low or interme-
diate bleeding risk) for which long-term DAPT was associated
with lower rates of ischemic end points compared with a
shortened DAPT regimen. This may reﬂect the null ﬁnding of
the PRODIGY trial with respect to the beneﬁt of long-term
DAPT on death, MI, or stroke. In contrast, our study, which
recruited an all-comer patient population, observed a distinct
increase in bleeding end points in patients treated with 24-
month DAPT. The current stratiﬁed analysis largely expands
on previous ﬁndings by showing that in patients with low to
intermediate risk, prolonging DAPT was not associated with a
signiﬁcant bleeding risk consistently across bleeding scales.
Conversely, we observed bleeding and blood transfusion
hazards associated with long-term DAPT in the selected
cohort of patients with high bleeding risk. Given the
magnitude of this association on both relative and absolute
scales, it may be reasonable to stop DAPT after 6 months in
this selected patient population, given that the risks seem to
largely outweigh the potential beneﬁts. At the same time, in
patients not meeting high bleeding risk criteria according to
the CRUSADE score, bleeding risk appears acceptable and
not different from those undergoing 6-month therapy dura-
tion. This may be the ideal patient population in which to
prolong DAPT for long-term secondary prevention.
The recent DAPT trial6 demonstrated that 30-month DAPT
with clopidogrel or prasugrel resulted in a signiﬁcant
reduction of both stent thrombosis and major adverse
cardiac event rates compared with patients treated with 12-
month DAPT. Importantly, patients were eligible for random-
ization only if they were free of both ischemic and bleeding
events at 12 months. The implementation of the DAPT study
results into practice would imply that clinicians should adopt
a 2-step strategy for deciding whether DAPT should or
should not be prolonged beyond 12 months and that only
patients free from bleeding events may be selected to
continue DAPT. This approach may expose patients already
identiﬁable as potential bleeders to treatment-related side
effects that could be prevented by stopping DAPT earlier.
Current European Society of Cardiology revascularization
guidelines call for a shorter DAPT duration in patients at high
bleeding risk.8 ACC/AHA guidelines state that if the bleeding
risk is greater than the anticipated beneﬁt, a shortened
duration of DAPT should be considered.7 The results of our
study may help standardize risk assessment for bleeding in
Table 12. Other Ischemic Outcomes in the High and Low to Intermediate CRUSADE Score Groups After 24- or 6-Month Dual
Antiplatelet Therapy
HCS (>40) LICS (≤40)
Pint
24-Month
Clopidogrel
(n=144)
6-Month
Clopidogrel
(n=163) ARD (95% CI)
P
Value
24-Month
Clopidogrel
(n=831)
6-Month
Clopidogrel
(n=808) ARD (95% CI)
P
Value
Death
from all
causes
20.1% (29) 20.9% (34) 0.8% (9.6% to 8.4%) 0.87 4.1% (34) 3.7% (30) 0.4% (1.5% to 2.3%) 0.69 0.56
MI 11.1% (16) 10.4%(17) 0.7% (6.3% to 7.9%) 0.86 2.5% (21) 2.8% (23) 0.3% (1.9% to 1.2%) 0.69 0.71
Definite/
probable
ST*
1.4% (2) 1.2% (2) 0.2% (3.1 to 3.8%) 0.90 1.3% (11) 1.6% (13) 0.3% (1.5 to 0.9%) 0.63 0.83
CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; MI, myocardial
infarction; ST, stent thrombosis.
*Deﬁnite or probable ST deﬁned according to the academic research consortium.
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Ischemic events
The risk of death, MI, or cerebrovascular accident did not
differ in the 24- versus 6-month DAPT groups, both in patients
with HCS (28.5% versus 25.8%; ARD 2.7%; 95% CI 7.2% to
12.6%; P=0.59) and with low to intermediate CRUSADE score
(6.7% versus 6.7%; ARD 0%; 95% CI 2.5% to 2.4%; P=0.96)
(Pint=0.58). (Figure 4C and Table 11) Similarly, when sepa-
rately assessed, the risk of all-cause death, MI, or deﬁnite or
probable stent thrombosis remained homogeneously dis-
tributed between DAPT groups in patients with and without
HCS (Table 12).
Discussion
The main ﬁndings of this study can be summarized as follows.
First, the CRUSADE, HAS-BLED, and ACUITY risk scores
demonstrated reasonably good predictive value with respect
to major bleeding in the PRODIGY all-comer population,
regardless of the bleeding deﬁnition used. Second, bleeding
risk scores also displayed a signiﬁcant capability to predict
ischemic events in terms of major adverse cardiac events, MI,
or stent thrombosis. Third, the CRUSADE risk score, predicted
bleeding signiﬁcantly better than HAS-BLED, with improved
reclassiﬁcation and discrimination performance. Fourth,
patients with HCS treated with 24-month DAPT experienced
a 3-fold higher risk of major bleeding and a 5-fold risk of red
blood cell transfusion compared with 6-month DAPT, without
clear evidence of beneﬁt. The NNTH with an HCS was as low
as 17 for major bleeding and 15 for red blood cell transfusion;
these values were lower than corresponding values in the
unselected patient cohort, suggesting that long-term DAPT
has a narrow therapeutic window and high potential for harm
in this selected patient population with high bleeding risk.
Fifth, conversely, patients not meeting the threshold for the
HCS category—corresponding to as many as 84.2% of the
patients originally included in our study—did not have higher
Figure 5. Hemorrhagic and ischemic outcomes in patients with
high and low to intermediate CRUSADE scores. The forest plot
shows the absolute risk difference and the P value of the
interaction effect for major bleeding, red blood cell transfusion,
and MACE after 24- versus 6-month DAPT in the groups of
patients with high and low to intermediate CRUSADE scores.
CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Imple-
mentation of the ACC/AHA Guidelines; DAPT, dual antiplatelet
therapy; int, interaction; MACE, major adverse cardiovascular
events.
Figure 6. Effects of long- and short-term DAPT on patients with a high CRUSADE score and in the overall
population. The number of patients needed to treat to experience major bleeding or red blood cell
transfusion after 24-month DAPT compared with 6-month treatment is signiﬁcantly lower in the group of
patients with a high CRUSADE score (>40) than in the overall study population. CRUSADE indicates Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy.
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bleeding risk, consistently across bleeding risk scales, if
treated with 24- versus 6-month DAPT duration.
There is consensus currently about the need to choose
intensity and/or duration of potent antithrombotic therapy
after percutaneous coronary intervention through the assess-
ment of actual individual bleeding risk. Nevertheless, it
remains undeﬁned how bleeding risk should be properly
assessed and whether it should truly inﬂuence therapeutic
decisions in clinical practice. The ultimate goal of this
analysis was to select 1 bleeding risk score that could guide
duration of DAPT in clinical practice to maximize beneﬁts
over risks. Among the risk scores explored, we found
CRUSADE to have a better predictive proﬁle for major
bleeding compared with HAS-BLED and a similar proﬁle
compared to ACUITY. This observation is consistent with
some previous studies and with the European Society of
Cardiology guidelines that recommended the CRUSADE
score for bleeding risk stratiﬁcation in non–ST-segment
elevation MI.9,15,16 It might be speculated that the set of
covariates used to predict bleeding risk for the CRUSADE
score better reﬂects the bleeding risk in patients undergoing
stent implantation and subsequent DAPT. Accordingly, we
stratiﬁed the PRODIGY patient population into high versus
nonhigh bleeding risk status based on CRUSADE and
assessed whether a priori bleeding risk could be a treatment
modiﬁer with respect to DAPT duration. We failed to identify
a speciﬁc patient population (eg, those at low or interme-
diate bleeding risk) for which long-term DAPT was associated
with lower rates of ischemic end points compared with a
shortened DAPT regimen. This may reﬂect the null ﬁnding of
the PRODIGY trial with respect to the beneﬁt of long-term
DAPT on death, MI, or stroke. In contrast, our study, which
recruited an all-comer patient population, observed a distinct
increase in bleeding end points in patients treated with 24-
month DAPT. The current stratiﬁed analysis largely expands
on previous ﬁndings by showing that in patients with low to
intermediate risk, prolonging DAPT was not associated with a
signiﬁcant bleeding risk consistently across bleeding scales.
Conversely, we observed bleeding and blood transfusion
hazards associated with long-term DAPT in the selected
cohort of patients with high bleeding risk. Given the
magnitude of this association on both relative and absolute
scales, it may be reasonable to stop DAPT after 6 months in
this selected patient population, given that the risks seem to
largely outweigh the potential beneﬁts. At the same time, in
patients not meeting high bleeding risk criteria according to
the CRUSADE score, bleeding risk appears acceptable and
not different from those undergoing 6-month therapy dura-
tion. This may be the ideal patient population in which to
prolong DAPT for long-term secondary prevention.
The recent DAPT trial6 demonstrated that 30-month DAPT
with clopidogrel or prasugrel resulted in a signiﬁcant
reduction of both stent thrombosis and major adverse
cardiac event rates compared with patients treated with 12-
month DAPT. Importantly, patients were eligible for random-
ization only if they were free of both ischemic and bleeding
events at 12 months. The implementation of the DAPT study
results into practice would imply that clinicians should adopt
a 2-step strategy for deciding whether DAPT should or
should not be prolonged beyond 12 months and that only
patients free from bleeding events may be selected to
continue DAPT. This approach may expose patients already
identiﬁable as potential bleeders to treatment-related side
effects that could be prevented by stopping DAPT earlier.
Current European Society of Cardiology revascularization
guidelines call for a shorter DAPT duration in patients at high
bleeding risk.8 ACC/AHA guidelines state that if the bleeding
risk is greater than the anticipated beneﬁt, a shortened
duration of DAPT should be considered.7 The results of our
study may help standardize risk assessment for bleeding in
Table 12. Other Ischemic Outcomes in the High and Low to Intermediate CRUSADE Score Groups After 24- or 6-Month Dual
Antiplatelet Therapy
HCS (>40) LICS (≤40)
Pint
24-Month
Clopidogrel
(n=144)
6-Month
Clopidogrel
(n=163) ARD (95% CI)
P
Value
24-Month
Clopidogrel
(n=831)
6-Month
Clopidogrel
(n=808) ARD (95% CI)
P
Value
Death
from all
causes
20.1% (29) 20.9% (34) 0.8% (9.6% to 8.4%) 0.87 4.1% (34) 3.7% (30) 0.4% (1.5% to 2.3%) 0.69 0.56
MI 11.1% (16) 10.4%(17) 0.7% (6.3% to 7.9%) 0.86 2.5% (21) 2.8% (23) 0.3% (1.9% to 1.2%) 0.69 0.71
Definite/
probable
ST*
1.4% (2) 1.2% (2) 0.2% (3.1 to 3.8%) 0.90 1.3% (11) 1.6% (13) 0.3% (1.5 to 0.9%) 0.63 0.83
CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; MI, myocardial
infarction; ST, stent thrombosis.
*Deﬁnite or probable ST deﬁned according to the academic research consortium.
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clinical practice and may have implications for tailored DAPT
duration.
Our study has several limitations. First, as a retrospective
analysis, the results provided are hypothesis generating, and a
speciﬁcally designed randomized trial is needed to conﬁrm or
refute our ﬁndings. Second, the scores evaluated in this study
were not validated in an all-comer population and were
designed mostly to predict events in the ﬁrst 30 days after
the index procedure. When assessed individually, all variables
included in each score were independent bleeding predictors.
Third, the outcome of interest for the current analysis was
clinically signiﬁcant major bleeding deﬁned according to the
BARC class 3 or 5 deﬁnition. These events are relatively rare in
modern clinical trials and occurred in only 2.7% of the PRODIGY
population. As such, bigger sample sizes are needed to further
corroborate our ﬁndings. Fourth, CRUSADE, ACUITY, and HAS-
BLED scores were validated using a bleeding deﬁnition that was
different from BARC class 3 or 5, as used in the PRODIGY trial;
however, at sensitivity analysis, the result observed for BARC
were conﬁrmedusing TIMIminor ormajor andGUSTOmoderate
and severe deﬁnitions. Fifth, we did not evaluate the perfor-
mance of other bleeding risk scores apart from those presented
in this analysis; consequently, their incremental value in an all-
comer population should be investigated. Sixth, the bleeding
risk scores were collected only on admission. Considering the
sudden variability of clinical status in this population, the result
of the scores at the moment of randomization or during follow-
up may change over time. Continuous and progressive evalu-
ation of bleeding risk would be ideal but, unfortunately, hardly
feasible.
Conclusions
The CRUSADE, ACUITY, and HAS-BLED bleeding risk scores
displayed reasonable predictive performance in an all-comer
population treated with coronary stenting; among them,
CRUSADE showed the best predictive proﬁle in our dataset.
DAPT for 24 months was associated with a higher risk of major
bleeding in patients at high risk based on the CRUSADE score
but not in those with low or intermediate risk proﬁles. The
CRUSADE score has potential to guide DAPT duration based on
standardization of bleeding risk assessed for each individual
patient.
Disclosures
None.
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clinical practice and may have implications for tailored DAPT
duration.
Our study has several limitations. First, as a retrospective
analysis, the results provided are hypothesis generating, and a
speciﬁcally designed randomized trial is needed to conﬁrm or
refute our ﬁndings. Second, the scores evaluated in this study
were not validated in an all-comer population and were
designed mostly to predict events in the ﬁrst 30 days after
the index procedure. When assessed individually, all variables
included in each score were independent bleeding predictors.
Third, the outcome of interest for the current analysis was
clinically signiﬁcant major bleeding deﬁned according to the
BARC class 3 or 5 deﬁnition. These events are relatively rare in
modern clinical trials and occurred in only 2.7% of the PRODIGY
population. As such, bigger sample sizes are needed to further
corroborate our ﬁndings. Fourth, CRUSADE, ACUITY, and HAS-
BLED scores were validated using a bleeding deﬁnition that was
different from BARC class 3 or 5, as used in the PRODIGY trial;
however, at sensitivity analysis, the result observed for BARC
were conﬁrmedusing TIMIminor ormajor andGUSTOmoderate
and severe deﬁnitions. Fifth, we did not evaluate the perfor-
mance of other bleeding risk scores apart from those presented
in this analysis; consequently, their incremental value in an all-
comer population should be investigated. Sixth, the bleeding
risk scores were collected only on admission. Considering the
sudden variability of clinical status in this population, the result
of the scores at the moment of randomization or during follow-
up may change over time. Continuous and progressive evalu-
ation of bleeding risk would be ideal but, unfortunately, hardly
feasible.
Conclusions
The CRUSADE, ACUITY, and HAS-BLED bleeding risk scores
displayed reasonable predictive performance in an all-comer
population treated with coronary stenting; among them,
CRUSADE showed the best predictive proﬁle in our dataset.
DAPT for 24 months was associated with a higher risk of major
bleeding in patients at high risk based on the CRUSADE score
but not in those with low or intermediate risk proﬁles. The
CRUSADE score has potential to guide DAPT duration based on
standardization of bleeding risk assessed for each individual
patient.
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Derivation and validation of the predicting bleeding 
complications in patients undergoing stent implantation 
and subsequent dual antiplatelet therapy (PRECISE-DAPT) 
score: a pooled analysis of individual-patient datasets from 
clinical trials
Francesco Costa*, David van Klaveren*, Stefan James, Dik Heg, Lorenz Räber, Fausto Feres, Thomas Pilgrim, Myeong-Ki Hong, Hyo-Soo Kim, 
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Ewout W Steyerberg, Marco Valgimigli, for the PRECISE-DAPT Study Investigators
Summary
Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor prevents ischaemic events after 
coronary stenting, but increases bleeding. Guidelines support weighting bleeding risk before the selection of 
treatment duration, but no standardised tool exists for this purpose.
Methods A total of 14 963 patients treated with DAPT after coronary stenting—largely consisting of aspirin and 
clopidogrel and without indication to oral anticoagulation—were pooled at a single-patient level from eight multicentre 
randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we 
identiﬁed predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratiﬁed 
by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in 
the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet 
inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed 
within patients randomised to diﬀerent DAPT durations (n=10 081) to identify the eﬀect on bleeding and ischaemia of 
a long (12–24 months) or short (3–6 months) treatment in relation to baseline bleeding risk.
Findings The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous 
spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61–0·85) 
in the derivation cohort, and 0·70 (0·65–0·74) in the PLATO trial validation cohort and 0·66 (0·61–0·71) in the 
BernPCI registry validation cohort. A longer DAPT duration signiﬁcantly increased bleeding in patients at high risk 
(score ≥25), but not in those with lower risk proﬁles (pinteraction=0·007), and exerted a signiﬁcant ischaemic beneﬁt only 
in this latter group.
Interpretation The PRECISE-DAPT score is a simple ﬁve-item risk score, which provides a standardised tool for the 
prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, 
this tool can support clinical decision making for treatment duration.
Funding None.
Introduction
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 
inhibitor reduces ischaemic recurrences in patients with 
coronary artery disease treated with coronary stents.1–3 
However, this beneﬁt is counterbalanced by higher 
bleeding risk, which is linearly related to the treatment 
duration. Both ischaemic and bleeding risks have 
potential to negatively impact prognosis.4 As a result, 
although 12 months of DAPT after stenting has been 
commonly suggested, the optimal duration of treatment 
is still debated.5,6
Shortening DAPT duration from 12 months to 6 or 
3 months signiﬁcantly reduced bleeding liability.4 
However, a prolonged treatment beyond 12 months 
reduced both stent-related and non-stent-related 
ischaemic events in selected patients who tolerated the 
ﬁrst year of treatment without bleeding.4,7
International guidelines encourage weighting bleeding 
risk before selection of treatment duration and suggest a 
shorter than 12 month treatment regimen in patients at 
high bleeding risk.5,6 No standardised tool exists to weigh 
bleeding risk at the time of DAPT initiation. A prediction 
rule was recently proposed for patients who tolerated 
12 month DAPT to select those eligible for treatment 
prolongation.8 This strategy cannot be applied earlier, at 
the time of treatment initiation, to select a shorter than 
12 month treatment duration in patients at high bleeding 
risk. Thus, no standardised algorithm is available for 
deﬁning optimal DAPT duration at the time of coronary 
stent implantation.
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inhibitor reduces ischaemic recurrences in patients with 
coronary artery disease treated with coronary stents.1–3 
However, this beneﬁt is counterbalanced by higher 
bleeding risk, which is linearly related to the treatment 
duration. Both ischaemic and bleeding risks have 
potential to negatively impact prognosis.4 As a result, 
although 12 months of DAPT after stenting has been 
commonly suggested, the optimal duration of treatment 
is still debated.5,6
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We created a bleeding risk score for patients treated with 
DAPT after coronary stent implantation, in a large pooled 
dataset of contemporary randomised clinical trials 
implementing diﬀerent DAPT duration strategies. We 
externally validated this novel risk score in two independent 
cohorts of patients treated with percutaneous coronary 
intervention (PCI) from a large randomised clinical trial 
and a contemporary real-world registry. The score was 
retrospectively applied among patients randomly assigned 
to a shortened or prolonged DAPT duration to assess 
ischaemic and bleeding outcomes according to each 
bleeding risk category with each DAPT regimen.
Methods
Study design and population
The PRECISE-DAPT collaborative study included a total 
of 14 963 patients with coronary artery disease who 
underwent elective, urgent, or emergent PCI with 
coronary stent implantation and subsequent DAPT 
(appendix p 24). DAPT consisted of an association of 
aspirin plus a P2Y12 inhibitor, most commonly clopidogrel 
(88%), whereas patients with an indication for long-term 
oral anticoagulation were excluded. Patients were pooled 
at an individual level from eight contemporary multicentre 
randomised clinical trials.9–16 The patients were enrolled in 
139 diﬀerent clinical sites from 12 countries worldwide 
(appendix p 25). Extensive details regarding the pooled 
datasets are provided in the appendix (p 4). Inclusion and 
exclusion criteria are presented in the appendix (p 6). 
Details regarding population type, randomisation, DAPT 
duration, and drug adherence are presented in the 
appendix (p 8). All clinical trials were approved by the 
ethics committees at each study centre, and all patients 
provided written informed consent.
Outcomes
All clinical and laboratory variables included in this 
analysis were prospectively collected. The primary 
endpoint of this analysis was out-of-hospital bleeding 
deﬁned according to the Thrombosis in Myocardial 
Infarction (TIMI) deﬁnition, and occurring 7 days or later 
after the initial invasive procedure, while bleeding 
occurring earlier was censored. We selected the 7 day 
timeframe as a conservative estimate based on the upper 
limit of current hospitalisation trends in patients with 
acute coronary syndrome, and to exclude events 
occurring during hospital stay, which are largely related 
to invasive procedures.17 Further deﬁnitions for bleeding 
and clinical variables are provided in the appendix (p 4).
Validation cohorts
An external validation of the risk score was done in the 
context of two independent PCI-treated populations from 
the PLATelet inhibition and patient Outcomes (PLATO) 
Research in context
Evidence before this study
Spontaneous bleeding during treatment with dual antiplatelet 
therapy (DAPT) is the most common complication after 
coronary stenting, and its incidence increased with the 
introduction of novel and more potent antithrombotic 
agents. Despite recommendations from international 
guidelines, methods to gauge out-of-hospital bleeding risk in 
patients treated with DAPT are limited. A dedicated risk score 
speciﬁcally designed to predict spontaneous on-DAPT 
bleeding events might improve risk assessment and support 
clinicians’ decisions with respect to dual antiplatelet therapy.
We searched PubMed without language or date restrictions for 
publications until Sept 30, 2016, about bleeding risk scores in 
patients treated with DAPT. We used the search terms 
“percutaneous coronary intervention”, “coronary stent”, 
“acute coronary syndrome”, “stable coronary artery disease”, 
“bleeding risk score”, “bleeding”, “antiplatelet therapy”, “dual 
antiplatelet therapy”, “clopidogrel”, “prasugrel”, and 
“ticagrelor”. We excluded articles regarding antithrombotic 
treatment in atrial ﬁbrillation, concomitant use of oral 
anticoagulants, and risk prediction models for in-hospital 
bleeding. We identiﬁed two reports focused on out-of-hospital 
events in patients treated with DAPT, and one was only 
applicable after a 12 month course with DAPT was completed 
without complications.
Added value of this study
We propose a novel risk score for the prediction of 
out-of-hospital bleeding in patients treated with DAPT using age, 
creatinine clearance, white-blood-cell count, haemoglobin, and 
history of bleeding. The PRECISE-DAPT score is a simple bedside 
risk assessment tool, which can be easily implemented in 
everyday clinical practice, and that might be particularly useful 
for its applicability at the time of treatment initiation. 
The PRECISE-DAPT score showed potential to identify patients 
at high bleeding risk (score ≥25) who might beneﬁt from a 
shortened (ie, <12 months) DAPT duration. Patients not at high 
bleeding risk (score <25) might receive a standard (ie, 12 months) 
or prolonged (ie, >12 months) treatment without being exposed 
to signiﬁcant bleeding liability.
Implication of all the available evidence
Our study provides awareness to clinicians regarding 
out-of-hospital bleeding risk factors in patients treated with 
DAPT after coronary stent implantation and oﬀers an objective 
and standardised tool to quantify such risk in clinical practice. 
Systematic evaluation of these predictors with the novel 
PRECISE-DAPT bleeding risk score has potential to support 
clinical decision making with respect to the optimal duration of 
DAPT, selecting patients at high bleeding risk (score ≥25) to a 
shorter treatment and patients at non-high risk to a standard 
or long treatment.
See Online for appendix
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trial and the BernPCI Registry (appendix p 24).2 In brief, 
the PLATO trial (NCT00391872) included patients with ST 
elevation or non-ST elevation acute coronary syndrome 
randomly assigned to receive DAPT with either clopidogrel 
or ticagrelor in addition to aspirin for up to 12 months. In 
the current study, we restricted our analysis to patients 
undergoing PCI during index hospitalisation. The 
BernPCI registry (NCT02241291) included all patients 
undergoing PCI at Bern University Hospital, Switzerland, 
between Feb 23, 2009, and Dec 31, 2014.
The novel score was calculated and assigned to each 
participant in a similar manner as in the derivation cohort. 
The information on previous bleeding in PLATO was 
related to previous gastrointestinal bleeding, as no other 
previous bleeding types were prospectively collected in the 
study case report form. We calculated the PARIS bleeding 
risk score (age, body-mass index, current smoking, 
anaemia, creatinine clearance, triple therapy on discharge) 
in the external validation cohorts to provide comparative 
assessment of two prediction models.18 Further details for 
score calculation in the validation cohorts are provided in 
the appendix (p 4). The primary endpoint for score 
validation was the occurrence of TIMI major or minor 
bleeding at 7 days or later after study inclusion and at up to 
12 months. Data in both validation cohorts were 
prospectively collected and a blinded clinical events 
committee independently adjudicated adverse events. All 
patients enrolled provided written informed consent.
Statistical analysis
A detailed description of the statistical analysis is provided 
in the appendix (p 4). We estimated the 1 year cumulative 
incidence of bleeding by one minus the Kaplan-Meier 
estimate of bleeding-free survival at 1 year, to take loss to 
follow-up into account. We studied the associations 
between possible predictors and TIMI bleeding from day 7 
onwards with a Cox regression analysis, stratiﬁed by trial. 
Potential predictors of bleeding were selected at univariable 
analysis (p<0·10).19 Independent bleeding predictors were 
selected with multivariable backward selection (p<0·10). 
Linear predictor values were scaled and rounded to a score 
with integer values between 0 and 100. Discrimination of 
the bleeding risk score was assessed by trial-speciﬁc 
Harrell’s c-indices, which were pooled with a random 
eﬀects meta-analysis.20,21 We evaluated the score 
performance by censoring patients’ follow-up time and 
events occurring after the intended DAPT treatment 
duration and excluded patients who were not treated with 
DAPT at discharge (1·7%). The ability to identify patients at 
high bleeding risk was visualised by Kaplan-Meier 
cumulative bleeding incidence curves in bleeding risk 
score quartiles. Calibration was assessed by comparing 
predicted probabilities with 1 year Kaplan-Meier bleeding 
incidence estimates. Furthermore, discrimination and 
calibration of the bleeding risk score were assessed in the 
two external validation cohorts. c-Indices, integrated 
discrimination improvement (IDI), and net reclassiﬁcation 
improvement (NRI) were computed to compare the 
performance of the PRECISE-DAPT score with the PARIS 
bleeding score in both validation cohorts.22,23 Finally, we 
evaluated the eﬀect of short (ie, 3–6 months) and long (ie, 
12–24 months) DAPT duration on bleeding and ischaemic 
events across bleeding risk score quartiles in patients 
(n=10 081) randomly allocated to DAPT duration. 
Interaction between high (highest quartile) versus non-
high (lowest three quartiles) bleeding risk score and DAPT 
duration was assessed by the heterogeneity in absolute risk 
diﬀerences for bleeding and ischaemic events. The analyses 
were done in accordance with the TRIPOD statement.24 
Data were analysed with R version 3.6 (R Foundation, 
Vienna, Austria).
Role of the funding source
All trials included in the PRECISE-DAPT collaborative 
study were investigator initiated and each sponsor had 
no role in the data analysis, interpretation, or writing of 
the report. The corresponding and ﬁrst, second, and 
fourth authors (MV, FC, DvK, and DH) had full access to 
the data and had ﬁnal responsibility for the decision to 
submit for publication.
Results
The study population included 14 963 patients with 
established coronary artery disease, and treated with 
coronary stent implantation (appendix p 9). DAPT at 
discharge was implemented in most patients (14 590 of 
14 848 patients; 98·3%) with a median treatment duration 
of 360 days (IQR 95–365).
In a total of 21 963 person-years of follow-up (median 
follow-up 552 days, IQR 365–725), out-of-hospital TIMI 
major or minor bleeding occurred in 218 patients 
(incidence at 1 year 12·5 per 1000 patients), 124 of 
whom were major (incidence at 1 year 6·9 per 
1000 patients). The median time to ﬁrst occurrence of 
TIMI major or minor bleeding was 158 days 
(IQR 57–333) and 150 days (62–326) for TIMI major 
bleeding. The rate of bleeding stratiﬁed by clinical trial 
Hazard ratio (95% CI) p value
Age (for each increase of 10 years) 1·34 (1·11–1·48) 0·005
Previous bleeding 4·14 (1·22–14·02) 0·023
White-blood-cell count (for each 
increase of 103 cells per μL)
1·06 (0·99–1·13) 0·078
Haemoglobin at baseline (for each 
increase of 1 g/dL)
0·67 (0·53–0·84) 0·001
Creatinine clearance (for each increase 
of 10 mL/min)
0·90 (0·82–0·99) 0·004
Age was truncated above 90 years and below 50 years. Haemoglobin at baseline 
was truncated above 12 g/dL and below 10 g/dL. Creatinine clearance was 
truncated above 100 mL/min. White-blood-cell count was truncated above 
20×10³ cells per μL and below 5×10³ cells per μL.
Table 1: Multivariable analysis for out-of-hospital Thrombosis in 
Myocardial Infarction major or minor bleeding, study stratiﬁed with 
backward selection at an α level of 0·1
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We created a bleeding risk score for patients treated with 
DAPT after coronary stent implantation, in a large pooled 
dataset of contemporary randomised clinical trials 
implementing diﬀerent DAPT duration strategies. We 
externally validated this novel risk score in two independent 
cohorts of patients treated with percutaneous coronary 
intervention (PCI) from a large randomised clinical trial 
and a contemporary real-world registry. The score was 
retrospectively applied among patients randomly assigned 
to a shortened or prolonged DAPT duration to assess 
ischaemic and bleeding outcomes according to each 
bleeding risk category with each DAPT regimen.
Methods
Study design and population
The PRECISE-DAPT collaborative study included a total 
of 14 963 patients with coronary artery disease who 
underwent elective, urgent, or emergent PCI with 
coronary stent implantation and subsequent DAPT 
(appendix p 24). DAPT consisted of an association of 
aspirin plus a P2Y12 inhibitor, most commonly clopidogrel 
(88%), whereas patients with an indication for long-term 
oral anticoagulation were excluded. Patients were pooled 
at an individual level from eight contemporary multicentre 
randomised clinical trials.9–16 The patients were enrolled in 
139 diﬀerent clinical sites from 12 countries worldwide 
(appendix p 25). Extensive details regarding the pooled 
datasets are provided in the appendix (p 4). Inclusion and 
exclusion criteria are presented in the appendix (p 6). 
Details regarding population type, randomisation, DAPT 
duration, and drug adherence are presented in the 
appendix (p 8). All clinical trials were approved by the 
ethics committees at each study centre, and all patients 
provided written informed consent.
Outcomes
All clinical and laboratory variables included in this 
analysis were prospectively collected. The primary 
endpoint of this analysis was out-of-hospital bleeding 
deﬁned according to the Thrombosis in Myocardial 
Infarction (TIMI) deﬁnition, and occurring 7 days or later 
after the initial invasive procedure, while bleeding 
occurring earlier was censored. We selected the 7 day 
timeframe as a conservative estimate based on the upper 
limit of current hospitalisation trends in patients with 
acute coronary syndrome, and to exclude events 
occurring during hospital stay, which are largely related 
to invasive procedures.17 Further deﬁnitions for bleeding 
and clinical variables are provided in the appendix (p 4).
Validation cohorts
An external validation of the risk score was done in the 
context of two independent PCI-treated populations from 
the PLATelet inhibition and patient Outcomes (PLATO) 
Research in context
Evidence before this study
Spontaneous bleeding during treatment with dual antiplatelet 
therapy (DAPT) is the most common complication after 
coronary stenting, and its incidence increased with the 
introduction of novel and more potent antithrombotic 
agents. Despite recommendations from international 
guidelines, methods to gauge out-of-hospital bleeding risk in 
patients treated with DAPT are limited. A dedicated risk score 
speciﬁcally designed to predict spontaneous on-DAPT 
bleeding events might improve risk assessment and support 
clinicians’ decisions with respect to dual antiplatelet therapy.
We searched PubMed without language or date restrictions for 
publications until Sept 30, 2016, about bleeding risk scores in 
patients treated with DAPT. We used the search terms 
“percutaneous coronary intervention”, “coronary stent”, 
“acute coronary syndrome”, “stable coronary artery disease”, 
“bleeding risk score”, “bleeding”, “antiplatelet therapy”, “dual 
antiplatelet therapy”, “clopidogrel”, “prasugrel”, and 
“ticagrelor”. We excluded articles regarding antithrombotic 
treatment in atrial ﬁbrillation, concomitant use of oral 
anticoagulants, and risk prediction models for in-hospital 
bleeding. We identiﬁed two reports focused on out-of-hospital 
events in patients treated with DAPT, and one was only 
applicable after a 12 month course with DAPT was completed 
without complications.
Added value of this study
We propose a novel risk score for the prediction of 
out-of-hospital bleeding in patients treated with DAPT using age, 
creatinine clearance, white-blood-cell count, haemoglobin, and 
history of bleeding. The PRECISE-DAPT score is a simple bedside 
risk assessment tool, which can be easily implemented in 
everyday clinical practice, and that might be particularly useful 
for its applicability at the time of treatment initiation. 
The PRECISE-DAPT score showed potential to identify patients 
at high bleeding risk (score ≥25) who might beneﬁt from a 
shortened (ie, <12 months) DAPT duration. Patients not at high 
bleeding risk (score <25) might receive a standard (ie, 12 months) 
or prolonged (ie, >12 months) treatment without being exposed 
to signiﬁcant bleeding liability.
Implication of all the available evidence
Our study provides awareness to clinicians regarding 
out-of-hospital bleeding risk factors in patients treated with 
DAPT after coronary stent implantation and oﬀers an objective 
and standardised tool to quantify such risk in clinical practice. 
Systematic evaluation of these predictors with the novel 
PRECISE-DAPT bleeding risk score has potential to support 
clinical decision making with respect to the optimal duration of 
DAPT, selecting patients at high bleeding risk (score ≥25) to a 
shorter treatment and patients at non-high risk to a standard 
or long treatment.
See Online for appendix
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trial and the BernPCI Registry (appendix p 24).2 In brief, 
the PLATO trial (NCT00391872) included patients with ST 
elevation or non-ST elevation acute coronary syndrome 
randomly assigned to receive DAPT with either clopidogrel 
or ticagrelor in addition to aspirin for up to 12 months. In 
the current study, we restricted our analysis to patients 
undergoing PCI during index hospitalisation. The 
BernPCI registry (NCT02241291) included all patients 
undergoing PCI at Bern University Hospital, Switzerland, 
between Feb 23, 2009, and Dec 31, 2014.
The novel score was calculated and assigned to each 
participant in a similar manner as in the derivation cohort. 
The information on previous bleeding in PLATO was 
related to previous gastrointestinal bleeding, as no other 
previous bleeding types were prospectively collected in the 
study case report form. We calculated the PARIS bleeding 
risk score (age, body-mass index, current smoking, 
anaemia, creatinine clearance, triple therapy on discharge) 
in the external validation cohorts to provide comparative 
assessment of two prediction models.18 Further details for 
score calculation in the validation cohorts are provided in 
the appendix (p 4). The primary endpoint for score 
validation was the occurrence of TIMI major or minor 
bleeding at 7 days or later after study inclusion and at up to 
12 months. Data in both validation cohorts were 
prospectively collected and a blinded clinical events 
committee independently adjudicated adverse events. All 
patients enrolled provided written informed consent.
Statistical analysis
A detailed description of the statistical analysis is provided 
in the appendix (p 4). We estimated the 1 year cumulative 
incidence of bleeding by one minus the Kaplan-Meier 
estimate of bleeding-free survival at 1 year, to take loss to 
follow-up into account. We studied the associations 
between possible predictors and TIMI bleeding from day 7 
onwards with a Cox regression analysis, stratiﬁed by trial. 
Potential predictors of bleeding were selected at univariable 
analysis (p<0·10).19 Independent bleeding predictors were 
selected with multivariable backward selection (p<0·10). 
Linear predictor values were scaled and rounded to a score 
with integer values between 0 and 100. Discrimination of 
the bleeding risk score was assessed by trial-speciﬁc 
Harrell’s c-indices, which were pooled with a random 
eﬀects meta-analysis.20,21 We evaluated the score 
performance by censoring patients’ follow-up time and 
events occurring after the intended DAPT treatment 
duration and excluded patients who were not treated with 
DAPT at discharge (1·7%). The ability to identify patients at 
high bleeding risk was visualised by Kaplan-Meier 
cumulative bleeding incidence curves in bleeding risk 
score quartiles. Calibration was assessed by comparing 
predicted probabilities with 1 year Kaplan-Meier bleeding 
incidence estimates. Furthermore, discrimination and 
calibration of the bleeding risk score were assessed in the 
two external validation cohorts. c-Indices, integrated 
discrimination improvement (IDI), and net reclassiﬁcation 
improvement (NRI) were computed to compare the 
performance of the PRECISE-DAPT score with the PARIS 
bleeding score in both validation cohorts.22,23 Finally, we 
evaluated the eﬀect of short (ie, 3–6 months) and long (ie, 
12–24 months) DAPT duration on bleeding and ischaemic 
events across bleeding risk score quartiles in patients 
(n=10 081) randomly allocated to DAPT duration. 
Interaction between high (highest quartile) versus non-
high (lowest three quartiles) bleeding risk score and DAPT 
duration was assessed by the heterogeneity in absolute risk 
diﬀerences for bleeding and ischaemic events. The analyses 
were done in accordance with the TRIPOD statement.24 
Data were analysed with R version 3.6 (R Foundation, 
Vienna, Austria).
Role of the funding source
All trials included in the PRECISE-DAPT collaborative 
study were investigator initiated and each sponsor had 
no role in the data analysis, interpretation, or writing of 
the report. The corresponding and ﬁrst, second, and 
fourth authors (MV, FC, DvK, and DH) had full access to 
the data and had ﬁnal responsibility for the decision to 
submit for publication.
Results
The study population included 14 963 patients with 
established coronary artery disease, and treated with 
coronary stent implantation (appendix p 9). DAPT at 
discharge was implemented in most patients (14 590 of 
14 848 patients; 98·3%) with a median treatment duration 
of 360 days (IQR 95–365).
In a total of 21 963 person-years of follow-up (median 
follow-up 552 days, IQR 365–725), out-of-hospital TIMI 
major or minor bleeding occurred in 218 patients 
(incidence at 1 year 12·5 per 1000 patients), 124 of 
whom were major (incidence at 1 year 6·9 per 
1000 patients). The median time to ﬁrst occurrence of 
TIMI major or minor bleeding was 158 days 
(IQR 57–333) and 150 days (62–326) for TIMI major 
bleeding. The rate of bleeding stratiﬁed by clinical trial 
Hazard ratio (95% CI) p value
Age (for each increase of 10 years) 1·34 (1·11–1·48) 0·005
Previous bleeding 4·14 (1·22–14·02) 0·023
White-blood-cell count (for each 
increase of 103 cells per μL)
1·06 (0·99–1·13) 0·078
Haemoglobin at baseline (for each 
increase of 1 g/dL)
0·67 (0·53–0·84) 0·001
Creatinine clearance (for each increase 
of 10 mL/min)
0·90 (0·82–0·99) 0·004
Age was truncated above 90 years and below 50 years. Haemoglobin at baseline 
was truncated above 12 g/dL and below 10 g/dL. Creatinine clearance was 
truncated above 100 mL/min. White-blood-cell count was truncated above 
20×10³ cells per μL and below 5×10³ cells per μL.
Table 1: Multivariable analysis for out-of-hospital Thrombosis in 
Myocardial Infarction major or minor bleeding, study stratiﬁed with 
backward selection at an α level of 0·1
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and type of P2Y12 inhibitor are presented in the appendix 
(pp 12, 26).
Predictors with a p value less than 0·10 at univariable 
analysis (appendix p 9) were included in the multivariable 
model. Use of proton-pump inhibitors at discharge was 
excluded because of lack of prediction within studies 
where DAPT duration was randomised. Five predictors 
remained in the ﬁnal model at a p value less than 
0·10 (table 1), and showed consistent association with 
bleeding during the ﬁrst trimester after treatment 
initiation as well as beyond (appendix p 13). An alternative 
model, which has been generated after excluding white-
blood-cell count, is shown in the appendix (p 14).
From the ﬁnal multivariable model, we developed a 
ﬁve-item bleeding risk score (age, creatinine clearance, 
haemoglobin, white-blood-cell count at baseline, and 
previous spontaneous bleeding—the PRECISE-DAPT 
score) assigning points to each factor based on the 
magnitude of association of each predictor with bleeding. 
A nomogram to calculate the score and the risk of 
bleeding at 12 months is presented in ﬁgure 1.
Similar information derived from the model lacking 
white-blood-cell count is presented in the appendix (p 27). 
A web calculator and mobile app are available online.
The PRECISE-DAPT score showed a c-index of 0·73 
(95% CI 0·61–0·85) for out-of-hospital TIMI major or 
minor bleeding and 0·71 (0·57–0·85) for TIMI major 
bleeding within 12 months (table 2). c-Indices for each of 
the included studies are presented in the appendix (p 15). 
The score discrimination was consistent regardless of 
the clinical presentation at the time of PCI or treatment 
with clopidogrel or ticagrelor, but was apparently lower 
for patients treated with prasugrel and higher for those 
treated with proton-pump inhibitors (appendix pp 16–18). 
The performance of the score lacking white-blood-cell 
count is presented in table 2 and the appendix (p 29). 
Kaplan-Meier bleeding rates were consistently separated 
by score quartiles (very low risk: score ≤10; low risk: 
score 11–17; moderate risk: score 18–24; and high risk 
risk: score ≥25; ﬁgure 2).
The PRECISE-DAPT score was validated in 
8595 PCI patients from the PLATO trial and 
6172 participants from the BernPCI registry (appendix 
p 19). TIMI major or minor bleeding occurred in 
145 patients (1·69%) in the PLATO trial and 94 patients 
(1·52%) in the BernPCI registry. TIMI major bleeding was 
noted in 94 patients (1·09%) in the PLATO trial and 
62 patients (1·00%) in the BernPCI registry. The c-indices 
for out-of-hospital TIMI major or minor bleeding were 
0·70 (95% CI 0·65–0·74) in the PLATO trial and 0·66 
(0·61–0·71) in the BernPCI registry (table 2). Calibration 
appeared good between the derivation and BernPCI 
validation cohorts. In the PLATO validation cohort, the 
score maintained a consistent association between 
predicted probabilities and observed frequencies, whereas 
bleeding risk was slightly underestimated (appendix p 28). 
Score discrimination appeared consistent for Bleeding 
Academic Research Consortium (BARC) bleeding in the 
BernPCI cohort (BARC 3 or 5: c-index 0·68 [95% CI 
0·63–0·73]; BARC 2, 3, or 5: c-index 0·68 [0·63–0·72]; 
appendix p 22). Score performance was also consistent, 
including bleeding occurring earlier than 7 days after PCI 
(appendix p 23). Discrimination for the score lacking 
white-blood-cell count was similar to the score including 
white-blood-cell count in the PLATO trial, whereas it was 
lower in the BernPCI registry (table 2, appendix p 29).
The PRECISE-DAPT score showed improved integrated 
discrimination and reclassiﬁcation performance as 
For the web calculator and 
mobile app see www.
precisedaptscore.com
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Figure 1: The PRECISE-DAPT score nomogram for bedside application
Risk curves refer to out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding and TIMI 
major bleeding at 12 months while on-treatment with dual antiplatelet therapy (DAPT). Histogram refers to the 
PRECISE-DAPT score distribution in the derivation cohort: green bars, the ﬁrst score quartile (very low risk); blue 
bars,  the second score quartile (low risk); purple bars, the third score quartile (moderate risk); and red bars, the 
fourth score quartile (high risk).
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com pared with the PARIS score in both validation cohorts 
for TIMI major or minor bleeding (table 2). Discriminative 
ability according to the c-index was similar between the 
two scores (table 2). The alternative version of the 
score lacking white-blood-cell count showed improved 
discrimination and reclassiﬁcation in the PLATO validation 
cohort, and similar performance as compared with the 
PARIS score in the BernPCI second validation cohort.
DAPT duration was randomly allocated in ﬁve of the 
eight studies included in the generation dataset, with 
5050 patients assigned to either 12 months or 24 months of 
treatment and 5031 to 3 months or 6 months.11–15 We 
observed a signiﬁcant increase in bleeding with a 
long (12–24 months) rather than short (3–6 months) 
duration of treatment exclusively in patients at high 
bleeding risk (absolute risk diﬀerence [ARD] +2·59% 
[95% CI +0·82 to +4·34]; number needed to treat: 38) but 
not in those without a high bleeding risk proﬁle (ie, very 
low risk, low risk, and moderate risk: mean of the ﬁrst 
three quartiles ARD +0·14% [–0·22 to +0·49]; 
pinteraction=0·007; ﬁgure 3). This remained consistent after 
censoring events occurring beyond 1 year after PCI (pinteraction 
=0·047; appendix p 30). Concurrently, longer DAPT 
duration reduced the composite ischaemic endpoint of 
myocardial infarction, deﬁnite stent thrombosis, stroke, or 
target vessel revascularisation in those at non-high 
bleeding risk (ARD –1·53% [95% CI –2·64 to –0·41]; 
number needed to treat: 65), but not in those at high 
bleeding risk (ARD +1·41% [–1·67 to +4·50]; pinteraction=0·07; 
ﬁgure 4). When the composite of myocardial infarction, 
deﬁnite ST, or stroke was assessed, longer DAPT duration 
was not associated with a clear beneﬁt in patients at non-
high bleeding risk (ARD –0·42% [95% CI –1·02 to +0·17]) 
and to the possibility of harm in those at high bleeding risk 
(ARD +1·96% [–0·39 to +4·30]; pinteraction=0·054; appendix 
p 31). The resulting net eﬀect on bleeding and ischaemia 
suggested a favourable outcome with 12–24 month DAPT 
in patients at non-high bleeding risk, but not in those at 
high PRECISE-DAPT risk (ﬁgure 4).
At sensitivity analysis, we tested the eﬀect of randomised 
DAPT duration among bleeding risk strata in the 
subgroup of patients presenting with acute coronary 
syndrome at the time of PCI, with results remaining 
largely consistent with those observed in the overall 
population (appendix pp 32, 33). Patients presenting with 
acute coronary syndrome and with a PRECISE-DAPT 
score of at least 25 showed a signiﬁcant increase in TIMI 
bleeding after treatment with longer DAPT (ARD +2·61% 
[95% CI +0·19 to +4·99]; number needed to treat: 38), 
whereas those with a non-high PRECISE-DAPT risk 
score did not (ARD +0·14% [–0·22 to +0·49]; 
pinteraction=0·034). At the same time, longer DAPT duration 
reduced the composite ischaemic endpoint in patients 
with acute coronary syndrome at a non-high PRECISE-
DAPT score (ARD –4·13% [95% CI –6·09 to –2·15]; 
number needed to treat: 24), but not in those with a 
PRECISE-DAPT score of at least 25 (ARD +1·54% 
[–3·27 to +6·32]; pinteraction=0·032; appendix p 32).
Discussion
Ischaemic recurrences after stenting have dropped 
considerably in the last years thanks to the introduction 
of novel stent technologies and progressive reﬁnement 
of pharmaco-interventional techniques. However, due to 
more potent and prolonged platelet inhibition, the 
incidence of major bleeding has increased.25 DAPT-
TIMI major or minor bleeding TIMI major bleeding
c-Index (95% CI) p value* NRI IDI c-Index (95% CI) p value* NRI IDI
Index p value Index p value Index p value Index p value
Derivation cohort
PRECISE-DAPT 0·73 (0·61–0·85) ·· ·· ·· ·· ·· 0·71 (0·57–0·85) ·· ·· ·· ·· ··
PRECISE-DAPT alternative 0·71 (0·57–0·84) ·· ·· ·· ·· ·· 0·69 (0·53–0·85) ·· ·· ·· ·· ··
Validation cohort 1 (PLATO)
PRECISE-DAPT 0·70 (0·65–0·74) 0·06 0·16 0·047 0·004 0·007 0·68 (0·63–0·74) 0·01 0·23 0·02 0·004 0·002
PRECISE-DAPT alternative 0·70 (0·66–0·74) 0·02 0·20 0·02 0·005 0·003 0·68 (0·63–0·74) 0·008 0·23 0·02 0·004 0·002
PARIS 0·66 (0·61–0·70) Ref Ref ·· Ref ·· 0·62 (0·56–0·68) Ref Ref ·· Ref ··
Validation cohort 2 (BernPCI)
PRECISE-DAPT 0·66 (0·61–0·71) 0·09 0·21 0·037 0·004 0·01 0·65 (0·58–0·71) 0·17 0·14 0·23 0·002 0·049
PRECISE-DAPT alternative 0·63 (0·58–0·68) 0·82 0·09 0·37 0·001 0·07 0·62 (0·55–0·68) 0·57 0·03 0·77 0·0001 0·15
PARIS 0·63 (0·58–0·67) Ref Ref ·· Ref ·· 0·62 (0·56–0·69) Ref Ref ·· Ref ··
PRECISE-DAPT score is age, creatinine clearance, haemoglobin, white-blood-cell count at baseline, and previous spontaneous bleeding. PRECISE-DAPT alternative score is age, creatinine clearance, haemoglobin 
at baseline, and previous spontaneous bleeding. PARIS is age, body-mass index, current smoking status, presence of anaemia (haemoglobin <12 g/dL in men and <11 g/dL in women), creatinine clearance 
<60 mL/dL, and treatment with triple therapy (ie, aspirin plus P2Y12 inhibitor plus oral anticoagulant) at discharge. TIMI=Thrombosis in Myocardial Infarction. NRI=net reclassiﬁcation improvement. 
IDI=integrated discrimination improvement. *The PARIS score has been used as reference to test c-indices, IDI, and NRI as compared with the PRECISE-DAPT scores.
Table 2: Discriminative ability of the PRECISE-DAPT score in the derivation cohort and discriminative–reclassiﬁcation ability in comparison with the PARIS score in the validation cohorts 
for out-of-hospital bleeding occurring while on-treatment with dual antiplatelet therapy (DAPT)
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and type of P2Y12 inhibitor are presented in the appendix 
(pp 12, 26).
Predictors with a p value less than 0·10 at univariable 
analysis (appendix p 9) were included in the multivariable 
model. Use of proton-pump inhibitors at discharge was 
excluded because of lack of prediction within studies 
where DAPT duration was randomised. Five predictors 
remained in the ﬁnal model at a p value less than 
0·10 (table 1), and showed consistent association with 
bleeding during the ﬁrst trimester after treatment 
initiation as well as beyond (appendix p 13). An alternative 
model, which has been generated after excluding white-
blood-cell count, is shown in the appendix (p 14).
From the ﬁnal multivariable model, we developed a 
ﬁve-item bleeding risk score (age, creatinine clearance, 
haemoglobin, white-blood-cell count at baseline, and 
previous spontaneous bleeding—the PRECISE-DAPT 
score) assigning points to each factor based on the 
magnitude of association of each predictor with bleeding. 
A nomogram to calculate the score and the risk of 
bleeding at 12 months is presented in ﬁgure 1.
Similar information derived from the model lacking 
white-blood-cell count is presented in the appendix (p 27). 
A web calculator and mobile app are available online.
The PRECISE-DAPT score showed a c-index of 0·73 
(95% CI 0·61–0·85) for out-of-hospital TIMI major or 
minor bleeding and 0·71 (0·57–0·85) for TIMI major 
bleeding within 12 months (table 2). c-Indices for each of 
the included studies are presented in the appendix (p 15). 
The score discrimination was consistent regardless of 
the clinical presentation at the time of PCI or treatment 
with clopidogrel or ticagrelor, but was apparently lower 
for patients treated with prasugrel and higher for those 
treated with proton-pump inhibitors (appendix pp 16–18). 
The performance of the score lacking white-blood-cell 
count is presented in table 2 and the appendix (p 29). 
Kaplan-Meier bleeding rates were consistently separated 
by score quartiles (very low risk: score ≤10; low risk: 
score 11–17; moderate risk: score 18–24; and high risk 
risk: score ≥25; ﬁgure 2).
The PRECISE-DAPT score was validated in 
8595 PCI patients from the PLATO trial and 
6172 participants from the BernPCI registry (appendix 
p 19). TIMI major or minor bleeding occurred in 
145 patients (1·69%) in the PLATO trial and 94 patients 
(1·52%) in the BernPCI registry. TIMI major bleeding was 
noted in 94 patients (1·09%) in the PLATO trial and 
62 patients (1·00%) in the BernPCI registry. The c-indices 
for out-of-hospital TIMI major or minor bleeding were 
0·70 (95% CI 0·65–0·74) in the PLATO trial and 0·66 
(0·61–0·71) in the BernPCI registry (table 2). Calibration 
appeared good between the derivation and BernPCI 
validation cohorts. In the PLATO validation cohort, the 
score maintained a consistent association between 
predicted probabilities and observed frequencies, whereas 
bleeding risk was slightly underestimated (appendix p 28). 
Score discrimination appeared consistent for Bleeding 
Academic Research Consortium (BARC) bleeding in the 
BernPCI cohort (BARC 3 or 5: c-index 0·68 [95% CI 
0·63–0·73]; BARC 2, 3, or 5: c-index 0·68 [0·63–0·72]; 
appendix p 22). Score performance was also consistent, 
including bleeding occurring earlier than 7 days after PCI 
(appendix p 23). Discrimination for the score lacking 
white-blood-cell count was similar to the score including 
white-blood-cell count in the PLATO trial, whereas it was 
lower in the BernPCI registry (table 2, appendix p 29).
The PRECISE-DAPT score showed improved integrated 
discrimination and reclassiﬁcation performance as 
For the web calculator and 
mobile app see www.
precisedaptscore.com
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Figure 1: The PRECISE-DAPT score nomogram for bedside application
Risk curves refer to out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding and TIMI 
major bleeding at 12 months while on-treatment with dual antiplatelet therapy (DAPT). Histogram refers to the 
PRECISE-DAPT score distribution in the derivation cohort: green bars, the ﬁrst score quartile (very low risk); blue 
bars,  the second score quartile (low risk); purple bars, the third score quartile (moderate risk); and red bars, the 
fourth score quartile (high risk).
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com pared with the PARIS score in both validation cohorts 
for TIMI major or minor bleeding (table 2). Discriminative 
ability according to the c-index was similar between the 
two scores (table 2). The alternative version of the 
score lacking white-blood-cell count showed improved 
discrimination and reclassiﬁcation in the PLATO validation 
cohort, and similar performance as compared with the 
PARIS score in the BernPCI second validation cohort.
DAPT duration was randomly allocated in ﬁve of the 
eight studies included in the generation dataset, with 
5050 patients assigned to either 12 months or 24 months of 
treatment and 5031 to 3 months or 6 months.11–15 We 
observed a signiﬁcant increase in bleeding with a 
long (12–24 months) rather than short (3–6 months) 
duration of treatment exclusively in patients at high 
bleeding risk (absolute risk diﬀerence [ARD] +2·59% 
[95% CI +0·82 to +4·34]; number needed to treat: 38) but 
not in those without a high bleeding risk proﬁle (ie, very 
low risk, low risk, and moderate risk: mean of the ﬁrst 
three quartiles ARD +0·14% [–0·22 to +0·49]; 
pinteraction=0·007; ﬁgure 3). This remained consistent after 
censoring events occurring beyond 1 year after PCI (pinteraction 
=0·047; appendix p 30). Concurrently, longer DAPT 
duration reduced the composite ischaemic endpoint of 
myocardial infarction, deﬁnite stent thrombosis, stroke, or 
target vessel revascularisation in those at non-high 
bleeding risk (ARD –1·53% [95% CI –2·64 to –0·41]; 
number needed to treat: 65), but not in those at high 
bleeding risk (ARD +1·41% [–1·67 to +4·50]; pinteraction=0·07; 
ﬁgure 4). When the composite of myocardial infarction, 
deﬁnite ST, or stroke was assessed, longer DAPT duration 
was not associated with a clear beneﬁt in patients at non-
high bleeding risk (ARD –0·42% [95% CI –1·02 to +0·17]) 
and to the possibility of harm in those at high bleeding risk 
(ARD +1·96% [–0·39 to +4·30]; pinteraction=0·054; appendix 
p 31). The resulting net eﬀect on bleeding and ischaemia 
suggested a favourable outcome with 12–24 month DAPT 
in patients at non-high bleeding risk, but not in those at 
high PRECISE-DAPT risk (ﬁgure 4).
At sensitivity analysis, we tested the eﬀect of randomised 
DAPT duration among bleeding risk strata in the 
subgroup of patients presenting with acute coronary 
syndrome at the time of PCI, with results remaining 
largely consistent with those observed in the overall 
population (appendix pp 32, 33). Patients presenting with 
acute coronary syndrome and with a PRECISE-DAPT 
score of at least 25 showed a signiﬁcant increase in TIMI 
bleeding after treatment with longer DAPT (ARD +2·61% 
[95% CI +0·19 to +4·99]; number needed to treat: 38), 
whereas those with a non-high PRECISE-DAPT risk 
score did not (ARD +0·14% [–0·22 to +0·49]; 
pinteraction=0·034). At the same time, longer DAPT duration 
reduced the composite ischaemic endpoint in patients 
with acute coronary syndrome at a non-high PRECISE-
DAPT score (ARD –4·13% [95% CI –6·09 to –2·15]; 
number needed to treat: 24), but not in those with a 
PRECISE-DAPT score of at least 25 (ARD +1·54% 
[–3·27 to +6·32]; pinteraction=0·032; appendix p 32).
Discussion
Ischaemic recurrences after stenting have dropped 
considerably in the last years thanks to the introduction 
of novel stent technologies and progressive reﬁnement 
of pharmaco-interventional techniques. However, due to 
more potent and prolonged platelet inhibition, the 
incidence of major bleeding has increased.25 DAPT-
TIMI major or minor bleeding TIMI major bleeding
c-Index (95% CI) p value* NRI IDI c-Index (95% CI) p value* NRI IDI
Index p value Index p value Index p value Index p value
Derivation cohort
PRECISE-DAPT 0·73 (0·61–0·85) ·· ·· ·· ·· ·· 0·71 (0·57–0·85) ·· ·· ·· ·· ··
PRECISE-DAPT alternative 0·71 (0·57–0·84) ·· ·· ·· ·· ·· 0·69 (0·53–0·85) ·· ·· ·· ·· ··
Validation cohort 1 (PLATO)
PRECISE-DAPT 0·70 (0·65–0·74) 0·06 0·16 0·047 0·004 0·007 0·68 (0·63–0·74) 0·01 0·23 0·02 0·004 0·002
PRECISE-DAPT alternative 0·70 (0·66–0·74) 0·02 0·20 0·02 0·005 0·003 0·68 (0·63–0·74) 0·008 0·23 0·02 0·004 0·002
PARIS 0·66 (0·61–0·70) Ref Ref ·· Ref ·· 0·62 (0·56–0·68) Ref Ref ·· Ref ··
Validation cohort 2 (BernPCI)
PRECISE-DAPT 0·66 (0·61–0·71) 0·09 0·21 0·037 0·004 0·01 0·65 (0·58–0·71) 0·17 0·14 0·23 0·002 0·049
PRECISE-DAPT alternative 0·63 (0·58–0·68) 0·82 0·09 0·37 0·001 0·07 0·62 (0·55–0·68) 0·57 0·03 0·77 0·0001 0·15
PARIS 0·63 (0·58–0·67) Ref Ref ·· Ref ·· 0·62 (0·56–0·69) Ref Ref ·· Ref ··
PRECISE-DAPT score is age, creatinine clearance, haemoglobin, white-blood-cell count at baseline, and previous spontaneous bleeding. PRECISE-DAPT alternative score is age, creatinine clearance, haemoglobin 
at baseline, and previous spontaneous bleeding. PARIS is age, body-mass index, current smoking status, presence of anaemia (haemoglobin <12 g/dL in men and <11 g/dL in women), creatinine clearance 
<60 mL/dL, and treatment with triple therapy (ie, aspirin plus P2Y12 inhibitor plus oral anticoagulant) at discharge. TIMI=Thrombosis in Myocardial Infarction. NRI=net reclassiﬁcation improvement. 
IDI=integrated discrimination improvement. *The PARIS score has been used as reference to test c-indices, IDI, and NRI as compared with the PRECISE-DAPT scores.
Table 2: Discriminative ability of the PRECISE-DAPT score in the derivation cohort and discriminative–reclassiﬁcation ability in comparison with the PARIS score in the validation cohorts 
for out-of-hospital bleeding occurring while on-treatment with dual antiplatelet therapy (DAPT)
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related bleeding is the most common complication after 
coronary stent implantation in current practice, and it is 
associated with lower survival, lower quality of life, and 
higher health costs.26,27
Numerous bleeding and ischaemic risk scores have 
been proposed for the prediction of events occurring 
alternatively in-hospital or out-of-hospital after PCI.8,18,28,29 
However, most failed to be implemented in everyday 
clinical practice largely because their use did not aﬀect 
treatment decisions.8,29
This study developed and validated the PRECISE-
DAPT score, a tool for the prediction of out-of-hospital 
bleeding in patients undergoing coronary stenting. The 
novel score showed reasonable discrimination and 
calibration in two independent validation cohorts of 
patients with contemporary use of all three oral P2Y12 
inhibitors and has potential to inform decision making 
on DAPT duration. We conﬁrmed the role of well-known 
risk factors associated with out-of-hospital bleeding such 
as age and haemoglobin at baseline. Similarly, covariates, 
which have been previously associated with in-hospital 
bleeding, such as renal function, and white-blood-cell 
count, remained associated with bleeding occurring at 
later timepoints.27,30 Additionally, we featured the 
relevance of previous bleeding, which is commonly 
appraised in practice,31 and emerged as the strongest 
predictor of bleeding in our score.
International guidelines suggest individualisation of the 
antiplatelet treatment duration,5,6 as all randomised studies 
invariably showed real or potential bleeding liability 
associated with prolonged versus shortened DAPT 
duration regimens.4,7,13 We observed that among patients 
deemed at high bleeding risk based on the PRECISE-DAPT 
score, prolonged DAPT was associated with no ischaemic 
beneﬁt but a remarkable bleeding burden leading to a 
number needed to treat for harm of 38. A longer treatment 
in patients without high bleeding risk was associated with a 
marginal or even no increase of bleeding and a signiﬁcant 
reduction of the composite ischaemic endpoint. Selecting 
upfront a shorter than 12 month treatment duration in 
patients deemed at high bleeding risk (PRECISE-DAPT 
score ≥25) might prevent exposing them to an excessive 
bleeding hazard. In turn, patients at non-high bleeding risk 
(PRECISE-DAPT score <25) might receive a standard (ie, 
12 months) or a prolonged (ie, >12 months) course of 
treatment if tolerated. A separate assessment of this 
treatment strategy in patients with acute coronary 
syndrome provided consistent ﬁndings. Current 
recommendations for DAPT duration suggest that patients 
with acute coronary syndrome should undergo at least 
12 month treatment unless the bleeding outweighs 
ischaemic risks.5 The PRECISE-DAPT score was able to 
select patients with acute coronary syndrome with an 
excessive bleeding risk, who failed to derive ischaemic 
beneﬁt from 12 month or 24 month DAPT duration, 
whereas a more favourable net outcome was observed in 
these selected patients with a shorter DAPT duration.
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Figure 2: Kaplan-Meier estimates of survival free from bleeding in both 
derivation and validation cohorts stratiﬁed by score quartiles
Estimates for Thrombosis in Myocardial Infarction (TIMI) major or minor 
bleeding occurring while on-treatment with dual antiplatelet therapy are 
presented. Validation cohort 1 from the PLATO trial. Validation cohort 2 from 
the BernPCI registry.
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A prediction algorithm was recently proposed for 
patients who tolerated 12 month DAPT to select those 
eligible for treatment prolongation.8 However, this 
strategy cannot be applied earlier at the time of treatment 
initiation, to select a shorter than 12 month treatment 
duration in patients at high bleeding risk. Earlier decision 
making is especially desirable for bleeding prevention, 
considering that, as observed in our analysis, median 
time to bleeding was 5–6 months.
Two risk scores have been developed to evaluate the 
absolute ischaemic and bleeding risk after coronary 
stenting in the context of the PARIS registry.18 At variance 
with our analysis, the PARIS study did not provide a 
decision-making algorithm for deciding upon DAPT 
duration. With respect to bleeding risk prediction, our 
score ultimately proved at least as good as PARIS, 
showing improved integrated discrimination and net 
reclassiﬁcation, whereas c-indices were numerically but 
not always statistically superior.
Our study had a number of strengths. We derived a 
simple risk score that was developed and validated from 
three largely representative, prospectively investigated 
patient cohorts with rigorous event adjudication, and 
based on a well standardised and accepted bleeding 
deﬁnition.2,5,6 At variance with previous scores designed 
to predict in-hospital bleeding,28 our model was 
developed to predict out-of-hospital bleeding events, 
which are more relevant in the decision making on 
secondary prevention with antithrombotic medications. 
This novel score is the ﬁrst being validated in patients 
Very low bleeding risk
Number at risk
Long DAPT
(12–24 months)
Short DAPT
(3–6 months)
0
1340
1352
3
1311
1337
6
1300
1322
9
1293
1312
12
1125
1186
15
714
747
18
661
689
21
532
557
24 0 3 6 9 12 15 18 21 24
0 3 6 9 12 15 18 21 24 0 3 6 9 12 15 18 21 24
184
189
0·96
0·97
0·98
0·99
1·00
Pr
ob
ab
ili
ty
 o
f T
IM
I m
aj
or
 o
r m
in
or
 b
le
ed
in
g
Moderate bleeding risk
Number at risk
Long DAPT
(12–24 months)
Short DAPT
(3–6 months)
1307
1273
1270
1240
1266
1230
1293
1312
1091
1074
654
632
603
588
504
482
149
141
Time (months)
0·96
0·97
0·98
0·99
Low bleeding risk
1297
1304
1271
1279
1258
1266
1252
1262
1081
1122
681
673
625
615
497
507
162
151
High bleeding risk
1106
1102
1042
1019
1027
1011
1005
993
880
884
545
528
511
493
459
434
82
71
Time (months)
1·00
Pr
ob
ab
ili
ty
 o
f T
IM
I m
aj
or
 o
r m
in
or
 b
le
ed
in
g
Long DAPT (12–24 months)
Short DAPT (3–6 months)
ARD: –0·21% (95% CI –0·76 to 0·30) ARD: 0·37% (95% CI –0·22 to 0·95)
ARD: 0·28% (95% CI –0·39 to 0·94) ARD: 2·59% (95% CI 0·82 to 4·34)
Figure 3: 24 month Kaplan-Meier estimates of survival free from Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding among PRECISE-DAPT 
bleeding risk quartiles (ie, very low, low, moderate, and high bleeding risk) for patients randomly assigned to long (12–24 months) or short (3–6 months) 
dual antiplatelet therapy (DAPT)
Absolute risk diﬀerences (ARDs) are presented: a positive ARD represents the risk increase for a long, as compared with a short, course of DAPT.
DERIVATION AND VALIDATION OF THE PRECISE-DAPT SCORE
323322
5
Articles
1030 www.thelancet.com   Vol 389   March 11, 2017
related bleeding is the most common complication after 
coronary stent implantation in current practice, and it is 
associated with lower survival, lower quality of life, and 
higher health costs.26,27
Numerous bleeding and ischaemic risk scores have 
been proposed for the prediction of events occurring 
alternatively in-hospital or out-of-hospital after PCI.8,18,28,29 
However, most failed to be implemented in everyday 
clinical practice largely because their use did not aﬀect 
treatment decisions.8,29
This study developed and validated the PRECISE-
DAPT score, a tool for the prediction of out-of-hospital 
bleeding in patients undergoing coronary stenting. The 
novel score showed reasonable discrimination and 
calibration in two independent validation cohorts of 
patients with contemporary use of all three oral P2Y12 
inhibitors and has potential to inform decision making 
on DAPT duration. We conﬁrmed the role of well-known 
risk factors associated with out-of-hospital bleeding such 
as age and haemoglobin at baseline. Similarly, covariates, 
which have been previously associated with in-hospital 
bleeding, such as renal function, and white-blood-cell 
count, remained associated with bleeding occurring at 
later timepoints.27,30 Additionally, we featured the 
relevance of previous bleeding, which is commonly 
appraised in practice,31 and emerged as the strongest 
predictor of bleeding in our score.
International guidelines suggest individualisation of the 
antiplatelet treatment duration,5,6 as all randomised studies 
invariably showed real or potential bleeding liability 
associated with prolonged versus shortened DAPT 
duration regimens.4,7,13 We observed that among patients 
deemed at high bleeding risk based on the PRECISE-DAPT 
score, prolonged DAPT was associated with no ischaemic 
beneﬁt but a remarkable bleeding burden leading to a 
number needed to treat for harm of 38. A longer treatment 
in patients without high bleeding risk was associated with a 
marginal or even no increase of bleeding and a signiﬁcant 
reduction of the composite ischaemic endpoint. Selecting 
upfront a shorter than 12 month treatment duration in 
patients deemed at high bleeding risk (PRECISE-DAPT 
score ≥25) might prevent exposing them to an excessive 
bleeding hazard. In turn, patients at non-high bleeding risk 
(PRECISE-DAPT score <25) might receive a standard (ie, 
12 months) or a prolonged (ie, >12 months) course of 
treatment if tolerated. A separate assessment of this 
treatment strategy in patients with acute coronary 
syndrome provided consistent ﬁndings. Current 
recommendations for DAPT duration suggest that patients 
with acute coronary syndrome should undergo at least 
12 month treatment unless the bleeding outweighs 
ischaemic risks.5 The PRECISE-DAPT score was able to 
select patients with acute coronary syndrome with an 
excessive bleeding risk, who failed to derive ischaemic 
beneﬁt from 12 month or 24 month DAPT duration, 
whereas a more favourable net outcome was observed in 
these selected patients with a shorter DAPT duration.
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Figure 2: Kaplan-Meier estimates of survival free from bleeding in both 
derivation and validation cohorts stratiﬁed by score quartiles
Estimates for Thrombosis in Myocardial Infarction (TIMI) major or minor 
bleeding occurring while on-treatment with dual antiplatelet therapy are 
presented. Validation cohort 1 from the PLATO trial. Validation cohort 2 from 
the BernPCI registry.
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A prediction algorithm was recently proposed for 
patients who tolerated 12 month DAPT to select those 
eligible for treatment prolongation.8 However, this 
strategy cannot be applied earlier at the time of treatment 
initiation, to select a shorter than 12 month treatment 
duration in patients at high bleeding risk. Earlier decision 
making is especially desirable for bleeding prevention, 
considering that, as observed in our analysis, median 
time to bleeding was 5–6 months.
Two risk scores have been developed to evaluate the 
absolute ischaemic and bleeding risk after coronary 
stenting in the context of the PARIS registry.18 At variance 
with our analysis, the PARIS study did not provide a 
decision-making algorithm for deciding upon DAPT 
duration. With respect to bleeding risk prediction, our 
score ultimately proved at least as good as PARIS, 
showing improved integrated discrimination and net 
reclassiﬁcation, whereas c-indices were numerically but 
not always statistically superior.
Our study had a number of strengths. We derived a 
simple risk score that was developed and validated from 
three largely representative, prospectively investigated 
patient cohorts with rigorous event adjudication, and 
based on a well standardised and accepted bleeding 
deﬁnition.2,5,6 At variance with previous scores designed 
to predict in-hospital bleeding,28 our model was 
developed to predict out-of-hospital bleeding events, 
which are more relevant in the decision making on 
secondary prevention with antithrombotic medications. 
This novel score is the ﬁrst being validated in patients 
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Figure 3: 24 month Kaplan-Meier estimates of survival free from Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding among PRECISE-DAPT 
bleeding risk quartiles (ie, very low, low, moderate, and high bleeding risk) for patients randomly assigned to long (12–24 months) or short (3–6 months) 
dual antiplatelet therapy (DAPT)
Absolute risk diﬀerences (ARDs) are presented: a positive ARD represents the risk increase for a long, as compared with a short, course of DAPT.
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PLATO validation cohort was limited to 
previous gastrointestinal bleeding. Our score slightly 
underestimated bleeding risk in the PLATO PCI 
population possibly because of the higher bleeding risk in 
the PLATO trial, which included only patients with acute 
coronary syndrome, or as a reﬂection of chance. However, 
given the calibration results observed in the all-comer 
BernPCI registry, our score appears well suited to predict 
bleeding risk status in real-world patients. Discrimination 
in patients treated with prasugrel was poorer. Since 
prasugrel administration was not randomised in both 
derivation and BernPCI validation cohorts, and its use in 
individuals older than 75 years or with increased bleeding 
liability is discouraged, patients at lower bleeding risk 
might have been selected for this treatment, potentially 
hampering the score’s ability to correctly discriminate 
bleeding. Based on similar considerations, the score did 
slightly better in patients taking proton-pump inhibitors. 
The PARIS score discrimination might have been 
underestimated since patients on oral anticoagulants 
were not included in our study. However, these patients 
are per se considered at high bleeding risk. Dedicated 
bleeding risk score for patients on oral anticoagulants 
should probably be used to better estimate bleeding risk 
and corresponding treatment strategies. Whether the 
routine use of the PRECISE-DAPT risk score in 
an unselected population substantially mitigates bleeding 
risk by better informing decision making remains to be 
prospectively ascertained.
In conclusion, we developed and validated the 
PRECISE-DAPT score, a simple ﬁve-item prediction 
algorithm for the prediction of out-of-hospital bleeding 
in patients treated with DAPT. The PRECISE-DAPT 
score identiﬁed patients in whom the beneﬁts of 
prolonged DAPT outweighed the risks and vice versa. In 
the context of a comprehensive clinical evaluation 
process, this tool can support clinical decision making 
for treatment duration. Prospective validation of this 
score in practice remains desirable.
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applied among patients randomly assigned to a 
shortened or prolonged DAPT duration to propose and 
validate simple DAPT duration treatment strategy 
according to bleeding risk. A simpliﬁed score modelled 
without white-blood-cell count was also derived and 
validated, which might prove useful in cases where 
white-blood-cell count is not available.
Among the limitations, we acknowledge that event 
discrimination in our score ranged from moderate to 
good. Emerging predictors for bleeding, including frailty, 
might be missing in our model,32 and future studies 
should implement clinical, laboratory, or genetic factors 
to possibly improve its discriminative capability. 
Information regarding single patients’ drug adherence 
was lacking in our dataset and each patient was considered 
on-DAPT treatment according to the prespeciﬁed or 
randomised treatment duration at the time of PCI. 
A granular collection of patient on-treatment or oﬀ-
treatment status during follow-up would have been 
desirable. Information regarding previous bleeding in the 
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Figure 4: Absolute risk diﬀerence (ARD) for a long (12–24 months) as compared with a short (3–6 months) 
dual antiplatelet therapy (DAPT) duration with respect to ischaemia (myocardial infarction, deﬁnite stent 
thrombosis, stroke, or target vessel revascularisation) and bleeding (Thrombosis in Myocardial Infarction 
major or minor bleeding) within the four PRECISE-DAPT score quartiles
ARD curves plotted on the upper side of the zero line represent beneﬁt from a long DAPT treatment, whereas curves 
plotted on the lower side of the zero line represent harm from a long DAPT as compared with a short treatment (A). 
Event rate for ischaemia and bleeding after a long or short DAPT treatment within the four PRECISE-DAPT quartiles. 
A positive ARD represents the risk increase for a long as compared with a short course of DAPT (B).
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PLATO validation cohort was limited to 
previous gastrointestinal bleeding. Our score slightly 
underestimated bleeding risk in the PLATO PCI 
population possibly because of the higher bleeding risk in 
the PLATO trial, which included only patients with acute 
coronary syndrome, or as a reﬂection of chance. However, 
given the calibration results observed in the all-comer 
BernPCI registry, our score appears well suited to predict 
bleeding risk status in real-world patients. Discrimination 
in patients treated with prasugrel was poorer. Since 
prasugrel administration was not randomised in both 
derivation and BernPCI validation cohorts, and its use in 
individuals older than 75 years or with increased bleeding 
liability is discouraged, patients at lower bleeding risk 
might have been selected for this treatment, potentially 
hampering the score’s ability to correctly discriminate 
bleeding. Based on similar considerations, the score did 
slightly better in patients taking proton-pump inhibitors. 
The PARIS score discrimination might have been 
underestimated since patients on oral anticoagulants 
were not included in our study. However, these patients 
are per se considered at high bleeding risk. Dedicated 
bleeding risk score for patients on oral anticoagulants 
should probably be used to better estimate bleeding risk 
and corresponding treatment strategies. Whether the 
routine use of the PRECISE-DAPT risk score in 
an unselected population substantially mitigates bleeding 
risk by better informing decision making remains to be 
prospectively ascertained.
In conclusion, we developed and validated the 
PRECISE-DAPT score, a simple ﬁve-item prediction 
algorithm for the prediction of out-of-hospital bleeding 
in patients treated with DAPT. The PRECISE-DAPT 
score identiﬁed patients in whom the beneﬁts of 
prolonged DAPT outweighed the risks and vice versa. In 
the context of a comprehensive clinical evaluation 
process, this tool can support clinical decision making 
for treatment duration. Prospective validation of this 
score in practice remains desirable.
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treated with more potent P2Y12 inhibitors, which 
represent the standard of care for patients with acute 
coronary syndrome. This score was retrospectively 
applied among patients randomly assigned to a 
shortened or prolonged DAPT duration to propose and 
validate simple DAPT duration treatment strategy 
according to bleeding risk. A simpliﬁed score modelled 
without white-blood-cell count was also derived and 
validated, which might prove useful in cases where 
white-blood-cell count is not available.
Among the limitations, we acknowledge that event 
discrimination in our score ranged from moderate to 
good. Emerging predictors for bleeding, including frailty, 
might be missing in our model,32 and future studies 
should implement clinical, laboratory, or genetic factors 
to possibly improve its discriminative capability. 
Information regarding single patients’ drug adherence 
was lacking in our dataset and each patient was considered 
on-DAPT treatment according to the prespeciﬁed or 
randomised treatment duration at the time of PCI. 
A granular collection of patient on-treatment or oﬀ-
treatment status during follow-up would have been 
desirable. Information regarding previous bleeding in the 
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Figure 4: Absolute risk diﬀerence (ARD) for a long (12–24 months) as compared with a short (3–6 months) 
dual antiplatelet therapy (DAPT) duration with respect to ischaemia (myocardial infarction, deﬁnite stent 
thrombosis, stroke, or target vessel revascularisation) and bleeding (Thrombosis in Myocardial Infarction 
major or minor bleeding) within the four PRECISE-DAPT score quartiles
ARD curves plotted on the upper side of the zero line represent beneﬁt from a long DAPT treatment, whereas curves 
plotted on the lower side of the zero line represent harm from a long DAPT as compared with a short treatment (A). 
Event rate for ischaemia and bleeding after a long or short DAPT treatment within the four PRECISE-DAPT quartiles. 
A positive ARD represents the risk increase for a long as compared with a short course of DAPT (B).
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Summary and Conclusions: 
 
In the last years there was a radical change in the perception of the 
ischemia/bleeding balance in patients undergoing percutaneous coronary intervention 
(PCI), which was reflected in both guidelines and the community (Chapter 1.1, 1.2, 1.3). 
Despite the reduction of ischemic recurrences has been traditionally the main focus of 
clinical research, recent data pointed the attention towards bleeding events, which are 
common after more potent and prolonged treatments. In patients managed with 
antithrombotics after an acute coronary syndrome, the impact of major bleeding as 
compared to recurrent myocardial infarction appeared similar or even greater in particular 
cases (Chapter 2.1). This data reinforces the concept that both ischemia and bleeding 
should be prevented, and a careful assessment of ischemia/bleeding risk should be made.  
 
Many pharmacological and mechanical strategies have been proposed to reduce 
bleeding and ischemia early and late after PCI.  
The use of the radial artery rather than femoral artery as access site for PCI reduces 
access site bleeding (Chapter 3.1). However, radial intervention is technically more 
challenging and might be complicated by radial artery occlusion, which hampers future 
catheterizations from this route. Radial catheterization, provoke ubiquitous acute injuries to 
the radial artery wall and increase arterial intima and total wall thickness (Chapter 3.2). 
Still, these changes did not seem to be associated with radial artery occlusion or 
symptoms onset up to one month after the procedure. Bigger studies with novel lesion 
definition and classification are required to unravel the association of these microscopic 
SUMMARY AND CONCLUSIONS
329328
Summary and Conclusions: 
 
In the last years there was a radical change in the perception of the 
ischemia/bleeding balance in patients undergoing percutaneous coronary intervention 
(PCI), which was reflected in both guidelines and the community (Chapter 1.1, 1.2, 1.3). 
Despite the reduction of ischemic recurrences has been traditionally the main focus of 
clinical research, recent data pointed the attention towards bleeding events, which are 
common after more potent and prolonged treatments. In patients managed with 
antithrombotics after an acute coronary syndrome, the impact of major bleeding as 
compared to recurrent myocardial infarction appeared similar or even greater in particular 
cases (Chapter 2.1). This data reinforces the concept that both ischemia and bleeding 
should be prevented, and a careful assessment of ischemia/bleeding risk should be made.  
 
Many pharmacological and mechanical strategies have been proposed to reduce 
bleeding and ischemia early and late after PCI.  
The use of the radial artery rather than femoral artery as access site for PCI reduces 
access site bleeding (Chapter 3.1). However, radial intervention is technically more 
challenging and might be complicated by radial artery occlusion, which hampers future 
catheterizations from this route. Radial catheterization, provoke ubiquitous acute injuries to 
the radial artery wall and increase arterial intima and total wall thickness (Chapter 3.2). 
Still, these changes did not seem to be associated with radial artery occlusion or 
symptoms onset up to one month after the procedure. Bigger studies with novel lesion 
definition and classification are required to unravel the association of these microscopic 
SUMMARY AND CONCLUSIONS
331330
injuries and radial artery occlusion, as well as the eventual role of antithrombotic therapy to 
prevent this complication.  
Similarly, the use of intravenous antiplatelet agents such as glycoprotein IIb/IIIa 
inhibitors (GPI) during the procedure reduce peri-procedural ischemic complications in 
selected patients at the cost of increased bleeding risk (Chapter 3.3). Tirofiban, a GPI with 
a short half-life, is now distributed in Europe as a generic drug in a phosphate buffered 
formulation and as a branded drug in a citrate buffered formulation. Phosphate buffered 
formulation of tirofiban as compared with unfractionated heparin (UFH) was associated 
with a higher rate of thrombocytopenia with a potentially increased risk for serious bleeding 
events. In contrast, this effect was not present with the citrate buffered formulation 
(Chapter 3.4). These findings warrant caution and further evaluation of the safety profile of 
the generic formulation of tirofiban, which is currently marketed in Europe. 
 
Coronary stent selection has been traditionally considered a major determinant of 
post-procedural antithrombotic treatment duration, hence impacting bleeding/ischemia 
balance (Chapter 4.1). Since drug-eluting stents (DES) have traditionally been considered 
more thrombogenic, based on the preliminary data coming from first-generation devices, it 
was common practice to provide longer DAPT treatments to patients treated with DES as 
compared to bare-metal stents (BMS). Consequently, patients deemed at high bleeding 
risk, which would not tolerate prolonged DAPT courses, have been more commonly 
selected for BMS implantation (Chapter 1.2). Nonetheless, modern DES demonstrated 
better outcomes as compared to BMS in patients at high bleeding risk and a fixed short 
DAPT duration (Chapter 4.2). These results were also replicated in patients with chronic 
kidney disease that were randomized to short vs. long DAPT duration (Chapter 4.3). These 
evidence, together with that coming from recent randomized trials, set the basis for a 
paradigm shift for stent selection in patients at high bleeding risk, in which the routine use 
of BMS does not seem anymore justifiable.  
 
Despite the fact that adverse event rate is relatively higher during the first month after 
the procedure, the vast majority of ischemic and bleeding complications occur late after 
revascularization, and might be modulated by adjusting DAPT duration. As such the 
selection of optimal DAPT duration after PCI has a central role in the balance of 
ischemic/bleeding risk (Chapter 1.1). Longer DAPT duration was associated with a 
consistent reduction of major adverse cardiovascular events (MACE) and stent thrombosis 
(Chapter 5.1). Still, longer treatment duration was also associated with an increase in 
major bleeding and a worrisome increase in mortality (Chapter 5.1), which raised concern 
in the community (Chapter 1.3). This was mostly driven by events occurred in the DAPT 
trial, in which longer DAPT was associated with a significant mortality increase among 
patients with stable coronary artery disease (CAD) but not among patients with acute 
coronary syndrome (ACS) at the time of PCI. In addition, at least part of the increased risk 
of mortality in DAPT and PEGASUS trials was related to cancer. The higher incidence of 
malignancy related mortality in patients treated with longer DAPT was observed when data 
from these two trials were pooled, prompting careful evaluation for longer treatment 
duration in patients with active or recent malignancy (Chapter 5.3). The definitive impact of 
DAPT duration on mortality remains unclear, and whether this effect is class-specific or 
drug-specific should be further investigated (Chapter 5.2). 
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“It is more important to know what sort of person has a disease than to know what 
sort of disease a person has.”  With this statement more than 2,400 years ago, 
Hippocrates, the father of western medicine, recognized the individuality of each patient 
and the importance of adapting treatment accordingly. Since than, clinicians struggled 
understanding patients’ characteristics that predict a different response to treatment. 
Adjusting treatment based on baseline characteristics, biohumoral or genomic markers is 
the premise of Precision Medicine, which aims to the construction of an evidence-based 
medical model for customized decision-making based on single patient characteristics. 
This assumes particular importance when treatment benefits might be outweighed by its 
harm, like it is in the case of antithrombotic drug selection. Unravelling patients’ 
characteristics, which might modify DAPT duration selection appears of paramount 
importance. Clinical presentation at the time of PCI (i.e. stable vs. unstable CAD) is an 
important factor to be considered for DAPT selection. Patients with prior myocardial 
infarction showed a significant benefit in terms of MACE and stent thrombosis reduction 
after extended DAPT duration (i.e. more than 12 months). Despite this was associated 
with a consistent increase of non-fatal bleeding, this strategy was associated with a 
significant reduction of cardiac mortality (Chapter 5.6). Similarly, serious bleeding 
complications were relatively more frequent after 24- as compared to 6-months DAPT in 
stable patients as compared to unstable patients at the time of PCI (Chapter 5.5). As a 
consequence, net adverse clinical events were significantly more common after a 
prolonged DAPT treatment in patients with stable CAD, but not in those with unstable CAD 
at the time of PCI (Chapter 5.5). This evidence strongly suggests that clinical presentation 
should be a primary factor in DAPT duration selection (Chapter 5.5 and 5.6). Similarly, 
anatomical considerations for lesion complexity should also be accounted. The presence 
of a lumen narrowing (i.e. >30%) or stenting in the left main or proximal left anterior 
descending coronary artery was associated with a significant ischemic benefit after a 24- 
as compared to 6-months DAPT treatment (Chapter 5.7). This remained consistent 
irrespective coronary stenting was performed in these proximal segments, underscoring 
how the presence of CAD in proximal segments might be itself a marker of more extensive 
coronary disease, which benefit from a more aggressive antithrombotic approach. 
 
International guidelines support weighting bleeding risk prior to selection of treatment 
duration and suggest a shorter than 12 month DAPT regimen in patients at high bleeding 
risk. Although this seems a reasonable strategy to at least reduce the risk for harm, no 
standardized tool exists to weigh bleeding risk at the time of DAPT initiation. Clinical risk 
scores, which integrate predictors to establish an individual’s absolute risk of a condition, 
are often used in practice to estimate the bleeding risk in patients with atrial fibrillation who 
are treated with oral anticoagulants, but their application in the field of DAPT has never 
been evaluated. We tested three different bleeding risk scores which has been developed 
to predict bleeding events occurring in-hospital in patients with ACS (i.e. CRUSADE and 
ACUITY) or out-of-hospital in patients with atrial fibrillation (i.e. HAS BLED) to a population 
of patients randomized to 6 vs. 24 months DAPT (Chapter 5.10). We observed that 
CRUSADE score predicted bleeding significantly better than HAS BLED and similar to 
ACUITY. CRUSADE score showed ability to select patients at high bleeding risk, which 
were significantly harmed from a longer treatment with DAPT in terms of major bleeding 
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and transfusion. However, CRUSADE score was developed to predict in hospital bleeding, 
and might not be the best tool to predict bleeding occurring months or years after the initial 
hospital admission. In order to develop a novel tool to predict bleeding during DAPT and 
potentially supporting decision-making for DAPT duration we developed the PRECISE-
DAPT score (Chapter 5.11). This score was developed in a pooled dataset of almost 
15,000 patients and externally validated in two independent large cohorts of patients with 
clinically adjudicated events. PRECISE-DAPT showed good discrimination and calibration 
for out-of-hospital major bleeding in both derivation and validation cohorts. Among patients 
randomized to different DAPT duration, a longer DAPT (i.e. 12-24 months) as compared to 
a short treatment (i.e. 3-6 months) significantly increased the rate of major bleeding 
without providing any ischemic benefit in patients deemed at high bleeding risk (PRECISE-
DAPT score ≥25). Contrariwise, longer DAPT in patients deemed at low bleeding risk 
(PRECISE-DAPT score <25) provided a significant reduction of ischemic events with no 
significant trade-off in bleeding (Chapter 5.11). The PRECISE-DAPT score might be useful 
to objectively define long term bleeding risk in patients treated with PCI, hence supporting 
decision-making for DAPT duration.  
 
 
 
 
 
 

Samenvatting en Conclusies: 
In recente jaren heeft een radicale verandering plaatsgevonden in de perceptie over 
de balans tussen ischemie en bloedingen in patiënten die een percutane coronaire 
interventie (PCI) ondergaan, wat zichtbaar werd in de zowel de behandelrichtlijnen als in 
de wetenschappelijke gemeenschap (Hoofdstuk 1.1, 1.2). Ondanks de traditioneel sterke 
focus van klinisch onderzoek op de reductie van ischemische herhalingen, hebben recente 
data de aandacht verlegt naar bloedingen, die vaker voorkomen na krachtigere en langere 
behandelingen. In patiënten die na een acuut coronair syndroom met antitrombotica 
behandeld worden, is de impact van ernstige bloedingen vergelijkbaar of in specifieke 
gevallen sterker dan die van een herhaald hartinfarct (Hoofdstuk 2.1). Deze data 
benadrukken het concept dat zowel ischemie als bloedingen voorkomen moeten worden, 
en dat een voorzichtige afweging van ischemisch risico en bloedingsrisico moet worden 
gemaakt. 
 
Een groot aantal farmacologische en mechanische strategieën is voorgesteld om 
bloedingen en ischemie na PCI, zowel vroeg als laat, te reduceren. 
 
Het gebruik van de radiale slagader in plaats van de femorale slagader als toegang 
voor PCI reduceert toegangslocatie-gerelateerde bloedingen (Hoofdstuk 3.1). Echter, 
radiale interventie is technisch uitdagender en kan leiden tot radiale arteriële occlusie, wat 
toekomstige radiale katheterisatie bemoeilijkt. Radiale katheterisatie leidt onomstreden tot 
acute beschadiging van de radiale slagaderwand en vergroot de dikte van de arteriële 
intima en de totale vaatwand (Hoofdstuk 3.2). Toch lijken deze veranderingen niet 
geassocieerd te zijn met radiale arteriële occlusie of het ontstaan van symptomen tot een 
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maand na de procedure. Grotere studies met een grondige definitie en classificatie van 
slagadervernauwingen zijn noodzakelijk om het verband te ontrafelen tussen deze 
microscopisch beschadigingen en radiale arteriële occlusie, en de eventuele rol van 
antitrombotische therapie om deze complicatie te voorkomen. 
 
Evenzo vermindert het gebruik bij geselecteerde patiënten van intraveneuze 
antibloedplaatjesagentia, zoals glycoproteïne IIb/IIIa-remmers (GPI), peri-procedurele 
ischemische complicaties tijdens de procedure ten koste van een verhoogd bloedingsrisico 
(hoofdstuk 3.3). Tirofiban, een GPI met een korte halfwaardetijd, wordt nu in Europa 
gedistribueerd als een generiek geneesmiddel in een fosfaat-gebufferde formulering en als 
een merkgeneesmiddel in een citraat gebufferde formulering. De fosfaat-gebufferde 
formulering van tirofiban was geassocieerd met een hoger percentage trombocytopenie in 
vergelijking met ongefractioneerde heparine (UFH), met mogelijk een verhoogd risico op 
ernstige bloeding. Dit effect was echter niet aanwezig met de citraat-gebufferde 
formulering (hoofdstuk 3.4). Deze bevindingen vereisen voorzichtigheid en verdere 
evaluatie van het veiligheidsprofiel van de generieke formulering van tirofiban die 
momenteel in Europa op de markt wordt gebracht. 
 
Coronaire stent-selectie wordt van oudsher beschouwd als een belangrijke 
bepalende factor voor de post-procedurele antithrombotische behandelingsduur, en heeft 
derhalve invloed op de bloeding / ischemiebalans (Hoofdstuk 4.1). Aangezien drug-eluting 
stents (DES) van oudsher als meer trombogeen werden beschouwd – gebaseerd op 
gegevens afkomstig van de eerste generatie stents – was het gebruikelijk om langere 
DAPT-behandelingen te bieden aan patiënten die met DES werden behandeld in in plaats 
van met bare-metal stents (BMS). Patiënten met een hoog bloedingsrisico, die geen 
langdurige DAPT-behandeling zouden tolereren, werden daarom vaker geselecteerd voor 
BMS-implantatie (hoofdstuk 1.2). Desalniettemin lieten moderne DES betere resultaten 
zien in vergelijking met BMS bij patiënten met een hoog bloedingsrisico en een vaste korte 
DAPT-duur (hoofdstuk 4.2). Deze resultaten werden gerepliceerd in patiënten met 
chronische nierziekte die werden gerandomiseerd naar een korte versus lange DAPT-duur 
(hoofdstuk 4.3). Dit bewijsmateriaal, samen met dat van recente gerandomiseerde studies, 
heeft de basis gelegd voor een paradigmaverschuiving in stentselectie bij patiënten met 
een hoog bloedingsrisico, waarbij het routinematige gebruik van BMS niet meer te 
rechtvaardigen lijkt. 
 
Ondanks het feit dat de mate van complicaties in de eerste maand na de procedure 
relatief hoog is, treedt de overgrote meerderheid van de ischemische en 
bloedingscomplicaties pas lang na revascularisatie op en kan deze worden beïnvloed door 
de DAPT-duur aan te passen. Als zodanig heeft de selectie van de optimale DAPT-duur 
na PCI een centrale rol in de balans van ischemisch en bloedingsrisico (hoofdstuk 5.4). 
Langere DAPT-duur ging gepaard met een consistente vermindering van ernstige 
ongunstige cardiovasculaire voorvallen (MACE) en stenttrombose (Hoofdstuk 5.1). Toch 
was langere behandelingsduur ook geassocieerd met een toename van ernstige 
bloedingen en een zorgwekkende toename van de mortaliteit (Hoofdstuk 5.1), die 
bezorgdheid wekte in de gemeenschap (Hoofdstuk 1.2). Dit werd voornamelijk veroorzaakt 
door voorvallen in de DAPT-trial, waarbij langere DAPT geassocieerd was met een 
significante mortaliteitstoename bij patiënten met stabiele coronaire hartziekte (CAD) maar 
niet bij patiënten met een acuut coronair syndroom (ACS) op het moment van PCI. 
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Bovendien was minstens een deel van de verhoogde mortaliteit in de DAPT- en de 
PEGASUS-trials gerelateerd aan kanker. De hogere maligniteit-gerelateerde mortaliteit bij 
patiënten die met langere DAPT werden behandeld, werd waargenomen in de 
samengevoegde data van deze twee trials, wat een zorgvuldige evaluatie instigeert van de 
langere behandelingsduur bij patiënten met actieve of recente maligniteit (Hoofdstuk 5.3). 
De precieze impact van de DAPT-duur op mortaliteit blijft onduidelijk en of dit effect klasse-
specifiek of specifiek voor het geneesmiddel is, moet verder worden onderzocht (hoofdstuk 
5.2). 
 
"Het is belangrijker om te weten wat voor soort persoon een ziekte heeft dan te 
weten wat voor soort ziekte een persoon heeft." Met deze verklaring meer dan 2400 jaar 
geleden, erkende Hippocrates, de vader van de westerse geneeskunde, de individualiteit 
van elke patiënt en het belang om de behandeling dienovereenkomstig aan te passen. 
Sindsdien worstelden clinici met het begrijpen van de kenmerken van patiënten die een 
andere reactie op de behandeling voorspellen. Aanpassing van de behandeling op basis 
van baselinekenmerken, bio-humorale of genomische markers is de premisse van de 
Precisiegeneeskunde, die gericht is op de constructie van een evidence-based medisch 
model voor gepersonaliseerde besluitvorming op basis van de individuele kenmerken van 
een patiënt. 
Dit is in het bijzonder belangrijk wanneer de voordelen van de behandeling teniet 
kunnen worden gedaan door de nadelen, zoals het geval is bij de antitrombotische 
geneesmiddelenkeuze. Het ontrafelen van de patiëntkenmerken die de duur van DAPT-
selectie zouden kunnen bepalen, lijkt van het allergrootste belang. Klinische presentatie op 
het moment van PCI (d.w.z. stabiele vs. instabiele CAD) is een belangrijke factor waarmee 
rekening moet worden gehouden voor DAPT-selectie. Patiënten met een voorafgaand 
myocardinfarct vertoonden een significant voordeel in reductie van MACE en 
stenttrombose na verlengde DAPT-duur (dat wil zeggen meer dan 12 maanden). Ondanks 
dat dit gepaard ging met een consistente toename van niet-fatale bloedingen, was deze 
strategie geassocieerd met een significante verlaging van de cardiale mortaliteit 
(Hoofdstuk 5.6). Evenzo kwamen ernstige bloedingscomplicaties relatief vaker voor na 24 
in vergelijking met 6 maanden DAPT bij stabiele patiënten in vergelijking met instabiele 
patiënten ten tijde van PCI (hoofdstuk 5.5). Als gevolg hiervan kwamen klinische 
ongewenste voorvallen significant vaker voor bij een langdurige DAPT-behandeling bij 
patiënten met stabiele CAD, maar niet bij patiënten met instabiele CAD op het moment 
van PCI (Hoofdstuk 5.5). Dit bewijs suggereert krachtig dat klinische presentatie een 
primaire factor zou moeten zijn bij de selectie van de DAPT-duur (hoofdstuk 5.5 en 5.6). 
Evenzo moeten ook anatomische overwegingen van de complexiteit van de laesie in 
aanmerking worden genomen. De aanwezigheid van een vernauwing van het lumen 
(d.w.z.> 30%) of stent implantatie in de linker grote kransslagader of de proximale linker 
voorste dalende kransslagader was geassocieerd met een significant ischemisch voordeel 
na 24 vergeleken met 6 maanden durende DAPT-behandeling (Hoofdstuk 5.7). Dit effect 
bleef consistent ongeacht of coronaire stent implantatie plaatsvond in deze proximale 
segmenten, wat onderstreept hoe de aanwezigheid van CAD in proximale segmenten zelf 
een marker kan zijn van een uitgebreidere coronaire ziekte, die baat heeft bij een 
agressievere antitrombotische aanpak. 
 
Internationale richtlijnen ondersteunen de weging van het bloedingsrisico 
voorafgaand aan de selectie van de behandelingsduur en suggereren een DAPT-regime 
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van minder dan 12 maanden bij patiënten met een hoog bloedingsrisico. Hoewel dit een 
redelijke strategie lijkt om het risico op schade op zijn minst af te laten nemen, bestaat er 
geen gestandaardiseerd hulpmiddel om het risico op bloedingen te wegen op het moment 
van de DAPT-initiatie. Klinische risicoscores, die voorspellers integreren om het absolute 
risico van een aandoening vast te stellen, worden in de praktijk vaak gebruikt om het 
bloedingsrisico te schatten bij patiënten met atriale fibrillatie die worden behandeld met 
orale anticoagulantia, maar hun toepassing op het gebied van DAPT is nooit geëvalueerd. 
We hebben drie verschillende bloedingsrisico-scores getest die zijn ontwikkeld om 
bloedingen in het ziekenhuis bij patiënten met ACS (CRUSADE en ACUITY) of na ontslag 
uit het ziekenhuis bij patiënten met atriale fibrillatie (HAS BLED) te voorspellen voor een 
populatie van patiënten gerandomiseerd naar 6 versus 24 maanden DAPT (hoofdstuk 
5.10). We hebben vastgesteld dat CRUSADE een bloeding significant beter voorspelde 
dan HAS BLED en vergelijkbaar met ACUITY. CRUSADE score toonde mogelijkheid om 
patiënten te selecteren met een hoog bloedingsrisico, die significant werden geschaad 
door een langere behandeling met DAPT in termen van ernstige bloedingen en transfusie. 
CRUSADE-score werd echter ontwikkeld om bloedingen in het ziekenhuis te voorspellen 
en is mogelijk niet het beste hulpmiddel om bloedingen te voorspellen die zich maanden of 
jaren na de eerste ziekenhuisopname voordoen. Om een nieuw hulpmiddel te ontwikkelen 
om bloeding tijdens DAPT te voorspellen en mogelijk de besluitvorming over DAPT-duur te 
ondersteunen, hebben we de PRECISE-DAPT-score ontwikkeld (hoofdstuk 5.11). Deze 
score is ontwikkeld op basis van een gepoolde dataset van bijna 15.000 patiënten en 
extern gevalideerd in twee onafhankelijke grote cohorten patiënten met klinisch 
beoordeelde voorvallen. PRECISE-DAPT toonde goede discriminatie en kalibratie voor 
ernstige bloedingen na ontslag uit het ziekenhuis, in zowel ontwikkel- als validatiecohorten. 
Van de patiënten die werden gerandomiseerd naar verschillende DAPT-duren, verhoogde 
een langere DAPT (12-24 maanden) – in vergelijking met een korte behandeling (3-6 
maanden) – significant het aantal ernstige bloedingen, zonder een ischemisch voordeel te 
bieden bij patiënten met een hoog voorspeld bloedingsrisico (PRECISE-DAPT score ≥25). 
Daarentegen gaf een langere DAPT bij patiënten met een laag voorspeld bloedingsrisico 
(PRECISE-DAPT score <25) een significante vermindering van het aantal ischemische 
voorvallen zonder significante toename in bloedingen (Hoofdstuk 5.11). De PRECISE-
DAPT-score kan nuttig zijn om langdurig bloedingsrisico's objectief te definiëren bij 
patiënten die worden behandeld met PCI, en ondersteunt daarmee de besluitvorming over 
de DAPT-duur. 
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“Life can only be understood backwards; but it must be lived forwards.” 
 
If I dig back into my memory to the first time I have heard of the Thoraxcenter, I think it 
was at the 1st year of my residency in Cardiology: when I asked which was the very best 
center for interventional cardiology in Europe the answer was firm: “The Thoraxcenter in 
Rotterdam”. While my interest for interventional cardiology was increasing during my 
residency training, I remember perusing the Thoraxcenter internet page in search of a 
possible way to start a fellowship there, but all seemed out of my reach. 
A couple of years later, in May 2014 I was covering my shift in echocardiography in 
Messina (my hometown), and I have been summoned down in the cath-lab by one of the 
senior interventionalists, Giuseppe Andò, which was quite uncommon at that time. Walking 
down the 6 floors separating the echo-lab and the cath-lab, I was trying to quickly review 
all the possible things that I could have done wrong during the previous week, preparing a 
persuasive explanation for the possible scenarios. Yet, the topic of the conversation was 
different than I expected: “There is a possible opening for a fellowship with Prof. Valgimigli, 
he is moving to Rotterdam, Are you interested?”. I believe it took me 1.5 seconds to 
answer to that proposal (1.3 were used to kill the previous “excuse primer”). Dr. Andò, I will 
always be grateful for this opportunity, if it wasn’t for your work including the hospital in the 
MATRIX trial, that dream would have never become real. At that time my hospital was one 
main recruiter in the MATRIX trial, and the study coordinator, Enrico Frigoli, was a former 
colleague resident in Messina. I called Enrico the very same day to see if that possibility 
was viable and trying to schedule an introductory call with Prof. Valgimigli. Enrico, you 
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have always been supportive, I am sure that your great patience and human skills will 
allow you to coordinate the MASTER-DAPT in the very successful way as it was for the 
MATRIX. I did a preliminary call with Prof. Valgimigli and he explained me some of the 
projects that he had in mind and some of the “rules” of the Thoraxcenter world: first and 
foremost the fellow-interview run by all the staff members. Two weeks after I was in 
Rotterdam for my very first time to undergo the interviews. Stepping into the Thoraxcenter 
entrance, at the bottom of a colossal white building, I remember I felt deeply out of place. I 
know now that this sensation would have accompanied me every time I happened making 
a good decision in my career. Walking in the dedalus of the Thoraxcenter, I went up to the 
5th floor and met Elles Schaap, the secretary of Prof. Zijlstra that gave me an accurate 
(and minute pointing) schedule of my interviews for that day. Elles and Wil you have been 
nice and patient to me since that very first moment, thank you for all the support (also at a 
distance) you gave me during these years.  
After completing the interview with all the cath-lab staff members I finally met for the first 
time, what would have became my mentor for the years to come, Prof. Valgimigli. During 
that very first meeting, he was organizing his new office in the room BA-593, located in the 
fifth floor, together with all the other faculty members. He anticipated me that the interview 
was successful and I could start the fellowship in July. A dream was coming true. In the 
same meeting, he also gave me a detailed outlook of the possible areas of research I 
could be involved: duration of dual antiplatelet therapy with a focus on special populations, 
risks scores, bleeding vs. ischemic risk, coronary stents, endothelial function etc. all these 
were beautifully drawn in a detailed flow-chart which I store like a treasure (see picture 
section).  While discussing about my expectations from the period at the Thoraxcenter, I 
confessed that I would have liked to write a PhD thesis. By saying that I suddenly captured 
all his attention. He started searching his library and he finally handed me a book that was 
more or less 3 cm thick. It was the Vasim Farooq’s PhD thesis, one of the former fellows of 
Prof. Serruys, which was defeinding his PhD that year. “This is what a thesis looks like 
here, do you still want to do this?” That thesis was incredible: a huge book including more 
than 20 articles, most as first author, and all in top journals, including the original SYNTAX 
II score paper, published in the Lancet, and a research letter in the New England Journal 
of Medicine. Vasim I don't know you in person and I hope I could meet you someday. 
Reading your thesis gave me the first impression of what was like to be a fellow in 
Rotterdam, and it totally inspired me. 
During those days I was also struggling finding a place to stay in Rotterdam: Ramon 
Rodriguez, a clinical fellow that was completing his first year shared some precious 
information regarding how to find a place to live in Rotterdam. Ramon, thank you for the 
support in the early stage of my adventure. Finally I happened to find one small flat that 
was just 10 minutes away from the hospital. The landlord, a Turkish-Dutch man called 
Ugur, with a terrible English, showed me the house. The house was quite eccentric as it 
was full of souvenirs that Ugur collected from his travels around the world: there were 
three crystal lamps (for this reason renamed “la casa dei lampadari”), a 1.5mt tall jar 
accommodating a huge plant, at least 5 statues of Buddha, 2 stuffed birds and a wooden 
giraffe (..yes a giraffe). Ugur, even if our communication in English was very problematic, 
thank you for your kindness and positive attitude, believe me or not, I felt your house as a 
home.  
My first month in Rotterdam was quite tough. Getting used to the new place, without any 
friend close, was a challenge that I am happy I endured. My office was in the fellows’ room 
BD-412 in the old building. I was initially sharing the room with the three clinical fellows 
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Joost Daemen, Bert Everaert and Ramon Rodriguez. Joost was the only native dutch, and 
had completed both his residency and PhD at the Thoraxcenter. In the fellows room there 
was a big shelf hosting all PhD thesis from the interventional cardiology group. Joost’s 
thesis was lying there and was intimidating. By contrast, he was a very sociable and 
friendly person, with an exquisite dutch attitude, sharp and direct. Thank you Joost for 
helping me surviving the Thoraxcenter, and for all the good tips for my future career. In 
one of our lunches in the canteen you once told me about the beautiful landscape from the 
rooftop restaurant at the Inselspital in Bern (where you have also been as a fellow), 
admiring the snowcapped Alps. I couldn’t imagine that I would be see that view someday, 
which was indeed fantastic, but the restaurant in turn, was way too expensive.  
Bert instead was coming from Belgium, he was extremely funny, sociable and with an 
excellent taste for good wines and whiskies (owe him a great introduction to the various 
Talisker, Laphroaig and Lagavulin). Bert, I really enjoyed our conversations. I could never 
forgive myself for not attending your champagne-tasting trip in Antwerp, hope we will have 
another occasion in the future. 
In that period I was mostly occupied with patients’ inclusion in the MATRIX trial, and I 
spent most of my time in the cath-lab. That gave me the opportunity of knowing better the 
cath-lab staff and all nurses and technicians. The level of competence of all the people 
working there was simply impressive. It is impossible to count the number of things related 
and not related to interventional cardiology that I learnt in the cath-lab of the Thoraxcenter, 
and it’s very difficult to properly thank all the senior staff for their teachings. Roberto Diletti, 
being both Italians was a great advantage to get to know you better, thank you for your 
advices and for the great time when you invited us in your house, I wish you all the best 
with your career and with the little Riccardo. Prof. De Jaegere it was great attending your 
TAVI sessions in the lab, that was top notch. Nicolas van Mieghem, seeing you defending 
your thesis was so impressive and high-level. Luckily I was reassured by the nurses that 
that was not by far the average level of a doctorate. I had the opportunity of witnessing 
both your talent and tenacity as an operator and as a researcher. Your idea for the R-
RADAR central figure (I keep the first draft - see pictures section) was a game changer 
and it is really beautiful. Another memory that I keep in my mind is from one afternoon shift 
in the cath-lab (more or less at 19.30 – 20:00) when the last patient on schedule turns out 
having a severe lesion at the distal LM trifurcation and active chest pain. You treated with 
trifurcation stenting and used the crooked buddy technique… amazing. Nicolas, thank you 
for the time spent with me in the R-RADAR and for all our conversations about work/life 
balance, it definitely expanded my view of this difficult, but incredibly fascinating 
profession.   
Alongside the great talent of the doctors, the competence and skills of the nurses and 
technicians was really incredible. Anne Marie you were my nurse guru, thank you being so 
kind especially when I didn’t understand a single word in Dutch: “even wachten…ok, ga 
maar door!”. Rob and Patrick, we had a great time in the lab, you are among the most 
skilled people I met, and your knowledge and curiosity was a great inspiration. Our paper 
on the rotational angiography of the dummy stent was no published in the end, but the 
video of the fractured cypher stent rotating in 3d was way too cool. Linda, Paul, Elco, 
Sander, Leonie, and all the other staff nurses and technicians, thank you for all the great 
time and all your teaching. 
 
A big part of my job was carried in conjunction with the trial bureau. The trial bureau is a 
big office coordinating the myriad of studies that the Thoraxcenter was running. Two key 
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people in that task were Arno Ruiter and Nico van der Berg. Arno, I always appreciated 
your good mood and your advices about running and running shoes, after 4 years of very 
bad results as a runner, sorry for wasting your time. Nico, thank you for helping me with all 
the visits of the MATRIX, we had a very great time together. Another initial task I had was 
adapting the protocol of the HI-TECH trial and preparing for its submission to the 
Rotterdam ethics committee and to EudraCT. For this project I worked with Mattie Lenzen. 
Thank you Mattie for all your help, and also for your advices while getting through the final 
stage of the BigRegister.  
The 4th floor of the old building, was once the venue of the cathlab rooms, before they 
have been moved in a novel area. There it was also the office of the intravascular imaging 
group, and of one person in particular, Jurgen Lighthart. Jurgen is a real legend in the 
Thoraxcenter. He has been interpreting IVUS since the early days, and was considered 
the guru of intravascular imaging. Jurgen I will always remember your enthusiasm and 
curiosity for research, your sense of humor and your exquisite coffee preparation (I hope 
that the batch I brought from Messina was of an acceptable level!). I want also to thank 
Karen Witberg, thank you Karen for your great work.  
Among the other people working in the 4th floor there were the “OCT guys” Antonios 
Karanasos, Jors van der Sijde and Fam which under the lead of Prof. Evelyn Regar, an 
absolute international expert in OCT, were working full time in intravascular imaging 
projects. Prof. Regar, I did not have the opportunity of working with you, but your kindness 
and enthusiasm towards all Italians was a great way to make me feel confortable. 
Antonios, Jors and Fam, thank you for all the coffees and the small-talk about Greece, 
Italy and the Netherlands. While I was desperate preparing my speech for the oral 
presentation at EuroPCR, I once asked Antonios how does he prepare his speeches, and 
he answered with a “Olympic” greek calm: I never prepare a speech. That advice evidently 
got even me more nervous. At that time The Thoraxcenter was also hosting various italian 
fellows, engaged in different projects. Giulia Paoletti, Marcella De Paolis and Giorgia Galli, 
it was great sharing with you those (free) coffees in front of the fellows’ room. What would 
occur if they decide to put in an Italian hospital a free coffee machine was often a fun topic 
of conversation… I wish you the best for the future. Maybe Marcella’s talisman (do you 
remember that peculiar colorful owl), will work for all of us.  
Unfortunately, due to my commitments I did not have the opportunity of meeting many of 
the Cardiology residents. Yet, I am very fortunate of getting to know one very well, Rohit 
Oemrawsingh. Rohit, you have been a great resource during my stay in Rotterdam, but 
most importantly you have been a great friend. Among our multiple snacks and dinners 
you taught me a lot of the surface and under-surface world of the Thoraxcenter. You are a 
wonderful person, and I am totally sure that your great scientific and clinical skills, together 
with your great social and human ability will give you a lot of satisfactions in the future. I 
really looking forward having you in Sicily for some serious “Gelato” tasting.  
After the first few months my fellowship was often on a move. Roughly half of the time was 
spent in the Thoraxcenter, and the other half in Cardialysis, a world-renown clinical 
research organization, located just 1 km away from the hospital. The venue was 
impressive, located in a high building in the center of Rotterdam with a wonderful view of 
the skyline. Cardialysis runs some of the most important clinical trials in the cardiovascular 
field, and is the meeting place of prominent clinical trialists and researchers. On my 
second day strolling through Cardialysis rooms I run into Prof. Serruys, the living legend of 
interventional cardiology, that looking right at me said “Who is this young man here?” I 
thought so hard to a clever answer, but in the meantime he was already gone… I had the 
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opportunity of talking to him longer in a conference in Madrid, and I will never forget his 
advice about having a good accent during presentations “You are Italian, you don't have to 
talk like an English-man, having an accent is a trademark, a distinctive trait”.  
Working so often in Cardialysis gave me the opportunity of knowing better its wonderful 
team: Garritte-Anne, Anna it was a great pleasure knowing you and participating to the 
meetings of the A-ARC. Yoshi, you are such a kind and pleasant person, I enjoyed your 
presence and your teachings regarding bioresorbable scaffolds. The latest acquisition of 
Cardialysis was Ernest Spitzer. Ernest is a cardiologist coming from Perù, who arrived at 
Cardalysis late during my stay in Rotterdam. He is a person that transmits a great calm but 
at the same time a resolute and ambitious attitude. As a native Spanish speaker was really 
easy getting to know each other and having also some time out of work. Thank you Ernest 
for your advices, for the discussion about our future, thank you for being so reassuring, it 
has been a lot of fun hanging out with you, I consider you a real friend. I hope we could 
have sometime the opportunity to hang out with Freddie, your friend from Dubai…you 
know what I mean. Cardialysis was a very exciting environment also because it was 
pullulating of fellows from around the world. Among them the one I could get to know 
better was Carlos Campos, a Brazilian cardiologist from Sau Paulo. Carlos, it was both 
great and extremely easy working with you. I am happy I had the opportunity of meeting 
you and your wonderful family. In Cardialysis I also met Eugene McFadden, an Irish 
interventional cardiologist who once used to be staff at the Thoraxcenter and now moved 
to Ireland, while remaining involved in many research projects. He has that kind of calm 
aura that put you immediately at ease, and is a formidable writer. Eugene I have learned a 
lot from your proofreading, I hope I will have the opportunity of meeting you again in the 
future.   
Other two key people during my time in Rotterdam were frequent Cardialysis visitors. 
Pascal Vranckx. The first time I met him it was in the external advisors office, a beautiful 
angular office with glass walls projecting a beautiful view of the Rotterdam city center. I 
knew him by name, but his aura really impressed me: he has a very strong character, 
which challenges you at first, sometimes putting you at unease. After a while I understood 
that this is his way he weighs who has in front. Pascal was one of the key people for me in 
Rotterdam, not counting the never-ending sessions of events adjudication and 
brainstorming on clinical trials I assisted with him. I will never forget his support and 
advices, especially during congresses. American college of Cardiology, 2015, I was having 
my first oral presentation in front of a large audience, and public speaking was not a skill 
that I have invested much time upon. Pascal, thank you so much for those multiple 
sessions repeating over and over again the PRODIGY-ACS, that presentation was perfect 
in the end, and a bit of the style that you transmitted me on that occasion will always be 
part of my armamentarium, I really owe you a lot. 
The second person I would like to mention is Prof. Jan Tijssen. Jan, I have been so 
fortunate working with you in several projects. Thank you for all the time you have been 
schooling me about all the possible statistical methods we could implement in the 
PRODIGY-SCORE paper, for all the pitfalls of different study design we have discussed in 
the NARC, and the basics for developing my own risk score. That all sounded scary and 
difficult at first, but you always had the capacity to explain in a disarmingly easy way even 
the more complex concepts.  
The PRECISE-DAPT project was the last one I have started in Rotterdam and in the end 
came out to be, by far, the most demanding. All this started with a first seminal meeting 
with Prof. Steyerberg, the head of the Medical decision making department of the Erasmus 
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MC, and with David van Klaveren, a mathematician working with him in multiple research 
projects. Prof. Steyerberg, thank you for your key addresses and for steering the project at 
important stages. David, we have been working in close contact for years, even if always 
at a distance. Nevertheless, I always had the feeling of working side-by-side. You are 
clever and smart, a relentless worker, an elegant statistician and in general a great person. 
I am deeply honored that you will take part to my defense. I wish you could be able to 
come to Barcelona more often, we would definitely repeat the PRECISE-DAPT celebration, 
thank you. I would also like to deeply thank all the co-authors involved in the PRECISE-
DAPT project, I have been privileged of working together with real legends of interventional 
cardiology, I am humbled having had the opportunity of being part of all this: Prof. James, 
thank you for your cooperation, with your help we have been able to achieve an important 
validation of the PRECISE-DAPT score. I will never forget the first time that I met you at 
the ACC, your attitude is an inspiration for all young researchers. Prof. Colombo I will 
always remember your advice in Madrid: “research is important, but is like the pepper in a 
dish, you have always to be a good doctor, or you will eat pepper only”. Prof. Bhatt, I owe 
you the title of this thesis, which is coming from your great editorial on the TRITON trial in 
the NEJM. I borrowed it because it was perfect for my topic and for my Sicilian roots, I 
have been honored working with you in this project. Prof. Steg, thank you for your 
insightful comments, your capacity of synthetizing complex concepts in few lines is a great 
inspiration. Dr. Raber, the validation of the PRECISE-DAPT in the BernPCI registry was 
key to demonstrate the ability of this novel tool in a real-world setting, thank you for your 
invaluable cooperation.  Dear Dik, the time of the validation and additional analysis asked 
during all revision rounds was tough, but your good attitude and character made that time 
more enjoyable. I have still to carry you a cake with the PRECISE-DAPT logo, I know. 
Prof. Windecker, it has been an honor working with you in several projects, and being 
hosted in your institution during the time I have been working to the PRECISE-DAPT. 
To conclude the list of the people I met in Cardialysis, and to which I am deeply connected 
until today, I want to mention Dr. Hector M. Garcia-Garcia. I met Hector for the first time 
during my initial visit in Rotterdam in June 2014. I was visiting Cardialysis and we were 
supposed to have dinner at Shabu Shabu, a Japanese restaurant in Blaack, right under 
the office, that would be the center of many memorable moments later on. Hector is the 
kind of person that with a simple glimpse can transmit such good vibrations. It’s just 
impossible not to like him. He is able in any situation to understand the kind of person that 
he has in front, and adapt to make them feel at ease. Hector, you have been an example 
for me. When I was stubborn and conflictive with people, Victoria often suggested me: “Be 
Hector!” Following that advice t helped me a lot in these years, believe me. The first time 
you invited us to your home I was supposed to cook something from my region: I can 
admit now that it was the very first time I was cooking that pasta. The result was extremely 
surprising to me as well, and I was not able to replicate that dish anymore. A clear 
example of error due to limited observation.  
I hope I will have sometimes the opportunity of showing you Sicily, staying in my place and 
cook real Italian/Mexican food while “platicar sobre las cosas de la vida”. Dear Hector, I 
started seeing you as a famous researcher, than as a peer, and finally as a real friend. We 
always felt at home when we were with you and we could not ever thank you enough for 
being so supportive, friendly and honest with us. Thanks also to Lulu, Andres and to the 
small Matteo, you are a wonderful family and you will always be an example for us.    
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There is plenty of people in Italy and elsewhere that helped me during the period 
immediately before/after Rotterdam. I really hope not to forget anyone, and if I do please 
forgive me. First, nothing would have been possible without the unrestricted support from 
all the people at my home University in Messina. Prof. Oreto, thank you for your trust, your 
respect and your genuine politeness. I will always take with me your teaching both about 
cardiology and life. Your integrity and honesty is the greatest teaching that you could give 
to your students. Prof. Carerj, you have been mentoring me since my early days as a med 
student, thank you for being always an example of integrity and humanity. Your authentic 
devotion to work, enduring long hours in the hospital, has been a great teaching, as it was 
your ability of putting all the patients at ease in any situation. I would like to thank all the 
faculty of the cardiology department of the University of Messina, and all the doctors 
working in the cardiology department, thank you for all that you taught me.  
To all the people of the cath-lab in Messina, Dr. Saporito, Andò and Di Giorgio, and all the 
technicians and nurse staff (Pierpaolo, Giacomo, Giovanni, Franco and Antonella) thank 
you for all your teaching and support, I have moved my first steps in that cath-lab, no 
matter where I go, it will always feel like home.  
To Marco Cerrito, thank you for being there on my first day in cardiology and for mentoring 
me while I was an intern. You have been great igniting my interest and passion for 
cardiology and a major reason why I have chosen this career. You are born for being an 
educator; I hope you could transmit your enthusiasm, talent and passion to newer 
generations, as you did with me 10 years ago.  
To all my colleagues sharing the residency training in Messina, but especially to the class 
of 2012, Anna, Angela, Peppe, Matteo, Maria, Marta e Alessandra. Thank you for letting 
me pursue this dream without ever pointing the finger, but instead defending me from the 
others. I have felt being part of a wonderful group, and I hope I will still feel it for a long 
time. Thank also to all the other colleagues that have shared that time with me: Pasquale, 
Giampiero, we should repeat some “time-out” in Barcelona, Ilaria, Salvina, Roberta, 
Antonio, Fausto, Giovanni, Vito, Gabriele, Irene and all the others (you are too much to 
quote you all!). To the interventional cardiology team of the Hospital Umberto I in Siracusa, 
the Director Marco Contarini, his wonderful staff, Giovanni De Velli, Paola Murè, Giorgio 
Sacchetta, Nadia Garro, Titta Barrano, and all the nurses and paramedicals (Giovanni, 
Danilo, Rita, Biagio, Lino, Luca, Maurizio, Massimo, Piero e Salvo). Thank you for hosting 
me and making me feel at home. I have learned a lot from you, about interventional 
cardiology, friendship and life. You work as a real team, without jealousy, deceits and 
hypocrisy; this translates in the superior quality and humanity that you put at service of 
your patients. I would also like to thank the fellows in Bern, that during my brief stay there 
have been extremely nice: thanks Giuseppe, Raffaele, Anna and Marco for the time spent 
together, I have appreciated your company and your advices during the Swiss survival 
bootcamp, I am sure you will have a wonderful career. To Prof. Davide Capodanno; 
Davide you believed in me when you were chair of the EAPCI young committee. Being 
Young national ambassador for Italy was a great honor, I hope I will serve well helping 
other young interventionalists pursuing their dream. Prof. Dominick Angiolillo, you have 
always been an example of an elegant researcher and a great mentor for young 
cardiologists. Thank you for the time and for all your precious advices.  
I would finally like to thank all the team in Barcelona where I am currently working: Prof. 
Sabaté and Dr. Brugaletta that have been introducing me to this new experience and 
welcomed and supported me better than I could imagine. To the senior staff members 
Monica Masotti, Victoria Martin, Xavier Freixa and Ander Regueiro from which I am 
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learning new things everyday. To the great team of nurses and technicians (Marc, Dani, 
Rosa, las Montses, Jorge, Joan, Jordi, Tere, Eva and all the others). Your competence 
and knowledge is perfectly melted with your friendliness, creating an extremely familiar 
environment, an invaluable quality of this institution. And to my great colleagues Alberto, 
John, Elisabetta and Luis, that accepted me in the very best way I could imagine, thank 
you guys for all your support, we are a great team.  
Going back to Rotterdam for a moment, I have to admit that my social life out of the 
hospital was definitely not super-active. Yet, I would never expect to find a person like 
Pietro Profeta. Pietro was the only friend I had outside the cardiology world and hanging 
out with him was a great way to wash-out some stress. Pietro, we had a lot of fun in many 
occasions, I really cannot count them. After discovering all your great qualities I am 
grateful that our path crossed. My time in Rotterdam would have never be the same 
without you. I wish you all the best my friend, 2018 will be an year to remember, and I am 
sure that you will be a great dad, thanks for everything. 
Two additional people shared (in different moments) most of the time of my fellowship at 
the Thoraxcenter. I owe to these two people much more than I can write in these pages. I 
thank them for being formidable working partners, with whom I survived to the “Matrix 
crisis” and to the “A-A-Arc”. I also owe you my mental sanity, I think that I could never 
stand the pressure without having you at my side, simply talking about the events or 
laughing about the strange things that happens between that walls. Thank you girls, you 
made that experience one of the most constructive of my career, but also one of the most 
significant of my life. Marianna, I have always appreciated your determination, self-
consciousness and indifference for political correctness. Your clarity of mind and your 
intellectual honesty are one of the best qualities a person could have. I wish you all the 
best for your career in interventional cardiology. I am sure that the patients in Brescia will 
have a great resource when they will need it. Sara, you have been the first fellow I have 
been sharing my work burden with, and we came across so much troubles, doubts and 
satisfactions I can hardly remember. Unfortunately, we have shared some of the worst 
experiences one person could face in life, the kind you ask yourself in the middle of the 
night, why me, why like this, what have I done to deserve it. For this reason you ultimately 
had to go back away early from Rotterdam. Thank you for your words in some of the worst 
moments of my life; you knew what you were talking about. On the other hand, I am happy 
to think that we also shared some good events: you have just started dating Mirko the 
month you hosted me in Bern (thank you for that one also!) and I had the occasion of 
meeting him in person. I am happy that after all the sufferings, faith gave you the occasion 
of meeting someone worth fighting for. I wish you guys all the best for your life together, 
and I hope that you will get all the happiness you really deserve.    
Last and definitely not least, I would like to thank my promotors that accompanied me in 
this wonderful journey. Back in 2014, the very first interview for the selection in Rotterdam 
was with Prof. Felix Zijlstra, the head of the department. I couldn’t expect that he would 
become one of the most significant individuals during my stay there, and for the years 
following. Prof. Zijlstra is a real legend of interventional cardiology. His research and 
achievement shaped the history of medicine (primary angioplasty and thromboaspiration 
only to cite some). Despite his reputation and his position as head of department he 
always maintained a humble profile, surrounded by an aura of unimposed greatness. The 
close relationship he maintained with all the people in the cath-lab including physicians, 
nurses and fellows will always be an example for me. Prof. Zijlstra you have been a great 
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example of what an excellent chief, a brilliant researcher, a good doctor and a great 
person should look like, thank you. 
I have known Marco Valgimigli since four years now, he has been my mentor at the 
Thoraxcenter, and my promotor for this PhD thesis. I have been impressed, and I am 
continuously impressed, by different aspects of Prof. Valgimigli’s personality: his creativity; 
his intelligence and the sharpness of his mind; his capacity of keeping focused; his 
curiosity that gives him the way to frame significant research questions; his clear vision on 
how to develop a project 1,2, 5 years away; and most importantly, his resiliency, accepting 
the drawbacks and working harder to get to the goal. Never satisfied, always on top of the 
next project, always hungry for novel achievements. What really impressed me though, 
was the way he managed to do all these things respecting the others, including 
colleagues, peers and a 27 year old fellow coming in a big center with only a minor 
research background; while being a father of two, wonderful, and intelligent kids. Life is not 
about all the steps you have taken, it’s about the footprints you leave behind.  
Marco, my key proposition for this thesis is a phrase that you told me during a GISE 
congress in 2015, probably you wouldn’t even remember: “L’unica cosa che conta, è il 
contatto umano – All that really matters is the human connection”. During these years 
working in close contact with you, I am even more convinced that, for every aspect in life, 
you were right. You have been more than a teacher, more than an advisor, more than a 
mentor. You teached me how to question, how to search, how to read, how to think, how to 
write and how to question again. I owe you all my scientific achievements and beyond.  
I hope I could pay back your trust and dedication someday.  
 
Finally, I would like to thank my family and my friends. My mother and sister that are with 
me everyday, wherever I am, I love you so much. Mamma, you dedicated your life to raise 
us with good principles, sacrificing your ambition. I hope you could be proud of us. 
Roberta, you obtained your doctorate before your older brother, I am sure you will soon 
realize how strong and really talented you are, I am proud of you. To my friends (I don’t 
need to write names in here), that supports me no matter the distance. I have read that 
“We are the average of the five people we spend the most time with”. Well I am proud of 
myself for choosing such a group of talented and honest people.  
You are the family that I have chosen.  
To my wonderful girlfriend Victoria, that is the person that knows me the most, and that 
lived on her own skin the hard work needed to complete this thesis. Thank you for your 
support, for your patience and your sacrifice. For comforting me when I needed it, and for 
encouraging me when I needed it. For keeping my feet on the ground when I levitated, and 
for getting me back on my feet when I collapsed. You are my compass and my home.  
 
And to my Father. I am sure that seeing this book would make you proud. Thank you for all 
you have been to me in the good and in the bad days. I owe you simply everything I am. 
I miss you everyday. I love you. 
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